"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,B1,US 11688017 B1,015-504-612-641-460,2023-06-27,2023,US 202117553949 A,2021-12-17,US 202117553949 A;;US 202017061650 A;;US 201962909494 P,2019-10-02,"Computer system and method for detecting, extracting, weighing, benchmarking, scoring, reporting and capitalizing on complex risks found in buy/sell transactional agreements, financing agreements and research documents","Computer-implemented systems and methods enhance a user's sophistication as she/he reviews complex information sources using specialized detective tools provided by a user interface of the computer system. The specialized investigative inquiries are stored in a database and are particularly tailored a priori by a subject-matter content designer for the type of documents being reviewed for risk and opportunity. The investigative scripts are organized into to a path of risk-related subjects or topics, and within each path of subjects/topics the investigative scripts are organized into a specialized inquiry or flow chart.",CALLAHAN JAMES,CALLAHAN JAMES,,https://lens.org/015-504-612-641-460,Granted Patent,yes,2,1,3,3,0,G06Q40/08;;G06Q40/12;;G06Q40/06;;G06Q30/018;;G06Q10/103;;G06V30/10;;G06V30/40;;G06Q40/03;;G06Q40/08;;G06F16/9558;;G06F16/9538;;G06F16/986;;G06Q10/103;;G06Q30/018;;G06Q40/06;;G06Q40/12;;G06V30/10;;G06V30/40;;G06Q40/03;;G06V30/41;;G06V30/19133,G06Q40/08;;G06F16/9538;;G06F16/955;;G06F16/958;;G06Q10/10;;G06Q30/018;;G06Q40/03;;G06Q40/06;;G06Q40/12;;G06V30/10;;G06V30/40,,0,0,,,,ACTIVE
2,US,B1,US 11205233 B1,058-193-290-543-220,2021-12-21,2021,US 202017061650 A,2020-10-02,US 202017061650 A;;US 201962909494 P,2019-10-02,"Computer system and method for detecting, extracting, weighing, benchmarking, scoring, reporting and capitalizing on complex risks found in buy/sell transactional agreements, financing agreements and research documents","Computer-implemented systems and methods enhance a user's sophistication as she/he reviews complex information sources using specialized detective tools provided by a user interface of the computer system. The specialized investigative inquiries are stored in a database and are particularly tailored a priori by a subject-matter content designer for the type of documents being reviewed for risk and opportunity. The investigative scripts are organized into to a path of risk-related subjects or topics, and within each path of subjects/topics the investigative scripts are organized into a specialized inquiry or flow chart.",CALLAHAN JAMES,CALLAHAN JAMES,,https://lens.org/058-193-290-543-220,Granted Patent,yes,2,2,3,3,0,G06Q40/08;;G06Q40/12;;G06Q40/06;;G06Q30/018;;G06Q10/103;;G06V30/10;;G06V30/40;;G06Q40/03;;G06Q40/08;;G06F16/9558;;G06F16/9538;;G06F16/986;;G06Q10/103;;G06Q30/018;;G06Q40/06;;G06Q40/12;;G06V30/10;;G06V30/40;;G06Q40/03;;G06V30/41;;G06V30/19133,G06F16/955;;G06F16/9538;;G06F16/958;;G06K9/00;;G06Q10/10;;G06Q30/00;;G06Q40/00;;G06Q40/02;;G06Q40/06;;G06Q40/08,,0,0,,,,ACTIVE
3,US,A,US 1490314 A,065-370-554-410-826,1924-04-15,1924,US 53180022 A,1922-01-25,US 53180022 A,1922-01-25,Sanitary cover,,JAMES CALLAHAN,JAMES CALLAHAN,,https://lens.org/065-370-554-410-826,Granted Patent,no,0,6,1,1,0,B65F7/00;;B65F7/00,B65F7/00,,0,0,,,,EXPIRED
4,US,A1,US 2023/0334591 A1,045-387-527-752-770,2023-10-19,2023,US 202318340056 A,2023-06-23,US 202318340056 A;;US 202117553949 A;;US 202017061650 A;;US 201962909494 P,2019-10-02,"COMPUTER SYSTEM AND METHOD FOR DETECTING, EXTRACTING, WEIGHING, BENCHMARKING, SCORING, REPORTING AND CAPITALIZING ON COMPLEX RISKS FOUND IN BUY/SELL TRANSACTIONAL AGREEMENTS, FINANCING AGREEMENTS AND RESEARCH DOCUMENTS","Computer-implemented systems and methods enhance a user’s sophistication as she/he reviews complex information sources using specialized detective tools provided by a user interface of the computer system. The specialized investigative inquiries are stored in a database and are particularly tailored a priori by a subject-matter content designer for the type of documents being reviewed for risk and opportunity. The investigative scripts are organized into to a path of risk-related subjects or topics, and within each path of subjects/topics the investigative scripts are organized into a specialized inquiry or flow chart.",CALLAHAN JAMES,CALLAHAN JAMES,,https://lens.org/045-387-527-752-770,Patent Application,yes,0,0,3,3,0,G06Q40/08;;G06Q40/12;;G06Q40/06;;G06Q30/018;;G06Q10/103;;G06V30/10;;G06V30/40;;G06Q40/03;;G06Q40/08;;G06F16/9558;;G06F16/9538;;G06F16/986;;G06Q10/103;;G06Q30/018;;G06Q40/06;;G06Q40/12;;G06V30/10;;G06V30/40;;G06Q40/03;;G06V30/41;;G06V30/19133,G06Q40/08;;G06F16/9538;;G06F16/955;;G06F16/958;;G06Q10/10;;G06Q30/018;;G06Q40/03;;G06Q40/06;;G06Q40/12,,0,0,,,,PENDING
5,US,B1,US 10783578 B1,196-837-790-392-152,2020-09-22,2020,US 201514985924 A,2015-12-31,US 201514985924 A;;US 201462098689 P,2014-12-31,"Computerized systems and methods for detecting, risk scoring and automatically assigning follow-on action codes to resolve violations of representation and warranties found in loan servicing contracts, loan purchase and sale contracts, and loan financing contracts","Computerized systems and methods (1) detect an item (e.g., loan or practice) within a securitization trust or other financing vehicle that may fall below the standards outlined by representations and warranties made by the securitization trust, and (2) automatically export reports to other systems so such other systems can systematically analyze the identified item, which may then be possibly used to remedy the item.",CALLAHAN JAMES,CALLAHAN JAMES,,https://lens.org/196-837-790-392-152,Granted Patent,yes,14,2,1,1,0,G06Q40/03;;G06Q40/03,G06Q40/02;;G06Q40/00,,1,1,118-413-286-371-290,10.1109/isa.2011.5873366,"Z. Zhang, “Research of Default Risk of Commercial Bank's Personal Loan Based on Rough Sets and Neural Network,” 2011 3rd International Workshop on Intelligent Systems and Applications, Wuhan, 2011, pp. 1-4, doi: 10.1109/ISA.2011.5873366. (Year: 2011).",ACTIVE
6,UA,C2,UA 60311 C2,043-664-520-091-324,2003-10-15,2003,UA 99031739 A,1997-10-01,US 2732096 P;;US 4377697 P;;US 9718001 W,1996-10-02,VITRONECTIN RECEPTOR ANTAGONISTS,"Compounds having a benzodiazepinyl core structure are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis, angiogenesis, tumor growth and metastasis, atherosclerosis, restenosis and inflammation.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS,,https://lens.org/043-664-520-091-324,Limited Patent,no,0,0,59,64,0,A61K31/55;;A61K45/06;;C07D223/16;;C07D401/12;;C07D403/12;;C07D417/12;;Y02P20/582;;Y02P20/55;;A61P19/10;;A61P29/00;;A61P35/00;;A61P35/04;;A61P43/00;;A61P9/00;;A61P9/10;;A61K33/243;;C07D223/00;;A61K33/243,A61K31/55;;A61K31/415;;C07D223/00;;A61K31/44;;A61K31/445;;A61K31/47;;A61K31/4704;;A61K31/495;;A61K31/52;;A61K31/551;;A61K33/243;;A61K45/06;;A61P9/00;;A61P9/00;;A61P9/10;;A61P19/10;;A61P29/00;;A61P29/00;;A61P35/00;;A61P35/00;;A61P43/00;;A61P43/00;;C07D223/00;;C07D223/16;;C07D233/56;;C07D233/64;;C07D235/18;;C07D235/22;;C07D243/14;;C07D401/00;;C07D401/12;;C07D401/14;;C07D403/12;;C07D413/12;;C07D417/12;;C07D487/00,,0,0,,,,EXPIRED
7,US,A,US 1992413 A,052-121-586-822-586,1935-02-26,1935,US 47598030 A,1930-08-18,US 47598030 A,1930-08-18,Side wing bracket,,CALLAHAN JAMES P,CALLAHAN JAMES P,,https://lens.org/052-121-586-822-586,Granted Patent,no,0,3,1,1,0,B60J1/14;;E05Y2900/506;;E05Y2900/55;;B60J1/14;;E05Y2900/55;;E05Y2900/506,B60J1/14,,0,0,,,,EXPIRED
8,AU,A,AU 2000/068032 A,060-737-274-707-71X,2001-01-22,2001,AU 2000/068032 A,2000-07-05,US 34843699 A;;US 0040306 W,1999-07-07,Tire cutting machine and method,,NORTH AMERICAN TIRE RES AND RE,CALLAHAN JAMES W,,https://lens.org/060-737-274-707-71X,Patent Application,no,0,0,2,2,0,B26D3/005;;B26D7/14,B26D1/00;;B26D7/14,,0,0,,,,DISCONTINUED
9,US,A,US 2057878 A,126-434-470-913-195,1936-10-20,1936,US 73775634 A,1934-07-31,US 73775634 A,1934-07-31,Electric cooking device,,WALTER B BOWSER,CALLAHAN JAMES T,,https://lens.org/126-434-470-913-195,Granted Patent,no,0,1,1,1,0,H05B3/0004;;H05B3/0004,H05B3/00,,0,0,,,,EXPIRED
10,MX,A,MX PA03000556 A,151-923-478-733-803,2003-06-06,2003,MX PA03000556 A,2001-07-16,US 21984200 P;;US 22063600 P;;US 0122267 W,2000-07-21,CALCILYTIC COMPOUNDS.,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F,,https://lens.org/151-923-478-733-803,Patent Application,no,0,0,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,A61K31/4418;;C07D213/77;;A61K31/4436;;A61K45/06;;A61K47/10;;A61K47/24;;A61K47/28;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,EXPIRED
11,FR,A1,FR 2291186 A1,154-083-177-895-112,1976-06-11,1976,FR 7535167 A,1975-11-18,US 52472974 A,1974-11-18,PROCEDE DE PREPARATION DE DINITRILES A PARTIR DE THIODINITRILES,,STANDARD OIL CO,CALLAHAN JAMES LOUIS,,https://lens.org/154-083-177-895-112,Patent Application,no,2,1,23,23,0,B01J23/72;;B01J23/76;;C07C253/30;;B01J23/72;;B01J23/76;;C07C253/30,B01J21/00;;C07B61/00;;B01J23/00;;B01J23/72;;B01J23/76;;B01J27/00;;C07C67/00;;C07C253/00;;C07C255/04;;C07C255/33,,0,0,,,,EXPIRED
12,DE,A1,DE 2550228 A1,168-340-179-969-157,1976-05-20,1976,DE 2550228 A,1975-11-08,US 52472974 A,1974-11-18,VERFAHREN ZUR HERSTELLUNG VON DINITRILEN AUS THIODINITRILEN,,STANDARD OIL CO OHIO,CALLAHAN JAMES LOUIS,,https://lens.org/168-340-179-969-157,Patent Application,no,0,0,23,23,0,B01J23/72;;B01J23/76;;C07C253/30;;B01J23/72;;B01J23/76;;C07C253/30,B01J21/00;;B01J23/00;;C07B61/00;;B01J23/72;;B01J23/76;;B01J27/00;;C07C67/00;;C07C253/00;;C07C255/04;;C07C255/33,,0,0,,,,DISCONTINUED
13,US,A,US 1117549 A,149-834-168-584-164,1914-11-17,1914,US 1913/0748909 A,1913-02-17,US 1913/0748909 A,1913-02-17,GRAB-BUCKET.,,CALLAHAN FRANK E;;CALLAHAN JAMES J,CALLAHAN FRANK E;;CALLAHAN JAMES J,,https://lens.org/149-834-168-584-164,Granted Patent,no,0,0,1,1,0,B66C3/12;;B66C3/12,,,0,0,,,,EXPIRED
14,FI,A,FI 36856 A,000-248-984-938-009,1967-05-10,1967,FI 36856D A,1960-04-12,FI 36856T A,1960-04-12,Sätt att framställa katalytiska ämnen,,STANDARD OIL CO,LOUIS CALLAHAN JAMES,,https://lens.org/000-248-984-938-009,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
15,US,A,US 3096109 A,041-489-977-633-148,1963-07-02,1963,US 16943662 A,1962-01-29,US 16943662 A,1962-01-29,Clamping device,,CALLAHAN JAMES P,CALLAHAN JAMES P,,https://lens.org/041-489-977-633-148,Granted Patent,no,4,13,1,1,0,E04G7/18;;E04G7/18;;F16B2/10;;F16B2/10;;F16B7/0493;;F16B7/0493;;Y10T24/3428;;Y10T24/3428;;Y10T403/7105;;Y10T403/7105,E04G7/18;;F16B2/10;;F16B7/04,,0,0,,,,EXPIRED
16,US,A,US 1339162 A,082-962-703-233-428,1920-05-04,1920,US 28405619 A,1919-03-21,US 28405619 A,1919-03-21,Swagger-stick,,CALLAHAN JAMES M,CALLAHAN JAMES M,,https://lens.org/082-962-703-233-428,Granted Patent,no,0,0,1,1,0,A45B3/00;;A45B3/00,A45B3/00,,0,0,,,,EXPIRED
17,US,A,US 3044965 A,081-573-686-123-327,1962-07-17,1962,US 80678159 A,1959-04-16,US 80678159 A,1959-04-16,Process for the manufacture of bismuth catalysts,,STANDARD OIL CO,CALLAHAN JAMES L,,https://lens.org/081-573-686-123-327,Granted Patent,no,4,8,7,7,0,B01J23/31;;B01J23/31;;B01J23/18;;B01J23/18;;B01J27/192;;B01J27/192,B01J23/18;;B01J23/31;;B01J27/192,,0,0,,,,EXPIRED
18,RO,A,RO 69625 A,122-797-133-580-198,1980-12-30,1980,RO 8391875 A,1975-11-14,US 52472974 A,1974-11-18,PROCEDE POUR LA PREPARATION DU NITRYLE ADIPIQUE,,STANDARD OIL CO,CALLAHAN JAMES L,,https://lens.org/122-797-133-580-198,Unknown,no,0,0,23,23,0,B01J23/72;;B01J23/76;;C07C253/30;;B01J23/72;;B01J23/76;;C07C253/30,B01J21/00;;B01J23/00;;C07B61/00;;B01J23/72;;B01J23/76;;B01J27/00;;C07C67/00;;C07C253/00;;C07C255/04;;C07C255/33,,0,0,,,,DISCONTINUED
19,US,A,US 3395178 A,009-932-147-023-109,1968-07-30,1968,US 3803765 A,1965-03-08,US 3803765 A;;US 43803765 A,1965-03-08,Process for producing unsaturated carboxylic acids with phosphomolybdic acid on silicon carbide as catalyst,,STANDARD OIL CO,CALLAHAN JAMES L,,https://lens.org/009-932-147-023-109,Granted Patent,no,3,3,1,1,0,B01J27/19;;B01J27/19;;C07C51/252;;C07C51/252,B01J27/19;;C07C51/25;;C07C57/055,260/530,0,0,,,,EXPIRED
20,US,A1,US 2004/0225497 A1,030-446-956-597-767,2004-11-11,2004,US 42932603 A,2003-05-05,US 42932603 A,2003-05-05,Compressed yet quickly searchable digital textual data format,"
   A data processing method is disclosed for storing and retrieving text. The method achieves a significant level of efficiency in compression over prior art without having to compress the token dictionary through an iterative tokenization of the text and tokens. A benefit of the uncompressed token dictionary is faster searches and decompression of tokenized text. To achieve faster searches, an index with a given text resolution for each unique word is created and added as an additional column element in the alphabetized word table. Since tokens consisting of multiple tokens populate the tokenized text, they are parsed to tokens that represent unique words before a search for a word or phrase is conducted. In a relatively large text such as a Bible, there could be a large number of tokens that consist of multiple tokens, which could take fair amount of time to parse. Therefore, the method includes a step of creating an additional index that is added as an additional column element in the alphabetized word table. The resulting invention enables high levels of compression and faster searches of text in documents. 
",CALLAHAN JAMES PATRICK,CALLAHAN JAMES PATRICK,,https://lens.org/030-446-956-597-767,Patent Application,yes,8,41,1,1,0,H03M7/3084;;H03M7/3084,H03M7/30,704/235,0,0,,,,DISCONTINUED
21,CS,B2,CS 193533 B2,043-121-648-199-026,1979-10-31,1979,CS 769775 A,1975-11-13,US 52472974 A,1974-11-18,PROCESS FOR PREPARING DINITRILES,,STANDARD OIL CO OHIO,CALLAHAN JAMES L,,https://lens.org/043-121-648-199-026,Granted Patent,no,0,0,23,23,0,B01J23/72;;B01J23/76;;C07C253/30;;B01J23/72;;B01J23/76;;C07C253/30,B01J21/00;;B01J23/00;;C07B61/00;;B01J23/72;;B01J23/76;;B01J27/00;;C07C67/00;;C07C253/00;;C07C255/04;;C07C255/33,,0,0,,,,EXPIRED
22,DE,A1,DE 2752168 A1,119-093-222-989-522,1978-06-01,1978,DE 2752168 A,1977-11-23,US 74502476 A,1976-11-26,"VERFAHREN ZUR HERSTELLUNG VON 1,4- DICYANOBUTEN DURCH KATALYTISCHE DIMERISIERUNG VON ACRYLNITRIL",,STANDARD OIL CO OHIO,CALLAHAN JAMES LOUIS,,https://lens.org/119-093-222-989-522,Patent Application,no,1,0,13,13,0,B01J27/04;;B01J37/20;;C07C255/00;;Y02P20/52,C07B61/00;;B01J27/00;;B01J27/04;;B01J37/20;;C07C67/00;;C07C253/00;;C07C255/03;;C07C255/09,,1,0,,,"Chem. Abstr. 76, 1972, Ref. 33830 t",DISCONTINUED
23,CA,A,CA 893504 A,113-562-648-338-55X,1972-02-22,1972,CA 893504D A,,CA 893504T A,,GARTER CHECK VALVE,,HOUDAILLE INDUSTRIES INC,CALLAHAN JAMES J,,https://lens.org/113-562-648-338-55X,Granted Patent,no,0,0,1,1,0,,F01M1/08;;F16K15/00,,0,0,,,,EXPIRED
24,CA,A,CA 1117549 A,143-460-861-311-664,1982-02-02,1982,CA 291804 A,1977-11-25,US 74502476 A,1976-11-26,HIGH TEMPERATURE VAPOR PHASE CATALYTIC DIMERIZATION OF ACRYLONITRILE,"HIGH TEMPERATURE VAPOR PHASE CATALYTIC DIMERIZATION OF ACRYLONITRILE Acrylonitrile is dimerized to 1,4-dicyanobutenes and adiponitrile by contacting acrylonitrile in the vapor phase with a catalyst comprising activated alumina containing inorganic sulfide ion.",CALLAHAN JAMES L,CALLAHAN JAMES L,,https://lens.org/143-460-861-311-664,Granted Patent,no,0,0,13,13,0,B01J27/04;;B01J37/20;;C07C255/00;;Y02P20/52,C07B61/00;;B01J27/00;;B01J27/04;;B01J37/20;;C07C67/00;;C07C253/00;;C07C255/03;;C07C255/09,260-560.3,0,0,,,,EXPIRED
25,DE,A1,DE 1902587 A1,041-387-565-509-792,1969-08-28,1969,DE 1902587 A,1969-01-20,US 70239268 A,1968-02-01,Schmiermittelverteilervorrichtung,,MCCORD CORP,JOSEPH CALLAHAN JAMES,,https://lens.org/041-387-565-509-792,Patent Application,no,0,3,5,5,0,F16N25/02;;F16N25/02;;H02G15/1813;;H02G15/1813;;Y10T137/5283;;Y10T137/5283,F16N25/02;;H02G15/18,,0,0,,,,PENDING
26,US,A,US 934425 A,076-630-429-027-833,1909-09-21,1909,US 1909/0476659 A,1909-02-08,US 1909/0476659 A,1909-02-08,BRAKING MECHANISM.,,CALLAHAN JAMES P,CALLAHAN JAMES P,,https://lens.org/076-630-429-027-833,Granted Patent,no,0,4,1,1,0,B61K3/02;;B61K3/02,,,0,0,,,,EXPIRED
27,CA,A,CA 1066201 A,153-800-497-273-470,1979-11-13,1979,CA 275280 A,1977-03-31,US 75036976 A,1976-12-14,SINGLE LINE LUBRICANT REVERSING FEEDER,"A single line lubricant reversing feeder for use in a centralized lubricating system, the feeder having a valving piston and a metering piston, by virtue of the movement of which a measured portion of the lubricant supplied to the feeder is delivered to a point of use such as a bearing, and the remaining portion is directed to the next succeeding feeder in the system. The feeder is arranged so that only a single check valve is required to accomplish the foregoing.",HOUDAILLE INDUSTRIES INC,CALLAHAN JAMES J,,https://lens.org/153-800-497-273-470,Granted Patent,no,0,0,2,2,0,F16N25/02;;F16N25/02;;Y10T137/86413;;Y10T137/86413,F16N25/02,184-33,0,0,,,,EXPIRED
28,US,A,US 2996147 A,192-709-157-149-470,1961-08-15,1961,US 84620059 A,1959-10-13,US 84620059 A,1959-10-13,Double header lubricating system,,TRABON ENGINEERING CORP,CALLAHAN JAMES J,,https://lens.org/192-709-157-149-470,Granted Patent,no,3,10,1,1,0,F16N27/00;;F16N27/00,F16N27/00,,0,0,,,,EXPIRED
29,MX,A,MX PA94000047 A,048-325-502-290-405,2003-05-05,2003,MX 9400047 A,1994-01-03,US 99288592 A;;US 3794893 A,1992-12-21,FIBRINOGEN BICYCLIC ANTAGONISTS.,"The present invention is related with compounds of the formula: (see formula I), its pharmaceutical acceptable salts, which are effective for inhibiting the platelets aggregation. The present also relates to the pharmaceutical compositions to perform said activity and a method for inhibiting the platelet aggregation.",SMITHKLINE BEECHAM CORP,JAMES FRANCIS CALLAHAN,,https://lens.org/048-325-502-290-405,Patent Application,no,0,0,23,24,0,C07D211/18;;C07D211/70;;C07D213/24;;C07D223/16;;C07D243/04;;C07D243/14;;C07D243/24;;C07D267/14;;C07D401/12;;C07D403/12;;C07D453/02;;A61P7/02;;C07D243/14;;C07D401/12,A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/445;;A61K31/4465;;A61K31/451;;A61K31/55;;A61K31/551;;A61P7/02;;C07D211/18;;C07D211/22;;C07D211/26;;C07D211/70;;C07D213/24;;C07D213/74;;C07D223/16;;C07D243/04;;C07D243/14;;C07D243/24;;C07D267/14;;C07D295/04;;C07D295/08;;C07D295/10;;C07D295/12;;C07D401/12;;C07D401/14;;C07D403/12;;C07D453/02,,0,0,,,,PENDING
30,AU,A,AU 1973/052768 A,113-057-014-488-575,1974-09-05,1974,AU 1973/052768 A,1973-03-01,US 26092472 A,1972-06-08,HIGH-PRESSURE LUBRICATION INJECTION PUMP,,MCCORD CORP,CALLAHAN JAMES J,,https://lens.org/113-057-014-488-575,Patent Application,no,0,3,5,5,0,F16N13/16,F16N7/32;;F16N13/16,,0,0,,,,DISCONTINUED
31,CA,A,CA 171160 A,104-367-086-834-008,1916-08-01,1916,CA 171160D A,1913-04-04,CA 171160T A,1913-04-04,CIGARETTE TIPPING MACHINE,,CALLAHAN JAMES H,CALLAHAN JAMES H,,https://lens.org/104-367-086-834-008,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
32,MX,A,MX PA03003688 A,163-180-098-675-542,2003-08-07,2003,MX PA03003688 A,2001-10-25,US 24300600 P;;US 0146184 W,2000-10-25,CALCILYTIC COMPOUNDS.,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F,,https://lens.org/163-180-098-675-542,Patent Application,no,0,0,20,20,0,A61K31/565;;A61K31/59;;A61K31/66;;A61K38/23;;A61K45/06;;C07D213/84;;A61P1/02;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P35/04;;A61P43/00;;A61P5/18;;A61P5/22;;C07D213/63;;C07D213/84;;A61K31/59;;A61K31/565;;A61K31/66;;A61K45/06;;A61K38/23,A61K31/137;;A61K31/44;;A61K31/565;;A61K31/59;;A61K31/593;;A61K31/66;;A61K38/00;;A61K38/23;;A61K45/00;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P5/22;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P35/04;;A61P43/00;;C07D213/84,,0,0,,,,PENDING
33,US,A,US 1134587 A,185-627-132-944-037,1915-04-06,1915,US 1914/0850207 A,1914-07-10,US 1914/0850207 A,1914-07-10,KNIFE-SHARPENER.,,CALLAHAN PATRICK JAMES,CALLAHAN PATRICK JAMES,,https://lens.org/185-627-132-944-037,Granted Patent,no,0,6,1,1,0,B24D15/081;;B24D15/081,B24D15/08,,0,0,,,,EXPIRED
34,AU,A,AU 1977/030898 A,091-614-576-046-018,1979-07-05,1979,AU 1977/030898 A,1977-11-23,US 74502476 A,1976-11-26,HIGH TEMPERATURE VAPOR PHASE CATALYTIC DIMERIZATION OF ACRYLONITRILE,,STANDARD OIL CO OHIO,CALLAHAN JAMES LOUIS,,https://lens.org/091-614-576-046-018,Patent Application,no,0,0,13,13,0,B01J27/04;;B01J37/20;;C07C255/00;;Y02P20/52,C07B61/00;;B01J27/00;;B01J27/04;;B01J37/20;;C07C67/00;;C07C253/00;;C07C255/03;;C07C255/09,,0,0,,,,DISCONTINUED
35,US,A,US 1433934 A,126-727-250-802-687,1922-10-31,1922,US 50983421 A,1921-10-24,US 50983421 A,1921-10-24,Side-wing and sunshade supporting bracket,,CALLAHAN JAMES P,CALLAHAN JAMES P,,https://lens.org/126-727-250-802-687,Granted Patent,no,0,1,1,1,0,B60J1/04;;B60J1/04,B60J1/04,,0,0,,,,EXPIRED
36,US,A,US 3476214 A,193-887-200-790-289,1969-11-04,1969,US 3476214D A,1968-02-01,US 70239268 A,1968-02-01,DIVISIONAL LUBRICANT FEEDER WITH BYPASS MEANS,,MCCORD CORP,CALLAHAN JAMES J,,https://lens.org/193-887-200-790-289,Granted Patent,no,6,23,5,5,0,F16N25/02;;F16N25/02;;H02G15/1813;;H02G15/1813;;Y10T137/5283;;Y10T137/5283,F16N25/02;;H02G15/18,184/7,0,0,,,,EXPIRED
37,AU,A,AU 1978/039512 A,002-110-164-154-592,1980-03-13,1980,AU 1978/039512 A,1978-09-04,US 83226077 A,1977-09-12,EXTRUSION OF SULFUR FROM ORGANIC COMPOUNDS,,STANDARD OIL CO OHIO,CALLAHAN JAMES LOUIS,,https://lens.org/002-110-164-154-592,Patent Application,no,0,0,6,6,0,C07C1/322;;C07C37/00,C07C1/32;;C07C37/00;;C07C37/52,,0,0,,,,DISCONTINUED
38,UA,C2,UA 58586 C2,040-269-423-824-232,2003-08-15,2003,UA 00105670 A,1999-04-08,US 8109398 P;;US 9907722 W,1998-04-08,"CALCILYTIC COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND TREATMENT METHOD","Novel calcilytic compounds, pharmaceutical compositions containing said compounds and their use as calcium receptor antagonists.",SMITHKLINE BEECHAM CORP;;NPS PHARMA INC,CALLAHAN JAMES FRANCIS,,https://lens.org/040-269-423-824-232,Limited Patent,no,0,0,41,41,0,C07C217/22;;C07C217/60;;C07C255/37;;C07C255/54;;C07C255/57;;C07C311/06;;C07D209/48;;A61P19/00;;A61P19/02;;A61P19/10;;A61P29/00;;A61P3/14;;A61P43/00;;C07C255/33;;C07D209/48;;C07C311/06;;C07C217/60;;C07C255/54;;C07C255/37;;C07C217/22;;C07C255/57,A61P3/14;;A61K31/135;;A61K31/18;;A61K31/216;;A61K31/275;;A61P19/02;;A61P19/10;;A61P29/00;;A61P43/00;;C07C217/22;;C07C217/60;;C07C255/37;;C07C255/54;;C07C255/57;;C07C311/06;;C07D209/48,,0,0,,,,EXPIRED
39,US,A,US 2039212 A,084-199-363-935-832,1936-04-28,1936,US 1477335 A,1935-04-05,US 1477335 A,1935-04-05,Side windshield,,CALLAHAN JAMES P,CALLAHAN JAMES P,,https://lens.org/084-199-363-935-832,Granted Patent,no,0,2,1,1,0,B60J1/14;;B60J1/14,B60J1/14,,0,0,,,,EXPIRED
40,US,A,US 1339257 A,104-417-943-544-877,1920-05-04,1920,US 32057119 A,1919-08-29,US 32057119 A,1919-08-29,Swagger-stick,,CALLAHAN JAMES M,CALLAHAN JAMES M,,https://lens.org/104-417-943-544-877,Granted Patent,no,0,14,1,1,0,A45B3/00;;A45B3/00,A45B3/00,,0,0,,,,EXPIRED
41,GR,B,GR 21054 B,068-684-561-268-187,1960-07-14,1960,GR 600121054 A,1960-04-05,GR 600121054 A,1960-04-05,ΚΑΤΑΣΚΕΥΗ ΚΑΤΑΛΥΤΩΝ.,"ία μέθοδος παρασκευής καταλυτών εκ πυριτο-μολυβδαινικού βισμουθίου και/ή πυριτο-φωσφομολυβδαινικού βισμουθίου, προσηρμοσμένων να χρησιμοποιούνται ειςυποδοχείς αντιδράσεως νετ' εκνεφελωμένης κοίτης, ήτις μέθοδος περιλαμβάνει την παρασκευήν ενός απαιωρήματος των διαφόρων συστατικών του καταλύτου ομού μετά νιτρικού αμμωνίου, την υποβολήν του ρηθέντος απαιωρήματος, περιέχοντος νιτρικόν αμμώνιον, ειςξήρανσιν διά ψεκασμού συνεπεία του οποίου παράγονται τεμαχίδια σφαιρικού σχήματος έχοντα σχετικώς ομοιόμορφον μικρόν μέγεθος, και την υποβολήν των ρηθέντων τεμαχιδίων εις μίαν υψηλήν θερμοκρασίαν προς πύρωσιν του καταλύτου.",STANDARD OIL CO,CALLAHAN JAMES LOUIS,,https://lens.org/068-684-561-268-187,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
42,CA,A,CA 1056401 A,061-476-934-184-330,1979-06-12,1979,CA 238475 A,1975-10-28,US 52472974 A,1974-11-18,MANUFACTURE OF DINITRILES FROM THIODINITRILES,"MANUFACTURE OF DINITRILES FROM THIODINITRILES The invention is the extrusion of sulphur from thiodinitriles to obtain the corresponding dinitrile by heating the thiodinitrile at a temperature of 200.degree. to 700.degree.C. For example, sulfur is extruded from to thiodipropionitrile obtain adiponitrile. This extrusion reaction can be either a strictly thermal reaction employing no other reactant or a reaction conducted in the presence of other gases, liquids or solids.",STANDARD OIL CO OHIO,CALLAHAN JAMES L,,https://lens.org/061-476-934-184-330,Granted Patent,no,0,0,23,23,0,B01J23/72;;B01J23/76;;C07C253/30;;B01J23/72;;B01J23/76;;C07C253/30,B01J21/00;;C07B61/00;;B01J23/00;;B01J23/72;;B01J23/76;;B01J27/00;;C07C67/00;;C07C253/00;;C07C255/04;;C07C255/33,260-561.7,0,0,,,,EXPIRED
43,US,A,US 3459278 A,153-224-972-872-673,1969-08-05,1969,US 3459278D A,1967-09-27,US 67083367 A,1967-09-27,INDICATING MEANS FOR DIVISIONAL LUBRICANT FEEDER,,MCCORD CORP,CALLAHAN JAMES J,,https://lens.org/153-224-972-872-673,Granted Patent,no,5,12,1,1,0,F16N25/02;;F16N25/02,F16N25/02,184/7,0,0,,,,EXPIRED
44,AT,A,AT A876975 A,170-310-866-570-214,1977-05-15,1977,AT 876975 A,1975-11-18,US 52472974 A,1974-11-18,VERFAHREN ZUR HERSTELLUNG VON DINITRILEN AUS THIODINITRILEN,,STANDARD OIL CO OHIO,CALLAHAN JAMES LOUIS,,https://lens.org/170-310-866-570-214,Patent Application,no,0,0,23,23,0,B01J23/72;;B01J23/76;;C07C253/30;;B01J23/72;;B01J23/76;;C07C253/30,C07B61/00;;B01J21/00;;B01J23/00;;B01J23/72;;B01J23/76;;B01J27/00;;C07C67/00;;C07C253/00;;C07C255/04;;C07C255/33,"12E1,017/01",0,0,,,,EXPIRED
45,US,A,US 3459217 A,193-143-506-704-767,1969-08-05,1969,US 3459217D A,1966-03-21,US 53599466 A,1966-03-21,GARTER CHECK VALVE,,HOUDAILLE INDUSTRIES INC,CALLAHAN JAMES J,LUBRIQUIP - HOUDAILLE INC. A CORP OF DE (1985-01-31);;LUBRIQUIP-HOUDAILLE INC (1987-01-15),https://lens.org/193-143-506-704-767,Granted Patent,no,5,26,1,1,0,F01M1/08;;Y10T137/7839;;Y10T137/7855;;Y10T137/7856;;Y10T137/7861;;Y10T137/784;;F16K15/145;;Y10T137/7855;;Y10T137/7856;;Y10T137/7861;;F01M1/08;;F16K15/142;;F16K15/1401;;F16K15/1402,F01M1/08,137/516.15,0,0,,,,EXPIRED
46,US,A,US 3929859 A,099-802-619-964-53X,1975-12-30,1975,US 52472974 A,1974-11-18,US 52472974 A,1974-11-18,Manufacture of dinitriles from thiodinitriles,"The invention is the extrusion of sulfur from thiodinitriles to obtain the corresponding dinitrile by heating the thiodinitrile at a temperature of 200 DEG to 700 DEG C. For example, sulfur is extruded from thiodipropionitrile to obtain adiponitrile. This extrusion reaction can be either a strictly thermal reaction employing no other reactant or a reaction conducted in the presence of other gases, liquids or solids.",STANDARD OIL CO OHIO,CALLAHAN JAMES L,,https://lens.org/099-802-619-964-53X,Granted Patent,no,2,2,23,23,0,B01J23/72;;B01J23/76;;C07C253/30;;B01J23/72;;B01J23/76;;C07C253/30,B01J21/00;;B01J23/00;;B01J23/72;;B01J23/76;;B01J27/00;;C07B61/00;;C07C67/00;;C07C253/00;;C07C255/04;;C07C255/33,2604658 R,0,0,,,,EXPIRED
47,CA,A,CA 182640 A,112-833-678-456-712,1918-03-05,1918,CA 182640D A,1917-06-16,CA 182640T A,1917-06-16,FOOT ARCH SUPPORT,,CALLAHAN JAMES M,CALLAHAN JAMES M,,https://lens.org/112-833-678-456-712,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
48,NO,B,NO 142711 B,131-061-209-651-082,1980-06-23,1980,NO 753842 A,1975-11-17,US 52472974 A,1974-11-18,FREMGANGSMAATE VED FREMSTILLING AV DINITRILER FRA THIODINITRILER,,STANDARD OIL CO OHIO,CALLAHAN JAMES LOUIS,,https://lens.org/131-061-209-651-082,Unknown,no,0,0,23,23,0,B01J23/72;;B01J23/76;;C07C253/30;;B01J23/72;;B01J23/76;;C07C253/30,B01J21/00;;B01J23/00;;B01J23/72;;C07B61/00;;B01J23/76;;B01J27/00;;C07C67/00;;C07C253/00;;C07C255/04;;C07C255/33,,0,0,,,,EXPIRED
49,US,A,US 4309310 A,023-273-925-079-979,1982-01-05,1982,US 13557080 A,1980-03-31,US 13557080 A,1980-03-31,Catalytic composition for allylic oxidation of olefins,"Olefins, such as propylene, are allylically oxidized to corresponding unsaturated aldehydes and carboxylic acids, such as acrolein and acrylic acid, by contacting the olefin with molecular oxygen at allylic oxidation conditions in the presence of a trifluoroalkyl sulfonate or phosphonate catalyst, such as a catalyst formed by the reaction of vanadyl oxide and trifluoromethyl sulfonate.",STANDARD OIL CO,CALLAHAN JAMES L,,https://lens.org/023-273-925-079-979,Granted Patent,yes,9,8,1,1,0,B01J31/185;;B01J31/185;;B01J31/2256;;B01J31/2256;;B01J2531/0216;;B01J2531/0216;;B01J2531/56;;B01J2531/56;;B01J2531/64;;B01J2531/64;;B01J2540/225;;B01J2540/225;;C07C45/35;;C07C45/35;;C07C45/34;;C07C45/34;;C07C51/252;;C07C51/252,B01J31/12;;B01J31/18;;B01J31/22;;C07C45/34;;C07C45/35;;C07C51/25,252431P,2,0,,,"Chemical Abstracts 76 25379n, (1972).;;Chemical Abstracts 81 177827y, (1974).",EXPIRED
50,AT,B,AT 340891 B,056-292-339-446-298,1978-01-10,1978,AT 876975 A,1975-11-18,US 52472974 A,1974-11-18,VERFAHREN ZUR HERSTELLUNG VON DINITRILEN AUS THIODINITRILEN,,STANDARD OIL CO OHIO,CALLAHAN JAMES LOUIS,,https://lens.org/056-292-339-446-298,Granted Patent,no,0,0,23,23,0,B01J23/72;;B01J23/76;;C07C253/30;;B01J23/72;;B01J23/76;;C07C253/30,C07B61/00;;B01J21/00;;B01J23/00;;B01J23/72;;B01J23/76;;B01J27/00;;C07C67/00;;C07C253/00;;C07C255/04;;C07C255/33,"12E1,017/01",0,0,,,,EXPIRED
51,US,A,US 3038557 A,106-690-936-334-353,1962-06-12,1962,US 6103160 A,1960-10-06,US 6103160 A,1960-10-06,"Positive proportioning, open-line-indicating lubricating system",,TRABON ENGINEERING CORP,CALLAHAN JAMES J,,https://lens.org/106-690-936-334-353,Granted Patent,no,1,17,1,1,0,F16N27/00;;Y10T137/7731;;Y10T137/7731;;F16N27/00,F16N27/00,,0,0,,,,EXPIRED
52,HR,A2,HR P980006 A2,188-027-397-880-411,1998-10-31,1998,HR P980006 A,1998-01-07,US 3405997 P;;US 6588697 P,1997-01-08,ACETYLCHOLINESTERAZE INHIBITORS IN COMBINATION WITH MUSCARINIC AGONISTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE,,MICHAEL JAMES CALLAHAN,CALLAHAN MICHAEL JAMES,,https://lens.org/188-027-397-880-411,Patent Application,no,0,0,4,5,0,A61K45/06;;A61K31/00,A61K45/06,,0,0,,,,DISCONTINUED
53,FR,A1,FR 2372149 A1,030-992-491-761-392,1978-06-23,1978,FR 7735713 A,1977-11-28,US 74502476 A,1976-11-26,"DIMERISATION EN PHASE VAPEUR, ET A TEMPERATURE ELEVEE, D'ACRYLONITRILE","<P>Dimérisation en phase vapeur, à température élevée, d'acrylonitrile. </P><P>Cette dimérisation est obtenue en mettant en contact l'acrylonitrile en phase vapeur avec un catalyseur à base d'alumine activée contenant des ions sulfure inorganique. </P><P>Utilisable pour préparer les 1,4-dicyanobutènes et l'adiponitrile.</P>",STANDARD OIL CO,CALLAHAN JAMES LOUIS,,https://lens.org/030-992-491-761-392,Patent Application,no,0,3,13,13,0,B01J27/04;;B01J37/20;;C07C255/00;;Y02P20/52,C07B61/00;;B01J27/00;;B01J27/04;;B01J37/20;;C07C67/00;;C07C253/00;;C07C255/03;;C07C255/09,,0,0,,,,DISCONTINUED
54,NO,C,NO 142711 C,064-773-421-646-026,1980-10-01,1980,NO 753842 A,1975-11-17,US 52472974 A,1974-11-18,FREMGANGSMAATE VED FREMSTILLING AV DINITRILER FRA THIODINITRILER,,STANDARD OIL CO OHIO,CALLAHAN JAMES LOUIS,,https://lens.org/064-773-421-646-026,Granted Patent,no,0,0,23,23,0,B01J23/72;;B01J23/76;;C07C253/30;;B01J23/72;;B01J23/76;;C07C253/30,B01J21/00;;B01J23/00;;B01J23/72;;C07B61/00;;B01J23/76;;B01J27/00;;C07C67/00;;C07C253/00;;C07C255/04;;C07C255/33,,0,0,,,,EXPIRED
55,EP,A1,EP 0001179 A1,102-218-449-324-559,1979-03-21,1979,EP 78300358 A,1978-09-07,US 83226077 A,1977-09-12,A process for producing an organic compound by extrusion of sulfur from sulfur containing organic compounds.,"Sulfur is ""extruded"" from various autfur-containino organic compounds by heating the compounds at a temperature of 200-700°C. in the presence of a sulfur-acceptor.",STANDARD OIL CO OHIO,CALLAHAN JAMES LOUIS,,https://lens.org/102-218-449-324-559,Patent Application,yes,3,0,6,6,0,C07C1/322;;C07C37/00,C07C1/32;;C07C37/00;;C07C37/52,,1,0,,,"W. TEILHEIMER ""Synthetic Methods of Organic Chemistry"", vol.25, page 502, paragraph 691 (1971) S. Karger, Basel etc.",DISCONTINUED
56,CH,A,CH 416569 A,125-820-450-262-363,1966-07-15,1966,CH 418460 A,1960-04-13,US 80678159 A,1959-04-16,Procédé de préparation d'un catalyseur,,STANDARD OIL CO OHIO,JAMES LOUIS CALLAHAN,,https://lens.org/125-820-450-262-363,Granted Patent,no,0,0,7,7,0,B01J23/31;;B01J23/31;;B01J23/18;;B01J23/18;;B01J27/192;;B01J27/192,B01J23/18;;B01J23/31;;B01J27/192,"12G,11/06",0,0,,,,EXPIRED
57,CA,A,CA 629027 A,142-787-587-898-906,1961-10-10,1961,CA 629027D A,,CA 629027T A,,PROCESS FOR THE MANUFACTURE OF BISMUTH CATALYSTS,,STANDARD OIL CO,CALLAHAN JAMES L,,https://lens.org/142-787-587-898-906,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
58,US,A,US 1995415 A,156-891-134-486-333,1935-03-26,1935,US 56025731 A,1931-08-31,US 56025731 A,1931-08-31,Automobile side wing bracket,,CALLAHAN JAMES P,CALLAHAN JAMES P,,https://lens.org/156-891-134-486-333,Granted Patent,no,0,1,1,1,0,B60J1/14;;B60J1/14,B60J1/14,,0,0,,,,EXPIRED
59,US,A,US 2974110 A,183-486-943-098-55X,1961-03-07,1961,US 78381258 A,1958-12-30,US 78381258 A,1958-12-30,Manufacture of spheroidal catalysts,,STANDARD OIL CO,CALLAHAN JAMES L,,https://lens.org/183-486-943-098-55X,Granted Patent,no,2,3,1,1,0,B01J27/192;;B01J27/192;;B01J21/00;;B01J21/00;;B01J23/31;;B01J23/31,B01J21/00;;B01J23/31;;B01J27/192,,0,0,,,,EXPIRED
60,US,A,US 1940995 A,003-594-188-434-302,1933-12-26,1933,US 65892733 A,1933-02-28,US 65892733 A,1933-02-28,Side windshield attaching construction,,CALLAHAN JAMES P,CALLAHAN JAMES P,,https://lens.org/003-594-188-434-302,Granted Patent,no,0,0,1,1,0,B60J1/14;;B60J1/14,B60J1/14,,0,0,,,,EXPIRED
61,US,A,US 3445520 A,134-565-993-379-104,1969-05-20,1969,US 3445520D A,1965-09-30,US 50888065 A,1965-09-30,PROCESS OF OXIDATION OF OLEFINS TO UNSATURATED ALDEHYDES,,STANDARD OIL CO,CALLAHAN JAMES L,,https://lens.org/134-565-993-379-104,Granted Patent,no,1,1,1,1,0,B01J23/34;;B01J23/34;;C07C45/34;;C07C45/34;;C07C45/35;;C07C45/35,B01J23/34;;C07C45/34;;C07C45/35,260/604,0,0,,,,EXPIRED
62,WO,A1,WO 2001/002142 A1,019-163-334-314-648,2001-01-11,2001,US 0040306 W,2000-07-05,US 34843699 A,1999-07-07,TIRE CUTTING MACHINE AND METHOD,A tire cutting machine easily cuts tires with steel wire beads by bending and pulling the tire over an anvil so as to stress the bead wires prior to cutting.,NORTH AMERICAN TIRE RES AND RE,CALLAHAN JAMES W,,https://lens.org/019-163-334-314-648,Patent Application,yes,2,1,2,2,0,B26D3/005;;B26D7/14,B26D1/00;;B26D7/14,,0,0,,,,PENDING
63,US,A,US 1238493 A,058-647-264-575-847,1917-08-28,1917,US 11394816 A,1916-08-09,US 11394816 A,1916-08-09,ADJUSTABLE ARCH-SUPPORT FOR SHOES.,,CALLAHAN JAMES MARION,CALLAHAN JAMES MARION,,https://lens.org/058-647-264-575-847,Granted Patent,no,0,1,1,1,0,A43B7/142;;A43B7/142,,,0,0,,,,EXPIRED
64,DE,B,DE 1223358 B,082-119-049-612-618,1966-08-25,1966,DE ST021365 A,1963-11-27,US 1223358X A,1962-11-28,Verfahren zur Herstellung von Acrolein bzw. Methacrolein,,STANDARD OIL CO,CALLAHAN JAMES LOUIS,,https://lens.org/082-119-049-612-618,Patent Application,no,6,0,1,1,0,B01J8/30;;C07C45/35,B01J8/30;;C07C45/35,,0,0,,,,DISCONTINUED
65,US,A,US 4105094 A,099-295-659-899-564,1978-08-08,1978,US 75036976 A,1976-12-14,US 75036976 A,1976-12-14,Single line lubricant reversing feeder,"A single line lubricant reversing feeder for use in a centralized lubricating system, the feeder having a valving piston and a metering piston, by virtue of the movement of which a measured portion of the lubricant supplied to the feeder is delivered to a point of use such as a bearing, and the remaining portion is directed to the next succeeding feeder in the system. The feeder is arranged so that only a single check valve is required to accomplish the foregoing.",HOUDAILLE INDUSTRIES INC,CALLAHAN JAMES J,LUBRIQUIP - HOUDAILLE INC. A CORP OF DE (1985-01-31);;LUBRIQUIP INC (1987-01-15),https://lens.org/099-295-659-899-564,Granted Patent,yes,7,35,2,2,0,F16N25/02;;F16N25/02;;Y10T137/86413;;Y10T137/86413,F16N25/02,184  7F,0,0,,,,EXPIRED
66,CA,A,CA 844936 A,190-805-594-345-354,1970-06-23,1970,CA 844936D A,,CA 844936T A,,DIVISIONAL LUBRICANT FEEDER,,MCCORD CORP,CALLAHAN JAMES J,,https://lens.org/190-805-594-345-354,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
67,US,A,US 3461150 A,000-107-882-443-436,1969-08-12,1969,US 3461150D A,1965-01-11,US 43510765 A;;US 20132162 A;;US 25000863 A,1962-06-11,PROCESS FOR THE OXIDATION OF OLEFIN-AMMONIA MIXTURES TO UNSATURATED NITRILES,,STANDARD OIL CO,CALLAHAN JAMES L,,https://lens.org/000-107-882-443-436,Granted Patent,no,5,3,1,14,0,B01J23/8435;;B01J23/8435;;C07C253/26;;C07C253/26;;Y02P20/52;;Y02P20/52,B01J23/843,260/465.3,0,0,,,,EXPIRED
68,CH,A5,CH 613187 A5,010-825-956-508-298,1979-09-14,1979,CH 1459575 A,1975-11-11,US 52472974 A,1974-11-18,CH 613187 A5,,STANDARD OIL CO,CALLAHAN JAMES LOUIS,,https://lens.org/010-825-956-508-298,Granted Patent,no,0,0,23,23,0,B01J23/72;;B01J23/76;;C07C253/30;;B01J23/72;;B01J23/76;;C07C253/30,B01J21/00;;B01J23/00;;C07B61/00;;B01J23/72;;B01J23/76;;B01J27/00;;C07C67/00;;C07C253/00;;C07C255/04;;C07C255/33,,0,0,,,,EXPIRED
69,DE,A1,DE 1417731 A1,010-474-499-051-912,1969-05-22,1969,DE 1417731 A,1960-04-12,US 80678159 A,1959-04-16,Herstellung von Katalysatoren,,STANDARD OIL CO,LOUIS CALLAHAN JAMES,,https://lens.org/010-474-499-051-912,Patent Application,no,0,0,7,7,0,B01J23/31;;B01J23/31;;B01J23/18;;B01J23/18;;B01J27/192;;B01J27/192,B01J23/18;;B01J23/31;;B01J27/192,,0,0,,,,EXPIRED
70,US,A,US 1221833 A,020-036-837-185-108,1917-04-10,1917,US 1582415 A,1915-03-20,US 1582415 A,1915-03-20,ARCH-SUPPORT.,,CALLAHAN JAMES MARION,CALLAHAN JAMES MARION,,https://lens.org/020-036-837-185-108,Granted Patent,no,0,0,1,1,0,A43B7/22;;A43B7/22,,,0,0,,,,EXPIRED
71,US,A,US 1980976 A,043-940-355-986-367,1934-11-20,1934,US 62074332 A,1932-07-05,US 62074332 A,1932-07-05,Side windshield,,CALLAHAN JAMES P,CALLAHAN JAMES P,,https://lens.org/043-940-355-986-367,Granted Patent,no,0,0,1,1,0,B60J1/14;;B60J1/14,B60J1/14,,0,0,,,,EXPIRED
72,US,A,US 3468958 A,161-254-652-056-690,1969-09-23,1969,US 3468958D A,1965-09-30,US 50542465 A,1965-09-30,PROCESS FOR OXIDATION OF OLEFINS TO UNSATURATED ALDEHYDES AND ACIDS,,STANDARD OIL CO,CALLAHAN JAMES L,,https://lens.org/161-254-652-056-690,Granted Patent,no,1,3,1,1,0,C07C45/35;;C07C45/35;;C07C45/34;;C07C45/34;;C07C51/25;;C07C51/25;;C07C51/252;;C07C51/252,C07C45/34;;C07C45/35;;C07C51/25,260/604,0,0,,,,EXPIRED
73,US,A,US 1187255 A,162-524-717-894-382,1916-06-13,1916,US 4086815 A,1915-07-20,US 4086815 A,1915-07-20,ADJUSTABLE ARCH-SUPPORT FOR SHOES.,,CALLAHAN JAMES MARION,CALLAHAN JAMES MARION,,https://lens.org/162-524-717-894-382,Granted Patent,no,0,0,1,1,0,A43B7/22;;A43B7/22,,,0,0,,,,EXPIRED
74,US,A,US 1102570 A,179-761-721-434-967,1914-07-07,1914,US 1912/0714925 A,1912-08-13,US 1912/0714925 A,1912-08-13,CUSHION DEVICE.,,CALLAHAN JAMES J,CALLAHAN JAMES J,,https://lens.org/179-761-721-434-967,Granted Patent,no,0,4,1,1,0,A01K13/006;;A01K13/006,,,0,0,,,,EXPIRED
75,US,A,US 2051365 A,188-471-808-788-70X,1936-08-18,1936,US 2342735 A,1935-05-25,US 2342735 A,1935-05-25,Side wing construction,,CALLAHAN JAMES P,CALLAHAN JAMES P,,https://lens.org/188-471-808-788-70X,Granted Patent,no,0,1,1,1,0,B60J1/14;;B60J1/14,B60J1/14,,0,0,,,,EXPIRED
76,DE,A1,DE 2442846 A1,045-399-406-116-936,1975-03-13,1975,DE 2442846 A,1974-09-06,US 39662173 A,1973-09-12,RECHENVERSTAERKER,,TEXAS INSTRUMENTS INC,CALLAHAN JUN MICHAEL JAMES,,https://lens.org/045-399-406-116-936,Patent Application,no,0,3,4,4,0,H03F3/45085;;H03F3/3071;;H03F2203/45388;;H03F2203/45664;;H03F2203/45674;;H03F2203/45708,H03F3/30;;H03F3/45,,0,0,,,,DISCONTINUED
77,US,B2,US 8248747 B2,095-732-303-084-871,2012-08-21,2012,US 62772909 A,2009-11-30,US 62772909 A;;US 20397808 P,2008-12-31,Protection for bi-directional switch,"A bi-directional protection circuit employs a single comparator for detecting fault conditions. Diodes are coupled between a detection node and voltage dividers setting references for inverting and non-inverting comparator inputs, each diode forward biased during one of the positive and negative halves of the alternating current input signal cycle and coupling the detection node to a respective one of the inverting and non-inverting comparator inputs, and reverse biased during the other of the positive and negative halves and decoupling the detection node from the other of the inverting and non-inverting comparator inputs. Upon an overcurrent condition during the positive half, a voltage at the inverting comparator input is drawn above the reference voltage at the non-inverting input. Upon an overcurrent condition during the negative half, a voltage at the non-inverting comparator input is drawn below the reference voltage at the inverting input.",CALLAHAN JR MICHAEL JAMES;;ST MICROELECTRONICS INC,CALLAHAN JR MICHAEL JAMES,STMICROELECTRONICS INC (2010-01-05),https://lens.org/095-732-303-084-871,Granted Patent,yes,5,0,2,2,0,G01R19/16571;;G01R19/16571;;H03K17/0826;;H03K17/0826,H02H3/08;;H02H9/02,361/93.1,2,0,,,"Abstract for JP 2000002724 A. Jan. 7, 2000.;;Abstract for JP 2001165966 A. Jun. 22, 2001.",ACTIVE
78,AT,T1,AT E373648 T1,039-046-433-765-316,2007-10-15,2007,AT 03721638 T,2003-04-11,US 37194602 P,2002-04-11,NF-KAPPAB-INHIBITOREN,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES;;LI YUE,,https://lens.org/039-046-433-765-316,Granted Patent,no,0,0,16,16,0,C07D333/74;;C07D333/78;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/08;;A61P9/10;;A61P3/10;;C07D333/74;;C07D333/78,C07D333/50;;A61K31/381;;A61P1/00;;A61P3/10;;A61P9/00;;A61P9/08;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/02;;A61P43/00;;C07D333/74;;C07D333/78,,0,0,,,,EXPIRED
79,US,A1,US 2018/0172835 A1,106-923-027-989-365,2018-06-21,2018,US 201615738528 A,2016-06-22,AU 2015/902400 A;;AU 2016/050527 W,2015-06-22,SYSTEM AND METHOD FOR PROVIDING A USER WITH AN INDICATION OF POSITION,"A system for providing to a plurality of users in a group of users, participating in a community running race along a predetermined path, with an indication of respective positions of the users relative to one or more of the other users. System includes a database for containing location data for the users; a processing station for accessing the database and being responsive selectively to data for generating first signals that are transmitted from a plurality of base stations physically spaced apart along the path; a plurality of wearable devices worn by respective users, the devices including a receiver for receiving first signals, a processor for processing first signals to generate a second signal, and an interface that is responsive to the second signal for visually displaying to the respective user the indication of the position relative to one or more of the other users in the group.",ELITE POSITIONING TECH PTY LIMITED,KOOCHEW FERGUS;;CALLAHAN JAMES,,https://lens.org/106-923-027-989-365,Patent Application,yes,0,7,2,2,0,G01S19/51;;G01S5/0018;;G01S5/0072;;G01S5/0284;;G06Q10/0639;;G06Q30/02;;G07C1/22;;G01S19/19;;G01S19/51;;G01S5/0018;;G01S5/0284;;G07C1/22;;G01S5/0072;;G06Q30/02;;G06Q10/0639;;G01S19/19,G01S19/19;;G01S5/00;;G01S5/02;;G01S19/51;;G07C1/22,,0,0,,,,DISCONTINUED
80,US,A1,US 2010/0165527 A1,184-310-776-386-200,2010-07-01,2010,US 62772909 A,2009-11-30,US 62772909 A;;US 20397808 P,2008-12-31,PROTECTION FOR BI-DIRECTIONAL SWITCH,"A bi-directional protection circuit employs a single comparator for detecting fault conditions. Diodes are coupled between a detection node and voltage dividers setting references for inverting and non-inverting comparator inputs, each diode forward biased during one of the positive and negative halves of the alternating current input signal cycle and coupling the detection node to a respective one of the inverting and non-inverting comparator inputs, and reverse biased during the other of the positive and negative halves and decoupling the detection node from the other of the inverting and non-inverting comparator inputs. Upon an overcurrent condition during the positive half, a voltage at the inverting comparator input is drawn above the reference voltage at the non-inverting input. Upon an overcurrent condition during the negative half, a voltage at the non-inverting comparator input is drawn below the reference voltage at the inverting input.",ST MICROELECTRONICS INC,CALLAHAN JR MICHAEL JAMES,STMICROELECTRONICS INC (2010-01-05),https://lens.org/184-310-776-386-200,Patent Application,yes,5,5,2,2,0,G01R19/16571;;G01R19/16571;;H03K17/0826;;H03K17/0826,H02H3/00;;G01R31/08,361/79;;324/522,2,0,,,Abstract for JP 2000002724 A. 7 January 2000.;;Abstract for JP 2001165966 A. 22 June 2001.,ACTIVE
81,DE,A1,DE 2358471 A1,122-331-339-047-415,1974-05-30,1974,DE 2358471 A,1973-11-23,DE 2257574 A;;US 30931472 A,1972-11-24,STROMAUFHEBUNGSSCHALTUNG,,TEXAS INSTRUMENTS INC,CALLAHAN JUN MICHAEL JAMES,,https://lens.org/122-331-339-047-415,Patent Application,no,0,2,16,18,0,H03B2200/004;;H03B2200/0048;;H03B2200/0056;;H03B2201/0208;;H03F1/56;;H03F3/45071;;H03J5/244;;H03B5/1203;;H03B5/1231;;H03B5/1243;;H03J5/244;;H03B2200/0048;;H03B2201/0208;;H03F1/56;;H03B2200/0056;;H03B2200/004;;H03F3/45071;;H03B5/1203;;H03B5/1243;;H03B5/1231,H03F3/343;;H03B1/00;;H03B5/12;;H03F1/56;;H03F3/34;;H03F3/45;;H03J5/24;;H04B1/26,,0,0,,,,PENDING
82,WO,A1,WO 2016/205879 A1,027-087-453-945-045,2016-12-29,2016,AU 2016/050527 W,2016-06-22,AU 2015/902400 A,2015-06-22,A SYSTEM AND METHOD FOR PROVIDING A USER WITH AN INDICATION OF POSITION,"A system for providing to a plurality of users in a group of users, participating in a community running race along a predetermined path, with an indication of respective positions of the users relative to one or more of the other users. System includes a database for containing location data for the users; a processing station for accessing the database and being responsive selectively to data for generating first signals that are transmitted from a plurality of base stations physically spaced apart along the path; a plurality of wearable devices worn by respective users, the devices including a receiver for receiving first signals, a processor for processing first signals to generate a second signal, and an interface that is responsive to the second signal for visually displaying to the respective user the indication of the position relative to one or more of the other users in the group.",ELITE POSITIONING TECH PTY LTD,KOOCHEW FERGUS;;CALLAHAN JAMES,,https://lens.org/027-087-453-945-045,Patent Application,yes,5,3,2,2,0,G01S19/51;;G01S5/0018;;G01S5/0072;;G01S5/0284;;G06Q10/0639;;G06Q30/02;;G07C1/22;;G01S19/19;;G01S19/51;;G01S5/0018;;G01S5/0284;;G07C1/22;;G01S5/0072;;G06Q30/02;;G06Q10/0639;;G01S19/19,A63B71/06;;G01S19/19;;H04B1/38,,0,0,,,,PENDING
83,US,A,US 6043687 A,105-074-761-581-700,2000-03-28,2000,US 12435098 A,1998-07-29,US 12435098 A,1998-07-29,Integrated circuit precision resistor ratio matching,"A precision analog circuit ensures precision matching between two or more resistive elements. In order that the two or more resistive elements are truly matched, a first electrical value, such as V.sub.DS, of the two or more resistive elements are equal and a second electrical value, such as V.sub.GS, of the two or more resistive elements are equal so that a ratio of the first resistive element to the second resistive element is a predetermined value regardless of the voltage coefficients of the resistive elements.",ST MICROELECTRONICS INC,CALLAHAN JR MICHAEL JAMES,SGS-THOMSON MICROELECTRONICS INC (1998-07-23),https://lens.org/105-074-761-581-700,Granted Patent,yes,7,7,1,1,0,H01L21/761;;H01L27/0802;;H01L21/761;;H01L27/0802,H01L21/761;;H01L27/08,327/73;;327/72;;327/59;;327/538,0,0,,,,EXPIRED
84,DE,A1,DE 2336593 A1,179-618-338-391-931,1974-02-07,1974,DE 2336593 A,1973-07-18,US 27566472 A,1972-07-27,MAGNETFELDFUEHLER-HALBLEITERVORRICHTUNG,,TEXAS INSTRUMENTS INC,CALLAHAN JUN MICHAEL JAMES,,https://lens.org/179-618-338-391-931,Patent Application,no,0,1,4,4,0,G01R33/06;;H01L29/82,H01L43/00;;G01R33/06;;H01L27/22,,0,0,,,,DISCONTINUED
85,WO,A1,WO 1996/017833 A1,090-035-989-803-109,1996-06-13,1996,US 9515932 W,1995-12-07,US 35304594 A,1994-12-09,BICYCLIC FIBRINOGEN ANTAGONISTS,"This invention relates to compounds of formula (I) which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.",SMITHKLINE BEECHAM CORP;;CALLAHAN JAMES FRANCIS;;SAMANEN JAMES MARTIN,CALLAHAN JAMES FRANCIS;;SAMANEN JAMES MARTIN,,https://lens.org/090-035-989-803-109,Patent Application,yes,3,39,4,4,0,A61P7/02;;C07D223/16;;C07D243/14,A61K31/55;;A61K31/551;;A61P7/02;;C07D223/16;;C07D243/14;;C07D243/16;;C07D243/24,,2,0,,,"CHEMICAL ABSTRACTS, Volume 79, Number 11, issued 17 September 1973, GOGOLAK et al., ""Anticonvulsant Activity of Clonazepam and Ro 8-4192 Against Penicillin- and Lidocaine-Induced Seizures"", page 20, Abstract No. 61480; & ARZNEIM.-FORSCH., 23(4), pages 545-549.;;See also references of EP 0796252A4",PENDING
86,GB,A,GB 2382384 A,154-604-873-668-598,2003-05-28,2003,GB 0219547 A,2002-08-22,US 98206801 A,2001-10-17,A compressor having oil collection grooves,"A swash plate type compressor 10 has a cylinder block 12 defining a cylinder bore and a crank chamber 16; a housing member 24 attached to the cylinder block and defining a main aperture 38. The housing has an annular groove 46 disposed around the main aperture and a plurality of lubricating oil collection grooves 48 extending outward from the annular groove. Each oil collection groove is in fluid communication with the annular groove and has a first wall (52) that is substantially perpendicular to the plane of the housing member and a second wall (54) that is angled with respect to the first wall and the plane of the housing member. A bearing 40 is disposed in the main aperture and a shaft 18 is mounted on the bearing, a swashplate 20 is mounted on the shaft and shoes 44 intervene between the swashplate and a piston such that rotation of the shaft and swashplate translates to linear motion of the piston.",VISTEON GLOBAL TECH INC,CALLAHAN RODNEY JAMES;;MANGIAPANE RONALD JAMES,,https://lens.org/154-604-873-668-598,Patent Application,no,5,0,6,6,0,F04B27/109;;F04B27/109,F04B27/10,F1W WDJ           WDJ;;F1W W500          WDJ,0,0,,,,EXPIRED
87,EP,A4,EP 0796252 A4,164-501-059-961-395,1998-02-04,1998,EP 95942590 A,1995-12-07,US 9515932 W;;US 35304594 A,1994-12-09,BICYCLIC FIBRINOGEN ANTAGONISTS,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;SAMANEN JAMES MARTIN,,https://lens.org/164-501-059-961-395,Search Report,no,7,0,4,4,0,A61P7/02;;C07D223/16;;C07D243/14,A61K31/55;;A61K31/551;;A61P7/02;;C07D223/16;;C07D243/14;;C07D243/16;;C07D243/24,,2,1,067-496-829-769-667,2261014;;10.1021/jm00167a033,"M. REIFFEN ET AL.: ""Specific bradycardic agents. 1. Chemistry, pharmacology, and structure-activity relationships of substituted benzazepinones, a new class of compounds exerting antiischemic properties"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, no. 5, May 1990 (1990-05-01), WASHINGTON DC, US, pages 1496 - 1504, XP002047919;;See also references of WO 9617833A1",DISCONTINUED
88,EP,A1,EP 0796252 A1,170-499-874-027-504,1997-09-24,1997,EP 95942590 A,1995-12-07,US 9515932 W;;US 35304594 A,1994-12-09,BICYCLIC FIBRINOGEN ANTAGONISTS,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;SAMANEN JAMES MARTIN,,https://lens.org/170-499-874-027-504,Patent Application,yes,0,0,4,4,0,A61P7/02;;C07D223/16;;C07D243/14,A61K31/55;;A61K31/551;;A61P7/02;;C07D223/16;;C07D243/14;;C07D243/16;;C07D243/24,,0,0,,,,DISCONTINUED
89,US,B1,US 6523455 B1,011-257-272-531-829,2003-02-25,2003,US 98206801 A,2001-10-17,US 98206801 A,2001-10-17,Compressor having an oil collection groove,"
    A swashplate-type compressor is provided. The compressor has a housing member that defines a plurality of grooves having features that allow the grooves to direct lubricating oil splashed against the housing member toward a central opening that houses a bearing and shaft. Preferably, the grooves comprise an annular groove and a series of oil collection grooves emanating outward from the annular groove. Each oil collection groove has a first wall that is substantially perpendicular to the plane of the housing member and a second wall that is angled with respect to both the first wall and the plane of the housing member. Also, each oil collection groove is in fluid communication with the annular groove. The housing member may further define one or more axial holes disposed within the annular groove. 
",VISTEON GLOBAL TECH INC,CALLAHAN RODNEY JAMES;;MANGIAPANE RONALD JAMES,VISTEON GLOBAL TECHNOLOGIES INC (2001-10-15);;HANON SYSTEMS (2013-07-26),https://lens.org/011-257-272-531-829,Granted Patent,yes,11,6,6,6,0,F04B27/109;;F04B27/109,F04B27/10,92/71;;92/153,0,0,,,,EXPIRED
90,DE,A1,DE 10248069 A1,095-277-998-288-78X,2003-05-15,2003,DE 10248069 A,2002-10-10,US 98206801 A,2001-10-17,Verdichter mit einer Ölsammelnut,"Zur Verfügung gestellt wird ein Taumelscheibenverdichter. Er besitzt ein Gehäusebauteil, das eine Vielzahl von derart ausgelegten Nuten definiert, dass sie gegen das Gehäusebauteil spritzendes Schmieröl zu einer zentralen Öffnung leiten, in der ein Lager und eine Welle angeordnet sind. Vorzugsweise umfassen die Nuten eine Ringnut und eine Reihe von Ölsammelnuten, die von der Ringnut nach außen verlaufen. Jede Ölsammelnut hat eine erste Wand, die im Wesentlichen senkrecht zur Gehäusebauteilebene angeordnet ist, und eine zweite Wand, die in Bezug auf die erste Wand und die Gehäusebauteilebene winklig angeordnet ist. Außerdem steht jede Ölsammelnut in Strömungsverbindung mit der Ringnut. Das Gehäusebauteil kann ferner ein oder mehrere innerhalb der Ringnut angeordnete axiale Durchgangslöcher definieren.",VISTEON GLOBAL TECH INC,CALLAHAN RODNEY JAMES;;MANGIAPANE RONALD JAMES,"HANON SYSTEMS, KR (2016-10-06);;HALLA VISTEON CLIMATE CONTROL CORPORATION, KR (2013-09-10)",https://lens.org/095-277-998-288-78X,Patent Application,no,0,1,6,6,0,F04B27/109;;F04B27/109,F04B27/10,,0,0,,,,EXPIRED
91,DE,B4,DE 10248069 B4,053-119-576-709-081,2005-06-02,2005,DE 10248069 A,2002-10-10,US 98206801 A,2001-10-17,Verdichter mit einer Ölsammelnut,,VISTEON GLOBAL TECH INC,CALLAHAN RODNEY JAMES;;MANGIAPANE RONALD JAMES,"HANON SYSTEMS, KR (2016-10-06);;HALLA VISTEON CLIMATE CONTROL CORPORATION, KR (2013-09-10)",https://lens.org/053-119-576-709-081,Granted Patent,no,1,0,6,6,0,F04B27/109;;F04B27/109,F04B27/10,,0,0,,,,EXPIRED
92,GB,B,GB 2382384 B,050-256-737-027-762,2003-12-24,2003,GB 0219547 A,2002-08-22,US 98206801 A,2001-10-17,Compressor having an oil collection groove,,VISTEON GLOBAL TECH INC,CALLAHAN RODNEY JAMES;;MANGIAPANE RONALD JAMES,,https://lens.org/050-256-737-027-762,Granted Patent,no,5,0,6,6,0,F04B27/109;;F04B27/109,F04B27/10,F1W WDJ           WDJ;;F1W W500          WDJ,0,0,,,,EXPIRED
93,US,A,US 4574920 A,005-712-214-706-330,1986-03-11,1986,US 63698984 A,1984-08-02,US 63698984 A,1984-08-02,Hydropneumatic monitoring device,"A hydropneumatic monitoring device in which a hydraulic fluid passageway is controlled by a piston and plunger spring biased in one direction and shiftable by air pressure in opposition to the bias for aligning a passageway-connecting bypass in the plunger with the passageway which is intersected by the plunger. Air pressure metered through the piston passes to an air passage. Air pressure failure or blockage in the air passage cause deviation of the piston and plunger from a state of open passageway equilibrium, for blocking the passageway.",LUBRIQUIP HOUDAILLE INC,CALLAHAN JAMES J;;HAMMELL JAMES M,LUBRIQUIP - HOUDAILLE INC. A CORP OF DE (1985-01-31);;HOUDAILLE INDUSTRIES INC. A CORP. OF DE (1984-07-24);;LUBRIQUIP INC (1987-01-15),https://lens.org/005-712-214-706-330,Granted Patent,yes,16,5,1,1,0,F16N29/00;;F16N29/00;;F16N7/32;;F16N7/32,F16N7/32;;F16N29/00,184/39.1;;239/412,0,0,,,,EXPIRED
94,CA,A1,CA 2606823 A1,004-652-621-502-927,2006-11-09,2006,CA 2606823 A,2006-05-03,US 67755205 P;;US 70952805 P;;US 72647305 P;;US 35218406 A;;US 2006/0017172 W,2005-05-04,DIRECT ELECTRIC RESISTANCE LIQUID HEATER,,CALLAHAN JEREMIAH M;;BARZYK JAMES,CALLAHAN JEREMIAH M;;BARZYK JAMES,,https://lens.org/004-652-621-502-927,Patent Application,no,0,0,19,44,0,F24H1/106;;H05B3/60;;H05B2203/021;;F24H1/10;;F24H1/20;;H05B7/144;;F24H1/106;;H05B2203/021;;H05B3/60,H05B7/144,,0,0,,,,ACTIVE
95,GB,A,GB 2514932 A,152-968-058-773-070,2014-12-10,2014,GB 201411698 A,2012-12-12,GB 201121401 A;;GB 2012053111 W,2011-12-13,Device for inducing nucleation,"Described is a device for inducing crystal nucleation in a crystalliser. The device comprises a vessel for fluid and a surface abrader, wherein the surface abrader is configured to abrade a surface within the vessel to induce crystal nucleation. The friction of the abrader against the surface within the vessel creates nano-sized particulates which induce crystal nucleation. Crystal growth can then take place in the crystalliser. Also described is a crystallisation apparatus comprising the device and a crystallisation process using the device or similar. The device is significantly cheaper and more reliable than known ultrasound devices and facilitates the separation of crystal nucleation and crystal growth. The device also enables the avoidance of the use of seeding as a source of secondary nucleation.",UNIV HERIOT WATT,NI XIONGWEI;;CALLAHAN CRAIG JAMES,,https://lens.org/152-968-058-773-070,Patent Application,no,5,0,8,8,0,B01D9/0013;;B01D9/0036;;B01J19/0013;;B01J19/006;;B01J19/1812;;B01J19/185;;B01J19/242;;B01J19/243;;B01J2219/00094;;B01J2219/00159;;B01J2219/00765;;B01J2219/1943;;B01D9/0059;;B01D9/00;;B01J19/00;;B01J19/18;;B01J19/24;;F28F1/40;;B01D9/0013;;B01D9/0036;;B01J19/0013;;B01J19/006;;B01J19/1812;;B01J19/185;;B01J19/242;;B01J19/243;;B01J2219/00094;;B01J2219/00159;;B01J2219/00765;;B01J2219/1943;;B01D9/0059;;B01D9/005;;B01D2009/0086,B01J19/24;;B01D9/00;;B01J19/00;;B01J19/18;;F28F1/40,,0,0,,,,INACTIVE
96,US,A,US 3200081 A,166-889-000-299-153,1965-08-10,1965,US 23068462 A,1962-10-15,US 23068462 A,1962-10-15,Mixed antimony oxide-manganese oxide oxidation catalyst,,STANDARD OIL CO,CALLAHAN JAMES L;;BERTHOLD GERTISSER,,https://lens.org/166-889-000-299-153,Granted Patent,no,11,14,1,2,0,B01J23/18;;B01J23/18;;B01J23/34;;B01J23/34;;C07C253/26;;C07C253/26;;Y02P20/52;;Y02P20/52;;Y10S585/906;;Y10S585/906,B01J23/18;;B01J23/34,,0,0,,,,EXPIRED
97,DE,A1,DE 1468716 A1,049-162-786-629-150,1969-01-16,1969,DE 1468716 A,1963-06-07,US 20132162 A;;US 25000863 A,1962-06-11,Verfahren zur Herstellung von Methacrylnitril,,STANDARD OIL CO,LOUIS CALLAHAN JAMES;;GERTISSER BERTHOLD,,https://lens.org/049-162-786-629-150,Patent Application,no,0,0,11,14,0,B01J23/8435;;B01J23/8435;;C07C45/34;;C07C45/34;;C07C45/35;;C07C45/35;;C07C51/252;;C07C51/252;;C07C253/26;;C07C253/26;;Y02P20/52;;Y02P20/52;;Y10S585/906;;Y10S585/906,B01J23/84;;B01J23/843;;C07C45/34;;C07C45/35;;C07C51/25,,0,0,,,,EXPIRED
98,GB,B,GB 2514932 B,130-063-994-221-397,2018-03-28,2018,GB 201411698 A,2012-12-12,GB 201121401 A;;GB 2012053111 W,2011-12-13,Device for inducing nucleation,,UNIV HERIOT WATT,XIONGWEI NI;;CRAIG JAMES CALLAHAN,,https://lens.org/130-063-994-221-397,Granted Patent,no,5,0,8,8,0,B01D9/0013;;B01D9/0036;;B01J19/0013;;B01J19/006;;B01J19/1812;;B01J19/185;;B01J19/242;;B01J19/243;;B01J2219/00094;;B01J2219/00159;;B01J2219/00765;;B01J2219/1943;;B01D9/0059;;B01D9/00;;B01J19/00;;B01J19/18;;B01J19/24;;F28F1/40;;B01D9/0013;;B01D9/0036;;B01J19/0013;;B01J19/006;;B01J19/1812;;B01J19/185;;B01J19/242;;B01J19/243;;B01J2219/00094;;B01J2219/00159;;B01J2219/00765;;B01J2219/1943;;B01D9/0059;;B01D9/005;;B01D2009/0086,B01J19/24;;B01D9/00;;B01J19/00;;B01J19/18;;F28F1/40,,0,0,,,,INACTIVE
99,EP,A4,EP 1532135 A4,156-074-248-000-653,2005-11-09,2005,EP 03731435 A,2003-05-29,US 0316876 W;;US 38655702 P,2002-06-06,NF-KB INHIBITORS,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-beta phosphorylation of IkappaB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-kappaB in which diseases excessive activation of NF-kappaB is implicated.,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;WAN ZEHONG,,https://lens.org/156-074-248-000-653,Search Report,no,2,0,12,12,0,C07D333/68;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D333/68,A61K31/381;;A61P1/04;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;C07D333/68,,2,2,040-106-587-827-898;;113-143-408-158-975,9046348;;10.1021/jm950866t;;10.1002/cber.19681010607,"MODICA M ET AL: ""ÚÚ(ARYLPIPERAZINYL)ALKYLTHIOTHIENOLÚ2,3-DPYRIMIDINONE DERIVATIVES AS HIGH-AFFINITY, SELECTIVE 5-HT1A RECEPTOR LIGANDS"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 40, no. 4, 1997, pages 574 - 585, XP000652305, ISSN: 0022-2623;;GEWALD K ET AL: ""2-AMINO-THIONAPHTHENE"", CHEMISCHE BERICHTE, vol. 101, 1968, pages 1933 - 1939, XP001007224, ISSN: 0009-2940",EXPIRED
100,US,B2,US 9682332 B2,007-153-208-143-185,2017-06-20,2017,US 201214364628 A,2012-12-12,GB 201121401 A;;GB 2012053111 W,2011-12-13,Device for inducing nucleation,"Described is a device for inducing crystal nucleation in a crystallizer. The device comprises a vessel for fluid and a surface abrader, wherein the surface abrader is configured to abrade a surface within the vessel to induce crystal nucleation. The friction of the abrader against the surface within the vessel creates nano-sized particulates which induce crystal nucleation. Crystal growth can then take place in the crystallizer. Also described is a crystallization apparatus comprising the device and a crystallization process using the device or similar. The device is significantly cheaper and more reliable than known ultrasound devices and facilitates the separation of crystal nucleation and crystal growth. The device also enables the avoidance of the use of seeding as a source of secondary nucleation.",UNIV HERIOT WATT,NI XIONGWEI;;CALLAHAN CRAIG JAMES,HERIOT WATT UNIVERSITY (2014-07-01),https://lens.org/007-153-208-143-185,Granted Patent,yes,12,0,8,8,0,B01D9/0013;;B01D9/0036;;B01J19/0013;;B01J19/006;;B01J19/1812;;B01J19/185;;B01J19/242;;B01J19/243;;B01J2219/00094;;B01J2219/00159;;B01J2219/00765;;B01J2219/1943;;B01D9/0059;;B01D9/00;;B01J19/00;;B01J19/18;;B01J19/24;;F28F1/40;;B01D9/0013;;B01D9/0036;;B01J19/0013;;B01J19/006;;B01J19/1812;;B01J19/185;;B01J19/242;;B01J19/243;;B01J2219/00094;;B01J2219/00159;;B01J2219/00765;;B01J2219/1943;;B01D9/0059;;B01D9/005;;B01D2009/0086,B01J19/02;;B01D9/00;;B01J19/00;;B01J19/18;;B01J19/24,,1,0,,,International Search Report and Written Opinion of related PCT/GB2012/053111.,INACTIVE
101,US,A1,US 2006/0058371 A1,139-865-430-702-146,2006-03-16,2006,US 51711104 A,2004-12-03,US 51711104 A;;US 38655702 P;;US 0316876 W,2002-06-06,Nf-kb inhibitors,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-β phosphorylation of IκB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-κB in which diseases excessive activation of NF-κB is implicated.,CALLAHAN JAMES F;;WAN ZEHONG,CALLAHAN JAMES F;;WAN ZEHONG,SMITHKLINE BEECHAM CORPORATION (2003-06-19),https://lens.org/139-865-430-702-146,Patent Application,yes,2,2,12,12,0,C07D333/68;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D333/68,A61K31/381;;A61P1/04;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;C07D327/08;;C07D333/68,514/443;;549/16,0,0,,,,EXPIRED
102,EP,A1,EP 2790824 A1,153-011-377-467-172,2014-10-22,2014,EP 12823248 A,2012-12-12,GB 201121401 A;;GB 2012053111 W,2011-12-13,DEVICE FOR INDUCING NUCLEATION,,UNIV HERIOT WATT,NI XIONGWEI;;CALLAHAN CRAIG JAMES,,https://lens.org/153-011-377-467-172,Patent Application,yes,0,0,8,8,0,B01D9/0013;;B01D9/0036;;B01J19/0013;;B01J19/006;;B01J19/1812;;B01J19/185;;B01J19/242;;B01J19/243;;B01J2219/00094;;B01J2219/00159;;B01J2219/00765;;B01J2219/1943;;B01D9/0059;;B01D9/00;;B01J19/00;;B01J19/18;;B01J19/24;;F28F1/40;;B01D9/0013;;B01D9/0036;;B01J19/0013;;B01J19/006;;B01J19/1812;;B01J19/185;;B01J19/242;;B01J19/243;;B01J2219/00094;;B01J2219/00159;;B01J2219/00765;;B01J2219/1943;;B01D9/0059;;B01D9/005;;B01D2009/0086,B01J19/00;;B01D9/00;;B01J19/18;;B01J19/24;;F28F1/40,,0,0,,,,DISCONTINUED
103,AU,A1,AU 2003/240935 A1,144-568-546-441-160,2003-12-22,2003,AU 2003/240935 A,2003-05-29,US 38655702 P;;US 0316876 W,2002-06-06,NF-KB INHIBITORS,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-beta phosphorylation of IkappaB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-kappaB in which diseases excessive activation of NF-kappaB is implicated.,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;WAN ZEHONG,,https://lens.org/144-568-546-441-160,Patent Application,no,0,0,12,12,0,C07D333/68;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D333/68,A61K31/381;;A61P1/04;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;C07D333/68,,0,0,,,,DISCONTINUED
104,AT,T1,AT E383769 T1,011-876-523-692-444,2008-02-15,2008,AT 99930345 T,1999-06-18,US 8982798 P,1998-06-19,INHIBITOREN DES TRANSKRIPTIONSFAKTORS NF-KAPPA B,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES;;CHABOT-FLETCHER MARIE,,https://lens.org/011-876-523-692-444,Granted Patent,no,0,0,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A61P1/00;;A61K31/167;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,,0,0,,,,EXPIRED
105,KR,A,KR 20080017018 A,021-307-756-045-291,2008-02-25,2008,KR 20077028191 A,2006-05-03,US 35218406 A;;US 67755205 P;;US 70952805 P;;US 72647305 P;;US 2006/0017172 W,2005-05-04,DIRECT ELECTRIC RESISTANCE LIQUID HEATER,"The Direct Electric Resistance Liquid Heater comprises a liquid heating chamber containing a plurality of electrodes. The electrodes are spaced apart to create a plurality of channels through which the liquid to be heated passes. The electrodes are each connected to a power supply by one or more switches. A controller controls the switches based upon data received from a temperature sensor, sensing the temperature of the liquid, and/or an electric current sensor, sensing the current utilized by the liquid heater. Selection of the number and spacing of the electrodes, and the number of switches, provides the controller with various current levels options to apply to the liquid to be heated. The current levels available due to the number and spacing of the electrodes and the number of switches, span the range from minimum current to maximum current such that the controller can incrementally increase or decrease the current applied to the liquid to be heated without disrupting other users of the same power source.",CALLAHAN JEREMIAH M;;BARZYK JAMES,CALLAHAN JEREMIAH M;;BARZYK JAMES,,https://lens.org/021-307-756-045-291,Patent Application,no,0,1,19,44,0,F24H1/106;;H05B3/60;;H05B2203/021;;F24H1/10;;F24H1/20;;H05B7/144;;F24H1/106;;H05B2203/021;;H05B3/60,F24H1/20;;F24H1/10;;H05B7/144,,0,0,,,,ACTIVE
106,AU,A1,AU 2014/398594 A1,022-193-710-234-082,2017-01-19,2017,AU 2014/398594 A,2014-09-23,US 201414311836 A;;US 2014/0056896 W,2014-06-23,Content distribution platform for beverage dispensing environments,"A system configured to manage the distribution of content to one or more cooperating media/substrates in beverage dispensing environments, wherein the system receives data representative of environment conditions for one or more cooperating media/substrates adapted to display digital content, where the media/substrates may be located in beverage environments (e.g., bar/restaurants, hotels, or event venues), and where the system compares the received data representative of environment conditions regarding the purchase of a beverage with selection criteria to identify content for distribution to the media/substrates such that the selected content is distributed to the one or more cooperating media/substrates.",TAPP TECHNOLOGIES LLC,ROBINSON JAMES;;CALLAHAN JOSEPH M,,https://lens.org/022-193-710-234-082,Patent Application,no,0,0,16,29,0,G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/009;;G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/023,G06Q30/02,,0,0,,,,ACTIVE
107,DE,B,DE 1265731 B,027-999-691-592-291,1968-04-11,1968,DE ST023957 A,1963-06-07,US 20132162 A;;US 25000863 A,1962-06-11,Verfahren zur Herstellung ungesaettigter Aldehyde durch katalytische Oxydation von Olefinen,,STANDARD OIL CO,CALLAHAN JAMES LOUIS;;GERTISSER BERTHOLD,,https://lens.org/027-999-691-592-291,Patent Application,no,1,0,11,14,0,B01J23/8435;;B01J23/8435;;C07C45/34;;C07C45/34;;C07C45/35;;C07C45/35;;C07C51/252;;C07C51/252;;C07C253/26;;C07C253/26;;Y02P20/52;;Y02P20/52;;Y10S585/906;;Y10S585/906,B01J23/84;;B01J23/843;;C07C45/34;;C07C45/35;;C07C51/25,,0,0,,,,DISCONTINUED
108,MX,A,MX 2016016636 A,047-225-649-446-377,2017-10-04,2017,MX 2016016636 A,2014-09-23,US 201414311836 A;;US 2014/0056896 W,2014-06-23,CONTENT DISTRIBUTION PLATFORM FOR BEVERAGE DISPENSING ENVIRONMENTS.,"A system configured to manage the distribution of content to one or more cooperating media/substrates in beverage dispensing environments, wherein the system receives data representative of environment conditions for one or more cooperating media/substrates adapted to display digital content, where the media/substrates may be located in beverage environments (e.g., bar/restaurants, hotels, or event venues), and where the system compares the received data representative of environment conditions regarding the purchase of a beverage with selection criteria to identify content for distribution to the media/substrates such that the selected content is distributed to the one or more cooperating media/substrates.",TAPP TECH LLC,JAMES ROBINSON;;JOSEPH M CALLAHAN,,https://lens.org/047-225-649-446-377,Patent Application,no,0,0,16,29,0,G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/009;;G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/023,G06Q30/02,,0,0,,,,PENDING
109,US,A,US 3308151 A,051-441-589-742-561,1967-03-07,1967,US 46246065 A,1965-01-11,US 46246065 A,1965-01-11,Process for the oxidation of olefinammonia mixtures to unsaturated nitriles,,STANDARD OIL CO,CALLAHAN JAMES L;;BERTHOLD GERTISSER,,https://lens.org/051-441-589-742-561,Granted Patent,no,4,16,1,2,0,B01J23/18;;C07C45/35;;G06G7/163;;Y10S585/906;;G06G7/163;;B01J23/18;;C07C45/35;;Y10S585/906,B01J23/18;;C07C45/35;;G06G7/163,,0,0,,,,EXPIRED
110,CN,A,CN 106471532 A,060-132-719-283-867,2017-03-01,2017,CN 201480080112 A,2014-09-23,US 201414311836 A;;US 2014/0056896 W,2014-06-23,Content distribution platform for beverage dispensing environments,"A system configured to manage the distribution of content to one or more cooperating media/substrates in beverage dispensing environments, wherein the system receives data representative of environment conditions for one or more cooperating media/substrates adapted to display digital content, where the media/substrates may be located in beverage environments (e.g., bar/restaurants, hotels, or event venues), and where the system compares the received data representative of environment conditions regarding the purchase of a beverage with selection criteria to identify content for distribution to the media/substrates such that the selected content is distributed to the one or more cooperating media/substrates.",TAPP TECH LLC,ROBINSON JAMES;;CALLAHAN JOSEPH M,,https://lens.org/060-132-719-283-867,Patent Application,no,4,2,16,29,0,G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/009;;G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/023,G06Q30/02,,0,0,,,,DISCONTINUED
111,AT,T1,AT E358673 T1,077-717-783-970-38X,2007-04-15,2007,AT 03731435 T,2003-05-29,US 38655702 P,2002-06-06,NF-KB-INHIBITOREN,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-beta phosphorylation of IkappaB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-kappaB in which diseases excessive activation of NF-kappaB is implicated.,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;WAN ZEHONG,,https://lens.org/077-717-783-970-38X,Granted Patent,no,0,0,12,12,0,C07D333/68;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D333/68,A61K31/381;;A61P1/04;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;C07D333/68,,0,0,,,,EXPIRED
112,US,A1,US 2014/0372505 A1,091-097-623-485-951,2014-12-18,2014,US 201414311836 A,2014-06-23,US 201414311836 A;;US 201213659155 A;;US 20120508 A,2008-08-29,CONTENT DISTRIBUTION PLATFORM FOR BEVERAGE DISPENSING ENVIRONMENTS,"A system configured to manage the distribution of content to one or more cooperating media/substrates in beverage dispensing environments, wherein the system receives data representative of environment conditions for one or more cooperating media/substrates adapted to display digital content, where the media/substrates may be located in beverage environments (e.g., bar/restaurants, hotels, or event venues), and where the system compares the received data representative of environment conditions regarding the purchase of a beverage with selection criteria to identify content for distribution to the media/substrates such that the selected content is distributed to the one or more cooperating media/substrates.",TAPP TECHNOLOGIES LLC,ROBINSON JAMES;;CALLAHAN JOSEPH M,TAPP TECHNOLOGIES LLC (2014-07-01),https://lens.org/091-097-623-485-951,Patent Application,yes,9,12,2,29,0,G06Q30/02;;G06Q30/0268;;G06Q30/0252;;G07F13/00;;G06Q30/0268;;G06Q30/0252;;H04L67/10;;G06Q30/02;;H04L67/51,H04L29/08;;G06Q30/02;;G07F13/00,709/202,0,0,,,,ACTIVE
113,US,A,US 3276910 A,191-657-485-567-534,1966-10-04,1966,US 14468161 A,1961-10-12,US 14468161 A,1961-10-12,Ion transfer medium for electrochemical reaction apparatus,,STANDARD OIL CO,ROBERT GRASSELLI;;CALLAHAN JAMES L,,https://lens.org/191-657-485-567-534,Granted Patent,no,2,41,1,1,0,H01M8/08;;H01M8/08;;Y02E60/50,H01M8/08,,0,0,,,,EXPIRED
114,US,A,US 3198750 A,027-039-424-800-22X,1965-08-03,1965,US 24733162 A,1962-12-26,US 24733162 A,1962-12-26,Mixed antimony oxide-uranium oxide oxidation catalyst,,STANDARD OIL CO,CALLAHAN JAMES L;;BERTHOLD GERTISSER,,https://lens.org/027-039-424-800-22X,Granted Patent,no,10,44,1,23,0,B01J23/12;;B01J23/16;;B01J23/18;;C07C5/48;;C07C45/34;;C07C45/35;;C07C51/252;;Y10S585/906;;C07C45/35;;C07C45/34;;C07C5/48;;B01J23/12;;B01J23/16;;C07C51/252;;B01J23/18;;Y10S585/906,B01J23/12;;B01J23/16;;B01J23/18;;C07C5/48;;C07C45/34;;C07C45/35;;C07C51/25,,0,0,,,,EXPIRED
115,CA,C,CA 2950894 C,149-351-233-214-113,2019-03-19,2019,CA 2950894 A,2014-09-23,US 201414311836 A;;US 2014/0056896 W,2014-06-23,CONTENT DISTRIBUTION PLATFORM FOR BEVERAGE DISPENSING ENVIRONMENTS,"A system configured to manage the distribution of content to one or more cooperating media/substrates in beverage dispensing environments, wherein the system receives data representative of environment conditions for one or more cooperating media/substrates adapted to display digital content, where the media/substrates may be located in beverage environments (e.g., bar/restaurants, hotels, or event venues), and where the system compares the received data representative of environment conditions regarding the purchase of a beverage with selection criteria to identify content for distribution to the media/substrates such that the selected content is distributed to the one or more cooperating media/substrates.",TAPP TECH LLC,ROBINSON JAMES;;CALLAHAN JOSEPH M,,https://lens.org/149-351-233-214-113,Granted Patent,no,0,0,16,29,0,G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/009;;G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/023,G07F9/02;;G06Q30/02;;G07F17/16,,0,0,,,,ACTIVE
116,US,A,US 3282982 A,149-250-625-052-931,1966-11-01,1966,US 44065365 A,1965-01-11,US 44065365 A;;US 23068462 A,1962-10-15,Process for the oxidation of olefinammonia mixtures to unsaturated nitriles,,STANDARD OIL CO,CALLAHAN JAMES L;;BERTHOLD GERTISSER,,https://lens.org/149-250-625-052-931,Granted Patent,no,4,6,1,2,0,B01J23/18;;B01J23/18;;B01J23/34;;B01J23/34;;C07C253/26;;C07C253/26;;C07C45/35;;C07C45/35;;Y02P20/52;;Y02P20/52,B01J23/18;;B01J23/34;;C07C45/35,,0,0,,,,EXPIRED
117,US,A1,US 2014/0328731 A1,197-957-967-325-557,2014-11-06,2014,US 201214364628 A,2012-12-12,GB 201121401 A;;GB 2012053111 W,2011-12-13,DEVICE FOR INDUCING NUCLEATION,"Described is a device for inducing crystal nucleation in a crystalliser. The device comprises a vessel for fluid and a surface abrader, wherein the surface abrader is configured to abrade a surface within the vessel to induce crystal nucleation. The friction of the abrader against the surface within the vessel creates nano-sized particulates which induce crystal nucleation. Crystal growth can then take place in the crystalliser. Also described is a crystallisation apparatus comprising the device and a crystallisation process using the device or similar. The device is significantly cheaper and more reliable than known ultrasound devices and facilitates the separation of crystal nucleation and crystal growth. The device also enables the avoidance of the use of seeding as a source of secondary nucleation.",UNIV HERIOT WATT,NI XIONGWEI;;CALLAHAN CRAIG JAMES,HERIOT WATT UNIVERSITY (2014-07-01),https://lens.org/197-957-967-325-557,Patent Application,yes,7,2,8,8,0,B01D9/0013;;B01D9/0036;;B01J19/0013;;B01J19/006;;B01J19/1812;;B01J19/185;;B01J19/242;;B01J19/243;;B01J2219/00094;;B01J2219/00159;;B01J2219/00765;;B01J2219/1943;;B01D9/0059;;B01D9/00;;B01J19/00;;B01J19/18;;B01J19/24;;F28F1/40;;B01D9/0013;;B01D9/0036;;B01J19/0013;;B01J19/006;;B01J19/1812;;B01J19/185;;B01J19/242;;B01J19/243;;B01J2219/00094;;B01J2219/00159;;B01J2219/00765;;B01J2219/1943;;B01D9/0059;;B01D9/005;;B01D2009/0086,B01D9/00,422/254,0,0,,,,INACTIVE
118,ZA,B,ZA 201607971 B,006-711-425-990-10X,2018-05-30,2018,ZA 201607971 A,2016-11-17,US 201414311836 A;;US 2014/0056896 W,2014-06-23,CONTENT DISTRIBUTION PLATFORM FOR BEVERAGE DISPENSING ENVIRONMENTS,,TAPP TECH LLC,JAMES ROBINSON;;JOSEPH M CALLAHAN,,https://lens.org/006-711-425-990-10X,Granted Patent,no,0,0,16,29,0,G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/009;;G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/023,,,0,0,,,,ACTIVE
119,AU,B2,AU 2014/398594 B2,012-366-775-116-490,2018-03-22,2018,AU 2014/398594 A,2014-09-23,US 201414311836 A;;US 2014/0056896 W,2014-06-23,Content distribution platform for beverage dispensing environments,"A system configured to manage the distribution of content to one or more cooperating media/substrates in beverage dispensing environments, wherein the system receives data representative of environment conditions for one or more cooperating media/substrates adapted to display digital content, where the media/substrates may be located in beverage environments (e.g., bar/restaurants, hotels, or event venues), and where the system compares the received data representative of environment conditions regarding the purchase of a beverage with selection criteria to identify content for distribution to the media/substrates such that the selected content is distributed to the one or more cooperating media/substrates.",TAPP TECHNOLOGIES LLC,ROBINSON JAMES;;CALLAHAN JOSEPH M,,https://lens.org/012-366-775-116-490,Granted Patent,no,1,0,16,29,0,G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/009;;G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/023,G06Q30/02,,0,0,,,,ACTIVE
120,US,A,US 3428674 A,059-330-279-498-005,1969-02-18,1969,US 3428674D A,1965-09-30,US 50522165 A;;US 46246065 A,1965-01-11,PROCESS OF OXIDATION OF OLEFINS TO UNSATURATED ALDEHYDES AND ACIDS,,STANDARD OIL CO,CALLAHAN JAMES L;;GERTISSER BERTHOLD,,https://lens.org/059-330-279-498-005,Granted Patent,no,2,3,1,2,0,B01J23/18;;B01J23/18;;C07C253/26;;C07C253/26;;C07C45/35;;C07C45/35;;C07C51/252;;C07C51/252;;Y02P20/52;;Y02P20/52,B01J23/18;;C07C45/35;;C07C51/25,260/533,0,0,,,,EXPIRED
121,CA,A1,CA 2950894 A1,154-905-811-432-124,2015-12-30,2015,CA 2950894 A,2014-09-23,US 201414311836 A;;US 2014/0056896 W,2014-06-23,CONTENT DISTRIBUTION PLATFORM FOR BEVERAGE DISPENSING ENVIRONMENTS,"A system configured to manage the distribution of content to one or more cooperating media/substrates in beverage dispensing environments, wherein the system receives data representative of environment conditions for one or more cooperating media/substrates adapted to display digital content, where the media/substrates may be located in beverage environments (e.g., bar/restaurants, hotels, or event venues), and where the system compares the received data representative of environment conditions regarding the purchase of a beverage with selection criteria to identify content for distribution to the media/substrates such that the selected content is distributed to the one or more cooperating media/substrates.",TAPP TECH LLC,ROBINSON JAMES;;CALLAHAN JOSEPH M,,https://lens.org/154-905-811-432-124,Patent Application,no,0,0,16,29,0,G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/009;;G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/023,G06Q30/02,,0,0,,,,ACTIVE
122,US,A,US 3200084 A,046-463-661-931-292,1965-08-10,1965,US 23071762 A,1962-10-15,US 23071762 A,1962-10-15,Mixed antimony oxide-cerium oxide oxidation catalysts,,STANDARD OIL CO,CALLAHAN JAMES L;;BERTHOLD GERTISSER,,https://lens.org/046-463-661-931-292,Granted Patent,no,10,11,1,1,0,B01J23/18;;B01J23/18;;C07C253/26;;C07C253/26;;Y02P20/52;;Y02P20/52;;Y10S585/906;;Y10S585/906,B01J23/18;;C01G30/02,,0,0,,,,EXPIRED
123,US,B2,US 7300952 B2,186-847-027-338-079,2007-11-27,2007,US 51711104 A,2004-12-03,US 51711104 A;;US 38655702 P;;US 0316876 W,2002-06-06,NF-kappab inhibitors,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-β phosphorylation of IκB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-κB in which diseases excessive activation of NF-κB is implicated.,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;WAN ZEHONG,SMITHKLINE BEECHAM CORPORATION (2003-06-19),https://lens.org/186-847-027-338-079,Granted Patent,yes,4,0,12,12,0,C07D333/68;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D333/68,A61K31/381;;A61P1/04;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;C07D333/52;;C07D333/68,514/447;;549/29;;549/41;;549/49;;549/57;;514/438;;514/443,2,2,040-106-587-827-898;;113-143-408-158-975,9046348;;10.1021/jm950866t;;10.1002/cber.19681010607,"Modica et al., ""[[(Arylpiperazinyl)alkyl]thio]thieno[2,3-d]pyrimidinone Derivatives as High Affinity, Selective 5-HT<SUB>1A </SUB>Receptor Ligands"". J. Med. Chem., 40: 574-585 (1997).;;Gewald et al., ""2-Amino-thionaphthene"". Chemische Berichte, 101: 1933-1939 (1968).",INACTIVE
124,ES,T3,ES 2285125 T3,047-152-407-211-853,2007-11-16,2007,ES 03731435 T,2003-05-29,US 38655702 P,2002-06-06,INHIBIDORES DE NF-KB.,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-beta phosphorylation of IkappaB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-kappaB in which diseases excessive activation of NF-kappaB is implicated.,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;WAN ZEHONG,,https://lens.org/047-152-407-211-853,Granted Patent,no,0,0,12,12,0,C07D333/68;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D333/68,C07D333/52;;A61K31/381;;A61P1/04;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;C07D333/68,,0,0,,,,EXPIRED
125,US,B2,US 9253264 B2,105-974-914-015-333,2016-02-02,2016,US 201414311836 A,2014-06-23,US 201414311836 A;;US 201213659155 A;;US 20120508 A,2008-08-29,Content distribution platform for beverage dispensing environments,"A system configured to manage the distribution of content to one or more cooperating media/substrates in beverage dispensing environments, wherein the system receives data representative of environment conditions for one or more cooperating media/substrates adapted to display digital content, where the media/substrates may be located in beverage environments (e.g., bar/restaurants, hotels, or event venues), and where the system compares the received data representative of environment conditions regarding the purchase of a beverage with selection criteria to identify content for distribution to the media/substrates such that the selected content is distributed to the one or more cooperating media/substrates.",TAPP TECHNOLOGIES LLC,ROBINSON JAMES;;CALLAHAN JOSEPH M,TAPP TECHNOLOGIES LLC (2014-07-01),https://lens.org/105-974-914-015-333,Granted Patent,yes,12,3,2,29,0,G06Q30/02;;G06Q30/0268;;G06Q30/0252;;G07F13/00;;G06Q30/0268;;G06Q30/0252;;H04L67/10;;G06Q30/02;;H04L67/51,H04N7/10;;G06Q30/02;;G07F13/00;;H04L29/08,,0,0,,,,ACTIVE
126,WO,A1,WO 2003/104219 A1,157-410-497-409-608,2003-12-18,2003,US 0316876 W,2003-05-29,US 38655702 P,2002-06-06,NF-KB INHIBITORS,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-β phosphorylation of IλB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-λB in which diseases excessive activation of NF-λB is implicated.,SMITHKLINE BEECHAM CORP;;CALLAHAN JAMES F;;WAN ZEHONG,CALLAHAN JAMES F;;WAN ZEHONG,,https://lens.org/157-410-497-409-608,Patent Application,yes,2,0,12,12,0,C07D333/68;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D333/68,A61K31/381;;A61P1/04;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;C07D333/68,,0,0,,,,PATENTED
127,AU,B2,AU 2006/243758 B2,181-918-424-158-008,2011-04-28,2011,AU 2006/243758 A,2006-05-03,US 70952805 P;;US 35218406 A;;US 67755205 P;;US 72647305 P;;US 2006/0017172 W,2005-05-04,Direct Electric Resistance Liquid Heater,,ISI TECHNOLOGY LLC,CALLAHAN JEREMIAH M;;BARZYK JAMES,"ISI TECHNOLOGY, LLC (2008-10-23);;HEATWORKS TECHNOLOGIES, INC. (2017-01-19)",https://lens.org/181-918-424-158-008,Granted Patent,no,0,0,19,44,0,F24H1/106;;H05B3/60;;H05B2203/021;;F24H1/10;;F24H1/20;;H05B7/144;;F24H1/106;;H05B2203/021;;H05B3/60,F24H1/10,,1,0,,,See reference of WO 2006/119440,ACTIVE
128,CN,A,CN 110056420 A,091-541-559-754-069,2019-07-26,2019,CN 201910039577 A,2019-01-16,US 201815874288 A,2018-01-18,VEHICLE FRAME WITH ACOUSTIC VOLUME FOR AN EXHAUST SYSTEM,The invention relates to a vehicle exhaust system which includes a first component that receives exhaust gas output from an engine and a second component that is fluidly coupled to the first componentto define an upstream portion of a vehicle exhaust system. A vehicle frame member includes an internal acoustic volume. A pipe connects the internal acoustic volume in parallel to the upstream portion of the vehicle exhaust system.,FAURECIA EMISSIONS CONTROL TECHNOLOGIES USA LLC,EGAN JAMES;;CALLAHAN JOSEPH E,,https://lens.org/091-541-559-754-069,Patent Application,no,7,0,4,4,0,F01N13/00;;F01N1/023;;B60K13/04;;B62D21/17;;F01N1/023;;F01N2340/04;;F01N3/08;;F01N3/103;;F01N3/021;;Y02A50/20;;B62D21/17;;F01N1/003;;F01N1/02;;F01N13/001;;F01N2340/04,F01N13/00;;B60K13/04;;F01N1/02,,0,0,,,,DISCONTINUED
129,CA,A,CA 706421 A,107-127-045-141-594,1965-03-23,1965,CA 706421D A,,US 20127962 A;;US 20132962 A;;US 24733162 A,1962-06-11,OXIDATION CATALYST AND PROCESS OF OXIDATION OF OLEFINS THEREWITH,,STANDARD OIL CO,GERTISSER BERTHOLD;;CALLAHAN JAMES L,,https://lens.org/107-127-045-141-594,Granted Patent,no,0,0,18,23,0,B01J23/12;;B01J23/16;;B01J23/18;;C07C45/35;;C07C5/48;;C07C45/34;;C07C51/252,B01J23/12;;B01J23/16;;B01J23/18;;C07C5/48;;C07C45/34;;C07C45/35;;C07C51/25,,0,0,,,,EXPIRED
130,EP,B1,EP 1532135 B1,115-541-173-964-767,2007-04-04,2007,EP 03731435 A,2003-05-29,US 0316876 W;;US 38655702 P,2002-06-06,NF-KB INHIBITORS,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-beta phosphorylation of IkappaB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-kappaB in which diseases excessive activation of NF-kappaB is implicated.,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;WAN ZEHONG,,https://lens.org/115-541-173-964-767,Granted Patent,yes,4,0,12,12,0,C07D333/68;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D333/68,C07D333/52;;A61K31/381;;A61P1/04;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;C07D333/68,,2,0,,,"MODICA M ET AL: ""  (ARYLPIPERAZINYL)ALKYLTHIOTHIENOL 2,3-D PYRIMIDINONE DERIVATIVES AS HIGH-AFFINITY, SELECTIVE 5-HT1A RECEPTOR LIGANDS"" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 40, no. 4, 1997, pages 574-585, XP000652305 ISSN: 0022-2623;;GEWALD K ET AL: ""2-AMINO-THIONAPHTHENE"" CHEMISCHE BERICHTE, vol. 101, 1968, pages 1933-1939, XP001007224 ISSN: 0009-2940",EXPIRED
131,CA,A,CA 740928 A,157-151-949-168-101,1966-08-16,1966,CA 740928D A,,CA 740928T A,,CATALYST AND PROCESS OF OXIDATION OF OLEFINS,,STANDARD OIL CO,GERTISSER BERTHOLD;;CALLAHAN JAMES L,,https://lens.org/157-151-949-168-101,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
132,AU,A1,AU 2006/243758 A1,177-111-382-486-721,2006-11-09,2006,AU 2006/243758 A,2006-05-03,US 70952805 P;;US 35218406 A;;US 67755205 P;;US 72647305 P;;US 2006/0017172 W,2005-05-04,Direct Electric Resistance Liquid Heater,,CALLAHAN JEREMIAH;;BARZYK JAMES,CALLAHAN JEREMIAH M;;BARZYK JAMES,"ISI TECHNOLOGY, LLC (2008-10-23);;HEATWORKS TECHNOLOGIES, INC. (2017-01-19)",https://lens.org/177-111-382-486-721,Patent Application,no,0,0,19,44,0,F24H1/106;;H05B3/60;;H05B2203/021;;F24H1/10;;F24H1/20;;H05B7/144;;F24H1/106;;H05B2203/021;;H05B3/60,H05B7/144,,0,0,,,,ACTIVE
133,DE,D1,DE 60312997 D1,195-202-673-558-621,2007-05-16,2007,DE 60312997 T,2003-05-29,US 38655702 P;;US 0316876 W,2002-06-06,NF-KB-INHIBITOREN,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-beta phosphorylation of IkappaB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-kappaB in which diseases excessive activation of NF-kappaB is implicated.,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;WAN ZEHONG,,https://lens.org/195-202-673-558-621,Granted Patent,no,0,0,12,12,0,C07D333/68;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D333/68,C07D333/52;;A61K31/381;;A61P1/04;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;C07D333/68,,0,0,,,,EXPIRED
134,EP,A4,EP 3158522 A4,011-642-188-416-458,2017-12-06,2017,EP 14896061 A,2014-09-23,US 201414311836 A;;US 2014/0056896 W,2014-06-23,CONTENT DISTRIBUTION PLATFORM FOR BEVERAGE DISPENSING ENVIRONMENTS,,TAPP TECH LLC,ROBINSON JAMES;;CALLAHAN JOSEPH M,,https://lens.org/011-642-188-416-458,Search Report,no,5,0,16,29,0,G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/009;;G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/023,G07F9/02;;G06Q30/02,,1,0,,,See also references of WO 2015199746A1,DISCONTINUED
135,CN,A,CN 114175079 A,028-439-157-549-286,2022-03-11,2022,CN 202080053314 A,2020-07-22,US 201916520191 A;;US 2020/0043001 W,2019-07-23,Systems and methods for biometric protocol standards,"Secure communications are provided between a user computing device and a server computing device. A registration request is received from a user computing device configured via a distributed client software application and processed. The enrollment request may be used to enrollment the user computing device in a network and include an encrypted partial initial biometric vector associated with a user. A subsequently received authentication request is processed, the authentication request including an encrypted portion of the second biometric vector and associated with a user of the user computing device. A comparison of the encrypted portion initial biometric vector to the encrypted portion second biometric vector is performed, and a value representative of the comparison is generated and transmitted to the user computing device. If the value is above a minimum threshold, the user computing device is authenticated.",WELTIG INTELLECTUAL PROPERTY LTD COMPANY,CALLAHAN JAMES R;;OSMAN AKHTAR,,https://lens.org/028-439-157-549-286,Patent Application,no,0,0,10,57,0,G06F21/32;;G06F21/645;;H04L63/0861;;H04L9/085;;H04L9/0861;;H04L9/3239;;H04L9/3231;;H04L9/0825;;H04L9/3247;;H04L9/14;;G06Q20/3829;;G06Q20/3827;;G06Q20/4014;;G06Q20/40145;;G06Q20/065;;H04L9/50;;G06F21/32;;G06F21/645;;H04L9/0825;;H04L9/085;;H04L9/0861;;H04L9/14;;H04L9/3231;;H04L9/3239;;H04L9/3247;;H04L63/0861;;H04L9/50,G06Q20/38;;G06F21/32;;G06F21/64;;G06Q20/06;;G06Q20/40;;H04L9/08;;H04L9/14;;H04L9/32;;H04L9/40,,0,0,,,,PENDING
136,BR,A2,BR 112016030442 A2,034-976-707-536-027,2018-07-17,2018,BR 112016030442 A,2014-09-23,US 2014/0056896 W;;US 201414311836 A,2014-06-23,plataforma de distribuição de conteúdos para ambientes de dispensação de bebida,,TAPP TECH LLC,JAMES ROBINSON;;JOSEPH M CALLAHAN,,https://lens.org/034-976-707-536-027,Patent Application,no,0,0,16,29,0,G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/009;;G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/023,G06Q30/02,,0,0,,,,DISCONTINUED
137,US,A,US 2235419 A,085-728-044-450-915,1941-03-18,1941,US 19658238 A,1938-03-18,US 19658238 A,1938-03-18,Fracture nail and director,,CALLAHAN JAMES J;;CARLO SEUDERI,CALLAHAN JAMES J;;CARLO SEUDERI,,https://lens.org/085-728-044-450-915,Granted Patent,no,0,109,1,1,0,A61B17/1604;;A61B17/3403;;A61B17/72;;A61B17/7283;;A61B17/742;;A61B2017/320052;;A61B17/742;;A61B2017/320052;;A61B17/72;;A61B17/1604;;A61B17/3403;;A61B17/7283,A61B17/16;;A61B17/32;;A61B17/34;;A61B17/72;;A61B17/74,,0,0,,,,EXPIRED
138,US,B2,US 10941693 B2,090-483-072-547-966,2021-03-09,2021,US 201815874288 A,2018-01-18,US 201815874288 A,2018-01-18,Vehicle frame with acoustic volume for an exhaust system,A vehicle exhaust system includes a first component that receives exhaust gas output from an engine and a second component that is fluidly coupled to the first component to define an upstream portion of a vehicle exhaust system. A vehicle frame member includes an internal acoustic volume. A pipe connects the internal acoustic volume in parallel to the upstream portion of the vehicle exhaust system.,FAURECIA EMISSIONS CONTROL TECHNOLOGIES USA LLC,EGAN JAMES;;CALLAHAN JOSEPH E,FAURECIA EMISSIONS CONTROL TECHNOLOGIES USA LLC (2018-01-17),https://lens.org/090-483-072-547-966,Granted Patent,yes,33,0,4,4,0,B62D21/17;;B60K13/04;;B62D21/17;;F01N13/001;;F01N1/003;;F01N1/02;;F01N1/023;;F01N1/023;;F01N3/021;;F01N3/08;;F01N3/103;;F01N13/00;;F01N2340/04;;F01N2340/04;;Y02A50/20,F01N13/00;;B62D21/17;;F01N1/00;;F01N1/02,,0,0,,,,ACTIVE
139,WO,A2,WO 2006/119440 A2,122-916-260-862-074,2006-11-09,2006,US 2006/0017172 W,2006-05-03,US 67755205 P;;US 70952805 P;;US 72647305 P;;US 35218406 A,2005-05-04,DIRECT ELECTRIC RESISTANCE LIQUID HEATER,"The Direct Electric Resistance Liquid Heater comprises a liquid heating chamber containing a plurality of electrodes The electrodes are spaced apart to create a plurality of channels through which the liquid to be heated passes The electrodes are each connected to a power supply by one or more switches A controller controls the switches based upon data received from a temperature sensor sensing the temperature of the liquid and/or an electric current sensor sensing the current utilized by the liquid heater Selection of the number and spacing of the electrodes, and the number of switches provides the controller with various current levels options to apply to the liquid to be heated The current levels available span the range from minimum current to maximum current such that the controller can incrementally Increase or decrease the current applied to the liquid without disrupting other users of the same power source",CALLAHAN JEREMIAH M;;BARZYK JAMES,CALLAHAN JEREMIAH M;;BARZYK JAMES,,https://lens.org/122-916-260-862-074,Patent Application,yes,2,8,19,44,0,F24H1/106;;H05B3/60;;H05B2203/021;;F24H1/10;;F24H1/20;;H05B7/144;;F24H1/106;;H05B2203/021;;H05B3/60,H05B7/144,,1,0,,,See also references of EP 1878315A4,PENDING
140,WO,A1,WO 2015/199746 A1,174-581-375-498-828,2015-12-30,2015,US 2014/0056896 W,2014-09-23,US 201414311836 A,2014-06-23,CONTENT DISTRIBUTION PLATFORM FOR BEVERAGE DISPENSING ENVIRONMENTS,"A system configured to manage the distribution of content to one or more cooperating media/substrates in beverage dispensing environments, wherein the system receives data representative of environment conditions for one or more cooperating media/substrates adapted to display digital content, where the media/substrates may be located in beverage environments (e.g., bar/restaurants, hotels, or event venues), and where the system compares the received data representative of environment conditions regarding the purchase of a beverage with selection criteria to identify content for distribution to the media/substrates such that the selected content is distributed to the one or more cooperating media/substrates.",TAPP TECHNOLOGIES LLC,ROBINSON JAMES;;CALLAHAN JOSEPH M,,https://lens.org/174-581-375-498-828,Patent Application,yes,3,1,16,29,0,G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/009;;G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/023,G06Q30/02,,1,0,,,See also references of EP 3158522A4,PENDING
141,EP,A1,EP 1532135 A1,083-552-053-834-137,2005-05-25,2005,EP 03731435 A,2003-05-29,US 0316876 W;;US 38655702 P,2002-06-06,NF-KB INHIBITORS,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-beta phosphorylation of IkappaB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-kappaB in which diseases excessive activation of NF-kappaB is implicated.,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;WAN ZEHONG,,https://lens.org/083-552-053-834-137,Patent Application,yes,0,0,12,12,0,C07D333/68;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D333/68,A61K31/381;;A61P1/04;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;C07D333/68,,0,0,,,,EXPIRED
142,WO,A3,WO 2006/119440 A3,091-523-271-381-276,2007-11-29,2007,US 2006/0017172 W,2006-05-03,US 67755205 P;;US 70952805 P;;US 72647305 P;;US 35218406 A,2005-05-04,DIRECT ELECTRIC RESISTANCE LIQUID HEATER,"The Direct Electric Resistance Liquid Heater comprises a liquid heating chamber containing a plurality of electrodes The electrodes are spaced apart to create a plurality of channels through which the liquid to be heated passes The electrodes are each connected to a power supply by one or more switches A controller controls the switches based upon data received from a temperature sensor sensing the temperature of the liquid and/or an electric current sensor sensing the current utilized by the liquid heater Selection of the number and spacing of the electrodes, and the number of switches provides the controller with various current levels options to apply to the liquid to be heated The current levels available span the range from minimum current to maximum current such that the controller can incrementally Increase or decrease the current applied to the liquid without disrupting other users of the same power source",CALLAHAN JEREMIAH M;;BARZYK JAMES,CALLAHAN JEREMIAH M;;BARZYK JAMES,,https://lens.org/091-523-271-381-276,Search Report,yes,4,0,19,44,0,F24H1/106;;H05B3/60;;H05B2203/021;;F24H1/10;;F24H1/20;;H05B7/144;;F24H1/106;;H05B2203/021;;H05B3/60,F24H1/10,,0,0,,,,PENDING
143,DE,D1,DE 3063982 D1,136-601-307-871-608,1983-08-04,1983,DE 3063982 T,1980-09-15,US 7611579 A,1979-09-17,PROCESS FOR THE PRODUCTION OF A SUPPORTED SOLID OXIDE COMPLEX CATALYST AND USE THEREOF,,STANDARD OIL CO OHIO,PAPERIZOS CHRISTOS;;CALLAHAN JAMES LOUIS,,https://lens.org/136-601-307-871-608,Granted Patent,no,0,0,12,13,0,B01J23/28;;C07C45/35;;B01J23/28;;C07C45/35,C07C27/14;;B01J21/08;;B01J23/28;;B01J23/31;;B01J27/057;;B01J37/04;;C07B33/00;;C07B61/00;;C07C27/00;;C07C45/35;;C07C47/22;;C07C67/00,,0,0,,,,EXPIRED
144,EP,A1,EP 3158522 A1,136-869-835-924-379,2017-04-26,2017,EP 14896061 A,2014-09-23,US 201414311836 A;;US 2014/0056896 W,2014-06-23,CONTENT DISTRIBUTION PLATFORM FOR BEVERAGE DISPENSING ENVIRONMENTS,,TAPP TECH LLC,ROBINSON JAMES;;CALLAHAN JOSEPH M,,https://lens.org/136-869-835-924-379,Patent Application,yes,0,0,16,29,0,G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/009;;G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/023,G06Q30/02,,0,0,,,,DISCONTINUED
145,WO,A1,WO 2013/088145 A1,136-914-364-864-663,2013-06-20,2013,GB 2012053111 W,2012-12-12,GB 201121401 A,2011-12-13,DEVICE FOR INDUCING NUCLEATION,"Described is a device for inducing crystal nucleation in a crystalliser. The device comprises a vessel for fluid and a surface abrader, wherein the surface abrader is configured to abrade a surface within the vessel to induce crystal nucleation. The friction of the abrader against the surface within the vessel creates nano-sized particulates which induce crystal nucleation. Crystal growth can then take place in the crystalliser. Also described is a crystallisation apparatus comprising the device and a crystallisation process using the device or similar. The device is significantly cheaper and more reliable than known ultrasound devices and facilitates the separation of crystal nucleation and crystal growth. The device also enables the avoidance of the use of seeding as a source of secondary nucleation.",UNIV HERIOT WATT;;NI XIONGWEI;;CALLAHAN CRAIG JAMES,NI XIONGWEI;;CALLAHAN CRAIG JAMES,,https://lens.org/136-914-364-864-663,Patent Application,yes,6,0,8,8,0,B01D9/0013;;B01D9/0036;;B01J19/0013;;B01J19/006;;B01J19/1812;;B01J19/185;;B01J19/242;;B01J19/243;;B01J2219/00094;;B01J2219/00159;;B01J2219/00765;;B01J2219/1943;;B01D9/0059;;B01D9/00;;B01J19/00;;B01J19/18;;B01J19/24;;F28F1/40;;B01D9/0013;;B01D9/0036;;B01J19/0013;;B01J19/006;;B01J19/1812;;B01J19/185;;B01J19/242;;B01J19/243;;B01J2219/00094;;B01J2219/00159;;B01J2219/00765;;B01J2219/1943;;B01D9/0059;;B01D9/005;;B01D2009/0086,B01J19/00;;B01D9/00;;B01J19/18;;B01J19/24;;F28F1/40,,3,2,088-468-616-047-576;;049-364-455-206-263,10.1016/0022-0248(72)90287-4;;10.1016/0022-0248(72)90320-x,"DENK, E.G.; BOTSARIS G.D.: ""Fundamental studies in secondary nucleation from solution"", J. CRYST. GROWTH, vol. 13/14, 1972, pages 493 - 499, XP024732571;;DENK, E.G.; BOTSARIS G.D.: ""Mechanism of contact nucleation"", J. CRYST. GROWTH, vol. 15, 1972, pages 57 - 60, XP024627405, DOI: doi:10.1016/0022-0248(72)90320-X;;BAIRD, M.H.I.; STONESTREET P.: ""Energy dissipation in oscillatory flow within a baffled tube"", CHEMICAL ENGINEERING RESEARCH AND DESIGN, vol. 73, no. 5, 1995, pages 503 - 511",PENDING
146,DE,A1,DE 102018132787 A1,142-124-778-042-767,2019-07-18,2019,DE 102018132787 A,2018-12-19,US 201815874288 A,2018-01-18,Fahrzeugrahmen mit akustischem Volumen für eine Abgasanlage,"Eine Fahrzeugabgasanlage weist eine erste Komponente, die von einem Motor abgegebenes Abgas aufnimmt, und eine zweite Komponente auf, die strömungsmäßig so mit der ersten Komponente gekoppelt ist, dass ein stromaufwärtiger Abschnitt einer Fahrzeugabgasanlage gebildet ist. Ein Fahrzeugrahmenelement weist ein inneres akustisches Volumen auf. Über ein Rohr ist das innere akustische Volumen parallel mit dem stromaufwärtigen Abschnitt der Fahrzeugabgasanlage verbunden.",FAURECIA EMISSIONS CONTROL TECHNOLOGIES USA LLC,EGAN JAMES;;CALLAHAN JOSEPH E,,https://lens.org/142-124-778-042-767,Patent Application,no,0,0,4,4,0,B62D21/17;;B60K13/04;;B62D21/17;;F01N13/001;;F01N1/003;;F01N1/02;;F01N1/023;;F01N1/023;;F01N3/021;;F01N3/08;;F01N3/103;;F01N13/00;;F01N2340/04;;F01N2340/04;;Y02A50/20,F01N1/06;;F01N1/02;;F01N13/00,,0,0,,,,DISCONTINUED
147,DE,T2,DE 60312997 T2,067-789-121-329-198,2007-12-13,2007,DE 60312997 T,2003-05-29,US 38655702 P;;US 0316876 W,2002-06-06,NF-KB-INHIBITOREN,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-beta phosphorylation of IkappaB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-kappaB in which diseases excessive activation of NF-kappaB is implicated.,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;WAN ZEHONG,,https://lens.org/067-789-121-329-198,Granted Patent,no,0,0,12,12,0,C07D333/68;;A61P1/04;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;A61P9/00;;A61P9/10;;A61P3/10;;C07D333/68,C07D333/52;;A61K31/381;;A61P1/04;;A61P3/10;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/04;;A61P43/00;;C07D333/68,,0,0,,,,EXPIRED
148,RU,C2,RU 2674925 C2,127-228-545-231-703,2018-12-13,2018,RU 2016146579 A,2014-09-23,US 201414311836 A;;US 2014/0056896 W,2014-06-23,CONTENT DISTRIBUTION PLATFORM FOR BEVERAGE DISTRIBUTION ENVIRONMENT,"FIELD: calculating; counting.SUBSTANCE: invention relates to the management and distribution of content in one or more interacting media carriers in a beverage distribution environment. System contains: display system, devices that respond to environmental conditions, at least one computational processor, computational memory, moreover, the system obtains data representing environmental conditions for one or several interacting media carriers adapted to display digital content, where media can be located in beverage distribution environments (such as bars, restaurants, hotels, or social events), and where the system compares the data obtained, representing the environmental conditions when buying a beverage, with the selection criteria for identifying content for distribution in media, as a result, the selected content is distributed on one or several interacting media carriers.EFFECT: technical result is to increase the accuracy of content distribution by taking into account the location and environmental conditions.29 cl, 10 dwg",TAPP TECH LLC,ROBINSON JAMES;;CALLAHAN JOSEPH M,,https://lens.org/127-228-545-231-703,Granted Patent,no,4,0,16,29,0,G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/009;;G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/023,G06Q30/02,,0,0,,,,ACTIVE
149,US,A,US 3264225 A,135-207-543-995-053,1966-08-02,1966,US 23074162 A,1962-10-15,US 23074162 A,1962-10-15,Mixed antimony oxide-thorium oxide oxidation catalyst,,STANDARD OIL CO,CALLAHAN JAMES L;;BERTHOLD GERTISSER,,https://lens.org/135-207-543-995-053,Granted Patent,no,10,12,1,1,0,B01J23/16;;C07C45/35;;C07C253/26;;Y02P20/52;;C07C253/26;;B01J23/16;;C07C45/35;;Y02P20/52,B01J23/16;;C07C45/35,,0,0,,,,EXPIRED
150,US,A1,US 2019/0218955 A1,062-436-612-705-252,2019-07-18,2019,US 201815874288 A,2018-01-18,US 201815874288 A,2018-01-18,VEHICLE FRAME WITH ACOUSTIC VOLUME FOR AN EXHAUST SYSTEM,A vehicle exhaust system includes a first component that receives exhaust gas output from an engine and a second component that is fluidly coupled to the first component to define an upstream portion of a vehicle exhaust system. A vehicle frame member includes an internal acoustic volume. A pipe connects the internal acoustic volume in parallel to the upstream portion of the vehicle exhaust system.,FAURECIA EMISSIONS CONTROL TECHNOLOGIES USA LLC,EGAN JAMES;;CALLAHAN JOSEPH E,FAURECIA EMISSIONS CONTROL TECHNOLOGIES USA LLC (2018-01-17),https://lens.org/062-436-612-705-252,Patent Application,yes,16,1,4,4,0,B62D21/17;;B60K13/04;;B62D21/17;;F01N13/001;;F01N1/003;;F01N1/02;;F01N1/023;;F01N1/023;;F01N3/021;;F01N3/08;;F01N3/103;;F01N13/00;;F01N2340/04;;F01N2340/04;;Y02A50/20,F01N13/00;;B62D21/17;;F01N1/00;;F01N1/02,,0,0,,,,ACTIVE
151,DE,B,DE 1232552 B,180-739-880-465-298,1967-01-19,1967,DE ST020704 A,1963-06-07,US 20132162 A;;US 25000863 A,1962-06-11,Verfahren zur Herstellung eines Oxydationskatalysators,,STANDARD OIL CO,CALLAHAN JAMES LOUIS;;GERTISSER BERTHOLD,,https://lens.org/180-739-880-465-298,Patent Application,no,6,0,11,14,0,B01J23/8435;;B01J23/8435;;C07C45/34;;C07C45/34;;C07C45/35;;C07C45/35;;C07C51/252;;C07C51/252;;C07C253/26;;C07C253/26;;Y02P20/52;;Y02P20/52;;Y10S585/906;;Y10S585/906,B01J23/84;;B01J23/843;;C07C45/34;;C07C45/35;;C07C51/25,,0,0,,,,DISCONTINUED
152,IL,A0,IL 249657 A0,082-384-180-832-816,2017-02-28,2017,IL 24965716 A,2016-12-20,US 201414311836 A;;US 2014/0056896 W,2014-06-23,Content distribution platform for beverage dispensing environments,,TAPP TECH LLC;;ROBINSON JAMES;;CALLAHAN JOSEPH M,ROBINSON JAMES;;CALLAHAN JOSEPH M,,https://lens.org/082-384-180-832-816,Patent Application,no,0,0,16,29,0,G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/009;;G06Q30/0207;;G06Q30/0241;;G07F9/023;;G07F9/023,,,0,0,,,,PENDING
153,US,A,US 3197419 A,117-066-120-701-608,1965-07-27,1965,US 25000863 A,1963-01-08,US 25000863 A;;US 20132162 A,1962-06-11,Mixed antimony oxide-iron oxide oxidation catalyst,,STANDARD OIL CO,CALLAHAN JAMES L;;BERTHOLD GERTISSER,,https://lens.org/117-066-120-701-608,Granted Patent,no,12,22,11,14,0,B01J23/8435;;B01J23/8435;;C07C45/34;;C07C45/34;;C07C45/35;;C07C45/35;;C07C51/252;;C07C51/252;;C07C253/26;;C07C253/26;;Y02P20/52;;Y02P20/52;;Y10S585/906;;Y10S585/906,B01J23/84;;B01J23/843;;C07C45/34;;C07C45/35;;C07C51/25,,0,0,,,,EXPIRED
154,US,A,US 3214037 A,061-153-000-330-174,1965-10-26,1965,US 24847862 A,1962-12-31,US 24847862 A,1962-12-31,Trash cart and container,,MCDONALD S SYSTEMS INC,SCHINDLER JAMES C;;CALLAHAN JR JAMES C,,https://lens.org/061-153-000-330-174,Granted Patent,no,12,4,1,1,0,B65F1/12;;B65F1/141;;B65F1/1468;;B65F1/12;;B65F1/141;;B65F1/1468,B65F1/12;;B65F1/14,,0,0,,,,EXPIRED
155,EP,B1,EP 0159633 B1,019-046-215-847-158,1990-01-24,1990,EP 85104461 A,1985-04-12,US 60213384 A,1984-04-19,REVERSIBLE FEEDER SYSTEM,,LUBRIQUIP INC.,"POWELL, JOHN J.;;CALLAHAN, JAMES J.",LUBRIQUIP  INC. (1989-12-06),https://lens.org/019-046-215-847-158,Granted Patent,yes,10,0,6,6,0,F16N25/02;;Y10T137/86445;;Y10T137/86445;;F16N25/02,F16N25/02,,1,0,,,"PATENTS ABSTRACTS OF JAPAN, vol. 8, no. 132 (M-303)[1569], 20th June 1984; & JP-A-59 34 097 (SHIYOUICHI SAITOU) 24-02-1984",EXPIRED
156,CA,A,CA 718939 A,009-166-656-278-96X,1965-09-28,1965,CA 718939D A,,CA 718939T A,,METHOD FOR THE MANUFACTURE OF ACETONITRILE,,STANDARD OIL CO,STAMM JOHN A;;CALLAHAN JAMES L,,https://lens.org/009-166-656-278-96X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
157,AT,T1,AT E231143 T1,086-870-597-300-494,2003-02-15,2003,AT 00930101 T,2000-04-06,US 12868799 P;;US 0009147 W,1999-04-09,TRIARYLIMIDAZOLE,"Compounds of formula (I) or a pharmaceutically acceptable salt thereof:wherein R1, R2 and R3 are various substituent groups; andone of X1 and X2 is N or CR', and the other is NR' or CHR' wherein R' is hydrogen, OH, C1-6alkyl, or C3-7cycloalkyl; or when one of X1 and X2 is N or CR' then the other may be S or O;and their use as pharmaceuticals.",SMITHKLINE BEECHAM CORP,BURGESS JOELLE LORRAINE;;CALLAHAN JAMES FRANCIS,,https://lens.org/086-870-597-300-494,Granted Patent,no,0,0,11,11,0,C07D401/04;;C07D405/14;;C07D413/04;;A61P13/12;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/28;;A61P27/02;;A61P43/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D401/04;;C07D413/04;;C07D405/14,A61K31/443;;A61K31/4433;;A61K31/4439;;A61P3/10;;A61P9/04;;A61P9/10;;A61P13/12;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/28;;A61P27/02;;A61P43/00;;C07D401/04;;C07D405/14;;C07D413/04;;C07D413/14,,0,0,,,,DISCONTINUED
158,DE,A1,DE 1468721 A1,115-165-488-611-214,1969-01-23,1969,DE 1468721 A,1963-11-27,US 24073362 A,1962-11-28,Verfahren zur Herstellung olefinisch ungesaettigter Nitrile,,STANDARD OIL CO,LOUIS CALLAHAN JAMES;;CARL MILBERGER ERNEST,,https://lens.org/115-165-488-611-214,Patent Application,no,0,0,14,14,0,B01J8/26;;B01J21/00;;B01J21/08;;B01J27/188;;C07C253/26;;Y02P20/52;;B01J8/26;;B01J21/00;;B01J27/188;;C07C253/26;;B01J21/08;;Y02P20/52,B01J8/26;;B01J21/00;;B01J21/08;;B01J27/188,,0,0,,,,DISCONTINUED
159,EP,A2,EP 1569924 A2,131-135-887-830-871,2005-09-07,2005,EP 03812858 A,2003-12-05,US 0338970 W;;US 43149602 P,2002-12-06,NF-KB INHIBITORS,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCES;;LI YUE HU,,https://lens.org/131-135-887-830-871,Patent Application,yes,0,0,8,8,0,A61K31/381;;C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P17/16;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/08;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/10;;A61P9/14;;A61P3/10;;A61K31/381;;C07D333/38,A61P19/02;;C07D333/38;;A61K31/381,,0,0,,,,DISCONTINUED
160,EP,A4,EP 1324759 A4,183-653-459-088-996,2004-05-12,2004,EP 01979731 A,2001-10-12,US 0131866 W;;US 23975900 P,2000-10-12,NF-G(K)B INHIBITORS,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;ROSHAK AMY K,,https://lens.org/183-653-459-088-996,Search Report,no,3,0,6,6,0,A61K31/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00;;A61P7/00;;A61P9/00;;A61P9/10;;A61P3/10,A61K31/38;;A61K31/381;;A61P1/04;;C07D333/38;;A61P3/10;;A61P7/00;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00;;C07D409/04,,0,0,,,,DISCONTINUED
161,ES,T3,ES 2294276 T3,009-656-821-286-069,2008-04-01,2008,ES 03721638 T,2003-04-11,US 37194602 P,2002-04-11,INHIBIDORES DE NF-KAPPAB.,"Un compuesto de fórmula (I): en la que: R1 representa NR4R5; R2 representa CONH2 o SO2NH2; R3 se selecciona entre el grupo constituido por halógeno, alquilo C1-4, NH2, CF3, OCF3, O-alquilo, S-alquilo, CN, CHO, SO2-alquilo, (CH2)qNR7R8, O-(CH2)qNR7R8, (CH2)q-arilo, O-(CH2)q-arilo, (CH2)q-heteroarilo, O-(CH2)q-heteroarilo, (CH2)q-heteroalquilo, O-(CH2)q-heteroalquilo y NO2; R4 representa H o alquilo C1-4; R5 representa H o CONHR6; R6 se selecciona entre el grupo constituido por hidrógeno, alquilo y arilo; R7 representa alquilo C1-4; R8 representa alquilo C1-4; m es 0, 1, 2 ó 3; n es 0, 1, 2 ó 3; p es 1, 2 ó 3; y q es 1, 2, 3 ó 4; en la que: cada alquilo está opcionalmente sustituido con sustituyentes seleccionados entre el grupo constituido por arilo, OH, O-alquilo, CO, halógeno, CF3 y OCF3; cada arilo está opcionalmente sustituido con sustituyentes seleccionados entre el grupo constituido por halógeno, alquilo C1-4, NH2, OCF3, CF3, O-alquilo, S-alquilo, CN, CHO, SO2-alquilo y NO2; y cada heteroarilo está opcionalmente sustituido con sustituyentes seleccionados entre el grupo constituido por halógeno, alquilo C1-4, NH2, OCF3, CF3, O-alquilo, S-alquilo, CN, CHO, SO2-alquilo y NO2; o una sal farmacéuticamente aceptable del mismo.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;LI YUE H,,https://lens.org/009-656-821-286-069,Granted Patent,no,0,0,16,16,0,C07D333/74;;C07D333/78;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/08;;A61P9/10;;A61P3/10;;C07D333/74;;C07D333/78,C07D333/50;;C07D333/74;;A61K31/38;;A61K31/381;;A61P1/00;;A61P3/10;;A61P9/00;;A61P9/08;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P43/00;;C07D333/78,,0,0,,,,EXPIRED
162,US,A,US 3229786 A,003-588-698-447-997,1966-01-18,1966,US 32066263 A,1963-11-01,US 32066263 A,1963-11-01,Adjustable feed sequential fluid distribution means,,TRABON ENGINEERING CORP,ROBSON NORMAN S;;CALLAHAN JAMES J,,https://lens.org/003-588-698-447-997,Granted Patent,no,0,6,1,1,0,F16N25/02;;F16N25/02,F16N25/02,,0,0,,,,EXPIRED
163,CO,A1,CO 5031285 A1,027-682-113-740-592,2001-04-27,2001,CO 00026001 A,2000-04-10,US 12868799 P,1999-04-09,TRIARILIMIDAZOLES,"Compounds of formula (I) or a pharmaceutically acceptable salt thereof:wherein R1, R2 and R3 are various substituent groups; andone of X1 and X2 is N or CR', and the other is NR' or CHR' wherein R' is hydrogen, OH, C1-6alkyl, or C3-7cycloalkyl; or when one of X1 and X2 is N or CR' then the other may be S or O;and their use as pharmaceuticals.",SMITHKLINE BEECHMAN CORP,JOELLE LORRAINE BURGESS;;CALLAHAN JAMES FRANCIS,,https://lens.org/027-682-113-740-592,Patent Application,no,0,0,11,11,0,C07D401/04;;C07D405/14;;C07D413/04;;A61P13/12;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/28;;A61P27/02;;A61P43/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D401/04;;C07D413/04;;C07D405/14,A61K31/41;;A61K31/435;;A61K31/443;;A61K31/4433;;A61K31/4439;;A61P3/10;;A61P9/04;;A61P9/10;;A61P13/12;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/28;;A61P27/02;;A61P43/00;;C07D401/04;;C07D405/14;;C07D413/04;;C07D413/14,,0,0,,,,PENDING
164,AU,A,AU 2002/011662 A,037-783-252-781-98X,2002-04-22,2002,AU 2002/011662 A,2001-10-12,US 23976000 P;;US 0131865 W,2000-10-12,Nf-kappab inhibitors,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;ROSHAK AMY K,,https://lens.org/037-783-252-781-98X,Patent Application,no,0,0,4,4,0,A61K31/4164;;A61P1/04;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00;;C07D233/90,A61K31/4164;;A61P1/04;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00;;C07D233/90,,0,0,,,,PENDING
165,WO,A1,WO 2000/061576 A1,049-937-606-536-493,2000-10-19,2000,US 0009147 W,2000-04-06,US 12868799 P,1999-04-09,TRIARYLIMIDAZOLES,"Compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R2 and R3 are various substituent groups; and one of X1 and X2 is N or CR', and the other is NR' or CHR' wherein R' is hydrogen, OH, C1-6alkyl, or C3-7cycloalkyl; or when one of X1 and X2 is N or CR' then the other may be S or O; and their use as pharmaceuticals.",SMITHKLINE BEECHAM CORP;;BURGESS JOELLE LORRAINE;;CALLAHAN JAMES FRANCIS,BURGESS JOELLE LORRAINE;;CALLAHAN JAMES FRANCIS,,https://lens.org/049-937-606-536-493,Patent Application,yes,5,48,11,11,0,C07D401/04;;C07D405/14;;C07D413/04;;A61P13/12;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/28;;A61P27/02;;A61P43/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D401/04;;C07D413/04;;C07D405/14,A61K31/443;;A61K31/4433;;A61K31/4439;;A61P3/10;;A61P9/04;;A61P9/10;;A61P13/12;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/28;;A61P27/02;;A61P43/00;;C07D401/04;;C07D405/14;;C07D413/04;;C07D413/14,,1,0,,,"CHEMICAL ABSTRACTS, vol. 131, no. 7, 1999, Columbus, Ohio, US; abstract no. 87659s, page 641; XP002146305",PATENTED
166,CO,A2,CO 5570664 A2,067-515-433-043-633,2005-10-31,2005,CO 05050416 A,2005-05-24,US 42910502 P,2002-11-26,"DERIVADOS DE ACIDOS 2-HIDROXI-3(2-INDAN-2-IL-1,1-DIMETIL-ETILAMINO)-PROPOXI-FENIL-PROPIONICO Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN COMO AGENTES CALCILITICOS","1.- en la cual R1 y R5 son independientemente seleccionados del grupo que consiste en H y halógeno;R2, R3 y R4 son independientemente seleccionados del grupo que consiste en H, halógeno y J-K en donde:J es un enlace covalente, alquileno o alquenilo; y K es seleccionado del grupo de CO2R8, siendo R8 H o alquilo;R6 es seleccionado del grupo que consiste en H o alquilo;R7 es seleccionado del grupo que consiste en arilo o arilo condensado, dihidro, tetrahidro arilo condensado, heteroarilo, sin substituir o substituidos con cualquier substituyente seleccionado del grupo que consiste en OH, halógeno, alquilo C1-4, alcoxilo C1-4, cicloalquilo C3-6, CF3, OCF3, CN y NO2;y sales y complejos farmacéuticamente aceptables de los mismos.2.- Un compuesto de acuerdo con la reivindicación 1, seleccionado del grupo que consiste en clorhidrato de ácido (E)-3-{3,4-difluor-5-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)-propoxi]-fenil}-acrílico;clorhidrato de ácido 3-{3,4-difluor-5-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)propoxi]-fenil}-propiónico;clorhidrato de éster etílico del ácido 3-{3,4-difluor-5-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)-propoxi]-fenil}-propiónico;clorhidrato de ácido (E)-3-{3,4-difluor-5-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)-propoxi]-fenil}-pent-4-enoico;clorhidrato de ácido 5-{3,4-difluor-5-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)propoxi]-fenil}-pentanoico;éster etílico del ácido 5-{3,4-difluor-5-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetiI-etil-amino)-propoxi]-fenil}-pentanoico; clorhidrato de éster etílico del ácido 3-{4-bromo-3-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)-propoxi]-fenil}-propiónico;clorhidrato de ácido 3-{4-bromo-3-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)propoxi]-fenil}-propiónico;clorhidrato de ácido 3-{2,3-difluor-4-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)propoxi]-fenil}-propiónico;clorhidrato de éster etílico del ácido 3-{2,3-difluor-4-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)-propoxi]-fenil}-propiónico; ...",SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;CALLAHAN JAMES FRANCIS,,https://lens.org/067-515-433-043-633,Patent Application,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/34;;C07C217/36;;C07C229/00,,0,0,,,,ACTIVE
167,DE,D1,DE 3575597 D1,071-262-653-645-021,1990-03-01,1990,DE 3575597 T,1985-04-12,US 60213384 A,1984-04-19,UMKEHRBARES ZUFUEHRUNGSSYSTEM.,,LUBRIQUIP INC,POWELL JOHN J;;CALLAHAN JAMES J,,https://lens.org/071-262-653-645-021,Granted Patent,no,0,0,6,6,0,F16N25/02;;Y10T137/86445;;Y10T137/86445;;F16N25/02,F16N25/02,,0,0,,,,EXPIRED
168,EP,A2,EP 0159633 A2,077-279-117-054-470,1985-10-30,1985,EP 85104461 A,1985-04-12,US 60213384 A,1984-04-19,Reversible feeder system.,"A cyclical lubricant feeder utilizing series spool valves to dispense measured quantities of lubricant to dispensing outlets (120,121) from a common feed source (11) with a plurality of the spool valves arranged in series in valve block assemblies (15) which in turn are in series with one another whereby dispensing through the outlet (120,121) for each spool valve in a block assembly (15) is in progression with the other outlets from the spool valves (120, 121) in the valve block assembly (15) is provided with a control valve (124) controlling inlet and outlet flow to the valve block assembly bypassing flow from the inlet (140) to the outlet (141) when all of the valves in the block have been shifted to one side and bypassing flow from the outlet (141) to the inlet (140) upon reverse lubricant flow to the block only when all of the valves in the block have been shifted to the other side.",LUBRIQUIP HOUDAILLE INC,POWELL JOHN J;;CALLAHAN JAMES J,LUBRIQUIP  INC. (1989-12-06),https://lens.org/077-279-117-054-470,Patent Application,yes,0,6,6,6,0,F16N25/02;;Y10T137/86445;;Y10T137/86445;;F16N25/02,F16N25/02,,0,0,,,,EXPIRED
169,EP,A1,EP 1328272 A1,084-543-164-913-091,2003-07-23,2003,EP 01979730 A,2001-10-12,US 0131865 W;;US 23976000 P,2000-10-12,NF-KAPPA-B INHIBITORS,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;ROSHAK AMY K,,https://lens.org/084-543-164-913-091,Patent Application,yes,0,0,4,4,0,A61K31/4164;;A61P1/04;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00;;C07D233/90,A61K31/4164;;A61P1/04;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00;;C07D233/90,,1,0,,,See references of WO 0230423A1,DISCONTINUED
170,WO,A3,WO 2004/053087 A3,080-984-172-748-346,2004-09-10,2004,US 0338970 W,2003-12-05,US 43149602 P,2002-12-06,NF-KappaB INHIBITORS,The present invention provides a specific compound and methods for treating diseases related to the inhibition of IKK-&bgr; phosphorylation of I&kappa;.,SMITHKLINE BEECHAM CORP;;CALLAHAN JAMES FRANCES;;LI YUE HU,CALLAHAN JAMES FRANCES;;LI YUE HU,,https://lens.org/080-984-172-748-346,Search Report,yes,1,0,8,8,0,A61K31/381;;C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P17/16;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/08;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/10;;A61P9/14;;A61P3/10;;A61K31/381;;C07D333/38,A61K31/381;;C07D333/38,,1,0,,,"DATABASE CA [online] 2001, BAXTER ET AL: ""Preparation of thiophenecarboxamides as inhibitors of the enzyme IKK-2"", XP002978201, Database accession no. 135:180698",PENDING
171,ES,T3,ES 2187473 T3,143-913-238-409-861,2003-06-16,2003,ES 00930101 T,2000-04-06,US 12868799 P,1999-04-09,TRIARYLIMIDAZOLES.,"Compounds of formula (I) or a pharmaceutically acceptable salt thereof:wherein R1, R2 and R3 are various substituent groups; andone of X1 and X2 is N or CR', and the other is NR' or CHR' wherein R' is hydrogen, OH, C1-6alkyl, or C3-7cycloalkyl; or when one of X1 and X2 is N or CR' then the other may be S or O;and their use as pharmaceuticals.",SMITHKLINE BEECHAM CORP,BURGESS JOELLE LORRAINE;;CALLAHAN JAMES FRANCIS,,https://lens.org/143-913-238-409-861,Granted Patent,no,0,0,11,11,0,C07D401/04;;C07D405/14;;C07D413/04;;A61P13/12;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/28;;A61P27/02;;A61P43/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D401/04;;C07D413/04;;C07D405/14,A61K31/443;;A61K31/4433;;A61K31/4439;;A61P3/10;;A61P9/04;;A61P9/10;;A61P13/12;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/28;;A61P27/02;;A61P43/00;;C07D401/04;;C07D405/14;;C07D413/04;;C07D413/14,,0,0,,,,EXPIRED
172,US,A1,US 2006/0291527 A1,016-763-705-333-371,2006-12-28,2006,US 35218406 A,2006-02-10,US 35218406 A;;US 67755205 P;;US 70952805 P;;US 72647305 P,2005-05-04,Direct electric resistance liquid heater,"The Direct Electric Resistance Liquid Heater comprises a liquid heating chamber containing a plurality of electrodes. The electrodes are spaced apart to create a plurality of channels through which the liquid to be heated passes. The electrodes are each connected to a power supply by one or more switches. A controller controls the switches based upon data received from a temperature sensor, sensing the temperature of the liquid, and/or an electric current sensor, sensing the current utilized by the liquid heater. Selection of the number and spacing of the electrodes, and the number of switches, provides the controller with various current levels options to apply to the liquid to be heated. The current levels available due to the number and spacing of the electrodes and the number of switches, span the range from minimum current to maximum current such that the controller can incrementally increase or decrease the current applied to the liquid to be heated without disrupting other users of the same power source.",CALLAHAN JEREMIAH M;;BARZYK JAMES E,CALLAHAN JEREMIAH M;;BARZYK JAMES E,ISI TECHNOLOGY LLC (2006-08-08);;HEATWORKS TECHNOLOGIES INC (2016-05-23);;OHMIQ INC (2022-12-21),https://lens.org/016-763-705-333-371,Patent Application,yes,18,24,19,44,0,F24H1/106;;H05B3/60;;H05B2203/021;;F24H1/10;;F24H1/20;;H05B7/144;;F24H1/106;;H05B2203/021;;H05B3/60,H05B7/144,373/108,0,0,,,,ACTIVE
173,US,A,US 3375291 A,053-441-006-958-268,1968-03-26,1968,US 35602864 A,1964-03-31,US 35602864 A,1964-03-31,Process for preparing diolefins,,STANDARD OIL CO,CALLAHAN JAMES L;;MILBERGER ERNEST C,,https://lens.org/053-441-006-958-268,Granted Patent,no,5,7,7,8,0,B01J21/00;;B01J23/18;;B01J23/8435;;C07C5/48;;C07C5/48;;B01J23/8435;;B01J23/18;;B01J21/00,B01J21/00;;B01J23/18;;B01J23/843;;C07C5/48,260/680,0,0,,,,EXPIRED
174,CA,A1,CA 2696945 A1,073-152-360-325-724,2009-03-12,2009,CA 2696945 A,2008-09-08,US 96784207 P;;US 2008/0075641 W,2007-09-07,DYNAMICALLY UPDATING PRIVACY SETTINGS IN A SOCIAL NETWORK,"A social network allows its members to regulate what data is accessible to other members using one or more privacy settings. A particular member of the social network can modify the one or privacy settings to grant or deny different users access to different data. When a member modifies a privacy setting, the social network determines which information pathways communicating data between members are affected. The affected information pathways are then modified responsive to the privacy setting to communicate data identified by the modified privacy setting and enforce the new privacy restrictions.",FACEBOOK INC,CALLAHAN EZRA;;WANG JAMES;;VERA NICO,,https://lens.org/073-152-360-325-724,Patent Application,no,0,0,11,11,0,G06F21/604;;G06F21/6245;;G06F21/6263;;G06F2221/2141;;G06Q30/02;;H04L63/102;;H04L67/306;;G06F21/604;;G06F21/6245;;G06F21/6263;;G06F2221/2141;;G06Q30/02;;H04L63/102;;H04L67/306;;G06F2221/2115;;G06F2221/2119;;G06F21/62,G06F17/30;;G06F21/00;;G06F21/60;;G06F21/62,,0,0,,,,INACTIVE
175,DE,C3,DE 1417731 C3,082-868-158-307-944,1974-02-07,1974,DE 1417731 A,1960-04-12,US 80678159 A,1959-04-16,DE 1417731 C3,,"THE STANDAR D OIL CO., CLEVELAND, OHIO (V.ST.A.)","CALLAHAN, JAMES LOUIS, BEDFORD, OHIO (V.ST.A.)",,https://lens.org/082-868-158-307-944,Granted Patent,no,0,0,7,7,0,B01J23/31;;B01J23/31;;B01J23/18;;B01J23/18;;B01J27/192;;B01J27/192,B01J23/18;;B01J23/31;;B01J27/192,,0,0,,,,EXPIRED
176,US,A1,US 2004/0006118 A1,087-532-870-383-580,2004-01-08,2004,US 39900803 A,2003-04-10,US 39900803 A;;US 0131865 W,2001-10-12,Nf-kb inhibitors,"
   The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK- phosphorylation of IB. 
",CALLAHAN JAMES F;;ROSHAK AMY K,CALLAHAN JAMES F;;ROSHAK AMY K,SMITHKLINE BEECHAM CORPORATION (2001-11-30),https://lens.org/087-532-870-383-580,Patent Application,yes,0,1,1,1,0,A61K31/4172;;A61K31/4178;;A61K31/4172;;A61K31/4178,A61K31/4172;;A61K31/4178,514/397;;514/398,0,0,,,,DISCONTINUED
177,AT,T1,AT E380177 T1,108-266-230-869-663,2007-12-15,2007,AT 01954696 T,2001-07-16,US 21984200 P;;US 22063600 P,2000-07-21,KALZILYTISCHE VERBINDUNGEN,,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP;;CALLAHAN JAMES;;LAGO AMPARO,,https://lens.org/108-266-230-869-663,Granted Patent,no,0,0,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,C07D213/77;;A61K31/4418;;A61K31/4436;;A61K45/06;;A61K47/10;;A61K47/24;;A61K47/28;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,EXPIRED
178,AU,A8,AU 2003/300832 A8,105-026-029-229-523,2004-06-30,2004,AU 2003/300832 A,2003-12-05,US 43149602 P;;US 0338970 W,2002-12-06,Nf-kappab inhibitors,,SMITHKLINE BEECHAM CORP,LI YUE HU;;CALLAHAN JAMES FRANCES,,https://lens.org/105-026-029-229-523,Patent Application,no,0,0,8,8,0,A61K31/381;;C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P17/16;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/08;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/10;;A61P9/14;;A61P3/10;;A61K31/381;;C07D333/38,A61K31/381;;C07D333/38,,0,0,,,,DISCONTINUED
179,US,A1,US 2019/0240818 A1,105-381-849-108-678,2019-08-08,2019,US 201815891236 A,2018-02-07,US 201815891236 A,2018-02-07,"TOOLS FOR ROTATING FASTENERS, METHODS OF UTILIZING THE TOOLS, AND METHODS OF MANUFACTURING THE TOOLS","Tools for rotating fasteners, methods of utilizing the tools, and methods of manufacturing the tools. The tools include a gripping region, a fastener receptacle, and an interlock structure. The gripping region is configured to be gripped by a user of the tool. The fastener receptacle is shaped to receive the fasteners and includes a fastener-receiving opening on a fastener-facing side of the tool. The fastener-facing side faces in a fastener-facing direction. The fastener-receiving opening is sized to permit the fastener to enter the fastener receptacle from the fastener-facing side of the tool. The interlock structure is configured to interlock with the fastener while the fastener is received within the fastener receptacle. The interlock structure also is configured to prevent motion of the tool away from the fastener in a fastener-opposed direction, which is opposed to the fastener-facing side of the tool, while the interlock region is interlocked with the fastener.",BOEING CO,ETTLING KARL JAMES;;CALLAHAN RUSSELL PETE,THE BOEING COMPANY (2018-02-06),https://lens.org/105-381-849-108-678,Patent Application,yes,32,2,6,6,0,B25B11/00;;B25B13/5091;;B25G1/102;;B25B23/105;;B25B21/002;;B23P2700/01;;B25B23/1427;;B25B21/004;;B25G1/00;;B25B13/5091,B25B23/10;;B25B21/00;;B25B23/142,,0,0,,,,ACTIVE
180,EP,A2,EP 1324759 A2,121-677-722-918-078,2003-07-09,2003,EP 01979731 A,2001-10-12,US 0131866 W;;US 23975900 P,2000-10-12,NF-G(K)B INHIBITORS,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;ROSHAK AMY K,,https://lens.org/121-677-722-918-078,Patent Application,yes,0,0,6,6,0,A61K31/38;;A61P1/04;;A61P3/10;;A61P7/00;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00,C07D333/38;;A61K31/38;;A61K31/381;;A61P1/04;;A61P3/10;;A61P7/00;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00;;C07D409/04,,0,0,,,,DISCONTINUED
181,US,A,US 3501470 A,127-528-374-321-345,1970-03-17,1970,US 3501470D A,1966-09-30,US 58866566 A,1966-09-30,DIGUANAMINES,,STANDARD OIL CO,GRASSELLI ROBERT K;;CALLAHAN JAMES L,,https://lens.org/127-528-374-321-345,Granted Patent,no,8,1,1,1,0,C07D251/18;;C07D251/18,C07D251/18,260/249.9,0,0,,,,EXPIRED
182,GB,A,GB 1145750 A,138-168-631-127-707,1969-03-19,1969,GB 5700466 A,1966-12-20,GB 5700466 A,1966-12-20,Lubrication and monitoring system,"1,145,750. Lubricating. HOUDAILLE INDUSTRIES Inc. 20 Dec., 1966, No. 57004/66. Heading F2A. A lubrication system comprises a cyclic distributer supplying a plurality of lubrication points and having an element moving backwards and forwards, means resetting a timing device after a back and forth movement, so that the timing device only finishes timing and operates an indicator when the delivery rates to the points are too low. In Fig. 1 a primary cyclic distributer 21 supplies secondary cyclic distributers 22-25. A contact arm of a switch 27 is biased to close leads 41, 42 (Fig. 2), and is transferred to close leads 42, 43 when plunger extension 26 is moved in one direction. Thus condenser 46 periodically discharges through relay 47 which opens a switch 54 and resets timer 48. If the rate of movement of extension 26, and thus the rate of supply to the application points, drops below a given value, timer 48 finishes timing and opens switches 51, 53 and closes switch 52 to light a warning light and to shut off pump 11. Breakage of lines supplying distributers 21, 22 are detected.",HOUDAILLE INDUSTRIES INC,CALLAHAN JAMES J;;ROBERTS ROBERT D,,https://lens.org/138-168-631-127-707,Granted Patent,no,0,0,1,1,0,F16N29/04,F16N29/04,F2A ACX5          -;;F2A ALAA          ALAA;;F2A A35B3A        -;;F2A A43           -;;F2A A56           -,0,0,,,,EXPIRED
183,US,A,US 3414631 A,148-350-366-094-310,1968-12-03,1968,US 46303665 A,1965-06-10,US 46303665 A,1965-06-10,Oxydehydrogenation process,,STANDARD OIL CO,GRASSELLI ROBERT K;;CALLAHAN JAMES L,,https://lens.org/148-350-366-094-310,Granted Patent,no,3,24,14,15,0,B01J27/192;;B01J27/192;;C07C5/48;;C07C5/48,B01J27/192;;C07C5/48,260/680,0,0,,,,EXPIRED
184,EP,A3,EP 0159633 A3,160-716-427-079-076,1987-01-14,1987,EP 85104461 A,1985-04-12,US 60213384 A,1984-04-19,REVERSIBLE FEEDER SYSTEM,"A cyclical lubricant feeder utilizing series spool valves to dispense measured quantities of lubricant to dispensing outlets (120,121) from a common feed source (11) with a plurality of the spool valves arranged in series in valve block assemblies (15) which in turn are in series with one another whereby dispensing through the outlet (120,121) for each spool valve in a block assembly (15) is in progression with the other outlets from the spool valves (120, 121) in the valve block assembly (15) is provided with a control valve (124) controlling inlet and outlet flow to the valve block assembly bypassing flow from the inlet (140) to the outlet (141) when all of the valves in the block have been shifted to one side and bypassing flow from the outlet (141) to the inlet (140) upon reverse lubricant flow to the block only when all of the valves in the block have been shifted to the other side.","LUBRIQUIP - HOUDAILLE, INC.","POWELL, JOHN J.;;CALLAHAN, JAMES J.",LUBRIQUIP  INC. (1989-12-06),https://lens.org/160-716-427-079-076,Search Report,yes,10,0,6,6,0,F16N25/02;;Y10T137/86445;;Y10T137/86445;;F16N25/02,F16N25/02,,1,0,,,"PATENTS ABSTRACTS OF JAPAN, vol. 8, no. 132 (M-303)[1569], 20th June 1984; & JP-A-59 34 097 (SHIYOUICHI SAITOU) 24-02-1984",EXPIRED
185,US,A,US 3370103 A,174-537-943-296-194,1968-02-20,1968,US 24073462 A,1962-11-28,US 24073462 A,1962-11-28,Process for preparing diolefins,,STANDARD OIL CO,CALLAHAN JAMES L;;MILBERGER ERNEST C,,https://lens.org/174-537-943-296-194,Granted Patent,no,4,5,1,1,0,B01J8/24;;C07C5/48;;B01J8/24;;C07C5/48,B01J8/24;;C07C5/48,260/680,0,0,,,,EXPIRED
186,WO,A1,WO 1993/009133 A1,003-348-574-269-559,1993-05-13,1993,US 9209467 W,1992-10-30,US 78567291 A,1991-10-31,C8-CYCLIC PEPTIDOMIMETICS AS FIBRINOGEN ANTAGONISTS,"This invention relates to a method of inhibiting platelet aggregation, and 1,4-diazocine compounds which are mimics of the peptide sequence Arg-Gly-Asp.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS,,https://lens.org/003-348-574-269-559,Patent Application,yes,1,23,4,4,0,C07D245/02;;C07K5/0202;;C07K5/06139;;C07K5/0821;;C07K14/75;;A61P7/02;;C07K5/06139;;C07K5/0202;;C07K14/75;;C07D245/02;;C07K5/0821,A61P7/02;;C07D245/02;;C07D401/12;;C07D403/12;;C07K5/02;;C07K5/078;;A61K31/395;;C07K5/097;;C07K14/75,,1,0,,,"PEPTIDES, CHEMISTRY AND BIOLOGY. PROCEEDINGS OF THE XTH AMERICAN PEPTIDE SYMPOSIUM, MAY 23-28,1987, SAINT LOUIS, MISSOURI, USA ESCOM, LEIDEN ,1988 pages 105 - 108 W F HUFFMAN ET AL. 'reverse turn mimics'",PENDING
187,CA,A,CA 577116 A,038-894-741-483-674,1959-06-02,1959,CA 577116D A,,CA 577116T A,,ISOMERIZATION PROCESS AND CATALYST THEREFOR,,STANDARD OIL CO,STINE HARRISON M;;CALLAHAN JAMES L,,https://lens.org/038-894-741-483-674,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
188,WO,A3,WO 2003/086309 A3,060-040-370-075-142,2003-12-04,2003,US 0311297 W,2003-04-11,US 37194602 P,2002-04-11,NF-kappaB INHIBITORS,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-&bgr; phosphorylation of I&kappa;B. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-&kappa;B in which diseases excessive activation of NF-&kappa;B is implicated.,SMITHKLINE BEECHAM CORP;;CALLAHAN JAMES F;;LI YUE H,CALLAHAN JAMES F;;LI YUE H,,https://lens.org/060-040-370-075-142,Search Report,yes,2,0,16,16,0,C07D333/74;;C07D333/78;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/08;;A61P9/10;;A61P3/10;;C07D333/74;;C07D333/78,C07D333/50;;A61K31/381;;A61P1/00;;A61P3/10;;A61P9/00;;A61P9/08;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/02;;A61P43/00;;C07D333/74;;C07D333/78,,0,0,,,,PATENTED
189,US,A1,US 2003/0146654 A1,066-157-449-836-773,2003-08-07,2003,US 6156102 A,2002-02-01,US 6156102 A,2002-02-01,Privacy seat divider for transport vehicles,"
   A fan-type foldable device for sub-dividing for privacy purposes, the space occupied by a passenger seated in a moving vehicle or a movie theatre, is described. The fan type device incorporates a means for coupling onto a side of a seat back, thereby maintaining privacy within the sub-divide. Said fan type device folds out of the way when not in use. The fan type foldable device may be used in a seating arrangement wherein rows of seats are divided by the fan type such that each seated passenger is able to enjoy privacy from adjoining passengers. 
",BOEING CO,NGUYEN TONY HOANG;;CALLAHAN JAMES D,BOEING COMPANY THE (2001-12-12),https://lens.org/066-157-449-836-773,Patent Application,yes,0,41,2,2,0,A47C1/12;;A47C7/62;;B64D11/0606;;B64D11/0606,A47C1/12;;A47C7/62;;B64D11/06,297/463.2;;297/232;;297/184.15,0,0,,,,EXPIRED
190,US,A,US 3993860 A,096-867-098-432-738,1976-11-23,1976,US 60538975 A,1975-08-18,US 60538975 A,1975-08-18,Electrical cable adapted for use on a tractor trailer,"An electrical cable of conventional or retractable helical coil form which is relatively small in diameter and sufficiently flexible to be used to advantage on a tractor-trailer to connect the power supply on the tractor with the electrical system carried by the trailer has a polymeric sheath, an insulated 10 gauge stranded conductor substantially coaxial with the sheath, four to six insulated stranded 12 gauge conductors substantially evenly spaced about the periphery of the 10 gauge conductor, a plurality of uninsulated stranded conductors of 14 gauge disposed between the smaller insulated conductors, filler material filling the spaces between the conductors and preferably a plastic film helically wound about the conductors. The 12 and 14 gauge conductors are helically wound about the 10 gauge conductor. The assembly of conductors, filler and plastic film combine to form a cable having a substantially circular cross-section and substantially fill the sheath. The cable is preferably coiled into a self-storing configuration.",MOORE & CO SAMUEL,SNOW JOHN P;;CALLAHAN JAMES J,FLUROCARBON COMPANY THE (1987-05-29),https://lens.org/096-867-098-432-738,Granted Patent,yes,2,35,7,7,0,H01B7/041;;H01B7/06;;H01B7/041;;H01B7/06,H01B7/04;;H01B7/06;;H01B7/17,174/69,0,0,,,,EXPIRED
191,US,A,US 3444234 A,123-659-315-532-331,1969-05-13,1969,US 3444234D A,1966-11-09,US 59299266 A,1966-11-09,AMMONIA RECOVERY WITH A MOLTEN SALT IN PROCESSES FOR THE PRODUCTION OF MONOOLEFINICALLY UNSATURATED NITRILES,,STANDARD OIL CO,CALLAHAN JAMES L;;CROSS GORDON G,,https://lens.org/123-659-315-532-331,Granted Patent,no,1,1,1,1,0,C01C1/12;;C07C253/26;;C07C253/26;;C01C1/12,C01C1/12,260/465.3,0,0,,,,EXPIRED
192,AU,A,AU 2000/047980 A,151-993-755-353-31X,2000-11-14,2000,AU 2000/047980 A,2000-04-06,US 12868799 P;;US 0009147 W,1999-04-09,Triarylimidazoles,"Compounds of formula (I) or a pharmaceutically acceptable salt thereof:wherein R1, R2 and R3 are various substituent groups; andone of X1 and X2 is N or CR', and the other is NR' or CHR' wherein R' is hydrogen, OH, C1-6alkyl, or C3-7cycloalkyl; or when one of X1 and X2 is N or CR' then the other may be S or O;and their use as pharmaceuticals.",SMITHKLINE BEECHAM CORP,BURGESS JOELLE LORRAINE;;CALLAHAN JAMES FRANCIS,,https://lens.org/151-993-755-353-31X,Patent Application,no,0,0,11,11,0,C07D401/04;;C07D405/14;;C07D413/04;;A61P13/12;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/28;;A61P27/02;;A61P43/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D401/04;;C07D413/04;;C07D405/14,A61K31/443;;A61K31/4433;;A61K31/4439;;A61P3/10;;A61P9/04;;A61P9/10;;A61P13/12;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/28;;A61P27/02;;A61P43/00;;C07D401/04;;C07D405/14;;C07D413/04;;C07D413/14,,0,0,,,,DISCONTINUED
193,US,A,US 3618202 A,172-949-650-407-522,1971-11-09,1971,US 3618202D A,1969-05-12,US 82366769 A,1969-05-12,CERAMIC CHIP ELECTRICAL COMPONENTS,,MALLORY & CO INC P R,CALLAHAN JAMES P;;STARK RICHARD A,,https://lens.org/172-949-650-407-522,Granted Patent,no,0,7,1,1,0,H01G2/065;;H01G13/00;;H01G2/065;;H01G13/00,H01G2/06;;H01G13/00,29/580,0,0,,,,EXPIRED
194,EP,B1,EP 1169317 B1,187-911-436-619-082,2003-01-15,2003,EP 00930101 A,2000-04-06,US 0009147 W;;US 12868799 P,1999-04-09,TRIARYLIMIDAZOLES,"Compounds of formula (I) or a pharmaceutically acceptable salt thereof:wherein R1, R2 and R3 are various substituent groups; andone of X1 and X2 is N or CR', and the other is NR' or CHR' wherein R' is hydrogen, OH, C1-6alkyl, or C3-7cycloalkyl; or when one of X1 and X2 is N or CR' then the other may be S or O;and their use as pharmaceuticals.",SMITHKLINE BEECHAM CORP,BURGESS JOELLE LORRAINE;;CALLAHAN JAMES FRANCIS,SMITHKLINE BEECHAM CORPORATION (2002-05-02),https://lens.org/187-911-436-619-082,Granted Patent,yes,5,0,11,11,0,C07D401/04;;C07D405/14;;C07D413/04;;A61P13/12;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/28;;A61P27/02;;A61P43/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D401/04;;C07D413/04;;C07D405/14,A61K31/443;;A61K31/4433;;A61K31/4439;;A61P3/10;;A61P9/04;;A61P9/10;;A61P13/12;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/28;;A61P27/02;;A61P43/00;;C07D401/04;;C07D405/14;;C07D413/04;;C07D413/14,,1,0,,,"CHEMICAL ABSTRACTS, vol. 131, no. 7, 1999 Columbus, Ohio, US; abstract no. 87659s, page 641; XP002146305 & JP 11 180958 A (YAMANOUCHI) 6 July 1999 (1999-07-06)",EXPIRED
195,EP,A4,EP 1569924 A4,192-898-698-825-81X,2007-02-21,2007,EP 03812858 A,2003-12-05,US 0338970 W;;US 43149602 P,2002-12-06,NF-KB INHIBITORS,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCES;;LI YUE HU,,https://lens.org/192-898-698-825-81X,Search Report,no,4,0,8,8,0,A61K31/381;;C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P17/16;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/08;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/10;;A61P9/14;;A61P3/10;;A61K31/381;;C07D333/38,A61P19/02;;A61K31/381;;C07D333/38,,0,0,,,,DISCONTINUED
196,US,A,US 3371745 A,199-977-707-515-486,1968-03-05,1968,US 35098164 A,1964-03-11,US 35098164 A,1964-03-11,Unidirectional-flow lubricating means,,TRABON ENGINEERING CORP,CALLAHAN JAMES J;;SHIVAK ROBERT A,LUBRIQUIP - HOUDAILLE INC. A CORP OF DE (1985-01-31);;LUBRIQUIP-HOUDAILLE INC (1987-01-15),https://lens.org/199-977-707-515-486,Granted Patent,no,4,13,2,2,0,F16N25/02;;F16N25/02,F16N25/02,184/7,0,0,,,,EXPIRED
197,US,A1,US 2009/0070334 A1,003-131-221-581-937,2009-03-12,2009,US 20655608 A,2008-09-08,US 20655608 A;;US 96784207 P,2007-09-07,DYNAMICALLY UPDATING PRIVACY SETTINGS IN A SOCIAL NETWORK,"A social network allows its members to regulate what data is accessible to other members using one or more privacy settings. A particular member of the social network can modify the one or privacy settings to grant or deny different users access to different data. When a member modifies a privacy setting, the social network determines which information pathways communicating data between members are affected. The affected information pathways are then modified responsive to the privacy setting to communicate data identified by the modified privacy setting and enforce the new privacy restrictions.",CALLAHAN EZRA;;WANG JAMES;;VERA NICOLAS,CALLAHAN EZRA;;WANG JAMES;;VERA NICOLAS,META PLATFORMS INC (2008-11-06),https://lens.org/003-131-221-581-937,Patent Application,yes,24,161,11,11,0,G06F21/604;;G06F21/6245;;G06F21/6263;;G06F2221/2141;;G06Q30/02;;H04L63/102;;H04L67/306;;G06F21/604;;G06F21/6245;;G06F21/6263;;G06F2221/2141;;G06Q30/02;;H04L63/102;;H04L67/306;;G06F2221/2115;;G06F2221/2119;;G06F21/62,G06F17/30;;G06F21/00;;G06F21/60;;G06F21/62,707/9;;X707E17005,0,0,,,,ACTIVE
198,US,B2,US 7375131 B2,040-556-126-928-467,2008-05-20,2008,US 51683604 A,2004-12-03,US 51683604 A;;US 38655602 P;;US 0317385 W,2002-06-06,NF-kappaB inhibitors,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-β phosphorylation of IκB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-κB in which diseases excessive activation of NF-κB is implicated.,SMITHKLINEBEECHAM CORP,CALLAHAN JAMES F;;LI YUE HU,,https://lens.org/040-556-126-928-467,Granted Patent,yes,19,1,9,9,0,A61P1/04;;A61P3/10;;A61P7/00;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;C07D333/38;;C07D333/38,A61K31/38;;A61K31/381;;A61P1/04;;A61P3/10;;A61P7/00;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P43/00;;C07D333/36;;C07D333/38;;C07D333/40,514/445;;514/447;;514/448;;549/63;;549/64;;549/69;;549/72,4,0,,,"Bonafoux, Dominique et al, CA 143: 460021, 2005.;;Bonafoux, Dominique et al, CA143: 153240, 2005.;;Griffiths et al., ""Preparation of Ureido-Carboxamido Thiophenes as Inhibitors of IKK2 Kinase"". Database HCAPLUS on STN, AN 2003:97415. CA 138: 153430.;;Database Registry-Chemical Abstracts Service, Columbus, OH, Feb. 25, 2003. Database Accession No. RN 494772-50-8 (Abstract) & Database Caplus Chemical Abstracts Service, Columbus, OH. XP002398375.",EXPIRED
199,TW,A,TW 200403991 A,058-739-317-243-204,2004-03-16,2004,TW 92108058 A,2003-04-09,US 37194602 P,2002-04-11,NF-κb inhibitors,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-κ phosphorylation of IkB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-Κb in which diseases excessive activation of NF-Κb is implicated.,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;LI YUE-HU,,https://lens.org/058-739-317-243-204,Patent of Addition,no,0,0,16,16,0,C07D333/74;;C07D333/78;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/08;;A61P9/10;;A61P3/10;;C07D333/74;;C07D333/78,C07D333/50;;A61K31/381;;A61P1/00;;A61P3/10;;A61P9/00;;A61P9/08;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/02;;A61P43/00;;C07D333/74;;C07D333/78,,0,0,,,,PENDING
200,US,A,US 3341471 A,071-137-104-250-120,1967-09-12,1967,US 27930863 A,1963-05-09,US 27930863 A;;US 31165763 A;;US 63857767 A,1963-05-09,Attrition resistant solid catalysts,,STANDARD OIL CO,CALLAHAN JAMES L;;KNIPPLE WARREN R,,https://lens.org/071-137-104-250-120,Granted Patent,no,6,13,12,15,0,B01J21/00;;B01J21/00;;B01J23/16;;B01J23/16;;B01J23/18;;B01J23/18;;B01J23/6445;;B01J23/6445;;B01J23/681;;B01J23/681;;B01J23/8435;;B01J23/8435;;B01J27/1815;;B01J27/1815;;B01J37/0009;;B01J37/0009;;C07C5/48;;C07C5/48;;C07C45/35;;C07C45/35;;C07C253/26;;C07C253/26;;Y02P20/52;;Y02P20/52;;Y10S502/503;;Y10S502/503;;Y10S502/504;;Y10S502/504;;Y10S585/906;;Y10S585/906,B01J21/00;;B01J23/16;;B01J23/18;;B01J23/644;;B01J23/68;;B01J23/843;;B01J27/18;;B01J37/00;;C07C5/48;;C07C45/35,,0,0,,,,EXPIRED
201,US,A,US 4312425 A,095-907-873-758-251,1982-01-26,1982,US 94155778 D,1978-09-11,US 94155778 A,1978-09-11,Cyclic lubricant distributor valve,"A cyclic lubricant distributor valve has an inlet block unit, an end block unit and at least three intermediate block units. Each of the intermediate block units has a bore, a spool movable in the bore and at least one lubricant outlet. A series of ports and passages are formed in the various block units to provide for cyclic operation of the distributor valve. Each of the intermediate block units is formed of a base member, in which the outlet (or outlets) is formed, and a separate and separable spool member, in which a bore is formed containing a movable spool. Through bolts connect the inlet block unit, the end block unit and the base members of the intermediate block units in fixed assembly. Other bolts connect each of the spool members in fixed assembly only with its corresponding base member.",HOUDAILLE INDUSTRIES INC,SNOW JOHN P;;CALLAHAN JAMES J,LUBRIQUIP - HOUDAILLE INC. A CORP OF DE (1985-01-31);;LUBRIQUIP INC (1987-01-15),https://lens.org/095-907-873-758-251,Granted Patent,yes,5,38,3,3,0,F16N25/02,F16N25/02,184  7D,0,0,,,,EXPIRED
202,DE,A1,DE 1493230 A1,105-790-365-786-496,1969-02-06,1969,DE 1493230 A,1965-12-31,US 42381865 A,1965-01-06,Verfahren zur Herstellung aromatischer Aldehyde und Nitrile,,STANDARD OIL CO,KARL GRASSELLI ROBERT;;LOUIS CALLAHAN JAMES,,https://lens.org/105-790-365-786-496,Patent Application,no,0,0,6,6,0,B01J23/16;;B01J23/16;;B01J23/6445;;B01J23/6445;;B01J23/681;;B01J23/681;;B01J23/84;;B01J23/84;;B01J23/8435;;B01J23/8435;;B01J27/19;;B01J27/19;;C07C253/28;;C07C253/28;;C07C45/36;;C07C45/36,B01J23/16;;B01J23/18;;B01J23/644;;B01J23/68;;B01J23/84;;B01J23/843;;B01J27/19;;C07C45/36;;C07C47/20;;C07C255/34,,0,0,,,,DISCONTINUED
203,CA,A1,CA 2118372 A1,164-282-676-036-739,1996-04-19,1996,CA 2118372 A,1994-10-18,CA 2118372 A,1994-10-18,Manual Resin Extruder for Effecting Glass Repair,,CALLAHAN MICHAEL J;;FIKSE JAMES A,CALLAHAN MICHAEL J;;FIKSE JAMES A,,https://lens.org/164-282-676-036-739,Patent Application,no,0,0,2,2,0,,,,0,0,,,,EXPIRED
204,CA,A,CA 1102662 A,169-610-483-662-057,1981-06-09,1981,CA 310698 A,1978-09-06,US 83732077 A,1977-09-28,REGENERATION OF USED DISHWASHING WATER WITHOUT CHEMICAL ADDITIVES FOR SANITIZING AND SPOT-FREE RINSE USES,"An improved dishwashing system includes operating methods and apparatus for water and energy conservation and elimination of spot-reducing chemicals in the rinse water. return water from the rinse cycle is stored in insulated tanks and rinse water flowing to the dishwasher absorbs heat from the return water to thereby conserve the heat energy of the return water while simultaneously cooling the return water to a selected temperature in preparing a feed solution for membrane separation. A controlled quantity of make-up water is added to the feed solution which is raised to a selected pressure to provide for reverse osmosis purification and deionization. The reverse osmosis effluent is accumulated and, when needed, boosted in pressure to a desired operational dishwasher pressure, and heated to sanitizing level so as to achieve desired bacterial count levels during rinse cycles. Rinsing with the purified and deionized water results in filmfree and spot-free dishes after drying.",AMERICAN STERILIZER CO,ANDREWS JAMES P;;CALLAHAN ARTHUR C,,https://lens.org/169-610-483-662-057,Granted Patent,no,0,0,2,2,0,A47L15/4291;;B01D61/025;;B01D2311/10;;B01D2313/50;;Y02B40/00;;A47L15/4291;;B01D2311/10;;B01D61/025;;B01D2313/50;;Y02B40/00,A47L15/24;;A47L15/42,141-28,0,0,,,,EXPIRED
205,US,A,US 5470849 A,034-672-172-121-307,1995-11-28,1995,US 5017893 A,1993-04-30,US 5017893 A;;US 60813890 A;;US 9108166 W,1990-11-01,gamma -turn peptidomimetics as fibrinogen antagonists,"This invention relates to a method of inhibiting platelet aggregation, and compounds which are mimics of the peptide sequence Arg-Gly-Asp.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;HUFFMAN WILLIAM F,SMITHKLINE BEECHAM CORP (1993-04-30),https://lens.org/034-672-172-121-307,Granted Patent,yes,7,17,5,5,0,A61P7/02;;A61P9/04;;C07D223/10;;C07D223/10;;C07D243/06;;C07D243/06,A61K31/55;;A61K38/46;;A61P7/02;;A61P9/04;;C07D223/04;;C07D223/06;;C07D223/08;;C07D223/10;;C07D243/06;;C07D401/06;;C07D401/14;;C07D403/06;;C07D403/14;;C07D409/06;;C07D409/14,514/212;;540/524;;540/531;;540/533;;540/596;;540/597;;540/602;;540/603;;540/609;;540/610,0,0,,,,EXPIRED
206,US,A,US 3546174 A,035-974-915-894-125,1970-12-08,1970,US 3546174D A,1969-07-22,US 84385469 A,1969-07-22,DIGUANAMINE-ALDEHYDE CONDENSATION PRODUCTS,,STANDARD OIL CO,GRASSELLI ROBERT K;;CALLAHAN JAMES L,,https://lens.org/035-974-915-894-125,Granted Patent,no,4,0,1,1,0,C08G12/266;;C08G12/30;;C08G12/30;;C08G12/266,C08G12/26;;C08G12/30,260/67.6,0,0,,,,EXPIRED
207,WO,A1,WO 2002/030423 A1,045-179-682-336-519,2002-04-18,2002,US 0131865 W,2001-10-12,US 23976000 P,2000-10-12,NF- kappa B INHIBITORS,The present invention provides novel compounds and methods for using them to treat diseases with aminoimidazole inhibitors of IKK-β phosphorylation of IλB.,SMITHKLINE BEECHAM CORP;;CALLAHAN JAMES F;;ROSHAK AMY K,CALLAHAN JAMES F;;ROSHAK AMY K,,https://lens.org/045-179-682-336-519,Patent Application,yes,2,26,4,4,0,A61K31/4164;;A61P1/04;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00;;C07D233/90,A61K31/4164;;A61P1/04;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00;;C07D233/90,,2,1,038-739-677-745-958,10.1016/0006-2952(88)90336-x;;3144286,"DATABASE CAPLUS [online] 1973, HEYES ET AL.: ""Antiinflammatory acylimidazoles"", XP002907021, accession no. ACS Database accession no. 1973:111321;;DATABASE CAPLUS [online] 1989, KNOX ET AL.: ""The nitroreductase enzyme in walker cells that activate 5-(aziridin-1-yl)-2,4-dinitrobenzamide to 5-aziridin-1-yl-4-hydroxylamino-2-nitrobenzamide in form of NAD(P)H dehydrogenase"", XP002907022, accession no. ACS Database accession no. 1989:107728",PENDING
208,WO,A1,WO 1998/030243 A1,048-878-591-637-529,1998-07-16,1998,US 9723792 W,1997-12-29,US 3405997 P;;US 6588697 P,1997-01-08,ACETYLCHOLINESTERASE INHIBITORS IN COMBINATION WITH MUSCARINIC AGONISTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE,"New compositions of matter and a method for treating bodily disorders involving cholinergic hypofunction such as Alzheimer's disease in a mammal are disclosed. The compositions comprise a combination of an acetylcholinesterase inhibitor and a muscarinic agonist. The method comprises administration of the combination to a mammal. The instant invention demonstrates that the combination of an acetylcholinesterase inhibitor and a muscarinic agonist can be safely administered, that doses of each agent which by themselves showed no activity yielded positive responses and minimal side effects in combination, and that the active dose range for both agents could be widened when used in combination. These results imply that the combined treatment may eliminate the need to individually tritrate doses and also increase the separation between efficacy and adverse events.",WARNER LAMBERT CO;;SCHWARZ ROY DOUVILLE;;CALLAHAN MICHAEL JAMES,SCHWARZ ROY DOUVILLE;;CALLAHAN MICHAEL JAMES,,https://lens.org/048-878-591-637-529,Patent Application,yes,7,57,4,5,0,A61K45/06;;A61K31/00,A61K45/06,,1,1,019-731-078-355-67X,3346520;;10.1093/geronj/43.2.b54,"FLOOD: ""Effect of Acute Arecoline, Tacrine, and Arecoline + Tacrine Post-Training Administration on Retention in Late Middle-Aged Mice"", JOURNAL OF GERONTOLOGY, vol. 43, no. 2, 1988, pages B54 - B56, XP002064273",PENDING
209,DE,D1,DE 60316425 D1,079-684-668-949-547,2007-10-31,2007,DE 60316425 T,2003-04-11,US 37194602 P;;US 0311297 W,2002-04-11,NF-kappaB-INHIBITOREN,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;LI YUE H,,https://lens.org/079-684-668-949-547,Granted Patent,no,0,0,16,16,0,C07D333/74;;C07D333/78;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/08;;A61P9/10;;A61P3/10;;C07D333/74;;C07D333/78,C07D333/50;;C07D333/74;;A61K31/38;;A61K31/381;;A61P1/00;;A61P3/10;;A61P9/00;;A61P9/08;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P43/00;;C07D333/78,,0,0,,,,EXPIRED
210,AU,A8,AU 2003/224941 A8,086-616-206-632-35X,2003-10-27,2003,AU 2003/224941 A,2003-04-11,US 37194602 P;;US 0311297 W,2002-04-11,Nf-kappab inhibitors,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;LI YUE H,,https://lens.org/086-616-206-632-35X,Patent Application,no,0,0,16,16,0,C07D333/74;;C07D333/78;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/08;;A61P9/10;;A61P3/10;;C07D333/74;;C07D333/78,C07D333/50;;A61K31/381;;A61P1/00;;A61P3/10;;A61P9/00;;A61P9/08;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/02;;A61P43/00;;C07D333/74;;C07D333/78,,0,0,,,,DISCONTINUED
211,EP,A4,EP 1499605 A4,175-047-110-841-682,2006-01-25,2006,EP 03721638 A,2003-04-11,US 0311297 W;;US 37194602 P,2002-04-11,NF-KappaB INHIBITORS,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;LI YUE H,,https://lens.org/175-047-110-841-682,Search Report,no,2,0,16,16,0,C07D333/74;;C07D333/78;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/08;;A61P9/10;;A61P3/10;;C07D333/74;;C07D333/78,C07D333/50;;A61K31/381;;A61P1/00;;A61P3/10;;A61P9/00;;A61P9/08;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/02;;A61P43/00;;C07D333/74;;C07D333/78,,0,0,,,,EXPIRED
212,US,A,US 3415981 A,174-214-944-551-111,1968-12-10,1968,US 67435067 A,1967-10-10,US 67435067 A,1967-10-10,Electronic computer with program debugging facility,,RCA CORP,SMITH RICHARD D;;CALLAHAN JAMES F,,https://lens.org/174-214-944-551-111,Granted Patent,no,2,21,1,1,0,G06F11/362;;G06F11/362,G06F11/36,235/153,0,0,,,,EXPIRED
213,CA,A,CA 613982 A,028-001-907-072-047,1961-02-07,1961,CA 613982D A,,CA 613982T A,,ISOMERIZATION PROCESS AND CATALYST THEREFOR,,STANDARD OIL CO,STINE HARRISON M;;CALLAHAN JAMES L,,https://lens.org/028-001-907-072-047,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
214,EP,A1,EP 1532133 A1,034-094-630-560-939,2005-05-25,2005,EP 03757317 A,2003-05-29,US 0317385 W;;US 38655602 P,2002-06-06,NF-:B INHIBITORS,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;LI YUE H,GLAXOSMITHKLINE LLC (2010-03-31),https://lens.org/034-094-630-560-939,Patent Application,yes,0,0,9,9,0,A61P1/04;;A61P3/10;;A61P7/00;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;C07D333/38;;C07D333/38,A61K31/381;;A61P1/04;;A61P3/10;;A61P7/00;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P43/00;;C07D333/36;;C07D333/38;;C07D333/40,,0,0,,,,DISCONTINUED
215,US,A,US 3472892 A,048-122-606-887-441,1969-10-14,1969,US 3472892D A,1967-05-10,US 63740767 A,1967-05-10,FLUID BED PROCESS FOR SYNTHESIS OF NITRILES BY AMMOXIDATION AND THE RECYCLING OF AMMONIA-RICH CATALYST FROM A QUENCH ZONE TO A REACTION ZONE,,STANDARD OIL CO,CALLAHAN JAMES L;;MILBERGER ERNEST C,,https://lens.org/048-122-606-887-441,Granted Patent,no,1,26,1,1,0,B01J8/0055;;B01J8/24;;B01J8/34;;B01J8/386;;B01J2208/0084;;C07C253/26;;Y02P20/584;;C07C253/26;;B01J8/386;;B01J2208/0084;;B01J8/34;;B01J8/24;;B01J8/0055;;Y02P20/584,B01J8/00;;B01J8/24;;B01J8/34;;B01J8/38,260/465.3,0,0,,,,EXPIRED
216,US,A,US 4572331 A,061-159-777-634-377,1986-02-25,1986,US 60213384 A,1984-04-19,US 60213384 A,1984-04-19,Reversible feeder system,A cyclical lubricant feeder utilizing series spool valves to dispense measured quantities of lubricant to dispensing outlets from a common feed source with a plurality of the spool valves arranged in series in valve block assemblies which in turn are in series with one another whereby dispensing through the outlet for each spool valve in a block assembly is in progression with the other outlets from the spool valves in the valve block assembly is provided with a control valve controlling inlet and outlet flow to the valve block assembly bypassing flow from the inlet to the outlet when all of the valves in the block have been shifted to one side and bypassing flow from the outlet to the inlet upon reverse lubricant flow to the block only when all of the valves in the block have been shifted to the other side.,LUBRIQUIP HOUDAILLE INC,POWELL JOHN H;;CALLAHAN JAMES J,LUBRIQUIP - HOUDAILLE INC. A CORP OF DE (1985-01-31);;LUBRIQUIP INC (1987-01-15);;HOUDAILLE INDUSTRIES INC. ON FINANCIAL PLAZA FT. LAUDERDALE FLA. A DE CORP (1984-03-29),https://lens.org/061-159-777-634-377,Granted Patent,yes,6,29,6,6,0,F16N25/02;;Y10T137/86445;;Y10T137/86445;;F16N25/02,F16N25/02,184/7.4;;137/624.18,0,0,,,,EXPIRED
217,CA,A,CA 1065029 A,087-092-365-438-644,1979-10-23,1979,CA 250368 A,1976-04-15,US 60538975 A,1975-08-18,ELECTRICAL CABLE ADAPTED FOR USE ON A TRACTOR TRAILER,"ELECTRICAL CABLE ADAPTED FOR USE ON A TRACTOR-TRAILER An electrical cable of conventional or retractable helical coil form which is relatively small in diameter and sufficiently flexible to be used to advantage on a tractortrailer to connect the power supply on the tractor with the electrical system carried by the trailer has a polymeric sheath, an insulated 10 gauge stranded conductor substantially coaxial with the sheath, four to six insulated stranded 12 gauge conductors substantially evenly spaced about the periphery of the 10 gauge conductor, a plurality of uninsulated stranded conductors of 14 gauge disposed between the smaller insulated conductors, filler material filling the spaces between the conductors and preferably a plastic film helically wound about the conductors. The 12 and 14 gauge conductors are helically wound about the 10 gauge conductor. The assembly of conductors, filler and plastic film combine to form a cable having a substantially circular cross-section and substantially fill the sheath. The cable is preferably coiled into a self-storing configuration.",MOORE & CO SAMUEL,SNOW JOHN P;;CALLAHAN JAMES J,,https://lens.org/087-092-365-438-644,Granted Patent,no,0,0,7,7,0,H01B7/041;;H01B7/06;;H01B7/041;;H01B7/06,H01B7/04;;H01B7/06;;H01B7/17,337-27,0,0,,,,EXPIRED
218,US,A,US 5407338 A,125-597-895-341-815,1995-04-18,1995,US 92688992 A,1992-08-07,US 92688992 A,1992-08-07,Manual resin extruder for effecting glass repair,A resin extruder for supplying resin to flaws in laminated glass includes a casing forming a resin reservoir from which resin is dispensed through a nozzle by screwing inward a ram partially received in the casing and carrying a pressure gauge communicating with the reservoir.,CALLAHAN; MICHAEL J.;;FIKSE; JAMES A.,CALLAHAN MICHAEL J;;FIKSE JAMES A,,https://lens.org/125-597-895-341-815,Granted Patent,yes,21,12,1,1,0,B29C73/025;;B29L2031/3052;;B29C48/03;;B29C48/475;;B29C73/025;;B29L2031/3052;;B29C48/475;;B29C48/03,B29C48/475;;B29C73/02,425/12;;264/36;;264/40.3;;425/13;;425/170,0,0,,,,EXPIRED
219,CA,A,CA 848965 A,130-110-407-795-02X,1970-08-11,1970,CA 848965D A,,CA 848965T A,,ATTRITION RESISTANT SOLID CATALYSTS,,STANDARD OIL CO,CALLAHAN JAMES L;;KNIPPLE WARREN R,,https://lens.org/130-110-407-795-02X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
220,CA,C,CA 2081960 C,153-011-111-743-723,1996-01-23,1996,CA 2081960 A,1992-11-02,US 79027991 A,1991-11-07,WIDE NIP WEB PRESS AND METHOD USING A PRESS SHOE WITH TWO PIVOTS,"A wide area type of wet press for dewatering an endless traveling web, such as paper, wherein a shoe having a curved face is applied to a traveling belt which travels through a high pressure zone between the shoe and a rotating backing roll. The nip line of the most intense nip pressure along the length of contact of the shoe over the backing roll is selectively located, as desired, by pivotally supporting the shoe about two, parallel, longitudinally extending axes which, in turn, are supported on separately controlled hydraulic pistons. The pressure profile of the nip pressure over the face of the shoe can also be altered by controlling the hydraulic pressure in the support pistons.",BELOIT TECHNOLOGIES INC,CRONIN DENNIS CALLAHAN;;ROERIG ARNOLD JAMES,,https://lens.org/153-011-111-743-723,Granted Patent,no,0,0,5,5,0,D21F3/0218;;D21F3/0218,D21F3/02,,0,0,,,,EXPIRED
221,EP,A4,EP 1532133 A4,181-881-725-539-22X,2006-11-15,2006,EP 03757317 A,2003-05-29,US 0317385 W;;US 38655602 P,2002-06-06,NF-:B INHIBITORS,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;LI YUE H,GLAXOSMITHKLINE LLC (2010-03-31),https://lens.org/181-881-725-539-22X,Search Report,no,2,0,9,9,0,C07D333/38;;A61P1/04;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;A61P7/00;;A61P9/10;;A61P3/10;;C07D333/38,A61K31/381;;A61P1/04;;A61P3/10;;A61P7/00;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P43/00;;C07D333/36;;C07D333/38;;C07D333/40,,2,0,,,"DATABASE REGISTRY CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 25 February 2003 (2003-02-25), XP002398374, retrieved from STN Database accession no. RN 494772-50-8;;See also references of WO 03104218A1",DISCONTINUED
222,DE,A1,DE 1593543 A1,055-812-674-830-932,1970-07-16,1970,DE ST025439 A,1966-05-21,US 46303665 A,1965-06-10,Verfahren zur Herstellung von Diolefinen,,STANDARD OIL CO,KARL GRASSELLI ROBERT;;LOUIS CALLAHAN JAMES,,https://lens.org/055-812-674-830-932,Patent Application,no,0,0,14,15,0,B01J27/192;;B01J27/192;;C07C5/48;;C07C5/48,B01J27/192;;C07C5/48,,0,0,,,,DISCONTINUED
223,AT,T1,AT E414697 T1,054-179-441-466-466,2008-12-15,2008,AT 02800491 T,2002-10-04,US 32697601 P,2001-10-04,NF-KB-INHIBITOREN,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-beta phosphorylation of IkappaB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-kappaB in which diseases excessive activation of NF-kappaB is implicated.,SMITHKLINE BEECHAM CORP,WAN ZEHONG;;BURGESS JOELLE;;CALLAHAN JAMES,,https://lens.org/054-179-441-466-466,Granted Patent,no,0,0,10,10,0,C07D333/36;;C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;A61P9/00;;A61P3/10;;C07D333/36;;C07D333/38,A61K31/381;;A61P1/04;;A61P3/10;;A61P9/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;C07D333/36;;C07D333/38;;C07D333/40,,0,0,,,,EXPIRED
224,AU,A,AU 1976/016899 A,092-609-945-212-297,1978-02-23,1978,AU 1976/016899 A,1976-08-17,US 60538975 A,1975-08-18,FLEXIBLE CABLES,,EATON CORP,SNOW JOHN P;;CALLAHAN JAMES J,,https://lens.org/092-609-945-212-297,Patent Application,no,0,0,7,7,0,H01B7/041;;H01B7/06;;H01B7/041;;H01B7/06,H01B7/04;;H01B7/06;;H01B7/17,,0,0,,,,EXPIRED
225,WO,A1,WO 1994/022440 A1,113-632-531-704-166,1994-10-13,1994,US 9403387 W,1994-03-29,US 3839393 A,1993-03-29,BICYCLIC COMPOUNDS WHICH INHIBIT PLATELET AGGREGATION,"This invention relates to compounds of formula (I), or a pharmaceutically acceptable salt thereof, which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.",SMITHKLINE BEECHAM CORP;;CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM F,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM F,,https://lens.org/113-632-531-704-166,Patent Application,yes,1,2,1,1,0,C07D245/06,C07D245/06,,0,0,,,,PENDING
226,WO,A2,WO 2002/030353 A2,131-595-339-217-678,2002-04-18,2002,US 0131866 W,2001-10-12,US 23975900 P,2000-10-12,NF- DOLLAR G(K)B INHIBITORS,The present invention provides novel compounds and methods for treating diseases with aminothiophene inhibitors of IKK-ß phosphorylation of IλB.,SMITHKLINE BEECHAM CORP;;CALLAHAN JAMES F;;ROSHAK AMY K,CALLAHAN JAMES F;;ROSHAK AMY K,,https://lens.org/131-595-339-217-678,Patent Application,yes,0,42,6,6,0,A61K31/38;;A61P1/04;;A61P3/10;;A61P7/00;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00,C07D333/38;;A61K31/38;;A61K31/381;;A61P1/04;;A61P3/10;;A61P7/00;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00;;C07D409/04,,0,0,,,,PENDING
227,AU,B2,AU 498332 B2,160-004-642-546-989,1979-03-01,1979,AU 1976/016899 A,1976-08-17,US 60538975 A,1975-08-18,COILED TRAILOR CABLE,,MOORE & CO SAMUEL,SNOW JOHN P;;CALLAHAN JAMES J,,https://lens.org/160-004-642-546-989,Granted Patent,no,0,1,7,7,0,H01B7/041;;H01B7/06;;H01B7/041;;H01B7/06,H01B7/04;;H01B7/06;;H01B7/17,,0,0,,,,EXPIRED
228,US,S,US D0252812 S,167-583-465-082-741,1979-09-04,1979,US 81398377 F,1977-07-08,US 81398377 F,1977-07-08,Water treatment diswashing apparatus,,AMERICAN STERILIZER CO,ANDREWS JAMES P;;CALLAHAN ARTHUR C,AUTOMATED WASHING SYSTEMS INC. A CORP. OF N.Y (1980-08-01),https://lens.org/167-583-465-082-741,Design Right,yes,0,1,1,1,0,,,D15/35;;D1505,2,0,,,"institutions/Volume Feeding-Feb. 1, 1976, p.7, Hobart Diswasher.;;Institutions/Volume Feeding-Feb. 1, 1976, p. 15, Vulcan Diswasher.",EXPIRED
229,US,B2,US 7183311 B2,181-582-172-717-62X,2007-02-27,2007,US 51084104 A,2004-10-08,US 51084104 A;;US 37194602 P;;US 0311297 W,2002-04-11,NF-kappaB inhibitors,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-β phosphorylation of IκB. In yso doing these aminothiophene inhibitors block pathological activation of transcription factor NF-κB in which diseases excessive activation of NF-κB is implicated.,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;LI YUE H,SMITHKLINE BEECHAM CORPORATION (2003-04-09),https://lens.org/181-582-172-717-62X,Granted Patent,yes,9,0,16,16,1,C07D333/74;;C07D333/78;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/08;;A61P9/10;;A61P3/10;;C07D333/74;;C07D333/78,A61K31/38;;C07D333/50;;A61K31/381;;A61P1/00;;A61P3/10;;A61P9/00;;A61P9/08;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/02;;A61P43/00;;C07D327/04;;C07D333/74;;C07D333/78,514/443;;549/31,0,0,,,,EXPIRED
230,AU,A1,AU 2003/249683 A1,188-961-793-836-511,2003-12-22,2003,AU 2003/249683 A,2003-05-29,US 38655602 P;;US 0317385 W,2002-06-06,NF-:B INHIBITORS,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;LI YUE H,,https://lens.org/188-961-793-836-511,Patent Application,no,0,0,9,9,0,A61P1/04;;A61P3/10;;A61P7/00;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;C07D333/38;;C07D333/38,A61K31/381;;A61P1/04;;A61P3/10;;A61P7/00;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P43/00;;C07D333/36;;C07D333/38;;C07D333/40,,0,0,,,,DISCONTINUED
231,WO,A1,WO 1994/022444 A1,197-720-055-344-696,1994-10-13,1994,US 9403383 W,1994-03-29,US 3838293 A,1993-03-29,TRICYCLIC COMPOUNDS FOR INHIBITING PLATELET AGGREGATION,"This invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof, which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.",SMITHKLINE BEECHAM CORP;;CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM F,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM F,,https://lens.org/197-720-055-344-696,Patent Application,yes,1,3,1,1,0,C07D487/04,C07D487/04,,0,0,,,,PENDING
232,AU,A,AU 1976/020999 A,037-379-246-012-098,1978-07-06,1978,AU 1976/020999 A,1976-12-31,US 65309276 A,1976-01-28,POWER SUPPLY FOR SPARK PLUG TESTER,,CHAMPION SPARK PLUG CO,GREEN SAM JAMES;;CALLAHAN RICHARD EDWARD,,https://lens.org/037-379-246-012-098,Patent Application,no,0,0,20,20,0,H01T13/58;;H01T13/58,H01T13/58,,0,0,,,,EXPIRED
233,US,A,US 3538571 A,057-650-001-730-965,1970-11-10,1970,US 3538571D A,1969-04-04,US 84086869 A,1969-04-04,APPARATUS FOR PRODUCING CERAMIC CHIP ELECTRICAL COMPONENTS,,MALLORY & CO INC P R,CALLAHAN JAMES P;;STARK RICHARD A,,https://lens.org/057-650-001-730-965,Granted Patent,no,10,19,1,1,0,H01G13/00;;H01G13/00;;Y10T29/43;;Y10T29/43;;Y10T29/435;;Y10T29/435,H01G13/00,29/25.41,0,0,,,,EXPIRED
234,PH,A,PH 20384 A,068-157-959-417-774,1986-12-08,1986,PH 31152 A,1984-08-28,US 53500083 A,1983-09-22,BASIC HEPTAPEPTIDE VASOPRESSIN ANTAGONISTS,"Compounds of the formula (I) <CHEM> in which: A is -NR-(CH2)n,-NH2 or -NR-(CH2)n-NH-@@NR2; Z is Phe, Phe(4 min -Alk) or Tyr(Alk); X is D-Phe, D-Phe(4 min Alk), D-Val, D-Nva, D-Leu, D-Ile, D-Pba, D-Nle, D-Cha, D-Abu, D-Met, D-Chg, D-Tyr, L-Tyr, D-Tyr(Alk) or L-Tyr(Alk); P is D-Pro, L-Pro, DELTA <3>-Pro, L-Ala, L-N-MeAla, L-Gly, L-Sar or a single bond; Y is Val, Ile, Abu, Ala, Chg, Gln, Lys, Cha, Nle, Phe, Leu or Gly; R is, in each case, hydrogen or C1-5-alkyl; n is an integer from 2-8; m is an integer from 0-2; and Alk is C1-4-alkyl; and pharmaceutically acceptable acid addition salts thereof are vasopressin antagonists. Their preparation and pharmaceutical use are described.",SMITHKLINE BECKMAN CORP,FRANCIS CALLAHAN JAMES;;LEE MOORE MICHAEL,,https://lens.org/068-157-959-417-774,Granted Patent,no,0,0,30,31,0,A61K38/00;;C07K7/16;;A61P5/00;;A61P7/10;;C07K7/06,A61K38/00;;A61K38/095;;A61P5/00;;A61P7/10;;C07K1/00;;C07K1/113;;C07K7/16;;C07K7/50;;C07K14/575,,0,0,,,,EXPIRED
235,US,B2,US 6644736 B2,071-359-592-133-436,2003-11-11,2003,US 6156102 A,2002-02-01,US 6156102 A,2002-02-01,Privacy seat divider for transport vehicles,"
    A fan-type foldable device for sub-dividing for privacy purposes, the space occupied by a passenger seated in a moving vehicle or a movie theatre, is described. The fan type device incorporates a means for coupling onto a side of a seat back, thereby maintaining privacy within the sub-divide. Said fan type device folds out of the way when not in use. The fan type foldable device may be used in a seating arrangement wherein rows of seats are divided by the fan type such that each seated passenger is able to enjoy privacy from adjoining passengers. 
",BOEING CO,NGUYEN TONY HOANG;;CALLAHAN JAMES D,BOEING COMPANY THE (2001-12-12),https://lens.org/071-359-592-133-436,Granted Patent,yes,22,53,2,2,0,A47C1/12;;A47C7/62;;B64D11/0606;;B64D11/0606,A47C1/12;;A47C7/62;;B64D11/06,297/184.17;;297/184.15;;160/84.07,0,0,,,,EXPIRED
236,CH,A,CH 438227 A,079-030-030-611-827,1967-06-30,1967,CH 600064 A,1964-05-08,US 27930863 A;;US 31165763 A;;US 63857767 A,1963-05-09,Procédé pour préparer des catalyseurs solides contenant de l'antimoine,,STANDARD OIL CO OHIO,JAMES LOUIS CALLAHAN;;WARREN RUSSEL KNIPPLE,,https://lens.org/079-030-030-611-827,Granted Patent,no,0,0,12,15,0,B01J21/00;;B01J21/00;;B01J23/16;;B01J23/16;;B01J23/18;;B01J23/18;;B01J23/6445;;B01J23/6445;;B01J23/681;;B01J23/681;;B01J23/8435;;B01J23/8435;;B01J27/1815;;B01J27/1815;;B01J37/0009;;B01J37/0009;;C07C5/48;;C07C5/48;;C07C45/35;;C07C45/35;;C07C253/26;;C07C253/26;;Y02P20/52;;Y02P20/52;;Y10S502/503;;Y10S502/503;;Y10S502/504;;Y10S502/504;;Y10S585/906;;Y10S585/906,B01J21/00;;B01J23/16;;B01J23/18;;B01J23/644;;B01J23/68;;B01J23/843;;B01J27/18;;B01J37/00;;C07C5/48;;C07C45/35,"12G,11/32",0,0,,,,EXPIRED
237,US,A1,US 2004/0024047 A1,105-553-219-833-873,2004-02-05,2004,US 39884703 A,2003-04-10,US 39884703 A;;US 0131866 W,2001-10-12,Nf-kb inhibitors,"
   The present invention provides novel compounds and methods for treating diseases with aminothiophene inhibitors of IKK- phosphorylation of IB. 
",CALLAHAN JAMES F.;;ROSHAK AMY K.,CALLAHAN JAMES F;;ROSHAK AMY K,SMITHKLINE BEECHMAN CORPORATION (2001-11-30),https://lens.org/105-553-219-833-873,Patent Application,yes,0,6,2,2,0,A61K31/381;;A61K31/4436;;A61K31/4436;;A61K31/381,A61K31/381,514/438;;514/444;;514/447,0,0,,,,DISCONTINUED
238,ZA,B,ZA 98118 B,102-513-674-601-577,1998-07-08,1998,ZA 98118 A,1998-01-07,US 3405997 P,1997-01-08,Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease,,WARNER LAMBERT CO,SCHWARZ ROY DOUVILLE;;CALLAHAN MICHAEL JAMES,,https://lens.org/102-513-674-601-577,Granted Patent,no,0,0,1,5,0,,A61K/,,0,0,,,,EXPIRED
239,CA,A,CA 861404 A,107-801-495-415-873,1971-01-19,1971,CA 861404D A,,CA 861404T A,,METHOD OF PRODUCING CERAMIC WAFER,,MALLORY & CO INC P R,STARK RICHARD A;;CALLAHAN JAMES P,,https://lens.org/107-801-495-415-873,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
240,DE,A1,DE 2314151 A1,099-585-457-384-824,1973-10-18,1973,DE 2314151 A,1973-03-21,US 23852072 A,1972-03-27,VERFAHREN ZUR HERSTELLUNG EINES AROMATISCHEN ODER HETEROCYCLISCHEN AROMATISCHEN NITRILS,,STANDARD OIL CO OHIO,CRASSELLI ROBERT KARL;;CALLAHAN JAMES LOUIS,,https://lens.org/099-585-457-384-824,Patent Application,no,1,2,12,12,0,B01J23/8872;;B01J23/8872;;B01J23/8876;;B01J23/8876;;C07C253/28;;C07C253/28,C07D215/48;;B01J23/00;;B01J23/88;;C07B61/00;;C07C67/00;;C07C253/00;;C07C255/49;;C07C255/50;;C07C255/51;;C07D213/84,,0,0,,,,EXPIRED
241,CA,C,CA 2118372 C,117-003-181-162-339,1999-08-24,1999,CA 2118372 A,1994-10-18,CA 2118372 A,1994-10-18,MANUAL RESIN EXTRUDER FOR EFFECTING GLASS REPAIR,A resin extruder for supplying resin to flaws in laminated glass includes a casing forming a resin reservoir from which resin is dispensed through a nozzle by screwing inward a ram partially received in the casing and carrying a pressure gauge communicating with the reservoir.,CALLAHAN MICHAEL J;;FIKSE JAMES A,CALLAHAN MICHAEL J;;FIKSE JAMES A,,https://lens.org/117-003-181-162-339,Granted Patent,no,0,0,2,2,0,,,,0,0,,,,EXPIRED
242,US,A1,US 2006/0030596 A1,144-867-061-725-923,2006-02-09,2006,US 23723205 A,2005-09-28,US 23723205 A;;US 39884703 A;;US 0131866 W;;US 23975900 P,2000-10-12,NF-kappaB inhibitors,The present invention provides novel compounds and methods for treating diseases with aminothiophene inhibitors of IKK-β phosphorylation of IκB.,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;ROSHAK AMY K,,https://lens.org/144-867-061-725-923,Patent Application,yes,1,1,2,2,0,A61K31/381;;A61K31/4436;;A61K31/4436;;A61K31/381,A61K31/4436;;A61K31/381,514/336;;514/448;;514/445,0,0,,,,DISCONTINUED
243,CA,A,CA 846997 A,146-457-504-077-234,1970-07-14,1970,CA 846997D A,,CA 846997T A,,CERAMIC CHIP ELECTRICAL COMPONENTS,,MALLORY & CO INC P R,STARK RICHARD A;;CALLAHAN JAMES P,,https://lens.org/146-457-504-077-234,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
244,EP,A4,EP 0557406 A4,154-984-919-057-926,1993-10-06,1993,EP 92900014 A,1991-10-31,US 60813890 A,1990-11-01,-G(G)-TURN PEPTIDOMIMETICS AS FIBRINOGEN ANTAGONISTS,,SMITH-KLINE BEECHAM CORPORATION,"CALLAHAN, JAMES, FRANCIS;;HUFFMAN, WILLIAM, FRANCIS",,https://lens.org/154-984-919-057-926,Search Report,no,1,0,5,5,0,A61P7/02;;A61P9/04;;C07D223/10;;C07D223/10;;C07D243/06;;C07D243/06,A61K31/55;;A61K38/46;;A61P7/02;;A61P9/04;;C07D223/04;;C07D223/06;;C07D223/08;;C07D223/10;;C07D243/06;;C07D401/06;;C07D401/14;;C07D403/06;;C07D403/14;;C07D409/06;;C07D409/14,,4,1,079-760-668-100-692,10.1021/jm00099a027;;1433204,"SYNTHETIC PEPTIDES: APPROACHES TO BIOLOGICAL PROBLEMS 1986, NEW YORK pages 257 - 266 'Mimics of Secondary Structural elements of peptides and proteins';;PEPTIDES:CHEMISTRY AND BIOLOGY,PROCEEDINGS OF THE TENTH AMERICAN PEPTIDE SYMPOSIUM 1988, LEIDEN pages 105 - 108 'Reverse turn mimics';;JOURNAL OF MEDICINAL CHEMISTRY vol. 35, 1992, pages 3970 - 3972 'Design and synthesis of a c7 mimetic for the predicted gamma-turn conformation found in several constrained RGD antagonists';;See also references of WO 9207568A1",DISCONTINUED
245,US,A,US 4099597 A,173-718-107-704-670,1978-07-11,1978,US 71638176 A,1976-08-23,US 71638176 A,1976-08-23,Lubrication pump,"A lubrication device employing a reciprocable plunger, as the actuating member, which is driven by a rotatable cam member through a pivoted rocker arm engaged with the plunger and having roller means engaging the cam, with the axis of the plunger, respective pivotal axes of the cam, arm and roller means, and line contacts between the roller and cam and between plunger and arm being so related that actuating forces are transmitted from the cam to the plunger substantially on the axis of the plunger, substantially eliminating undesirable lateral forces on component parts and enabling the use of simple bearing structures for the cam shaft. Operation is further improved by a novel disposition of valve means in the lubricant supply line.",HOUDAILLE INDUSTRIES INC,POWELL JOHN H;;CALLAHAN JAMES J,LUBRIQUIP - HOUDAILLE INC. A CORP OF DE (1985-01-31);;LUBRIQUIP INC (1987-01-15),https://lens.org/173-718-107-704-670,Granted Patent,yes,10,24,4,4,0,F04B9/042;;F04B9/14;;F04B23/021;;F04B23/06;;F16N13/14;;F04B23/06;;F16N13/14;;F04B23/021;;F04B9/14;;F04B9/042,F04B9/04;;F04B9/14;;F04B23/02;;F04B23/06;;F16N13/14,184 27B,0,0,,,,EXPIRED
246,EP,A2,EP 1499605 A2,169-281-022-024-779,2005-01-26,2005,EP 03721638 A,2003-04-11,US 0311297 W;;US 37194602 P,2002-04-11,NF-KappaB INHIBITORS,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;LI YUE H,,https://lens.org/169-281-022-024-779,Patent Application,yes,0,0,16,16,0,C07D333/74;;C07D333/78;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/08;;A61P9/10;;A61P3/10;;C07D333/74;;C07D333/78,C07D333/50;;A61K31/381;;A61P1/00;;A61P3/10;;A61P9/00;;A61P9/08;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/02;;A61P43/00;;C07D333/74;;C07D333/78,,0,0,,,,EXPIRED
247,AU,A1,AU 2003/224941 A1,181-471-907-544-984,2003-10-27,2003,AU 2003/224941 A,2003-04-11,US 37194602 P;;US 0311297 W,2002-04-11,NF-KappaB INHIBITORS,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;LI YUE H,,https://lens.org/181-471-907-544-984,Patent Application,no,0,0,16,16,0,C07D333/74;;C07D333/78;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/08;;A61P9/10;;A61P3/10;;C07D333/74;;C07D333/78,C07D333/50;;A61K31/381;;A61P1/00;;A61P3/10;;A61P9/00;;A61P9/08;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/02;;A61P43/00;;C07D333/74;;C07D333/78,,0,0,,,,DISCONTINUED
248,CH,A,CH 420118 A,014-175-277-592-84X,1966-09-15,1966,CH 1457263 A,1963-11-28,US 24073362 A,1962-11-28,Procédé de préparation de nitriles,,STANDARD OIL CO OHIO,JAMES LOUIS CALLAHAN;;ERNEST CARL MILBERGER,,https://lens.org/014-175-277-592-84X,Granted Patent,no,0,0,14,14,0,B01J8/26;;B01J21/00;;B01J21/08;;B01J27/188;;C07C253/26;;Y02P20/52;;B01J8/26;;B01J21/00;;B01J27/188;;C07C253/26;;B01J21/08;;Y02P20/52,B01J8/26;;B01J21/00;;B01J21/08;;B01J27/188,"12O,21",0,0,,,,EXPIRED
249,WO,A1,WO 2009/033182 A1,018-239-915-668-788,2009-03-12,2009,US 2008/0075641 W,2008-09-08,US 96784207 P,2007-09-07,DYNAMICALLY UPDATING PRIVACY SETTINGS IN A SOCIAL NETWORK,"A social network allows its members to regulate what data is accessible to other members using one or more privacy settings. A particular member of the social network can modify the one or privacy settings to grant or deny different users access to different data. When a member modifies a privacy setting, the social network determines which information pathways communicating data between members are affected. The affected information pathways are then modified responsive to the privacy setting to communicate data identified by the modified privacy setting and enforce the new privacy restrictions.",FACEBOOK INC;;CALLAHAN EZRA;;WANG JAMES;;VERA NICO,CALLAHAN EZRA;;WANG JAMES;;VERA NICO,,https://lens.org/018-239-915-668-788,Patent Application,yes,2,20,11,11,0,G06F21/604;;G06F21/6245;;G06F21/6263;;G06F2221/2141;;G06Q30/02;;H04L63/102;;H04L67/306;;G06F21/604;;G06F21/6245;;G06F21/6263;;G06F2221/2141;;G06Q30/02;;H04L63/102;;H04L67/306;;G06F2221/2115;;G06F2221/2119;;G06F21/62,G06F17/30;;G06F21/00;;G06F21/60;;G06F21/62,,0,0,,,,PENDING
250,CA,A,CA 767676 A,008-432-386-514-59X,1967-09-19,1967,CA 767676D A,,CA 767676T A,,MANUFACTURE OF AROMATIC ALDEHYDES AND NITRILES,,STANDARD OIL CO,GRASSELLI ROBERT K;;CALLAHAN JAMES L,,https://lens.org/008-432-386-514-59X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
251,US,A,US 3563138 A,034-178-406-750-066,1971-02-16,1971,US 3563138D A,1969-06-23,US 83540069 A,1969-06-23,DIFFERENTIAL PRESSURE RESPONSIVE DEVICE WITH DIAPHRAGM EQUALIZATION,,SYBRON CORP,SYMONDS JAMES A;;CALLAHAN JOHN J,COMBUSTION ENGINEERING INC. A COR OF DE (1983-09-30),https://lens.org/034-178-406-750-066,Granted Patent,no,5,10,1,1,0,F15B5/00;;G01L13/025;;F15B5/00;;G01L13/025,F15B5/00;;G01L13/02,92/48,0,0,,,,EXPIRED
252,CN,A,CN 110116380 A,118-458-418-343-670,2019-08-13,2019,CN 201910096477 A,2019-01-31,US 201815891236 A,2018-02-07,"TOOLS FOR ROTATING FASTENERS, METHODS OF UTILIZING THE TOOLS, AND METHODS OF MANUFACTURING THE TOOLS","The invention relates to tools (100) for rotating fasteners (22), methods of utilizing the tools (100), and methods of manufacturing the tools (100). The tools (100) include a gripping region (110), afastener receptacle (120), and an interlock structure (140). The gripping region (110) is configured to be gripped by a user of the tool (100). The fastener receptacle (120) is shaped to receive thefasteners (22) and includes a fastener-receiving opening on a fastener-facing side (102) of the tool. The fastener-facing side (102) faces in a fastener-facing direction. The fastener-receiving opening (122) is sized to permit the fastener (22) to enter the fastener receptacle (120) from the fastener-facing side (102) of the tool (100). The interlock structure (140) is configured to interlock withthe fastener (22) while the fastener (22) is received within the fastener receptacle (120). The interlock structure (140) also is configured to prevent motion of the tool away from the fastener (22)in a fastener-opposed direction, which is opposed to the fastener-facing side (102) of the tool (100), while the interlock region is interlocked with the fastener.",BOEING CO LTD,ETTLING KARL JAMES;;CALLAHAN RUSSELL PETE,,https://lens.org/118-458-418-343-670,Patent Application,no,5,0,6,6,0,B25B11/00;;B25B13/5091;;B25G1/102;;B25B23/105;;B25B21/002;;B23P2700/01;;B25B23/1427;;B25B21/004;;B25G1/00;;B25B13/5091,B25B11/00,,0,0,,,,ACTIVE
253,AU,A,AU 1971/031224 A,160-203-132-910-068,1973-03-01,1973,AU 1971/031224 A,1971-07-14,US 6041170 A,1970-08-03,LUBRICATING APPARATUS,,MCCORD CORP,CALLAHAN JAMES J;;SNOW JOHN PROCTOR,,https://lens.org/160-203-132-910-068,Patent Application,no,0,0,9,10,0,F01M1/04;;F01M1/04;;F16N7/30;;F16N7/30,F01M1/04;;F16N7/30,,0,0,,,,DISCONTINUED
254,US,A,US 3230246 A,001-910-915-866-136,1966-01-18,1966,US 24073362 A,1962-11-28,US 24073362 A,1962-11-28,Process for preparing olefinically unsaturated nitriles,,STANDARD OIL CO,CALLAHAN JAMES L;;MILBERGER ERNEST C,,https://lens.org/001-910-915-866-136,Granted Patent,no,6,25,14,14,0,B01J8/26;;B01J21/00;;B01J21/08;;B01J27/188;;C07C253/26;;Y02P20/52;;B01J8/26;;B01J21/00;;B01J27/188;;C07C253/26;;B01J21/08;;Y02P20/52,B01J8/26;;B01J21/00;;B01J21/08;;B01J27/188,,0,0,,,,EXPIRED
255,US,A1,US 2006/0116419 A1,005-902-933-718-415,2006-06-01,2006,US 53769705 A,2005-06-06,US 53769705 A;;US 43149602 P;;US 0338970 W,2002-12-06,Nf-kb inhibitors,The present invention provides a specific compound and methods for treating diseases related to the inhibition of IKK-β phosphorylation of IK.,CALLAHAN JAMES F;;LI YUE H,CALLAHAN JAMES F;;LI YUE H,SMITHKLINE BEECHAM CORPORATION (2004-01-19),https://lens.org/005-902-933-718-415,Patent Application,yes,1,25,8,8,1,A61K31/381;;C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P17/16;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/08;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/10;;A61P9/14;;A61P3/10;;A61K31/381;;C07D333/38,A61K31/381;;C07D333/38;;C07D333/42,514/447;;549/63,0,0,,,,DISCONTINUED
256,DE,A1,DE 2654091 A1,023-341-188-076-226,1977-08-11,1977,DE 2654091 A,1976-11-29,US 65309276 A,1976-01-28,ANORDNUNG ZUM PRUEFEN VON ZUENDKERZEN,,CHAMPION SPARK PLUG CO,GREEN SAM JAMES;;CALLAHAN RICHARD EDWARD,,https://lens.org/023-341-188-076-226,Patent Application,no,0,0,20,20,0,H01T13/58;;H01T13/58,H01T13/58,,0,0,,,,DISCONTINUED
257,US,A1,US 2020/0265822 A1,060-268-085-319-938,2020-08-20,2020,US 201916275635 A,2019-02-14,US 201916275635 A,2019-02-14,ACTIVE HELMHOLTZ RESONATOR WITH ACTUATED MEMBRANE,A vehicle exhaust component includes a body with an open inner cavity providing a fixed volume and a neck having one end associated with the fixed volume and an opposite end associated with an exhaust gas flow path. A flexible membrane separates the fixed volume into a first chamber and a second chamber. An actuator is used to vary a tension of the flexible membrane.,FAURECIA EMISSIONS CONTROL TECHNOLOGIES USA LLC,EGAN JAMES;;BERGER MATTHIAS;;CALLAHAN JOE,FAURECIA EMISSIONS CONTROL TECHNOLOGIES USA LLC (2019-02-11),https://lens.org/060-268-085-319-938,Patent Application,yes,0,0,1,1,0,F01N1/023;;F01N1/023;;F01N1/161;;F01N1/22;;F01N2340/00;;G10K11/172;;G10K11/161;;G10K11/172;;G10K2210/12822;;G10K2210/3226;;G10K2210/32272,G10K11/172;;F01N1/02;;G10K11/16,,0,0,,,,DISCONTINUED
258,DE,B,DE 1289372 B,062-548-033-307-934,1969-02-13,1969,DE T0032947 A,1967-01-10,DE T0032947 A,1967-01-10,Einrichtung zur UEberwachung der Schmiermittelfoerderung in einem Schmiersystem,,HOUDAILLE INDUSTRIES INC,J CALLAHAN JAMES;;D ROBERTS ROBERT,,https://lens.org/062-548-033-307-934,Patent Application,no,3,0,1,1,0,F16N29/04,F16N29/04,,0,0,,,,DISCONTINUED
259,EP,A1,EP 0557406 A1,064-652-663-513-153,1993-09-01,1993,EP 92900014 A,1991-10-31,US 60813890 A,1990-11-01,-g(g)-TURN PEPTIDOMIMETICS AS FIBRINOGEN ANTAGONISTS.,L'invention se rapporte à un procédé de prévention de l'agrégation des plaquettes et à des composés imitant la séquence de peptides Arg-Gly-Asp.,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS,,https://lens.org/064-652-663-513-153,Patent Application,yes,0,0,5,5,0,A61P7/02;;A61P9/04;;C07D223/10;;C07D223/10;;C07D243/06;;C07D243/06,A61K31/55;;A61K38/46;;A61P7/02;;A61P9/04;;C07D223/04;;C07D223/06;;C07D223/08;;C07D223/10;;C07D243/06;;C07D401/06;;C07D401/14;;C07D403/06;;C07D403/14;;C07D409/06;;C07D409/14,,0,0,,,,DISCONTINUED
260,US,A,US 4852566 A,096-281-598-329-747,1989-08-01,1989,US 21480888 A,1988-07-01,US 21480888 A;;US 92850086 A,1986-11-07,Device for implantation of intraocular lens,"A device for controlling the release of retracted haptics on an intraocular lens is described. By controlling the retraction of the haptics, it is possible to obtain a more precise placement of the lens in the eye. The lens is attached to the device by means of sutures, which allows the lens to be safely and conveniently positioned in the eye.",CALLAHAN WAYNE B;;BURNES JAMES E,CALLAHAN WAYNE B;;BURNES JAMES E,,https://lens.org/096-281-598-329-747,Granted Patent,yes,13,50,1,1,0,A61F2/1662;;A61F2/1662,A61F2/16,128303R,0,0,,,,EXPIRED
261,WO,A3,WO 2002/030353 A3,106-542-221-634-817,2002-06-27,2002,US 0131866 W,2001-10-12,US 23975900 P,2000-10-12,NF- kappa B INHIBITORS,The present invention provides novel compounds and methods for treating diseases with aminothiophene inhibitors of IKK-ß phosphorylation of IλB.,SMITHKLINE BEECHAM CORP;;CALLAHAN JAMES F;;ROSHAK AMY K,CALLAHAN JAMES F;;ROSHAK AMY K,,https://lens.org/106-542-221-634-817,Search Report,yes,1,0,6,6,0,A61K31/38;;A61P1/04;;A61P3/10;;A61P7/00;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00,C07D333/38;;A61K31/38;;A61K31/381;;A61P1/04;;A61P3/10;;A61P7/00;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00;;C07D409/04,,3,0,,,"DATABASE HCAPLUS [online] (COLUMBUS, OHIO, USA); KAFUKU ET AL., XP002908444, accession no. STN Database accession no. 1995:330565;;DATABASE HCAPLUS [online] (COLUMBUS, OHIO, USA); KAFUKU ET AL., XP002908443, accession no. STN Database accession no. 1995:259796;;See also references of EP 1324759A4",PENDING
262,DE,B,DE 1259307 B,197-707-578-863-034,1968-01-25,1968,DE ST022102 A,1964-05-08,US 27930863 A;;US 31165763 A;;US 63857767 A,1963-05-09,Verfahren zur Herstellung von gegen Abrieb bestaendigen Oxydationskatalysatoren,,STANDARD OIL CO,CALLAHAN JAMES LOUIS;;KNIPPLE WARREN RUSSELL,,https://lens.org/197-707-578-863-034,Patent Application,no,3,0,12,15,0,B01J21/00;;B01J21/00;;B01J23/16;;B01J23/16;;B01J23/18;;B01J23/18;;B01J23/6445;;B01J23/6445;;B01J23/681;;B01J23/681;;B01J23/8435;;B01J23/8435;;B01J27/1815;;B01J27/1815;;B01J37/0009;;B01J37/0009;;C07C5/48;;C07C5/48;;C07C45/35;;C07C45/35;;C07C253/26;;C07C253/26;;Y02P20/52;;Y02P20/52;;Y10S502/503;;Y10S502/503;;Y10S502/504;;Y10S502/504;;Y10S585/906;;Y10S585/906,B01J21/00;;B01J23/16;;B01J23/18;;B01J23/644;;B01J23/68;;B01J23/843;;B01J27/18;;B01J37/00;;C07C5/48;;C07C45/35,,0,0,,,,DISCONTINUED
263,WO,A2,WO 2004/053087 A2,031-739-828-400-486,2004-06-24,2004,US 0338970 W,2003-12-05,US 43149602 P,2002-12-06,NF-KappaB INHIBITORS,The present invention provides a specific compound and methods for treating diseases related to the inhibition of IKK-&bgr; phosphorylation of I&kappa;.,SMITHKLINE BEECHAM CORP;;CALLAHAN JAMES FRANCES;;LI YUE HU,CALLAHAN JAMES FRANCES;;LI YUE HU,,https://lens.org/031-739-828-400-486,Patent Application,yes,0,10,8,8,0,A61K31/381;;C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P17/16;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/08;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/10;;A61P9/14;;A61P3/10;;A61K31/381;;C07D333/38,A61K31/381;;C07D333/38,,0,0,,,,PENDING
264,US,A,US 1116832 A,049-695-596-065-296,1914-11-10,1914,US 1914/0812513 A,1914-01-16,US 1914/0812513 A,1914-01-16,HEATER.,,MILNER JAMES E;;CALLAHAN JOHN N,MILNER JAMES E;;CALLAHAN JOHN N,,https://lens.org/049-695-596-065-296,Granted Patent,no,0,3,1,1,0,F24C3/042;;F24C3/042,,,0,0,,,,EXPIRED
265,CA,A,CA 807205 A,049-151-559-376-719,1969-02-25,1969,CA 807205D A,,CA 807205T A,,OXYDEHYDROGENATION PROCESS,,STANDARD OIL CO,GRASSELLI ROBERT K;;CALLAHAN JAMES L,,https://lens.org/049-151-559-376-719,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
266,US,A,US 4156621 A,068-744-944-337-196,1979-05-29,1979,US 83732077 A,1977-09-28,US 83732077 A,1977-09-28,Regeneration of used dishwashing water without chemical additives for sanitizing and spot-free rinse uses,"An improved dishwashing system includes operating methods and apparatus for water and energy conservation and elimination of spot-reducing chemicals in the rinse water. Return water from the rinse cycle is stored in insulated tanks and rinse water flowing to the dishwasher absorbs heat from the return water to thereby conserve the heat energy of the return water while simultaneously cooling the return water to a selected temperature in preparing a feed solution for membrane separation. A controlled quantity of make-up water is added to the feed solution which is raised to a selected pressure to provide for reverse osmosis purification and deionization. The reverse osmosis effluent is accumulated and, when needed, boosted in pressure to a desired operational dishwasher pressure, and heated to sanitizing level so as to achieve desired bacterial count levels during rinse cycles. Rinsing with the purified and deionized water results in film-free and spot-free dishes after drying.",AMERICAN STERILIZER CO,ANDREWS JAMES P;;CALLAHAN ARTHUR C,AUTOMATED WASHING SYSTEMS INC. A CORP. OF N.Y (1980-08-01),https://lens.org/068-744-944-337-196,Granted Patent,yes,9,71,2,2,0,A47L15/4291;;B01D61/025;;B01D2311/10;;B01D2313/50;;Y02B40/00;;A47L15/4291;;B01D2311/10;;B01D61/025;;B01D2313/50;;Y02B40/00,A47L15/24;;A47L15/42,134/10,1,0,,,"Tech Data Champion Industries Inc. R.O. Unit 6802(1M), 4/76.",EXPIRED
267,US,A,US 3095452 A,124-728-933-614-919,1963-06-25,1963,US 461160 A,1960-01-26,US 461160 A,1960-01-26,Manufacture of crotonaldehyde,,STANDARD OIL CO,CALLAHAN JAMES L;;FOREMAN ROBERT W,,https://lens.org/124-728-933-614-919,Granted Patent,no,2,1,1,1,0,B01J27/19;;B01J27/19;;C07C45/28;;C07C45/28,B01J27/19;;C07C45/28,,0,0,,,,EXPIRED
268,AU,A1,AU 2003/300832 A1,156-603-548-298-907,2004-06-30,2004,AU 2003/300832 A,2003-12-05,US 43149602 P;;US 0338970 W,2002-12-06,NF-KappaB INHIBITORS,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCES;;LI YUE HU,,https://lens.org/156-603-548-298-907,Patent Application,no,0,0,8,8,0,A61K31/381;;C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P17/16;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/08;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/06;;A61P37/08;;A61P43/00;;A61P9/10;;A61P9/14;;A61P3/10;;A61K31/381;;C07D333/38,A61K31/381;;C07D333/38,,0,0,,,,DISCONTINUED
269,CA,A,CA 817542 A,162-792-799-404-009,1969-07-08,1969,CA 817542D A,,CA 817542T A,,LUBRICATION AND MONITORING SYSTEM,,HOUDAILLE INDUSTRIES INC,CALLAHAN JAMES J;;ROBERTS ROBERT D,,https://lens.org/162-792-799-404-009,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
270,US,A,US 2819229 A,176-739-075-050-546,1958-01-07,1958,US 40008753 A,1953-12-23,US 40008753 A,1953-12-23,Preparation of microsphere chromiaalumina catalyst,,STANDARD OIL CO,STRECKER HAROLD A;;CALLAHAN JAMES L,,https://lens.org/176-739-075-050-546,Granted Patent,no,5,5,1,1,0,B01J23/26;;B01J23/26,B01J23/26,,0,0,,,,EXPIRED
271,US,A1,US 2005/0165086 A1,002-605-898-383-268,2005-07-28,2005,US 51084104 A,2004-10-08,US 51084104 A;;US 37194602 P;;US 0311297 W,2002-04-11,Nf-kb inhibitors,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-β phosphorylation of IκB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-κB in which diseases excessive activation of NF-κB is implicated.,CALLAHAN JAMES F.;;LI YUE H.,CALLAHAN JAMES F;;LI YUE H,SMITHKLINE BEECHAM CORPORATION (2003-04-09),https://lens.org/002-605-898-383-268,Patent Application,yes,7,8,16,16,1,C07D333/74;;C07D333/78;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/08;;A61P9/10;;A61P3/10;;C07D333/74;;C07D333/78,C07D333/50;;A61K31/381;;A61P1/00;;A61P3/10;;A61P9/00;;A61P9/08;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/02;;A61P43/00;;C07D333/74;;C07D333/78,514/443;;549/43,0,0,,,,EXPIRED
272,DE,A1,DE 1764018 A1,004-804-539-857-729,1971-04-08,1971,DE 1764018 A,1968-03-22,US 62545967 A,1967-03-23,Verfahren zur Herstellung von elektrischen Elementen aus Keramikscheiben und Einrichtung zur Durchfuehrung des Verfahrens,,MALLORY & CO INC P R,PATRICK CALLAHAN JAMES;;ANTHONY STARK RICHARD,,https://lens.org/004-804-539-857-729,Patent Application,no,0,0,2,2,0,H01G13/00;;H01G4/1272,H01G4/12;;H01G13/00,,0,0,,,,DISCONTINUED
273,TW,A,TW 200404791 A,007-051-226-148-96X,2004-04-01,2004,TW 92115160 A,2003-06-05,US 38655602 P,2002-06-06,NF-kB inhibitors,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-β phosphorylation of IκB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-κB in which diseases excessive activation of NF-κB is implicated.,SMITHKLINE BEECHAM CORP,LI YUE-HU;;CALLAHAN JAMES F,,https://lens.org/007-051-226-148-96X,Patent of Addition,no,0,0,9,9,0,A61P1/04;;A61P3/10;;A61P7/00;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;C07D333/38;;C07D333/38,A61K31/381;;A61P1/04;;A61P3/10;;A61P7/00;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P43/00;;C07D333/36;;C07D333/38;;C07D333/40,,0,0,,,,PENDING
274,DE,T2,DE 60316425 T2,020-419-989-138-309,2008-06-19,2008,DE 60316425 T,2003-04-11,US 37194602 P;;US 0311297 W,2002-04-11,NF-kappaB-INHIBITOREN,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;LI YUE H,,https://lens.org/020-419-989-138-309,Granted Patent,no,0,0,16,16,0,C07D333/74;;C07D333/78;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/08;;A61P9/10;;A61P3/10;;C07D333/74;;C07D333/78,C07D333/50;;C07D333/74;;A61K31/38;;A61K31/381;;A61P1/00;;A61P3/10;;A61P9/00;;A61P9/08;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P43/00;;C07D333/78,,0,0,,,,EXPIRED
275,US,A1,US 2005/0165087 A1,051-199-096-826-57X,2005-07-28,2005,US 51683604 A,2004-12-03,US 51683604 A;;US 38655602 P;;US 0317385 W,2002-06-06,Nf-kb inhibitors,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-β phosphorylation of IκB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-κB in which diseases excessive activation of NF-κB is implicated.,CALLAHAN JAMES F.;;LI YUE HU,CALLAHAN JAMES F;;LI YUE HU,,https://lens.org/051-199-096-826-57X,Patent Application,yes,12,10,9,9,0,A61P1/04;;A61P3/10;;A61P7/00;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;C07D333/38;;C07D333/38,A61K31/381;;A61P1/04;;A61P3/10;;A61P7/00;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P43/00;;C07D333/36;;C07D333/38;;C07D333/40,514/447;;549/69,0,0,,,,EXPIRED
276,DE,B,DE 1206883 B,075-688-265-727-969,1965-12-16,1965,DE ST018648 A,1961-12-06,US 1206883X A,1960-12-19,Verfahren zur Herstellung von Acetonitril,,STANDARD OIL CO,CALLAHAN JAMES LOUIS;;STAMM JOHN ALBERT,,https://lens.org/075-688-265-727-969,Patent Application,no,0,0,1,1,0,B01J27/192;;C07C253/24,B01J27/192,,0,0,,,,DISCONTINUED
277,CA,A,CA 122880 A,089-115-670-728-48X,1909-12-28,1909,CA 122880D A,1909-08-24,CA 122880T A,1909-08-24,SIGNAL LANTERN,,CALLAHAN JAMES H;;BROWN GEORGE P,CALLAHAN JAMES H;;BROWN GEORGE P,,https://lens.org/089-115-670-728-48X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
278,CA,A,CA 1082112 A,107-430-123-106-199,1980-07-22,1980,CA 275283 A,1977-03-31,US 71638176 A,1976-08-23,LUBRICATION PUMP,"A lubrication device employing a reciprocable plunger, as the actuating member, which is driven by a rotatable cam member through a pivoted rocker arm engaged with the plunger and having roller means engaging the cam, with the axis of the plunger, respective pivotal axes of the cam, arm and roller means, and line contacts between the roller and cam and between plunger and arm being so related that actuating forces are transmitted from the cam to the plunger substantially on the axis of the plunger, substantially eliminating undesirable lateral forces on component parts and enabling the use of simple bearing structures for the cam shaft. Operation is further improved by a novel disposition of valve means in the lubricant supply line.",HOUDAILLE INDUSTRIES INC,POWELL JOHN H;;CALLAHAN JAMES J,,https://lens.org/107-430-123-106-199,Granted Patent,no,0,0,4,4,0,F04B9/042;;F04B9/14;;F04B23/021;;F04B23/06;;F16N13/14;;F04B23/06;;F16N13/14;;F04B23/021;;F04B9/14;;F04B9/042,F04B9/04;;F04B9/14;;F04B23/02;;F04B23/06;;F16N13/14,184-40,0,0,,,,EXPIRED
279,CA,A,CA 742727 A,101-979-135-538-802,1966-09-13,1966,CA 742727D A,,US 24073362 A,1962-11-28,PROCESS FOR PREPARING OLEFINICALLY UNSATURATED NITRILES,,STANDARD OIL CO,CALLAHAN JAMES L;;MILBERGER ERNEST C,,https://lens.org/101-979-135-538-802,Granted Patent,no,0,0,14,14,0,B01J8/26;;B01J21/00;;B01J21/08;;B01J27/188;;C07C253/26;;Y02P20/52;;B01J8/26;;B01J21/00;;B01J27/188;;C07C253/26;;B01J21/08;;Y02P20/52,B01J8/26;;B01J21/00;;B01J21/08;;B01J27/188,,0,0,,,,EXPIRED
280,JP,A,JP 2019166630 A,114-391-939-813-325,2019-10-03,2019,JP 2019008969 A,2019-01-23,US 201815891236 A,2018-02-07,"TOOLS FOR ROTATING FASTENERS, METHODS OF UTILIZING THOSE TOOLS, AND METHODS OF MANUFACTURING THOSE TOOLS","To provide improved tools for rotating fasteners, improved methods of utilizing the tools, and/or improved methods of manufacturing the tools.SOLUTION: A gripping region 110 is configured to be gripped by a user of a tool 100. A fastener receptacle 120 is shaped to receive the fasteners and includes a fastener-receiving opening on a fastener-facing side 102 of the tool 100. The fastener-facing side 102 faces in a fastener-facing direction 106. The fastener-receiving opening 122 is sized to permit the fastener to enter the fastener receptacle 120 from the fastener-facing side 102 of the tool 100. An interlock structure 140 is configured to interlock with the fastener while the fastener is received within the fastener receptacle 120. The interlock structure 140 is also configured to prevent motion of the tool 100 away from the fastener in a fastener-opposed direction 108, which is opposed to the fastener-facing side 102 of the tool 100, while the interlock region is interlocked with the fastener.SELECTED DRAWING: Figure 3",BOEING CO,KARL JAMES ETTLING;;RUSSELL PETE CALLAHAN,,https://lens.org/114-391-939-813-325,Patent Application,no,0,0,6,6,0,B25B11/00;;B25B13/5091;;B25G1/102;;B25B23/105;;B25B21/002;;B23P2700/01;;B25B23/1427;;B25B21/004;;B25G1/00;;B25B13/5091,B25B13/50,,0,0,,,,ACTIVE
281,CA,A,CA 874690 A,119-378-708-694-926,1971-06-29,1971,CA 874690D A,,CA 874690T A,,CERAMIC CHIP ELECTRICAL COMPONENT,,MALLORY & CO INC P R,CALLAHAN JAMES P;;STARK RICHARD A,,https://lens.org/119-378-708-694-926,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
282,EP,A1,EP 1169317 A1,159-101-882-333-535,2002-01-09,2002,EP 00930101 A,2000-04-06,US 0009147 W;;US 12868799 P,1999-04-09,TRIARYLIMIDAZOLES,"Compounds of formula (I) or a pharmaceutically acceptable salt thereof:wherein R1, R2 and R3 are various substituent groups; andone of X1 and X2 is N or CR', and the other is NR' or CHR' wherein R' is hydrogen, OH, C1-6alkyl, or C3-7cycloalkyl; or when one of X1 and X2 is N or CR' then the other may be S or O;and their use as pharmaceuticals.",SMITHKLINE BEECHAM CORP,BURGESS JOELLE LORRAINE;;CALLAHAN JAMES FRANCIS,SMITHKLINE BEECHAM CORPORATION (2002-05-02),https://lens.org/159-101-882-333-535,Patent Application,yes,0,0,11,11,0,C07D401/04;;C07D405/14;;C07D413/04;;A61P13/12;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/28;;A61P27/02;;A61P43/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D401/04;;C07D413/04;;C07D405/14,A61K31/443;;A61K31/4433;;A61K31/4439;;A61P3/10;;A61P9/04;;A61P9/10;;A61P13/12;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/28;;A61P27/02;;A61P43/00;;C07D401/04;;C07D405/14;;C07D413/04;;C07D413/14,,0,0,,,,EXPIRED
283,EP,B1,EP 1499605 B1,077-996-279-492-571,2007-09-19,2007,EP 03721638 A,2003-04-11,US 0311297 W;;US 37194602 P,2002-04-11,NF-KappaB INHIBITORS,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;LI YUE H,,https://lens.org/077-996-279-492-571,Granted Patent,yes,4,0,16,16,0,C07D333/74;;C07D333/78;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/08;;A61P9/10;;A61P3/10;;C07D333/74;;C07D333/78,C07D333/50;;C07D333/74;;A61K31/38;;A61K31/381;;A61P1/00;;A61P3/10;;A61P9/00;;A61P9/08;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P43/00;;C07D333/78,,0,0,,,,EXPIRED
284,AU,A,AU 2002/011663 A,073-203-682-648-558,2002-04-22,2002,AU 2002/011663 A,2001-10-12,US 23975900 P;;US 0131866 W,2000-10-12,NF-$G(K)B inhibitors,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;ROSHAK AMY K,,https://lens.org/073-203-682-648-558,Patent Application,no,0,0,6,6,0,A61K31/38;;A61P1/04;;A61P3/10;;A61P7/00;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00,C07D333/38;;A61K31/38;;A61K31/381;;A61P1/04;;A61P3/10;;A61P7/00;;A61P9/00;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/08;;A61P43/00;;C07D409/04,,0,0,,,,PENDING
285,US,A,US 5539104 A,093-661-701-279-393,1996-07-23,1996,US 23216994 A,1994-04-29,US 23216994 A;;US 78567291 A;;US 9209467 W,1991-10-31,"1,4 Diazocines as fibrinogen antagonists","This invention relates to a method of inhibiting platelet aggregation using 1,4-diazocine compounds which are mimics of the peptide sequence Arg--Gly--Asp.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;HUFFMAN WILLIAM F,SMITHKLINE BEECHAM CORPORATION (1994-04-22),https://lens.org/093-661-701-279-393,Granted Patent,yes,7,0,4,4,0,C07D245/02;;C07K5/0202;;C07K5/06139;;C07K5/0821;;C07K14/75;;A61P7/02;;C07K5/06139;;C07K5/0202;;C07K14/75;;C07D245/02;;C07K5/0821,A61P7/02;;C07D245/02;;C07D401/12;;C07D403/12;;C07K5/02;;C07K5/078;;A61K31/395;;C07K5/097;;C07K14/75,540/460;;540/451,1,0,,,"Huffman et al, Peptides Chemistry & Biol., 10th Symposium, pp. 105 108 (1988).",EXPIRED
286,CA,A,CA 954521 A,082-983-708-791-341,1974-09-10,1974,CA 166671 A,1973-03-21,US 23852072 A,1972-03-27,PREPARATION OF AROMATIC NITRILES,,STANDARD OIL CO OHIO,GRASSELLI ROBERT K;;CALLAHAN JAMES L,,https://lens.org/082-983-708-791-341,Granted Patent,no,0,0,12,12,0,B01J23/8872;;B01J23/8872;;B01J23/8876;;B01J23/8876;;C07C253/28;;C07C253/28,C07D215/48;;B01J23/00;;B01J23/88;;C07B61/00;;C07C67/00;;C07C253/00;;C07C255/49;;C07C255/50;;C07C255/51;;C07D213/84,260-288,0,0,,,,EXPIRED
287,AU,B2,AU 2008/295996 B2,113-231-094-998-68X,2012-09-06,2012,AU 2008/295996 A,2008-09-08,US 96784207 P;;US 2008/0075641 W,2007-09-07,Dynamically updating privacy settings in a social network,"A social network allows its members to regulate what data is accessible to other members using one or more privacy settings. A particular member of the social network can modify the one or privacy settings to grant or deny different users access to different data. When a member modifies a privacy setting, the social network determines which information pathways communicating data between members are affected. The affected information pathways are then modified responsive to the privacy setting to communicate data identified by the modified privacy setting and enforce the new privacy restrictions.",FACEBOOK INC,VERA NICOLAS;;CALLAHAN EZRA;;WANG JAMES,,https://lens.org/113-231-094-998-68X,Granted Patent,no,2,0,11,11,0,G06F21/604;;G06F21/6245;;G06F21/6263;;G06F2221/2141;;G06Q30/02;;H04L63/102;;H04L67/306;;G06F21/604;;G06F21/6245;;G06F21/6263;;G06F2221/2141;;G06Q30/02;;H04L63/102;;H04L67/306;;G06F2221/2115;;G06F2221/2119;;G06F21/62,G06F17/30;;G06F21/00;;G06F21/60;;G06F21/62,,0,0,,,,INACTIVE
288,US,A,US 2945908 A,124-837-794-941-014,1960-07-19,1960,US 55644955 A,1955-12-30,US 55644955 A,1955-12-30,Isomerization process and catalyst therefor,,STANDARD OIL CO,STINE HARRISON M;;CALLAHAN JAMES L,,https://lens.org/124-837-794-941-014,Granted Patent,no,6,0,1,1,0,C07C5/2772;;C07C5/2772,C07C5/27,,0,0,,,,EXPIRED
289,AU,A1,AU 2008/295996 A1,112-965-837-747-926,2009-03-12,2009,AU 2008/295996 A,2008-09-08,US 96784207 P;;US 2008/0075641 W,2007-09-07,Dynamically updating privacy settings in a social network,,FACEBOOK INC,WANG JAMES;;CALLAHAN EZRA;;VERA NICOLAS,,https://lens.org/112-965-837-747-926,Patent Application,no,0,0,11,11,0,G06F21/604;;G06F21/6245;;G06F21/6263;;G06F2221/2141;;G06Q30/02;;H04L63/102;;H04L67/306;;G06F21/604;;G06F21/6245;;G06F21/6263;;G06F2221/2141;;G06Q30/02;;H04L63/102;;H04L67/306;;G06F2221/2115;;G06F2221/2119;;G06F21/62,G06F17/30;;G06F21/00;;G06F21/60;;G06F21/62,,0,0,,,,INACTIVE
290,US,A,US 2945909 A,131-713-283-302-068,1960-07-19,1960,US 55645055 A,1955-12-30,US 55645055 A,1955-12-30,Isomerization process and catalyst therefor,,STANDARD OIL CO,STINE HARRISON M;;CALLAHAN JAMES L,,https://lens.org/131-713-283-302-068,Granted Patent,no,5,3,1,1,0,B01J23/26;;C07C5/2772;;B01J23/26;;C07C5/2772,B01J23/26;;C07C5/27,,0,0,,,,EXPIRED
291,US,A,US 3693757 A,130-773-746-809-809,1972-09-26,1972,US 3693757D A,1970-08-03,US 6041170 A,1970-08-03,LUBRICATING APPARATUS,"Lubricating apparatus for automatically providing a constant supply of lubricant to air operated tools during the operation of such tools, including an expansible and contractible pump chamber having an intake port for connection with a supply of lubricant and a delivery port for delivering lubricant from the pump chamber to the tool being lubricated. The apparatus includes a main air passage for connection with a source of air under pressure for driving the tool, and a normally closed control valve controls flow through the main air passage and is movable to an open position to permit flow through the air passage in response to a pressure drop between the upstream and downstream sides of the valve caused by starting the tool into operation. Means operable in response to air flow through the main passage causes the pump chamber to alternately expand and contract and pump lubricant to the working parts of the tool so long as the tool is in operation. The cycle of the pump can be selectively adjusted to increase or decrease the rate of flow of lubricant to the tool.",MCCORD CORP,CALLAHAN JAMES J;;SNOW JOHN PROCTOR,,https://lens.org/130-773-746-809-809,Granted Patent,no,5,29,9,10,0,F01M1/04;;F01M1/04;;F16N7/30;;F16N7/30,F01M1/04;;F16N7/30,184  7   D;;184/29;;184 56   A,0,0,,,,EXPIRED
292,DE,A1,DE 1493193 A1,144-846-901-291-986,1969-08-07,1969,DE 1493193 A,1964-05-22,US 35602864 A,1964-03-31,Verfahren zur Herstellung von Diolefinen und aromatischen Verbindungen,,STANDARD OIL CO,LOUIS CALLAHAN JAMES;;CARL MILBERGER ERNEST,,https://lens.org/144-846-901-291-986,Patent Application,no,0,0,7,8,0,B01J21/00;;B01J23/18;;B01J23/8435;;C07C5/48;;C07C5/48;;B01J23/8435;;B01J23/18;;B01J21/00,B01J21/00;;B01J23/18;;B01J23/843;;C07C5/48,,0,0,,,,DISCONTINUED
293,NO,L,NO 770256 L,005-614-101-843-911,1977-07-29,1977,NO 770256 A,1977-01-26,US 65309276 A,1976-01-28,SPENNINGSKILDE TIL } P}TRYKKE H¦YSPENNINGSPULSER OVER EN TENNPLUGG I ET TENNPLUGG-PR¦VEAPPARAT.,,CHAMPION SPARK PLUG CO,GREEN SAM JAMES;;CALLAHAN RICHARD EDWARD,,https://lens.org/005-614-101-843-911,Abstract,no,0,0,20,20,0,H01T13/58;;H01T13/58,H01T13/58,,0,0,,,,DISCONTINUED
294,WO,A1,WO 2003/104218 A1,053-270-795-562-114,2003-12-18,2003,US 0317385 W,2003-05-29,US 38655602 P,2002-06-06,NF-:B INHIBITORS,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-&szlig; phosphorylation of I:B. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-:B in which diseases excessive activation of NF-:B is implicated.,SMITHKLINE BEECHAM CORP;;CALLAHAN JAMES F;;LI YUE H,CALLAHAN JAMES F;;LI YUE H,,https://lens.org/053-270-795-562-114,Patent Application,yes,0,0,9,9,0,A61P1/04;;A61P3/10;;A61P7/00;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P37/06;;A61P43/00;;C07D333/38;;C07D333/38,A61K31/381;;A61P1/04;;A61P3/10;;A61P7/00;;A61P9/10;;A61P11/06;;A61P13/12;;A61P17/02;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/06;;A61P43/00;;C07D333/36;;C07D333/38;;C07D333/40,,2,0,,,"DATABASE HCAPLUS [online] GRIFFITHS D. ET AL.: ""Preparation of ureido-carboxamido thiophenes as inhibitors of IKK2 kinase"", XP002970303, accession no. STN Database accession no. 2003:97415;;See also references of EP 1532133A4",PENDING
295,US,B1,US 6465493 B1,086-460-034-063-585,2002-10-15,2002,US 95863901 A,2001-10-09,US 95863901 A;;US 12868799 P;;US 0009147 W,1999-04-09,Triarylimidazoles,"
    Compounds of formula (I) or a pharmaceutically acceptable salt thereof: 

    wherein R _{ 1 } , R _{ 2 } and R _{ 3 } are various substituent groups; and 

    one of X _{ 1 } and X _{ 2 } is N or CR, and the other is NR or CHR wherein R is hydrogen, OH, C _{ 1-6 } alkyl, or C _{ 3-7 } cycloalkyl; or when one of X _{ 1 } and X _{ 2 } is N or CR then the other may be S or O; 

    and their use as pharmaceuticals. 
",SMITHKLINE BEECHAM CORP,BURGESS JOELLE L;;CALLAHAN JAMES F,GLAXOSMITHKLINE LLC (2001-09-27),https://lens.org/086-460-034-063-585,Granted Patent,yes,5,41,11,11,0,C07D401/04;;C07D405/14;;C07D413/04;;A61P13/12;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/28;;A61P27/02;;A61P43/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D401/04;;C07D413/04;;C07D405/14,A61K31/443;;A61K31/4433;;A61K31/4439;;A61P3/10;;A61P9/04;;A61P9/10;;A61P13/12;;A61P17/02;;A61P19/00;;A61P19/02;;A61P19/10;;A61P25/28;;A61P27/02;;A61P43/00;;C07D401/04;;C07D405/14;;C07D413/04;;C07D413/14,514/341;;514/277;;514/340;;514/342;;514/357;;546/269.7;;546/271.4;;546/272.7;;546/276.4;;546/280.4;;546/283.4;;546/329;;546/339,1,0,,,"Chemical Abstracts, vol. 131, No. 7, 1999 Columbus Ohio, Abstract No. 87659s, p. 641 (XP002146305).",EXPIRED
296,US,A,US 3127954 A,082-955-791-171-005,1964-04-07,1964,US 21919962 A,1962-08-24,US 21919962 A,1962-08-24,Lubrication monitoring system,,TRABON ENGINEERING CORP,CALLAHAN JAMES J;;ROBERTS ROBERT D,,https://lens.org/082-955-791-171-005,Granted Patent,no,2,14,1,1,0,F16N25/02;;F16N29/04;;F16N2230/10;;F16N29/04;;F16N2230/10;;F16N25/02,F16N25/02;;F16N29/04,,0,0,,,,EXPIRED
297,CA,A,CA 1237992 A,088-914-359-757-637,1988-06-14,1988,CA 479436 A,1985-04-18,US 60213384 A,1984-04-19,REVERSIBLE FEEDER SYSTEM,"REVERSIBLE FEEDER SYSTEM A cyclical lubricant feeder utilizing series spool valves to dispense measured quantities of lubricant to dispensing outlets (120,121) from a common feed source (11) with a plurality of the spool valves arranged in series in valve block assemblies (15) which in turn are in series with one another whereby dispensing through the outlet (120,121) for each spool valve in a block assembly (15) is in progression with the other outlets from the spool valves (120,121) in the valve block assembly (15) is provided with a control valve (124) controlling inlet and outlet flow to the valve block assembly bypassing flow from the inlet (140) to the outlet (141) when all of the valves in the block have been shifted to one side and bypassing flow from the outlet (141) to the inlet (140) upon reverse lubricant flow to the block only when all of the valves in the block have been shifted to the other side.",LUBRIQUIP HOUDAILLE INC,POWELL JOHN H;;CALLAHAN JAMES J,,https://lens.org/088-914-359-757-637,Granted Patent,no,0,0,6,6,0,F16N25/02;;Y10T137/86445;;Y10T137/86445;;F16N25/02,F16N25/02,184-27,0,0,,,,EXPIRED
298,CA,A,CA 789056 A,114-038-628-919-061,1968-07-02,1968,CA 789056D A,,CA 789056T A,,PROCESS FOR PREPARING DIOLEFINS AND AROMATICS,,STANDARD OIL CO,CALLAHAN JAMES L;;MILBERGER ERNEST C,,https://lens.org/114-038-628-919-061,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
299,US,A,US 3088990 A,105-589-949-610-211,1963-05-07,1963,US 2440660 A,1960-04-25,US 2440660 A,1960-04-25,Energy conversion system,,STANDARD OIL CO,RIGHTMIRE ROBERT A;;CALLAHAN JAMES L,,https://lens.org/105-589-949-610-211,Granted Patent,no,2,39,1,1,0,H01M8/182;;Y02E60/50;;H01M8/182;;Y02E60/50,H01M8/18,,0,0,,,,EXPIRED
300,CO,A1,CO 5011095 A1,156-554-329-780-746,2001-02-28,2001,CO 98000653 A,1998-01-08,US 3405997 P;;US 6588697 P,1997-01-08,INHIBIDORES DE ACETILCOLINESTARASA EN COMBINACION CON AGO- NISTAS MUSCARINICOS PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER,"Una composición que comprende una cantidad efectiva de uninhibidor de acetilcolesterasa combinado con una cantidad efectiva de un agonista muscarínico. Una combinación de la Reivindicación 1, donde el inhibidor de acetilcolinesterasa es 1,2,3,4-tetrahidro-5-aminoacridina (tacrina): 1-bencil-4-(5.6-dimetioxi-1-indanon)-2-il) metil-piperidina (donepezil); (S)-[N-etil-3-[(1-dimetilamino)etil]-N-metil-fenil-carbamato]) (exelon); O,O-dimetil-(1-hidroxi-2.2- tricloroetil)fosfonato (metrifonato) ó benzazepinoles (galantamina). Una combinación de la Reivindicación 2, donde el agonista muscarínico es: clorhidrato de 1,2,5,6-tetrahidro-1-metil-3-piridina-carboxaldehi-do-O-metiloxima (milamelina): 3-(3-hexiloxi-1,2,5-tiodiazol-4-il)-1,2,5,6-tetrahidro-1-metilpi-ridina (xanomelina); 1-aza-biciclo-[2.2.1]heptan- 3-ona-O-[3-(3-metoxifenil)-prop-2-inil]oxima (CI-1017); (2R)-3-(2-propiniloxi)quiniclidina (talsaclidina); monohidrato de (S)-(-)-2.8-dimetil- 3-metilen-1-oxa-1-8-azaspirona-[4.5] decano L-tartrato (YM-796) ó R-(Z)-a-metoxi-imino)-1-azobiciclo[2.2.2] octano-3-acetonitrilo (memric).",WARNER LAMBERT CO,ROY DOUVILLE SCHWARZ;;CALLAHAN MICHAEL JAMES,,https://lens.org/156-554-329-780-746,Patent Application,no,0,0,4,5,0,A61K45/06;;A61K31/00,A61K45/06,,0,0,,,,PENDING
301,CA,C,CA 2696945 C,162-537-184-072-759,2014-12-02,2014,CA 2696945 A,2008-09-08,US 96784207 P;;US 2008/0075641 W,2007-09-07,DYNAMICALLY UPDATING PRIVACY SETTINGS IN A SOCIAL NETWORK,"A social network allows its members to regulate what data is accessible to other members using one or more privacy settings. A particular member of the social network can modify the one or privacy settings to grant or deny different users access to different data. When a member modifies a privacy setting, the social network determines which information pathways communicating data between members are affected. The affected information pathways are then modified responsive to the privacy setting to communicate data identified by the modified privacy setting and enforce the new privacy restrictions.",FACEBOOK INC,CALLAHAN EZRA;;WANG JAMES;;VERA NICO,,https://lens.org/162-537-184-072-759,Granted Patent,no,0,0,11,11,0,G06F21/604;;G06F21/6245;;G06F21/6263;;G06F2221/2141;;G06Q30/02;;H04L63/102;;H04L67/306;;G06F21/604;;G06F21/6245;;G06F21/6263;;G06F2221/2141;;G06Q30/02;;H04L63/102;;H04L67/306;;G06F2221/2115;;G06F2221/2119;;G06F21/62,H04L12/16;;G06F21/00;;G06F21/60;;G06F21/62,,0,0,,,,INACTIVE
302,US,A,US 3566204 A,171-465-963-089-257,1971-02-23,1971,US 3566204D A,1969-04-04,US 84086969 A,1969-04-04,CERAMIC CHIP CAPACITOR HAVING COPLANAR SURFACES,,MALLORY & CO INC P R,CALLAHAN JAMES P;;STARK RICHARD A,,https://lens.org/171-465-963-089-257,Granted Patent,no,0,5,1,1,0,H01G2/065;;H01G4/0085;;H05K1/0306;;H05K3/0097;;H01G2/065;;H05K3/0097;;H05K1/0306;;H01G4/0085,H01G2/06;;H01G4/008;;H05K1/03;;H05K3/00,317/230,0,0,,,,EXPIRED
303,WO,A2,WO 2003/086309 A2,175-346-600-842-100,2003-10-23,2003,US 0311297 W,2003-04-11,US 37194602 P,2002-04-11,NF-kappaB INHIBITORS,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-&bgr; phosphorylation of I&kappa;B. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-&kappa;B in which diseases excessive activation of NF-&kappa;B is implicated.,SMITHKLINE BEECHAM CORP;;CALLAHAN JAMES F;;LI YUE H,CALLAHAN JAMES F;;LI YUE H,,https://lens.org/175-346-600-842-100,Patent Application,yes,0,0,16,16,0,C07D333/74;;C07D333/78;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/00;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/02;;A61P43/00;;A61P9/00;;A61P9/08;;A61P9/10;;A61P3/10;;C07D333/74;;C07D333/78,C07D333/50;;A61K31/381;;A61P1/00;;A61P3/10;;A61P9/00;;A61P9/08;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/02;;A61P43/00;;C07D333/74;;C07D333/78,,0,0,,,,PATENTED
304,US,S,US D0351543 S,192-894-551-501-177,1994-10-18,1994,US 92689692 F,1992-08-07,US 92689692 F,1992-08-07,Glass crack repair tool,,CALLAHAN MICHAEL J;;FIKSE JAMES A,CALLAHAN MICHAEL J;;FIKSE JAMES A,,https://lens.org/192-894-551-501-177,Design Right,yes,9,3,1,1,0,,,D 8 51,0,0,,,,EXPIRED
305,US,A,US 3862544 A,063-418-173-448-73X,1975-01-28,1975,US 22157772 A,1972-01-28,US 22157772 A;;US 6041170 A,1970-08-03,LUBRICATING APPARATUS,"Lubricating apparatus for automatically providing a constant supply of lubricant to air operated tools during the operation of such tools, including an expansible and contractible pump chamber having an intake port for connection with a supply of lubricant and a delivery port for delivering lubricant from the pump chamber to the tool being lubricated. The apparatus includes a main air passage for connection with a source of air under pressure for driving the tool, and a normally closed control valve controls flow through the main air passage and is movable to an open position to permit flow through the air passage in response to a pressure drop between the upstream and downstream sides of the valve caused by starting the tool into operation. Means operable in response to air flow through the main passage causes the pump chamber to alternately expand and contract and pump lubricant to the working parts of the tool so long as the tool is in operation. The cycle of the pump can be selectively adjusted to increase or decrease the rate of flow of lubricant to the tool.",MCNEIL CORP,CALLAHAN JAMES J;;SNOW JOHN PROCTER,,https://lens.org/063-418-173-448-73X,Granted Patent,no,2,6,1,10,0,F01M1/04;;F16N7/30;;F16N7/30;;F01M1/04,F01M1/04;;F16N7/30,60/546,0,0,,,,EXPIRED
306,US,A,US 3106574 A,095-357-902-236-353,1963-10-08,1963,US 7650860 A,1960-12-19,US 7650860 A,1960-12-19,Method for the manufacture of acetonitrile,,STANDARD OIL CO,CALLAHAN JAMES L;;STAMM JOHN A,,https://lens.org/095-357-902-236-353,Granted Patent,no,5,5,3,3,0,B01J27/192;;C07C253/24;;B01J27/192;;C07C253/24,B01J27/192,,0,0,,,,EXPIRED
307,US,A,US 4194593 A,120-989-013-597-546,1980-03-25,1980,US 94155778 A,1978-09-11,US 94155778 A,1978-09-11,CYCLIC LUBRICANT DISTRIBUTOR VALVE,"A cyclic lubricant distributor valve has an inlet block unit, an end block unit and at least three intermediate block units. Each of the intermediate block units has a bore, a spool movable in the bore and at least one lubricant outlet. A series of ports and passages are formed in the various block units to provide for cyclic operation of the distributor valve. Each of the intermediate block units is formed of a base member, in which the outlet (or outlets) is formed, and a separate and separable spool member, in which a bore is formed containing a movable spool. Through bolts connect the inlet block unit, the end block unit and the base members of the intermediate block units in fixed assembly. Other bolts connect each of the spool members in fixed assembly only with its corresponding base member.",HOUDAILLE INDUSTRIES INC,CALLAHAN JAMES J;;SNOW JOHN P,,https://lens.org/120-989-013-597-546,Granted Patent,no,0,4,3,3,0,F16N25/02,F16N25/02,184007000D,0,0,,,,EXPIRED
308,WO,A1,WO 1992/007568 A1,120-486-843-846-527,1992-05-14,1992,US 9108166 W,1991-10-31,US 60813890 A,1990-11-01,gamma -TURN PEPTIDOMIMETICS AS FIBRINOGEN ANTAGONISTS,"This invention relates to a method of inhibiting platelet aggregation, and compounds which are mimics of the peptide sequence Arg-Gly-Asp.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS,,https://lens.org/120-486-843-846-527,Patent Application,yes,3,21,5,5,0,A61P7/02;;A61P9/04;;C07D223/10;;C07D223/10;;C07D243/06;;C07D243/06,A61K31/55;;A61K38/46;;A61P7/02;;A61P9/04;;C07D223/04;;C07D223/06;;C07D223/08;;C07D223/10;;C07D243/06;;C07D401/06;;C07D401/14;;C07D403/06;;C07D403/14;;C07D409/06;;C07D409/14,,1,0,,,See also references of EP 0557406A4,PENDING
309,EP,A1,EP 0610432 A1,147-283-288-714-583,1994-08-17,1994,EP 92924265 A,1992-10-30,US 9209467 W;;US 78567291 A,1991-10-31,C8-CYCLIC PEPTIDOMIMETICS AS FIBRINOGEN ANTAGONISTS.,"Cette invention concerne un procédé d'inhibition de l'agrégation des plaquettes, ainsi que des composés de 1,4-diazocine qui sont des agents mimiques de la séquence peptidique Arg-Gly-Asp.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS,,https://lens.org/147-283-288-714-583,Patent Application,yes,0,0,4,4,0,C07D245/02;;C07K5/0202;;C07K5/06139;;C07K5/0821;;C07K14/75;;A61P7/02;;C07K5/06139;;C07K5/0202;;C07K14/75;;C07D245/02;;C07K5/0821,A61K31/395;;A61P7/02;;C07D245/02;;C07D401/12;;C07D403/12;;C07K5/02;;C07K5/078;;C07K5/097;;C07K14/75,,0,0,,,,DISCONTINUED
310,US,A,US 3435061 A,174-534-839-759-335,1969-03-25,1969,US 42381865 A,1965-01-06,US 42381865 A,1965-01-06,MANUFACTURE OF AROMATIC ALDEHYDES AND NITRILES,,STANDARD OIL CO,GRASSELLI ROBERT K;;CALLAHAN JAMES L,,https://lens.org/174-534-839-759-335,Granted Patent,no,7,5,6,6,0,B01J23/16;;B01J23/16;;B01J23/6445;;B01J23/6445;;B01J23/681;;B01J23/681;;B01J23/84;;B01J23/84;;B01J23/8435;;B01J23/8435;;B01J27/19;;B01J27/19;;C07C253/28;;C07C253/28;;C07C45/36;;C07C45/36,B01J23/16;;B01J23/18;;B01J23/644;;B01J23/68;;B01J23/84;;B01J23/843;;B01J27/19;;C07C45/36;;C07C47/20;;C07C255/34,260/465,0,0,,,,EXPIRED
311,AU,A,AU 1998/057168 A,179-333-431-753-387,1998-08-03,1998,AU 1998/057168 A,1997-12-29,US 3405997 P;;US 6588697 P;;US 9723792 W,1997-01-08,Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease,,WARNER LAMBERT CO,SCHWARZ ROY DOUVILLE;;CALLAHAN MICHAEL JAMES,,https://lens.org/179-333-431-753-387,Patent Application,no,0,0,4,5,0,A61K45/06;;A61K31/00,A61K45/06,,0,0,,,,PENDING
312,US,B2,US 10661417 B2,199-501-223-618-178,2020-05-26,2020,US 201815891236 A,2018-02-07,US 201815891236 A,2018-02-07,"Tools for rotating fasteners, methods of utilizing the tools, and methods of manufacturing the tools","Tools for rotating fasteners, methods of utilizing the tools, and methods of manufacturing the tools. The tools include a gripping region, a fastener receptacle, and an interlock structure. The gripping region is configured to be gripped by a user of the tool. The fastener receptacle is shaped to receive the fasteners and includes a fastener-receiving opening on a fastener-facing side of the tool. The fastener-facing side faces in a fastener-facing direction. The fastener-receiving opening is sized to permit the fastener to enter the fastener receptacle from the fastener-facing side of the tool. The interlock structure is configured to interlock with the fastener while the fastener is received within the fastener receptacle. The interlock structure also is configured to prevent motion of the tool away from the fastener in a fastener-opposed direction, which is opposed to the fastener-facing side of the tool, while the interlock region is interlocked with the fastener.",BOEING CO,ETTLING KARL JAMES;;CALLAHAN RUSSELL PETE,THE BOEING COMPANY (2018-02-06),https://lens.org/199-501-223-618-178,Granted Patent,yes,32,0,6,6,0,B25B11/00;;B25B13/5091;;B25G1/102;;B25B23/105;;B25B21/002;;B23P2700/01;;B25B23/1427;;B25B21/004;;B25G1/00;;B25B13/5091,B25B23/10;;B25B13/50;;B25B21/00;;B25B23/142;;B25G1/00,,0,0,,,,ACTIVE
313,WO,A3,WO 2006/104889 A3,053-463-994-636-770,2007-04-12,2007,US 2006/0010792 W,2006-03-24,US 66534705 P,2005-03-25,NOVEL COMPOUNDS,"Novel substituted l,5,7-trisubstituted-354-dihydro-pyriinido[4,5-(flpyrimidin- 2-(2H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.",GLAXO GROUP LTD;;CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/053-463-994-636-770,Search Report,yes,2,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,A61K31/519;;C07D475/00;;A61K31/535;;A61K31/55;;A61K31/5513;;C07D239/47;;C07D243/08;;C07D413/12;;C07D413/14,,0,0,,,,PENDING
314,WO,A1,WO 2009/100170 A1,041-197-382-950-086,2009-08-13,2009,US 2009/0033133 W,2009-02-05,US 2657608 P,2008-02-06,DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS,"The present invention is directed to novel compounds of Formula (I), for treating an inflammatory or allergic diseases such as chronic obstructive pulmonary disease (COPD).",GLAXO GROUP LTD;;CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/041-197-382-950-086,Patent Application,yes,3,2,3,3,0,C07D471/04;;A61P29/00;;A61P37/08,A61P29/00;;A61K31/437;;A61P37/08,,0,0,,,,PENDING
315,EP,A2,EP 1085848 A2,062-044-516-700-045,2001-03-28,2001,EP 99930345 A,1999-06-18,US 9913652 W;;US 8982798 P,1998-06-19,INHIBITORS OF TRANSCRIPTION FACTOR NF-KAPPA B,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,SMITHKLINE BEECHAM CORPORATION (2008-01-02),https://lens.org/062-044-516-700-045,Patent Application,yes,0,0,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A61K31/167;;A61P1/00;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,,0,0,,,,EXPIRED
316,AP,A0,AP 2007004171 A0,122-510-114-053-21X,2007-10-31,2007,AP 2007004171 A,2006-03-24,US 66534705 P;;US 2006/0010792 W,2005-03-25,Novel compounds,,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/122-510-114-053-21X,Patent Application,no,0,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,C07D475/00;;A61K31/519;;A61K31/535;;A61K31/55;;A61K31/5513;;C07D239/47;;C07D243/08;;C07D413/12;;C07D413/14,,0,0,,,,ACTIVE
317,NO,L,NO 20006452 L,171-087-029-749-986,2001-02-16,2001,NO 20006452 A,2000-12-18,US 9001698 P;;US 9913897 W,1998-06-19,Inhibitorer av transkripsjonsfaktor NF-kB,"Det beskrives amino-indanon-inhibitorer av transkripsjonsfaktor NF-KB og farmasøytisk akseptable salter, hydrater og solvater derav, farmasøytiske prepara- ter av slike forbindelser, samt fremgangsmåter for behandling av sykdommer hvor aktivering av NF-tcB er implisert. Mer spesifikt beskrives fremgangsmåter for be- handling av en rekke sykdommer som er assosiert med NF-icB-aktivering, inklusi- ve inflammatoriske lidelser; spesielt reumatoid artritt; inflammatorisk tarmsykdom og astma; dermatose, inklusive psoriasis og akutt dermatose; autoimmune syk- dommer, vevs- og organavstøtning; Alzheimers sykdom; slag, aterosklerose; restenose; kreft, inklusive Hodgkins sykdom; og visse virusinfeksjoner, inklusive AIDS; osteoartritt; osteoporose; og Ataxia Telangiestasia, ved å administrere til en pasient som trenger det, en forbindelse i henhold til oppfinnelsen.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;CHABOT-FLETCHER MARIE C,,https://lens.org/171-087-029-749-986,Abstract,no,0,0,19,19,0,A61K31/135;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06;;A61P39/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61K31/535,A61K31/135;;C07D295/10;;A61K31/4453;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P9/00;;A61P9/02;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06,,0,0,,,,DISCONTINUED
318,PE,A1,PE 20100741 A1,186-137-409-763-146,2010-11-25,2010,PE 2010000198 A,2006-03-23,US 66534705 P,2005-03-25,"COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38","SE REFIERE A UN COMPUESTO DE FORMULA 1, DONDE R1 ES DE PREFERENCIA -C(O)N-CH(CH3)-CH3, C(O)NCH2-CH2-CH3, ENTRE OTROS; R1' ES HALOGENO, ALQUILO C1-4 SUSTITUIDO O NO CON HALO. CIANO, NITRO, ENTRE OTROS; G1 Y G2 SON INDEPENDIENTEMENTE NITROGENO; G3 ES NH; R3 ES FENILO OPCIONALMENTE SUSTITUIDO UNA O MAS VECES CON HALOGENO, NITRO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 3-[2-(4-AMINO-1-PIPERIDINIL)-8-(2,6-DIFLUOROFENIL)-7-OXO-5,6,7,8-TETRAHIDROPIRIMIDO[4,5-d]PIRIMIDIN-4-IL]-N-CICLOBUTIL-4-METILBENZAMIDA; 3-{8-(2,6-DIFLUOROFENIL)-2-[[3-(DIMETILAMINO)PROPIL](METIL)AMINO]-7-OXO-5,6,7,8-TETRAHIDROPIRIMIDO[4,5-d]PIRIMIDIN-4-IL}-4-METIL-N-(FENILMETIL)BENZAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE CINASAS CSBP/p38/RK UTIL EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/186-137-409-763-146,Patent Application,no,0,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,C07D239/47;;A61K31/19;;A61K31/535;;A61K31/55;;A61K31/5513;;A61P29/00;;A61P35/00;;A61P37/00;;C07D243/08;;C07D413/12;;C07D413/14;;C07D475/00,,0,0,,,,DISCONTINUED
319,US,B2,US 8091964 B2,003-734-776-058-114,2012-01-10,2012,US 45489209 A,2009-05-26,US 45489209 A,2009-05-26,Blast mitigating seat,A blast mitigating seat features a base and a seat frame. The seat frame includes a pan and a backrest including an open area for gear worn by a user. A first damping subsystem between the base and the seat frame has a first force/stroke relationship and a second damping subsystem between the base and the seat frame has a second force/stroke relationship.,CARTER JAMES A;;MACLEOD DONALD;;CALLAHAN PATRICK;;FOSTER MILLER INC,CARTER JAMES A;;MACLEOD DONALD;;CALLAHAN PATRICK,FOSTER-MILLER INC (2009-09-01),https://lens.org/003-734-776-058-114,Granted Patent,yes,12,15,2,2,0,B60N2/24;;B60N2/4242;;B60N2/42736;;F41H7/042;;F41H7/046;;B60N2/643;;B60N2/986;;B60N2/99;;B60N2/986;;B60N2/24;;F41H7/046;;B60N2/4242;;B60N2/42736;;F41H7/042;;B60N2/643,A47C7/02;;B60N2/42,297/216.17;;297/284.3,0,0,,,,ACTIVE
320,US,B2,US 9218496 B2,023-556-074-694-614,2015-12-22,2015,US 201414205837 A,2014-03-12,US 201414205837 A;;US 20655608 A;;US 96784207 P,2007-09-07,Dynamically updating privacy settings in a social network,"A social network allows its members to regulate what data is accessible to other members using one or more privacy settings. A particular member of the social network can modify the one or privacy settings to grant or deny different users access to different data. When a member modifies a privacy setting, the social network determines which information pathways communicating data between members are affected. The affected information pathways are then modified responsive to the privacy setting to communicate data identified by the modified privacy setting and enforce the new privacy restrictions.",FACEBOOK INC,CALLAHAN EZRA;;WANG JAMES H;;VERA NICOLAS,META PLATFORMS INC (2021-10-28),https://lens.org/023-556-074-694-614,Granted Patent,yes,31,1,11,11,0,G06F21/604;;G06F21/6245;;G06F21/6263;;G06F2221/2141;;G06Q30/02;;H04L63/102;;H04L67/306;;G06F21/604;;G06F21/6245;;G06F21/6263;;G06F2221/2141;;G06Q30/02;;H04L63/102;;H04L67/306;;G06F2221/2115;;G06F2221/2119;;G06F21/62,G06F17/30;;G06F21/00;;G06F21/60;;G06F21/62;;G06Q30/02;;H04L29/06;;H04L29/08,,11,1,109-382-519-037-109,10.1109/percomw.2007.7,"Saternus et al., A Middleware for Context-Aware Applications and Services Based on Messenger Protocols, Pervasive Computing and Communications Workshops, 2007. Percom Workshops '07. Fifth Annual IEEE International Conference on, DOI: 10.1109/PERCOMW.2007.7, Publication Year: 2007, pp. 467-471.;;PCT International Search Report and Written Opinion, PCT/US2008/075641, Nov. 18, 2008, 8 Pages.;;IP Australia, Examiner's First Report on Australian Patent Application No. 2008295996, May 24, 2012, two pages.;;PCT International Preliminary Report on Patentability, PCT Application No. PCT/US2008/075641, Mar. 18, 2010, six pages.;;Japanese Patent Office, Office Action, Japanese Patent Application No. P2010-524230, Jun. 4, 2013, four pages.;;Canadian Intellectual Property Office, First Office Action, Canadian Patent Application No. 2,696,945, May 2, 2013, two pages.;;United States Office Action, U.S. Appl. No. 12/206,556, Jul. 30, 2013, 6 pages.;;United States Office Action, U.S. Appl. No. 12/206,556, Oct. 24, 2012, 14 pages.;;United States Office Action, U.S. Appl. No. 12/206,556, Feb. 2, 2012, 13 pages.;;United States Office Action, U.S. Appl. No. 12/206,556, Aug. 8, 2011, 11 pages.;;United States Office Action, U.S. Appl. No. 12/206,556, Dec. 17, 2010, 13 pages.",ACTIVE
321,CN,B,CN 101184758 B,051-489-398-768-059,2012-05-02,2012,CN 200680018398 A,2006-03-24,US 2006/0010792 W;;US 66534705 P,2005-03-25,Novel compounds,"Novel substituted l,5,7-trisubstituted-3,4-dihydro-pyriinido[4,5-(flpyrimidin- 2-(1H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.",GLAXO GROUP LTD,ZEHONG WAN;;HONGXING YAN;;CALLAHAN JAMES F,,https://lens.org/051-489-398-768-059,Granted Patent,no,0,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,C07D475/00;;A61K31/519;;A61K31/535;;A61K31/55;;A61K31/5513;;C07D239/47;;C07D243/08;;C07D413/12;;C07D413/14,,0,0,,,,INACTIVE
322,AU,A,AU 1999/046900 A,084-023-474-154-941,2000-01-05,2000,AU 1999/046900 A,1999-06-18,US 8982798 P;;US 9913652 W,1998-06-19,Inhibitors of transcription factor NF-KappaB,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,,https://lens.org/084-023-474-154-941,Patent Application,no,0,0,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A61P1/00;;A61K31/167;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,,0,0,,,,DISCONTINUED
323,ZA,B,ZA 200007448 B,117-713-038-851-162,2001-12-12,2001,ZA 200007448 A,2000-12-13,US 9001698 P,1998-06-19,Inhibitors of transcription factor NF-kB.,,SMITHKLINE BEECHAM CORP,FRANCIS CALLAHAN JAMES;;CHABOT-FLETCHER MARIE C,,https://lens.org/117-713-038-851-162,Granted Patent,no,0,0,19,19,0,A61K31/135;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06;;A61P39/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61K31/535,A61K31/135;;C07D295/10;;A61K31/4453;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P9/00;;A61P9/02;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06,,0,0,,,,EXPIRED
324,ES,T3,ES 2491219 T3,127-913-009-084-426,2014-09-05,2014,ES 06752232 T,2006-05-03,US 67755205 P;;US 70952805 P;;US 72647305 P;;US 35218406 A;;US 2006/0017172 W,2005-05-04,Calentador de líquido por resistencia eléctrica directa,"Un calentador de líquido que comprende: una cámara (1) que tiene una entrada (2) y una salida (3); y al menos tres electrodos (4) dentro de dicha cámara (1) que definen una pluralidad de canales contiguos para el flujo de líquido desde dicha entrada (2) a dicha salida (3) por lo que el flujo de líquido se divide entre los canales, estando conectados los electrodos (4) mediante conexiones (5) a una matriz de conmutadores (6) por medio de la que se comunica una potencia eléctrica de corriente alterna (7) a los electrodos (4), caracterizado porque el espaciado entre los electrodos (4) no es uniforme y porque la selección del espaciado entre electrodos (4) es tal que se puede conseguir una selección de configuraciones de la matriz de conmutadores (6) que produce escalones de corriente espaciados uniformemente de modo más o menos logarítmico.",CALLAHAN JEREMIAH M;;BARZYK JAMES,CALLAHAN JEREMIAH M;;BARZYK JAMES;;BOWERS JOHN,,https://lens.org/127-913-009-084-426,Granted Patent,no,0,0,19,44,0,F24H1/106;;H05B3/60;;H05B2203/021;;F24H1/10;;F24H1/20;;H05B7/144;;F24H1/106;;H05B2203/021;;H05B3/60,F24H1/10;;H05B3/60,,0,0,,,,ACTIVE
325,CA,A1,CA 2335294 A1,159-161-410-129-194,1999-12-23,1999,CA 2335294 A,1999-06-18,US 8982798 P;;US 9913652 W,1998-06-19,INHIBITORS OF TRANSCRIPTION FACTOR NF-.KAPPA.B,"The present invention provides pharmaceutical compositions of salicylanilide inhibitors of transcription factor NF-.kappa.B, and methods for treating diseases in which activation of NF-.kappa.B is implicated. More specifically , the present invention provides methods of treatment of a variety of diseases associated with NF-.kappa.B activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and atopic dermatitis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkin's disease; certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia by administering to a patient in need thereof a compound of the present inventi on.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,,https://lens.org/159-161-410-129-194,Patent Application,no,0,0,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A61P1/00;;A61K31/167;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,,0,0,,,,DISCONTINUED
326,US,A,US 2623387 A,175-767-963-530-46X,1952-12-30,1952,US 59913445 A,1945-06-13,US 59913445 A,1945-06-13,Well drilling indicating apparatus,,ENGINEERING LAB INC,PITCHER JAMES W;;CALLAHAN JR JOHN T,,https://lens.org/175-767-963-530-46X,Granted Patent,no,6,10,1,1,0,E21B45/00;;E21B47/04;;E21B45/00;;E21B47/04,E21B45/00;;E21B47/04,,0,0,,,,EXPIRED
327,BR,A,BR 9911152 A,020-628-656-001-305,2001-03-06,2001,BR 9911152 A,1999-06-18,US 8982798 P;;US 9913652 W,1998-06-19,Inibidores de transcrição de fator nf-kb,"""INIBIDORES DE TRANSCRIçãO DE FATOR NF-<sym>B"" A presente invenção provê composições farmacêuticas de salicil anilida inibidoras de fator de transcrição NF-<sym>B, e processos para tratamento de doenças nas quais ativação de NF-<sym>B está implicada. Mais especificamente, a presente invenção provê processos de tratamento de uma variedade de doenças associadas com ativação de NF-<sym>B incluindo desordens inflamatórias; particularmente artrite reumatóide, doença inflamatória de intestino e asma; dermatose, incluíndo psoríase e dermatite atópica; doenças autoimunes; rejeição de tecido e órgão; mal de Alzheimer, acidente vascular cerebral, aterosclerose, restenose, câncer, incluindo doença de Hodgkin, certas infecções virais, incluindo AIDS, osteoartrite, osteoporose, e Ataxia Telangiestasia através de administração a um paciente em sua necessidade, de um composto da presente invenção.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,,https://lens.org/020-628-656-001-305,Patent Application,no,0,0,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A61P1/00;;A61K31/167;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,,0,0,,,,DISCONTINUED
328,EP,B1,EP 1878315 B1,021-503-848-056-615,2014-06-25,2014,EP 06752232 A,2006-05-03,US 2006/0017172 W;;US 67755205 P;;US 70952805 P;;US 72647305 P;;US 35218406 A,2005-05-04,DIRECT ELECTRIC RESISTANCE LIQUID HEATER,,CALLAHAN JEREMIAH M;;BARZYK JAMES,CALLAHAN JEREMIAH M;;BARZYK JAMES;;BOWERS JOHN,"HEATWORKS TECHNOLOGIES, INC. (N. D. GES. D. ST, US (2017-02-14);;BARZYK, JAMES (2014-12-03);;CALLAHAN, JEREMIAH M. (2014-12-03);;ISI TECHNOLOGY, LLC, US (2018-10-09);;HEATWORKS TECHNOLOGIES, INC.; US (2019-08-08);;HEATWORKS TECHNOLOGIES, INC (2019-08-14)",https://lens.org/021-503-848-056-615,Granted Patent,yes,6,0,19,44,0,F24H1/106;;H05B3/60;;H05B2203/021;;F24H1/10;;F24H1/20;;H05B7/144;;F24H1/106;;H05B2203/021;;H05B3/60,F24H1/10;;H05B3/60,,0,0,,,,ACTIVE
329,EP,B1,EP 2765363 B1,064-188-697-182-763,2017-03-01,2017,EP 14165076 A,2006-05-03,US 67755205 P;;US 70952805 P;;US 72647305 P;;US 35218406 A;;EP 06752232 A,2005-05-04,Direct electric resistance liquid heater,,CALLAHAN JEREMIAH M;;BARZYK JAMES,CALLAHAN JEREMIAH M;;BARZYK JAMES;;BOWERS JOHN,"HEATWORKS TECHNOLOGIES, INC. (2017-07-05)",https://lens.org/064-188-697-182-763,Granted Patent,yes,1,0,19,44,0,F24H1/106;;H05B3/60;;H05B2203/021;;F24H1/10;;F24H1/20;;H05B7/144;;F24H1/106;;H05B2203/021;;H05B3/60,F24H1/10;;H05B3/60,,0,0,,,,ACTIVE
330,NO,L,NO 20006451 L,139-232-426-056-452,2000-12-18,2000,NO 20006451 A,2000-12-18,US 8982798 P;;US 9913652 W,1998-06-19,Inhibitorer av transkripsjonsfaktor NF-kB,"Foreliggende oppfinnelse tilveiebringer farmasøytiske preparater av salicylanilidinhibitorer av transkripsjonsfaktor NF-kB og metoder for behandling av sykdommer hvor aktivering av NF-kB er involvert. Mer spesifikt tilveiebringer foreliggende oppfinnelse metoder for behandling av en rekke sykdommer forbundet med NF-icB-aktivering omfattende inflammatoriske lidelser; spesielt revmatoid artritt, inflammatorisk tarmsykdom og astma; dermatose, omfattende psoriasis og atopisk dermatitt; autoimmune sykdommer; vev- og organawisning; Alzheimers sykdom; slag; aterosklerose; restenose; kreft, omfattende Hodgkin's sykdom; visse virale infeksjoner, omfattende AIDS; osteoartritt; osteoporose; og Ataksia Telangiestasia ved administrering til en pasient med behov for dette av en forbindelse ifølge foreliggende oppfinnelse.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;CHABOT-FLETCHER MARIE C,,https://lens.org/139-232-426-056-452,Abstract,no,0,0,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A61K31/167;;A61P1/00;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,,0,0,,,,DISCONTINUED
331,US,A1,US 2010/0301647 A1,145-368-570-731-774,2010-12-02,2010,US 45489209 A,2009-05-26,US 45489209 A,2009-05-26,Blast mitigating seat,A blast mitigating seat features a base and a seat frame. The seat frame includes a pan and a backrest including an open area for gear worn by a user. A first damping subsystem between the base and the seat frame has a first force/stroke relationship and a second damping subsystem between the base and the seat frame has a second force/stroke relationship.,CARTER JAMES A;;MACLEOD DONALD;;CALLAHAN PATRICK,CARTER JAMES A;;MACLEOD DONALD;;CALLAHAN PATRICK,FOSTER-MILLER INC (2009-09-01),https://lens.org/145-368-570-731-774,Patent Application,yes,8,16,2,2,0,B60N2/24;;B60N2/4242;;B60N2/42736;;F41H7/042;;F41H7/046;;B60N2/643;;B60N2/986;;B60N2/99;;B60N2/986;;B60N2/24;;F41H7/046;;B60N2/4242;;B60N2/42736;;F41H7/042;;B60N2/643,F41H5/06;;B60N2/42,297/216.1;;89/36.08;;89/918,0,0,,,,ACTIVE
332,KR,A,KR 20080005223 A,178-063-996-426-320,2008-01-10,2008,KR 20077024433 A,2007-10-24,US 66534705 P,2005-03-25,NOVEL COMPOUNDS,"Novel substituted l,5,7-trisubstituted-354-dihydro-pyriinido[4,5-(flpyrimidin-2-(2H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/178-063-996-426-320,Patent Application,no,0,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,C07D487/04,,0,0,,,,DISCONTINUED
333,CZ,A3,CZ 20004761 A3,188-491-321-938-954,2001-08-15,2001,CZ 20004761 A,1999-06-18,US 8982798 P,1998-06-19,Inhibitors of NF-KB transcription factor,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,,https://lens.org/188-491-321-938-954,Patent Application,no,0,0,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A61K31/167;;A61P1/00;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,,0,0,,,,PENDING
334,CO,A1,CO 5021213 A1,023-608-624-701-690,2001-03-27,2001,CO 99038264 A,1999-06-18,US 8982798 P,1998-06-19,INHIBIDORES DE FACTOR DE TRANSCRIPCION NF-k8,"Una composición farmacéutica, que comprende un compuesto defórmula I:en la cual :RA sustituye el anillo A 0-3 veces y se selecciona independientemente entre el grupo que consiste en : NO2 , halógeno, alquilo C1-6 , trifluorometilo, O-alquilo C1-6 y S-alquilo C1-6 ; yRB sustituye el anillo B O-3 veces y se selecciona independientemente entre el grupo que consiste en: halógeno, C(O)-alquilo C1-6 , alquilo C1-6 , O-alquilo C1-6 , S-alquilo C1-6 , CH2 -arilo y arilo; y sus sales, hidratos y solvatos farmacéuticamente aceptables.Un método para inhibir NF-kB, que comprende administrar a un paciente que lo necesita una cantidad eficaz de un compuesto de fórmula I:en la cual :RA sustituye el anillo A 0-3 veces y se selecciona independientemente entre el grupo que consiste en : NO2 , halógeno, alquilo C1-6 , trifluorometilo, O-alquilo C1-6 y S-alquilo C1-6 ; y RB sustituye el anillo B 0-3 veces y se selecciona independientemente entre el grupo que consiste en : halógeno, C(O)-alquilo C1-6 , alquilo C1-6 , O-alquilo C1-6 , S-alquilo C1-6 , CH2 -arilo y arilo; y sus sales, hidratos y solvatos farmacéuticamente aceptables.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;CHABOT FLETCHER MARIE C,,https://lens.org/023-608-624-701-690,Patent Application,no,0,0,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A61P1/00;;A61K31/167;;A61K31/44;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,,0,0,,,,PENDING
335,WO,A1,WO 1999/065495 A1,017-360-567-386-626,1999-12-23,1999,US 9913897 W,1999-06-18,US 9001698 P,1998-06-19,INHIBITORS OF TRANSCRIPTION FACTOR NF- kappa B,"The present invention provides amino-indanone inhibitors of transcription factor NF-λB and pharmaceutically acceptable salts, hydrates and solvates thereof, pharmaceutical compositions of such compounds, and methods for treating diseases in which activation of NF-λB is implicated. More specifically, the present invention provides methods of treatment of a variety of diseases associated with NF-λB activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and acute dermatosis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkins disease; and certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia by administering to a patient in need thereof a compound of the present invention.",SMITHKLINE BEECHAM CORP;;CALLAHAN JAMES F;;CHABOT FLETCHER MARIE C,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,,https://lens.org/017-360-567-386-626,Patent Application,yes,0,26,19,19,0,A61K31/135;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06;;A61P39/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61K31/535,A61K31/135;;A61K31/4453;;A61K31/4462;;A61K31/5375;;A61P1/04;;C07D295/10;;A61P9/00;;A61P9/02;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06,,3,2,084-629-521-566-938;;019-611-896-434-971,12338431;;10.1021/jo01255a024,"DATABASE HCAPLUS ON STN, AMERICAN CHEMICAL SOCIETY, AN 1981:514971, GUPTA R.C. et al., ""N-Substituted .alpha.-Aminoalkylacrylophenones and Some Related Compounds: A New Class of Spermicidal Agents""; & INDIAN J. CHEM., 1981, 20(B), pages 303-307.;;DATABASE HCAPLUS ON STN, AMERICAN CHEMICAL SOCIETY, AN 1969:106237, MAURY G. et al., ""Mobile Keto Allyl Systems. VIII. Properties of 2-(.alpha.-Aminobenzyl)-1-indenones""; & J. ORG. CHEM., 1969, 34(3), pages 596-601.;;See also references of EP 1085872A4",PENDING
336,TR,T2,TR 200003779 T2,090-751-277-701-523,2001-06-21,2001,TR 200003779 T,1999-06-18,US 9001698 P,1998-06-19,Transkripsiyon faktörü NF-kB inhibitörleri,"Bu bulus, trankripsiyon faktörü NF-kB nin farmasötik olarak kabul edilebilir tuzlari, hidratlari ve solventlerinin amino-indanon inhibitörlerini, bu bilesimlerin terkiplerini ve NF-kB aktivasyonunun rol oyandigi hastaliklari tedavi yöntemleri saglamaktadir. Bu bulus özellikle örnegin enflamatuar hastaliklarin, özellikle romatizmal artrit, enflamatuar barsak hastaligi, ve astim; sedef hastaligi ve atopik dermatil dahil, dermatoz; oto-immün hastaliklar; doku ve organ reddi; alzheimer hastaligi; felç; ateroskleroz; restenoz; kanser ve Hodojken hastaligi; bazi viral enfeksiyonlar, AIDS dahil; osteoartrit; osteoporoz; ve Ataxia Telangiestasia gibi NF-kB aktivasyonuyla baglantili çesitli hastaliklarin, ihtiyaci olan hastaya bir bulus bilesimi verilmesi için yöntemler saglar.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;CHABOT-FLETCHER MARIE C,,https://lens.org/090-751-277-701-523,Patent Application,no,0,0,19,19,0,A61K31/135;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06;;A61P39/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61K31/535,A61K31/135;;A61K31/4453;;A61K31/4462;;A61K31/5375;;A61P1/04;;C07D295/10;;A61P9/00;;A61P9/02;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06,,0,0,,,,PENDING
337,PL,A1,PL 348969 A1,157-967-388-796-328,2002-06-17,2002,PL 34896999 A,1999-06-18,US 9913652 W;;US 8982798 P,1998-06-19,INHIBITORS OF TRANSCRIPTION FACTOR NF-ΚB,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,,https://lens.org/157-967-388-796-328,Patent Application,no,0,0,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A61K31/167;;A61P9/00;;A61P1/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,,0,0,,,,PENDING
338,WO,A2,WO 2006/104889 A2,010-427-035-847-961,2006-10-05,2006,US 2006/0010792 W,2006-03-24,US 66534705 P,2005-03-25,NOVEL COMPOUNDS,"Novel substituted l,5,7-trisubstituted-354-dihydro-pyriinido⏧4,5-(flpyrimidin- 2-(2H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.",GLAXO GROUP LTD;;CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/010-427-035-847-961,Patent Application,yes,48,11,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,C07D487/02;;A61K31/519,,40,30,122-627-349-497-578;;066-171-379-367-457;;038-105-202-686-806;;101-539-955-805-081;;034-334-788-871-50X;;174-103-218-570-797;;085-109-294-118-867;;051-341-161-739-275;;063-234-570-863-113;;174-103-218-570-797;;157-525-541-164-397;;004-733-031-584-023;;010-945-971-327-360;;069-359-873-985-449;;065-910-877-309-25X;;002-217-128-090-827;;056-362-966-337-366;;064-931-017-755-256;;024-792-986-385-671;;085-439-840-914-302;;062-224-469-353-287;;053-912-117-245-015;;009-672-786-510-052;;007-518-612-833-566;;007-364-858-655-289;;136-443-683-787-88X;;031-093-628-703-132;;003-809-679-901-29X;;040-299-395-201-392;;070-293-335-615-447,10.1016/0092-8674(95)90401-8;;7834738;;10.1016/0076-6879(91)00125-g;;1835513;;12951578;;10.1038/nrd1177;;3148560;;10.1016/0192-0561(88)90007-0;;10.1111/j.1749-6632.1993.tb17149.x;;8109825;;17708980;;10.1016/s0962-8924(97)01105-7;;10.1016/s0163-7258(99)00008-x;;10454214;;10.1074/jbc.274.43.30858;;10521478;;12725866;;10.1016/s0163-7258(03)00016-0;;17708980;;10.1016/s0962-8924(97)01105-7;;10.1161/01.cir.0000053730.47739.3c;;12551853;;10.1161/01.cir.0000056767.69054.b3;;12654609;;10.1093/humrep/17.2.426;;11821289;;10.1016/s0015-0282(99)00556-7;;10685517;;10.1016/s0898-6568(99)00071-6;;10676842;;11274345;;10.1152/physrev.2001.81.2.807;;8968371;;9454815;;10734180;;10.1002/1529-0131(200001)43:1<175::aid-anr22>3.0.co;2-s;;10643714;;10.1074/jbc.274.38.27161;;10480932;;10.1124/mol.62.1.58;;12065755;;14996754;;10.1158/0008-5472.can-03-3448;;10.1074/jbc.m307869200;;12933797;;10.1002/jps.2600660104;;833720;;10.3891/acta.chem.scand.43-0062;;9279247;;10.1164/ajrccm.156.2.9610079;;pmc507033;;10.1172/jci118431;;8567963;;pmc185229;;10.1172/jci118067;;7615827;;10.1016/s0968-0896(96)00212-x;;9043657,"MARSHALL, J. C., CELL, vol. 80, 1995, pages 179 - 278;;HUNTER, T: ""Methods in Enzvmology"", vol. 200, 1991, ACADEMIC PRESS;;KUMAR, S., NATURE REV. DRUG DISCOVERY, vol. 2, 2003, pages 717;;LEE ET AL., INT. J. HNMUNOPHANNAC, vol. 10, no. 7, 1988, pages 835;;LEE ET AL., ANNALS N. Y. ACAD. SCI, vol. 696, 1993, pages 149;;COHEN, P., TRENDS CELL BIOL., 1997, pages 353 - 361;;LEE, J. C ET AL., PHARMACOL. THER., vol. 82, no. 2-3, 1999, pages 389 - 397;;SACCINI, S., NATURE IMMUNOL., vol. 3, 2002, pages 69 - 75;;CARTER, AB ET AL., J BIOL CHEM, vol. 274, 1999, pages 30858 - 63;;PLATANIAS, PHARMACOL. THERAP., vol. 98, 2003, pages 129 - 142;;COHEN, P, TRENDS CELL BIOI., 1997, pages 353 - 361;;DINARELLO ET AL., REV. INFECT. DISEASE, vol. 6, 1984, pages 51;;DINARELLO, J., CLINICAL IMMUNOLOGY, vol. 5, no. 5, 1985, pages 1 287 - 297;;CIRCULATION, vol. 107, 2003, pages 363 - 369;;CIRCULATION, vol. 107, 2003, pages 1514 - 1519;;BEDAIWY ET AL., HUMAN REPRODUCTION, vol. 17, 2002, pages 426 - 431;;WITZ, FERTILITY AND STERILITY, vol. 73, 2000, pages 212 - 214;;ONO, K., HAN, J., CELLULAR SIGNALLING, vol. 12, 2000, pages 1 - 13;;KYRIAKIS, JM, AVRUCH, J., PHYSIOL REV, vol. 81, 2001, pages 807 - 869;;BADGER ET AL., J. PHARM. EXP. THERA, vol. 279, no. 3, 1996, pages 1453 - 1461;;GRISWOLD ET AL., PHARMACOL. COMM., vol. 7, 1996, pages 323 - 229;;JACKSON ET AL., J. PHARMACOL. EXP. THOR., vol. 284, 1998, pages 687 - 692;;UNDERWOOD ET AL., J. PHARMACOL. EXP. THER., vol. 293, 2000, pages 281 - 288;;BADGER ET AL., ARTHRITIS RHEUM, vol. 43, 2000, pages 175 - 183;;HANAFUSA ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 27161 - 27167;;LAPING ET AL., MOLEC. PHARMACOL., vol. 62, 2002, pages 58 - 64;;MORIN, HUOT, CANCER RESEARCH, vol. 64, 2004, pages 1893 - 1898;;YOO ET AL., J. BIOL. CHEM., vol. 278, 2003, pages 43001 - 43007;;""Principles and Practice"", vol. 1, article ""Burger's Medicinal Chemistry and Drug Discovery"";;BERGE ET AL., J. PHARM. SCI., vol. 66, 1977, pages 1 - 19;;SOLBERG, J., UNDHEIM, K., ACTA CHEMICA SCANDINAVIA, 1989, pages 62 - 68;;""ACS Style Guide"", 1986, AMERICAN CHEMICAL SOCIETY;;TURNER ET AL., CLIN. INFEC. DIS., vol. 26, 1998, pages 840;;TEREN ET AL., AM. J. RESPIR. CRIT. CARE MED., vol. 155, 1997, pages 1362;;GRUNBERG ET AL., AM. J. RESPIR. CRIT. CARE MED., vol. 156, 1997, pages 609;;ZHU ET AL., J CLIN. INVEST, vol. 97, 1996, pages 421;;SUBAUSTE ET AL., J. CLIN. INVEST, vol. 96, 1995, pages 549;;GALLAGHER ET AL.: ""Regulation of Stress Induced Cytokine Production by Pyridinyl Imidazoles: Inhibition of CSBP Kinase"", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 5, 1997, pages 49 - 64;;LEE ET AL., NATURE, vol. 300, no. 72, December 1994 (1994-12-01), pages 639 - 746;;See also references of EP 1866311A4",PENDING
339,US,A,US 3251900 A,114-597-308-294-673,1966-05-17,1966,US 23074262 A,1962-10-15,US 23074262 A,1962-10-15,Oxidative dehydrogenation of olefins with an antimony oxide-cerium oxide catalyst,,STANDARD OIL CO,CALLAHAN JAMES L;;BERTHOLD GERTISSER;;ROBERT GRASSELLI,,https://lens.org/114-597-308-294-673,Granted Patent,no,4,3,1,1,0,B01J23/18;;B01J23/18;;C07C5/48;;C07C5/48,B01J23/18;;C07C5/48,,0,0,,,,EXPIRED
340,EP,A4,EP 1085872 A4,187-002-577-197-153,2003-04-16,2003,EP 99930459 A,1999-06-18,US 9913897 W;;US 9001698 P,1998-06-19,INHIBITORS OF TRANSCRIPTION FACTOR NF-$g(k)B,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,,https://lens.org/187-002-577-197-153,Search Report,no,0,0,19,19,0,A61K31/135;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06;;A61P39/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61K31/535,A61K31/135;;A61K31/4453;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P9/00;;A61P9/02;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;C07D295/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06,,3,2,172-377-561-600-119;;088-525-385-389-453,10.1021/jo01056a012;;10.1021/jo01269a043,"PEARSON, BARRY D. ET AL: ""Elimination reactions of.alpha.-halogenated ketones. IX. Comparison of the reactions of 2-bromo-2-(.alpha.-bromobenzyl)1-indanone with those of 2-bromo-2-(.alpha.-bromobenzyl)-3,3dimethyl-l-indanone"", J. ORG. CHEM. (1962), 27, 3038-44, XP002230730;;MAURY, GEORGES ET AL: ""Mobile keto-allyl systems. VII. Amine-exchange reactions in the indanone-indenone series"", JOURNAL OF ORGANIC CHEMISTRY (1968), 33(5), 1907-13, XP002230731;;See also references of WO 9965495A1",DISCONTINUED
341,EP,A2,EP 2765363 A2,014-408-588-545-068,2014-08-13,2014,EP 14165076 A,2006-05-03,US 67755205 P;;US 70952805 P;;US 72647305 P;;US 35218406 A;;EP 06752232 A,2005-05-04,Direct electric resistance liquid heater,"The Direct Electric Resistance Liquid Heater comprises a liquid heating chamber containing a plurality of electrodes. The electrodes are spaced apart to create a plurality of channels through which the liquid to be heated passes. The electrodes are each connected to a power supply by one or more switches. A controller controls the switches based upon data received from a temperature sensor, sensing the temperature of the liquid, and/or an electric current sensor, sensing the current utilized by the liquid heater. Selection of the number and spacing of the electrodes, and the number of switches, provides the controller with various current levels options to apply to the liquid to be heated.; The current levels available due to the number and spacing of the electrodes and the number of switches, span the range from minimum current to maximum current such that the controller can incrementally increase or decrease the current applied to the liquid to be heated without disrupting other users of the same power source.
",CALLAHAN JEREMIAH M;;BARZYK JAMES,CALLAHAN JEREMIAH M;;BARZYK JAMES;;BOWERS JOHN,"HEATWORKS TECHNOLOGIES, INC. (2017-07-05)",https://lens.org/014-408-588-545-068,Patent Application,yes,12,0,19,44,0,F24H1/106;;H05B3/60;;H05B2203/021;;F24H1/10;;F24H1/20;;H05B7/144;;F24H1/106;;H05B2203/021;;H05B3/60,F24H1/10;;H05B3/60,,0,0,,,,ACTIVE
342,MX,A,MX 2007011883 A,037-644-583-712-495,2007-11-13,2007,MX 2007011883 A,2006-03-24,US 66534705 P;;US 2006/0010792 W,2005-03-25,NOVEL COMPOUNDS.,"Novel substituted l,5,7-trisubstituted-354-dihydro-pyriinido[4,5-(flpyrimidin- 2-(2H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.",GLAXO GROUP LTD,WAN ZEHONG;;CALLAHAN JAMES FRANCIS;;HONGXING YAN,,https://lens.org/037-644-583-712-495,Patent Application,no,0,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,A61K31/519;;C07D475/00;;A61K31/535;;A61K31/55;;A61K31/5513;;C07D239/47;;C07D243/08;;C07D413/12;;C07D413/14,,0,0,,,,ACTIVE
343,HU,A2,HU P0102782 A2,041-077-588-849-497,2001-12-28,2001,HU P0102782 A,1998-06-19,US 8982798 P;;US 9913652 W,1998-06-19,SALYCILANILIDE AS INHIBITORS OF TRANSCRIPTION FACTOR NF-KB,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;CHABOT-FLETCHER MARIE C,,https://lens.org/041-077-588-849-497,Patent Application,no,0,0,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A61K31/167;;A61P1/00;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,,0,0,,,,PENDING
344,DE,B3,DE 102006034334 B3,072-339-695-456-99X,2008-01-10,2008,DE 102006034334 A,2006-07-19,DE 102006034334 A,2006-07-19,"Compressor cylinder head, for a vehicle air conditioning system, has outer and inner ring walls with an inner acoustic damper wall and chamber","The compressor cylinder head (20), taking low pressure fluid out and passing high pressure fluid in, has ring-shaped outer and inner walls (22,23) forming an intake chamber (26) and an outflow chamber (28). The intake chamber is connected to an inflow (30). The outflow (34) from the outflow chamber has an outflow channel (36) and a tubular unit (38) extending into the outflow chamber. The tubular unit has a side wall with drillings and a closed end wall, where the cross section surface of the drillings matches the outflow channel cross section. An acoustic damper wall (40) is within the inner wall, forming an acoustic damper chamber (42).",VISTEON GLOBAL TECH INC,BHATIA KANWAL;;CALLAHAN RODNEY JAMES;;SHASKA KASTRIOT,"HALLA VISTEON CLIMATE CONTROL CORPORATION, DAE, KR (2013-10-23);;HANON SYSTEMS, KR (2016-10-06);;HALLA VISTEON CLIMATE CONTROL CORPORATION, KR (2013-10-23)",https://lens.org/072-339-695-456-99X,Granted Patent,no,2,2,1,1,0,F04B39/125;;F04B27/1081;;F04B39/0055;;F04B39/0061,F04B39/12,,0,0,,,,ACTIVE
345,ZA,B,ZA 200707798 B,101-120-435-645-931,2009-08-26,2009,ZA 200707798 A,2007-09-12,US 66534705 P,2005-03-25,Novel compounds,,GLAXO GROUP LTD,FRANCIS CALLAHAN JAMES;;ZEHONG WAN;;HONGXING YAN,,https://lens.org/101-120-435-645-931,Granted Patent,no,0,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,A61K/;;C07D/,,0,0,,,,ACTIVE
346,WO,A2,WO 1999/065449 A2,088-986-178-479-052,1999-12-23,1999,US 9913652 W,1999-06-18,US 8982798 P,1998-06-19,INHIBITORS OF TRANSCRIPTION FACTOR NF- kappa B,"The present invention provides pharmaceutical compositions of salicylanilide inhibitors of transcription factor NF- kappa B, and methods for treating diseases in which activation of NF- kappa B is implicated. More specifically, the present invention provides methods of treatment of a variety of diseases associated with NF- kappa B activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and atopic dermatitis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkin's disease; certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia by administering to a patient in need thereof a compound of the present invention.",SMITHKLINE BEECHAM CORP;;CALLAHAN JAMES F;;CHABOT FLETCHER MARIE C,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,,https://lens.org/088-986-178-479-052,Patent Application,no,0,67,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A61K31/167;;A61P9/00;;A61P1/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,,0,0,,,,PATENTED
347,US,A,US 4061886 A,121-857-309-416-435,1977-12-06,1977,US 61795575 A,1975-09-29,US 61795575 A,1975-09-29,Dual tone multiple frequency generator,"A dual-tone multiple frequency signal generator is provided for use with telecommunications systems, data transfer systems and other applications. The tone encoding system utilizes MOS/LSI integrated circuitry on a single chip powered directly by telephone line voltages. An electronic keyboard circuit provides synchronized pulses to decode single-pole, single-throw keyboard switches by row and column. A crystal-controlled oscillator generates a reference frequency which is divided according to the row and column of an activated keyboard switch to obtain two pulse signals having frequencies representative of the activated switch. The outputs of the divider circuitry are fed to programmed logic array which generates two digitally coded signals each representing a sinusoidal waveform. A digital-to-analog ladder network converts the digitally coded signals to continuous sine waves, and an operational amplifier combines the sinusoidal waveforms to provide a dual-tone output. The integrated circuitry also utilizes electronic switches for the common functions of tone transmission, including applying power to the oscillator, disconnecting the audio transmitter and attenuating the input to the receiver. Complementary-symmetry, metal-oxide semi-conductor elements implement the circuitry design with bi-polar transistors on the same chip performing some of the common function switching.",MOSTEK CORP,CALLAHAN JR MICHAEL JAMES;;HOFFMAN GORDON BATES,SGS-THOMSON MICROELECTRONICS INC (1987-12-24),https://lens.org/121-857-309-416-435,Granted Patent,yes,4,16,23,24,0,H04M1/505;;H04M1/505,H03B28/00;;H03L7/18;;H03B11/00;;H04L27/26;;H04M1/50,179 84VF,0,0,,,,EXPIRED
348,ZA,B,ZA 200007447 B,140-525-321-745-707,2002-02-13,2002,ZA 200007447 A,2000-12-13,US 8982798 P,1998-06-19,Inhibitors of transcription factor NF-kB.,,SMITHKLINE BEECHAM CORP,FRANCIS CALLAHAN JAMES;;CHABOT-FLETCHER MARIE C,,https://lens.org/140-525-321-745-707,Granted Patent,no,0,0,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A61K31/167;;A61P1/00;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,,0,0,,,,EXPIRED
349,ES,T3,ES 2299251 T3,155-675-568-761-109,2008-05-16,2008,ES 99930345 T,1999-06-18,US 8982798 P,1998-06-19,INHIBIDORES DEL FACTOR DE TRANSCRIPCION NF-KAPPA B.,"Un compuesto que es: N-(4-acetilfenil)-2-hidroxi-5-yodofenilcarboxamida; N-(2, 4-difluorofenil)-2-hidroxi-5-nitrofenilcarboxamida; N-(2, 4-difluorofenil)-2-hidroxi-5-yodofenilcarboxamida; o una sal, hidrato o solvato del mismo farmacéuticamente aceptable",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,,https://lens.org/155-675-568-761-109,Granted Patent,no,0,0,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A01N37/18;;A61K31/167;;A61P1/00;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,,0,0,,,,EXPIRED
350,BR,A,BR 9911151 A,152-717-332-389-789,2001-03-06,2001,BR 9911151 A,1999-06-18,US 9001698 P;;US 9913897 W,1998-06-19,Inibidores do fator de transcrição nf-kb,"""INIBIDORES DO FATOR DE TRANSCRIçãO NF-<sym>B"" A presente invenção proporciona inibidores aminoindanona do fator de transcrição NF-<sym>B e sais, hidratos e solvatos farmaceuticamente aceitáveis deles provenientes, composições farmacêuticas de tais compostos, e métodos para o tratamento de doenças nas quais a ativação do NF -<sym>B está implicada. Mais especificamente, a presente invenção proporciona métodos de tratamento de uma variedade de doenças associadas com a ativação do NF-<sym>B incluindo distúrbios inflamatórios; particularmente a artrite reumatóide, doença inflamatória do intestino, e asma; dermatoses, incluindo psoríase e dermatoses agudas; doenças da autoimunidade; rejeição de tecidos e órgãos; doença de Alzheimer; derrame; arteriosclerose; restenose; câncer, incluindo doença de Hodgkins; e algumas infecções virais, incluindo AIDS; osteoartrite; osteoporose; e Ataxia Telangiectasia mediante a administração de um composto da presente invenção a um paciente com necessidade disto.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,,https://lens.org/152-717-332-389-789,Patent Application,no,0,0,19,19,0,A61K31/135;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06;;A61P39/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61K31/535,C07D295/10;;A61K31/135;;A61K31/4453;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P9/00;;A61P9/02;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06,,0,0,,,,DISCONTINUED
351,SG,A1,SG 166100 A1,189-974-775-401-070,2010-11-29,2010,SG 2010069268 A,2006-03-24,US 66534705 P,2005-03-25,NOVEL COMPOUNDS,"Novel substituted 1,5,7-trisubstituted-354-dihydro-pyriinido[4,5-flpyrimidin- 2-(2H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/189-974-775-401-070,Patent Application,no,0,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,,,0,0,,,,PENDING
352,UA,C2,UA 95230 C2,135-012-629-899-10X,2011-07-25,2011,UA A200710644 A,2006-03-24,US 66534705 P,2005-03-25,"SUBSTITUTED DIHYDRO-PYRIMIDO[4,5-d]PYRIMIDINES, PHARMACEUTICAL COMPOSITION AND USE THEREOF","Novel substituted 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidine-2-(2H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/135-012-629-899-10X,Limited Patent,no,0,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,A61K31/519;;C07D487/02,,0,0,,,,EXPIRED
353,CA,A1,CA 2602546 A1,125-996-601-616-624,2006-10-05,2006,CA 2602546 A,2006-03-24,US 66534705 P;;US 2006/0010792 W,2005-03-25,NOVEL COMPOUNDS,,GLAXO GROUP LTD,WAN ZEHONG;;YAN HONGXING;;CALLAHAN JAMES FRANCIS,,https://lens.org/125-996-601-616-624,Patent Application,no,0,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,A61K31/519;;C07D475/00;;A61K31/535;;A61K31/55;;A61K31/5513;;C07D239/47;;C07D243/08;;C07D413/12;;C07D413/14,,0,0,,,,DISCONTINUED
354,US,B2,US 8713055 B2,169-503-828-386-42X,2014-04-29,2014,US 20655608 A,2008-09-08,US 20655608 A;;US 96784207 P,2007-09-07,Dynamically updating privacy settings in a social network,"A social network allows its members to regulate what data is accessible to other members using one or more privacy settings. A particular member of the social network can modify the one or privacy settings to grant or deny different users access to different data. When a member modifies a privacy setting, the social network determines which information pathways communicating data between members are affected. The affected information pathways are then modified responsive to the privacy setting to communicate data identified by the modified privacy setting and enforce the new privacy restrictions.",CALLAHAN EZRA;;WANG JAMES H;;VERA NICOLAS,CALLAHAN EZRA;;WANG JAMES H;;VERA NICOLAS,META PLATFORMS INC (2008-11-06),https://lens.org/169-503-828-386-42X,Granted Patent,yes,27,12,11,11,0,G06F21/604;;G06F21/6245;;G06F21/6263;;G06F2221/2141;;G06Q30/02;;H04L63/102;;H04L67/306;;G06F21/604;;G06F21/6245;;G06F21/6263;;G06F2221/2141;;G06Q30/02;;H04L63/102;;H04L67/306;;G06F2221/2115;;G06F2221/2119;;G06F21/62,G06F17/30;;G06F21/00;;G06F21/60;;G06F21/62,707/785;;705/319;;709/224,5,0,,,"PCT International Search Report and Written Opinion, PCT/US2008/075641, Nov. 18, 2008, 8 Pages.;;IP Australia, Examiner's First Report on Australian Patent Application No. 2008295996, May 24, 2012, two pages.;;Canadian Intellectual Property Office, First Office Action, Canadian Patent Application No. 2,696,945, May 2, 2013, two pages.;;PCT International Preliminary Report on Patentability, PCT Application No. PCT/US2008/075641, Mar. 18, 2010, six pages.;;Japanese Patent Office, Office Action, Japanese Patent Application No. P2010-524230, Jun. 4, 2013, four pages.",ACTIVE
355,WO,A3,WO 1999/065449 A3,103-444-021-425-81X,2000-03-30,2000,US 9913652 W,1999-06-18,US 8982798 P,1998-06-19,INHIBITORS OF TRANSCRIPTION FACTOR NF- kappa B,"The present invention provides pharmaceutical compositions of salicylanilide inhibitors of transcription factor NF-λB, and methods for treating diseases in which activation of NF-λB is implicated. More specifically, the present invention provides methods of treatment of a variety of diseases associated with NF-λB activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and atopic dermatitis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkin's disease; certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia by administering to a patient in need thereof a compound of the present invention.",SMITHKLINE BEECHAM CORP;;CALLAHAN JAMES F;;CHABOT FLETCHER MARIE C,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,,https://lens.org/103-444-021-425-81X,Search Report,yes,3,0,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A61K31/167;;A61P1/00;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,,0,0,,,,PATENTED
356,NO,D0,NO 20006452 D0,117-688-440-828-241,2000-12-18,2000,NO 20006452 A,2000-12-18,US 9001698 P;;US 9913897 W,1998-06-19,Inhibitorer av transkripsjonsfaktor NF-kB,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;CHABOT-FLETCHER MARIE C,,https://lens.org/117-688-440-828-241,Patent Application,no,0,0,19,19,0,A61K31/135;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06;;A61P39/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61K31/535,A61K31/135;;C07D295/10;;A61K31/4453;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P9/00;;A61P9/02;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06,,0,0,,,,DISCONTINUED
357,US,B2,US 7494328 B2,135-277-342-943-031,2009-02-24,2009,US 17550705 A,2005-07-06,US 17550705 A,2005-07-06,NVH and gas pulsation reduction in AC compressor,"A rear housing for a compressor reduces NVH without increasing the overall size of the compressor or inducing flow loss. Generally, the compressor includes a cylinder block receiving lower pressure fluid from the rear housing and providing higher pressure fluid back to the rear housing. The rear housing includes an annular outer wall and an annular inner wall defining a suction chamber and a discharge chamber. An inlet is in fluid communication with the suction chamber. An outlet is in fluid communication with the discharge chamber. The outlet includes a discharge passageway having a tubular member projecting into the discharge chamber. The tubular member is defined by a side wall and a closed end wall. The side wall includes a plurality of holes fluidically connecting the discharge chamber and the discharge passageway.",VISTEON GLOBAL TECH INC,BHATIA KANWAL;;CALLAHAN RODNEY JAMES;;SHASKA KASTRIOT,VISTEON GLOBAL TECHNOLOGIES INC (2005-07-05);;HANON SYSTEMS (2013-07-26),https://lens.org/135-277-342-943-031,Granted Patent,yes,49,0,2,2,0,F04B53/001;;F04B53/001,F04B1/12;;F04B39/00;;F04B27/08;;F04B53/00,417/312;;417/269,0,0,,,,ACTIVE
358,EP,A4,EP 1085848 A4,128-659-744-682-815,2004-09-08,2004,EP 99930345 A,1999-06-18,US 9913652 W;;US 8982798 P,1998-06-19,INHIBITORS OF TRANSCRIPTION FACTOR NF-KAPPA B,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,SMITHKLINE BEECHAM CORPORATION (2008-01-02),https://lens.org/128-659-744-682-815,Search Report,no,4,0,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A61K31/167;;A61P1/00;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,,0,0,,,,EXPIRED
359,NZ,A,NZ 561438 A,167-522-691-423-701,2011-02-25,2011,NZ 56143806 A,2006-03-24,US 66534705 P;;US 2006/0010792 W,2005-03-25,"Novel substituted 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-[1H]-one compounds, pharmaceutical compositions, and use in the manufacture of medicines","Disclosed are the following three compounds: 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide; 3-[8-(2,6-difluorophenyl)-2-(4-methyl-1,4'-bipiperidin-1'-yl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide; and 3-{8-(2,6-difluorophenyl)-2-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yI}-4-methyl-N-(1-methyl ethyl)benzamide, and salts thereof. Also more generally disclosed are compound of the pictured formulas, where the substituents and variables are as defined in the specification. Also disclosed is the use of the above compound to treat CSBP/RK/p38 kinase mediated diseases such as asthma, adult respiratory distress syndrome, chronic pulmonary inflammatory disease, and chronic obstructive pulmonary disease (COPD).",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/167-522-691-423-701,Patent Application,no,0,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,C07D475/00;;A61K31/519;;A61K31/535;;A61K31/55;;A61K31/5513;;C07D239/47;;C07D243/08;;C07D413/12;;C07D413/14,,0,0,,,,DISCONTINUED
360,PL,A1,PL 345577 A1,184-990-873-086-076,2001-12-17,2001,PL 34557799 A,1999-06-18,US 9913897 W;;US 9001698 P,1998-06-19,INHIBITORS OF TRANSCRIPTION FACTOR NF-ΚB,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,,https://lens.org/184-990-873-086-076,Patent Application,no,0,0,19,19,0,A61K31/135;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06;;A61P39/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61K31/535,A61K31/135;;A61K31/4453;;C07D295/10;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P9/00;;A61P9/02;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06,,0,0,,,,DISCONTINUED
361,DE,A1,DE 2643359 A1,001-021-328-047-857,1977-04-07,1977,DE 2643359 A,1976-09-25,US 61795575 A,1975-09-29,SIGNALGENERATOR UND VERFAHREN ZUR ERZEUGUNG EINES EINER TASTENFELDVORWAHL ENTSPRECHENDEN AUSGANGSSIGNALS,,MOSTEK CORP,HOFFMANN GORDON BATES;;CALLAHAN JUN MICHAEL JAMES,"SGS-THOMSON MICROELECTRONICS, INC. (N.D.GES.DES ST (1994-07-28)",https://lens.org/001-021-328-047-857,Patent Application,no,2,2,23,24,0,H04M1/505;;H04M1/505,H03B11/00;;H03B28/00;;H03L7/18;;H04L27/26;;H04M1/50,,0,0,,,,EXPIRED
362,WO,A8,WO 1999/065449 A8,036-072-269-701-934,2001-03-08,2001,US 9913652 W,1999-06-18,US 8982798 P,1998-06-19,INHIBITORS OF TRANSCRIPTION FACTOR NF- kappa B,"The present invention provides pharmaceutical compositions of salicylanilide inhibitors of transcription factor NF- kappa B, and methods for treating diseases in which activation of NF- kappa B is implicated. More specifically, the present invention provides methods of treatment of a variety of diseases associated with NF- kappa B activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and atopic dermatitis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkin's disease; certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia by administering to a patient in need thereof a compound of the present invention.",SMITHKLINE BEECHAM CORP;;CALLAHAN JAMES F;;CHABOT FLETCHER MARIE C,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,,https://lens.org/036-072-269-701-934,Patent Application,no,0,0,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A61K31/167;;A61P1/00;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,,0,0,,,,PATENTED
363,CO,A1,CO 5080752 A1,132-570-425-356-426,2001-09-25,2001,CO 99037918 A,1999-06-17,US 9001698 P,1998-06-19,INHIBIDORES DEL FACTOR DE TRANSCRIPCION NF-kB,"Una composición farmacéutica que comprende un compuesto de fórmula I:<EMI FILE=""99037918_1"" ID=""1"" IMF=JPEG >En la que:R1 es arilo;R2 se selecciona entre el grupo que consta de: H, alquilo C1-6 y arilo;R3 se selecciona entre el grupo que consta de: alquilo C1-6 y cicloalquilo C3-8; y R2 y R3 pueden ser unidos conjuntamente para formar un anillo heterocíclico de 5-7 átomos seleccionados entre le grupo que consta de: C, N, O y S; y un vehículo, diluyente o excipiente farmacéuticamente aceptable.Un método para inhibir el NF-kB que comprende administrar a un paciente que necesita de ello una cantidad eficaz de un compuesto de fórmula I:<EMI FILE=""99037918_2"" ID=""2"" IMF=JPEG >en la que:R1 es arilo;R2 se selecciona entre el grupo que consta de: H, alquilo C1-6 y arilo;R3 se selecciona entre el grupo que consta de : alquilo C1-6 y cicloalquilo C3-8 ; yR2 y R3 pueden ser unidos conjuntamente para formar un anillo heterocíclico de 5-7 átomos, seleccionados entre el grupo que consta de: C, N, O y S.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;CHABOT FLETCHER MARIE C,,https://lens.org/132-570-425-356-426,Patent Application,no,0,0,19,19,0,A61K31/135;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06;;A61P39/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61K31/535,C07D295/10;;A61K31/12;;A61K31/13;;A61K31/135;;A61K31/4453;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P9/00;;A61P9/02;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06,,0,0,,,,PENDING
364,MA,B1,MA 29340 B1,164-717-014-020-412,2008-03-03,2008,MA 30236 A,2007-09-24,US 66534705 P,2005-03-25,NOUVEAUX COMPOSES,"L'INVENTION CONCERNE DE NOUVEAUX COMPOSÉS SUBSTITUÉS DE 3,5,4-DIHYDRO-PYRIINIDO[4,5-(FLPYRIMIDIN-2-(2H)-ONE? 1,5,7 TRISUBSTITUÉS ET DES COMPOSITIONS ASSOCIÉES, AINSI QUE LEUR UTILISATION DANS UNE THÉRAPIE EN TANT QU'INHIBITEURS DE CSBP/RK/P38 KINASES.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/164-717-014-020-412,Granted Patent,no,0,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,,,0,0,,,,ACTIVE
365,US,B1,US 6492425 B1,191-724-391-934-10X,2002-12-10,2002,US 72001800 A,2000-12-19,US 72001800 A;;US 8982798 P;;US 9913652 W,1998-06-19,Inhibitors of transcription factor-NF-kappaB,"
    The present invention provides pharmaceutical compositions of salicylanilide inhibitors of transcription factor NF-B, and methods for treating diseases in which activation of NF-B is implicated. More specifically, the present invention provides methods of treatment of a variety of diseases associated with NF-B activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and atopic dermatitis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkin's disease; certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia by administering to a patient in need thereof a compound of the present invention. 
",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,SMITHKLINE BEECHAM CORPORATION (1999-07-07),https://lens.org/191-724-391-934-10X,Granted Patent,yes,5,40,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A61K31/167;;A61P1/00;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,514/622,4,4,008-496-181-170-220;;172-377-561-600-119;;008-611-681-518-618;;000-740-796-087-600,10.1021/jo01269a042;;10.1021/jo01056a012;;10.1021/ja01537a037;;10.1021/jm00151a004;;3941411,"Maury, et al., ""Mobile Keto Allyl Systems. Via. Reaction of 3-Bromo-2-benzal-1-indanone with Amines"", Journal of Organic Chemistry, (1968), 33(5), pp. 1900-1907.;;Pearson, et al., ""Elimination Reactions of alpha-Halogenated Ketones. IX.1a A Comparison of the Reactions of 2-Bromo-20(alpha-bromobenzyl)-1-indanone with Those of 2-Bromo-2-(alpha-bromobenzyl)-3,3-dimethyl-1-indanone"", (1962), 27, pp. 3038-3044.;;Hassner, et al., ""The Chemistry of Derivatives of 2-Benzaltetralone. II. Absorption Spectra and Stereostructure"", (1958), J. Amer. Chem. Society, 80, pp. 893-901.;;Clark, et al., ""5-(Alkylsulfonyl)salicylanilides as Potential Dental Antiplaque Agents"", (1986), J. Med. Chem., 29, pp. 25-29.",EXPIRED
366,EP,A1,EP 2249830 A1,197-491-062-949-38X,2010-11-17,2010,EP 09709405 A,2009-02-05,US 2009/0033133 W;;US 2657608 P,2008-02-06,DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS,,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,GLAXO GROUP LIMITED (2013-05-01),https://lens.org/197-491-062-949-38X,Patent Application,yes,0,0,3,3,0,A61P29/00;;A61P37/08;;C07D471/04,A01N43/42;;C07D471/04;;C07D519/00,,0,0,,,,DISCONTINUED
367,US,A,US 3257474 A,009-914-121-362-699,1966-06-21,1966,US 23069462 A,1962-10-15,US 23069462 A,1962-10-15,Process for the oxidative dehydrogenation of olefins using an antimony oxide-manganese oxide catalyst,,STANDARD OIL CO,CALLAHAN JAMES L;;BERTHOLD GERTISSER;;ROBERT GRASSELLI,,https://lens.org/009-914-121-362-699,Granted Patent,no,3,1,1,1,0,C07C5/48;;C07C45/34;;C07C45/35;;C07C5/48;;C07C45/34;;C07C45/35,C07C5/48;;C07C45/34;;C07C45/35,,0,0,,,,EXPIRED
368,DE,T2,DE 69937997 T2,019-714-924-870-968,2009-02-19,2009,DE 69937997 T,1999-06-18,US 8982798 P;;US 9913652 W,1998-06-19,DE 69937997 T2,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,,https://lens.org/019-714-924-870-968,Granted Patent,no,0,0,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A01N37/18;;A61K31/167;;A61P1/00;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,,0,0,,,,EXPIRED
369,AP,A,AP 2281 A,063-643-186-210-73X,2011-10-31,2011,AP 2007004171 A,2006-03-24,US 66534705 P;;US 2006/0010792 W,2005-03-25,Novel compounds.,,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/063-643-186-210-73X,Granted Patent,no,2,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,A61K31/519;;C07D487/02,,0,0,,,,ACTIVE
370,NO,L,NO 20075273 L,078-457-610-616-698,2007-12-12,2007,NO 20075273 A,2007-10-15,US 66534705 P;;US 2006/0010792 W,2005-03-25,Nye forbindelser,"Nye substituerte 1,5,7-trisubstituerte-3,4-dihydropyrimido[4,5-d]pyrimidin-2-[IH]-on-forbindelser og sammensetninger og deres anvendelse ved behandling som CSBP/RK/p38-kinaseinhibitorer.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/078-457-610-616-698,Abstract,no,0,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,C07D487/04;;A61K31/519,,0,0,,,,DISCONTINUED
371,US,A1,US 2006/0035979 A1,187-811-920-470-082,2006-02-16,2006,US 24257205 A,2005-10-03,US 24257205 A;;US 21056002 A;;US 72001800 A;;US 9913652 W;;US 8982798 P,1998-06-19,Inhibitors of transcription factor NF-kappaB,"The present invention provides pharmaceutical compositions of salicylanilide inhibitors of transcription factor NF-κB, and methods for treating diseases in which activation of NF-κB is implicated. More specifically, the present invention provides methods of treatment of a variety of diseases associated with NF-κB activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and atopic dermatitis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkin's disease; certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia by administering to a patient in need thereof a compound of the present invention.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,,https://lens.org/187-811-920-470-082,Patent Application,yes,2,9,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A61K31/165;;A61K31/167;;A61P1/00;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,514/622,0,0,,,,DISCONTINUED
372,AU,B2,AU 2006/229967 B2,025-310-258-228-506,2012-02-09,2012,AU 2006/229967 A,2006-03-24,US 66534705 P;;US 2006/0010792 W,2005-03-25,Novel compounds,"Novel substituted l,5,7-trisubstituted-354-dihydro-pyriinido[4,5-(flpyrimidin- 2-(2H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.",GLAXO GROUP LTD,WAN ZEHONG;;CALLAHAN JAMES FRANCIS;;YAN HONGXING,,https://lens.org/025-310-258-228-506,Granted Patent,no,0,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,C07D487/02;;A61K31/519,,0,0,,,,INACTIVE
373,EP,A4,EP 1866311 A4,040-397-476-297-962,2010-03-31,2010,EP 06748656 A,2006-03-24,US 2006/0010792 W;;US 66534705 P,2005-03-25,NOVEL COMPOUNDS,,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/040-397-476-297-962,Search Report,no,2,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,C07D475/00;;A61K31/19;;A61K31/535;;A61K31/55;;A61K31/5513;;A61P29/00;;A61P35/00;;A61P37/00;;C07D239/47;;C07D243/08;;C07D413/12;;C07D413/14,,1,0,,,See also references of WO 2006104889A2,DISCONTINUED
374,PE,A1,PE 20061193 A1,101-167-905-760-175,2006-12-02,2006,PE 2006000331 A,2006-03-23,US 66534705 P,2005-03-25,"DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38","SE REFIERE A COMPUESTOS DE FORMULAS I Y II DONDE G1 Y G2 SON CADA UNO N; G3 ES NH; G4 ES N; R1 ES CICLOPROPILMETIL-CARBAMIL, N-(4-FLUOROFENIL)-CARBAMIL, 3-TIOFENOCARBOXAMIDA, ENTRE OTROS; R1' ES HALOGENO, ALQUILO C1-C4, CIANO, NITRO, ENTRE OTROS; X ES 4-AMINO-PIPERIDINIL, 2-AMINOETIL-METILAMINO, 4-PIPERIDINILAMINO, ENTRE OTROS; R3 ES ALQUILO C1-C10, CICLOALQUILO C3-C7, ARILO, ARIL-ALQUILO C1-C10, ENTRE OTROS; g ES 0-4. SON COMPUESTOS PREFERIDOS: 3-[2-(4-AMINO-1-PIPERIDINIL)-8-(2,6-DIFLUOROFENIL)-7-OXO-5,6,,7,8,TETRAHIDRIPIRIMIDO[4,5-d]PIRIMIDIN-4-IL]-N-CICLOBUTIL-4-METILBENZAMIDA; 3-[2-(4-AMINO-1-PIPERIDINIL)-8-(2,6-DIFLUOROFENIL)-7-OXO-5,6,7,8-TETRAHIDROPIRIMIDO[4,5-d]PIRIMIDIN-4-IL]-N-[2-(4-FLUOROFENIL)ETIL]-4-METILBENZAMIDA; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE CITOQUINAS PROINFLAMATORIAS TALES COMO IL-1, IL-6, IL-8 Y TNF UTILES EN EL TRATAMIENTO DE DIVERSAS ENFERMEDADES TALES COMO OSTEOARTRITIS, ESCLEROSIS MULTIPLE, CHOQUE SEPTICO, ENTRE OTROS",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/101-167-905-760-175,Patent Application,no,0,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,A61K31/519;;C07D487/02,,0,0,,,,DISCONTINUED
375,US,A,US 2552454 A,132-233-327-014-070,1951-05-08,1951,US 59299245 A,1945-05-10,US 59299245 A,1945-05-10,Apparatus for measuring the rate of drilling fluid flow through a well,,ENGINEERING LAB INC,PITCHER JAMES W;;CALLAHAN JR JOHN T,,https://lens.org/132-233-327-014-070,Granted Patent,no,6,3,1,1,0,E21B47/10;;G01F3/16;;G01F3/16;;E21B47/10,E21B47/10;;G01F3/16,,0,0,,,,EXPIRED
376,DE,D1,DE 69937997 D1,139-691-691-813-939,2008-03-06,2008,DE 69937997 T,1999-06-18,US 8982798 P;;US 9913652 W,1998-06-19,DE 69937997 D1,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,,https://lens.org/139-691-691-813-939,Granted Patent,no,0,0,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A01N37/18;;A61K31/167;;A61P1/00;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,,0,0,,,,EXPIRED
377,AU,A,AU 1999/046996 A,045-471-727-893-182,2000-01-05,2000,AU 1999/046996 A,1999-06-18,US 9001698 P;;US 9913897 W,1998-06-19,Inhibitors of transcription factor NF-KappaB,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,,https://lens.org/045-471-727-893-182,Patent Application,no,0,0,19,19,0,A61K31/135;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06;;A61P39/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61K31/535,C07D295/10;;A61K31/135;;A61K31/4453;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P9/00;;A61P9/02;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06,,0,0,,,,DISCONTINUED
378,BR,A2,BR PI0609579 A2,092-503-847-880-229,2010-04-20,2010,BR PI0609579 A,2006-03-24,US 66534705 P;;US 2006/0010792 W,2005-03-25,compostos,"COMPOSTOS. Novos compostos e composições 1,5,7-trisubstituída-354-diidro-pirimido [4,5-(flpirimidin-2-(2H)-ona substituidas, e o uso destes em terapêutica como inibidores de cinase CSBP/RK/p38.",GLAXO GROUP LTD,WAN ZEHONG;;YAN HONGXING;;CALLAHAN JAMES FRANCIS,,https://lens.org/092-503-847-880-229,Patent Application,no,0,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,C07D475/00;;A61K31/519;;A61K31/535;;A61K31/55;;A61K31/5513;;C07D239/47;;C07D243/08;;C07D413/12;;C07D413/14,,0,0,,,,DISCONTINUED
379,EP,A2,EP 1866311 A2,097-657-815-362-703,2007-12-19,2007,EP 06748656 A,2006-03-24,US 2006/0010792 W;;US 66534705 P,2005-03-25,"3-{8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidinyl}-4-methyl-benzamides",,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/097-657-815-362-703,Patent Application,yes,0,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,A61K31/19;;C07D475/00;;A61K31/535;;A61K31/55;;A61K31/5513;;A61P29/00;;A61P35/00;;A61P37/00;;C07D239/47;;C07D243/08;;C07D413/12;;C07D413/14,,0,0,,,,DISCONTINUED
380,EP,A3,EP 2765363 A3,113-903-102-595-549,2014-11-26,2014,EP 14165076 A,2006-05-03,US 67755205 P;;US 70952805 P;;US 72647305 P;;US 35218406 A;;EP 06752232 A,2005-05-04,Direct electric resistance liquid heater,"The Direct Electric Resistance Liquid Heater comprises a liquid heating chamber containing a plurality of electrodes. The electrodes are spaced apart to create a plurality of channels through which the liquid to be heated passes. The electrodes are each connected to a power supply by one or more switches. A controller controls the switches based upon data received from a temperature sensor, sensing the temperature of the liquid, and/or an electric current sensor, sensing the current utilized by the liquid heater. Selection of the number and spacing of the electrodes, and the number of switches, provides the controller with various current levels options to apply to the liquid to be heated.; The current levels available due to the number and spacing of the electrodes and the number of switches, span the range from minimum current to maximum current such that the controller can incrementally increase or decrease the current applied to the liquid to be heated without disrupting other users of the same power source.
",CALLAHAN JEREMIAH M;;BARZYK JAMES,CALLAHAN JEREMIAH M;;BARZYK JAMES;;BOWERS JOHN,"HEATWORKS TECHNOLOGIES, INC. (2017-07-05)",https://lens.org/113-903-102-595-549,Search Report,yes,2,0,19,44,0,F24H1/106;;H05B3/60;;H05B2203/021;;F24H1/10;;F24H1/20;;H05B7/144;;F24H1/106;;H05B2203/021;;H05B3/60,F24H1/10;;H05B3/60,,0,0,,,,ACTIVE
381,DK,T3,DK 1878315 T3,145-786-013-286-374,2014-08-25,2014,DK 06752232 T,2006-05-03,US 67755205 P;;US 70952805 P;;US 72647305 P;;US 35218406 A;;US 2006/0017172 W,2005-05-04,Varmeapparat med direkte elektrisk modstand til opvarmning af væsker,,CALLAHAN JEREMIAH M;;BARZYK JAMES,CALLAHAN JEREMIAH M;;BARZYK JAMES;;BOWERS JOHN,,https://lens.org/145-786-013-286-374,Granted Patent,no,0,0,19,44,0,F24H1/106;;H05B3/60;;H05B2203/021;;F24H1/10;;F24H1/20;;H05B7/144;;F24H1/106;;H05B2203/021;;H05B3/60,F24H1/10;;H05B3/60,,0,0,,,,ACTIVE
382,EP,A4,EP 2249830 A4,149-583-399-636-861,2012-07-18,2012,EP 09709405 A,2009-02-05,US 2009/0033133 W;;US 2657608 P,2008-02-06,DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS,,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,GLAXO GROUP LIMITED (2013-05-01),https://lens.org/149-583-399-636-861,Search Report,no,3,0,3,3,0,A61P29/00;;A61P37/08;;C07D471/04,A01N43/42;;C07D471/04;;C07D519/00,,1,0,,,See also references of WO 2009100170A1,DISCONTINUED
383,EP,A4,EP 1878315 A4,184-776-749-543-041,2012-01-25,2012,EP 06752232 A,2006-05-03,US 2006/0017172 W;;US 67755205 P;;US 70952805 P;;US 72647305 P;;US 35218406 A,2005-05-04,DIRECT ELECTRIC RESISTANCE LIQUID HEATER,,CALLAHAN JEREMIAH M;;BARZYK JAMES,CALLAHAN JEREMIAH M;;BARZYK JAMES;;BOWERS JOHN,"HEATWORKS TECHNOLOGIES, INC. (N. D. GES. D. ST, US (2017-02-14);;BARZYK, JAMES (2014-12-03);;CALLAHAN, JEREMIAH M. (2014-12-03);;ISI TECHNOLOGY, LLC, US (2018-10-09);;HEATWORKS TECHNOLOGIES, INC.; US (2019-08-08);;HEATWORKS TECHNOLOGIES, INC (2019-08-14)",https://lens.org/184-776-749-543-041,Search Report,no,2,0,19,44,0,F24H1/106;;H05B3/60;;H05B2203/021;;F24H1/10;;F24H1/20;;H05B7/144;;F24H1/106;;H05B2203/021;;H05B3/60,H05B3/60;;F24H1/10,,1,0,,,See also references of WO 2006119440A2,ACTIVE
384,AU,B8,AU 2006/243758 B8,012-579-297-753-215,2011-06-02,2011,AU 2006/243758 A,2006-05-03,US 70952805 P;;US 35218406 A;;US 67755205 P;;US 72647305 P;;US 2006/0017172 W,2005-05-04,Direct Electric Resistance Liquid Heater,,HEATWORKS TECHNOLOGIES INC,CALLAHAN JEREMIAH M;;BARZYK JAMES;;BOWERS JOHN,"ISI TECHNOLOGY, LLC (2008-10-23);;HEATWORKS TECHNOLOGIES, INC. (2017-01-19)",https://lens.org/012-579-297-753-215,Amended Patent,no,0,0,19,44,0,F24H1/106;;H05B3/60;;H05B2203/021;;F24H1/10;;F24H1/20;;H05B7/144;;F24H1/106;;H05B2203/021;;H05B3/60,F24H1/10,,1,0,,,See reference of WO 2006/119440,ACTIVE
385,US,A1,US 2014/0196157 A1,087-989-992-042-127,2014-07-10,2014,US 201414205837 A,2014-03-12,US 201414205837 A;;US 20655608 A;;US 96784207 P,2007-09-07,DYNAMICALLY UPDATING PRIVACY SETTINGS IN A SOCIAL NETWORK,"A social network allows its members to regulate what data is accessible to other members using one or more privacy settings. A particular member of the social network can modify the one or privacy settings to grant or deny different users access to different data. When a member modifies a privacy setting, the social network determines which information pathways communicating data between members are affected. The affected information pathways are then modified responsive to the privacy setting to communicate data identified by the modified privacy setting and enforce the new privacy restrictions.",FACEBOOK INC,CALLAHAN EZRA;;WANG JAMES H;;VERA NICOLAS,META PLATFORMS INC (2021-10-28),https://lens.org/087-989-992-042-127,Patent Application,yes,4,5,11,11,0,G06F21/604;;G06F21/6245;;G06F21/6263;;G06F2221/2141;;G06Q30/02;;H04L63/102;;H04L67/306;;G06F21/604;;G06F21/6245;;G06F21/6263;;G06F2221/2141;;G06Q30/02;;H04L63/102;;H04L67/306;;G06F2221/2115;;G06F2221/2119;;G06F21/62,G06F21/62;;G06F21/00;;G06F21/60,726/28,1,1,109-382-519-037-109,10.1109/percomw.2007.7,"Saternus et al., A Middleware for Context-Aware Applications and Services Based on Messenger Protocols, Pervasive Computing and Communications Workshops, 2007. Percom Workshops '07. Fifth Annual IEEE International Conference on, DOI: 10.1109/PERCOMW.2007.7, Publication Year: 2007, Page(s): 467-471",ACTIVE
386,HU,A2,HU P0102492 A2,136-546-107-685-772,2001-11-28,2001,HU P0102492 A,1998-06-18,US 9001698 P;;US 9913897 W,1998-06-19,USE OF AMINO-INDANONE INHIBITORS OF TRANSCRIPTION FACTOR NF-KB FOR PRODUCING PHARMACEUTICAL COMPOSITIONS,"A találmány NF-KB transzkripciós faktor inhibitorok, közelebbről az(I) általános képletű amino-indanon inhibitorok alkalmazásáravonatkozik, amelyek képletében R1 jelentése arilcsoport; R2 jelentésehidrogénatom, 1-6 szénatomos alkilcsoport vagy arilcsoport; R3jelentése 1-6 szénatomos alkilcsoport vagy 3-8 szénatomoscikloalkilcsoport: valamint R2 és R3 egymáshoz kapcsolódva egy 5-7atomos heterociklusos gyűrűt képezhet, amely gyűrű atomjai a következőatomok közül kerülnek kiválasztásra: szén-, nitrogén-, oxigén- éskénatom. Ó",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,,https://lens.org/136-546-107-685-772,Patent Application,no,0,0,19,19,0,A61K31/135;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06;;A61P39/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61K31/535,A61K31/135;;C07D295/10;;A61K31/4453;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P9/00;;A61P9/02;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06,,0,0,,,,PENDING
387,EP,B1,EP 1085848 B1,166-980-105-290-160,2008-01-16,2008,EP 99930345 A,1999-06-18,US 9913652 W;;US 8982798 P,1998-06-19,INHIBITORS OF TRANSCRIPTION FACTOR NF-KAPPA B,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,SMITHKLINE BEECHAM CORPORATION (2008-01-02),https://lens.org/166-980-105-290-160,Granted Patent,yes,7,0,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A01N37/18;;A61K31/167;;A61P1/00;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,,0,0,,,,EXPIRED
388,TR,T2,TR 200003781 T2,193-763-346-963-07X,2001-07-23,2001,TR 200003781 T,1999-06-18,US 8982798 P,1998-06-19,Transkripsiyon faktörü NF- kB inhibitörleri,"Bu bulus, transkripsiyon faktörü NF-kB'nin farmasötik salisiyanilid inhibitör terkipleri ve NF-kB aktivasyonun rol oynadigi hastaliklari tedavi yöntemleri saglamaktadir. Bulus özellikle örnegin enflamatuar hastaliklarin, özellikle romatizmal artrit, enflamatuar barsak hastaligi, ve astim; sedef hastaligi ve atopik dermatit dahil, dermatoz; oto-immün hastaliklar; doku ve organ reddi; Alzheimer hastaligi, felç; ateroskleroz; kanser ve Hodgkin hastaligi; bazi viral enfeksiyonlar, ADIS dahil; osteoartrit; osteoporoz; ve Ataxia Telangiestasia gibi NF-kB aktivasyonuyla baglantili çesitli hastaliklarin, ihtiyaci olan hastaya bir bulus bilesimi verilmesiyle, tedavisi için yöntemler saglar.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;CHABOT-FLETCHER MARIE C,,https://lens.org/193-763-346-963-07X,Patent Application,no,0,0,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A61K31/167;;A61P1/00;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,,0,0,,,,PENDING
389,CZ,A3,CZ 20004760 A3,013-683-019-338-579,2001-08-15,2001,CZ 20004760 A,1999-06-18,US 9001698 P,1998-06-19,Inhibitors of NF-KB transcription factor,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,,https://lens.org/013-683-019-338-579,Patent Application,no,0,0,19,19,0,A61K31/135;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06;;A61P39/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61K31/535,A61K31/135;;A61K31/4453;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P9/00;;A61P9/02;;C07D295/10;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06,,0,0,,,,PENDING
390,US,A,US 3260768 A,152-734-055-417-132,1966-07-12,1966,US 20133062 A,1962-06-11,US 20133062 A,1962-06-11,Oxidative dehydrogenation of olefins using an antimony oxide-iron oxide catalyst,,STANDARD OIL CO,CALLAHAN JAMES L;;BERTHOLD GERTISSER;;ROBERT GRASSELLI,,https://lens.org/152-734-055-417-132,Granted Patent,no,6,1,12,12,0,B01J23/70;;B01J23/8435;;C07C5/48;;C07C45/34;;C07C45/34;;C07C5/48;;B01J23/70;;B01J23/8435,B01J23/70;;B01J23/843;;C07C5/48;;C07C45/34,,0,0,,,,EXPIRED
391,EP,A1,EP 1085872 A1,006-729-945-479-327,2001-03-28,2001,EP 99930459 A,1999-06-18,US 9913897 W;;US 9001698 P,1998-06-19,INHIBITORS OF TRANSCRIPTION FACTOR NF-$g(k)B,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,,https://lens.org/006-729-945-479-327,Patent Application,yes,0,0,19,19,0,A61K31/135;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06;;A61P39/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61K31/535,A61K31/135;;A61K31/4453;;A61K31/4462;;A61K31/5375;;A61P1/04;;C07D295/10;;A61P9/00;;A61P9/02;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06,,0,0,,,,DISCONTINUED
392,US,A1,US 2003/0092771 A1,037-458-401-625-835,2003-05-15,2003,US 21056002 A,2002-07-31,US 21056002 A;;US 72001800 A;;US 8982798 P,1998-06-19,Inhibitors of transcription factor NF-kappaB,"
   The present invention provides pharmaceutical compositions of salicylanilide inhibitors of transcription factor NF-B, and methods for treating diseases in which activation of NF-B is implicated. More specifically, the present invention provides methods of treatment of a variety of diseases associated with NF-B activation including inflammatory disorders; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and atopic dermatitis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkin's disease; certain viral infections, including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia by administering to a patient in need thereof a compound of the present invention. 
",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;CHABOT-FLETCHER MARIE C,,https://lens.org/037-458-401-625-835,Patent Application,yes,2,2,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A61K31/167;;A61P1/00;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,514/617;;514/619;;514/622,0,0,,,,DISCONTINUED
393,US,A1,US 2006/0235030 A1,090-303-486-836-230,2006-10-19,2006,US 38911206 A,2006-03-24,US 38911206 A;;US 66534705 P,2005-03-25,Novel compounds,"Novel substituted 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-(1H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.",CALLAHAN JAMES F;;WAN ZEHONG;;YAN HONGXING,CALLAHAN JAMES F;;WAN ZEHONG;;YAN HONGXING,GLAXO GROUP LIMITED (2006-05-26),https://lens.org/090-303-486-836-230,Patent Application,yes,49,21,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,A61K31/519;;C07D487/02,514/262.1;;544/262,0,0,,,,INACTIVE
394,EP,A2,EP 1878315 A2,096-350-496-196-10X,2008-01-16,2008,EP 06752232 A,2006-05-03,US 2006/0017172 W;;US 67755205 P;;US 70952805 P;;US 72647305 P;;US 35218406 A,2005-05-04,DIRECT ELECTRIC RESISTANCE LIQUID HEATER,,CALLAHAN JEREMIAH M;;BARZYK JAMES,CALLAHAN JEREMIAH M;;BARZYK JAMES;;BOWERS JOHN,"HEATWORKS TECHNOLOGIES, INC. (N. D. GES. D. ST, US (2017-02-14);;BARZYK, JAMES (2014-12-03);;CALLAHAN, JEREMIAH M. (2014-12-03);;ISI TECHNOLOGY, LLC, US (2018-10-09);;HEATWORKS TECHNOLOGIES, INC.; US (2019-08-08);;HEATWORKS TECHNOLOGIES, INC (2019-08-14)",https://lens.org/096-350-496-196-10X,Patent Application,yes,0,0,19,44,0,F24H1/106;;H05B3/60;;H05B2203/021;;F24H1/10;;F24H1/20;;H05B7/144;;F24H1/106;;H05B2203/021;;H05B3/60,F24H1/10;;H05B3/60,,0,0,,,,ACTIVE
395,NO,D0,NO 20006451 D0,100-136-413-080-079,2000-12-18,2000,NO 20006451 A,2000-12-18,US 8982798 P;;US 9913652 W,1998-06-19,Inhibitorer av transkripsjonsfaktor NF-kB,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;CHABOT-FLETCHER MARIE C,,https://lens.org/100-136-413-080-079,Patent Application,no,0,0,30,30,0,A61K31/165;;C07C235/64;;A61P1/00;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;A61P9/00;;A61P9/10;;A61K31/16;;A61K31/165;;C07C235/64,A61K31/167;;A61P1/00;;A61P9/00;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/02;;A61P37/04;;A61P37/06;;A61P43/00;;C07C235/64,,0,0,,,,DISCONTINUED
396,JP,A,JP 2008025556 A,122-761-457-739-295,2008-02-07,2008,JP 2006221700 A,2006-07-19,JP 2006221700 A,2006-07-19,"REDUCTION OF NOISE, VIBRATION, HARSHNESS AND GAS PULSATION IN COMPRESSOR FOR AIR-CONDITIONING","<P>PROBLEM TO BE SOLVED: To provide a rear housing for a compressor to reduce noise, vibration and harshness without increasing the total size of the compressor, and without causing the flow loss. <P>SOLUTION: The rear housing (20) has an outer wall (22) and an inner wall (24) comprising a suction chamber (26) to store a low pressure fluid and a discharge chamber (28) to store a high pressure fluid. An inlet (30) and an outlet (34) are fluid-communicated with the suction chamber and the discharge chamber respectively. The outlet has a discharge passage (36) comprising a tubular member (38) projecting into the discharge chamber. A side wall (44) of the tubular member has a plurality of holes (50) to fluid-connect the discharge chamber and a discharge passage. The total sectional area of a plurality of the holes is substantially equal to the cross sectional area of the discharge passage, which brings about an appropriate amount of fluid flow in a state where the loss is minimized. <P>COPYRIGHT: (C)2008,JPO&INPIT",VISTEON GLOBAL TECH INC,BHATIA KANWAL;;CALLAHAN RODNEY JAMES;;SHASKA KASTRIOT,,https://lens.org/122-761-457-739-295,Patent Application,no,7,0,1,1,0,,F04B27/08;;F04B27/10;;F04B39/00,,0,0,,,,PENDING
397,US,A,US 3251899 A,152-955-781-736-428,1966-05-17,1966,US 20127962 A,1962-06-11,US 20127962 A,1962-06-11,Process for the dehydrogenation of olefins,,STANDARD OIL CO,CALLAHAN JAMES L;;BERTHOLD GERTISSER;;ROBERT GRASSELLI,,https://lens.org/152-955-781-736-428,Granted Patent,no,5,8,3,23,0,B01J23/12;;B01J23/18;;C07C5/48;;B01J23/18;;B01J23/12;;C07C5/48,B01J23/12;;B01J23/18;;C07C5/48,,0,0,,,,EXPIRED
398,CA,A1,CA 2335293 A1,175-261-430-338-987,1999-12-23,1999,CA 2335293 A,1999-06-18,US 9001698 P;;US 9913897 W,1998-06-19,INHIBITORS OF TRANSCRIPTION FACTOR NF-.KAPPA.B,"The present invention provides amino-indanone inhibitors of transcription factor NF-B and pharmaceutically acceptable salts, hydrates and solvates thereof, pharmaceutical compositions of such compounds, and methods for treating diseases in which activation of NF-B is implicated. More specifically, the present invention provides methods of treatment of a varie ty of diseases associated with NF-B activation including inflammatory disorders ; particularly rheumatoid arthritis, inflammatory bowel disease, and asthma; dermatosis, including psoriasis and acute dermatosis; autoimmune diseases; tissue and organ rejection; Alzheimer's disease; stroke; atherosclerosis; restenosis; cancer, including Hodgkins disease; and certain viral infections , including AIDS; osteoarthritis; osteoporosis; and Ataxia Telangiestasia by administering to a patient in need thereof a compound of the present inventi on.",SMITHKLINE BEECHAM CORP,CHABOT-FLETCHER MARIE C;;CALLAHAN JAMES F,,https://lens.org/175-261-430-338-987,Patent Application,no,0,0,19,19,0,A61K31/135;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06;;A61P39/00;;A61P9/00;;A61P9/02;;A61P9/10;;A61K31/535,C07D295/10;;A61K31/135;;A61K31/4453;;A61K31/4462;;A61K31/5375;;A61P1/04;;A61P9/00;;A61P9/02;;A61P9/10;;A61P11/06;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/06,,0,0,,,,DISCONTINUED
399,AU,A1,AU 2006/229967 A1,197-597-610-783-276,2006-10-05,2006,AU 2006/229967 A,2006-03-24,US 66534705 P;;US 2006/0010792 W,2005-03-25,Novel compounds,,GLAXO GROUP LTD,WAN ZEHONG;;CALLAHAN JAMES FRANCIS;;YAN HONGXING,,https://lens.org/197-597-610-783-276,Patent Application,no,0,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,A61K31/519;;C07D487/02,,0,0,,,,INACTIVE
400,US,A,US 2881212 A,045-005-900-505-609,1959-04-07,1959,US 64658157 A,1957-03-18,US 64658157 A,1957-03-18,Process and catalyst for the production of unsaturated carboxylic acids,,STANDARD OIL CO,IDOL JR JAMES D;;CALLAHAN JAMES L;;FOREMAN ROBERT W,,https://lens.org/045-005-900-505-609,Granted Patent,no,8,26,5,5,0,B01J27/19;;B01J27/19;;C07C51/252;;C07C51/252,B01J27/19;;C07C51/25;;C07C57/055,,0,0,,,,EXPIRED
401,US,A,US 2881213 A,039-504-848-278-929,1959-04-07,1959,US 70326857 A,1957-12-17,US 70326857 A,1957-12-17,Process for the conversion of acrolein and methacrolein to the corresponding unsaturated acids,,STANDARD OIL CO,IDOL JR JAMES D;;CALLAHAN JAMES L;;FOREMAN ROBERT W,,https://lens.org/039-504-848-278-929,Granted Patent,no,1,8,1,1,0,B01J23/24;;C07C51/252;;B01J23/24;;C07C51/252,B01J23/24;;C07C51/25;;C07C57/055,,0,0,,,,EXPIRED
402,DE,B,DE 1245363 B,124-526-561-967-020,1967-07-27,1967,DE ST013555 A,1958-03-17,US 64658157 A,1957-03-18,Verfahren zur Herstellung von Acrylsaeure oder Methacrylsaeure durch Oxydation von Acrolein oder Methacrolein,,STANDARD OIL CO,JUN JAMES D IDOL;;CALLAHAN JAMES L;;FOREMAN ROBERT W,,https://lens.org/124-526-561-967-020,Patent Application,no,25,0,5,5,0,B01J27/19;;B01J27/19;;C07C51/252;;C07C51/252,B01J27/19;;C07C51/25;;C07C57/055,,0,0,,,,EXPIRED
403,CA,A,CA 616389 A,091-112-544-692-699,1961-03-14,1961,CA 616389D A,,CA 616389T A,,PROCESS AND CATALYST FOR THE PRODUCTION OF UNSATURATED CARBOXYLIC ACIDS,,STANDARD OIL CO,CALLAHAN JAMES L;;IDOL JAMES D JR;;FOREMAN ROBERT W,,https://lens.org/091-112-544-692-699,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
404,US,A,US 3021366 A,108-263-824-029-561,1962-02-13,1962,US 76638758 A,1958-10-10,US 76638758 A,1958-10-10,Process for the conversion of unsaturated aldehydes to the corresponding unsaturated acids,,STANDARD OIL CO,IDOL JR JAMES D;;CALLAHAN JAMES L;;FOREMAN ROBERT W,,https://lens.org/108-263-824-029-561,Granted Patent,no,7,1,1,1,0,C07C51/252;;C07C51/252,C07C51/25;;C07C57/055,,0,0,,,,EXPIRED
405,US,A,US 2881214 A,121-955-918-765-269,1959-04-07,1959,US 70326957 A,1957-12-17,US 70326957 A,1957-12-17,Process for the conversion of acrolein and methacrolein to the corresponding unsaturated acids,,STANDARD OIL CO,IDOL JR JAMES D;;CALLAHAN JAMES L;;FOREMAN ROBERT W,,https://lens.org/121-955-918-765-269,Granted Patent,no,3,9,1,1,0,B01J23/22;;B01J23/50;;B01J23/682;;C07C51/252;;B01J23/682;;B01J23/22;;C07C51/252;;B01J23/50,B01J23/22;;B01J23/50;;B01J23/68;;C07C51/25;;C07C57/055,,0,0,,,,EXPIRED
406,EP,B1,EP 1448545 B1,041-716-768-111-965,2008-11-19,2008,EP 02800491 A,2002-10-04,US 0231902 W;;US 32697601 P,2001-10-04,NF-KB INHIBITORS,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-beta phosphorylation of IkappaB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-kappaB in which diseases excessive activation of NF-kappaB is implicated.,SMITHKLINE BEECHAM CORP,WAN ZEHONG;;BURGESS JOELLE LORRAINE;;CALLAHAN JAMES FRANCIS,SMITHKLINE BEECHAM CORPORATION (2008-10-15),https://lens.org/041-716-768-111-965,Granted Patent,yes,5,0,10,10,0,C07D333/36;;C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;A61P9/00;;A61P3/10;;C07D333/36;;C07D333/38,C07D333/36;;A61K31/38;;A61K31/381;;A61P1/04;;A61P3/10;;A61P9/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;C07D333/38;;C07D333/40,,0,0,,,,EXPIRED
407,US,A,US 3322847 A,081-170-638-874-55X,1967-05-30,1967,US 49817665 A,1965-09-02,US 49817665 A,1965-09-02,Oxidative dehydrogenation of monoolefins,,STANDARD OIL CO,CALLAHAN JAMES L;;SZABO JOSEPH J;;BERTHOLD GERTISSER,,https://lens.org/081-170-638-874-55X,Granted Patent,no,3,5,1,1,0,B01J27/192;;B01J27/192;;B01J23/28;;B01J23/28;;B01J23/31;;B01J23/31;;C07C5/48;;C07C5/48,B01J23/28;;B01J23/31;;B01J27/192;;C07C5/48,,0,0,,,,EXPIRED
408,US,A1,US 2010/0200417 A1,137-084-565-387-679,2010-08-12,2010,US 70070210 A,2010-02-04,US 70070210 A;;US 20666109 P,2009-02-04,Method and Apparatus for Electrodeposition in Metal Acoustic Resonators,"Methods and systems for electrodeposition of Indium, Gallium, or other metals within a metal acoustic resonator chamber are provided, including for electrodeposition of Indium or Gallium as a strike layer on an interior surface of a cavitation chamber. The resultant strike layer affords an accommodating wetting surface for subsequent filling with a liquid metal and performing cavitation therein. In some embodiments, this allows for the use of liquid metal in an acoustic resonator without the damping effects inherent with oxide boundaries or other defects.",IMPULSE DEVICES INC,CALLAHAN BRANT JAMES;;GAITAN DARIO FELIPE;;SCOTT COREY,IMPULSE DEVICES INC (2010-02-03),https://lens.org/137-084-565-387-679,Patent Application,yes,4,6,1,1,0,C25D3/54;;C25D5/36;;C25D7/04;;C25D5/36;;C25D3/54;;C25D7/04,C25D5/34,205/210;;205/205,0,0,,,,DISCONTINUED
409,US,A,US 3354197 A,141-064-785-118-194,1967-11-21,1967,US 51041465 A,1965-08-09,US 51041465 A;;US 19003862 A,1962-04-25,Process for the manufacture of unsaturated nitriles from olefins and ammonia,,STANDARD OIL CO,LOUIS CALLAHAN JAMES;;BERTHOLD GERTISSER;;SZABO JOSEPH J,,https://lens.org/141-064-785-118-194,Granted Patent,no,2,3,1,14,0,B01J23/18;;B01J23/31;;B01J27/192;;C07C253/26;;Y02P20/52;;C07C253/26;;B01J23/31;;B01J23/18;;B01J27/192;;Y02P20/52,B01J23/18;;B01J23/31;;B01J27/192,,0,0,,,,EXPIRED
410,CH,A,CH 437222 A,150-605-360-670-253,1967-06-15,1967,CH 726463 A,1963-06-11,US 20133062 A,1962-06-11,"Composition catalytique, procédé pour sa préparation et utilisation de cette composition",,STANDARD OIL CO OHIO,JAMES LOUIS CALLAHAN;;ROBERT KARL GRASSELLI;;BERTHOLD GERTISSER,,https://lens.org/150-605-360-670-253,Granted Patent,no,0,0,12,12,0,B01J23/70;;B01J23/8435;;C07C5/48;;C07C45/34;;C07C45/34;;C07C5/48;;B01J23/70;;B01J23/8435,B01J23/70;;B01J23/843;;C07C5/48;;C07C45/34,"12O,1/01",0,0,,,,EXPIRED
411,US,A,US 5751281 A,178-270-373-062-534,1998-05-12,1998,US 57054295 A,1995-12-11,US 57054295 A,1995-12-11,Apparatus and method for storing a movie within a movie,"A hierarchical movie is provided. A hierarchical movie is a movie that contains one or more embedded movies. Embedded movies may themselves contain embedded movies. Each movie contains zero or more media sequences. Within a hierarchical movie, media sequences that should be edited together may be grouped together using embedded movies. The media sequences of a hierarchical movie may be sequenced during playback based on a different time coordinate system than the time coordinate system that governs any embedded movies. This allows a movie to contain both time-based and time-independent media sequences. Also, the relative timing of events in the movie may vary from performance to performance. The hierarchical movie structure allows movies to be used as user interface controls, and even as field-sensitive databases.",APPLE COMPUTER,HODDIE PETER;;BATSON JAMES D;;CALLAHAN SEAN MICHAEL,APPLE INC (2007-01-09);;APPLE COMPUTER INC (1995-11-30),https://lens.org/178-270-373-062-534,Granted Patent,yes,11,89,8,8,0,G11B27/034;;G11B27/10;;G11B27/34;;H04N21/234318;;H04N21/23608;;H04N21/422;;H04N21/4344;;H04N21/44029;;H04N21/845;;H04N21/8453;;H04N21/43072;;H04N21/845;;H04N21/4344;;H04N21/8453;;G11B27/34;;H04N21/234318;;G11B27/034;;H04N21/23608;;H04N21/422;;G11B27/10;;H04N21/44029;;H04N21/43072,G11B27/034;;G11B27/10;;G11B27/34;;H04N7/24;;H04N21/2343;;H04N21/236;;H04N21/422;;H04N21/43;;H04N21/434;;H04N21/4402;;H04N21/845,345/302,5,3,006-232-902-688-790;;139-921-095-004-976;;111-649-865-575-809,10.1145/166266.168399;;10.1109/mc.1985.1662718;;10.1145/125223.125238,"Adobe Premier User Guide, Adobe System Incorporated, May 1994.;;a structure for transportable dynamic multimedia documents, by Dick C. A. Bulterman et al., USENIX Summer 91 Nashville, Tn, Jun. 1991.;;Object Composition and playback models for Handling Multimedia Data, by Rei Hamakawa et al., National Conference on Multimedia, Anaheim, California U.S.A, Jan. 1993.;;CCWS: A computer Based Multimedia Information System, by a. Poggio et al., IEEE 1985, Jan. 1985.;;The O2 system, by O. Deux et al., Communication of the ACM/Oct. 1991/vol. 34, No. 30.",EXPIRED
412,US,A,US 2874191 A,145-579-527-969-998,1959-02-17,1959,US 63106356 A,1956-12-28,US 63106356 A,1956-12-28,Process for the manufacture of acetone,,STANDARD OIL CO,FOREMAN ROBERT W;;CALLAHAN JAMES L;;FRANKLIN VEATCH,,https://lens.org/145-579-527-969-998,Granted Patent,no,2,7,1,1,0,C07C45/28;;C07C45/28,C07C45/28,,0,0,,,,EXPIRED
413,EP,B1,EP 0025715 B1,155-358-722-066-130,1983-06-29,1983,EP 80303234 A,1980-09-15,US 7611579 A,1979-09-17,PROCESS FOR THE PRODUCTION OF A SUPPORTED SOLID OXIDE COMPLEX CATALYST AND USE THEREOF,,THE STANDARD OIL COMPANY,"SHAW WILFRID GARSIDE;;PAPERIZOS, CHRISTOS;;CALLAHAN, JAMES LOUIS",,https://lens.org/155-358-722-066-130,Granted Patent,yes,1,0,12,13,0,B01J23/28;;C07C45/35;;B01J23/28;;C07C45/35,C07C27/14;;B01J21/08;;B01J23/28;;B01J23/31;;B01J27/057;;B01J37/04;;C07B33/00;;C07B61/00;;C07C27/00;;C07C45/35;;C07C47/22;;C07C67/00,,0,0,,,,EXPIRED
414,CA,A,CA 619518 A,031-353-134-080-631,1961-05-02,1961,CA 619518D A,,CA 619518T A,,ATTRITION RESISTANT OXIDATION CATALYST,,STANDARD OIL CO,VEATCH FRANKLIN;;FOREMAN ROBERT W;;CALLAHAN JAMES L,,https://lens.org/031-353-134-080-631,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
415,WO,A3,WO 2007/102883 A3,044-191-018-640-059,2008-11-20,2008,US 2006/0060098 W,2006-10-20,US 72996905 P,2005-10-25,CHEMICAL COMPOUNDS,"The invention is directed to novel indazole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula (I) where R1 and R2 are as defined below. These compounds are useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, in particular in the treatment and prevention of disorders mediated by IKK2 mechanisms including inflammatory and tissue repair disorders. Such disorders include rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease).",SMITHKLINE BEECHAM CORP;;CALLAHAN JAMES FRANCIS;;KERNS JEFFREY K;;LIN XICHEN,CALLAHAN JAMES FRANCIS;;KERNS JEFFREY K;;LIN XICHEN,,https://lens.org/044-191-018-640-059,Search Report,yes,1,0,6,6,0,A61P1/04;;A61P3/10;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;C07D231/56;;C07D231/56;;C07D401/04;;C07D401/04;;C07D401/14;;C07D401/14,A61K31/54;;A61K31/497;;C07D231/56;;C07D401/00,,1,0,,,See also references of EP 1940394A4,PENDING
416,US,A1,US 2004/0047208 A1,062-877-978-305-628,2004-03-11,2004,US 63803703 A,2003-08-08,US 63803703 A;;US 91194601 A;;US 4971598 A;;US 57054295 A,1995-12-11,Apparatus and method for storing a movie within a movie,"
   A hierarchical movie is provided. A hierarchical movie is a movie that contains one or more embedded movies. Embedded movies may themselves contain embedded movies. Each movie contains zero or more media sequences. Within a hierarchical movie, media sequences that should be edited together may be grouped together using embedded movies. The media sequences of a hierarchical movie may be sequenced during playback based on a different time coordinate system than the time coordinate system that governs any embedded movies. This allows a movie to contain both time-based and time-independent media sequences. Also, the relative timing of events in the movie may vary from performance to performance. The hierarchical movie structure allows movies to be used as user interface controls, and even as field-sensitive databases. 
",HODDIE PETER;;BATSON JAMES D.;;CALLAHAN SEAN MICHAEL,HODDIE PETER;;BATSON JAMES D;;CALLAHAN SEAN MICHAEL,APPLE INC (2007-01-09),https://lens.org/062-877-978-305-628,Patent Application,yes,14,4,8,8,0,G11B27/034;;G11B27/10;;G11B27/34;;H04N21/234318;;H04N21/23608;;H04N21/422;;H04N21/4344;;H04N21/44029;;H04N21/845;;H04N21/8453;;H04N21/43072;;H04N21/845;;H04N21/4344;;H04N21/8453;;G11B27/34;;H04N21/234318;;G11B27/034;;H04N21/23608;;H04N21/422;;G11B27/10;;H04N21/44029;;H04N21/43072,G11B27/034;;G11B27/10;;G11B27/34;;H04N7/24;;H04N21/2343;;H04N21/236;;H04N21/422;;H04N21/43;;H04N21/434;;H04N21/4402;;H04N21/845,365/202,0,0,,,,EXPIRED
417,US,A1,US 2004/0192943 A1,069-104-782-374-285,2004-09-30,2004,US 49171004 A,2004-04-02,US 49171004 A;;US 32697601 P;;US 0231902 W,2001-10-04,Nf-kappab inhibitors,"
   The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK- phosphorylation of IB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-B in which diseases excessive activation of NF-B is implicated. 
",WAN ZEHONG;;BURGESS JOELLE L.;;CALLAHAN JAMES F.,WAN ZEHONG;;BURGESS JOELLE L;;CALLAHAN JAMES F,SMITHKLINE BEECHAM CORPORATION (2004-02-10),https://lens.org/069-104-782-374-285,Patent Application,yes,11,6,10,10,0,C07D333/36;;C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;A61P9/00;;A61P3/10;;C07D333/36;;C07D333/38,A61K31/381;;A61P1/04;;A61P3/10;;A61P9/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;C07D333/36;;C07D333/38;;C07D333/40,549/63;;549/68,0,0,,,,EXPIRED
418,CH,A,CH 452493 A,070-763-797-516-770,1968-05-31,1968,CH 699667 A,1963-04-25,US 19003862 A,1962-04-25,Procédé pour l'oxydation d'oléfines,,STANDARD OIL CO,JAMES LOUIS CALLAHAN;;JOSEPH JOHN SZABO;;BERTHOLD GERTISSER,,https://lens.org/070-763-797-516-770,Granted Patent,no,0,0,12,14,0,B01J23/16;;B01J23/28;;B01J23/31;;B01J27/186;;B01J27/192;;C07C5/48;;C07C45/34;;C07C45/35;;C07C253/26;;Y02P20/52;;B01J23/16;;B01J27/192;;B01J23/31;;C07C5/48;;C07C45/35;;B01J27/186;;C07C45/34;;B01J23/28;;C07C253/26;;Y02P20/52,B01J23/16;;B01J23/28;;B01J23/31;;B01J27/186;;B01J27/192;;C01G1/02;;C07B35/04;;C07B61/00;;C07C1/00;;C07C5/48;;C07C11/00;;C07C11/16;;C07C45/34;;C07C45/35;;C07C67/00;;C07C253/00;;C07C255/08,"12O,10",0,0,,,,EXPIRED
419,CH,A,CH 440256 A,077-718-435-890-302,1967-07-31,1967,CH 726263 A,1963-06-11,US 20127962 A;;US 20132962 A;;US 24733162 A,1962-06-11,Procédé de préparation d'un nitrile,,STANDARD OIL CO,JAMES LOUIS CALLAHAN;;ROBERT KARL GRASSELLI;;BERTHOLD GERTISSER,,https://lens.org/077-718-435-890-302,Granted Patent,no,0,0,18,23,0,B01J23/12;;B01J23/16;;B01J23/18;;C07C45/35;;C07C5/48;;C07C45/34;;C07C51/252,B01J23/12;;B01J23/16;;B01J23/18;;C07C5/48;;C07C45/34;;C07C45/35;;C07C51/25,"12O,21",0,0,,,,EXPIRED
420,CH,A,CH 462130 A,128-953-513-619-218,1968-09-15,1968,CH 502667 A,1963-06-11,US 20127962 A;;US 20132962 A;;US 24733162 A,1962-06-11,Procédé de préparation d'une aldéhyde par oxydation d'une oléfine par l'oxygène,,STANDARD OIL CO,JAMES LOUIS CALLAHAN;;ROBERT KARL GRASSELLI;;BERTHOLD GERTISSER,,https://lens.org/128-953-513-619-218,Granted Patent,no,0,0,18,23,0,B01J23/12;;B01J23/16;;B01J23/18;;C07C45/35;;C07C5/48;;C07C45/34;;C07C51/252,B01J23/12;;B01J23/16;;B01J23/18;;C07C5/48;;C07C45/34;;C07C45/35;;C07C51/25,"12O,7/03",0,0,,,,EXPIRED
421,US,B2,US 7166639 B2,185-282-226-282-360,2007-01-23,2007,US 49171004 A,2004-04-02,US 49171004 A;;US 32697601 P;;US 0231902 W,2001-10-04,NF-kappaB inhibitors,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-β phosphorylation of IκB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-κB in which diseases excessive activation of NF-κB is implicated.,SMITHKLINE BEECHAM CORP,WAN ZEHONG;;BURGESS JOELLE L;;CALLAHAN JAMES F,SMITHKLINE BEECHAM CORPORATION (2004-02-10),https://lens.org/185-282-226-282-360,Granted Patent,yes,13,37,10,10,0,C07D333/36;;C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;A61P9/00;;A61P3/10;;C07D333/36;;C07D333/38,A61K31/38;;A61K31/381;;A61P1/04;;A61P3/10;;A61P9/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;C07D333/36;;C07D333/38;;C07D333/40,514/447;;549/68,0,0,,,,EXPIRED
422,US,A,US 3186955 A,198-999-769-491-740,1965-06-01,1965,US 19793262 A,1962-05-28,US 19793262 A,1962-05-28,Bismuth-molybdenum oxidation catalyst promoted with a ba-si oxide mixture,,STANDARD OIL CO,CALLAHAN JAMES L;;SZABO JOSEPH J;;BERTHOLD GERTISSER,,https://lens.org/198-999-769-491-740,Granted Patent,no,15,11,2,2,0,B01J23/28;;B01J23/31;;B01J23/8437;;B01J23/88;;B01J23/8876;;B01J27/186;;B01J27/192;;B01J2523/00;;C01C3/0245;;C07C5/48;;C07C45/34;;C07C45/35;;C07C253/26;;Y10S585/906;;Y02P20/52;;B01J23/28;;B01J27/186;;B01J27/192;;B01J23/31;;C07C253/26;;C01C3/0245;;C07C5/48;;C07C45/34;;B01J23/88;;B01J23/8876;;B01J23/8437;;C07C45/35;;B01J2523/00;;Y10S585/906;;Y02P20/52,B01J23/28;;B01J23/31;;B01J23/843;;B01J23/88;;B01J23/887;;B01J27/186;;B01J27/192;;C01C3/02;;C01G29/00;;C07C5/48;;C07C45/34;;C07C45/35,,0,0,,,,EXPIRED
423,US,A1,US 2008/0262040 A1,006-553-305-156-339,2008-10-23,2008,US 9149106 A,2006-10-20,US 9149106 A;;US 72996905 P;;US 2006/0060098 W,2005-10-25,Chemical Compounds,"The invention is directed to novel indazole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula (I): where R1 and R2 are as defined below. These compounds are useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, in particular in the treatment and prevention of disorders mediated by IKK2 mechanisms including inflammatory and tissue repair disorders. Such disorders include rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease).",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;KERNS JEFFREY K;;LIN XICHEN,GLAXOSMITHKLINE LLC (2006-12-04),https://lens.org/006-553-305-156-339,Patent Application,yes,2,23,6,6,0,A61P1/04;;A61P3/10;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;C07D231/56;;C07D231/56;;C07D401/04;;C07D401/04;;C07D401/14;;C07D401/14,A61K31/4535;;A61P3/10;;A61P11/06;;A61P25/28;;A61P31/18;;C07D211/06,514/322;;546/199,0,0,,,,DISCONTINUED
424,EP,A4,EP 1448545 A4,079-661-828-311-20X,2005-01-12,2005,EP 02800491 A,2002-10-04,US 0231902 W;;US 32697601 P,2001-10-04,NF-KB INHIBITORS,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-beta phosphorylation of IkappaB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-kappaB in which diseases excessive activation of NF-kappaB is implicated.,SMITHKLINE BEECHAM CORP,WAN ZEHONG;;BURGESS JOELLE LORRAINE;;CALLAHAN JAMES FRANCIS,SMITHKLINE BEECHAM CORPORATION (2008-10-15),https://lens.org/079-661-828-311-20X,Search Report,no,3,0,10,10,0,C07D333/36;;C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;A61P9/00;;A61P3/10;;C07D333/36;;C07D333/38,A61K31/381;;A61P1/04;;A61P3/10;;A61P9/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;C07D333/36;;C07D333/38;;C07D333/40,,0,0,,,,EXPIRED
425,DE,B,DE 1223813 B,079-032-575-166-160,1966-09-01,1966,DE ST020526 A,1963-04-24,US 1223813X A,1962-04-25,Verfahren zur Herstellung eines verbesserten Oxydationskatalysators,,STANDARD OIL CO,CALLAHAN JAMES LOUIS;;GERTISSER BERTHOLD;;SZABO JOSEPH JOHN,,https://lens.org/079-032-575-166-160,Patent Application,no,1,0,1,1,0,B01J27/192;;B01J23/16,B01J23/16;;B01J27/192,,0,0,,,,DISCONTINUED
426,US,A,US 3320330 A,095-030-439-717-424,1967-05-16,1967,US 51041665 A,1965-09-30,US 51041665 A;;US 19003862 A,1962-04-25,Process for the catalytic oxidative dehydrogenation of olefins to diolefins,,STANDARD OIL CO,LOUIS CALLAHAN JAMES;;BERTHOLD GERTISSER;;SZABO JOSEPH J,,https://lens.org/095-030-439-717-424,Granted Patent,no,3,11,1,14,0,B01J23/18;;B01J23/31;;C07C5/48;;B01J23/31;;B01J23/18;;C07C5/48,B01J23/18;;B01J23/31;;C07C5/48,,0,0,,,,EXPIRED
427,CH,A,CH 455744 A,145-922-204-488-298,1968-05-15,1968,CH 502767 A,1963-06-11,US 20127962 A;;US 20132962 A;;US 24733162 A,1962-06-11,Procédé de déshydrogénation oxydante d'une oléfine,,STANDARD OIL CO,JAMES LOUIS CALLAHAN;;ROBERT KARL GRASSELLI;;BERTHOLD GERTISSER,,https://lens.org/145-922-204-488-298,Granted Patent,no,0,0,18,23,0,B01J23/12;;B01J23/16;;B01J23/18;;C07C45/35;;C07C5/48;;C07C45/34;;C07C51/252,B01J23/12;;B01J23/16;;B01J23/18;;C07C5/48;;C07C45/34;;C07C45/35;;C07C51/25,"12O,1/01",0,0,,,,EXPIRED
428,CH,A,CH 455747 A,166-336-955-672-600,1968-05-15,1968,CH 518463 A,1963-04-25,US 19003862 A,1962-04-25,Procédé pour la transformation d'oléfines en nitriles non saturés,,STANDARD OIL CO,JAMES LOUIS CALLAHAN;;JOSEPH JOHN SZABO;;BERTHOD GERTISSER,,https://lens.org/166-336-955-672-600,Granted Patent,no,0,0,12,14,0,B01J23/16;;B01J23/28;;B01J23/31;;B01J27/186;;B01J27/192;;C07C5/48;;C07C45/34;;C07C45/35;;C07C253/26;;Y02P20/52;;B01J23/16;;B01J27/192;;B01J23/31;;C07C5/48;;C07C45/35;;B01J27/186;;C07C45/34;;B01J23/28;;C07C253/26;;Y02P20/52,B01J23/16;;B01J23/28;;B01J23/31;;B01J27/186;;B01J27/192;;C01G1/02;;C07B35/04;;C07B61/00;;C07C1/00;;C07C5/48;;C07C11/00;;C07C11/16;;C07C45/34;;C07C45/35;;C07C67/00;;C07C253/00;;C07C255/08,"12O,21",0,0,,,,EXPIRED
429,ES,T3,ES 2388277 T3,166-602-964-771-335,2012-10-11,2012,ES 03783752 T,2003-11-25,US 42910502 P;;US 0337461 W,2002-11-26,Compuestos calcilíticos,"El ácido 3-{3,4-difluoro-5-[(R)-2-hidroxi-3-(2-indan-2-il-1,1-dimetil-etilamino)-propoxi]-fenil}-propionico o una de sussales farmacéuticamente aceptables.",GLAXOSMITHKLINE LLC,MARQUIS ROBERT;;CASILLAS LINDA;;RAMANJULU JOSHI;;CALLAHAN JAMES,,https://lens.org/166-602-964-771-335,Granted Patent,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C229/00;;A61K31/185;;A61K31/21;;A61P19/00;;A61P19/08;;C07C217/32;;C07C217/34;;C07C217/36,,0,0,,,,EXPIRED
430,US,A,US 4453006 A,055-909-587-496-789,1984-06-05,1984,US 23374281 A,1981-02-12,US 23374281 A;;US 7611579 A,1979-09-17,Oxidation of propylene or isobutylene with attrition resistant catalysts,"A method for preparing attrition resistant, high percentage active component catalysts comprises using two types of silica, one of which is fumed silica, in a two stage catalyst preparation.",STANDARD OIL CO OHIO,SHAW WILFRID G;;PAPARIZOS CHRISTOS;;CALLAHAN JAMES L,ADIDAS SARRAGAN FRANCE (1990-09-10),https://lens.org/055-909-587-496-789,Granted Patent,yes,3,5,1,13,0,B01J23/28;;B01J23/28;;C07C45/35;;C07C45/35,B01J23/28;;C07C45/35,562/545;;562/532;;562/534;;562/535;;562/546;;562/547;;568/476;;568/477;;568/479;;568/480;;502/200;;502/255,0,0,,,,EXPIRED
431,EP,A2,EP 0199530 A2,105-295-060-575-112,1986-10-29,1986,EP 86302818 A,1986-04-16,US 72453385 A,1985-04-18,Process for one step esterification using an intermetallic palladium based catalyst system.,"A process for the one esterification of aldehydes and alcohols comprises the steps of combining an aldehyde with an alcohol, in the presence of oxygen and in contact with a catalyst having the general formula  
PdTe.Zn d E. where E is one or more metals from the group consisting of group IA, IIA, IVA, IB, VIIB, or VIII metals, As or Sb; and a, d and e are from about 0 to 3 with the proviso that at least d or e ≠ 0.",STANDARD OIL CO OHIO,PAPARIZOS CHRISTOS;;SHAW WILFRID GARSIDE;;CALLAHAN JAMES LOUIS,,https://lens.org/105-295-060-575-112,Patent Application,yes,0,2,7,8,0,C07C67/39,B01J23/00;;B01J27/00;;C07B61/00;;C07C67/39;;C07C69/54,,0,0,,,,EXPIRED
432,WO,A2,WO 2007/102883 A2,130-638-670-241-61X,2007-09-13,2007,US 2006/0060098 W,2006-10-20,US 72996905 P,2005-10-25,CHEMICAL COMPOUNDS,"The invention is directed to novel indazole carboxamide derivatives. Specifically, the invention is directed to compounds according to formula (I) where R1 and R2 are as defined below. These compounds are useful in the treatment of disorders associated with inappropriate IKK2 (also known as IKKβ) activity, in particular in the treatment and prevention of disorders mediated by IKK2 mechanisms including inflammatory and tissue repair disorders. Such disorders include rheumatoid arthritis, asthma, and COPD (chronic obstructive pulmonary disease).",SMITHKLINE BEECHAM CORP;;CALLAHAN JAMES FRANCIS;;KERNS JEFFREY K;;LIN XICHEN,CALLAHAN JAMES FRANCIS;;KERNS JEFFREY K;;LIN XICHEN,,https://lens.org/130-638-670-241-61X,Patent Application,yes,0,23,6,6,0,A61P1/04;;A61P3/10;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;C07D231/56;;C07D231/56;;C07D401/04;;C07D401/04;;C07D401/14;;C07D401/14,A61K31/416,,1,0,,,See references of EP 1940394A4,PENDING
433,EP,A1,EP 0025715 A1,145-312-720-944-589,1981-03-25,1981,EP 80303234 A,1980-09-15,US 7611579 A,1979-09-17,Process for the production of a supported solid oxide complex catalyst and use thereof.,"A process for preparing a supported solid oxide complex catalyst using silica as support characterised in that one adds fumed silica to a mixture containing one or more active components of the catalyst; dries said mixture to form a dried first-stage mixture; adds, in solution. silica or a silica-containing compound other than fumed silica to the dried first stage mixture optionally with further fumed silica; and dries and calcines the resulting mixture is provided. The use of fumed silica produces a supported solid oxide complex catalyst of increased attrition resistance. Such catalyst is useful in the preparation of unsaturated aldehydes and acids from propylene or isobutylene by vapour phase oxidation. The use of inert or recycle gas increases the performance of such catalyst in this reaction.",STANDARD OIL CO OHIO,SHAW WILFRID GARSIDE;;PAPERIZOS CHRISTOS;;CALLAHAN JAMES LOUIS,,https://lens.org/145-312-720-944-589,Patent Application,yes,5,0,12,13,0,B01J23/28;;C07C45/35;;B01J23/28;;C07C45/35,C07C27/14;;B01J21/08;;B01J23/28;;B01J23/31;;B01J27/057;;B01J37/04;;C07B33/00;;C07B61/00;;C07C27/00;;C07C45/35;;C07C47/22;;C07C67/00,,0,0,,,,EXPIRED
434,ES,T3,ES 2315430 T3,026-517-351-880-122,2009-04-01,2009,ES 02800491 T,2002-10-04,US 32697601 P,2001-10-04,INHIBIDORES DE NF-KB.,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-beta phosphorylation of IkappaB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-kappaB in which diseases excessive activation of NF-kappaB is implicated.,SMITHKLINE BEECHAM CORP,WAN ZEHONG;;BURGESS JOELLE LORRAINE;;CALLAHAN JAMES FRANCIS,,https://lens.org/026-517-351-880-122,Granted Patent,no,0,0,10,10,0,C07D333/36;;C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;A61P9/00;;A61P3/10;;C07D333/36;;C07D333/38,C07D333/36;;A61K31/38;;A61K31/381;;A61P1/04;;A61P3/10;;A61P9/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;C07D333/38;;C07D333/40,,0,0,,,,EXPIRED
435,US,A1,US 2006/0262122 A1,036-055-481-715-490,2006-11-23,2006,US 49718306 A,2006-07-31,US 49718306 A;;US 63803703 A;;US 91194601 A;;US 4971598 A;;US 57054295 A,1995-12-11,Apparatus and method for storing a movie within a movie,"A hierarchical movie is provided. A hierarchical movie is a movie that contains one or more embedded movies. Embedded movies may themselves contain embedded movies. Each movie contains zero or more media sequences. Within a hierarchical movie, media sequences that should be edited together may be grouped together using embedded movies. The media sequences of a hierarchical movie may be sequenced during playback based on a different time coordinate system than the time coordinate system that governs any embedded movies. This allows a movie to contain both time-based and time-independent media sequences. Also, the relative timing of events in the movie may vary from performance to performance. The hierarchical movie structure allows movies to be used as user interface controls, and even as field-sensitive databases.",HODDIE PETER;;BATSON JAMES D;;CALLAHAN SEAN M,HODDIE PETER;;BATSON JAMES D;;CALLAHAN SEAN M,APPLE INC (2007-01-09),https://lens.org/036-055-481-715-490,Patent Application,yes,1,4,8,8,0,G11B27/034;;G11B27/10;;G11B27/34;;H04N21/234318;;H04N21/23608;;H04N21/422;;H04N21/4344;;H04N21/44029;;H04N21/845;;H04N21/8453;;H04N21/43072;;H04N21/845;;H04N21/4344;;H04N21/8453;;G11B27/34;;H04N21/234318;;G11B27/034;;H04N21/23608;;H04N21/422;;G11B27/10;;H04N21/44029;;H04N21/43072,G11B27/034;;G06T15/70;;G11B27/10;;G11B27/34;;H04N7/24;;H04N21/2343;;H04N21/236;;H04N21/422;;H04N21/43;;H04N21/434;;H04N21/4402;;H04N21/845,345/473,0,0,,,,EXPIRED
436,DE,B,DE 1129150 B,042-605-105-084-307,1962-05-10,1962,DE ST013854 A,1958-06-09,US 66449557 A,1957-06-10,Verfahren zur Herstellung von Acrolein bzw. Methacrolein,,STANDARD OIL CO,CALLAHAN JAMES LOUIS;;FROEMAN ROBERT WALTER;;VEATCH FRANKLIN,,https://lens.org/042-605-105-084-307,Patent Application,no,3,3,3,3,0,B01J23/31;;B01J27/186;;B01J27/192;;C07C45/34;;C07C45/35;;C07C45/34;;C07C45/35;;B01J27/192;;B01J23/31;;B01J27/186,B01J23/31;;B01J27/186;;B01J27/192;;C07C45/34;;C07C45/35,,0,0,,,,DISCONTINUED
437,US,A,US 3362998 A,145-706-806-159-532,1968-01-09,1968,US 49817765 A,1965-09-02,US 49817765 A;;US 39597864 A,1964-08-19,Process for the manufacture of unsaturated aldehydes from olefins,,STANDARD OIL CO,CALLAHAN JAMES L;;SZABO JOSEPH J;;BERTHOLD GERTISSER,,https://lens.org/145-706-806-159-532,Granted Patent,no,0,2,1,1,0,B01J23/28;;B01J23/28;;B01J23/31;;B01J23/31;;B01J27/192;;B01J27/192;;C07C45/34;;C07C45/34;;C07C45/35;;C07C45/35,B01J23/28;;B01J23/31;;B01J27/192;;C07C45/34;;C07C45/35,260/604,0,0,,,,EXPIRED
438,CH,A,CH 455745 A,029-551-031-709-236,1968-05-15,1968,CH 699767 A,1963-04-25,US 19003862 A,1962-04-25,Procédé pour la déshydrogénation d'oléfines,,STANDARD OIL CO,JAMES LOUIS CALLAHAN;;JOSEPH JOHN SZABO;;BERTHOLD GERTISSER,,https://lens.org/029-551-031-709-236,Granted Patent,no,0,0,12,14,0,B01J23/16;;B01J23/28;;B01J23/31;;B01J27/186;;B01J27/192;;C07C5/48;;C07C45/34;;C07C45/35;;C07C253/26;;Y02P20/52;;B01J23/16;;B01J27/192;;B01J23/31;;C07C5/48;;C07C45/35;;B01J27/186;;C07C45/34;;B01J23/28;;C07C253/26;;Y02P20/52,B01J23/16;;B01J23/28;;B01J23/31;;B01J27/186;;B01J27/192;;C01G1/02;;C07B35/04;;C07B61/00;;C07C1/00;;C07C5/48;;C07C11/00;;C07C11/16;;C07C45/34;;C07C45/35;;C07C67/00;;C07C253/00;;C07C255/08,"12O,19/01",0,0,,,,EXPIRED
439,CH,A,CH 462141 A,058-877-581-351-488,1968-09-15,1968,CH 833266 A,1966-06-09,US 46303665 A,1965-06-10,Procédé pour transformer une mono-oléfine en un diène conjugué,,STANDARD OIL CO,ROBERT KARL GRASSELLI;;GARFIELD HEIGHTS;;JAMES LOUIS CALLAHAN,,https://lens.org/058-877-581-351-488,Granted Patent,no,0,0,14,15,0,B01J27/192;;B01J27/192;;C07C5/48;;C07C5/48,B01J27/192;;C07C5/48,"12O,19/01",0,0,,,,EXPIRED
440,CA,A,CA 792263 A,119-379-316-754-533,1968-08-13,1968,CA 792263D A,,US 20133062 A,1962-06-11,DEHYDROGENATION OF OLEFINS,,STANDARD OIL CO,GERTISSER BERTHOLD;;CALLAHAN JAMES L;;GRASSELLI ROBERT K,,https://lens.org/119-379-316-754-533,Granted Patent,no,0,0,12,12,0,B01J23/70;;B01J23/8435;;C07C5/48;;C07C45/34;;C07C45/34;;C07C5/48;;B01J23/70;;B01J23/8435,B01J23/70;;B01J23/843;;C07C5/48;;C07C45/34,,0,0,,,,EXPIRED
441,CA,A,CA 616423 A,184-696-239-059-540,1961-03-14,1961,CA 616423D A,,CA 616423T A,,PROCESS FOR THE OXIDATION OF OLEFINS,,STANDARD OIL CO,CALLAHAN JAMES L;;FOREMAN ROBERT W;;VEATCH FRANKLIN,,https://lens.org/184-696-239-059-540,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
442,CA,C,CA 1278312 C,198-246-926-661-162,1990-12-27,1990,CA 505893 A,1986-04-04,US 72453385 A,1985-04-18,PROCESS FOR ONE STEP ESTERIFICATION USING AN INTERMETALLIC PALLADIUM BASED CATALYST SYSTEM,"A process for the one step esterification of aldehydes and alcohols comprises the steps of combining an aldehyde with an alcohol, in the presence of oxygen and in contact with a catalyst having the general formula PdTeaZndEe where E is one or more metals from the group consisting of group IA, IIA, IVA, IB, VIIB or VIII metals, As or Sb; and a, d and e are from about 0 to 3 with the proviso that at least d or e ? 0.",PAPARIZOS CHRISTOS,PAPARIZOS CHRISTOS;;SHAW WILFRID G;;CALLAHAN JAMES L,,https://lens.org/198-246-926-661-162,Granted Patent,no,0,1,7,8,0,C07C67/39,C07B61/00;;B01J23/00;;B01J27/00;;C07C67/39;;C07C69/54,D426004824   M,0,0,,,,EXPIRED
443,CH,A,CH 384553 A,023-318-871-849-224,1964-11-30,1964,CH 7735259 A,1959-08-25,US 75710758 A,1958-08-25,Catalyseur d'oxydation résistant à l'attrition,,STANDARD OIL CO OHIO,JAMES LOUIS CALLAHAN;;ROBERT WALTER FOREMAN;;FRANKLIN VEATCH,,https://lens.org/023-318-871-849-224,Granted Patent,no,0,0,7,7,0,B01J27/186;;B01J23/28;;B01J23/31;;B01J27/192,B01J23/28;;B01J23/31;;B01J27/186;;B01J27/192,"12G,4/01",0,0,,,,EXPIRED
444,US,B1,US 6297830 B1,075-879-560-727-066,2001-10-02,2001,US 4971598 A,1998-03-27,US 4971598 A;;US 57054295 A,1995-12-11,Apparatus and method for storing a move within a movie,"A hierarchical movie is provided. A hierarchical movie is a movie that contains one or more embedded movies. Embedded movies may themselves contain embedded movies. Each movie contains zero or more media sequences. Within a hierarchical movie, media sequences that should be edited together may be grouped together using embedded movies. The media sequences of a hierarchical movie may be sequenced during playback based on a different time coordinate system than the time coordinate system that governs any embedded movies. This allows a movie to contain both time-based and time-independent media sequences. Also, the relative timing of events in the movie may vary from performance to performance. The hierarchical movie structure allows movies to be used as user interface controls, and even as field-sensitive databases.",APPLE COMPUTER,HODDIE PETER;;BATSON JAMES D;;CALLAHAN SEAN MICHAEL,APPLE INC (2007-01-09),https://lens.org/075-879-560-727-066,Granted Patent,yes,13,16,8,8,0,G11B27/034;;G11B27/10;;G11B27/34;;H04N21/234318;;H04N21/23608;;H04N21/422;;H04N21/4344;;H04N21/44029;;H04N21/845;;H04N21/8453;;H04N21/43072;;H04N21/845;;H04N21/4344;;H04N21/8453;;G11B27/34;;H04N21/234318;;G11B27/034;;H04N21/23608;;H04N21/422;;G11B27/10;;H04N21/44029;;H04N21/43072,G11B27/034;;G11B27/10;;G11B27/34;;H04N7/24;;H04N21/2343;;H04N21/236;;H04N21/422;;H04N21/43;;H04N21/434;;H04N21/4402;;H04N21/845,345/473;;345/302,9,3,111-649-865-575-809;;139-921-095-004-976;;006-232-902-688-790,10.1145/125223.125238;;10.1109/mc.1985.1662718;;10.1145/166266.168399,"Adobe Premere3.0 User's Guide, p. (2), 1994.*;;Adobe Premere 4.0 User Guide, pp. 49, 264, May 1994.*;;Adobe Premiere 3.0 User Guide, pp. 5-6, 22, 28, 220-223, 1994.*;;RCA Model VR673HF User's Guide, pp. 12, 17, 19, 1994.*;;The O2 System, by O. Deux et al., Communications of the ACM/Oct. 1991/vol. 34, No. 10, pp. 34-48.;;CCWS: A Computer-Based, Multimedia Information System, by A. Poggio, et al., 1985 IEEE, pp. 92-103.;;Object Composition and Playback Models for Handling Multimedia Data, by Rei Hamakawa, et al., Proceedings of the First ACM International Conference on Multimedia, Anahaeim, CA, U.S.A., 1993, 9 pgs.;;A Structure for Transportable, Dynamic Multimedia Documents, by Dick C.A. Bulterman, et al., USENIX-Summer 91-Nashville, TN, pp. 137-155.;;Adobe Premier User Guide, version 4.0, Adobe Systems Incorporated, 1994.",EXPIRED
445,US,A,US 4877898 A,118-462-698-056-909,1989-10-31,1989,US 87342886 A,1986-06-12,US 87342886 A;;US 72453385 A,1985-04-18,Process for one step esterification using an intermetallic palladium based catalyst system,"A process for the one step esterification of aldehydes and alcohols comprises the steps of combining an aldehyde with an alcohol, in the presence of oxygen and in contact with a catalyst having the general formula PdTe.sub.a Zn.sub.d E.sub.e where E is one or more metals from the group consisting of group IA, IIA, IVA, VIIB or VIII metals, As or Sb; and a, d and e are from about 0 to 3 with the proviso that at least d or e.noteq.0.",STANDARD OIL CO OHIO,PAPARIZOS CHRISTOS;;SHAW WILFRID G;;CALLAHAN JAMES L,,https://lens.org/118-462-698-056-909,Granted Patent,yes,7,6,1,8,0,C07C67/39;;C07C67/39,C07C67/39;;C07C69/54,560/208;;560/100;;560/102;;560/103;;560/104;;560/105;;560/106;;560/109;;560/112;;560/113;;560/131;;560/238,0,0,,,,EXPIRED
446,CA,A,CA 115231 A,162-901-168-270-710,1908-11-24,1908,CA 115231D A,1908-07-30,CA 115231T A,1908-07-30,PNEUMATIC TIRE,,CALLAHAN WILLIAM A;;REDER CHARLES;;MAITLAND JAMES L,CALLAHAN WILLIAM A;;REDER CHARLES;;MAITLAND JAMES L,,https://lens.org/162-901-168-270-710,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
447,EP,B1,EP 0199530 B1,188-991-926-743-392,1990-06-27,1990,EP 86302818 A,1986-04-16,US 72453385 A,1985-04-18,PROCESS FOR ONE STEP ESTERIFICATION USING AN INTERMETALLIC PALLADIUM BASED CATALYST SYSTEM,"A process for the one esterification of aldehydes and alcohols comprises the steps of combining an aldehyde with an alcohol, in the presence of oxygen and in contact with a catalyst having the general formula PdTeaZndEe where E is one or more metals from the group consisting of group IA, IIA, IVA, IB, VIIB, or VIII metals, As or Sb; and a, d and e are from about 0 to 3 with the proviso that at least d or e NOTEQUAL 0.",THE STANDARD OIL COMPANY,"PAPARIZOS, CHRISTOS;;SHAW, WILFRID GARSIDE;;CALLAHAN, JAMES LOUIS",,https://lens.org/188-991-926-743-392,Granted Patent,yes,3,0,7,8,0,C07C67/39,B01J23/00;;B01J27/00;;C07B61/00;;C07C67/39;;C07C69/54,,0,0,,,,EXPIRED
448,EP,A1,EP 1140129 A1,004-450-934-635-696,2001-10-10,2001,EP 99967363 A,1999-12-15,US 9929924 W;;US 21215698 A,1998-12-15,HUMAN MAD PROTEINS AND USES THEREOF,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;LAPING NICHOLAS J;;WEINSTOCK JOSEPH,,https://lens.org/004-450-934-635-696,Patent Application,yes,0,0,2,2,5,C07K14/4703,A61K38/00;;C07K14/47,,1,0,,,See references of WO 0035470A1,DISCONTINUED
449,US,A,US 4714695 A,028-949-612-221-937,1987-12-22,1987,US 85273386 A,1986-04-16,US 85273386 A;;US 72453585 A,1985-04-18,Method for the preparation of high activity palladium based catalysts,"A method for the preparation of a high activity palladium metal based catalyst having the formula PdTe.sub.a Zn.sub.d E.sub.e where E is one or more metals from the group IIA, IVA, VA, IB, VIIB or VIII; and a, d and e are from about 0 to 3, with the proviso that at least d or e.noteq.0. The method comprises the step of forming an aqueous solution of a palladium compound, adding to the solution a powder of a reducing metal more electropositive than palladium and reducing the palladium to its metallic state on the surface of the reducing metal and, separating the resulting catalyst from the solution. Catalysts prepared according to this method are useful for producing esters from aldehydes and alcohols and provide greater conversions to the ester than catalysts prepared by previous processes.",STANDARD OIL CO OHIO,PAPARIZOS CHRISTOS;;SHAW WILFRID G;;CALLAHAN JAMES L,,https://lens.org/028-949-612-221-937,Granted Patent,yes,21,5,1,2,0,B01J23/60;;B01J23/622;;B01J23/644;;B01J23/656;;B01J23/89;;B01J27/0576;;C07C67/39;;B01J27/0576;;B01J23/89;;B01J23/644;;C07C67/39;;B01J23/60;;B01J23/622;;B01J23/656,B01J23/60;;B01J23/62;;B01J23/644;;B01J23/656;;B01J23/89;;B01J27/057;;C07C67/39,502/339;;502/170;;502/200;;502/215;;502/230;;502/241;;502/243;;502/246;;502/262;;502/324;;502/527,0,0,,,,EXPIRED
450,EP,A2,EP 1940394 A2,054-333-894-964-460,2008-07-09,2008,EP 06850059 A,2006-10-20,US 2006/0060098 W;;US 72996905 P,2005-10-25,CHEMICAL COMPOUNDS,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;KERNS JEFFREY K;;LIN XICHEN,,https://lens.org/054-333-894-964-460,Patent Application,yes,0,0,6,6,0,A61P1/04;;A61P3/10;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;C07D231/56;;C07D231/56;;C07D401/04;;C07D401/04;;C07D401/14;;C07D401/14,C07D231/56;;A61K31/454;;A61P29/00;;C07D401/04,,0,0,,,,DISCONTINUED
451,CA,C,CA 2606823 C,060-662-523-462-976,2014-01-14,2014,CA 2606823 A,2006-05-03,US 67755205 P;;US 70952805 P;;US 72647305 P;;US 35218406 A;;US 2006/0017172 W,2005-05-04,DIRECT ELECTRIC RESISTANCE LIQUID HEATER,"The Direct Electric Resistance Liquid Heater comprises a liquid heating chamber containing a plurality of electrodes. The electrodes are spaced apart to create a plurality of channels through which the liquid to be heated passes. The electrodes are each connected to a power supply by one or more switches. A controller controls the switches based upon data received from a temperature sensor, sensing the temperature of the liquid, and/or an electric current sensor, sensing the current utilized by the liquid heater. Selection of the number and spacing of the electrodes, and the number of switches, provides the controller with various current levels options to apply to the liquid to be heated. The current levels available due to the number and spacing of the electrodes and the number of switches, span the range from minimum current to maximum current such that the controller can incrementally increase or decrease the current applied to the liquid to be heated without disrupting other users of the same power source.",CALLAHAN JEREMIAH M;;BARZYK JAMES,CALLAHAN JEREMIAH M;;BARZYK JAMES;;BOWERS JOHN HENRY,,https://lens.org/060-662-523-462-976,Granted Patent,no,0,0,19,44,0,F24H1/106;;H05B3/60;;H05B2203/021;;F24H1/10;;F24H1/20;;H05B7/144;;F24H1/106;;H05B2203/021;;H05B3/60,H05B7/144,,0,0,,,,ACTIVE
452,US,B2,US 7636090 B2,053-987-658-735-945,2009-12-22,2009,US 49718306 A,2006-07-31,US 49718306 A;;US 63803703 A;;US 91194601 A;;US 4971598 A;;US 57054295 A,1995-12-11,Apparatus and method for storing a movie within a movie,"A hierarchical movie is provided. A hierarchical movie is a movie that contains one or more embedded movies. Embedded movies may themselves contain embedded movies. Each movie contains zero or more media sequences. Within a hierarchical movie, media sequences that should be edited together may be grouped together using embedded movies. The media sequences of a hierarchical movie may be sequenced during playback based on a different time coordinate system than the time coordinate system that governs any embedded movies. This allows a movie to contain both time-based and time-independent media sequences. Also, the relative timing of events in the movie may vary from performance to performance. The hierarchical movie structure allows movies to be used as user interface controls, and even as field-sensitive databases.",APPLE INC,HODDIE PETER;;BATSON JAMES D;;CALLAHAN SEAN MICHAEL,APPLE INC (2007-01-09),https://lens.org/053-987-658-735-945,Granted Patent,yes,15,0,8,8,0,G11B27/034;;G11B27/10;;G11B27/34;;H04N21/234318;;H04N21/23608;;H04N21/422;;H04N21/4344;;H04N21/44029;;H04N21/845;;H04N21/8453;;H04N21/43072;;H04N21/845;;H04N21/4344;;H04N21/8453;;G11B27/34;;H04N21/234318;;G11B27/034;;H04N21/23608;;H04N21/422;;G11B27/10;;H04N21/44029;;H04N21/43072,G11B27/034;;G06T15/00;;G11B27/10;;G11B27/34;;H04N7/24;;H04N21/2343;;H04N21/236;;H04N21/422;;H04N21/43;;H04N21/434;;H04N21/4402;;H04N21/845,345/419;;345/423;;345/473;;345/474;;345/475;;345/440;;345/536;;345/537;;715/514,9,3,006-232-902-688-790;;139-921-095-004-976;;111-649-865-575-809,10.1145/166266.168399;;10.1109/mc.1985.1662718;;10.1145/125223.125238,"Adobe Premier 4.0 User Guide, pp. 49, 264, May 1994.;;Adobe Premier 3.0 User Guide, pp. 5-6, 22, 28, 220-223, c. 1994.;;RCA Model VR673HF User's Guide, pp. 12, 17, 29, 1994.;;Adobe Premier User Guide , Adobe System Incorporated, May 1994.;;Object Composition and playback models for Handling Multimedia Data, by Rei Hamakawa et al., National Conference on Multimedia, Anaheim, California U.S.A, Jan. 1993.;;A structure for transportable dynamic multimedia documents, by Dick C. A. Bulterman et al., USENIX-Summer 91 -Nashville, TN, Jun. 1991.;;CCWS: A computer Based Multimedia Informatipon System, by a. Poggio et al., IEEE 1985, Jan. 1985.;;The O2 system, by O. Deux it el., Communication of the ACM/Oct. 1991/vol. 34. No. 30, Oct. 1991.;;Adobe Premiere 3.0 User Guide, Chapters 1 and 2, 1993.",EXPIRED
453,WO,A1,WO 2003/029242 A1,083-713-298-405-140,2003-04-10,2003,US 0231902 W,2002-10-04,US 32697601 P,2001-10-04,NF- kappa B INHIBITORS,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-β phosphorylation of IλB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-λB in which diseases excessive activation of NF-λB is implicated.,SMITHKLINE BEECHAM CORP;;WAN ZEHONG;;BURGESS JOELLE LORRAINE;;CALLAHAN JAMES FRANCIS,WAN ZEHONG;;BURGESS JOELLE LORRAINE;;CALLAHAN JAMES FRANCIS,,https://lens.org/083-713-298-405-140,Patent Application,yes,2,0,10,10,0,C07D333/36;;C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;A61P9/00;;A61P3/10;;C07D333/36;;C07D333/38,A61K31/381;;A61P1/04;;A61P3/10;;A61P9/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;C07D333/36;;C07D333/38;;C07D333/40,,0,0,,,,PENDING
454,US,A,US 3519688 A,128-033-370-977-787,1970-07-07,1970,US 3519688D A,1967-09-29,US 67242467 A,1967-09-29,PROCESS FOR THE MANUFACTURE OF UNSATURATED ALDEHYDES FROM OLEFINS,,STANDARD OIL CO,CALLAHAN JAMES LOUIS;;GERTISSER BERTHOLD;;SZABO JOSEPH J,,https://lens.org/128-033-370-977-787,Granted Patent,no,2,1,1,1,0,B01J23/31;;B01J27/192;;C07C45/34;;C07C45/35;;C07C45/34;;B01J27/192;;B01J23/31;;C07C45/35,B01J23/31;;B01J27/192;;C07C45/34;;C07C45/35,260/604,0,0,,,,EXPIRED
455,US,A,US 3248340 A,144-212-403-524-148,1966-04-26,1966,US 19003862 A,1962-04-25,US 19003862 A,1962-04-25,Promoted bismuth oxide-molybdenum oxide oxidation catalyst,,STANDARD OIL CO,LOUIS CALLAHAN JAMES;;BERTHOLD GERTISSER;;SZABO JOSEPH J,,https://lens.org/144-212-403-524-148,Granted Patent,no,6,11,12,14,0,B01J23/16;;B01J23/28;;B01J23/31;;B01J27/186;;B01J27/192;;C07C5/48;;C07C45/34;;C07C45/35;;C07C253/26;;Y02P20/52;;B01J23/16;;B01J27/192;;B01J23/31;;C07C5/48;;C07C45/35;;B01J27/186;;C07C45/34;;B01J23/28;;C07C253/26;;Y02P20/52,B01J23/16;;B01J23/28;;B01J23/31;;B01J27/186;;B01J27/192;;C01G1/02;;C07B35/04;;C07B61/00;;C07C1/00;;C07C5/48;;C07C11/00;;C07C11/16;;C07C45/34;;C07C45/35;;C07C67/00;;C07C253/00;;C07C255/08,,0,0,,,,EXPIRED
456,DE,D1,DE 60229975 D1,149-368-749-376-595,2009-01-02,2009,DE 60229975 T,2002-10-04,US 32697601 P;;US 0231902 W,2001-10-04,NF-KB-INHIBITOREN,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-beta phosphorylation of IkappaB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-kappaB in which diseases excessive activation of NF-kappaB is implicated.,SMITHKLINE BEECHAM CORP,WAN ZEHONG;;BURGESS JOELLE LORRAINE;;CALLAHAN JAMES FRANCIS,,https://lens.org/149-368-749-376-595,Granted Patent,no,0,0,10,10,0,C07D333/36;;C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;A61P9/00;;A61P3/10;;C07D333/36;;C07D333/38,C07D333/36;;A61K31/38;;A61K31/381;;A61P1/04;;A61P3/10;;A61P9/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;C07D333/38;;C07D333/40,,0,0,,,,EXPIRED
457,US,A,US 3044966 A,181-519-681-054-578,1962-07-17,1962,US 85191959 A,1959-11-09,CA 3044966X A,1959-08-05,Attrition resistant oxidation catalysts,,STANDARD OIL CO,CALLAHAN JAMES L;;FOREMAN ROBERT W;;FRANKLIN VEATCH,,https://lens.org/181-519-681-054-578,Granted Patent,no,1,31,1,1,0,B01J27/192;;B01J27/192,B01J27/192,,0,0,,,,EXPIRED
458,DD,A5,DD 155484 A5,193-763-062-264-736,1982-06-16,1982,DD 22395180 A,1980-09-17,US 7611579 A,1979-09-17,VERFAHREN ZUR HERSTELLUNG EINES KOMPLEXTRAEGERKATALYSATORS AUS FESTEM OXID,,STANDARD OIL CO OHIO,SHAW WILFRID G;;CALLAHAN JAMES L;;PAPARIZOS CHRISTOS,,https://lens.org/193-763-062-264-736,Granted Patent,no,0,0,12,13,0,B01J23/28;;C07C45/35;;B01J23/28;;C07C45/35,C07C27/14;;B01J21/08;;B01J23/28;;B01J23/31;;B01J27/057;;B01J37/04;;C07B33/00;;C07B61/00;;C07C27/00;;C07C45/35;;C07C47/22;;C07C67/00,,0,0,,,,EXPIRED
459,FI,A,FI 36780 A,047-884-932-132-575,1967-04-10,1967,FI 36780D A,1960-02-11,FI 36780T A,1960-02-11,Katalytblandning,,STANDARD OIL CO,LOUIS CALLAHAN JAMES;;WALTER FOREMAN ROBERT;;FRANKLIN VEATCH,,https://lens.org/047-884-932-132-575,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
460,CA,A,CA 764476 A,151-359-737-331-16X,1967-08-01,1967,CA 764476D A,,CA 764476T A,,OXIDATION CATALYST AND PROCESS OF OXIDATION AND DEHYDROGENATION OF OLEFINS THEREWITH,,STANDARD OIL CO,SZABO JOSEPH J;;GERTISSER BERTHOLD;;CALLAHAN JAMES L,,https://lens.org/151-359-737-331-16X,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
461,AT,T1,AT E54133 T1,178-055-729-411-394,1990-07-15,1990,AT 86302818 T,1986-04-16,EP 86302818 A;;US 72453385 A,1985-04-18,VERESTERUNGSVERFAHREN IN EINER STUFE UNTER ANWENDUNG EINES INTERMETALLISCHEN PALLADIUMKATALYSATORSYSTEMS.,"A process for the one esterification of aldehydes and alcohols comprises the steps of combining an aldehyde with an alcohol, in the presence of oxygen and in contact with a catalyst having the general formula PdTeaZndEe where E is one or more metals from the group consisting of group IA, IIA, IVA, IB, VIIB, or VIII metals, As or Sb; and a, d and e are from about 0 to 3 with the proviso that at least d or e NOTEQUAL 0.",STANDARD OIL CO OHIO,PAPARIZOS CHRISTOS;;SHAW WILFRID GARSIDE;;CALLAHAN JAMES LOUIS,,https://lens.org/178-055-729-411-394,Granted Patent,no,0,0,7,8,0,C07C67/39,C07B61/00;;B01J23/00;;B01J27/00;;C07C67/39;;C07C69/54,,0,0,,,,DISCONTINUED
462,WO,A1,WO 2000/035470 A1,000-075-247-704-023,2000-06-22,2000,US 9929924 W,1999-12-15,US 21215698 A,1998-12-15,HUMAN MAD PROTEINS AND USES THEREOF,"Human MADr3 or MADr4 polypeptides and DNA (RNA) encoding such MADr3 or MADr4 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such MADr3 or MADr4, or compounds which inhibit or stimulate MADr3 or MADr4 for stimulating wound healing, and treating cancers, among others, are also disclosed. Agonist and antagonists of these MAD proteins and methods of their use are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the MADr3 or MADr4 and for detecting altered levels of the polypeptide in a host.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;LAPING NICHOLAS J;;WEINSTOCK JOSEPH,,https://lens.org/000-075-247-704-023,Patent Application,yes,0,0,2,2,0,C07K14/4703,A61K38/00;;C07K14/47,,14,14,107-552-693-907-92X;;076-304-492-325-282;;160-927-867-886-71X;;101-978-587-237-328;;038-852-662-492-77X;;002-597-026-902-940;;004-193-975-435-08X;;055-804-614-702-787;;118-548-728-177-347;;011-134-872-365-991;;010-407-194-016-163;;048-302-258-668-629;;089-687-136-174-978;;051-133-997-383-428,10.1038/27945;;9665135;;9335505;;10.1038/39355;;10.1038/39369;;9335507;;9865696;;0009865696;;10.1016/s0092-8674(00)81701-8;;10.1097/00042737-199812000-00009;;9895050;;9490005;;10.1016/s0014-5793(98)00011-8;;10.1038/sj.onc.1202111;;9788439;;9662508;;10.1016/s1074-5521(98)90072-2;;10.1046/j.1432-0436.1998.6330101.x;;9697304;;10.1016/s0021-9150(97)00275-x;;9622270;;10.1016/s0014-5793(98)00658-9;;9688538;;10.1091/mbc.9.12.3309;;pmc25628;;9843571;;10.1159/000028222;;9670209;;10.1002/(sici)1097-4652(199708)172:2<200::aid-jcp7>3.3.co;2-x;;10.1002/(sici)1097-4652(199708)172:2<200::aid-jcp7>3.0.co;2-s;;9258341,"KUROKAWA ET AL.: ""The oncoprotein Evi-1 represses TGF-beta signalling by Inhibiting SMAD3"", NATURE,, vol. 394, no. 6688, 2 July 1998 (1998-07-02), pages 92 - 96, XP002927451;;IMAMURA ET AL.: ""Smad6 inhibits signalling by the TGF-beta superfamily"", NATURE,, vol. 389, no. 6651, 9 October 1997 (1997-10-09), pages 622 - 626, XP002927452;;NAKAO ET AL.: ""Identification of Smad7, a TGF-beta inducible antagonist of TGF-beta signalling"", NATURE,, vol. 389, no. 6651, 9 October 1997 (1997-10-09), pages 631 - 635, XP002927453;;TSUKAZAKI ET AL.: ""a FYVE domain protein that recruits Smad2 to the TGF-beta receptor"", CELL,, vol. 95, no. 6, 11 December 1998 (1998-12-11), pages 779 - 791, XP002927454;;BAER ET AL.: ""Transforming growth factor betas and their receptors in human liver cirrhosis"", EUROPEAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY,, vol. 10, no. 12, December 1998 (1998-12-01), pages 1031 - 1039, XP002927455;;WARD ET AL.: ""Vascular types I and II transforming growth factor-beta receptor expression: differential dependency on tyrosine kinases during induction by TGF-beta"", FEBS LETT.,, vol. 422, no. 2, January 1998 (1998-01-01), pages 197 - 200, XP002927456;;CHEN ET AL.: ""Suppression of transforming growth factor -beta- induced apoptosis through a phosphatidylinositol 3-kinase/Akt-dependent pathway"", ONCOGENE,, vol. 17, no. 15, October 1998 (1998-10-01), pages 1959 - 1968, XP002927457;;STOCKWELL ET AL.: ""TGF-beta-signaling with small molecule FKBP12 antagonists that bind myristoylated FKBP12-TGF-beta type I receptor fusion proteins"", CHEMISTRY AND BIOLOGY,, vol. 5, no. 7, July 1998 (1998-07-01), pages 385 - 395, XP002927458;;GOUMANS ET AL.: ""Mouse embryonic stem cells with aberrant transforming growth factor beta signalling exhibit impaired differentiation in vitro and in vivo"", DIFFERENTIATION,, vol. 63, no. 3, July 1998 (1998-07-01), pages 101 - 113, XP002927459;;WARD ET AL.: ""Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries"", ATHEROSCLEROSIS,, vol. 137, no. 2, April 1998 (1998-04-01), pages 267 - 275, XP002927460;;GOTO ET AL.: ""A single missense mutant of Smad3 inhibits activation of both Smad2 and Smad3 and has a dominant negative effect on TGF-beta signals"", FEBS LETT.,, vol. 430, no. 3, July 1998 (1998-07-01), pages 201 - 204, XP002927461;;SHEN ET AL.: ""TGF-beta-induced phosphorylation of Smad3 regulates its interaction with coactivator p300/CREB-binding protein"", vol. 9, no. 12, December 1998 (1998-12-01), pages 3309 - 3319, XP002927462;;ALI ET AL.: ""Angiotensin-converting enzyme inhibition attenuates proteinuria and renal TGF-beta mRNA expression in rats with chronic renal disease"", PHARMACOLOGY,, vol. 57, no. 1, July 1998 (1998-07-01), pages 20 - 27, XP002927463;;COPPA ET AL.: ""Restored expression of transforming growth factor beta type II receptor in k-ras-transformed thyroid cells, TGF beta-resistant, reverts their malignant phenotype"", JOURNAL OF CELLULAR PHYSIOLOGY,, vol. 172, no. 2, April 1997 (1997-04-01), pages 200 - 208, XP002927464",PENDING
463,US,A,US 3280166 A,045-544-530-959-787,1966-10-18,1966,US 39597864 A,1964-08-19,US 39597864 A;;US 19793262 A,1962-05-28,Process for the oxidation of olefin-ammonia mixtures to unsaturated nitriles,,STANDARD OIL CO,CALLAHAN JAMES L;;SZABO JOSEPH J;;BERTHOLD GERTISSER,,https://lens.org/045-544-530-959-787,Granted Patent,no,8,5,2,2,0,B01J23/28;;B01J23/31;;B01J23/8437;;B01J23/88;;B01J23/8876;;B01J27/186;;B01J27/192;;B01J2523/00;;C01C3/0245;;C07C5/48;;C07C45/34;;C07C45/35;;C07C253/26;;Y10S585/906;;Y02P20/52;;B01J23/28;;B01J27/186;;B01J27/192;;B01J23/31;;C07C253/26;;C01C3/0245;;C07C5/48;;C07C45/34;;B01J23/88;;B01J23/8876;;B01J23/8437;;C07C45/35;;B01J2523/00;;Y10S585/906;;Y02P20/52,B01J23/28;;B01J23/31;;B01J23/843;;B01J23/88;;B01J23/887;;B01J27/186;;B01J27/192;;C01C3/02;;C01G29/00;;C07C5/48;;C07C45/34;;C07C45/35,,0,0,,,,EXPIRED
464,US,B2,US 6630934 B2,079-780-745-876-231,2003-10-07,2003,US 91194601 A,2001-07-23,US 91194601 A;;US 4971598 A;;US 57054295 A,1995-12-11,Apparatus and method for storing a movie within a movie,"
    A hierarchical movie is provided. A hierarchical movie is a movie that contains one or more embedded movies. Embedded movies may themselves contain embedded movies. Each movie contains zero or more media sequences. Within a hierarchical movie, media sequences that should be edited together may be grouped together using embedded movies. The media sequences of a hierarchical movie may be sequenced during playback based on a different time coordinate system than the time coordinate system that governs any embedded movies. This allows a movie to contain both time-based and time-independent media sequences. Also, the relative timing of events in the movie may vary from performance to performance. The hierarchical movie structure allows movies to be used as user interface controls, and even as field-sensitive databases. 
",APPLE COMPUTER,HODDIE PETER;;BATSON JAMES D;;CALLAHAN SEAN MICHAEL,APPLE INC (2007-01-09),https://lens.org/079-780-745-876-231,Granted Patent,yes,14,12,8,8,0,G11B27/034;;G11B27/10;;G11B27/34;;H04N21/234318;;H04N21/23608;;H04N21/422;;H04N21/4344;;H04N21/44029;;H04N21/845;;H04N21/8453;;H04N21/43072;;H04N21/845;;H04N21/4344;;H04N21/8453;;G11B27/34;;H04N21/234318;;G11B27/034;;H04N21/23608;;H04N21/422;;G11B27/10;;H04N21/44029;;H04N21/43072,G11B27/034;;G11B27/10;;G11B27/34;;H04N7/24;;H04N21/2343;;H04N21/236;;H04N21/422;;H04N21/43;;H04N21/434;;H04N21/4402;;H04N21/845,345/473;;345/713;;345/723,10,3,006-232-902-688-790;;139-921-095-004-976;;111-649-865-575-809,10.1145/166266.168399;;10.1109/mc.1985.1662718;;10.1145/125223.125238,"Adobe Premiere 3.0 User Guide, Chapters 1 and 2, 1993.*;;Adobe Premier User Guide, Adobe System Incorporated, May 1994.*;;Object Composition and playback models for Handling Multimedia Data, by Rei Hamakawa et al., National Conference on Multimedia, Anaheim, California U.S.A, Jan. 1993.*;;A structure for transportable dynamic multimedia documents, by Dick C. A. Bulterman et al., USENIX-Summer 91-Nashville, TN, Jun. 1991.*;;CCWS: A computer Based Multimedia Informatipon System, by a. Poggio et al., IEEE, Jan. 1985.*;;The O2 system, by O. Deux et al., Communication of the ACM/Oct. 1991/vol. 34. No. 30.*;;Adobe Premiere 3.0 User's Guide, p. 121, 1994.*;;Abobe Premiere 4.0 User Guide, pp. 49, 264, May 1994.*;;Adobe Premiere 3.0 User Guide, pp. 5-6, 22, 28, 220-223, 1994.*;;RCA Model VR673 HF User's Guide, pp. 12, 17, 29, 1994.",EXPIRED
465,EP,A4,EP 1940394 A4,096-530-417-788-755,2009-07-08,2009,EP 06850059 A,2006-10-20,US 2006/0060098 W;;US 72996905 P,2005-10-25,CHEMICAL COMPOUNDS,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;KERNS JEFFREY K;;LIN XICHEN,,https://lens.org/096-530-417-788-755,Search Report,no,2,0,6,6,0,C07D231/56;;C07D401/04;;C07D401/14;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/10;;A61P25/28;;A61P29/00;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;A61P43/00;;A61P9/10;;A61P3/10;;C07D231/56;;C07D401/04;;C07D401/14,C07D231/56;;A61K31/454;;A61P29/00;;C07D401/04,,0,0,,,,DISCONTINUED
466,CA,A,CA 774633 A,104-442-729-899-153,1967-12-26,1967,CA 774633D A,,CA 774633T A,,PROCESS FOR THE DEHYDROGENATION OF OLEFINS,,STANDARD OIL CO,CALLAHAN JAMES L;;GERTISSER BERTHOLD;;GRASSELLI ROBERT K,,https://lens.org/104-442-729-899-153,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
467,US,A,US 2941007 A,019-381-684-163-507,1960-06-14,1960,US 66449557 A,1957-06-10,US 66449557 A,1957-06-10,Process for the oxidation of olefins,,STANDARD OIL CO,CALLAHAN JAMES L;;FOREMAN ROBERT W;;FRANKLIN VEATCH,,https://lens.org/019-381-684-163-507,Granted Patent,no,9,62,3,3,0,B01J23/31;;B01J27/186;;B01J27/192;;C07C45/34;;C07C45/35;;C07C45/34;;C07C45/35;;B01J27/192;;B01J23/31;;B01J27/186,B01J23/31;;B01J27/186;;B01J27/192;;C07C45/34;;C07C45/35,,0,0,,,,EXPIRED
468,EP,A1,EP 1448545 A1,022-550-144-124-972,2004-08-25,2004,EP 02800491 A,2002-10-04,US 0231902 W;;US 32697601 P,2001-10-04,NF-KB INHIBITORS,The present invention provides novel compounds and methods for using them to treat diseases with aminothiophene inhibitors of IKK-beta phosphorylation of IkappaB. In so doing these aminothiophene inhibitors block pathological activation of transcription factor NF-kappaB in which diseases excessive activation of NF-kappaB is implicated.,SMITHKLINE BEECHAM CORP,WAN ZEHONG;;BURGESS JOELLE LORRAINE;;CALLAHAN JAMES FRANCIS,SMITHKLINE BEECHAM CORPORATION (2008-10-15),https://lens.org/022-550-144-124-972,Patent Application,yes,0,0,10,10,0,C07D333/36;;C07D333/38;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;A61P9/00;;A61P3/10;;C07D333/36;;C07D333/38,A61K31/381;;A61P1/04;;A61P3/10;;A61P9/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/04;;A61P19/10;;A61P25/00;;A61P25/28;;A61P29/00;;A61P31/12;;A61P31/18;;A61P35/00;;A61P37/00;;A61P37/06;;C07D333/36;;C07D333/38;;C07D333/40,,0,0,,,,EXPIRED
469,AT,T1,AT E370952 T1,064-147-437-745-135,2007-09-15,2007,AT 03721779 T,2003-04-18,US 37421902 P;;US 38855702 P,2002-04-19,NEUE VERBINDUNGEN,,SMITHKLINE BEECHAM CORP,BOEHM JEFFREY;;WIDDOWSON KATHERINE;;CALLAHAN JAMES;;WAN ZEHONG,,https://lens.org/064-147-437-745-135,Granted Patent,no,0,0,23,24,0,C07D471/04;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P9/02;;A61P9/10;;A61P3/10;;C07D471/04;;A61K31/519;;C07D487/00;;C07D471/04,C07D239/42;;A01N43/90;;A61K31/519;;A61P1/04;;A61P3/10;;A61P9/02;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;C07D471/04;;C07D487/00,,0,0,,,,EXPIRED
470,CA,A,CA 764498 A,107-561-063-791-496,1967-08-01,1967,CA 764498D A,,CA 764498T A,,OXIDATION CATALYST AND PROCESS OF OXIDATION AND DEHYDROGENATION OF OLEFINS THEREWITH,,STANDARD OIL CO,CALLAHAN JAMES L;;GERTISSER BERTHOLD;;SZABO JOSEPH J,,https://lens.org/107-561-063-791-496,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
471,DE,A1,DE 1950501 A1,099-399-438-227-197,1970-05-14,1970,DE 1950501 A,1969-10-07,US 76720468 A,1968-10-14,Beschickungsvorrichtung fuer einen Muellverbrennungsofen,,AIR PREHEATER,BAKKER LUBERTUS;;DONALD KRUMM EUGENE;;CALLAHAN CONDE JAMES,,https://lens.org/099-399-438-227-197,Patent Application,no,0,0,14,14,0,F23G5/444;;F23G5/444,F23G5/44,,0,0,,,,EXPIRED
472,US,A,US 4623635 A,070-684-552-044-79X,1986-11-18,1986,US 72453585 A,1985-04-18,US 72453585 A,1985-04-18,Method for the preparation of high activity palladium based catalysts,"A method for the preparation of a high activity palladium metal based catalyst having the formula PdTe.sub.a Zn.sub.d E.sub.e where E is one or more metals from the group IIA, IVA, VA, IB, VIIB or VIII; and a, d and e are from about 0 to 3, with the proviso that at least d or e.noteq.0. The method comprises the step of forming an aqueous solution of a palladium compound, adding to the solution a powder of a reducing metal more electropositive than palladium and reducing the palladium to its metallic state on the surface of the reducing metal and, separating the resulting catalyst from the solution. Catalysts prepared according to this method are useful for producing esters from aldehydes and alcohols and provide greater conversions to the ester than catalysts prepared by previous processes.",STANDARD OIL CO OHIO,PAPARIZOS CHRISTOS;;SHAW WILFRID G;;CALLAHAN JAMES L,STANDAARD OIL COMPANY THE AN OH CORP (1985-04-04),https://lens.org/070-684-552-044-79X,Granted Patent,yes,21,6,1,2,0,B01J27/0576;;B01J27/0576;;B01J23/60;;B01J23/60;;B01J23/622;;B01J23/622;;B01J23/644;;B01J23/644;;B01J23/656;;B01J23/656;;B01J23/89;;B01J23/89;;C07C67/39;;C07C67/39,B01J23/60;;B01J23/62;;B01J23/644;;B01J23/656;;B01J23/89;;B01J27/057;;C07C67/39,502/215;;502/170;;502/200;;502/241;;502/243;;502/246;;502/262;;502/324;;502/339;;502/527;;502/230;;560/208,0,0,,,,EXPIRED
473,CH,A,CH 492932 A,149-714-980-098-881,1970-06-30,1970,CH 1008269 A,1969-07-01,US 76720468 A,1968-10-14,Beschickungsvorrichtung an einem Müllverbrennungsofen,,AIR PREHEATER,LUBERTUS BAKKER;;JAMES CALLAHAN CONDE;;EUGENE DONALD KRUMM,,https://lens.org/149-714-980-098-881,Granted Patent,no,0,0,14,14,0,F23G5/444;;F23G5/444,F23G5/44,,0,0,,,,EXPIRED
474,DE,B,DE 1205502 B,150-172-883-864-46X,1965-11-25,1965,DE ST020703 A,1963-06-07,US 20127962 A;;US 20132962 A;;US 24733162 A,1962-06-11,Verfahren zur Herstellung eines Oxydationskatalysators,,STANDARD OIL CO,CALLAHAN JAMES LOUIS;;GERTISSER BERTHOLD;;GRASSELLI ROBERT KARL,,https://lens.org/150-172-883-864-46X,Patent Application,no,3,9,18,23,0,B01J23/12;;B01J23/16;;B01J23/18;;C07C45/35;;C07C5/48;;C07C45/34;;C07C51/252,B01J23/12;;B01J23/16;;B01J23/18;;C07C5/48;;C07C45/34;;C07C45/35;;C07C51/25,,0,0,,,,DISCONTINUED
475,US,B2,US 7102644 B2,159-635-913-296-148,2006-09-05,2006,US 63803703 A,2003-08-08,US 63803703 A;;US 91194601 A;;US 4971598 A;;US 57054295 A,1995-12-11,Apparatus and method for storing a movie within a movie,"A hierarchical movie is provided. A hierarchical movie is a movie that contains one or more embedded movies. Embedded movies may themselves contain embedded movies. Each movie contains zero or more media sequences. Within a hierarchical movie, media sequences that should be edited together may be grouped together using embedded movies. The media sequences of a hierarchical movie may be sequenced during playback based on a different time coordinate system than the time coordinate system that governs any embedded movies. This allows a movie to contain both time-based and time-independent media sequences. Also, the relative timing of events in the movie may vary from performance to performance. The hierarchical movie structure allows movies to be used as user interface controls, and even as field-sensitive databases.",APPLE COMPUTER,HODDIE PETER;;BATSON JAMES D;;CALLAHAN SEAN MICHAEL,APPLE INC (2007-01-09),https://lens.org/159-635-913-296-148,Granted Patent,yes,14,4,8,8,0,G11B27/034;;G11B27/10;;G11B27/34;;H04N21/234318;;H04N21/23608;;H04N21/422;;H04N21/4344;;H04N21/44029;;H04N21/845;;H04N21/8453;;H04N21/43072;;H04N21/845;;H04N21/4344;;H04N21/8453;;G11B27/34;;H04N21/234318;;G11B27/034;;H04N21/23608;;H04N21/422;;G11B27/10;;H04N21/44029;;H04N21/43072,G11B27/034;;G06T15/70;;G11B27/10;;G11B27/34;;H04N7/24;;H04N21/2343;;H04N21/236;;H04N21/422;;H04N21/43;;H04N21/434;;H04N21/4402;;H04N21/845,345/473;;345/474;;345/475;;715/500.1;;715/501.1;;715/514;;715/713;;715/719;;365/202,10,2,006-232-902-688-790;;111-649-865-575-809,10.1145/166266.168399;;10.1145/125223.125238,"Adobe Premiere<SUP>3.ø</SUP>User's Guide, p. (2), 1994.;;Adobe Premiere 4.ø User Guide, pp. 49, 264, May 1994.;;Adobe Premiere 3.ø User Guide, pp. 5-6, 22, 28, 22ø-223, c. 1994.;;RCA Model VR673HF User's Guide, pp. 12, 17, 29, 1994.;;Adobe Premier User Guide , Adobe System Incorporated, May 1994.;;Object Composition and playback models for Handling Multimedia Data, by Rei Hamakawa et al., National Conference on Multimedia, Anaheim, California U.S.A., Jan. 1993.;;A structure for transportable dynamic multimedia documents, by Dick C. A. Bulterman et al., USENIX-Summer 91-Nashville, TN, Jun. 1991.;;CCWS: A computer Based Multimedia Informatip n Syst m, by A. Poggi et al., IEEE 1985, Jan. 1985.;;The O2 system, by O. Deux et al., Communication of the ACM/Oct. 1991/vol. 34. No. 30, Oct. 1991.;;Adobe Premiere 3.0 User Guide, Chapters 1 and 2, 1993.",EXPIRED
476,DE,D1,DE 3672245 D1,048-397-179-007-085,1990-08-02,1990,DE 3672245 T,1986-04-16,US 72453385 A,1985-04-18,VERESTERUNGSVERFAHREN IN EINER STUFE UNTER ANWENDUNG EINES INTERMETALLISCHEN PALLADIUMKATALYSATORSYSTEMS.,"A process for the one esterification of aldehydes and alcohols comprises the steps of combining an aldehyde with an alcohol, in the presence of oxygen and in contact with a catalyst having the general formula PdTeaZndEe where E is one or more metals from the group consisting of group IA, IIA, IVA, IB, VIIB, or VIII metals, As or Sb; and a, d and e are from about 0 to 3 with the proviso that at least d or e NOTEQUAL 0.",STANDARD OIL CO OHIO,PAPARIZOS CHRISTOS;;SHAW WILFRID GARSIDE;;CALLAHAN JAMES LOUIS,,https://lens.org/048-397-179-007-085,Granted Patent,no,0,0,7,8,0,C07C67/39,B01J23/00;;B01J27/00;;C07B61/00;;C07C67/39;;C07C69/54,,0,0,,,,EXPIRED
477,EP,A3,EP 0199530 A3,143-289-031-581-65X,1987-09-09,1987,EP 86302818 A,1986-04-16,US 72453385 A,1985-04-18,PROCESS FOR ONE STEP ESTERIFICATION USING AN INTERMETALLIC PALLADIUM BASED CATALYST SYSTEM,"A process for the one esterification of aldehydes and alcohols comprises the steps of combining an aldehyde with an alcohol, in the presence of oxygen and in contact with a catalyst having the general formula  
PdTe.Zn d E. where E is one or more metals from the group consisting of group IA, IIA, IVA, IB, VIIB, or VIII metals, As or Sb; and a, d and e are from about 0 to 3 with the proviso that at least d or e ≠ 0.",THE STANDARD OIL COMPANY,"PAPARIZOS, CHRISTOS;;SHAW, WILFRID GARSIDE;;CALLAHAN, JAMES LOUIS",,https://lens.org/143-289-031-581-65X,Search Report,yes,3,0,7,8,0,C07C67/39,B01J23/00;;B01J27/00;;C07B61/00;;C07C67/39;;C07C69/54,,0,0,,,,EXPIRED
478,DE,B,DE 1263712 B,195-058-493-164-023,1968-03-21,1968,DE ST015501 A,1959-08-24,US 75710758 A,1958-08-25,"Verfahren zur Herstellung eines Katalysators, der Wismut, Molybdaen, Silicium, Sauerstoff und gegebenenfalls Phosphor enthaelt",,STANDARD OIL CO,CALLAHAN JAMES LOUIS;;FOREMAN ROBERT WALTER;;VEATCH FRANKLIN,,https://lens.org/195-058-493-164-023,Patent Application,no,3,0,7,7,0,B01J27/186;;B01J23/28;;B01J23/31;;B01J27/192,B01J23/28;;B01J23/31;;B01J27/186;;B01J27/192,,0,0,,,,DISCONTINUED
479,CA,A,CA 1153754 A,024-907-351-708-921,1983-09-13,1983,CA 357963 A,1980-08-11,US 7611579 A,1979-09-17,ATTRITION RESISTANT HIGHER ACTIVE COMPONENT FLUID BED CATALYSTS AND USE THEREOF,"(5173) ATTRITION RESISTANT-HIGHER ACTIVE COMPONENT FLUID BED CATALYSTS A method for preparing attrition resistant, high percentage active component catalysts comprises using two types of silica, one of which is fumed silica, in a two stage catalyst preparation.",STANDARD OIL CO OHIO,SHAW WILFRID G;;CALLAHAN JAMES L;;PAPARIZOS CHRISTOS,,https://lens.org/024-907-351-708-921,Granted Patent,no,0,0,12,13,0,B01J23/28;;C07C45/35;;B01J23/28;;C07C45/35,C07C27/14;;B01J21/08;;B01J23/28;;B01J23/31;;B01J27/057;;B01J37/04;;C07B33/00;;C07B61/00;;C07C27/00;;C07C45/35;;C07C47/22;;C07C67/00,252-103,0,0,,,,EXPIRED
480,US,A1,US 2001/0043218 A1,015-321-370-169-818,2001-11-22,2001,US 91194601 A,2001-07-23,US 91194601 A;;US 4971598 A;;US 57054295 A,1995-12-11,Apparatus and method for storing a movie within a movie,"
   A hierarchical movie is provided. A hierarchical movie is a movie that contains one or more embedded movies. Embedded movies may themselves contain embedded movies. Each movie contains zero or more media sequences. Within a hierarchical movie, media sequences that should be edited together may be grouped together using embedded movies. The media sequences of a hierarchical movie may be sequenced during playback based on a different time coordinate system than the time coordinate system that governs any embedded movies. This allows a movie to contain both time-based and time-independent media sequences. Also, the relative timing of events in the movie may vary from performance to performance. The hierarchical movie structure allows movies to be used as user interface controls, and even as field-sensitive databases. 
",HODDIE PETER;;BATSON JAMES D.;;CALLAHAN SEAN MICHAEL,HODDIE PETER;;BATSON JAMES D;;CALLAHAN SEAN MICHAEL,APPLE INC (2007-01-09),https://lens.org/015-321-370-169-818,Patent Application,yes,0,10,8,8,0,G11B27/034;;G11B27/10;;G11B27/34;;H04N21/234318;;H04N21/23608;;H04N21/422;;H04N21/4344;;H04N21/44029;;H04N21/845;;H04N21/8453;;H04N21/43072;;H04N21/845;;H04N21/4344;;H04N21/8453;;G11B27/34;;H04N21/234318;;G11B27/034;;H04N21/23608;;H04N21/422;;G11B27/10;;H04N21/44029;;H04N21/43072,G11B27/034;;G11B27/10;;G11B27/34;;H04N7/24;;H04N21/2343;;H04N21/236;;H04N21/422;;H04N21/43;;H04N21/434;;H04N21/4402;;H04N21/845,345/473,0,0,,,,EXPIRED
481,CN,A,CN 1520401 A,039-922-096-033-479,2004-08-11,2004,CN 01821324 A,2001-10-25,US 24300600 P,2000-10-25,Calcilytic compounds,本发明提供了一种新的磷酸酯类化合物以及将其作为钙离子阻断化合物应用的方法。,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP;;BURGESS JOELLE L;;CALLAHAN JAMES F,,https://lens.org/039-922-096-033-479,Patent Application,no,0,0,20,20,0,A61K31/565;;A61K31/59;;A61K31/66;;A61K38/23;;A61K45/06;;C07D213/84;;A61P1/02;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P35/04;;A61P43/00;;A61P5/18;;A61P5/22;;C07D213/63;;C07D213/84;;A61K31/59;;A61K31/565;;A61K31/66;;A61K45/06;;A61K38/23,A61K31/137;;A61K31/44;;A61K31/565;;A61K31/59;;A61K31/593;;A61K31/66;;A61K38/00;;A61K38/23;;A61K45/00;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P5/22;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P35/04;;A61P43/00;;C07D213/84,,0,0,,,,DISCONTINUED
482,DE,C3,DE 2138544 C3,075-353-315-852-801,1974-04-04,1974,DE 2138544 A,1971-08-02,US 6041170 A,1970-08-03,DE 2138544 C3,,"MCCORD CORP., DETROIT, MICH. (V.ST.A.)","CALLAHAN, JAMES J., MENTOR;;SNOW, JOHN PROCTOR, MACEDONIA",,https://lens.org/075-353-315-852-801,Granted Patent,no,0,0,9,10,0,F01M1/04;;F01M1/04;;F16N7/30;;F16N7/30,F01M1/04;;F16N7/30,,0,0,,,,EXPIRED
483,DE,A1,DE 1468715 A1,066-723-361-246-596,1969-07-10,1969,DE 1468715 A,1963-06-07,US 20133062 A,1962-06-11,Verfahren zur oxydativen Dehydrogenierung von Olefinen,,STANDARD OIL CO,LOUIS CALLAHAN JAMES;;KARL GRASELLI ROBERT;;GERTISSER BETHOLD,,https://lens.org/066-723-361-246-596,Patent Application,no,0,0,12,12,0,B01J23/70;;B01J23/8435;;C07C5/48;;C07C45/34;;C07C45/34;;C07C5/48;;B01J23/70;;B01J23/8435,B01J23/70;;B01J23/843;;C07C5/48;;C07C45/34,,0,0,,,,DISCONTINUED
484,US,A,US 4280929 A,181-349-760-113-274,1981-07-28,1981,US 7611579 A,1979-09-17,US 7611579 A,1979-09-17,Attrition resistant-higher active component fluid bed catalysts,"A method for preparing attrition resistant, high percentage active component catalysts comprises using two types of silica, one of which is fumed silica, in a two stage catalyst preparation.",STANDARD OIL CO,SHAW WILFRID G;;PAPARIZOS CHRISTOS;;CALLAHAN JAMES L,,https://lens.org/181-349-760-113-274,Granted Patent,yes,4,27,12,13,0,B01J23/28;;C07C45/35;;B01J23/28;;C07C45/35,B01J21/08;;B01J23/28;;B01J23/31;;C07C27/14;;B01J27/057;;B01J37/04;;C07B33/00;;C07B61/00;;C07C27/00;;C07C45/35;;C07C47/22;;C07C67/00,252/439,0,0,,,,EXPIRED
485,US,A1,US 2005/0033308 A1,098-059-669-719-968,2005-02-10,2005,US 81972104 A,2004-04-07,US 81972104 A;;US 46199403 P,2003-04-11,Intraocular lens storage and insertion device and method of use thereof,"The present invention is a device for rolling, storing and inserting into an eye an extremely thin intraocular lens (IOL). The device performs as a roller and injector. Also disclosed herein are methods of using the lens rolling device. The chamber for rolling the intraocular lens includes curved walls, a hollow chamber, and a funnel for receiving a plunger, and a port for extruding a rolled lens. The IOL is effectively rolled by engaging the two parts of the rolling device. After rolling, the lens is ejected from the device through a cannula and into an eye.",CALLAHAN WAYNE B.;;CALLAHAN JEFFERY S.;;SIMMS JAMES J.;;DEMENTIEV DIMITRII D.;;WRIGHT WILLIAM BERNARD,CALLAHAN WAYNE B;;CALLAHAN JEFFERY S;;SIMMS JAMES J;;DEMENTIEV DIMITRII D;;WRIGHT WILLIAM BERNARD,THINOPTX INC (2004-09-07),https://lens.org/098-059-669-719-968,Patent Application,yes,28,63,3,3,0,A61F2/1678;;A61F2/167;;A61F2/1691,A61F2/16;;A61F9/013;;G02B/,606/107,0,0,,,,DISCONTINUED
486,WO,A1,WO 1996/018602 A1,074-031-100-515-455,1996-06-20,1996,US 9515937 W,1995-12-07,US 35535594 A,1994-12-13,BICYCLIC FIBRINOGEN ANTAGONISTS,"This invention relates to compound of formula (I) which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.",SMITHKLINE BEECHAM CORP;;CALLAHAN JAMES FRANCIS;;KEENAN RICHARD MCCULLOCH;;KWON CHET;;SAMANEN JAMES MARTIN,CALLAHAN JAMES FRANCIS;;KEENAN RICHARD MCCULLOCH;;KWON CHET;;SAMANEN JAMES MARTIN,,https://lens.org/074-031-100-515-455,Patent Application,yes,6,37,5,5,0,C07C233/32;;C07C257/18;;C07D217/06;;C07C2602/10;;A61P7/02;;A61P9/00;;A61P9/10;;C07D217/06;;C07C233/32;;C07C257/18;;C07C2602/10,A61K31/47;;A61K31/472;;A61P7/02;;A61P9/00;;A61P9/10;;C07C233/32;;C07C233/43;;C07C251/02;;C07C257/18;;C07D217/06,,1,0,,,See also references of EP 0799189A4,PENDING
487,US,A,US 6117910 A,003-285-364-504-789,2000-09-12,2000,US 87536197 A,1997-06-13,US 87536197 A;;US 35535594 A;;US 9515937 W,1994-12-13,Bicyclic fibrinogen antagonists,"This invention relates to compounds of the formula: ##STR1## which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;KEENAN RICHARD MCCULLOCH;;KWON CHET;;SAMANEN JAMES MARTIN,SMITHKLINE BEECHAM CORPORATION (1995-11-15),https://lens.org/003-285-364-504-789,Granted Patent,yes,9,24,5,5,0,C07C233/32;;C07C257/18;;C07D217/06;;C07C2602/10;;A61P7/02;;A61P9/00;;A61P9/10;;C07D217/06;;C07C233/32;;C07C257/18;;C07C2602/10,A61K31/47;;A61K31/472;;A61P7/02;;A61P9/00;;A61P9/10;;C07C233/32;;C07C233/43;;C07C251/02;;C07C257/18;;C07D217/06,514/614;;564/147;;546/147;;514/311,0,0,,,,EXPIRED
488,EP,A1,EP 0799189 A1,181-716-259-760-816,1997-10-08,1997,EP 95942592 A,1995-12-07,US 9515937 W;;US 35535594 A,1994-12-13,BICYCLIC FIBRINOGEN ANTAGONISTS,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;KEENAN RICHARD MCCULLOCH;;KWON CHET;;SAMANEN JAMES MARTIN,,https://lens.org/181-716-259-760-816,Patent Application,yes,0,0,5,5,0,C07C233/32;;C07C257/18;;C07D217/06;;C07C2602/10;;A61P7/02;;A61P9/00;;A61P9/10;;C07D217/06;;C07C233/32;;C07C257/18;;C07C2602/10,A61K31/47;;A61K31/472;;A61P7/02;;A61P9/00;;A61P9/10;;C07C233/32;;C07C233/43;;C07C251/02;;C07C257/18;;C07D217/06,,0,0,,,,DISCONTINUED
489,EP,A4,EP 0799189 A4,128-203-845-769-551,1999-03-17,1999,EP 95942592 A,1995-12-07,US 9515937 W;;US 35535594 A,1994-12-13,BICYCLIC FIBRINOGEN ANTAGONISTS,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;KEENAN RICHARD MCCULLOCH;;KWON CHET;;SAMANEN JAMES MARTIN,,https://lens.org/128-203-845-769-551,Search Report,no,3,0,5,5,0,C07C233/32;;C07C257/18;;C07D217/06;;C07C2602/10;;A61P7/02;;A61P9/00;;A61P9/10;;C07D217/06;;C07C233/32;;C07C257/18;;C07C2602/10,A61K31/47;;A61K31/472;;A61P7/02;;A61P9/00;;A61P9/10;;C07C233/32;;C07C233/43;;C07C251/02;;C07C257/18;;C07D217/06,,1,0,,,See also references of WO 9618602A1,DISCONTINUED
490,AU,A,AU 2002/030579 A,016-627-956-782-669,2002-05-06,2002,AU 2002/030579 A,2001-10-25,US 24300700 P;;US 0146233 W,2000-10-25,Calcilytic compounds,Novel calcilytic compounds and methods of using them are provided.,SMITHKLINE BEECHAM CORP,BRYAN WILLIAM M;;CALLAHAN JAMES F;;WILLIAM F HUFFMAN,,https://lens.org/016-627-956-782-669,Patent Application,no,0,0,13,13,0,A61K45/06;;C07C255/54;;C07F9/091;;C07F9/655345;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07F9/655345;;C07F9/091;;C07C255/54;;A61K45/06,A61K45/00;;A61K31/661;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07C255/54;;C07F9/09;;C07F9/6553,,0,0,,,,PENDING
491,EP,A2,EP 0183391 A2,030-158-779-580-596,1986-06-04,1986,EP 85307762 A,1985-10-28,US 67228684 A,1984-11-16,Synthesis of molecular sieving metallosilicates using silica-transition metal oxide sols.,"A method for preparing a molecular sieving metallosilicate which comprises:
 (A) providing an aqueous dispersion of colloidal particles comprising contiguous mixtures of silica and the oxide of a transition metal selected from the group consisting of Sc, Ti, V, Cr, Mn, Fe, Co. Ni, Zn, Zr, Y or a mixture of two or more of said metals; (B) mixing an effective amount of a mineralizing agent and/or synthesis directing agent with said dispersion to form a gel; and (C) maintaining said gel at a temperature of 80°C to 300°C for an effective period of time to provide said metallosilicate.",STANDARD OIL CO OHIO,PEPERA MARC ANTHONY;;CALLAHAN JAMES LOUIS;;DESMOND MICHAEL JOSEPH,,https://lens.org/030-158-779-580-596,Patent Application,yes,0,3,10,10,0,B01J29/04;;B01J29/04;;C01B33/2884;;C01B33/2884;;C01B33/2876;;C01B33/2876,C01B33/20;;B01J29/00;;B01J29/04;;C01B39/06;;C07B61/00;;C07C1/20;;C07C5/27;;C07C15/073;;C07C15/08,,0,0,,,,EXPIRED
492,US,A,US 3658877 A,025-863-645-654-96X,1972-04-25,1972,US 3658877D A,1970-07-13,US 5444570 A,1970-07-13,PROCESS FOR PREVENTION OF CATALYST HANG-UP IN AMMOXIDATION OF OLEFINS TO UNSATURATED NITRILES,,STANDARD OIL CO OHIO,CALLAHAN JAMES L;;PRESSON ROBERT D;;MILLER ARTHUR F,,https://lens.org/025-863-645-654-96X,Granted Patent,no,0,5,1,1,0,B01J8/005;;C07C253/26;;Y10S585/95;;Y10S585/921;;Y10S585/926;;Y10S585/922;;C07C253/26;;B01J8/005;;Y10S585/95;;Y10S585/922;;Y10S585/921;;Y10S585/926,B01J8/00,260/465.3,0,0,,,,EXPIRED
493,WO,A2,WO 2006/104917 A2,051-914-314-553-099,2006-10-05,2006,US 2006/0010859 W,2006-03-24,US 66515405 P,2005-03-25,"PROCESS FOR PREPARING PYRIDO[2,3-D]PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE DERIVATIVES","The present invention is directed to a novel method of preparing of 2,4,8- trisubstituted pyrido⏧2,3-d&rsqb;pyrimidin-7-one pharmacophores of Formula (II) or (Ha) wherein GHs CH2 Or NH: G2 is CH or nitrogen; Rx is chloro, bromo, iodo, or O-S(O)2CF3; Rg is a C1 10 alkyl; m is 0, or an integer having a value of 1 , or 2; R3 is a C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-10 alkyl, aryl, arylC1-10 alkyl, heteroaryl, heteroarylC1-10 alkyl, heterocyclic or a heterocyclylC1-10 alkyl moiety, and wherein each of these moieties may be optionally substituted. which comprises reacting a compound of the formula: wherein Ry is chloro, bromo, iodo, O-S(O)2CF3; and Rg is a C1-10 alkyl; with a olefin forming reagent in a suitable base to yield a compound of Formula (II), or (Ha) wherein m=0 and oxidizing the sulphur as necessary or desired.",GLAXO GROUP LTD;;CALLAHAN JAMES FRANCIS;;BOEHM JEFFREY;;WAN ZEHONG;;YAN HONGXING,CALLAHAN JAMES FRANCIS;;BOEHM JEFFREY;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/051-914-314-553-099,Patent Application,yes,0,0,22,22,0,C07D471/04;;C07D487/04;;A61P43/00;;C07D471/04;;C07D487/04;;C07D487/04;;C07D471/04,A61K31/519;;C07D487/02,,0,0,,,,PENDING
494,CR,A,CR 11666 A,075-034-230-020-442,2011-04-28,2011,CR 11666 A,2010-09-01,US 2656808 P,2008-02-06,FARMACOFOROS DUALES- ANTAGONISTAS MUSCARINICOS PDEA,"La presente invención se refiere a nuevos compuestos de Fórmula (I) y a su uso en el tratamiento de enfermedades respiratorias, incluyendo enfermedades anti-inflamatorias y alérgicas tales como enfermedad pulmonar obstructiva crónica (COPD), asma, rinitis (por ejemplo, rinitis alérgica), dermatitis atópica o psoriasis.",GLAXO GROUP LTD;;TOTAL SA,JAMES FRANCIS CALLAHAN;;GUOLIANG LIN;;ZEHONG WAN;;HONGXING YAN,,https://lens.org/075-034-230-020-442,Patent Application,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P1/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P17/04;;A61P17/06;;A61P27/02;;A61P37/08;;C07D471/04;;C07D519/00,A01N43/42,,0,0,,,,DISCONTINUED
495,NZ,A,NZ 562433 A,086-621-919-723-071,2010-12-24,2010,NZ 56243306 A,2006-03-24,US 66515405 P;;US 2006/0010859 W,2005-03-25,"Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives, and their precursors","Disclosed is a fused pyrimidine derivative of formula (II) or (IIa), wherein each G is carbon or nitrogen, Rg is alkyl, and wherein the other substituents are as defined in the specification. Also disclosed is a process for preparing the above compound from aldehyde-substituted pyrimidine intermediates.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;BOEHM JEFFREY;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/086-621-919-723-071,Patent Application,no,0,0,22,22,0,C07D471/04;;C07D487/04;;A61P43/00;;C07D471/04;;C07D487/04;;C07D487/04;;C07D471/04,A61K31/519;;C07D413/04;;C07D471/04;;C07D487/04,,0,0,,,,DISCONTINUED
496,US,B2,US 8067408 B2,081-642-781-146-750,2011-11-29,2011,US 36593409 A,2009-02-05,US 36593409 A;;US 2657208 P,2008-02-06,Dual pharmacophores—PDE4-muscarinic antagonistics,"The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.",CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING;;GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,GLAXO GROUP LIMITED (2009-03-12),https://lens.org/081-642-781-146-750,Granted Patent,yes,60,1,20,20,0,C07D471/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/00;;A61P37/08;;A61P43/00;;C07D471/04,A61K31/496;;A61K31/437;;A61K31/551;;C07D487/04,514/218;;514/253.04;;514/303;;540/575;;544/362;;546/119,19,18,160-648-363-217-721;;042-639-754-892-131;;043-607-002-676-313;;018-053-786-180-165;;076-570-583-816-169;;033-924-461-315-45X;;037-623-086-376-926;;033-654-076-845-238;;044-015-154-458-347;;079-742-950-125-229;;106-308-211-550-278;;167-283-521-131-663;;039-034-918-191-754;;144-276-616-179-010;;048-179-313-509-030;;022-114-988-092-666;;001-547-902-527-406;;051-293-667-054-800,10.1164/ajrccm.158.supplement_2.13tac120;;10.1016/s0024-3205(98)00587-6;;10069509;;10.1164/ajrccm.163.5.2101039;;11316667;;10.1016/j.pharmthera.2007.05.007;;17597218;;10.1016/j.ddmec.2006.02.008;;10.1002/jhet.5570090212;;6121711;;10.1016/0014-2999(82)90034-6;;10.1021/jm00132a011;;2573731;;10.1002/ardp.19743070304;;4849253;;10.1016/j.bmc.2004.05.032;;15246087;;10.1248/cpb.52.1098;;15340197;;10.1002/(sici)1098-2299(199709)42:1<41::aid-ddr4>3.0.co;2-r;;10.1016/s0960-894x(01)00483-8;;11549462;;12383013;;10.1021/jm0209580;;15481980;;10.1021/jm0401006;;16439121;;10.1016/j.bmcl.2006.01.006;;10.1016/j.bmcl.2007.03.047;;17398090;;10.1016/j.bmcl.2003.10.025;;14684291,"Fryer and Jacoby, ""Muscarinic Receptors and Control of Airway Smooth Muscle"" Am J. Respir Crit Care Med; 1998; vol. 158 (5); pp. S154-S160).;;Fryer, et al. ""Effects of inflammatory cells on neuronal M2 muscarinic receptor function in the lung"" Life Sciences; 1999; vol. 64(6-7); pp. 449-455.;;Pauwels, et al., ""Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease"" Am J. Respir Crit Care Med; 2001; vol. 163; pp. 1256-1276.;;Gwilt, et al., ""The non-neuronal cholinergic system in the airways: An unappreciated regulatory role in pulmonary inflammation?"" Pharmacology & Therapeutics; 2007; pp. 208-222.;;Kummer and Lips, ""Non-neuronal acetylcholine release and its contribution to COPD pathology"" Drug Discovery Today: Disease Mechanisms; 2006; vol. 3; pp. 47-52.;;Hohn, et al., ""1H-Pyrazolo[3,4-b] pyridines"" Journal of Heterocyclic Chemistry; 1972; vol. 9(2); pp. 235-253.;;Patel and Malick, ""Pharmacological Properties of Tracazolate: A New Non-Benzodiazepine Anxiolytic Agent"" European Journal of Pharmacology; 1982; vol. 78; pp. 323-333.;;Bare, et al., ""Synthesis and Structure-Activity Relationships of a Series of Anxioselective Pyrazolopyridine Ester and Amide Anxiolytic Agents"" J. Med. Chem; 1989; vol. 32; pp. 2561-2573.;;Denzel, ""Neue Synthese 1-unsubstituierter 1H-Pyrazolo [3,4-b] pyridin-5-carbon-saureeser"" Archiv der Pharmazie; 1974; vol. 307(3); pp. 177-186.;;Ochiai, et al., ""New orally active PDE4 inhibitors with therapeutic potential"" Bioorganic & Medicinal Chemistry; 2004; vol. 12; pp. 4089-4100.;;Ochiai, et al., ""Discovery of New Orally Active Phosphodiesterase (PDE4) Inhibitors"" Chem. Pharm. Bull.; 2004; vol. 52(9); pp. 1098-1104.;;Shi, et al., ""Pyrazolopyridines: Effect of Structural Alterations on Activity at Adenosine- and GABAa-Receptors"" Drug Development Research; 1997; vol. 42; pp. 41-56.;;Schenone, et al., ""Synthesis and Biological Data of 4-Amino-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-b] pyridine-5-carboxylic Acid Ethyl Esters, a New Series of A1-Adenosine Receptor (A1AR) Ligands"" Bioorganic & Medicinal Chemistry Letters; 2001; vol. 11; pp. 2529-2531.;;Bondavalli, et al., ""Synthesis, Molecular Modeling Studies, and Pharmacological Activity of Selective A1 Receptor Antagonists"" 2002; vol. 45; pp. 4875-4887.;;De Mello, et al., ""Antileishmanial Pyrazolopyridine Derivatives: Synthesis and Structure-Activity Relationship Analysis"" J. Med. Chem; 2004; vol. 47; pp. 5427-5432.;;Provins, et al., ""First dual M3 antagonists-PDE4 inhibitors: Synthesis and SAR of 4,6-diaminopyrimidine derivatives"" Bioorganic & Medicinal Chemistry Letters; 2006; vol. 16; pp. 1834-1839.;;Provins, et al., ""Dual M3 antagonists-PDE4 inhibitors. Part 2: Synthesis and SAR of 3-substituted azetidinyl derivatives"" Bioorganic & Medicinal Chemistry Letters; 2007; vol. 17; pp. 3077-3080.;;Ochiai, et al., ""New orally active PDE4 inhibitors with therapeutic potential"" Bioorganic & Medicinal Chemistry Letters; 2004; vol. 14; pp. 29-32.;;Daly J. W. et al.; 1-methy1-4-substituted-1H-pyrazolo [3, 4-b] pyridine-5-carboxylic acid derivatives: effect of structural alterations on activity at A1 and A2 adenosine receptors; Medicinal Chemistry Research; 1994; 4(5); pp. 293-306; Birkhaeuser; Boston US.",INACTIVE
497,MY,A,MY 133881 A,095-350-791-898-896,2007-11-30,2007,MY PI20013427 A,2001-07-19,US 21984200 P;;US 22063600 P,2000-07-21,"""CALCILYTIC COMPOUNDS""",NOVEL CALCILYTIC COMPOUNDS AND METHODS OF USING THEM ARE PROVIDED.,SMITHKLINE BEECHAM CORP,AMPARO M LAGO;;PRADIP K BHATNAGAR;;JAMES F CALLAHAN,,https://lens.org/095-350-791-898-896,Granted Patent,no,0,0,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,C07D213/77;;A61K31/4418;;C07D409/02;;A61K31/4436;;A61K45/06;;A61K47/10;;A61K47/24;;A61K47/28;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,EXPIRED
498,DE,A1,DE 3218936 A1,110-375-019-804-834,1982-12-23,1982,DE 3218936 A,1982-05-19,US 27145881 A;;US 27148781 A,1981-06-08,Process for preparing highly active catalysts on the basis of phosphomolybdic acid,"Process for preparing highly active catalysts on the basis of phosphomolybdic acid by preparing a solution of hydrated phosphomolybdic acid in an essentially anhydrous alkyl alcohol, optionally with the addition of a base to the solution, evaporating the solution to prepare a catalyst powder, and final drying and calcining of the powder to form the active catalyst. A further preparation process comprises preparing a solution of hydrated phosphomolybdic acid in an essentially anhydrous alkyl alcohol, evaporation of the solution to prepare a concentrate, impregnating a catalyst support material with the concentrate, bringing the impregnated support into contact with ammonia gas in an amount which is sufficient to form an insoluble precipitate of ammonium alkyl phosphomolybdic acid within the pore structure of the support material, followed by drying and calcining the impregnated support material to form a laminar catalyst.",STANDARD OIL CO OHIO,CALLAHAN JAMES LOUIS;;SHAW WILFRID GARSIDE;;MILLER ARTHUR FRANCIS,,https://lens.org/110-375-019-804-834,Patent Application,no,0,2,3,7,0,B01J27/188;;B01J27/19;;B01J37/0215;;C07C51/235;;C07C51/252,B01J27/188;;B01J27/19;;B01J37/02;;C07C51/235;;C07C51/25;;C07C57/055,,0,0,,,,DISCONTINUED
499,CN,A,CN 1215054 A,118-389-536-474-587,1999-04-28,1999,CN 98107358 A,1998-04-24,US 99288592 A;;US 3794893 A,1992-12-21,Bychclic fibrinogen antagonists,"This invention relates to compounds of formulae (I), (II), (II), wherein A<1> is O, S, N-R<1> or CHR<1>; A<4> is N-R<4> or CHR<4>; R<2> is a sidechain containing an acid or ester group; R<1>, R<4> and R<5> are substituents such as H, alkyl and aryl alkyl, and R<6> is a sidechain containing a nitrogen group; and pharmaceutically acceptable salts thereof, which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.",SMITHKLINE BEECHAM CORP,BONDINELL WILLIAM EDWARD;;KEENAN RICHARD MCCULLOCH;;CALLAHAN JAMES FRANCIS,,https://lens.org/118-389-536-474-587,Patent Application,no,0,1,23,24,0,C07D211/18;;C07D211/70;;C07D213/24;;C07D223/16;;C07D243/04;;C07D243/14;;C07D243/24;;C07D267/14;;C07D401/12;;C07D403/12;;C07D453/02;;A61P7/02;;C07D243/14;;C07D401/12,A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/445;;A61K31/4465;;A61K31/451;;A61K31/55;;A61K31/551;;A61P7/02;;C07D211/18;;C07D211/22;;C07D211/26;;C07D211/70;;C07D213/24;;C07D213/74;;C07D223/16;;C07D243/04;;C07D243/14;;C07D243/24;;C07D267/14;;C07D295/04;;C07D295/08;;C07D295/10;;C07D295/12;;C07D401/12;;C07D401/14;;C07D403/12;;C07D453/02,,0,0,,,,DISCONTINUED
500,US,A,US 4443555 A,155-617-227-305-572,1984-04-17,1984,US 43970482 A,1982-11-08,US 43970482 A;;US 27148781 A,1981-06-08,Method for the preparation of high activity phosphomolybdic acid based catalysts,"The present invention relates to a method for the preparation of phosphomolybdic acid based catalysts by forming a solution of hydrated phosphomolybdic acid in a substantially anhydrous alkyl alcohol, heating the solution to form a concentrate, and thereafter drying and calcining the concentrate support material so as to form the catalyst. Because the catalyst is prepared in alcoholic rather than aqueous solution, it has a greater activity in converting aldehydes to their respective unsaturated carboxylic acids than known phosphomolybdic acid based catalysts. Furthermore, the deammoniation step of the prior art is no longer required.",STANDARD OIL CO OHIO,CALLAHAN JAMES L;;SHAW WILFRID G;;MILLER ARTHUR F,,https://lens.org/155-617-227-305-572,Granted Patent,yes,21,7,1,7,0,C07C51/235;;C07C51/235;;C07C51/252;;C07C51/252,C07C51/235;;C07C51/25,502/211;;502/212,0,0,,,,EXPIRED
501,WO,A1,WO 2009/100166 A1,158-816-828-822-437,2009-08-13,2009,US 2009/0033128 W,2009-02-05,US 2656308 P,2008-02-06,DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS,"The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.",GLAXO GROUP LTD;;CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/158-816-828-822-437,Patent Application,yes,3,2,21,21,0,C07D471/04;;C07D519/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/08;;A61P43/00;;C07D471/04;;C07D519/00,A01N43/90;;A01N43/56;;A61K31/519,,1,0,,,See also references of EP 2259681A4,PENDING
502,WO,A3,WO 2002/007673 A3,144-327-176-256-066,2003-10-16,2003,US 0122267 W,2001-07-16,US 21984200 P;;US 22063600 P,2000-07-21,CALCILYTIC COMPOUNDS,"Certain N-(2R)-hydroxy--3-cyano-5-⏧⏧carboxy&rsqb;-3-pyridyl&rsqb;phenoxy&rsqb;propyl&rsqb;&rsqb;-1,1-dimetyl-2-(aryl or heteroaryl)-ethylamines and derivatives thereof, methods for their preparation and their use as calcylitic agents.",SMITHKLINE BEECHAM CORP;;BHATNAGAR PRADIP K;;CALLAHAN JAMES F;;LAGO AMPARO M,BHATNAGAR PRADIP K;;CALLAHAN JAMES F;;LAGO AMPARO M,,https://lens.org/144-327-176-256-066,Search Report,yes,2,0,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,A61K31/4418;;A61K31/4436;;A61K45/06;;A61K47/10;;C07D213/77;;A61K47/24;;A61K47/28;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,PATENTED
503,FR,A1,FR 2393781 A1,148-299-141-813-299,1979-01-05,1979,FR 7825527 A,1978-09-05,US 80526477 A,1977-06-10,SEPARATION D'ISOBUTYLENE ET/OU D'ISOAMYLENE A PARTIR D'UN FLUX D'HYDROCARBURES LES CONTENANT,<P>Procédé de séparation d'une oléfine dans un flux d'hydrocarbures. </P><P>Ce procédé est caractérisé par le fait qu'on met en contact le flux d'hydrocarbures précité avec du méthanol de façon que l'oléfine précitée réagisse avec le méthanol pour donner le méthyl-tertioalkyl-éther correspondant; que l'on sépare le méthyl-tertioalkyl-éther du mélange réactionnel; que l'on fait réagir le méthyl-tertioalky-éther avec un acide carboxylique aliphatique saturé ou insaturé contenant de 1 à 6 atomes de carbone de façon à former l'ester méthylique de l'acide carboxylique précité et l'oléfine correspondante; et que l'on récupère la tertioalkyl-oléfine. </P><P>Utilisable pour séparer l'isobutylène et l'isoamylène à partir d'un flux d'hydrocarbures mixtes de raffinerie.</P>,STANDARD OIL CO,GUTTMANN ANDREW TYTUS;;CALLAHAN JAMES LOUIS;;GRASSELLI ROBERT KARL,,https://lens.org/148-299-141-813-299,Patent Application,no,0,0,16,18,0,C07C1/20;;C07C7/14891;;C07C67/24,B01J23/00;;B01J27/00;;C07C67/24;;C07B61/00;;C07C1/20;;C07C7/148,,0,0,,,,DISCONTINUED
504,EP,B1,EP 0010206 B1,192-113-572-140-628,1983-05-04,1983,EP 79103676 A,1979-09-28,US 95426278 A,1978-10-24,A PROCESS FOR THE OXIDATION OF PROPYLENE TO ACRYLIC ACID AND OF ISOBUTYLEN TO METHACRYLIC ACID,,THE STANDARD OIL COMPANY,"CALLAHAN, JAMES LOUIS;;SHAW, WILFRIED GARSIDE;;MILLER, ARTHUR FRANCIS",,https://lens.org/192-113-572-140-628,Granted Patent,yes,0,0,4,6,0,B01J8/0453;;B01J8/048;;B01J8/34;;C07C253/26;;C07C51/252,B01J8/24;;B01J8/04;;B01J8/34;;C07C51/25,,0,0,,,,EXPIRED
505,CN,A,CN 101990401 A,001-902-359-852-373,2011-03-23,2011,CN 200980112357 A,2009-02-05,US 2009/0033128 W;;US 2656308 P,2008-02-06,Dual pharmacophores - pde4-muscarinic antagonistics,"The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.",GLAXO GROUP LTD,FRANCIS CALLAHAN JAMES;;HONGXING YAN;;ZEHONG WAN;;GUOLIANG LIN,,https://lens.org/001-902-359-852-373,Patent Application,no,3,1,21,21,0,C07D471/04;;C07D519/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/08;;A61P43/00;;C07D471/04;;C07D519/00,A01N43/90;;A01N43/56;;A61K31/519,,0,0,,,,DISCONTINUED
506,DD,A5,DD 132860 A5,018-545-153-643-570,1978-11-15,1978,DD 20035677 A,1977-07-29,US 71101476 A,1976-08-02,VERFAHREN ZUR HERSTELLUNG VON METHACROLEIN AUS TERT.BUTYLGRUPPEN ENTHALTENDEN VERBINDUNGEN,,STANDARD OIL CO OHIO,HARDMAN HARLEY F;;GRASSELLI ROBERT K;;CALLAHAN JAMES L,,https://lens.org/018-545-153-643-570,Granted Patent,no,0,0,26,29,0,B01J23/8876;;B01J2523/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C51/235;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J23/8876;;C07C45/33;;C07C45/34;;C07C51/235;;C07C45/32;;C07C45/37;;C07C51/252;;C07C45/27;;B01J2523/00;;C07C253/24;;Y02P20/52,B01J23/00;;B01J23/88;;C07B61/00;;C07C1/00;;C07C5/48;;C07C57/05;;C07C11/00;;C07C45/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C47/22;;C07C51/00;;C07C51/235;;C07C51/25;;C07C67/00;;C07C253/00;;C07C255/08,,0,0,,,,EXPIRED
507,CA,A1,CA 2982184 A1,053-878-991-615-59X,2018-06-19,2018,CA 2982184 A,2017-10-10,US 201615383851 A,2016-12-19,SYSTEM FOR DISPLAYING THE STATUS OF USE OF AIRCRAFT OVERHEAD LUGGAGE STORAGE BINS,A system and method are disclosed for displaying the storage status of overhead luggage storage bins in an aircraft. A camera is provided that is mounted with a field of view directed at an inner portion of a group of open bins. The camera is communicatively coupled to a controller and selectively provides images of the inner portion of the bins immediately prior to when the bins are closed to the controller. A projector is also provided for each group of bins. The projector is communicatively coupled to the controller and is mounted such that an image received from the controller is projected onto an outer surface of the closed bins. The controller receives images from each of the cameras and selectively provides such images to the projector associated with each camera so that a storage status display is projected on an outer surface of the bins.,BOEING CO,IBRAHIM YAKENTIM M;;CALLAHAN KEVIN S;;SCHALLA JAMES P,,https://lens.org/053-878-991-615-59X,Patent Application,no,0,1,16,16,0,B64D11/00;;B64D11/003;;H04N23/63;;B64D47/08;;B61D37/003;;B64D45/00;;B64D2045/007;;B64D47/08;;B64D11/003;;H04N23/63;;B64D11/00;;B64D47/08;;H04N7/18;;H04N23/60;;H04N23/90;;B64D47/08;;B64D11/003;;H04N7/181;;H04N9/31;;B64D45/00;;B61D37/003;;B64D2045/007;;G06V20/52;;H04N23/63;;H04N23/90,B64D47/00;;B64D11/00;;B64D47/08;;H04N7/18,,0,0,,,,PENDING
508,CA,C,CA 2678361 C,064-733-102-255-849,2013-01-15,2013,CA 2678361 A,2008-02-15,US 90196307 P;;US 2765108 A;;US 2767208 A;;US 2008/0054092 W,2007-02-16,THERMAL SPRAY COATINGS AND APPLICATIONS THEREFOR,"This invention relates to coatings for a metal or non-metal substrate comprising (i) a thermal sprayed bondcoat layer applied to said substrate comprising an alloy of MCrAlM' wherein M is an element selected from nickel, cobalt, iron and mixtures thereof, and M' is an element selected from yttrium, zirconium, hafnium, ytterbium and mixtures thereof, and wherein M comprises from about 35 to about 80 weight percent of said alloy, Cr comprises from about 15 to about 45 weight percent of said alloy, Al comprises from about 5 to about 30 weight percent of said alloy, and M' comprises from about 0.01 to about 1.0 weight percent of said alloy, said alloy thermally sprayed from a powder having a mean particle size of 50 percentile point in distribution of from about 5 microns to about 100 microns, said bondcoat having a surface roughness of at least 200 micro-inches, and said bondcoat having a thermal expansion of about 6.5 millimeters per meter or less between a temperature of from about 25°C to about 525°C, and (ii) a thermal sprayed ceramic layer applied to said bondcoat layer; wherein said coating has a helium leak rate of less than 6 x 10""6 standard cubic centimeters per second. The coatings are useful for extending the service life under severe conditions, such as those associated with metallurgical vessels' lances, nozzles and tuyeres.",PRAXAIR TECHNOLOGY INC,APTE PRASAD SHRIKRISMNA;;MEAGHER JAMES PATRICK;;CALLAHAN SHAWN W,,https://lens.org/064-733-102-255-849,Granted Patent,no,0,0,9,9,0,C23C4/02;;C23C28/3215;;C23C28/34;;C23C28/341;;C23C28/345;;C23C28/3455;;C23C28/36;;C23C28/321;;C23C4/073;;C22C19/05;;C22C19/058;;Y10T428/256;;Y10T428/24355;;Y10T428/24612;;Y10T428/12618;;Y10T428/12931;;Y10T428/24413;;Y10T428/249969;;Y10T428/256;;Y10T428/24355;;Y10T428/24612;;Y10T428/12618;;Y10T428/12931;;Y10T428/24413;;Y10T428/249969;;C23C4/02;;C23C28/34;;C23C28/3455;;C23C28/341;;C23C28/345;;C23C28/36;;C23C28/3215;;C23C28/321;;C22C19/058;;C22C19/05;;C23C4/073,C23C4/08;;C22C19/00;;C23C28/00,,0,0,,,,INACTIVE
509,BR,A,BR 0112600 A,083-093-205-869-313,2003-06-24,2003,BR 0112600 A,2001-07-16,US 21984200 P;;US 22063600 P;;US 0122267 W,2000-07-21,Compostos calcilìticos,"""COMPOSTOS CALCILìTICOS"" Fornece-se compostos calilíticos inovadores e métodos para usá-los.",SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP K;;CALLAHAN JAMES F;;LAGO AMPARO M,,https://lens.org/083-093-205-869-313,Patent Application,no,0,0,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,C07D213/77;;A61K31/4418;;A61K31/4436;;A61K45/06;;A61K47/10;;A61K47/24;;A61K47/28;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,DISCONTINUED
510,FI,A0,FI 833132 A0,091-025-315-027-307,1983-09-02,1983,FI 833132 A,1983-09-02,US 42824182 A,1982-09-29,BANOEVERFOERINGSFOERFARANDE,,BELOIT CORP,WICKS LAURIE DAVID;;CRONIN DENNIS CALLAHAN;;CHANCE JAMES LARRY,"BELOIT TECHNOLOGIES, INC. (1998-10-12)",https://lens.org/091-025-315-027-307,Patent Application,no,0,0,23,23,0,D21F2/00;;D21F3/04;;D21F3/045;;D21F3/04;;D21F3/045;;D21F2/00;;D21F3/04,D21F1/00;;B65H20/06;;D21F2/00;;D21F3/02;;D21F3/04,,0,0,,,,EXPIRED
511,US,B2,US 7883784 B2,095-426-366-189-51X,2011-02-08,2011,US 2767208 A,2008-02-07,US 2767208 A;;US 90196307 P,2007-02-16,Thermal spray coatings and applications therefor,"This invention relates to coatings for a metal or non-metal substrate comprising (a) a thermal sprayed bondcoat layer applied to the substrate, and (b) a thermal sprayed ceramic layer applied to said bondcoat layer; wherein said coating has a helium leak rate of less than 6×10 −6 standard cubic centimeters per second. The thermal sprayed bondcoat layer comprises (i) a thermal sprayed inner layer alloy, and (ii) a thermal sprayed outer layer alloy. The inner layer alloy is thermally sprayed from a powder having a mean particle size of 50 percentile point in distribution of from about 5 microns to about 50 microns. The outer layer alloy is thermally sprayed from a powder having a mean particle size of 50 percentile point in distribution of from about 30 microns to about 100 microns. The coatings are useful for extending the service life under severe conditions, such as those associated with metallurgical vessels' lances, nozzles and tuyeres.",PRAXAIR TECHNOLOGY INC,APTE PRASAD SHRIKRISNNA;;MEAGHER JAMES PATRICK;;CALLAHAN SHAWN W,PRAXAIR S. T. TECHNOLOGY INC (2008-02-14),https://lens.org/095-426-366-189-51X,Granted Patent,yes,16,3,9,9,0,C23C4/02;;C23C28/3215;;C23C28/34;;C23C28/341;;C23C28/345;;C23C28/3455;;C23C28/36;;C23C28/321;;C23C4/073;;C22C19/05;;C22C19/058;;Y10T428/256;;Y10T428/24355;;Y10T428/24612;;Y10T428/12618;;Y10T428/12931;;Y10T428/24413;;Y10T428/249969;;Y10T428/256;;Y10T428/24355;;Y10T428/24612;;Y10T428/12618;;Y10T428/12931;;Y10T428/24413;;Y10T428/249969;;C23C4/02;;C23C28/34;;C23C28/3455;;C23C28/341;;C23C28/345;;C23C28/36;;C23C28/3215;;C23C28/321;;C22C19/058;;C22C19/05;;C23C4/073,B32B15/04,428/633;;428/678;;X416241 R,2,1,031-501-410-876-970,10.31399/asm.hb.v05.a0001282,"Tucker, Robert C. Jr. ""Thermal Spray Coatings"". ASM Handbook, vol. 5, Surface Engineering (1994) pp. 497-509.;;Superalloys II, eds. Sims, Stoloff and Hagel, John Wiley (1987), p. 387-458 (alloy making), p. 459-494 (powder making).",ACTIVE
512,US,A,US 4427792 A,099-374-770-652-039,1984-01-24,1984,US 29160381 A,1981-08-10,US 29160381 A,1981-08-10,Iron-phosphorus mixed oxide catalysts and process for their preparation,"A process is provided for the preparation of iron phosphorous mixed oxide catalysts which are highly active at moderate temperatures by introducing iron and phosphorus containing compounds and promoter element containing compounds, if any, into a substantially organic liquid medium, heating, separating the resulting precursor, drying and calcining. The catalysts are useful for the dehydrogenation or oxydehydrogenation of organic compounds such as aldehydes or carboxylic acids.",STANDARD OIL CO OHIO,PEDERSEN S ERIK;;BREMER NOEL J;;CALLAHAN JAMES L,STANDARD OIL COMPANY THE A CORP. OF OHIO (1981-07-29),https://lens.org/099-374-770-652-039,Granted Patent,yes,5,7,1,1,0,B01J27/1853;;B01J27/186;;B01J27/1853;;B01J27/186,B01J27/185;;B01J27/186,502/210;;502/213;;560/214,0,0,,,,EXPIRED
513,EP,A2,EP 1368318 A2,141-076-281-572-738,2003-12-10,2003,EP 01954696 A,2001-07-16,US 0122267 W;;US 21984200 P;;US 22063600 P,2000-07-21,CALCILYTIC COMPOUNDS,,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP K;;CALLAHAN JAMES F;;LAGO AMPARO M,"ONE FRANKLIN PLAZA, PO BOX 7929, PHLILADELPHIA, PE (2007-12-05);;SMITHKLINE BEECHAM CORP. (2007-12-05);;SMITHKLINE BEECHAM CORPORATION (2008-04-09)",https://lens.org/141-076-281-572-738,Patent Application,yes,0,0,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,A61K31/44;;C07D213/77;;A61K31/4418;;C07D213/78;;A61K31/4436;;A61K45/06;;A61K47/10;;A61K47/24;;A61K47/28;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,EXPIRED
514,CA,A,CA 1030555 A,175-256-452-684-569,1978-05-02,1978,CA 206440 A,1974-08-07,US 39017573 A,1973-08-20,REACTIVATION OF MOLYBDENUM CONTAINING OXIDATION CATALYSTS IN FLUID-BED REACTORS,,STANDARD OIL CO OHIO,CALLAHAN JAMES L;;SHAW WILFRID G;;MILLER ARTHUR F,,https://lens.org/175-256-452-684-569,Granted Patent,no,0,0,23,23,0,B01J8/26;;B01J23/28;;B01J23/86;;B01J23/92;;B01J23/94;;B01J38/16;;C07C253/26;;Y10S585/901;;Y02P20/584;;Y02P20/52;;B01J35/19;;B01J38/16;;B01J8/26;;C07C253/26;;B01J23/94;;B01J23/28;;B01J23/92;;B01J23/86;;Y10S585/901;;Y02P20/584;;Y02P20/52;;B01J35/19,C07C5/48;;B01J8/26;;B01J23/36;;B01J23/86;;B01J23/92;;B01J23/94;;B01J38/00;;C07B31/00;;C07B33/00;;C07B61/00;;C07C1/00;;C07C11/00;;C07C67/00;;C07C253/00;;C07C255/08,260-560.93,0,0,,,,EXPIRED
515,CH,A,CH 462794 A,179-881-190-016-470,1968-09-30,1968,CH 1542067 A,1965-11-02,US 40872364 A,1964-11-04,Procédé pour préparer des aldéhydes à non saturation oléfinique,,STANDARD OIL CO,JAMES LOUIS CALLAHAN;;ERNEST CARL MILBERGER;;ROBERT CARL GRASSELLI,,https://lens.org/179-881-190-016-470,Granted Patent,no,0,0,15,16,0,B01J8/26;;B01J8/26;;B01J21/08;;B01J21/08;;B01J23/12;;B01J23/12;;B01J23/18;;B01J23/18;;C07C45/34;;C07C45/34;;C07C45/35;;C07C45/35;;C07C253/26;;C07C253/26;;Y02P20/52;;Y02P20/52,C07C47/22;;B01J8/26;;B01J21/08;;B01J23/00;;B01J23/12;;B01J23/18;;B01J35/00;;C07B61/00;;C07C45/00;;C07C45/34;;C07C45/35;;C07C67/00;;C07C253/00;;C07C255/08,"12O,7/03",0,0,,,,EXPIRED
516,CZ,A3,CZ 2003142 A3,176-641-115-684-653,2003-06-18,2003,CZ 2003142 A,2001-07-16,US 21984200 P;;US 22063600 P,2000-07-21,Calcilytic compounds,,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP K;;CALLAHAN JAMES F;;LAGO AMPARO M,,https://lens.org/176-641-115-684-653,Patent Application,no,0,0,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,A61K31/4418;;A61K31/4436;;A61K45/06;;A61K47/10;;A61K47/24;;A61K47/28;;C07D213/77;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,PENDING
517,DE,A1,DE 2732952 A1,014-238-619-174-003,1978-02-09,1978,DE 2732952 A,1977-07-21,US 71101476 A,1976-08-02,VERFAHREN ZUR HERSTELLUNG VON METHACRYLDERIVATEN AUS TERT.-BUTYLGRUPPEN ENTHALTENDEN VERBINDUNGEN,,STANDARD OIL CO OHIO,HARDMAN HARLEY FOCH;;GRASSELLI ROBERT KARL;;CALLAHAN JAMES LOUI,,https://lens.org/014-238-619-174-003,Patent Application,no,2,2,26,29,0,B01J23/8876;;B01J2523/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C51/235;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J23/8876;;C07C45/33;;C07C45/34;;C07C51/235;;C07C45/32;;C07C45/37;;C07C51/252;;C07C45/27;;B01J2523/00;;C07C253/24;;Y02P20/52,B01J23/00;;B01J23/88;;C07B61/00;;C07C1/00;;C07C57/05;;C07C5/48;;C07C11/00;;C07C45/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C47/22;;C07C51/00;;C07C51/235;;C07C51/25;;C07C67/00;;C07C253/00;;C07C255/08,,0,0,,,,EXPIRED
518,EP,A1,EP 2247184 A1,017-201-508-295-232,2010-11-10,2010,EP 09708465 A,2009-02-05,US 2009/0033129 W;;US 2656808 P,2008-02-06,DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS,,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,GLAXO GROUP LIMITED (2013-05-01),https://lens.org/017-201-508-295-232,Patent Application,yes,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P1/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P17/04;;A61P17/06;;A61P27/02;;A61P37/08;;C07D471/04;;C07D519/00,C07D471/04;;A01N43/42;;C07D519/00,,0,0,,,,DISCONTINUED
519,EP,B1,EP 0057320 B1,026-654-778-999-959,1985-06-05,1985,EP 81305782 A,1981-12-08,US 22185980 A,1980-12-31,MIXED METAL PHOSPHORUS OXIDE CATALYSTS FOR THE OXIDATIVE DEHYDROGENATION OF CARBOXYLIC ACIDS UTILIZING THEM AND PREPARATION THEREOF,,THE STANDARD OIL COMPANY,"PEDERSEN, SVEND ERIK;;CALLAHAN, JAMES LOUIS;;HARDMAN, HARLEY FOCH",,https://lens.org/026-654-778-999-959,Granted Patent,yes,0,0,9,11,0,B01J27/18;;B01J27/186;;B01J23/89;;B01J23/8933;;B01J27/1853;;C07C51/377;;C07C51/377,C07C57/04;;B01J23/89;;B01J27/00;;B01J27/18;;B01J27/185;;B01J27/186;;C07B61/00;;C07C51/00;;C07C51/377;;C07C67/00;;C07C253/00;;C07C255/23,,0,0,,,,EXPIRED
520,CA,C,CA 2982184 C,042-660-438-327-25X,2022-10-25,2022,CA 2982184 A,2017-10-10,US 201615383851 A,2016-12-19,SYSTEM FOR DISPLAYING THE STATUS OF USE OF AIRCRAFT OVERHEAD LUGGAGE STORAGE BINS,A system and method are disclosed for displaying the storage status of overhead luggage storage bins in an aircraft. A camera is provided that is mounted with a field of view directed at an inner portion of a group of open bins. The camera is communicatively coupled to a controller and selectively provides images of the inner portion of the bins immediately prior to when the bins are closed to the controller. A projector is also provided for each group of bins. The projector is communicatively coupled to the controller and is mounted such that an image received from the controller is projected onto an outer surface of the closed bins. The controller receives images from each of the cameras and selectively provides such images to the projector associated with each camera so that a storage status display is projected on an outer surface of the bins.,BOEING CO,IBRAHIM YAKENTIM M;;CALLAHAN KEVIN S;;SCHALLA JAMES P,,https://lens.org/042-660-438-327-25X,Granted Patent,no,0,0,16,16,0,B64D11/00;;B64D11/003;;H04N23/63;;B64D47/08;;B61D37/003;;B64D45/00;;B64D2045/007;;B64D47/08;;B64D11/003;;H04N23/63;;B64D11/00;;B64D47/08;;H04N7/18;;H04N23/60;;H04N23/90;;B64D47/08;;B64D11/003;;H04N7/181;;H04N9/31;;B64D45/00;;B61D37/003;;B64D2045/007;;G06V20/52;;H04N23/63;;H04N23/90,B64D47/00;;B64D11/00;;B64D47/08;;H04N7/18,,0,0,,,,PENDING
521,US,B2,US 8071588 B2,052-002-024-724-843,2011-12-06,2011,US 36593309 A,2009-02-05,US 36593309 A;;US 2656808 P,2008-02-06,Dual pharmacophores—PDE4-muscarinic antagonistics,"The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.",CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING;;GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,GLAXO GROUP LIMITED (2009-03-12),https://lens.org/052-002-024-724-843,Granted Patent,yes,60,0,21,21,0,C07D471/04;;C07D519/00;;A61P1/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P17/04;;A61P17/06;;A61P27/02;;A61P37/08;;C07D471/04;;C07D519/00,A61K31/496;;A61K31/437;;A61K31/551;;C07D487/04,514/218;;514/253.04;;514/303;;540/575;;544/362;;546/110,19,18,160-648-363-217-721;;042-639-754-892-131;;043-607-002-676-313;;018-053-786-180-165;;076-570-583-816-169;;033-924-461-315-45X;;037-623-086-376-926;;033-654-076-845-238;;044-015-154-458-347;;079-742-950-125-229;;106-308-211-550-278;;167-283-521-131-663;;039-034-918-191-754;;144-276-616-179-010;;048-179-313-509-030;;022-114-988-092-666;;001-547-902-527-406;;051-293-667-054-800,10.1164/ajrccm.158.supplement_2.13tac120;;10.1016/s0024-3205(98)00587-6;;10069509;;10.1164/ajrccm.163.5.2101039;;11316667;;10.1016/j.pharmthera.2007.05.007;;17597218;;10.1016/j.ddmec.2006.02.008;;10.1002/jhet.5570090212;;6121711;;10.1016/0014-2999(82)90034-6;;10.1021/jm00132a011;;2573731;;10.1002/ardp.19743070304;;4849253;;10.1016/j.bmc.2004.05.032;;15246087;;10.1248/cpb.52.1098;;15340197;;10.1002/(sici)1098-2299(199709)42:1<41::aid-ddr4>3.0.co;2-r;;10.1016/s0960-894x(01)00483-8;;11549462;;12383013;;10.1021/jm0209580;;15481980;;10.1021/jm0401006;;16439121;;10.1016/j.bmcl.2006.01.006;;10.1016/j.bmcl.2007.03.047;;17398090;;10.1016/j.bmcl.2003.10.025;;14684291,"Fryer and Jacoby, ""Muscarinic Receptors and Control of Airway Smooth Muscle"" Am J. Respir Crit Care Med; 1998; vol. 158 (5); pp. S154-S160).;;Fryer, et al. ""Effects of inflammatory cells on neuronal M2 muscarinic receptor function in the lung"" Life Sciences; 1999; vol. 64(6-7); pp. 449-455.;;Pauwels, et al., ""Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease"" Am J. Respir Crit Care Med; 2001; vol. 163; pp. 1256-1276.;;Gwilt, et al., ""The non-neuronal cholinergic system in the airways: An unappreciated regulatory role in pulmonary inflammation?"" Pharmacology & Therapeutics; 2007; pp. 208-222.;;Kummer and Lips, ""Non-neuronal acetylcholine release and its contribution to COPD pathology"" Drug Discovery Today: Disease Mechanisms; 2006; vol. 3; pp. 47-52.;;Hohn, et al., ""1H-Pyrazolo[3,4-b] pyridines"" Journal of Heterocyclic Chemistry; 1972; vol. 9(2); pp. 235-253.;;Patel and Malick, ""Pharmacological Properties of Tracazolate: A New Non-Benzodiazepine Anxiolytic Agent"" European Journal of Pharmacology; 1982; vol. 78; pp. 323-333.;;Bare, et al., ""Synthesis and Structure-Activity Relationships of a Series of Anxioselective Pyrazolopyridine Ester and Amide Anxiolytic Agents"" J. Med. Chem; 1989; vol. 32; pp. 2561-2573.;;Denzel, ""Neue Synthese 1-unsubstituierter 1H-Pyrazolo [3,4-b] pyridin-5-carbon-saureeser"" Archiv der Pharmazie; 1974; vol. 307(3); pp. 177-186.;;Ochiai, et al., ""New orally active PDE4 inhibitors with therapeutic potential"" Bioorganic & Medicinal Chemistry; 2004; vol. 12; pp. 4089-4100.;;Ochiai, et al., ""Discovery of New Orally Active Phosphodiesterase (PDE4) Inhibitors"" Chem. Pharm. Bull.; 2004; vol. 52(9); pp. 1098-1104.;;Shi, et al., ""Pyrazolopyridines: Effect of Structural Alterations on Activity at Adenosine~and GABAa-Receptors"" Drug Development Research; 1997; vol. 42; pp. 41-56.;;Schenone, et al., ""Synthesis and Biological Data of 4-Amino-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-b] pyridine-5-carboxylic Acid Ethyl Esters, a New Series of A1-Adenosine Receptor (A1AR) Ligands"" Bioorganic & Medicinal Chemistry Letters; 2001; vol. 11; pp. 2529-2531.;;Bondavalli, et al., ""Synthesis, Molecular Modeling Studies, and Pharmacological Activity of Selective A1 Receptor Antagonists"" 2002; vol. 45; pp. 4875-4887.;;De Mello, et al., ""Antileishmanial Pyrazolopyridine Derivatives: Synthesis and Structure-Activity Relationship Analysis"" J. Med. Chem; 2004; vol. 47; pp. 5427-5432.;;Provins, et al., ""First dual M3 antagonists-PDE4 inhibitors: Synthesis and SAR of 4,6-diaminopyrimidine derivatives"" Bioorganic & Medicinal Chemistry Letters; 2006; vol. 16; pp. 1834-1839.;;Provins, et al., ""Dual M3 antagonists-PDE4 inhibitors. Part 2: Synthesis and SAR of 3-substituted azetidinyl derivatives"" Bioorganic & Medicinal Chemistry Letters; 2007; vol. 17; pp. 3077-3080.;;Ochiai, et al., ""New orally active PDE4 inhibitors with therapeutic potential"" Bioorganic & Medicinal Chemistry Letters; 2004; vol. 14; pp. 29-32.;;Daly J. W. et al.; 1-methy1-4-substituted-1H-pyrazolo [3, 4-b] pyridine-5-carboxylic acid derivatives: effect of structural alterations on activity at A1 and A2 adenosine receptors; Medicinal Chemistry Research; 1994; 4(5); pp. 293-306; Birkhaeuser; Boston US.",INACTIVE
522,DE,D1,DE 3376990 D1,048-603-396-521-325,1988-07-14,1988,DE 3376990 T,1983-09-09,US 42824182 A,1982-09-29,METHOD OF SHEET TRANSFER,,BELOIT CORP,WICKS LAURIE DAVID;;CRONIN DENNIS CALLAHAN;;CHANCE JAMES LARRY,"BELOIT TECHNOLOGIES, INC., WILMINGTON, DEL., US (1996-09-19)",https://lens.org/048-603-396-521-325,Granted Patent,no,0,0,23,23,0,D21F2/00;;D21F3/04;;D21F3/045;;D21F3/04;;D21F3/045;;D21F2/00;;D21F3/04,B65H20/06;;D21F1/00;;D21F2/00;;D21F3/02;;D21F3/04,,0,0,,,,EXPIRED
523,US,B2,US 7817906 B2,071-862-818-063-556,2010-10-19,2010,US 35218406 A,2006-02-10,US 35218406 A;;US 67755205 P;;US 70952805 P;;US 72647305 P,2005-05-04,Direct electric resistance liquid heater,"The Direct Electric Resistance Liquid Heater comprises a liquid heating chamber containing a plurality of electrodes. The electrodes are spaced apart to create a plurality of channels through which the liquid to be heated passes. The electrodes are each connected to a power supply by one or more switches. A controller controls the switches based upon data received from a temperature sensor, sensing the temperature of the liquid, and/or an electric current sensor, sensing the current utilized by the liquid heater. Selection of the number and spacing of the electrodes, and the number of switches, provides the controller with various current levels options to apply to the liquid to be heated. The current levels available due to the number and spacing of the electrodes and the number of switches, span the range from minimum current to maximum current such that the controller can incrementally increase or decrease the current applied to the liquid to be heated without disrupting other users of the same power source.",ISI TECHNOLOGY LLC,CALLAHAN JEREMIAH M;;BARZYK JAMES E;;BOWERS JOHN H,ISI TECHNOLOGY LLC (2006-08-08);;HEATWORKS TECHNOLOGIES INC (2016-05-23);;OHMIQ INC (2022-12-21),https://lens.org/071-862-818-063-556,Granted Patent,yes,18,29,19,44,0,F24H1/106;;H05B3/60;;H05B2203/021;;F24H1/10;;F24H1/20;;H05B7/144;;F24H1/106;;H05B2203/021;;H05B3/60,H05B3/60,392/331;;392/311;;392/324,0,0,,,,ACTIVE
524,PE,A1,PE 20091552 A1,092-202-235-304-109,2009-10-25,2009,PE 2009000167 A,2009-02-04,US 2656308 P,2008-02-06,FARMACOFOROS DUALES - ANTAGONISTAS MUSCARINICOS DE PDE4,"SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE LINK ES PIRROLILO, IMIDAZOLILO, INDAZOLILO, BENZOTIOFENILO, ENTRE OTROS; X1 ES O, NH, NCH3, NCH2CH3; R5a ES H, METILO, ETILO; Z ES CO, CONH, COO, ENTRE OTROS; Z1 ES CO, NHCO, OCO, SO, ENTRE OTROS; n ES 1-3; m ES 1-2; v ES 1-5; R1 ES ALQUILO C1-C3, CH2-FLUOROALQUILO C1-C2, -CH2CH2OH-; R2 ES H, ALQUILO C1-C4, CICLOPROPILO, CICLOBUTILO, ENTRE OTROS; R3 ES CICLOALQUILO C4-C7 SUSTITUIDO O NO, CICLOALQUENILO MONOINSATURADO C5-C7 SUSTITUIDO O NO, ENTRE OTROS; R4 Y R5 SON CADA UNO H, ALQUILO C1-C4 SUSTITUIDO O NO, CICLOALQUILO C3-C7, HETEROCICLICO OPCIONALMENTE SUSTITUIDO, ENTRE OTROS; R6 ES ANILLO C5-C7 OPCIONALMENTE SUSTITUIDO QUE CONTIENE 1-2 NITROGENOS O SU CORRESPONDIENTE ANILLO BICICLICO; Ar1 Y Ar2 SON CADA UNO FENILO SUSITUIDO O NO, HETEROARILO MONOCICLICO SUSTITUIDO O NO; X ES O, CO, SO2, ENTRE OTROS. UN COMPUESTO PREFERIDO ES: N-{[1,6-DIETIL-4-(TETRAHIDRO-2H-PIRAN-4-ILAMINO)-1H-PIRAZOLO[3,4-b]PIRIDIN-5-IL]METIL}-N'-[(6-FLUORO-3'-{[(3S)-3-METIL-1-PIPERAZINIL]METIL}-3-BIFENIL)METIL]-2,6-PIRIDINDICARBOXAMIDA. DICHOS COMPUESTOS SON INHIBIDORES DE PDE4 Y RECEPTORES MUSCARINICOS DE ACETILCOLINA (mAChRs) UTIL EN EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS, ALERGICAS",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/092-202-235-304-109,Patent Application,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/08;;A61P43/00;;C07D471/04;;C07D519/00,A01N43/56;;A01N43/90;;A61K31/519,,0,0,,,,DISCONTINUED
525,KR,A,KR 20100113155 A,107-964-164-525-476,2010-10-20,2010,KR 20107019677 A,2009-02-05,US 2656308 P,2008-02-06,DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS,,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/107-964-164-525-476,Patent Application,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/08;;A61P43/00;;C07D471/04;;C07D519/00,C07D471/04;;A61K31/437;;A61P11/00;;C07D405/14,,0,0,,,,DISCONTINUED
526,US,A,US 3932551 A,121-521-569-998-639,1976-01-13,1976,US 40594073 A,1973-10-12,US 40594073 A,1973-10-12,Process for the preparation of diolefins from olefins,"Catalysts containing molybdenum, bismuth, iron and nickel, cobalt, magnesium, zinc, cadmium, manganese, calcium or mixture thereof are promoted by chromium, tellurium, germanium, tungsten, manganese, thorium, niobium, praseodymin, cerium, lanthanum, zinc or mixture thereof to give highly desirable catalysts for the oxidative dehydrogenation of olefins of 4 to about 10 carbon atoms.",STANDARD OIL CO OHIO,GRASSELLI ROBERT K;;SURESH DEV D;;CALLAHAN JAMES L,,https://lens.org/121-521-569-998-639,Granted Patent,yes,5,29,10,10,0,B01J23/887;;B01J23/8871;;B01J23/8872;;B01J23/8873;;B01J23/8874;;B01J23/8875;;B01J23/8876;;B01J23/8877;;B01J23/8878;;C07C5/48;;B01J23/8873;;B01J23/8875;;B01J23/8878;;B01J23/887;;B01J23/8876;;B01J23/8877;;B01J23/8871;;B01J23/8874;;C07C5/48;;B01J23/8872,B01J23/00;;B01J23/88;;C07B61/00;;C07C1/00;;C07C5/48;;C07C11/12;;C07C67/00,260680E,0,0,,,,EXPIRED
527,EP,B2,EP 0107606 B2,122-678-283-520-543,1992-01-22,1992,EP 83630142 A,1983-09-09,US 42824182 A,1982-09-29,METHOD OF SHEET TRANSFER,,BELOIT CORP,"WICKS, LAURIE DAVID;;CRONIN, DENNIS CALLAHAN;;CHANCE, JAMES LARRY",,https://lens.org/122-678-283-520-543,Granted Patent,yes,4,0,23,23,0,D21F2/00;;D21F3/04;;D21F3/045;;D21F3/04;;D21F3/045;;D21F2/00;;D21F3/04,D21F1/00;;D21F2/00;;B65H20/06;;D21F3/02;;D21F3/04,,0,0,,,,EXPIRED
528,DE,C3,DE 1468716 C3,152-887-372-044-250,1973-10-31,1973,DE 1468716 A,1963-06-07,US 20132162 A;;US 25000863 A,1962-06-11,DE 1468716 C3,,"THE STANDARD OIL CO., CLEVELAND, OHIO (V.ST.A.)","CALLAHAN, JAMES LOUIS, BEDFORD, OHIO;;GERTISSER, BERTHOLD, MONTCLAIR, N.J.",,https://lens.org/152-887-372-044-250,Granted Patent,no,0,0,11,14,0,B01J23/8435;;B01J23/8435;;C07C45/34;;C07C45/34;;C07C45/35;;C07C45/35;;C07C51/252;;C07C51/252;;C07C253/26;;C07C253/26;;Y02P20/52;;Y02P20/52;;Y10S585/906;;Y10S585/906,B01J23/84;;B01J23/843;;C07C45/34;;C07C45/35;;C07C51/25,,0,0,,,,EXPIRED
529,AU,A,AU 1978/033017 A,190-637-491-886-174,1979-08-16,1979,AU 1978/033017 A,1978-02-06,US 80526477 A,1977-06-10,ESTERIFICATION OF ALIPHATIC CARBOXYLIC ACIDS WITH METHYL TERTIARY ALKYL ETHERS,,STANDARD OIL CO,GUTTMANN ANDREW TYTUS;;GRASSELLI ROBERT KARL;;CALLAHAN JAMES LOUIS,,https://lens.org/190-637-491-886-174,Patent Application,no,0,0,16,18,0,C07C1/20;;C07C7/14891;;C07C67/24,C07C67/24;;B01J23/00;;B01J27/00;;C07B61/00;;C07C1/20;;C07C7/148,,0,0,,,,EXPIRED
530,DD,A5,DD 137582 A5,188-970-308-890-827,1979-09-12,1979,DD 20707177 A,1977-07-29,US 71101476 A,1976-08-02,VERFAHREN ZUR HERSTELLUNG VON METHACRYLNITRIL AUS TERT.BUTYLGRUPPEN ENTHALTENDEN VERBINDUNGEN,,STANDARD OIL CO OHIO,HARDMAN HARLEY F;;GRASSELLI ROBERT K;;CALLAHAN JAMES L,,https://lens.org/188-970-308-890-827,Granted Patent,no,0,0,26,29,0,B01J23/8876;;B01J2523/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C51/235;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J23/8876;;C07C45/33;;C07C45/34;;C07C51/235;;C07C45/32;;C07C45/37;;C07C51/252;;C07C45/27;;B01J2523/00;;C07C253/24;;Y02P20/52,B01J23/00;;B01J23/88;;C07B61/00;;C07C57/05;;C07C1/00;;C07C5/48;;C07C11/00;;C07C45/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C47/22;;C07C51/00;;C07C51/235;;C07C51/25;;C07C67/00;;C07C253/00;;C07C255/08,,0,0,,,,EXPIRED
531,US,A,US 4042153 A,194-060-620-149-536,1977-08-16,1977,US 63253675 A,1975-11-17,US 63253675 A;;US 34117973 A,1973-03-14,Liquid dropping device,"Distinct droplets of a slurry are dispersed by a dropping device consisting of a resilient tube connected to a liquid reservoir so that the liquid flows through the tube, and two valves and a plunger which work in a six-movement cycle on the outer surface of the resilient tube to discharge uniform droplets of liquid at equal drop intervals.",STANDARD OIL CO,CALLAHAN JAMES L;;MILLER ARTHUR F;;SHAW WILFRID G,,https://lens.org/194-060-620-149-536,Granted Patent,yes,3,101,1,1,0,B01J2/02;;B01J2/02,B01J2/02,222/207,0,0,,,,EXPIRED
532,AU,A1,AU 2002/256085 A1,012-233-501-436-383,2002-10-21,2002,AU 2002/256085 A,2002-04-04,US 28222901 P;;US 0210657 W,2001-04-06,Quinoline inhibitors of hyak1 and hyak3 kinases,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;BURGESS JOELLE L;;BRYAN DEBORAH L,,https://lens.org/012-233-501-436-383,Patent Application,no,0,0,8,8,0,A61K31/47;;A61K31/47;;A61K31/4709;;A61K31/4709;;A61P7/00;;A61P7/06;;A61P13/12;;A61P15/16;;A61P19/00;;A61P25/28;;A61P31/00;;A61P31/10;;A61P31/12;;A61P31/18;;A61P33/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P39/00;;A61P43/00;;C07D401/12;;C07D401/12;;C07D215/54;;C07D215/54,A61K31/47;;A61K31/4709;;A61K31/5377;;A61P7/00;;A61P7/06;;A61P13/12;;A61P15/16;;A61P19/00;;A61P25/28;;A61P31/00;;A61P31/10;;A61P31/12;;A61P31/18;;A61P33/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P39/00;;A61P43/00;;C07D215/54;;C07D401/12,,0,0,,,,DISCONTINUED
533,DE,T2,DE 60131781 T2,012-780-358-136-312,2008-12-24,2008,DE 60131781 T,2001-07-16,US 21984200 P;;US 22063600 P;;US 0122267 W,2000-07-21,KALZILYTISCHE VERBINDUNGEN,,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP K;;CALLAHAN JAMES F;;LAGO AMPARO M,"SMITHKLINE BEECHAM CORP., PHILADELPHIA, PA., US (2008-11-06)",https://lens.org/012-780-358-136-312,Granted Patent,no,0,0,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,C07D213/77;;A61K31/44;;C07D213/78;;A61K31/4418;;A61K31/4436;;A61K45/06;;A61K47/10;;A61K47/24;;A61K47/28;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,EXPIRED
534,NO,B1,NO 325333 B1,054-904-712-887-561,2008-03-31,2008,NO 20030303 A,2003-01-20,US 21984200 P;;US 22063600 P;;US 0122267 W,2000-07-21,Kalsilytiske forbindelser og anvendelsen av slike for fremstilling av et preparat for behandling av ulike lidelser,,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP KUMAR;;CALLAHAN JAMES FRANCIS;;LAGO AMPARO M,,https://lens.org/054-904-712-887-561,Granted Patent,no,0,0,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,C07D213/77;;A61K31/4418;;A61K31/4436;;A61K45/06;;A61K47/10;;A61K47/24;;A61K47/28;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,EXPIRED
535,US,A1,US 2010/0093766 A1,066-997-409-882-03X,2010-04-15,2010,US 61893309 A,2009-11-16,US 61893309 A;;US 38911206 A;;US 66534705 P,2005-03-25,NOVEL COMPOUNDS,"Novel substituted 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-(1H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.",CALLAHAN JAMES F;;WAN ZEHONG;;YAN HONGXING;;LIN XICHEN,CALLAHAN JAMES F;;WAN ZEHONG;;YAN HONGXING;;LIN XICHEN,,https://lens.org/066-997-409-882-03X,Patent Application,yes,16,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P35/00;;C07D475/06,514/262.1;;544/258,0,0,,,,DISCONTINUED
536,EP,B1,EP 3335991 B1,093-298-327-540-008,2019-12-04,2019,EP 17196258 A,2017-10-12,US 201615383851 A,2016-12-19,SYSTEM FOR DISPLAYING THE STATUS OF USE OF AIRCRAFT OVERHEAD LUGGAGE STORAGE BINS,,BOEING CO,IBRAHIM YAKENTIM M;;CALLAHAN KEVIN S;;SCHALLA JAMES P,,https://lens.org/093-298-327-540-008,Granted Patent,yes,5,0,16,16,0,B64D11/00;;B64D11/003;;H04N23/63;;B64D47/08;;B61D37/003;;B64D45/00;;B64D2045/007;;B64D47/08;;B64D11/003;;H04N23/63;;B64D11/00;;B64D47/08;;H04N7/18;;H04N23/60;;H04N23/90;;B64D47/08;;B64D11/003;;H04N7/181;;H04N9/31;;B64D45/00;;B61D37/003;;B64D2045/007;;G06V20/52;;H04N23/63;;H04N23/90,B64D11/00;;B60R5/00;;B60R7/04;;B61D37/00;;B64D45/00;;B64D47/08,,0,0,,,,ACTIVE
537,WO,A3,WO 2002/081728 A3,093-304-377-920-138,2002-11-21,2002,US 0210657 W,2002-04-04,US 28222901 P,2001-04-06,QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES,"This invention relates to novel quinoline inhibitors of hYAK1 and hYAK3 kinases and pharmaceutically acceptable salts, hydrates or solvates thereof, pharmaceutical compositions thereof, and methods of treatment of diseases in which an excessive amount of either such kinase is a factor.",SMITHKLINE BEECHAM CORP;;BRYAN DEBORAH L;;BURGESS JOELLE L;;CALLAHAN JAMES F,BRYAN DEBORAH L;;BURGESS JOELLE L;;CALLAHAN JAMES F,,https://lens.org/093-304-377-920-138,Search Report,yes,0,0,8,8,0,A61K31/47;;A61K31/47;;A61K31/4709;;A61K31/4709;;A61P7/00;;A61P7/06;;A61P13/12;;A61P15/16;;A61P19/00;;A61P25/28;;A61P31/00;;A61P31/10;;A61P31/12;;A61P31/18;;A61P33/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P39/00;;A61P43/00;;C07D401/12;;C07D401/12;;C07D215/54;;C07D215/54,A61K31/47;;A61K31/4709;;A61K31/5377;;A61P7/00;;A61P7/06;;A61P13/12;;A61P15/16;;A61P19/00;;A61P25/28;;A61P31/00;;A61P31/10;;A61P31/12;;A61P31/18;;A61P33/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P39/00;;A61P43/00;;C07D215/54;;C07D401/12,,6,0,,,"DATABASE USPATFULL [online] US PATENT AND TRADEMARK OFFICE (ARLINGTON, VA, USA); PETRIE C. ET AL.: ""Compositions and methods for treating bone deficit conditions"", XP002958121, accession no. STN Database accession no. 2002:19332;;DATABASE USPATFULL [online] US PATENT AND TRADEMARK OFFICE (ARLINGTON, VA, USA); RICHTER L.S. ET AL.: ""Modulators of protein tyrosine phosphatases (PTPases)"", XP002958120, accession no. STN Database accession no. 2001:63700;;DATABASE USPATFULL [online] US PATENT AND TRADEMARK OFFICE (ARLINGTON, VA, USA); DOW R.L. ET AL.: ""5,10-Dihydropyrimido(4,5-b)quinolin-4(1H)-one tyrosine kinase inhibitors"", XP002958119, accession no. STN Database accession no. 1999:63403;;DATABASE CA [online] (COLUMBUS, OHIO, USA); DOW R.L.: ""Preparation of 5,120-dihydropyrimido(4,5-b)quinolin-4(1H)-ones as tyrosine kinase"", XP002958118, accession no. STN Database accession no. 125:300981;;DATABASE USPATFULL [online] CHEM. ABSTRACTS (COLUMBUS, OHIO, USA); BURROWS K.D. ET AL.: ""Quinoline derivatives having anti-tumor activity"", XP002958117, accession no. STN Database accession no. 92:38392;;See also references of EP 1372654A4",PENDING
538,KR,A,KR 20100125295 A,105-524-324-538-873,2010-11-30,2010,KR 20107019775 A,2009-02-05,US 2656808 P,2008-02-06,DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS,,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/105-524-324-538-873,Patent Application,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P1/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P17/04;;A61P17/06;;A61P27/02;;A61P37/08;;C07D471/04;;C07D519/00,C07D471/04;;A61K31/437;;A61P11/06;;C07D405/12,,0,0,,,,DISCONTINUED
539,BR,A,BR 8305473 A,128-781-876-610-070,1984-05-15,1984,BR 8305473 A,1983-09-20,US 42824182 A,1982-09-29,METODO E MECANISMO PARA A TRANSFERENCIA POSITIVA DE UMA FAIXA CONTINUA DE PAPEL EM UMA SECAO DE PRENSAGEM DE UMA MAQUINA FABRICADORA DE PAPEL,,BELOIT CORP,WICKS LAURIE DAVID;;CRONIN DENNIS CALLAHAN;;CHANCE JAMES LARRY,,https://lens.org/128-781-876-610-070,Patent Application,no,0,0,23,23,0,D21F2/00;;D21F3/04;;D21F3/045;;D21F3/04;;D21F3/045;;D21F2/00;;D21F3/04,B65H20/06;;D21F1/00;;D21F2/00;;D21F3/02;;D21F3/04,,0,0,,,,DISCONTINUED
540,US,A,US 4543349 A,160-517-892-765-969,1985-09-24,1985,US 64512784 A,1984-08-28,US 64512784 A;;US 53500083 A,1983-09-22,Basic heptapeptide vasopressin antagonists,"Certain cyclic vasopressin-like peptides, which have an .omega.-amino- or guanidinoalkyl substituent attached to the cysteine in the 6-position of the ring, have vasopressin antagonist activity. A species of this series of new compounds is [1-(.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid)-2-(O-ethyl-D-tyrosine)-4-valine-8-(1,5-diaminopentane)-8-desarginine -9-desglycinamide]-vasopressin.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES F;;MOORE MICHAEL L;;YIM NELSON C,SMITHKLINE BECKMAN CORPORATION A CORP. OF PA (1984-08-20),https://lens.org/160-517-892-765-969,Granted Patent,yes,0,11,1,31,0,A61K38/00;;C07K7/06;;C07K7/16;;Y10S930/15;;C07K7/06;;C07K7/16;;A61K38/00;;Y10S930/15,A61K38/00;;C07K7/06;;C07K7/16,514/11;;514/807;;X2601125 R,1,1,027-224-402-419-545,10.1038/308652a0;;6709073,"M. Manning, et al., Nature, 308 652 & 653 (1984).",EXPIRED
541,FI,B,FI 80094 B,173-373-321-415-916,1989-12-29,1989,FI 833132 A,1983-09-02,US 42824182 A,1982-09-29,BANOEVERFOERINGSFOERFARANDE.,,BELOIT CORP,WICKS LAURIE DAVID;;CRONIN DENNIS CALLAHAN;;CHANCE JAMES LARRY,"BELOIT TECHNOLOGIES, INC. (1998-10-12)",https://lens.org/173-373-321-415-916,Patent Application,no,0,0,23,23,0,D21F2/00;;D21F3/04;;D21F3/045;;D21F3/04;;D21F3/045;;D21F2/00;;D21F3/04,D21F1/00;;B65H20/06;;D21F2/00;;D21F3/02;;D21F3/04,,0,0,,,,EXPIRED
542,PL,A1,PL 365703 A1,196-094-519-395-642,2005-01-10,2005,PL 36570301 A,2001-07-16,US 21984200 P;;US 22063600 P,2000-07-21,CALCILYTIC COMPOUNDS,,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP K;;CALLAHAN JAMES F;;LAGO AMPARO M,,https://lens.org/196-094-519-395-642,Patent Application,no,0,0,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,A61K31/4418;;A61K31/4436;;A61K45/06;;A61K47/10;;C07D213/77;;A61K47/24;;A61K47/28;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,DISCONTINUED
543,CL,A1,CL 2009000249 A1,009-012-251-946-251,2009-09-11,2009,CL 2009000249 A,2009-02-04,US 2656808 P,2008-02-06,"Compuestos derivados de pirazolo[3,4-b] piridin-butanodiamida; composicion farmaceutica; y su uso en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, rinitis, dermatitis atopica, psoriasis.","Compuestos derivados de pirazolo[3,4-b] piridin-butanodiamida; composición farmacéutica; y su uso en el tratamiento del asma, enfermedad pulmonar obstructiva crónica, rinitis, dermatitis atópica, psoriasis.",GLAXO GROUP LTD,WAN ZEHONG;;YAN HONGXING;;CALLAHAN JAMES FRANCIS;;LIN GOULIANG,,https://lens.org/009-012-251-946-251,Patent Application,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P1/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P17/04;;A61P17/06;;A61P27/02;;A61P37/08;;C07D471/04;;C07D519/00,A61K31/496;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/06;;C07D213/00;;C07D231/00;;C07D471/04,,0,0,,,,PENDING
544,EP,A3,EP 0107606 A3,003-441-302-970-831,1985-04-17,1985,EP 83630142 A,1983-09-09,US 42824182 A,1982-09-29,METHOD OF SHEET TRANSFER,"It includes an intermediate press nip (N-i) formed between first and second press members (21, 22) with a porous felt (20) on one surface of the web (W) and a nonpervious looped smooth surface belt (15) of nonextensible material impervious to water passing through the nip in direct contact with the other surface of the web so that the web follows the belt (15) downstream of the nip (N-I) with the web first being pressed between an earlier press (N) upstream of the intermediate press (N-I), and the web being removed from the belt (15) following the intermediate press (N-I) with rewetting of the web (W) on the offrunning side of the intermediate nip due to contact with the impervious belt (15) being eliminated.",BELOIT CORP,"WICKS, LAURIE DAVID;;CRONIN, DENNIS CALLAHAN;;CHANCE, JAMES LARRY",,https://lens.org/003-441-302-970-831,Search Report,yes,0,0,23,23,0,D21F2/00;;D21F3/04;;D21F3/045;;D21F3/04;;D21F3/045;;D21F2/00;;D21F3/04,D21F1/00;;D21F2/00;;B65H20/06;;D21F3/02;;D21F3/04,,0,0,,,,EXPIRED
545,WO,A1,WO 2009/100168 A1,024-045-756-805-192,2009-08-13,2009,US 2009/0033130 W,2009-02-05,US 2657208 P,2008-02-06,DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS,"The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/ and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.",GLAXO GROUP LTD;;CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/024-045-756-805-192,Patent Application,yes,2,1,20,20,0,C07D471/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/00;;A61P37/08;;A61P43/00;;C07D471/04,A01N43/42,,1,0,,,See also references of EP 2249647A4,PENDING
546,DO,A,DO P2010000238 A,041-804-653-348-911,2011-03-31,2011,DO 2010000238 A,2010-08-03,US 2657208 P,2008-02-06,FARMACOFOROS DUALES-ANTAGONISTAS MUSCARINICOS DE PDE4,"La presente invencion se refiere a nuevos compuestos de formula (I), a composiciones farmaceuticas y a su uso en terapia, por ejemplo como inhibidores de fosfodiesterasa tipo IV (PDE4) y como antagonistas de receptores muscarinicos de acetilcolina (mAChRs), en el tratamiento y/o profilaxis de enfermedades respiratorias, incluyendo enfermedades inflamatorias y/o alergicas tales como enfermedad pulmonar obstructiva cronica (COPD), asmas, rinitis (por ejemplo, rinitis alergica), dermatitis atopica o psoriasis.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/041-804-653-348-911,Patent Application,no,0,0,20,20,0,C07D471/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/00;;A61P37/08;;A61P43/00;;C07D471/04,,,0,0,,,,PENDING
547,AT,B,AT 353763 B,055-639-712-412-218,1979-12-10,1979,AT 112378 A,1978-02-16,US 80526477 A,1977-06-10,VERFAHREN ZUR GLEICHZEITIGEN HERSTELLUNG VON EINEM CARBONSAEUREMETHYLESTER UND EINEM ALKYLEN,,STANDARD OIL CO OHIO,GUTTMANN ANDREW TYTUS;;CALLAHAN JAMES LOUIS;;GRASSELLI ROBERT KARL,,https://lens.org/055-639-712-412-218,Granted Patent,no,0,0,16,18,0,C07C1/20;;C07C7/14891;;C07C67/24,C07C67/24;;B01J23/00;;B01J27/00;;C07B61/00;;C07C1/20;;C07C7/148,"12E1,008",0,0,,,,EXPIRED
548,HU,A,HU T36142 A,049-882-334-081-02X,1985-08-28,1985,HU 358484 A,1984-09-21,US 53500083 A,1983-09-22,PROCESS FOR PREPARING BASIC PEPTIDES WITH VASOPRESSINE ANTAGONIST ACTIVITY,"Compounds of the formula (I) <CHEM> in which: A is -NR-(CH2)n,-NH2 or -NR-(CH2)n-NH-@@NR2; Z is Phe, Phe(4 min -Alk) or Tyr(Alk); X is D-Phe, D-Phe(4 min Alk), D-Val, D-Nva, D-Leu, D-Ile, D-Pba, D-Nle, D-Cha, D-Abu, D-Met, D-Chg, D-Tyr, L-Tyr, D-Tyr(Alk) or L-Tyr(Alk); P is D-Pro, L-Pro, DELTA <3>-Pro, L-Ala, L-N-MeAla, L-Gly, L-Sar or a single bond; Y is Val, Ile, Abu, Ala, Chg, Gln, Lys, Cha, Nle, Phe, Leu or Gly; R is, in each case, hydrogen or C1-5-alkyl; n is an integer from 2-8; m is an integer from 0-2; and Alk is C1-4-alkyl; and pharmaceutically acceptable acid addition salts thereof are vasopressin antagonists. Their preparation and pharmaceutical use are described.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES F;;MOORE MICHEL L;;YIM NELSON-FAI,,https://lens.org/049-882-334-081-02X,Unknown,no,0,0,30,31,0,A61K38/00;;C07K7/16;;A61P5/00;;A61P7/10;;C07K7/06,A61K38/00;;A61K38/095;;A61P5/00;;A61P7/10;;C07K1/00;;C07K1/113;;C07K7/16;;C07K7/50;;C07K14/575,,0,0,,,,EXPIRED
549,PT,B,PT 66875 B,075-805-548-487-686,1979-01-23,1979,PT 6687577 A,1977-08-01,US 71101476 A,1976-08-02,PREPARATION OF METHACRYLIC DERIVATIVES FROM TERTIARY BUTYL-CONTAINING COMPOUND,,STANDARD OIL CO OHIO,HARDMAN HARLEY FOCH;;GRASSELLI ROBERT KARL;;CALLAHAN JAMES LOUIS,,https://lens.org/075-805-548-487-686,Granted Patent,no,0,0,26,29,0,B01J23/8876;;B01J2523/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C51/235;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J23/8876;;C07C45/33;;C07C45/34;;C07C51/235;;C07C45/32;;C07C45/37;;C07C51/252;;C07C45/27;;B01J2523/00;;C07C253/24;;Y02P20/52,C07C57/05;;B01J23/00;;B01J23/88;;C07B61/00;;C07C1/00;;C07C5/48;;C07C11/00;;C07C45/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C47/22;;C07C51/00;;C07C51/235;;C07C51/25;;C07C67/00;;C07C253/00;;C07C255/08,,0,0,,,,EXPIRED
550,AU,A,AU 2001/076923 A,069-890-879-816-968,2002-02-05,2002,AU 2001/076923 A,2001-07-16,US 21984200 P;;US 22063600 P;;US 0122267 W,2000-07-21,Calcilytic compounds,,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP K;;CALLAHAN JAMES F;;LAGO AMPARO M,,https://lens.org/069-890-879-816-968,Patent Application,no,0,0,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,C07D213/77;;A61K31/4418;;A61K31/4436;;A61K45/06;;A61K47/10;;A61K47/24;;A61K47/28;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,PENDING
551,DE,D1,DE 3170895 D1,076-601-573-628-075,1985-07-11,1985,DE 3170895 T,1981-12-08,US 22185980 A,1980-12-31,MIXED METAL PHOSPHORUS OXIDE CATALYSTS FOR THE OXIDATIVE DEHYDROGENATION OF CARBOXYLIC ACIDS UTILIZING THEM AND PREPARATION THEREOF,,STANDARD OIL CO OHIO,PEDERSEN SVEND ERIK;;CALLAHAN JAMES LOUIS;;HARDMAN HARLEY FOCH,,https://lens.org/076-601-573-628-075,Granted Patent,no,0,0,9,11,0,B01J27/18;;B01J27/186;;B01J23/89;;B01J23/8933;;B01J27/1853;;C07C51/377;;C07C51/377,C07C57/04;;B01J23/89;;B01J27/00;;B01J27/18;;B01J27/185;;B01J27/186;;C07B61/00;;C07C51/00;;C07C51/377;;C07C67/00;;C07C253/00;;C07C255/23,,0,0,,,,EXPIRED
552,WO,A1,WO 2009/100169 A1,078-567-823-922-282,2009-08-13,2009,US 2009/0033132 W,2009-02-05,US 2657408 P,2008-02-06,DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS,"The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.",GLAXO GROUP LTD;;CALLAHAN JAMES FRANCIS;;LI TINDY;;WAN ZEHONG;;YAN HONGXING,CALLAHAN JAMES FRANCIS;;LI TINDY;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/078-567-823-922-282,Patent Application,yes,4,16,3,3,0,C07D471/04;;A61P11/08;;A61P37/06,A01N43/42,,0,0,,,,PENDING
553,CA,A,CA 1007422 A,121-664-803-037-157,1977-03-29,1977,CA 173596 A,1973-06-08,US 27138772 A,1972-07-13,PROCESS FOR PREPARING AGGREGATES,,STANDARD OIL CO OHIO,CALLAHAN JAMES L;;MILLER ARTHUR F;;SHAW WILFRID G,,https://lens.org/121-664-803-037-157,Granted Patent,no,0,0,9,15,0,B01J2/02;;B01J2/02;;B01J37/0072;;B01J37/0072,B01J2/02;;B01J37/00,23-374,0,0,,,,EXPIRED
554,CN,A,CN 108202867 A,119-966-770-477-00X,2018-06-26,2018,CN 201711094864 A,2017-11-09,US 201615383851 A,2016-12-19,SYSTEM FOR DISPLAYING THE STATUS OF USE OF AIRCRAFT OVERHEAD LUGGAGE STORAGE BINS,A system for displaying the status of use of aircraft overhead luggage storage bins is disclosed. A system and method are disclosed for displaying the storage status of overhead luggage storage bins in an aircraft. A camera is provided that is mounted with a field of view directed at an inner portion of a group of open bins. The camera is communicatively coupled to a controller and selectively provides images of the inner portion of the bins immediately prior to when the bins are closed to the controller. A projector is also provided for each group of bins. The projector is communicatively coupled to the controller and is mounted such that an image received from the controller is projected onto an outer surface of the closed bins. The controller receives images from each of the cameras andselectively provides such images to the projector associated with each camera so that a storage status display is projected on an outer surface of the bins.,BOEING CO,KEVIN S CALLAHAN;;JAMES P SCHALLA;;YAKENTIM M IBRAHIM,,https://lens.org/119-966-770-477-00X,Patent Application,no,18,4,16,16,0,B64D11/00;;B64D11/003;;H04N23/63;;B64D47/08;;B61D37/003;;B64D45/00;;B64D2045/007;;B64D47/08;;B64D11/003;;H04N23/63;;B64D11/00;;B64D47/08;;H04N7/18;;H04N23/60;;H04N23/90;;B64D47/08;;B64D11/003;;H04N7/181;;H04N9/31;;B64D45/00;;B61D37/003;;B64D2045/007;;G06V20/52;;H04N23/63;;H04N23/90,B64D11/00,,0,0,,,,ACTIVE
555,EP,A4,EP 1349851 A4,144-442-300-384-57X,2004-09-08,2004,EP 01995214 A,2001-11-14,US 0143994 W;;US 24919900 P,2000-11-16,COMPOUNDS,,SMITHKLINE BEECHAM CORP,BENDER PAUL E;;BURGESS JOELLE L;;CALLAHAN JAMES F,,https://lens.org/144-442-300-384-57X,Search Report,no,2,0,6,6,0,C07D401/04;;C07D401/14;;C07D405/14;;A61P1/04;;A61P1/16;;A61P11/00;;A61P13/12;;A61P17/02;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P27/02;;A61P43/00;;A61P9/04;;A61P9/10;;C07D401/04;;C07D405/14;;C07D401/14,A61K31/4439;;A61K31/4709;;A61P1/04;;A61P1/16;;A61P9/04;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/02;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P27/02;;A61P43/00;;C07D401/04;;C07D401/14;;C07D405/14,,1,0,,,See also references of WO 0240468A1,DISCONTINUED
556,CH,A5,CH 635315 A5,157-329-479-075-466,1983-03-31,1983,CH 103082 A,1982-02-18,US 71101476 A,1976-08-02,VERFAHREN ZUR HERSTELLUNG VON METHACRYLNITRIL.,,STANDARD OIL CO,HARDMAN HARLEY FOCH;;GRASSELLI ROBERT KARL;;CALLAHAN JAMES LOUIS,,https://lens.org/157-329-479-075-466,Granted Patent,no,0,0,26,29,0,B01J23/8876;;B01J2523/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C51/235;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J23/8876;;C07C45/33;;C07C45/34;;C07C51/235;;C07C45/32;;C07C45/37;;C07C51/252;;C07C45/27;;B01J2523/00;;C07C253/24;;Y02P20/52,B01J23/00;;C07C57/05;;B01J23/88;;C07B61/00;;C07C1/00;;C07C5/48;;C07C11/00;;C07C45/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C47/22;;C07C51/00;;C07C51/235;;C07C51/25;;C07C67/00;;C07C253/00;;C07C255/08,,0,0,,,,EXPIRED
557,DE,T2,DE 3587065 T2,152-548-527-135-215,1993-05-19,1993,DE 3587065 T,1985-10-28,US 67228684 A,1984-11-16,SYNTHESE VON METALLSILIKATEN VOM MOLEKULARSIEBTYP UNTER VERWENDUNG VON KIESELSAEURE-UEBERGANGSMETALLOXIDSOLEN.,,STANDARD OIL CO OHIO,PEPERA MARC ANTHONY;;CALLAHAN JAMES LOUIS;;DESMOND MICHAEL JOSEPH,,https://lens.org/152-548-527-135-215,Granted Patent,no,0,0,10,10,0,B01J29/04;;B01J29/04;;C01B33/2884;;C01B33/2884;;C01B33/2876;;C01B33/2876,C01B33/20;;B01J29/00;;B01J29/04;;C01B39/06;;C07B61/00;;C07C1/20;;C07C5/27;;C07C15/073;;C07C15/08,,0,0,,,,EXPIRED
558,EP,A2,EP 2111476 A2,147-064-676-640-520,2009-10-28,2009,EP 08729978 A,2008-02-15,US 2008/0054092 W;;US 90196307 P;;US 2765108 A;;US 2767208 A,2007-02-16,THERMAL SPRAY COATINGS AND APPLICATIONS THEREFOR,,PRAXAIR TECHNOLOGY INC,APTE PRASAD SHRIKRISMNA;;MEAGHER JAMES PATRICK;;CALLAHAN SHAWN W,,https://lens.org/147-064-676-640-520,Patent Application,yes,0,0,9,9,0,C23C4/02;;C23C28/3215;;C23C28/34;;C23C28/341;;C23C28/345;;C23C28/3455;;C23C28/36;;C23C28/321;;C23C4/073;;C22C19/05;;C22C19/058;;Y10T428/256;;Y10T428/24355;;Y10T428/24612;;Y10T428/12618;;Y10T428/12931;;Y10T428/24413;;Y10T428/249969;;Y10T428/256;;Y10T428/24355;;Y10T428/24612;;Y10T428/12618;;Y10T428/12931;;Y10T428/24413;;Y10T428/249969;;C23C4/02;;C23C28/34;;C23C28/3455;;C23C28/341;;C23C28/345;;C23C28/36;;C23C28/3215;;C23C28/321;;C22C19/058;;C22C19/05;;C23C4/073,C23C4/08;;C22C19/00;;C23C28/00,,0,0,,,,DISCONTINUED
559,DE,A1,DE 2332880 A1,172-610-740-081-826,1974-01-31,1974,DE 2332880 A,1973-06-28,US 27138772 A,1972-07-13,VERFAHREN ZUR HERSTELLUNG VON AGGREGATEN,,STANDARD OIL CO OHIO,CALLAHAN JAMES LOUIS;;MILLER ARTHUR FRANCIS;;SHAW WILFRID GARSIDE,,https://lens.org/172-610-740-081-826,Patent Application,no,0,0,9,15,0,B01J2/02;;B01J2/02;;B01J37/0072;;B01J37/0072,B01J2/02;;B01J37/00,,0,0,,,,DISCONTINUED
560,WO,A1,WO 2002/040468 A1,180-829-615-119-705,2002-05-23,2002,US 0143994 W,2001-11-14,US 24919900 P,2000-11-16,COMPOUNDS,"2-Pyridyl substituted diarylimidazoles of formula (I) (I)wherein R1 is phenyl or naphthyl optionally substituted with one or more substituents selected from halo, C1-6alkoxy, C1-6alkylthio, C1-6alkyl, C1-6haloalkyl, -O-(CH2)m-Ph, -S-(CH2)m-Ph, cyano, phenyl, and CO2R, wherein R is hydrogen or C1-6alkyl and m is 0-3; or phenyl fused with a 5- to 7-membered aromatic or non-aromatic ring wherein said ring contains up to three heteroatoms, independently selected from N, O and S; R2, R3, R4 and R5 independently represent hydrogen, C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, halo, NH2, NH-C1-6alkyl or NH(CH2)n-Ph wherein n is 0-3; or an adjacent pair of R2, R3, R4 and R5 form a fused 6-membered aromatic ring optionally containing up to 2 nitrogen atoms, said ring being optionally substituted by one or more substituents independently selected from C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, halo, NH2, NH-C1-6alkyl or NH(CH2)n-Ph wherein n is 0-3, and the remainder of R2, R3, R4 and R5 represent hydrogen, C1-6alkyl, C1-6alkoxy, C1-6haloalkyl, halo, NH2, NH-C1-6alkyl or NH(CH2)n-Ph wherein n is 0-3; and one of X1 and X2 is N and the other is NR6, wherein R6 is hydrogen or C1-6alkyland salts and solvates thereof, are disclosed, as are methods for their preparation, pharmaceutical compositions containing them and their use in medicine.",SMITHKLINE BEECHAM CORP;;BENDER PAUL E;;BURGESS JOELLE L;;CALLAHAN JAMES F,BENDER PAUL E;;BURGESS JOELLE L;;CALLAHAN JAMES F,,https://lens.org/180-829-615-119-705,Patent Application,yes,2,31,6,6,0,A61P1/04;;A61P1/16;;A61P9/04;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/02;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P27/02;;A61P43/00;;C07D401/04;;C07D401/04;;C07D401/14;;C07D401/14;;C07D405/14;;C07D405/14,A61K31/4439;;A61K31/4709;;A61P1/04;;A61P1/16;;A61P9/04;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/02;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P27/02;;A61P43/00;;C07D401/04;;C07D401/14;;C07D405/14,,2,0,,,"DATABASE CAPLUS [online] BURGESS ET AL.: ""Preparation of triarylimidazoles as activin-like kinase (ALK)-5 receptor modulators"", XP002908489, retrieved from 133:309891 accession no. STN Database accession no. 2000:742089;;See also references of EP 1349851A4",PENDING
561,US,B2,US 7879457 B2,191-148-228-075-058,2011-02-01,2011,US 2765108 A,2008-02-07,US 2765108 A;;US 90196307 P,2007-02-16,Thermal spray coatings and applications therefor,"This invention relates to coatings for a metal or non-metal substrate comprising (i) a thermal sprayed bondcoat layer applied to the substrate, and (ii) a thermal sprayed ceramic layer applied to the bondcoat layer; wherein said coating has a helium leak rate of less than 6×10 −6 standard cubic centimeters per second. The thermal sprayed bondcoat layer comprises an alloy of MCrAlM′ wherein M is an element selected from nickel, cobalt, iron and mixtures thereof, and M′ is an element selected from yttrium, zirconium, hafnium, ytterbium and mixtures thereof. The alloy is thermally sprayed from a powder having a mean particle size of 50 percentile point in distribution of from about 5 microns to about 100 microns. The coatings are useful for extending the service life under severe conditions, such as those associated with metallurgical vessels' lances, nozzles and tuyeres.",PRAXAIR TECHNOLOGY INC,APTE PRASAD SHRIKRISHNA;;MEAGHER JAMES PATRICK;;CALLAHAN SHAWN W,PRAXAIR S. T. TECHNOLOGY INC (2008-02-14),https://lens.org/191-148-228-075-058,Granted Patent,yes,15,0,9,9,0,C23C4/02;;C23C28/3215;;C23C28/34;;C23C28/341;;C23C28/345;;C23C28/3455;;C23C28/36;;C23C28/321;;C23C4/073;;C22C19/05;;C22C19/058;;Y10T428/256;;Y10T428/24355;;Y10T428/24612;;Y10T428/12618;;Y10T428/12931;;Y10T428/24413;;Y10T428/249969;;Y10T428/256;;Y10T428/24355;;Y10T428/24612;;Y10T428/12618;;Y10T428/12931;;Y10T428/24413;;Y10T428/249969;;C23C4/02;;C23C28/34;;C23C28/3455;;C23C28/341;;C23C28/345;;C23C28/36;;C23C28/3215;;C23C28/321;;C22C19/058;;C22C19/05;;C23C4/073,B32B15/04,428/633;;428/678;;X416241 R,2,1,031-501-410-876-970,10.31399/asm.hb.v05.a0001282,"Tucker, Robert C. Jr. ""Thermal Spray Coatings"". ASM Handbook, vol. 5, Surface Engineering (1994) pp. 497-509.;;Superalloys II, eds. Sims, Stoloff and Hagel, John Wiley (1987), p. 387-458 (alloy making), p. 459-494 (powder making).",ACTIVE
562,AT,A,AT A112378 A,013-053-657-468-38X,1979-05-15,1979,AT 112378 A,1978-02-16,US 80526477 A,1977-06-10,VERFAHREN ZUR GLEICHZEITIGEN HERSTELLUNG VON EINEM CARBONSAEUREMETHYLESTER UND EINEM ALKYLEN,,STANDARD OIL CO OHIO,GUTTMANN ANDREW TYTUS;;CALLAHAN JAMES LOUIS;;GRASSELLI ROBERT KARL,,https://lens.org/013-053-657-468-38X,Patent Application,no,0,0,16,18,0,C07C1/20;;C07C7/14891;;C07C67/24,C07C67/24;;B01J23/00;;B01J27/00;;C07B61/00;;C07C1/20;;C07C7/148,"12E1,008",0,0,,,,EXPIRED
563,CN,A,CN 1582275 A,012-511-089-435-510,2005-02-16,2005,CN 01813116 A,2001-07-16,US 21984200 P;;US 22063600 P,2000-07-21,Calcium antagonistic compound,,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP K;;CALLAHAN JAMES F;;LAGO AMPARO M,,https://lens.org/012-511-089-435-510,Patent Application,no,0,0,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,C07D213/77;;A61K31/4418;;A61K31/4436;;A61K45/06;;A61K47/10;;A61K47/24;;A61K47/28;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,DISCONTINUED
564,US,A,US 3500958 A,021-730-791-981-585,1970-03-17,1970,US 3500958D A,1967-11-16,US 68371267 A,1967-11-16,FLOW RESPONSIVE VALVE FOR LUBRICATING SYSTEMS,,MCCORD CORP,CALLAHAN JAMES J;;URSO RALPH F;;SNOW JOHN P,,https://lens.org/021-730-791-981-585,Granted Patent,no,8,8,1,1,0,F16N29/04;;Y10T137/2703;;Y10T137/2703;;F16N29/04,F16N29/04,184/6,0,0,,,,EXPIRED
565,EP,A2,EP 0107606 A2,016-764-872-091-351,1984-05-02,1984,EP 83630142 A,1983-09-09,US 42824182 A,1982-09-29,Method of sheet transfer.,"It includes an intermediate press nip (N-i) formed between first and second press members (21, 22) with a porous felt (20) on one surface of the web (W) and a nonpervious looped smooth surface belt (15) of nonextensible material impervious to water passing through the nip in direct contact with the other surface of the web so that the web follows the belt (15) downstream of the nip (N-I) with the web first being pressed between an earlier press (N) upstream of the intermediate press (N-I), and the web being removed from the belt (15) following the intermediate press (N-I) with rewetting of the web (W) on the offrunning side of the intermediate nip due to contact with the impervious belt (15) being eliminated.",BELOIT CORP,WICKS LAURIE DAVID;;CRONIN DENNIS CALLAHAN;;CHANCE JAMES LARRY,,https://lens.org/016-764-872-091-351,Patent Application,yes,0,24,23,23,0,D21F2/00;;D21F3/04;;D21F3/045;;D21F3/04;;D21F3/045;;D21F2/00;;D21F3/04,D21F1/00;;D21F2/00;;B65H20/06;;D21F3/02;;D21F3/04,,0,0,,,,EXPIRED
566,EP,A3,EP 0183391 A3,025-183-659-250-828,1988-06-15,1988,EP 85307762 A,1985-10-28,US 67228684 A,1984-11-16,SYNTHESIS OF MOLECULAR SIEVING METALLOSILICATES USING SILICA-TRANSITION METAL OXIDE SOLS,"A method for preparing a molecular sieving metallosilicate which comprises:
 (A) providing an aqueous dispersion of colloidal particles comprising contiguous mixtures of silica and the oxide of a transition metal selected from the group consisting of Sc, Ti, V, Cr, Mn, Fe, Co. Ni, Zn, Zr, Y or a mixture of two or more of said metals; (B) mixing an effective amount of a mineralizing agent and/or synthesis directing agent with said dispersion to form a gel; and (C) maintaining said gel at a temperature of 80°C to 300°C for an effective period of time to provide said metallosilicate.",THE STANDARD OIL COMPANY,"PEPERA, MARC ANTHONY;;CALLAHAN, JAMES LOUIS;;DESMOND, MICHAEL JOSEPH",,https://lens.org/025-183-659-250-828,Search Report,yes,8,0,10,10,0,B01J29/04;;B01J29/04;;C01B33/2884;;C01B33/2884;;C01B33/2876;;C01B33/2876,C01B33/20;;B01J29/00;;B01J29/04;;C01B39/06;;C07B61/00;;C07C1/20;;C07C5/27;;C07C15/073;;C07C15/08,,0,0,,,,EXPIRED
567,DE,A1,DE 2329252 A1,040-435-738-338-379,1974-01-24,1974,DE 2329252 A,1973-06-08,US 26516372 A,1972-06-22,VERFAHREN ZUM ABTRENNEN VON AMMONIAK UND ORGANISCHEN VERUNREINIGUNGEN AUS REAKTIONSGASEN,,STANDARD OIL CO OHIO,ADAMS HARRY ARCHIBALD;;KUNCHAL SUBODH KUMAR;;CALLAHAN JAMES LOUIS,,https://lens.org/040-435-738-338-379,Patent Application,no,0,0,9,9,0,B01D53/34;;B01D53/8634;;C01C1/12;;Y02P20/52;;B01D53/8634;;B01D53/34;;C01C1/12;;Y02P20/52,B01D53/34;;B01D53/58;;B01D53/62;;B01D53/86;;B01J23/02;;B01J23/06;;B01J23/14;;B01J23/18;;B01J23/24;;B01J23/34;;B01J23/38;;B01J23/70;;B01J23/72;;C01C1/12,,0,0,,,,DISCONTINUED
568,EP,A4,EP 2249647 A4,032-923-314-580-48X,2012-07-18,2012,EP 09708556 A,2009-02-05,US 2009/0033130 W;;US 2657208 P,2008-02-06,DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS,,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,GLAXO GROUP LIMITED (2013-05-01),https://lens.org/032-923-314-580-48X,Search Report,no,3,0,20,20,0,C07D471/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/00;;A61P37/08;;A61P43/00;;C07D471/04,A01N43/42;;C07D471/04;;C07D519/00,,1,0,,,See also references of WO 2009100168A1,DISCONTINUED
569,US,A,US 4634502 A,068-532-274-862-949,1987-01-06,1987,US 76955785 A,1985-08-26,US 76955785 A;;US 66784384 A,1984-11-02,Process for the reductive deposition of polyoxometallates,"A process for the reductive deposition of polyoxometallate complexes on supports. The process includes the steps of forming a solution of at least one polyoxometallate compound in a solvent, said compound having the formula A.sub.a (L.sub.l M.sub.m J.sub.z O.sub.y), adding a quantity of a support material having electronic conductivity to the solution, charging the solution containing the support material to an electrolytic cell in contact with the cathode thereof, the cell having a separate compartment for the anode, passing a current of from about 0.1 to about 500 mA/cm.sup.2 of electrode area through the cell whereby the support material receives a deposit of a polyoxometallate wherein the average oxidation state of the metals therein has been reduced to a valence greater than zero and, thereafter separating and recovering the support material carrying the reduced metallate complex.",STANDARD OIL CO OHIO,CALLAHAN JAMES L;;DESMOND MICHAEL J;;PEPERA MARC A,,https://lens.org/068-532-274-862-949,Granted Patent,yes,9,81,1,1,0,B01J37/348;;B01J37/348;;C25D9/08;;C25D9/08,B01J37/34;;C25D9/08,204/23;;204/181.5,0,0,,,,EXPIRED
570,DO,A,DO P2010000235 A,066-097-919-428-677,2011-01-15,2011,DO 2010000235 A,2010-07-30,US 2656308 P,2008-02-06,FARMACOFOROS DUALES - ANTAGONISTAS MUSCARINICOS DE PDE4,,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/066-097-919-428-677,Patent Application,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/08;;A61P43/00;;C07D471/04;;C07D519/00,,,0,0,,,,PENDING
571,CN,A,CN 101495475 A,079-349-507-927-103,2009-07-29,2009,CN 200680018274 A,2006-03-24,US 66515405 P,2005-03-25,"Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives","The present invention is directed to a novel method of preparing of 2,4,8- trisubstituted pyrido[2,3-d]pyrimidin-7-one pharmacophores of Formula (II) or (Ha) wherein GHs CH2 Or NH: G2 is CH or nitrogen; Rx is chloro, bromo, iodo, or O-S(O)2CF3; Rg is a C1 10 alkyl; m is 0, or an integer having a value of 1 , or 2; R3 is a C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-10 alkyl, aryl, arylC1-10 alkyl, heteroaryl, heteroarylC1-10 alkyl, heterocyclic or a heterocyclylC1-10 alkyl moiety, and wherein each of these moieties may be optionally substituted. which comprises reacting a compound of the formula: wherein Ry is chloro, bromo, iodo, O-S(O)2CF3; and Rg is a C1-10 alkyl; with a olefin forming reagent in a suitable base to yield a compound of Formula (II), or (Ha) wherein m=0 and oxidizing the sulphur as necessary or desired.",GLAXO GROUP LTD,FRANCIS CALLAHAN JAMES;;JEFFREY BOEHM;;ZEHONG WAN;;HONGXING YAN,,https://lens.org/079-349-507-927-103,Patent Application,no,0,3,22,22,0,C07D471/04;;C07D487/04;;A61P43/00;;C07D471/04;;C07D487/04;;C07D487/04;;C07D471/04,C07D413/04,,0,0,,,,DISCONTINUED
572,US,B2,US 7218034 B2,080-066-838-798-153,2007-05-15,2007,US 12344105 A,2005-05-06,US 12344105 A;;US 93191804 A,2004-09-01,Acoustic driver assembly with restricted contact area,"An acoustic driver assembly for use with any of a variety of cavitation chamber configurations, including spherical and cylindrical chambers as well as chambers that include at least one flat coupling surface. The acoustic driver assembly includes at least one transducer, a head mass and a tail mass. The end surface of the head mass is shaped to limit the contact area between the head mass of the driver assembly and the cavitation chamber to which the driver is attached, the contact area being limited to a centrally located contact region. The area of contact is controlled by limiting its size and/or shaping its surface.",IMPULSE DEVICES INC,TESSIEN ROSS ALAN;;PHILLIPS DANIEL A;;CALLAHAN BRANT JAMES,BURST LABORATORIES INC (2013-05-24);;BURST ENERGIES INC (2013-09-30),https://lens.org/080-066-838-798-153,Granted Patent,yes,24,2,2,35,0,G10K15/043;;G10K15/043,H01L41/08;;B06B1/06;;G10K15/04,310/325;;310/334,6,2,088-266-221-638-384;;039-329-022-283-304,10.1103/physrevlett.83.1870;;10.1109/ultsym.1999.849179,"M. Dan et al., Ambient Pressure Effect on Single-Bubble Sonoluminescence, Physical Review Letters, Aug. 30, 1999, pp. 1870-1873, vol. 83, No. 9, Published in: US.;;C. Desilets et al., Analyses and Measurements of Acoustically Matched, Air-Coupled Tonpilz Transducers, IEEE Ultrasonics Symposium Proceedings-1999, Oct. 17, 1999, pp. 1045-1048, vol. 2, Publisher: IEEE.;;S.C. Butler et al., A Broadband Hybrid Magnetostrictive/Piezoelectric Transducer Array, Magsoft Update, Jul. 2001, pp. 1-7, vol. 7, No. 1, Publisher: Magsoft Corporation, Published in: US.;;M.J. Lodeiro et al., High Frequency Displacement and Dielectric Measurements in Piezoelectric Materials, CPM8.1 Characterization of Advanced Functional Materials-Final Project Deliverables, Mar. 2002, pp. 1-12, vol. MATC(MN), No. 21, Publisher: United Kingdom National Physical Laboratory, Published in: United Kingdom.;;J.P. Perkins, Power Ultrasonic Equipment, http://www.sonicsystems.co.uk/tech<SUB>-</SUB>paper.htm, May 3, 2005, pp. 1-14, based on a paper presented at the Sonochemistry Symposium, Annual Chemical Congress, held at Warwick University, UK, Apr. 8-11, 1996.;;S. Sherrit et al., Novel Horn Designs for Ultrasonic/Sonic Cleaning Welding, Soldering, Cutting and Drilling, Proceedings of the SPIE Smart Structures Conf., pp. 1-8, vol. 4701, Paper No. 34, Published in: US.",INACTIVE
573,KR,B1,KR 880001062 B1,110-619-571-303-556,1988-06-20,1988,KR 810005297 A,1981-12-30,US 22185980 A,1980-12-31,MIXED METAL PHOSPHORUS OXIDE CATALYST COMPOSITION,"Catalysts of formula (A)a(Fe)b(P)c(D)d(O)x are new (where A is Cd, Cr, Ge, Te, Th, Ti, U, V, Zr, or rare earth metal; D is Ag, Cu, or Mn; a=0-1.0; b=0.75-1.5; c=1.0-2.0; d=0-2.0; a+d is greater than zero; X is the no. of oxygens needed to satisfy the valancies of the other elements). The catalysts have a longer life and better thermal stability than prior art catalysts.",STANDARD OIL CO,PEDERSEN SVEND ERIK;;HARDMAN HARLEY FOCH;;CALLAHAN JAMES LOUIS,,https://lens.org/110-619-571-303-556,Granted Patent,no,0,0,9,11,0,B01J27/18;;B01J27/186;;B01J23/89;;B01J23/8933;;B01J27/1853;;C07C51/377;;C07C51/377,C07C57/04;;B01J23/89;;B01J27/00;;B01J27/18;;B01J27/185;;B01J27/186;;C07B61/00;;C07C51/00;;C07C51/377;;C07C67/00;;C07C253/00;;C07C255/23,,0,0,,,,EXPIRED
574,US,A,US 3933751 A,112-392-348-182-359,1976-01-20,1976,US 14138971 A,1971-05-07,US 14138971 A;;US 63863967 A,1967-05-15,Promoted catalysts for the oxidation of olefins,Olefinic aldehydes such as acrolein are produced by the oxidation of an olefin such as propylene in the presence of an antimony oxide-uranium oxide catalyst containing at least one of a number of specified promoter elements.,STANDARD OIL CO OHIO,CALLAHAN JAMES L;;GRASSELLI ROBERT K;;KNIPPLE WARREN R,,https://lens.org/112-392-348-182-359,Granted Patent,yes,9,20,1,1,0,B01J23/18;;B01J23/8435;;C07C45/35;;B01J23/8435;;B01J23/18;;C07C45/35,B01J23/18;;B01J23/843;;C07C45/35,260604R,2,0,,,"Tsutsumi et al., Chemical Abstracts, Vol. 52, Col. 12896, 1958.;;Union Chimique, Chem. Abst. Vol. 58, Col. 7413, April 1963.",EXPIRED
575,CN,A,CN 101983009 A,126-275-683-056-734,2011-03-02,2011,CN 200980111884 A,2009-02-05,US 2009/0033129 W;;US 2656808 P,2008-02-06,Dual pharmacophores-pde4-muscarinic antagonistics,"The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.",GLAXO GROUP LTD,FRANCIS CALLAHAN JAMES;;GUOLIANG LIN;;ZEHONG WAN;;HONGXING YAN,,https://lens.org/126-275-683-056-734,Patent Application,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P1/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P17/04;;A61P17/06;;A61P27/02;;A61P37/08;;C07D471/04;;C07D519/00,A01N43/42,,0,0,,,,DISCONTINUED
576,US,A,US 3427343 A,122-964-745-327-834,1969-02-11,1969,US 3427343D A,1964-11-04,US 40872364 A,1964-11-04,PROCESS FOR PREPARING OLEFINICALLY UNSATURATED ALDEHYDES AND NITRILES,,STANDARD OIL CO,CALLAHAN JAMES L;;MILBERGER ERNEST C;;GRASSELLI ROBERT K,,https://lens.org/122-964-745-327-834,Granted Patent,no,1,11,15,16,0,B01J8/26;;B01J8/26;;B01J21/08;;B01J21/08;;B01J23/12;;B01J23/12;;B01J23/18;;B01J23/18;;C07C45/34;;C07C45/34;;C07C45/35;;C07C45/35;;C07C253/26;;C07C253/26;;Y02P20/52;;Y02P20/52,C07C47/22;;B01J8/26;;B01J21/08;;B01J23/00;;B01J23/12;;B01J23/18;;B01J35/00;;C07B61/00;;C07C45/00;;C07C45/34;;C07C45/35;;C07C67/00;;C07C253/00;;C07C255/08,260/465.3,0,0,,,,EXPIRED
577,DE,A1,DE 1493224 A1,138-279-287-575-35X,1969-04-10,1969,DE 1493224 A,1965-10-30,US 40872364 A,1964-11-04,Verfahren zur Herstellung olefinisch ungesaettigter Aldehyde und Nitrile,,STANDARD OIL CO,LOUIS CALLAHAN JAMES;;CARL MILBERGER ERNEST;;KARL GRASSELLI ROBERT,,https://lens.org/138-279-287-575-35X,Patent Application,no,0,0,15,16,0,B01J8/26;;B01J8/26;;B01J21/08;;B01J21/08;;B01J23/12;;B01J23/12;;B01J23/18;;B01J23/18;;C07C45/34;;C07C45/34;;C07C45/35;;C07C45/35;;C07C253/26;;C07C253/26;;Y02P20/52;;Y02P20/52,C07C47/22;;B01J8/26;;B01J21/08;;B01J23/00;;B01J23/12;;B01J23/18;;B01J35/00;;C07B61/00;;C07C45/00;;C07C45/34;;C07C45/35;;C07C67/00;;C07C253/00;;C07C255/08,,0,0,,,,EXPIRED
578,SG,A1,SG 160438 A1,119-399-857-246-29X,2010-04-29,2010,SG 2010020444 A,2006-03-24,US 66515405 P,2005-03-25,"PROCESS FOR PREPARING PYRIDO[2,3-D]PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDO[4,5- D]PYRIMIDIN-2(1H)-ONE DERIVATIVES",,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;BOEHM JEFFREY;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/119-399-857-246-29X,Patent Application,no,0,0,22,22,0,C07D471/04;;C07D487/04;;A61P43/00;;C07D471/04;;C07D487/04;;C07D487/04;;C07D471/04,,,0,0,,,,PENDING
579,EP,A1,EP 0010206 A1,150-392-508-974-354,1980-04-30,1980,EP 79103676 A,1979-09-28,US 95426278 A,1978-10-24,A process for the oxidation of propylene to acrylic acid and of isobutylen to methacrylic acid.,"A combination of fixed and fluid-bed catalytic reactions is achieved by employing fixed-bed catalysts (3) on supports (4) within the fluid-bed (2). The fluid-bed catalysts (2) may move in toth directions through the fixed bed (3), thereby giving advantages of both types of beds in one reactor (1).",STANDARD OIL CO OHIO,CALLAHAN JAMES LOUIS;;SHAW WILFRIED GARSIDE;;MILLER ARTHUR FRANCIS,,https://lens.org/150-392-508-974-354,Patent Application,yes,7,0,4,6,0,B01J8/0453;;B01J8/048;;B01J8/34;;C07C253/26;;C07C51/252,B01J8/24;;B01J8/04;;B01J8/34;;C07C51/25,,0,0,,,,EXPIRED
580,CA,A1,CA 2714352 A1,155-567-161-602-159,2009-08-13,2009,CA 2714352 A,2009-02-05,US 2656308 P;;US 2009/0033128 W,2008-02-06,DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS,"The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/155-567-161-602-159,Patent Application,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/08;;A61P43/00;;C07D471/04;;C07D519/00,C07D471/04;;A61K31/4545;;A61K31/496;;A61P11/00,,0,0,,,,DISCONTINUED
581,DE,D1,DE 60131781 D1,162-861-623-867-073,2008-01-17,2008,DE 60131781 T,2001-07-16,US 21984200 P;;US 22063600 P;;US 0122267 W,2000-07-21,KALZILYTISCHE VERBINDUNGEN,,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP K;;CALLAHAN JAMES F;;LAGO AMPARO M,"SMITHKLINE BEECHAM CORP., PHILADELPHIA, PA., US (2008-11-06)",https://lens.org/162-861-623-867-073,Granted Patent,no,0,0,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,C07D213/77;;A61K31/44;;C07D213/78;;A61K31/4418;;A61K31/4436;;A61K45/06;;A61K47/10;;A61K47/24;;A61K47/28;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,EXPIRED
582,EP,A4,EP 2249646 A4,178-421-729-046-435,2013-09-25,2013,EP 09707940 A,2009-02-05,US 2009/0033132 W;;US 2657408 P,2008-02-06,DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS,,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LI TINDY;;WAN ZEHONG;;YAN HONGXING,GLAXO GROUP LIMITED (2013-05-01),https://lens.org/178-421-729-046-435,Search Report,no,1,0,3,3,0,A61P11/08;;A61P37/06;;C07D471/04,C07D471/04;;A01N43/42;;A61K31/437;;A61P11/08;;A61P37/06,,1,0,,,See also references of WO 2009100169A1,DISCONTINUED
583,AU,B2,AU 2017/245453 B2,180-780-196-999-271,2022-10-27,2022,AU 2017/245453 A,2017-10-13,US 201615383851 A,2016-12-19,System for displaying the status of use of aircraft overhead luggage storage bins,SYSTEM FOR DISPLAYING THE STATUS OF USE OF AIRCRAFT OVERHEAD LUGGAGE STORAGE BINS A system and method are disclosed for displaying the storage status of overhead luggage storage bins in an aircraft. A camera (150) is provided that is mounted with a field of view directed at an inner portion of a group of open bins. The camera (150) is communicatively coupled to a controller (310) and selectively provides images of the inner portion of the bins immediately prior to when the bins are closed to the controller (310). A projector (110) is also provided for each group of bins. The projector (110) is communicatively coupled to the controller (310) and is mounted such that an image received from the controller (310) is projected onto an outer surface of the closed bins. The controller (310) receives images from each of the cameras (150) and selectively provides such images to the projector (110) associated with each camera (150) so that a storage status display is projected on an outer surface (200) of the bins. 10 %110 1 50 150 110 110 150 °150 10l 155 oo 155 10120 130 180 165 170,BOEING CO,IBRAHIM YAKENTIM M;;CALLAHAN KEVIN S;;SCHALLA JAMES P,,https://lens.org/180-780-196-999-271,Granted Patent,no,2,0,16,16,0,B64D11/00;;B64D11/003;;H04N23/63;;B64D47/08;;B61D37/003;;B64D45/00;;B64D2045/007;;B64D47/08;;B64D11/003;;H04N23/63;;B64D11/00;;B64D47/08;;H04N7/18;;H04N23/60;;H04N23/90;;B64D47/08;;B64D11/003;;H04N7/181;;H04N9/31;;B64D45/00;;B61D37/003;;B64D2045/007;;G06V20/52;;H04N23/63;;H04N23/90,B64D47/08;;B64D9/00,,0,0,,,,ACTIVE
584,CA,A,CA 991383 A,000-039-137-197-560,1976-06-22,1976,CA 173339 A,1973-06-06,US 26516372 A,1972-06-22,REMOVAL OF AMMONIA AND ORGANIC IMPURITIES FROM AN AMMONIA PLANT EFFLUENT,,STANDARD OIL CO OHIO,ADAMS HARRY A;;KUNCHAL SUBODH K;;CALLAHAN JAMES L,,https://lens.org/000-039-137-197-560,Granted Patent,no,0,0,9,9,0,B01D53/34;;B01D53/8634;;C01C1/12;;Y02P20/52;;B01D53/8634;;B01D53/34;;C01C1/12;;Y02P20/52,B01D53/34;;B01D53/58;;B01D53/62;;B01D53/86;;B01J23/02;;B01J23/06;;B01J23/14;;B01J23/18;;B01J23/24;;B01J23/34;;B01J23/38;;B01J23/70;;B01J23/72;;C01C1/12,23-351,0,0,,,,EXPIRED
585,WO,A3,WO 2006/104917 A3,000-050-944-384-300,2009-04-16,2009,US 2006/0010859 W,2006-03-24,US 66515405 P,2005-03-25,"PROCESS FOR PREPARING PYRIDO[2,3-D]PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE DERIVATIVES","The present invention is directed to a novel method of preparing of 2,4,8- trisubstituted pyrido[2,3-d]pyrimidin-7-one pharmacophores of Formula (II) or (Ha) wherein GHs CH 2 Or NH: G2 is CH or nitrogen; Rx is chloro, bromo, iodo, or O-S(O) 2 CF 3 ; Rg is a C 1 10 alkyl; m is 0, or an integer having a value of 1 , or 2; R 3 is a C 1-10 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl C 1-10 alkyl, aryl, arylC 1-10 alkyl, heteroaryl, heteroarylC 1-10 alkyl, heterocyclic or a heterocyclylC 1-10 alkyl moiety, and wherein each of these moieties may be optionally substituted. which comprises reacting a compound of the formula: wherein Ry is chloro, bromo, iodo, O-S(O) 2 CF 3 ; and Rg is a C 1-10 alkyl; with a olefin forming reagent in a suitable base to yield a compound of Formula (II), or (Ha) wherein m=0 and oxidizing the sulphur as necessary or desired.",GLAXO GROUP LTD;;CALLAHAN JAMES FRANCIS;;BOEHM JEFFREY;;WAN ZEHONG;;YAN HONGXING,CALLAHAN JAMES FRANCIS;;BOEHM JEFFREY;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/000-050-944-384-300,Search Report,yes,1,0,22,22,0,C07D471/04;;C07D487/04;;A61P43/00;;C07D471/04;;C07D487/04;;C07D487/04;;C07D471/04,C07D413/04;;A61K31/519;;C07D471/04;;C07D487/04,,0,0,,,,PENDING
586,CA,A,CA 852760 A,016-240-340-835-746,1970-09-29,1970,CA 852760D A,,CA 852760T A,,PROCESS AND APPARATUS FOR PREVENTION OF CATALYST HANG-UP IN A FLUIDIZED SOLID CATALYST REACTOR,,STANDARD OIL CO,CALLAHAN JAMES L;;MILLER ARTHUR F;;PRESSON ROBERT D,,https://lens.org/016-240-340-835-746,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
587,DE,D1,DE 3587065 D1,018-171-734-527-259,1993-03-18,1993,DE 3587065 T,1985-10-28,US 67228684 A,1984-11-16,SYNTHESE VON METALLSILIKATEN VOM MOLEKULARSIEBTYP UNTER VERWENDUNG VON KIESELSAEURE-UEBERGANGSMETALLOXIDSOLEN.,,STANDARD OIL CO OHIO,PEPERA MARC ANTHONY;;CALLAHAN JAMES LOUIS;;DESMOND MICHAEL JOSEPH,,https://lens.org/018-171-734-527-259,Granted Patent,no,0,0,10,10,0,B01J29/04;;B01J29/04;;C01B33/2884;;C01B33/2884;;C01B33/2876;;C01B33/2876,C01B33/20;;B01J29/00;;B01J29/04;;C01B39/06;;C07B61/00;;C07C1/20;;C07C5/27;;C07C15/073;;C07C15/08,,0,0,,,,EXPIRED
588,AU,A1,AU 2017/245453 A1,023-478-264-072-639,2018-07-05,2018,AU 2017/245453 A,2017-10-13,US 201615383851 A,2016-12-19,System for displaying the status of use of aircraft overhead luggage storage bins,SYSTEM FOR DISPLAYING THE STATUS OF USE OF AIRCRAFT OVERHEAD LUGGAGE STORAGE BINS A system and method are disclosed for displaying the storage status of overhead luggage storage bins in an aircraft. A camera (150) is provided that is mounted with a field of view directed at an inner portion of a group of open bins. The camera (150) is communicatively coupled to a controller (310) and selectively provides images of the inner portion of the bins immediately prior to when the bins are closed to the controller (310). A projector (110) is also provided for each group of bins. The projector (110) is communicatively coupled to the controller (310) and is mounted such that an image received from the controller (310) is projected onto an outer surface of the closed bins. The controller (310) receives images from each of the cameras (150) and selectively provides such images to the projector (110) associated with each camera (150) so that a storage status display is projected on an outer surface (200) of the bins. 1272-71 1 1 10110 1 50 150 110 110 150 150 @ 160 120 130 180 170 155 oo 155 10120 130 180 165 170@,BOEING CO,IBRAHIM YAKENTIM M;;CALLAHAN KEVIN S;;SCHALLA JAMES P,,https://lens.org/023-478-264-072-639,Patent Application,no,0,0,16,16,0,B64D11/00;;B64D11/003;;H04N23/63;;B64D47/08;;B61D37/003;;B64D45/00;;B64D2045/007;;B64D47/08;;B64D11/003;;H04N23/63;;B64D11/00;;B64D47/08;;H04N7/18;;H04N23/60;;H04N23/90;;B64D47/08;;B64D11/003;;H04N7/181;;H04N9/31;;B64D45/00;;B61D37/003;;B64D2045/007;;G06V20/52;;H04N23/63;;H04N23/90,B64D47/08;;B64D9/00,,0,0,,,,ACTIVE
589,CA,A1,CA 2714419 A1,032-251-027-945-23X,2009-08-13,2009,CA 2714419 A,2009-02-05,US 2657208 P;;US 2009/0033130 W,2008-02-06,DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS,"The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/ and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/032-251-027-945-23X,Patent Application,no,0,0,20,20,0,C07D471/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/00;;A61P37/08;;A61P43/00;;C07D471/04,C07D471/04;;A61K31/437;;A61K31/4545;;A61K31/496;;A61K31/551;;A61P11/00;;C07D519/00,,0,0,,,,DISCONTINUED
590,HU,B,HU 199882 B,036-373-835-046-591,1990-03-28,1990,HU 11587 A,1987-01-15,US 81933686 A,1986-01-16,PROCESS FOR PRODUCING NEW POLYPEPTIDES WITH VASOPRESSIN ANTAGONIST EFFECT AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS ACTIVE INGREDIENT,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES F;;HUFFMAN WILLIAM F;;YIM NELSON C,,https://lens.org/036-373-835-046-591,Granted Patent,no,0,0,20,24,0,A61K38/00;;A61P7/10;;A61P9/12;;C07K7/16;;C07K7/16;;F28D15/02,C07K14/575;;A61K38/00;;A61K38/095;;A61P7/10;;A61P9/12;;C07C67/00;;C07C227/00;;C07C227/24;;C07C229/28;;C07C239/00;;C07C253/00;;C07C255/31;;C07C269/00;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,EXPIRED
591,US,A1,US 2009/0203657 A1,060-630-184-097-807,2009-08-13,2009,US 36593009 A,2009-02-05,US 36593009 A;;US 2656308 P,2008-02-06,Dual Pharmacophores - PDE4-Muscarinic Antagonistics,"The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,GLAXO GROUP LIMITED (2009-03-12),https://lens.org/060-630-184-097-807,Patent Application,yes,10,10,21,21,0,C07D471/04;;C07D519/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/08;;A61P43/00;;C07D471/04;;C07D519/00,A61K31/56;;A61K31/437;;A61K31/496;;A61K31/551;;A61P11/00;;C07D243/08;;C07D401/14;;C07D471/02,514/171;;546/119;;514/303;;544/362;;514/253.04;;540/575;;514/218,0,0,,,,INACTIVE
592,NO,D0,NO 20030303 D0,068-441-151-377-333,2003-01-20,2003,NO 20030303 A,2003-01-20,US 21984200 P;;US 22063600 P;;US 0122267 W,2000-07-21,Kalsilytiske forbindelser,,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP KUMAR;;CALLAHAN JAMES F;;LAGO AMPARO M,,https://lens.org/068-441-151-377-333,Patent Application,no,0,0,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,A61K31/4418;;C07D213/77;;A61K31/4436;;A61K45/06;;A61K47/10;;A61K47/24;;A61K47/28;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,EXPIRED
593,US,A,US 4335056 A,095-255-552-643-110,1982-06-15,1982,US 22244881 A,1981-01-05,US 22244881 A,1981-01-05,Processing acrylonitrile waste gas,"In the recovery of acrylonitrile from the gross reaction product produced during the commercial ammoxidation of propylene to produce acrylonitrile, an ammoxidation waste gas containing at least 65% nitrogen, carbon dioxide, carbon monoxide and a small amount of unreacted propylene is produced. In accordance with the invention, this ammoxidation waste gas is passed through a catalytic converter containing an oxidation or ammoxidation catalyst to convert the unreacted propylene into valuable product.",STANDARD OIL CO,CALLAHAN JAMES L;;SHAW WILFRID G;;TERRILL DAVID B,STANDARD OIL COMPANY THE (1980-12-23),https://lens.org/095-255-552-643-110,Granted Patent,yes,5,7,1,1,0,C07C253/26;;C07C253/34;;C07C253/26;;C07C253/34,C07C45/35;;C07C51/215,260/465.3,0,0,,,,EXPIRED
594,US,A,US 4444906 A,114-318-038-475-620,1984-04-24,1984,US 43995282 A,1982-11-08,US 43995282 A;;US 27145881 A,1981-06-08,Method for the preparation of high activity phosphomolybdic acid based catalysts,"The present invention relates to a method for the preparation of phosphomolybdic acid based catalysts by forming a solution of hydrated phosphomolybdic acid in a substantially anhydrous alkyl alcohol, adding a base to the solution, evaporating the solution to yield a catalyst powder and thereafter drying and calcining the powder to form the active catalysts. A second method for preparation is also provided and includes the steps of forming a solution of hydrated phosphomolybdic acid in a substantially anhydrous alkyl alcohol, evaporating the solution to form a concentrate, impregnating a catalyst support material with the concentrate, contacting the impregnated support with ammonia gas in an amount sufficient to form an insoluble precipitate of ammonium alkyl phosphomolybdic acid within the pore structure of said support material and thereafter drying and calcining said impregnated support material so as to form a coated catalyst.",STANDARD OIL CO OHIO,CALLAHAN JAMES L;;SHAW WILFRID G;;MILLER ARTHUR F,,https://lens.org/114-318-038-475-620,Granted Patent,yes,17,16,1,7,0,B01J27/188;;B01J37/0215;;C07C51/235;;C07C51/252;;C07C51/235;;C07C51/252;;B01J37/0215;;B01J27/188,B01J27/188;;B01J37/02;;C07C51/235;;C07C51/25,502/211;;502/209;;502/210;;502/212,0,0,,,,EXPIRED
595,US,A1,US 2009/0239846 A1,119-306-663-425-577,2009-09-24,2009,US 90843506 A,2006-03-24,US 90843506 A;;US 66534705 P;;US 2006/0010792 W,2005-03-25,Novel Compounds,"Novel substituted 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-(1H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.",GLAXO GROUP LTD,CALLAHAN JAMES F;;WAN ZEHONG;;YAN HONGXING;;LIN XICHEN,GLAXO GROUP LIMITED (2006-04-20),https://lens.org/119-306-663-425-577,Patent Application,yes,9,3,33,33,1,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,A61K31/551;;A61K31/519;;A61K31/5377;;C07D243/08;;C07D413/00;;C07D487/04,514/218;;514/234.5;;514/262.1;;540/575;;544/118;;544/256,0,0,,,,DISCONTINUED
596,CA,A1,CA 2416537 A1,132-549-177-079-32X,2002-01-31,2002,CA 2416537 A,2001-07-16,US 21984200 P;;US 22063600 P;;US 0122267 W,2000-07-21,CALCILYTIC COMPOUNDS,Novel calcilytic compounds and methods of using them are provided.,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;LAGO AMPARO M;;BHATNAGAR PRADIP K,,https://lens.org/132-549-177-079-32X,Patent Application,no,0,0,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,C07D213/77;;A61K31/4418;;A61K31/4436;;A61K45/06;;A61K47/10;;A61K47/24;;A61K47/28;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,DISCONTINUED
597,UY,A1,UY 31637 A1,134-885-478-652-025,2009-08-03,2009,UY 31637 A,2009-02-04,US 2656308 P,2008-02-06,FARMACOFOROS DUALES-ANTAGONISTAS MUSCARINICOS DE PDE4,"La presente invencion se refiere a nuevos compuestos de la formula (I) y a sus sales farmacéuticamente aceptables, a composiciones farmacéuticas y a su uso como cromoferos duales que tienen actividad inhibitoria contra receptores de PDE4 y receptores muscarínicos de acetilcolina (mAChRs), siendo así de utilidad para tratar enfermedades respiratorias.",,LIN GOULIANG;;YAN HONGXING;;WAN ZEHONG;;CALLAHAN JAMES FRANCIS,,https://lens.org/134-885-478-652-025,Patent Application,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/08;;A61P43/00;;C07D471/04;;C07D519/00,A61K31/437;;A61P11/02;;A61P11/06;;C07D471/04,,0,0,,,,DISCONTINUED
598,US,A1,US 2009/0197871 A1,164-775-361-201-117,2009-08-06,2009,US 36593409 A,2009-02-05,US 36593409 A;;US 2657208 P,2008-02-06,Dual Pharmacophores - PDE4-Muscarinic Antagonistics,"The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,GLAXO GROUP LIMITED (2009-03-12),https://lens.org/164-775-361-201-117,Patent Application,yes,10,5,20,20,0,C07D471/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/00;;A61P37/08;;A61P43/00;;C07D471/04,A61K31/437;;A61K31/496;;A61K31/5377;;A61K31/551;;A61P11/06;;C07D471/04,514/218;;546/119;;544/362;;540/575;;544/127;;514/303;;514/253.04;;514/236.5,0,0,,,,INACTIVE
599,CN,A,CN 101983010 A,175-938-260-318-597,2011-03-02,2011,CN 200980112027 A,2009-02-05,US 2009/0033130 W;;US 2657208 P,2008-02-06,Dual pharmacophores-pde4-muscarinic antagonistics,"The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/ and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.",GLAXO GROUP LTD,FRANCIS CALLAHAN JAMES;;GUOLIANG LIN;;ZEHONG WAN;;HONGXING YAN,,https://lens.org/175-938-260-318-597,Patent Application,no,3,0,20,20,0,C07D471/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/00;;A61P37/08;;A61P43/00;;C07D471/04,A01N43/42,,0,0,,,,DISCONTINUED
600,US,A1,US 2003/0212110 A1,172-195-538-383-438,2003-11-13,2003,US 33309603 A,2003-01-15,US 33309603 A;;US 0122267 W,2001-07-16,Calcilytic compounds,"
   Novel calcilytic compounds and methods of using them are provided. 
",BHATNAGAR PRADIP K.;;CALLAHAN JAMES F.;;LAGO AMPARO M.,BHATNAGAR PRADIP K;;CALLAHAN JAMES F;;LAGO AMPARO M,SMITHKLINE BEECHAM CORPORATION (2001-07-26),https://lens.org/172-195-538-383-438,Patent Application,yes,0,6,2,2,0,A61K31/4436;;C07D213/80;;C07D213/84;;C07D409/12;;C07D213/80;;A61K31/4436;;C07D409/12;;C07D213/84,A61K31/4436;;C07D213/80;;C07D213/84;;C07D409/12,514/336;;514/345;;546/280.4;;X5463,0,0,,,,EXPIRED
601,CN,A,CN 1094718 A,168-407-679-964-372,1994-11-09,1994,CN 93119926 A,1993-12-21,US 99288592 A;;US 3794893 A,1992-12-21,Bicyclic fibrinogen antagonists,"This invention relates to compounds of formulae (I), (II), (II), wherein A<1> is O, S, N-R<1> or CHR<1>; A<4> is N-R<4> or CHR<4>; R<2> is a sidechain containing an acid or ester group; R<1>, R<4> and R<5> are substituents such as H, alkyl and aryl alkyl, and R<6> is a sidechain containing a nitrogen group; and pharmaceutically acceptable salts thereof, which are effective for inhibiting platelet aggregation, pharmaceutical compositions for effecting such activity, and a method for inhibiting platelet aggregation.",SMITHKLINE BEECHAM CORP,BONDINELL WILLIAM EDWARD;;CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS,,https://lens.org/168-407-679-964-372,Patent Application,no,0,0,23,24,0,C07D211/18;;C07D211/70;;C07D213/24;;C07D223/16;;C07D243/04;;C07D243/14;;C07D243/24;;C07D267/14;;C07D401/12;;C07D403/12;;C07D453/02;;A61P7/02;;C07D243/14;;C07D401/12,A61K31/4409;;A61K31/4418;;A61K31/4427;;A61K31/445;;A61K31/4465;;A61K31/451;;A61K31/55;;A61K31/551;;A61P7/02;;C07D211/18;;C07D211/22;;C07D211/26;;C07D211/70;;C07D213/24;;C07D213/74;;C07D223/16;;C07D243/04;;C07D243/14;;C07D243/24;;C07D267/14;;C07D295/04;;C07D295/08;;C07D295/10;;C07D295/12;;C07D401/12;;C07D401/14;;C07D403/12;;C07D453/02,,0,0,,,,EXPIRED
602,EP,A4,EP 1368318 A4,168-473-494-012-653,2006-08-23,2006,EP 01954696 A,2001-07-16,US 0122267 W;;US 21984200 P;;US 22063600 P,2000-07-21,CALCILYTIC COMPOUNDS,,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP K;;CALLAHAN JAMES F;;LAGO AMPARO M,"ONE FRANKLIN PLAZA, PO BOX 7929, PHLILADELPHIA, PE (2007-12-05);;SMITHKLINE BEECHAM CORP. (2007-12-05);;SMITHKLINE BEECHAM CORPORATION (2008-04-09)",https://lens.org/168-473-494-012-653,Search Report,no,2,0,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,C07D213/77;;A61K31/44;;C07D213/78;;A61K31/4418;;A61K31/4436;;A61K45/06;;A61K47/10;;A61K47/24;;A61K47/28;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,EXPIRED
603,US,A,US 4303550 A,199-435-946-800-544,1981-12-01,1981,US 10798979 A,1979-12-28,US 10798979 A,1979-12-28,Methods for the regeneration of deactivated phosphomolybdic acid based catalysts,"The present invention relates to a method for the regeneration of deactivated PMA based catalysts by imbibing an aqueous volatile base within the pore structure of the deactivated catalyst so as to form a fluid phase within the pore structure, adding a volatile acid to the fluid phase to form a precipitate. The precipitate is thereafter dried and calcined to yield the regenerated catalyst. A second method for regeneration is also provided and includes the steps of imbibing a volatile solvent within the pore structure of the deactivated catalyst, adding a volatile acid to the system, and then adding a volatile base to the system to form a precipitate within the pore structure. The precipitate is again dried and calcined to yield the regenerated catalyst.",STANDARD OIL CO,CALLAHAN JAMES L;;SHAW WILFRID G;;MILLER ARTHUR F,,https://lens.org/199-435-946-800-544,Granted Patent,yes,5,25,1,1,0,B01J27/285;;C07C51/252;;Y02P20/584;;B01J27/285;;C07C51/252;;Y02P20/584,B01J27/28;;C07C51/25,252/413,0,0,,,,EXPIRED
604,AT,B,AT 358002 B,044-662-467-189-636,1980-08-11,1980,AT 555377 A,1977-07-28,US 71101476 A,1976-08-02,VERFAHREN ZUR HERSTELLUNG VON METHACROLEIN,,STANDARD OIL CO OHIO,HARDMAN HARLEY FOCH;;GRASSELLI ROBERT KARL;;CALLAHAN JAMES LOUIS,,https://lens.org/044-662-467-189-636,Granted Patent,no,0,0,26,29,0,B01J23/8876;;B01J2523/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C51/235;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J23/8876;;C07C45/33;;C07C45/34;;C07C51/235;;C07C45/32;;C07C45/37;;C07C51/252;;C07C45/27;;B01J2523/00;;C07C253/24;;Y02P20/52,C07C57/05;;B01J23/00;;B01J23/88;;C07B61/00;;C07C1/00;;C07C5/48;;C07C11/00;;C07C45/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C47/22;;C07C51/00;;C07C51/235;;C07C51/25;;C07C67/00;;C07C253/00;;C07C255/08,"12E1,010",0,0,,,,EXPIRED
605,EP,A4,EP 2247184 A4,032-346-799-010-639,2012-07-18,2012,EP 09708465 A,2009-02-05,US 2009/0033129 W;;US 2656808 P,2008-02-06,DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS,,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,GLAXO GROUP LIMITED (2013-05-01),https://lens.org/032-346-799-010-639,Search Report,no,3,0,21,21,0,C07D471/04;;C07D519/00;;A61P1/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P17/04;;A61P17/06;;A61P27/02;;A61P37/08;;C07D471/04;;C07D519/00,A01N43/42;;C07D471/04;;C07D519/00,,1,0,,,See also references of WO 2009100167A1,DISCONTINUED
606,CA,A1,CA 2714418 A1,070-030-416-282-088,2009-08-13,2009,CA 2714418 A,2009-02-05,US 2656808 P;;US 2009/0033129 W,2008-02-06,DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS,"The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/070-030-416-282-088,Patent Application,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P1/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P17/04;;A61P17/06;;A61P27/02;;A61P37/08;;C07D471/04;;C07D519/00,C07D471/04;;A61K31/437;;A61K31/496;;A61K31/5377;;A61K31/551;;A61P11/00;;C07D519/00,,0,0,,,,DISCONTINUED
607,UY,A1,UY 31636 A1,072-351-259-057-10X,2009-08-03,2009,UY 31636 A,2009-02-04,US 2656808 P,2008-02-06,FARMACOFOROS DUALES-ANTAGONISTAS MUSCARINICOS DE PDE4,"La presente invencion se refiere a nuevos compuestos de Formula (I) y a su uso en el tratamiento de enfermedades respiratorias, incluyendo enfermedades anti-inflamatorias y alérgicas tales como enfermedad pulmonar obstructiva cronica (COPD), asma , rinitis (por ejemplo, rinitis alérgica), dermatitis atopica o psoriasis.",,LIN GOULIANG;;YAN HONGXING;;WAN ZEHONG;;CALLAHAN JAMES FRANCIS,,https://lens.org/072-351-259-057-10X,Patent Application,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P1/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P17/04;;A61P17/06;;A61P27/02;;A61P37/08;;C07D471/04;;C07D519/00,A61P11/00;;C07D231/00;;C07D471/00;;C07D487/00,,0,0,,,,DISCONTINUED
608,CA,A,CA 1257247 A,081-962-947-283-062,1989-07-11,1989,CA 493801 A,1985-10-24,US 67228684 A,1984-11-16,SYNTHESIS OF MOLECULAR SIEVING METALLOSILICATES USING SILICA-TRANSITION METAL OXIDE SOLS,A method is disclosed for the preparation of a molecular sieving metallosillicate wherein an aqueous dispersion of colloidal particles comprising contiguous mixtures of silica and at least one oxide of a transition metal is mixed with an effective amount of a mineralizing agent and/or synthesis directing agent to form a gel. The formed gel is maintained at a temperature of about 80.degree.C to about 300.degree.C for a period of time effective to provide the desired molecular sieving metallosillicate.,STANDARD OIL CO OHIO,PEPERA MARC A;;DESMOND MICHAEL J;;CALLAHAN JAMES L,,https://lens.org/081-962-947-283-062,Granted Patent,no,0,0,10,10,0,B01J29/04;;B01J29/04;;C01B33/2884;;C01B33/2884;;C01B33/2876;;C01B33/2876,C01B33/20;;B01J29/00;;B01J29/04;;C01B39/06;;C07B61/00;;C07C1/20;;C07C5/27;;C07C15/073;;C07C15/08,252-52.B,0,0,,,,EXPIRED
609,EP,A1,EP 2249647 A1,091-586-417-278-449,2010-11-17,2010,EP 09708556 A,2009-02-05,US 2009/0033130 W;;US 2657208 P,2008-02-06,DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS,,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,GLAXO GROUP LIMITED (2013-05-01),https://lens.org/091-586-417-278-449,Patent Application,yes,0,0,20,20,0,C07D471/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/00;;A61P37/08;;A61P43/00;;C07D471/04,A01N43/42;;C07D471/04;;C07D519/00,,0,0,,,,DISCONTINUED
610,FR,A1,FR 2393786 A1,095-530-289-914-318,1979-01-05,1979,FR 7816230 A,1978-05-31,US 80526477 A,1977-06-10,ESTERIFICATION D'ACIDES CARBOXYLIQUES ALIPHATIQUES AU MOYEN DE METHYL-TERTIOALKYL-ETHERS,"<P>- Procédé d'estérification d'acides carboxyliques aliphatiques. Ce procédé consiste à faire réagir un acide carboxylique aliphatique contenant de 1 à 6 atomes de carbone avec un méthyl-tertioalkyl-éther dans lequel le groupe alkyl tertiaire contient de 4 à 7 atomes de carbone en présence d'un catalyseur acide choisi dans le groupe formé par l'acide sulfurique, un acide sulfonique aliphatique ou aromatique, un acide perfluoroalkyl sulfonique, un acide perfluoroalkyl phosphonique, et un hétéropolyacide représenté par la formule : </P><P>Hn Aa Dc Oy . XH2 O formule dans laquelle A représente le phosphore, le bore, le silicium, le germanium, l'étain, l'arsenic, l'antimoine, l'uranium, le manganèse, le rhénium, le cuivre, le nickel, le cobalt, le fer, le cérium, le thorium, le chrome et D représente le molybdène, le tungstène, le vanadium. </P><P>Utilisable pour l'obtention, avec d'excellentes sélectivités, d'esters méthyliques et de tertioalkyl-oléfines.</P>",STANDARD OIL CO,GUTTMANN ANDREW TYTUS;;CALLAHAN JAMES LOUIS;;GRASSELLI ROBERT KARL,,https://lens.org/095-530-289-914-318,Patent Application,no,1,0,16,18,0,C07C1/20;;C07C7/14891;;C07C67/24,B01J23/00;;B01J27/00;;C07C67/24;;C07B61/00;;C07C1/20;;C07C7/148,,1,0,,,EXBK/32,DISCONTINUED
611,CL,A1,CL 2009000248 A1,130-896-396-897-051,2009-09-11,2009,CL 2009000248 A,2009-02-04,US 2657208 P,2008-02-06,"Compuestos derivados de pirazolo [3,4-b] piridin-5-il, inhibidores de la fosfodiesterasa de tipo iv (pde4) y antagonista de receptores muscarinicos de acetilcolina (machr); composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles en el tratamiento de enferemedades respiratorias y alergicas","Compuestos derivados de pirazolo [3,4-b] piridin-bencenodicarboxamida; composición farmacéutica; y su uso en el tratamiento del asma, enfermedad pulmonar obstructiva crónica, rinitis, dermatitis atópica, psoriasis.",GLAXO GROUP LTD,WAN ZEHONG;;CALLAHAN JAMES FRANCIS;;LIN GOULIANG;;YAN HONXING,,https://lens.org/130-896-396-897-051,Patent Application,no,0,0,20,20,0,C07D471/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/00;;A61P37/08;;A61P43/00;;C07D471/04,A61K31/496;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;C07D213/00;;C07D231/00;;C07D471/04,,0,0,,,,PENDING
612,US,A,US 4705675 A,135-124-918-824-792,1987-11-10,1987,US 67228684 A,1984-11-16,US 67228684 A,1984-11-16,Synthesis of molecular sieving metallosilicates using silica-transition metal oxide sols,"A method for preparing a molecular sieving metallosilicate is disclosed which comprises (A) providing an aqueous dispersion of colloidal particles comprising contiguous mixtures of silica and the oxide of a transition metal selected from the group consisting of Sc, Ti, V, Cr, Mn, Fe, Co, Ni, Zn, Zr, Y or a mixture of two or more of said metals; (B) mixing an effective amount of a mineralizing agent and/or synthesis directing agent with said dispersion to form a gel; and (C) maintaining said gel at a temperature of about 80.degree. C. to about 300.degree. C. for an effective period of time to provide said metallosilicate.",STANDARD OIL CO OHIO,DESMOND MICHAEL J;;PEPERA MARC A;;CALLAHAN JAMES L,STANDARD OIL COMPANY THE (1984-10-29),https://lens.org/135-124-918-824-792,Granted Patent,yes,10,13,10,10,0,B01J29/04;;B01J29/04;;C01B33/2884;;C01B33/2884;;C01B33/2876;;C01B33/2876,C01B33/20;;B01J29/00;;B01J29/04;;C01B39/06;;C07B61/00;;C07C1/20;;C07C5/27;;C07C15/073;;C07C15/08,423/326;;423/328;;423/329;;423/330;;502/77,0,0,,,,EXPIRED
613,US,A,US 4470931 A,135-038-589-771-587,1984-09-11,1984,US 10886879 A,1979-12-13,US 10886879 A;;US 95426278 A,1978-10-24,Combination fixed-fluid bed reactor,"A process for conducting a combination of fixed and fluid-bed catalytic reactions is achieved by employing fixed-bed catalysts on supports within the fluid bed. The fluid-bed catalysts may move in both directions through the fixed bed, thereby giving advantages of both types of beds in one reactor.",STANDARD OIL CO OHIO,CALLAHAN JAMES L;;MILLER ARTHUR F;;SHAW WILFRID G,,https://lens.org/135-038-589-771-587,Granted Patent,yes,5,12,1,6,0,B01J8/0453;;B01J8/0453;;B01J8/048;;B01J8/048;;B01J8/34;;B01J8/34;;C07C253/26;;C07C253/26;;C07C51/252;;C07C51/252,B01J8/04;;B01J8/34;;C07C51/25,260/465.3;;422/141;;422/139;;549/262;;560/208;;562/545,0,0,,,,EXPIRED
614,NO,L,NO 772723 L,143-125-462-241-816,1978-02-03,1978,NO 772723 A,1977-08-01,US 71101476 A,1976-08-02,FREMGANGSM}TE VED FREMSTILLING AV METHACRYLDERIVATER FRAI T-BUTYLHOLDIGE FORBINDELSER,,STANDARD OIL CO OHIO,HARDMAN HARLEY FOCH;;GRASSELLI ROBERT KARL;;CALLAHAN JAMES LOUIS,,https://lens.org/143-125-462-241-816,Abstract,no,0,0,26,29,0,B01J23/8876;;B01J2523/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C51/235;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J23/8876;;C07C45/33;;C07C45/34;;C07C51/235;;C07C45/32;;C07C45/37;;C07C51/252;;C07C45/27;;B01J2523/00;;C07C253/24;;Y02P20/52,B01J23/00;;C07C57/05;;B01J23/88;;C07B61/00;;C07C1/00;;C07C5/48;;C07C11/00;;C07C45/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C47/22;;C07C51/00;;C07C51/235;;C07C51/25;;C07C67/00;;C07C253/00;;C07C255/08,,0,0,,,,DISCONTINUED
615,ES,T3,ES 2296774 T3,198-176-990-651-232,2008-05-01,2008,ES 01954696 T,2001-07-16,US 21984200 P;;US 22063600 P,2000-07-21,COMPUESTOS CALCIOLITICOS.,"Un compuesto de acuerdo con la fórmula (I) que sigue: en la que: A representa C o N con uno o dos N en el anillo I; D representa C o N con uno o dos N en el anillo II que está unido en la posición 4 o 5 al anillo I como se indica; X se selecciona del grupo que consiste en CN, NO2, Cl, F, y H; Y se selecciona cuando A es C del grupo que consiste en Cl, F, Br, I y H; Q se selecciona cuando D es C del grupo que consiste en H, R1, SO2R1'', R1C(O)OR''1, tetrazol, CH2OH, COH, SO2NR1''R1"", C(O)NR1''R1"", y NR1SO2R1'', donde R1 se selecciona independientemente del grupo que consiste en un enlace, hidrógeno, alquilo C1-4, y alquilo opcionalmente sustituido; R1'', y R1"" se seleccionan independientemente del grupo que consiste en hidrógeno, alquilo C1-4, y alquilo opcionalmente sustituido, o R1'', y R1"" forman juntos un anillo heterocíclico de 3 a 7 miembros opcionalmente sustituido; Ar es fenilo o naftilo, sin sustituir o sustituido, heteroarilo o heteroarilo condensado, de tal forma que el hetero-anillo puede contener N, O o S y puede ser aromático, dihidro o tetrahidro, sin sustituir o sustituido, o una de sus sales farmacéuticamente aceptables.",SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP K;;CALLAHAN JAMES F;;LAGO AMPARO M,,https://lens.org/198-176-990-651-232,Granted Patent,no,0,0,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,C07D213/77;;A61K31/44;;C07D213/78;;A61K31/4418;;A61K31/4436;;A61K45/06;;A61K47/10;;A61K47/24;;A61K47/28;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,EXPIRED
616,DE,A1,DE 2331139 A1,014-910-732-247-561,1974-01-17,1974,DE 2331139 A,1973-06-19,US 26516272 A,1972-06-22,VERFAHREN ZUR UEBERFUEHRUNG VON ORGANISCHEN VERUNREINIGUNGEN IN UNSCHAEDLICHE PRODUKTE,,STANDARD OIL CO OHIO,CALLAHAN JAMES LOUIS;;HARDMAN HARLEY FOCH;;GRASSELLI ROBERT KARL,,https://lens.org/014-910-732-247-561,Patent Application,no,0,0,9,9,0,B01D53/72;;B01D53/72,B01D53/86;;B01D53/72;;B01J23/72;;C02F1/72;;F23G7/07,,0,0,,,,DISCONTINUED
617,MX,A,MX 2010008685 A,018-072-526-546-937,2010-08-30,2010,MX 2010008685 A,2009-02-05,US 2656808 P;;US 2009/0033129 W,2008-02-06,DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS.,"The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.",GLAXO GROUP LTD,WAN ZEHONG;;YAN HONGXING;;CALLAHAN JAMES FRANCIS;;LIN GUOLIANG,,https://lens.org/018-072-526-546-937,Patent Application,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P1/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P17/04;;A61P17/06;;A61P27/02;;A61P37/08;;C07D471/04;;C07D519/00,A01N43/42,,0,0,,,,PENDING
618,PE,A1,PE 20091563 A1,033-920-887-614-619,2009-11-05,2009,PE 2009000165 A,2009-02-04,US 2656808 P,2008-02-06,FARMACOFOROS DUALES - ANTAGONISTAS MUSCARINICOS DE PDE4,"REFERIDA A DERIVADOS DE PIRAZOLO-PIRIDIN DE FORMULA (I), DONDE LINK REPRESENTA ((CReRe)s3-(CRf=CRf)v1-(CRgRg))s4-X2-((CReRe)t2-(CRf=CRf)v2-(CRgRg))t3; X2 ES ALQUILO C1-C10, UN ANILLO CICLOALQUILO C3-C7, ENTRE OTROS; X1 ES O O N(R4a); R4a ES H O ALQUILO C1-C2; R5a ES H O ALQUILO C1-C2; Z ES C(O), S(O)q, C(O)NH, C(O)O; Z1 ES C(O), S(O)q, HNC(O), OC(O); n ES 1, 2 O 3; q ES 0, 1 O 2; v ES UN ENTERO DE 1 A 5; v1, v2, s3, s4, t2 Y t3 SON UN ENTERO DE 0 A 5; Re, Rf Y Rg SON H O ALQUILO C1-C4; R1 ES ALQUILO C1-C3, CH2-FLUOROALQUILO C1-C2 O CH2CH2OH; R2 ES H, ALQUILO C1-C4, FLUOROALQUILO C1-C2, ENTRE OTROS; R3 ES CICLOALQUILO C4-C7, CICLOALQUENILO C5-C7, ENTRE OTROS; Ar1 Y Ar2 SON FENILO, HETEROARILO MONOCICLICO, ENTRE OTROS; R6 ES NR7R8, UN ANILLO DE 5 A 7 MIEMBROS QUE CONTIENE UNO O DOS NITROGENOS, ENTRE OTROS; R7 ES H O ALQUILO C1-C4; R8 ES (CRd1Rd1)t-NR11R12 O (CRd1Rd1)t1-R14; Rd1 ES H, ALQUILO C1-C4, ENTRE OTROS; R14 ES ALQUILO C1-C4, CICLOALQUILO C3-C6, ENTRE OTROS; t ES UN ENTERO DE 1 A 4; t1 ES UN ENTERO DE 0 A 4; R4 Y R5 SON H, ALQUILO C1-C4, CICLOALQUILO C3-C7-ALQUILO C1-C4, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-{[1,6-DIETIL-4-(TETRAHIDRO-2H-PIRAN-4-ILAMINO)-1H-PIRAZOLO[3,4-b]PIRIDIN-5-IL]METIL}-N'-[(6-FLUORO-3'-{[(3S)-3-METIL-1-PIPERAZINIL]METIL}-3-BIFENILIL)METIL]PROPANODIAMIDA, ENTRE OTROS. DICHOS COMPUESTOS SON INHIBIDORES DE LA FOSFODIESTERASA DE TIPO IV (PDE4) Y ANTAGONISTAS DE RECEPTORES MUSCARINICOS DE ACETILCOLINA (mAChR)",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/033-920-887-614-619,Patent Application,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P1/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P17/04;;A61P17/06;;A61P27/02;;A61P37/08;;C07D471/04;;C07D519/00,A61K31/4353;;A61K31/437;;A61K31/496;;A61K31/5375;;A61K31/5377;;A61K31/551;;A61P11/00;;A61P11/06;;C07D471/04,,0,0,,,,DISCONTINUED
619,CN,A,CN 1114321 A,036-960-200-817-619,1996-01-03,1996,CN 94106591 A,1994-06-29,CN 94106591 A,1994-06-29,Chemical compounds,"A compound with the formula: W-(CR'2)q-Z-(CR'R10)r-U-(CR'2)s-V-(Gly)n-(Asp)m-A, which can effectively suppress the aggregation of thrombocytes, its medicinal composition and the method to inhibit aggregation of thrombocytes are disclosed.",SMITHKLINE BEECHAM CORP,BONDINELL WILLIAM EDWARD;;CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS,,https://lens.org/036-960-200-817-619,Patent Application,no,0,1,1,1,0,,A61K38/04;;C07D213/56;;C07D235/30;;C07K5/00,,0,0,,,,PENDING
620,WO,A2,WO 2002/007673 A2,116-874-723-624-874,2002-01-31,2002,US 0122267 W,2001-07-16,US 21984200 P;;US 22063600 P,2000-07-21,CALCILYTIC COMPOUNDS,"Certain N-(2R)-hydroxy--3-cyano-5-⏧⏧carboxy&rsqb;-3-pyridyl&rsqb;phenoxy&rsqb;propyl&rsqb;&rsqb;-1,1-dimetyl-2-(aryl or heteroaryl)-ethylamines and derivatives thereof, methods for their preparation and their use as calcylitic agents.",SMITHKLINE BEECHAM CORP;;BHATNAGAR PRADIP K;;CALLAHAN JAMES F;;LAGO AMPARO M,BHATNAGAR PRADIP K;;CALLAHAN JAMES F;;LAGO AMPARO M,,https://lens.org/116-874-723-624-874,Patent Application,yes,0,18,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,A61K31/4418;;C07D213/77;;A61K31/4436;;A61K45/06;;A61K47/10;;A61K47/24;;A61K47/28;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,PATENTED
621,US,B2,US 6864267 B2,127-886-382-669-587,2005-03-08,2005,US 33309603 A,2003-01-15,US 33309603 A;;US 0122267 W,2001-07-16,Calcilytic compounds,Novel calcilytic compounds and methods of using them are provided.,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP K;;CALLAHAN JAMES F;;LAGO AMPARO M,SMITHKLINE BEECHAM CORPORATION (2001-07-26),https://lens.org/127-886-382-669-587,Granted Patent,yes,4,21,2,2,0,A61K31/4436;;C07D213/80;;C07D213/84;;C07D409/12;;C07D213/80;;A61K31/4436;;C07D409/12;;C07D213/84,A61K31/4436;;C07D213/80;;C07D213/84;;C07D409/12,514/336;;546/280.4;;546/288;;546/315;;546/326;;514/344;;514/354,0,0,,,,EXPIRED
622,US,A1,US 2018/0173962 A1,144-334-120-871-33X,2018-06-21,2018,US 201615383851 A,2016-12-19,US 201615383851 A,2016-12-19,SYSTEM FOR DISPLAYING THE STATUS OF USE OF AIRCRAFT OVERHEAD LUGGAGE STORAGE BINS,A system and method are disclosed for displaying the storage status of overhead luggage storage bins in an aircraft. A camera is provided that is mounted with a field of view directed at an inner portion of a group of open bins. The camera is communicatively coupled to a controller and selectively provides images of the inner portion of the bins immediately prior to when the bins are closed to the controller. A projector is also provided for each group of bins. The projector is communicatively coupled to the controller and is mounted such that an image received from the controller is projected onto an outer surface of the closed bins. The controller receives images from each of the cameras and selectively provides such images to the projector associated with each camera so that a storage status display is projected on an outer surface of the bins.,BOEING CO,IBRAHIM YAKENTIM M;;CALLAHAN KEVIN S;;SCHALLA JAMES P,THE BOEING COMPANY (2016-12-15),https://lens.org/144-334-120-871-33X,Patent Application,yes,6,10,16,16,0,B64D11/00;;B64D11/003;;H04N23/63;;B64D47/08;;B61D37/003;;B64D45/00;;B64D2045/007;;B64D47/08;;B64D11/003;;H04N23/63;;B64D11/00;;B64D47/08;;H04N7/18;;H04N23/60;;H04N23/90;;B64D47/08;;B64D11/003;;H04N7/181;;H04N9/31;;B64D45/00;;B61D37/003;;B64D2045/007;;G06V20/52;;H04N23/63;;H04N23/90,G06K9/00;;B64D11/00;;B64D47/08;;H04N5/232;;H04N5/247;;H04N7/18;;H04N9/31,,0,0,,,,ACTIVE
623,EP,A4,EP 1372654 A4,149-993-745-806-811,2007-10-03,2007,EP 02725526 A,2002-04-04,US 0210657 W;;US 28222901 P,2001-04-06,QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES,,SMITHKLINE BEECHAM CORP,BRYAN DEBORAH L;;BURGESS JOELLE L;;CALLAHAN JAMES F,,https://lens.org/149-993-745-806-811,Search Report,no,5,0,8,8,0,A61K31/47;;A61K31/4709;;C07D215/54;;C07D401/12;;A61P13/12;;A61P15/16;;A61P19/00;;A61P25/28;;A61P31/00;;A61P31/10;;A61P31/12;;A61P31/18;;A61P33/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P39/00;;A61P43/00;;A61P7/00;;A61P7/06;;C07D401/12;;A61K31/47;;C07D215/54;;A61K31/4709,A61K31/47;;A61K31/4709;;A61K31/5377;;A61P7/00;;A61P7/06;;A61P13/12;;A61P15/16;;A61P19/00;;A61P25/28;;A61P31/00;;A61P31/10;;A61P31/12;;A61P31/18;;A61P33/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P39/00;;A61P43/00;;C07D215/12;;C07D215/16;;C07D215/18;;C07D215/38;;C07D215/54;;C07D401/12,,2,0,,,"GANAPATHI K: ""Chemotherapy of bacterial infections. II. Synthesis of some sulfanilamide derivatives and the relation of chemical constitution to chemotherapeutic action"", CAPLUS, AN - 1940:41115, 1940, XP002430814;;SOMASEKHARA I S ET AL: ""Synthesis of fused heterocyclics"", CAPLUS, AN - 1956:16402, 1956, XP002430813",DISCONTINUED
624,CA,A1,CA 2678361 A1,187-495-301-374-911,2008-08-21,2008,CA 2678361 A,2008-02-15,US 90196307 P;;US 2765108 A;;US 2767208 A;;US 2008/0054092 W,2007-02-16,THERMAL SPRAY COATINGS AND APPLICATIONS THEREFOR,"This invention relates to coatings for a metal or non-metal substrate com prising (i) a thermal sprayed bondcoat layer applied to said substrate compr ising an alloy of MCrAlM' wherein M is an element selected from nickel, coba lt, iron and mixtures thereof, and M' is an element selected from yttrium, z irconium, hafnium, ytterbium and mixtures thereof, and wherein M comprises f rom about 35 to about 80 weight percent of said alloy, Cr comprises from abo ut 15 to about 45 weight percent of said alloy, Al comprises from about 5 to about 30 weight percent of said alloy, and M' comprises from about 0.01 to about 1.0 weight percent of said alloy, said alloy thermally sprayed from a powder having a mean particle size of 50 percentile point in distribution of from about 5 microns to about 100 microns, said bondcoat having a surface r oughness of at least 200 micro-inches, and said bondcoat having a thermal ex pansion of about 6.5 millimeters per meter or less between a temperature of from about 25°C to about 525°C, and (ii) a thermal sprayed ceramic layer app lied to said bondcoat layer; wherein said coating has a helium leak rate of less than 6 x 10""6 standard cubic centimeters per second. The coatings are u seful for extending the service life under severe conditions, such as those associated with metallurgical vessels' lances,nozzles and tuyeres.",PRAXAIR TECHNOLOGY INC,CALLAHAN SHAWN W;;MEAGHER JAMES PATRICK;;APTE PRASAD SHRIKRISMNA,,https://lens.org/187-495-301-374-911,Patent Application,no,0,3,9,9,0,C23C4/02;;C23C28/3215;;C23C28/34;;C23C28/341;;C23C28/345;;C23C28/3455;;C23C28/36;;C23C28/321;;C23C4/073;;C22C19/05;;C22C19/058;;Y10T428/256;;Y10T428/24355;;Y10T428/24612;;Y10T428/12618;;Y10T428/12931;;Y10T428/24413;;Y10T428/249969;;Y10T428/256;;Y10T428/24355;;Y10T428/24612;;Y10T428/12618;;Y10T428/12931;;Y10T428/24413;;Y10T428/249969;;C23C4/02;;C23C28/34;;C23C28/3455;;C23C28/341;;C23C28/345;;C23C28/36;;C23C28/3215;;C23C28/321;;C22C19/058;;C22C19/05;;C23C4/073,C23C4/08;;C22C19/00;;C23C28/00,,0,0,,,,INACTIVE
625,JP,A,JP 2018135087 A,013-591-491-933-971,2018-08-30,2018,JP 2017239456 A,2017-12-14,US 201615383851 A,2016-12-19,SYSTEM FOR DISPLAYING STATUS OF USE OF AIRCRAFT OVERHEAD LUGGAGE STORAGE BINS,PROBLEM TO BE SOLVED: To provide a system and method for displaying the storage status of overhead luggage storage bins in an aircraft.SOLUTION: A camera 150 is provided that is mounted with a field of view directed at an inner portion of a group of open bins. The camera is communicatively coupled to a controller and selectively provides the controller with images of the inner portion of the bins immediately prior to when the bins are closed. A projector 110 is also provided for each group of bins. The projector is communicatively coupled to the controller and is mounted such that an image received from the controller is projected onto an outer surface of the closed bins. The controller receives images from each of the cameras and selectively provides such images to the projector associated with each camera so that a storage status display is projected on an outer surface of the bins.SELECTED DRAWING: Figure 1A,BOEING CO,YAKENTIM M IBRAHIM;;KEVIN S CALLAHAN;;JAMES P SCHALLA,,https://lens.org/013-591-491-933-971,Patent Application,no,6,0,16,16,0,B64D11/00;;B64D11/003;;H04N23/63;;B64D47/08;;B61D37/003;;B64D45/00;;B64D2045/007;;B64D47/08;;B64D11/003;;H04N23/63;;B64D11/00;;B64D47/08;;H04N7/18;;H04N23/60;;H04N23/90;;B64D47/08;;B64D11/003;;H04N7/181;;H04N9/31;;B64D45/00;;B61D37/003;;B64D2045/007;;G06V20/52;;H04N23/63;;H04N23/90,B64D11/00;;B64D47/08;;H04N5/232;;H04N5/247,,0,0,,,,ACTIVE
626,CS,B2,CS 194845 B2,009-524-893-811-534,1979-12-31,1979,CS 290678 A,1977-07-29,US 71101476 A,1976-08-02,METHOD OF PRODUCING METHACRYLONITRILE,,STANDARD OIL CO OHIO,HARDMAN HARLEY F;;GRASSELLI ROBERT K;;CALLAHAN JAMES L,,https://lens.org/009-524-893-811-534,Granted Patent,no,0,0,26,29,0,B01J23/8876;;B01J2523/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C51/235;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J23/8876;;C07C45/33;;C07C45/34;;C07C51/235;;C07C45/32;;C07C45/37;;C07C51/252;;C07C45/27;;B01J2523/00;;C07C253/24;;Y02P20/52,B01J23/00;;C07C57/05;;B01J23/88;;C07B61/00;;C07C1/00;;C07C5/48;;C07C11/00;;C07C45/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C47/22;;C07C51/00;;C07C51/235;;C07C51/25;;C07C67/00;;C07C253/00;;C07C255/08,,0,0,,,,EXPIRED
627,AU,B2,AU 2001/276923 B2,010-546-038-062-942,2005-02-03,2005,AU 2001/276923 A,2001-07-16,US 22063600 P;;US 21984200 P;;US 0122267 W,2000-07-21,Calcilytic compounds,,SMITHKLINE BEECHAM CORP,LAGO AMPARO M;;CALLAHAN JAMES F;;BHATNAGAR PRADIP K,,https://lens.org/010-546-038-062-942,Granted Patent,no,0,0,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,C07D213/77;;A61K31/4418;;A61K31/4436;;A61K45/06;;A61K47/10;;A61K47/24;;A61K47/28;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,EXPIRED
628,CA,A,CA 1037500 A,028-328-663-773-588,1978-08-29,1978,CA 210722 A,1974-10-03,US 40594073 A,1973-10-12,PROCESS FOR THE PREPARATION OF DIOLEFINS FROM OLEFINS,"PROCESS FOR THE PREPARATION OF DIOLEFINS FROM OLEFINS A catalyst is disclosed wherein the atomic ratios are disclosed by the empirical formula: Aa Cc Dd Fee Bif Mog Ox wherein A is chromium, tellurium, germanium, tungsten, manganese, thorium, niobium, praseodymium, cerium, lanthanum, zinc or mixture thereof; C is an alkali metal, alkaline earth metal, Tl, In, Ag, Cu, Sn, Sb, rare earth metal or mixture thereof; D is nickel, cobalt, magnesium, zinc, cadmium, manganese, calcium or mixture thereof; A is not the same as D; and wherein a is greater than zero to about 4; c is 0 to about 4; d is 0.1 to about 20; e and f are 0.01 to 12; g is 10 to 15; and x is the number of oxygens required by the valence states of the other elements present. This catalyst may be employed for the oxidative dehydrogenation of olefins of 1 to about 10 carbon atoms.",STANDARD OIL CO OHIO,GRASSELLI ROBERT K;;SURESH DEV D;;CALLAHAN JAMES L,,https://lens.org/028-328-663-773-588,Granted Patent,no,0,0,10,10,0,B01J23/887;;B01J23/8871;;B01J23/8872;;B01J23/8873;;B01J23/8874;;B01J23/8875;;B01J23/8876;;B01J23/8877;;B01J23/8878;;C07C5/48;;B01J23/8873;;B01J23/8875;;B01J23/8878;;B01J23/887;;B01J23/8876;;B01J23/8877;;B01J23/8871;;B01J23/8874;;C07C5/48;;B01J23/8872,B01J23/00;;B01J23/88;;C07B61/00;;C07C1/00;;C07C5/48;;C07C11/12;;C07C67/00,260-702.4,0,0,,,,EXPIRED
629,US,A1,US 2005/0043352 A1,025-867-032-962-415,2005-02-24,2005,US 47408403 A,2003-10-06,US 47408403 A;;US 28222901 P;;US 0210657 W,2001-04-06,Quinoline inhibitors of hyak1 and hyak3 kinases,"This invention relates to novel quinoline inhibitors of hYAK1 and hYAK3 kinases and pharmaceutically acceptable salts, hydrates or solvates thereof, pharmaceutical compositions thereof, and methods of treatment of diseases in which an excessive amount of either such kinase is a factor.",BRYAN DEBORAH L.;;BURGESS JOELLE L;;CALLAHAN JAMES F,BRYAN DEBORAH L;;BURGESS JOELLE L;;CALLAHAN JAMES F,SMITHKLINE BEECHAM CORPORATION (2002-04-29),https://lens.org/025-867-032-962-415,Patent Application,yes,4,1,8,8,0,A61K31/47;;A61K31/47;;A61K31/4709;;A61K31/4709;;A61P7/00;;A61P7/06;;A61P13/12;;A61P15/16;;A61P19/00;;A61P25/28;;A61P31/00;;A61P31/10;;A61P31/12;;A61P31/18;;A61P33/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P39/00;;A61P43/00;;C07D401/12;;C07D401/12;;C07D215/54;;C07D215/54,A61K31/47;;A61K31/4709;;A61K31/5377;;A61P7/00;;A61P7/06;;A61P13/12;;A61P15/16;;A61P19/00;;A61P25/28;;A61P31/00;;A61P31/10;;A61P31/12;;A61P31/18;;A61P33/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P39/00;;A61P43/00;;C07D215/54;;C07D401/12,514/312;;514/313,0,0,,,,EXPIRED
630,EP,B1,EP 0107606 B1,030-181-482-385-832,1988-06-08,1988,EP 83630142 A,1983-09-09,US 42824182 A,1982-09-29,METHOD OF SHEET TRANSFER,,BELOIT CORP,"WICKS, LAURIE DAVID;;CRONIN, DENNIS CALLAHAN;;CHANCE, JAMES LARRY",,https://lens.org/030-181-482-385-832,Granted Patent,yes,4,7,23,23,0,D21F2/00;;D21F3/04;;D21F3/045;;D21F3/04;;D21F3/045;;D21F2/00;;D21F3/04,D21F1/00;;D21F2/00;;B65H20/06;;D21F3/02;;D21F3/04,,0,0,,,,EXPIRED
631,CS,B2,CS 184831 B2,053-706-755-227-906,1978-09-15,1978,CS 577874 A,1974-08-20,US 39017573 A,1973-08-20,"MODE OF REGENERATION OF CATALYST USED DURING AMOXIDATION,OXIDATION OR OXIDATION DEHYDROGENATION OF PROPYLENE",,STANDARD OIL CO OHIO,CALLAHAN JAMES L;;MILLER ARTHUR F;;SHAW WILFRID C,,https://lens.org/053-706-755-227-906,Granted Patent,no,0,0,23,23,0,B01J8/26;;B01J23/28;;B01J23/86;;B01J23/92;;B01J23/94;;B01J38/16;;C07C253/26;;Y10S585/901;;Y02P20/584;;Y02P20/52;;B01J35/19;;B01J38/16;;B01J8/26;;C07C253/26;;B01J23/94;;B01J23/28;;B01J23/92;;B01J23/86;;Y10S585/901;;Y02P20/584;;Y02P20/52;;B01J35/19,C07C5/48;;B01J8/26;;B01J23/36;;B01J23/86;;B01J23/92;;B01J23/94;;B01J38/00;;C07B31/00;;C07B33/00;;C07B61/00;;C07C1/00;;C07C11/00;;C07C67/00;;C07C253/00;;C07C255/08,,0,0,,,,EXPIRED
632,HU,A,HU T46342 A,049-768-467-902-400,1988-10-28,1988,HU 11587 A,1987-01-15,US 81933686 A,1986-01-16,PROCESS FOR PRODUCING NEW POLYPEPTIDES,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES F;;HUFFMAN WILLIAM F;;YIM NELSON CH,,https://lens.org/049-768-467-902-400,Unknown,no,0,0,20,24,0,A61K38/00;;A61P7/10;;A61P9/12;;C07K7/16;;C07K7/16;;F28D15/02,C07K14/575;;A61K38/00;;A61K38/095;;A61P7/10;;A61P9/12;;C07C67/00;;C07C227/00;;C07C227/24;;C07C229/28;;C07C239/00;;C07C253/00;;C07C255/31;;C07C269/00;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,EXPIRED
633,US,A1,US 2014/0379602 A1,066-596-150-224-849,2014-12-25,2014,US 201414314303 A,2014-06-25,US 201414314303 A;;US 201361839207 P,2013-06-25,SKILL-DRIVEN EDUCATION MARKETPLACE,"A method and apparatus for presenting education opportunities, careers, and/or job opportunities to a particular user based, at least in part, on the user's identified skill set. The system produces, based, at least in part, on a person's set of skills, one or more careers and/or job opportunities for which the person is currently qualified and/or for which the person may qualify with the acquisition of one or more additional skills. Further, the system identifies and presents educational courses that would help the user to acquire the skills that the user lacks to qualify for particular desired opportunities.",APOLLO EDUCATION GROUP INC,NELSON LANCE J;;CALLAHAN DAVID DRAKE;;UTTER JAMES R,THE UNIVERSITY OF PHOENIX INC (2020-06-26);;APOLLO EDUCATION GROUP INC (2014-07-01),https://lens.org/066-596-150-224-849,Patent Application,yes,0,24,1,1,0,G06Q10/1053;;G06Q10/00;;G06Q10/1053,G06Q50/20;;G06Q10/00,705/327,0,0,,,,DISCONTINUED
634,US,A1,US 2009/0203677 A1,085-433-572-103-02X,2009-08-13,2009,US 36593309 A,2009-02-05,US 36593309 A;;US 2656808 P,2008-02-06,Dual Pharmacophores - PDE4-Muscarinic Antagonistics,"The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,GLAXO GROUP LIMITED (2009-03-12),https://lens.org/085-433-572-103-02X,Patent Application,yes,10,1,21,21,0,C07D471/04;;C07D519/00;;A61P1/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P17/04;;A61P17/06;;A61P27/02;;A61P37/08;;C07D471/04;;C07D519/00,A61K31/437;;A61K31/496;;A61K31/5377;;A61K31/551;;A61P11/06;;C07D471/04,514/218;;546/119;;544/362;;544/127;;540/575;;514/303;;514/253.04;;514/234.2,0,0,,,,INACTIVE
635,US,A,US 3328315 A,097-994-009-179-100,1967-06-27,1967,US 31165763 A,1963-09-26,US 31165763 A;;US 27930863 A;;US 63857767 A,1963-05-09,Promoted catalysts for the oxidation of olefins,,STANDARD OIL CO,CALLAHAN JAMES L;;GRASSELLI ROBERT K;;KNIPPLE WARREN R,,https://lens.org/097-994-009-179-100,Granted Patent,no,14,15,12,15,0,B01J21/00;;B01J21/00;;B01J23/16;;B01J23/16;;B01J23/18;;B01J23/18;;B01J23/6445;;B01J23/6445;;B01J23/681;;B01J23/681;;B01J23/8435;;B01J23/8435;;B01J27/1815;;B01J27/1815;;B01J37/0009;;B01J37/0009;;C07C5/48;;C07C5/48;;C07C45/35;;C07C45/35;;C07C253/26;;C07C253/26;;Y02P20/52;;Y02P20/52;;Y10S502/503;;Y10S502/503;;Y10S502/504;;Y10S502/504;;Y10S585/906;;Y10S585/906,B01J21/00;;B01J23/16;;B01J23/18;;B01J23/644;;B01J23/68;;B01J23/843;;B01J27/18;;B01J37/00;;C07C5/48;;C07C45/35,,0,0,,,,EXPIRED
636,US,A1,US 2004/0039198 A1,140-156-860-546-327,2004-02-26,2004,US 41676103 A,2003-05-14,US 41676103 A;;US 24919900 P;;US 0143994 W,2000-11-16,Compounds,"
   This invention relates to 2-pyridyl substituted diarylimidazoles which are inhibitors of the transforming growth factor, (TGF)- signaling pathway, in particular, the phosphorylation of smad2 or smad3 by the type I or activin-like kinase (ALK)-5 receptor, methods for their preparation and their use in medicine. 
",BENDER PAUL E.;;BURGESS JOELLE L.;;CALLAHAN JAMES F.,BENDER PAUL E;;BURGESS JOELLE L;;CALLAHAN JAMES F,SMITHKLINE BEECHAM CORPORATION (2002-02-07),https://lens.org/140-156-860-546-327,Patent Application,yes,0,20,6,6,0,A61P1/04;;A61P1/16;;A61P9/04;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/02;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P27/02;;A61P43/00;;C07D401/04;;C07D401/04;;C07D401/14;;C07D401/14;;C07D405/14;;C07D405/14,A61K31/4439;;A61K31/4709;;A61P1/04;;A61P1/16;;A61P9/04;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/02;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P27/02;;A61P43/00;;C07D401/04;;C07D401/14;;C07D405/14,544/49;;544/105;;544/284;;544/353;;546/272.7,0,0,,,,DISCONTINUED
637,CH,A,CH 461466 A,161-308-883-413-203,1968-08-31,1968,CH 1509165 A,1965-11-02,US 40872364 A,1964-11-04,Procédé pour préparer des nitriles à non-saturation oléfinique,,STANDARD OIL CO,JAMES LOUIS CALLAHAN;;ERNEST C MILBERGER;;ROBERT KARL GRASSELLI,,https://lens.org/161-308-883-413-203,Granted Patent,no,0,0,15,16,0,B01J8/26;;B01J8/26;;B01J21/08;;B01J21/08;;B01J23/12;;B01J23/12;;B01J23/18;;B01J23/18;;C07C45/34;;C07C45/34;;C07C45/35;;C07C45/35;;C07C253/26;;C07C253/26;;Y02P20/52;;Y02P20/52,C07C47/22;;B01J8/26;;B01J21/08;;B01J23/00;;B01J23/12;;B01J23/18;;B01J35/00;;C07B61/00;;C07C45/00;;C07C45/34;;C07C45/35;;C07C67/00;;C07C253/00;;C07C255/08,"12O,21",0,0,,,,EXPIRED
638,AU,A1,AU 2009/212408 A1,171-762-174-501-078,2009-08-13,2009,AU 2009/212408 A,2009-02-05,US 2656308 P;;US 2009/0033128 W,2008-02-06,Dual pharmacophores-PDE4-muscarinic antagonistics,,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;YAN HONGXING;;WAN ZEHONG;;LIN GUOLIANG,,https://lens.org/171-762-174-501-078,Patent Application,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/08;;A61P43/00;;C07D471/04;;C07D519/00,A01N43/90;;A01N43/56;;A61K31/519,,0,0,,,,DISCONTINUED
639,AU,A1,AU 2006/229995 A1,199-536-178-994-528,2006-10-05,2006,AU 2006/229995 A,2006-03-24,US 66515405 P;;US 2006/0010859 W,2005-03-25,"Process for preparing pyrido(2,3-d)pyrimidin-7-one and 3,4-dihydropyrimido(4,5-d)pyrimidin-2(1H)-one derivatives",,GLAXO GROUP LTD,WAN ZEHONG;;YAN HONGXING;;BOEHM JEFFREY;;CALLAHAN JAMES FRANCIS,,https://lens.org/199-536-178-994-528,Patent Application,no,0,0,22,22,0,C07D471/04;;C07D487/04;;A61P43/00;;C07D471/04;;C07D487/04;;C07D487/04;;C07D471/04,A61K31/519;;C07D487/02,,0,0,,,,DISCONTINUED
640,CN,A,CN 114533927 A,027-811-705-249-332,2022-05-27,2022,CN 202111414125 A,2021-11-25,US 202063118031 P;;US 202117348889 A,2020-11-25,Ultraviolet light disinfection system and method,"An ultraviolet light disinfection system and method are disclosed. A system and method for sterilizing one or more components includes one or more ultraviolet (UV) lamps. The one or more UV lamps include one or more UV light emitters configured to emit UV light, and a mounting interface removably secured to the stationary mount.",BOEING CO,CHILDRESS JAMES J;;KEVIN S CALLAHAN;;KING TIMOTHY A,,https://lens.org/027-811-705-249-332,Patent Application,no,0,0,3,18,0,A61L2/24;;A61L2/10;;A61L2202/14;;A61L2/10;;A61L2/24;;A61L2202/11;;A61L2202/14;;A61L2202/25;;A61L9/20;;A61L2209/111;;A61L2209/15,A61L2/24;;A61L2/10,,0,0,,,,PENDING
641,US,A1,US 2010/0093765 A1,040-107-062-434-99X,2010-04-15,2010,US 61892709 A,2009-11-16,US 61892709 A;;US 38911206 A;;US 66534705 P,2005-03-25,NOVEL COMPOUNDS,"Novel substituted 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-(1H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.",CALLAHAN JAMES F;;WAN ZEHONG;;YAN HONGXING;;LIN XICHEN,CALLAHAN JAMES F;;WAN ZEHONG;;YAN HONGXING;;LIN XICHEN,,https://lens.org/040-107-062-434-99X,Patent Application,yes,0,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,A61K31/519;;A61P35/00;;C07D475/06,514/262.1;;544/258,0,0,,,,DISCONTINUED
642,DO,A,DO P2010000239 A,055-041-190-154-031,2011-03-31,2011,DO 2010000239 A,2010-08-03,US 2656808 P,2008-02-06,FARMACOFOROS DUALES-ANTAGONISTAS MUSCARINICOS DE PDE4,"La presente invencion se refiere a nuevos compuestos de Formula (I) y a su uso en el tratamiento de enfermedades respiratorias, incluyendo enfermedades antiinflamatorias y alergicas tales como enfermedad pulmonar obstructiva cronica (COPD), asma, rinitis (por ejemplo, rinitis alergica), dermatitis atopica o psoriasis.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/055-041-190-154-031,Patent Application,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P1/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P17/04;;A61P17/06;;A61P27/02;;A61P37/08;;C07D471/04;;C07D519/00,,,0,0,,,,PENDING
643,EP,B1,EP 0183391 B1,064-746-538-253-337,1993-02-03,1993,EP 85307762 A,1985-10-28,US 67228684 A,1984-11-16,SYNTHESIS OF MOLECULAR SIEVING METALLOSILICATES USING SILICA-TRANSITION METAL OXIDE SOLS,,THE STANDARD OIL COMPANY,"PEPERA, MARC ANTHONY;;CALLAHAN, JAMES LOUIS;;DESMOND, MICHAEL JOSEPH",,https://lens.org/064-746-538-253-337,Granted Patent,yes,8,0,10,10,0,B01J29/04;;B01J29/04;;C01B33/2884;;C01B33/2884;;C01B33/2876;;C01B33/2876,C01B33/20;;B01J29/00;;B01J29/04;;C01B39/06;;C07B61/00;;C07C1/20;;C07C5/27;;C07C15/073;;C07C15/08,,0,0,,,,EXPIRED
644,MX,A,MX 2010008690 A,078-857-465-673-655,2010-08-30,2010,MX 2010008690 A,2009-02-05,US 2656308 P;;US 2009/0033128 W,2008-02-06,DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS.,"The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.",GLAXO GROUP LTD,WAN ZEHONG;;YAN HONGXING;;CALLAHAN JAMES FRANCIS;;LIN GUOLIANG,,https://lens.org/078-857-465-673-655,Patent Application,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/08;;A61P43/00;;C07D471/04;;C07D519/00,A01N43/90;;A01N43/56;;A61K31/519,,0,0,,,,DISCONTINUED
645,BR,A2,BR PI0907519 A2,089-016-332-187-55X,2015-07-28,2015,BR PI0907519 A,2009-02-05,US 2656808 P;;US 2009/0033129 W,2008-02-06,Antagonistas farmacoforos-pde4-muscarínicos duais,,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/089-016-332-187-55X,Patent Application,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P1/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P17/04;;A61P17/06;;A61P27/02;;A61P37/08;;C07D471/04;;C07D519/00,A01N43/42,,0,0,,,,DISCONTINUED
646,CA,A,CA 756631 A,087-388-457-958-551,1967-04-11,1967,CA 756631D A,,CA 756631T A,,PROCESS FOR PREPARING OLEFINICALLY UNSATURATED ALDEHYDES AND NITRILES,,STANDARD OIL CO,CALLAHAN JAMES L;;GRASSELLI ROBERT K;;MILBERGER ERNEST C,,https://lens.org/087-388-457-958-551,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
647,EP,A1,EP 0057320 A1,088-900-813-864-540,1982-08-11,1982,EP 81305782 A,1981-12-08,US 22185980 A,1980-12-31,Mixed metal phosphorus oxide catalysts for the oxidative dehydrogenation of carboxylic acids utilizing them and preparation thereof.,"A catalyst composition represented by the formula
  wherein A is selected Cd, Cr, Ge, Te, Th, Ti, U, V, Zr, rare earths and mixtures thereof; wherein D is selected from Ag, Cu, Mn and mixtures thereof; and wherein
 a = 0-1.0 b = 0.75-1.5 c = 1.0-2.0 d = 0-2.0 a + d is greater than zero and x is the number of oxygens needed to satisfy the valence requirements of the remaining elements. This catalyst is particularly suitable for the oxydehydrogenation of saturated carboxylic acids, such as isobutyric acid, to form alpha, beta unsaturated carboxylic acids, such as methacrylic acid.",STANDARD OIL CO OHIO,PEDERSEN SVEND ERIK;;CALLAHAN JAMES LOUIS;;HARDMAN HARLEY FOCH,,https://lens.org/088-900-813-864-540,Patent Application,yes,4,0,9,11,0,B01J27/18;;B01J27/186;;B01J23/89;;B01J23/8933;;B01J27/1853;;C07C51/377;;C07C51/377,C07C57/04;;B01J23/89;;B01J27/00;;B01J27/18;;B01J27/185;;B01J27/186;;C07B61/00;;C07C51/00;;C07C51/377;;C07C67/00;;C07C253/00;;C07C255/23,,0,0,,,,EXPIRED
648,DE,D1,DE 2965319 D1,098-348-234-062-769,1983-06-09,1983,DE 2965319 T,1979-09-28,US 95426278 A,1978-10-24,A PROCESS FOR THE OXIDATION OF PROPYLENE TO ACRYLIC ACID AND OF ISOBUTYLEN TO METHACRYLIC ACID,,STANDARD OIL CO OHIO,CALLAHAN JAMES LOUIS;;SHAW WILFRIED GARSIDE;;MILLER ARTHUR FRANCIS,,https://lens.org/098-348-234-062-769,Granted Patent,no,0,0,4,6,0,B01J8/0453;;B01J8/048;;B01J8/34;;C07C253/26;;C07C51/252,B01J8/24;;B01J8/04;;B01J8/34;;C07C51/25,,0,0,,,,EXPIRED
649,US,B2,US 7674789 B2,130-310-896-165-024,2010-03-09,2010,US 38911206 A,2006-03-24,US 38911206 A;;US 66534705 P,2005-03-25,Compounds,"The present invention is directed to compounds of formula (I), (Ia),(Ic) and (Id), compositions, and uses thereof as an inhibitor of the p38 kinase, and wherein, inter alia R 1 is C(Z)N(R 10′ )(CR 10 R 20 ) v R b , C(Z)O(CR 10 R 20 ) v R b , N(R 10′ )C(Z)(CR 10 R 20 ) v R b ; N(R 10′ )C(Z)N(R 10′ )(CR 10 R 20 ) v R b ; or N(R 10′ )OC(Z)(CR 10 R 20 ) v R b ;R 3 is C 1-10 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl C 1-10 alkyl, aryl, arylC 1-10 alkyl, heteroarylC 1-10 alkyl, or a heterocyclylC 1-10 alkyl moiety, and wherein each of these moieties may be optionally substituted;X is R 2 , OR 2′ , S(O) m R 2′ , (CH 2 ) n′ N(R 10′ )S(O) m R 2′ , (CH 2 ) n′ N(R 10′ )C(O)R 2′ , (CH 2 ) n′ NR 4 R 14 , (CH 2 ) n′ N(R 2 ′ )(R 2″ ), or N(R 10′ )—R h —NH—C(═N—CN)NRqRq′; andR 2 is hydrogen, C 1-10 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkylalkyl, aryl, arylC 1-10 alkyl, heteroaryl, heteroarylC 1-10 alkyl, heterocyclic, or a heterocyclylC 1-10 alkyl moiety, and wherein each of these moieties, excluding hydrogen, may be optionally substituted; or a pharmaceutically acceptable salt thereof.",GLAXO GROUP LTD,CALLAHAN JAMES F;;WAN ZEHONG;;YAN HONGXING;;LIN XICHEN,GLAXO GROUP LIMITED (2006-05-26),https://lens.org/130-310-896-165-024,Granted Patent,yes,81,1,33,33,1,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,A61K31/5355;;A61K31/519;;A61P29/00;;C07D239/30;;C07D239/38;;C07D487/04,514/234.2;;514/264.1;;514/264.11;;514/218;;544/279;;544/118;;544/326;;544/316;;544/317;;540/553,99,56,075-868-082-984-637;;010-281-016-005-743;;050-202-509-159-647;;027-044-424-195-732;;009-270-336-024-717;;132-837-931-216-979;;008-272-662-905-432;;052-009-228-330-151;;116-338-838-439-338;;018-278-523-061-292;;012-960-512-921-932;;070-293-335-615-447;;086-270-071-053-469;;131-233-054-471-359;;062-434-801-823-152;;032-681-612-390-618;;182-920-176-787-532;;051-392-666-499-166;;149-456-985-467-499;;088-330-706-671-194;;115-003-256-166-770;;056-064-561-723-239;;031-226-339-998-209;;019-815-058-706-805;;076-427-946-117-710;;019-006-450-328-079;;014-078-643-675-713;;024-792-986-385-671;;124-684-411-903-025;;044-639-268-079-201;;021-487-746-185-54X;;085-439-840-914-302;;056-362-966-337-366;;010-945-971-327-360;;051-341-161-739-275;;125-819-089-880-217;;088-745-019-034-067;;125-111-771-320-163;;031-093-628-703-132;;062-224-469-353-287;;064-931-017-755-256;;038-105-202-686-806;;002-217-128-090-827;;053-912-117-245-015;;034-334-788-871-50X;;085-109-294-118-867;;122-627-349-497-578;;009-672-786-510-052;;065-910-877-309-25X;;063-234-570-863-113;;084-066-815-352-752;;040-299-395-201-392;;046-324-178-296-364;;041-231-504-503-302;;024-792-986-385-671;;069-359-873-985-449,8831759;;10.1021/jm960415o;;10.1016/8756-3282(94)90277-1;;7980964;;10.1135/cccc19811167;;7914033;;10.1126/science.7914033;;9308510;;10.1001/archinte.1997.00440380091009;;10.1001/archinte.157.17.1981;;10.1248/cpb.37.2214;;10.1074/jbc.272.30.18518;;9228012;;10.1016/s0040-4039(00)86691-5;;10.1021/jo01047a024;;10.1021/jo00200a045;;10.1021/jo00426a013;;839323;;10.1016/s0968-0896(96)00212-x;;9043657;;10.1016/s0040-4039(01)92491-8;;2101013;;10.1248/cpb.24.2057;;991360;;10.1002/jhet.5570210229;;10.1002/jhet.5570340520;;8627606;;10.1021/jm9508651;;12937622;;10.1517/13543776.7.7.729;;10.1016/s0960-894x(98)00589-7;;9873730;;10.1016/s1357-4310(99)01544-0;;10498912;;5671228;;10.1021/jm00310a015;;10.1089/jir.2005.25.1;;15684617;;10878289;;10.1016/s0162-3109(00)00206-x;;11468165;;10.1182/blood.v98.3.667;;10.1021/jo00815a045;;10734180;;10525088;;15341488;;10.1021/jm0499054;;12565952;;10.1016/s0960-894x(02)00990-3;;10.1002/1529-0131(200001)43:1<175::aid-anr22>3.0.co;2-s;;10643714;;8968371;;10.1093/humrep/17.2.426;;11821289;;10.1074/jbc.274.43.30858;;10521478;;6690624;;10.1007/bf00918247;;3902871;;3142488;;10.1002/art.1780311110;;9279247;;10.1164/ajrccm.156.2.9610079;;10.1074/jbc.274.38.27161;;10480932;;9454815;;12951578;;10.1038/nrd1177;;11274345;;10.1152/physrev.2001.81.2.807;;10.1124/mol.62.1.58;;12065755;;10.1111/j.1749-6632.1993.tb17149.x;;8109825;;10.1016/s0163-7258(99)00008-x;;10454214;;10.1016/0092-8674(95)90401-8;;7834738;;14996754;;10.1158/0008-5472.can-03-3448;;10.1016/s0898-6568(99)00071-6;;10676842;;12725866;;10.1016/s0163-7258(03)00016-0;;10.1038/ni748;;11743587;;pmc185229;;10.1172/jci118067;;7615827;;9001279;;10.1164/ajrccm.155.1.9001279;;9564459;;10.1086/513922;;10734180;;10.1016/s0015-0282(99)00556-7;;10685517,"U.S. Appl. No. 11/613,517, filed Dec. 20, 2006, Adams, et al.;;U.S. Appl. No. 11/613,598, filed Dec. 20, 2006, Adams, et al.;;U.S. Appl. No. 11/871,039, filed Oct. 11, 2007, Adams, et al.;;U.S. Appl. No. 11/839,830, filed Aug. 16, 2007, Adams, et al.;;U.S. Appl. No. 11/839,833, filed Aug. 16, 2007, Adams, et al.;;U.S. Appl. No. 11/839,834, filed Aug. 16, 2007, Adams, et al.;;U.S. Appl. No. 11/908,435, filed Sep. 12, 2007, Callahan, et al.;;U.S. Appl. No. 11/908,440, filed Sep. 12, 2007, Callahan, et al.;;U.S. Appl. No. 11/908,839, filed Sep. 17, 2007, Callahan, et al.;;Adams et al., Progress in Medicinal Chemistry, vol. 38, pp. 2-61 (2001).;;Armarego, W., Chem. Soc., Quinzolines, Part IV (JCSOA9) p. 561 (1962).;;Boehm et al., J. Med. Chem. vol. 39, pp. 3929-3937 (1996).;;Votta et al., Bone, vol. 15 (5) pp. 533-538 (1994).;;Bradlerova et al., Chem. Zvesti, vol. 29 (6), pp. 795-802 (1975).;;de Silva et al., J. Chem. Soc., vol. 4, pp. 685-690 (1995).;;Engel & Steglich, Liebigs Ann. Chem., p. 1916 (1978).;;Ferles et al., Collect. Czech. Chem. Commun., vol. 5 (46), pp. 1167-1172 (1981).;;Fischer et al., Rec. Trav. Chim. Pays. Bas., vol. 84, p. 439 (1965).;;Fulmer et al., J. Heterocycl. Chem., vol. 17 (4), pp. 799-800 (1980).;;Gilbert, E., Synthesis, pp. 30-32 (1972).;;Han et al., Science, vol. 265, pp. 808-811 (1994).;;Hunter et al., Academic Press, San Diego, vol. 200, p. 3 (1991).;;Irwin et al., Archives of Internal Medicine, vol. 157 (17), pp. 1981-1987 (1997).;;Ishibashi et al., Chem. Pharm. Bull., vol. 37(8), pp. 2214-2216 (1989).;;Johnson et al., PG.A., J.Chem.Soc., Perkin Trans., vol. 1, pp. 895-905 (1996).;;Jurkowska-Kowalczyk, R., Chem., vol. 51 (6), pp. 1191-1199 (1977).;;Katritzky et al., Synthesis, pp. 45-47 (Jan. 1993).;;Kawasaki et al., J. Bio. Chem., vol. 272(30), pp. 18518-18521 (1997).;;Mikailu et al., Zh. Obshch. Khim., vol. 56 (7), pp. 1513-1517 (1986).;;Morton et al., Tetrahedron Letters, p. 4123 (1982).;;Protecting Groups in Organic Synthesis, 2nd Edition, Greene TW and Wuts PSM, Wiley-Interscience, New York, pp. 10-174 (Hydroxyl and Phenolic) and pp. 309-403 (NH protection) (1991).;;Santilli et al., J. Heterocycl Chem., vol. 8, pp. 445-453 (1971).;;Snieckus, V., Tetrahedron Letters, vol. 29, p. 2135 (1988).;;Stille et al., J. Amer. Chem. Soc., vol. 109, p. 5478 (1978).;;Strzybny et al., J. Org. Chem., vol. 28, p. 3381 (1963).;;Terashimia et al., M., Chem. Pharm. Bull., vol. 11, p. 4755 (1985).;;Thompson et al., J. Org. Chem., vol. 49, p. 5237 (1984).;;Uno et al., Bull. Chem. Soc. Japan., vol. 69, pp. 1763-1767 (1996).;;Vartanyan et al., vol. 40, (9), pp. 552-560 (1987).;;Borrel, et al., Coll. Czech. Chem. Commun., 1996, 61(6) pp. 901-909.;;Baker et al., J. Heterocyclic Chem., 1964, vol. 1, pp. 263-270.;;Anderson et al., J. Org. Chem., 1977, vol. 42, p. 993.;;Victory et al., Heterocycles, 1985, 23(5), pp. 1135-1141.;;Gallagher et al., Bioorganic and Med Chem, vol. 5(1), pp. 49-64 (1997).;;Garigipati, R., Tetrahedron Letters, vol. 31,p. 190 (1989).;;Kumada et al., Tetrahedron Letters, vol. 22, p. 5319 (1981).;;Lamartina et al., Boll. Chim. Farm., vol. 129 (12), pp. 314-316 (1990).;;Victory et al., Heterocycles, 1985, 23(8), pp. 1947-1950.;;Victory et al., AFINIDAD, Mar. 1989, vol. 46, pp. 107-113 (Spanish).;;Victory et al., J. Heterocycl. Chem, 1988, vol. 25, pp. 245-247.;;Klotzer et al., Monatsh Chem., 1965, vol. 96, p. 1567.;;Nishikawa et al., Chemical Pharm. Bull., 1976, vol. 24(9), pp. 2057-2077.;;Carboni et al., Gazzetta Chimica Italiana, vol. 97(8) pp. 1262-1273 (1967).;;Carboni et al., Gazzetta Chimica Italiana, vol. 98(10) pp. 1174-1188 (1968).;;Ferrarini et al., Journal of Heterocyclic Chemistry, vol. 21(2) pp. 417-419 (1984).;;Ferrarini et al., Journal of Heterocyclic Chemistry, vol. 34(5) pp. 1501-1510 (1997).;;Rewcastle et al., Journal of Medicinal Chemistry, 1996 39(6), pp. 1823-1835.;;Zavyalov, et al., Khim Farm Zh, vol. 26(3), p. 88 (1992) (With Translation).;;Foster, et al., Drug News Perspect., vol. 13(8) pp. 488-497 (2000).;;Hanson, G., Expert Opinion on Therapeutic Patents, vol. 7(7) pp. 729-733 (1997).;;Henry, et al., Bioorganic & Medicinal Chemistry Letters, vol. 8 pp. 3335-3340 (1998).;;Herlaar, et al., Molecular Medicine Today, vol. 5 pp. 439-447 (1999).;;Hurlbert, et al., J. Med. Chem., 1968, vol. 11, pp. 703-707.;;Khabar, Khalid, Journal of Interferon & Cytokine Research, vol. 25 pp. 1-10 (2005).;;Lee, et al., Immunopharmacology, vol. 47(2-3) pp. 185-201 (2000).;;Marin, et al., Blood, vol. 98(3) pp. 667-673 (2001).;;Schoffstall, J Org Chem, vol. 36(16) pp. 2385-2387 (1971).;;Underwood, et al., Journal of Pharmacology and Experimental Therapeutics, vol. 293 (1) pp. 281-288 (2000).;;Wadsworth, et al., Journal of Pharmacology and Experimental Therapeutics, vol. 291(2) pp. 680-687 (1999).;;Hare, et al., J. Med Chem., vol. 47 pp. 4731-4740 (2004).;;Hunt, et al., Bioorganic & Medicinal Chemistry Letters, vol. 13 pp. 467-470 (2003).;;Badger et al., Circulatory Shock, vol. 27, 1991, pp. 51-61.;;Badger, et al., Arthritis Rheum., vol. 43 pp. 175-183 (2000).;;Badger, et al., J. Pharm. Exp. Thera., vol. 279(3) pp. 1453-1461 (1996).;;Bedaiwy, et al., Human Reproduction, vol. 17 pp. 426-431 (2002).;;Carter, et al., J. Biological Chem., vol. 274 pp. 30858-30864 (1999).;;Colotta et al., J. Immunol., 132(2), p. 936 (1984).;;Dinarello, J. Clinical Immunology, vol. 5(5) pp. 287-597 (1985).;;Griswold et al., Drugs Exptl. Clin. Res., XIX(6), 1993, pp. 243-248.;;Griswold et al., Arthritis and Rheumatism, vol. 31 No. 11, Nov. 1998, pp. 1406-1412.;;Grunberg et al., Am. J. Respir. Crit. Care Med., vol. 156, 1997, p. 609.;;Hanafusa, et al., J. Biol. Chem., vol. 274 pp. 27161-27167 (1999).;;Jackson, et al., J. Pharmacol. Exp. Ther., vol. 284 p. 687-692 (1998).;;Kumar, et al., Nature Rev. Drug Discovery, vol. 2 p. 717 (2003).;;Kyriakis, et al., J. Physiol. Rev., vol. 81 pp. 807-869 (2001).;;Laping, et al., Molec. Pharmacol., vol. 62 pp. 58-64 (2002).;;Lee, et al., Annals NY Acad. Sci., vol. 696 p. 149 (1993).;;Lee, et al., Pharmacol. Ther. vol. 82(2-3) pp. 389-397 (1999).;;Marshall, et al., Cell, vol. 80 pp. 179-278 (1995).;;Morin, et al., Cancer Research, vol. 64 pp. 1893-1898 (2004).;;Ono, et al., Cellular Signalling, vol. 12 pp. 1-13 (2000).;;Platanias, Pharmacol. Therap vol. 98 pp. 129-142 (2003).;;Saccini, Nature Immunology, vol. 3 pp. 69-75 (2002).;;Subauste et al., J. Clin. Invest., vol. 96, 1995, p. 549.;;Teren et al., Am. J. Respir. Crit. Care Med., vol. 155, 1997, p. 1362.;;Turner et al. Clin. Infect. Dis., vol. 26, 1998, p. 840.;;Underwood, et al., J. Pharmacol. Exp Ther., vol. 293 pp. 281-288 (2000).;;Votta et al., Int J Immunotherapy ,VI(1), 1990, pp. 1-12.;;Witz, Fertility and Sterility, vol. 73 pp. 212-214 (2000).",INACTIVE
650,US,A,US 4171454 A,168-206-566-917-296,1979-10-16,1979,US 56678275 A,1975-04-10,US 56678275 A;;US 27138772 A;;US 49042974 A,1972-07-13,Oxidation process utilizing amphora catalysts,"Catalysts having a substantially spherical shape, a void center and a hole in the external surface communicating to the void center have been found to be especially effective in the oxidation of monoolefins to the corresponding unsaturated oxygenated compounds.",STANDARD OIL CO OHIO,CALLAHAN JAMES L;;MILLER ARTHUR F;;SHAW WILFRID G,,https://lens.org/168-206-566-917-296,Granted Patent,yes,5,14,1,15,0,B01J23/8876;;B01J2523/00;;C07C45/35;;C07C51/252;;B01J35/50;;C07C45/35;;B01J2523/00;;C07C51/252;;B01J23/8876;;B01J35/50,B01J23/887;;B01J35/02;;C07C45/35;;C07C51/25,562/546,0,0,,,,EXPIRED
651,US,A,US 4864057 A,152-524-664-761-048,1989-09-05,1989,US 40886082 A,1982-08-17,US 40886082 A;;US 22185980 A,1980-12-31,Dehydrogenation of carboxylic acids with mixed metal phosphorus oxide catalysts,"A process is provided for the oxydehydrogenation of saturated carboxylic acids or a lower alkyl ester thereof with oxygen in the presence of iron phosphorus oxide catalysts containing promoters selected from the group Ag, Al, B, Be, Cd, Co, Cu, Ga, Ge, In, Mn, Ni, Te, Th, Ti, Tl, U, V, Zn, Zr, rare earths and mixtures thereof.",PEDERSEN S ERIK;;CALLAHAN JAMES L;;HARDMAN HARLEY F,PEDERSEN S ERIK;;CALLAHAN JAMES L;;HARDMAN HARLEY F,,https://lens.org/152-524-664-761-048,Granted Patent,yes,23,1,1,11,0,B01J27/186;;B01J27/186;;B01J23/8933;;B01J23/8933;;B01J27/1853;;B01J27/1853;;C07C51/377;;C07C51/377,B01J23/89;;B01J27/185;;B01J27/186;;C07C51/377,560/214;;502/208;;558/383;;562/405;;562/599,1,0,,,European Patent Appln. No. 0 000 617 The Standard Oil Company Production of Unsubstituted and Substituted Indene .,EXPIRED
652,US,A,US 3882159 A,181-148-216-311-604,1975-05-06,1975,US 39017573 A,1973-08-20,US 39017573 A,1973-08-20,Reactivation of molybdenum containing oxidation catalysts in fluid bed reactors,Molybdenum-containing oxidation catalysts used in a fluid-bed reactor have been discovered to become partially deactivated through loss of molybdenum from the catalyst. These partially deactivated catalysts are regenerated in situ by the addition of fluid-bed particles consisting of an essentially inert support material containing molybdenum.,STANDARD OIL CO,CALLAHAN JAMES L;;SHAW WILFRID G;;MILLER ARTHUR F,,https://lens.org/181-148-216-311-604,Granted Patent,no,7,45,23,23,0,B01J8/26;;B01J23/28;;B01J23/86;;B01J23/92;;B01J23/94;;B01J38/16;;C07C253/26;;Y10S585/901;;Y02P20/584;;Y02P20/52;;B01J35/19;;B01J38/16;;B01J8/26;;C07C253/26;;B01J23/94;;B01J23/28;;B01J23/92;;B01J23/86;;Y10S585/901;;Y02P20/584;;Y02P20/52;;B01J35/19,C07C5/48;;B01J8/26;;B01J23/36;;B01J23/86;;B01J23/92;;B01J23/94;;B01J38/00;;C07B31/00;;C07B33/00;;C07B61/00;;C07C1/00;;C07C11/00;;C07C67/00;;C07C253/00;;C07C255/08,260/465.3,0,0,,,,EXPIRED
653,US,A1,US 2008/0199684 A1,189-200-052-462-882,2008-08-21,2008,US 2767208 A,2008-02-07,US 2767208 A;;US 90196307 P,2007-02-16,THERMAL SPRAY COATINGS AND APPLICATIONS THEREFOR,"This invention relates to coatings for a metal or non-metal substrate comprising (a) a thermal sprayed bondcoat layer applied to said substrate, said bondcoat layer comprising: (i) a thermal sprayed inner layer comprising an inner layer alloy of MCrAlM′ wherein M is an element selected from nickel, cobalt, iron and mixtures thereof, and M′ is an element selected from yttrium, zirconium, hafnium, ytterbium and mixtures thereof; and (ii) a thermal sprayed outer layer comprising an outer layer alloy of MCrAlM′ wherein M is an element selected from nickel, cobalt, iron and mixtures thereof, and M′ is an element selected from yttrium, zirconium, hafnium, ytterbium and mixtures thereof, and (b) a thermal sprayed ceramic layer applied to said bondcoat layer. The coatings are useful for extending the service life under severe conditions, such as those associated with metallurgical vessels' lances, nozzles and tuyeres.",APTE PRASAD SHRIKRISNNA;;MEAGHER JAMES PATRICK;;CALLAHAN SHAWN W,APTE PRASAD SHRIKRISNNA;;MEAGHER JAMES PATRICK;;CALLAHAN SHAWN W,PRAXAIR S. T. TECHNOLOGY INC (2008-02-14),https://lens.org/189-200-052-462-882,Patent Application,yes,15,6,9,9,0,C23C4/02;;C23C28/3215;;C23C28/34;;C23C28/341;;C23C28/345;;C23C28/3455;;C23C28/36;;C23C28/321;;C23C4/073;;C22C19/05;;C22C19/058;;Y10T428/256;;Y10T428/24355;;Y10T428/24612;;Y10T428/12618;;Y10T428/12931;;Y10T428/24413;;Y10T428/249969;;Y10T428/256;;Y10T428/24355;;Y10T428/24612;;Y10T428/12618;;Y10T428/12931;;Y10T428/24413;;Y10T428/249969;;C23C4/02;;C23C28/34;;C23C28/3455;;C23C28/341;;C23C28/345;;C23C28/36;;C23C28/3215;;C23C28/321;;C22C19/058;;C22C19/05;;C23C4/073,B32B5/16;;B32B3/00;;C23C4/06,428/328;;427/456;;428/172;;428/141,0,0,,,,ACTIVE
654,US,B2,US 7087758 B2,177-153-506-743-490,2006-08-08,2006,US 47408403 A,2003-10-06,US 47408403 A;;US 28222901 P;;US 0210657 W,2001-04-06,Quinoline inhibitors of hyaki and hyak3 kinases,"This invention relates to novel quinoline inhibitors of hYAK1 and hYAK3 kinases and pharmaceutically acceptable salts, hydrates or solvates thereof, pharmaceutical compositions thereof, and methods of treatment of diseases in which an excessive amount of either such kinase is a factor.",SMITHKLINE BEECHAM CORP,BRYAN DEBORAH L;;BURGESS JOELLE L;;CALLAHAN JAMES F,SMITHKLINE BEECHAM CORPORATION (2002-04-29),https://lens.org/177-153-506-743-490,Granted Patent,yes,6,9,8,8,0,A61K31/47;;A61K31/47;;A61K31/4709;;A61K31/4709;;A61P7/00;;A61P7/06;;A61P13/12;;A61P15/16;;A61P19/00;;A61P25/28;;A61P31/00;;A61P31/10;;A61P31/12;;A61P31/18;;A61P33/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P39/00;;A61P43/00;;C07D401/12;;C07D401/12;;C07D215/54;;C07D215/54,A61K31/47;;A61K31/4709;;A61K31/5377;;A61P7/00;;A61P7/06;;A61P13/12;;A61P15/16;;A61P19/00;;A61P25/28;;A61P31/00;;A61P31/10;;A61P31/12;;A61P31/18;;A61P33/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P39/00;;A61P43/00;;C07D215/12;;C07D215/38;;C07D215/54;;C07D401/12,546/161;;546/167;;546/159;;514/311;;514/314,0,0,,,,EXPIRED
655,BR,A2,BR PI0908075 A2,193-483-188-152-098,2015-08-25,2015,BR PI0908075 A,2009-02-05,US 2657208 P;;US 2009/0033130 W,2008-02-06,Antagonísta muscarínicos de pde4-duplos farmacóforos,,GLAXO GROUP LIMIDED,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/193-483-188-152-098,Patent Application,no,0,0,20,20,0,C07D471/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/00;;A61P37/08;;A61P43/00;;C07D471/04,A01N43/42,,0,0,,,,DISCONTINUED
656,MX,A,MX 2007012951 A,021-156-655-288-213,2008-01-11,2008,MX 2007012951 A,2006-03-24,US 66515405 P;;US 2006/0010859 W,2005-03-25,"PROCESS FOR PREPARING PYRIDO[2,3-D]PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE DERIVATIVES.","The present invention is directed to a novel method of preparing of 2,4,8- trisubstituted pyrido[2,3-d]pyrimidin-7-one pharmacophores of Formula (II) or (Ha) wherein GHs CH2 Or NH: G2 is CH or nitrogen; Rx is chloro, bromo, iodo, or O-S(O)2CF3; Rg is a C1 10 alkyl; m is 0, or an integer having a value of 1 , or 2; R3 is a C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-10 alkyl, aryl, arylC1-10 alkyl, heteroaryl, heteroarylC1-10 alkyl, heterocyclic or a heterocyclylC1-10 alkyl moiety, and wherein each of these moieties may be optionally substituted. which comprises reacting a compound of the formula: wherein Ry is chloro, bromo, iodo, O-S(O)2CF3; and Rg is a C1-10 alkyl; with a olefin forming reagent in a suitable base to yield a compound of Formula (II), or (Ha) wherein m=0 and oxidizing the sulphur as necessary or desired.",GLAXO GROUP LTD,WAN ZEHONG;;CALLAHAN JAMES FRANCIS;;BOEHM JEFFREY;;YANG HONGXING,,https://lens.org/021-156-655-288-213,Patent Application,no,0,0,22,22,0,C07D471/04;;C07D487/04;;A61P43/00;;C07D471/04;;C07D487/04;;C07D487/04;;C07D471/04,C07D487/02;;A61K31/519,,0,0,,,,ACTIVE
657,DE,A1,DE 2447825 A1,034-325-734-743-268,1975-08-28,1975,DE 2447825 A,1974-10-08,US 40594073 A,1973-10-12,VERFAHREN ZUR HERSTELLUNG VON DIOLEFINEN DURCH OXYDATIVE DEHYDRIERUNG VON OLEFINEN,,STANDARD OIL CO OHIO,GRASSELLI ROBERT KARL;;SURESH DEV DHANARAJ;;CALLAHAN JAMES LOUIS,,https://lens.org/034-325-734-743-268,Patent Application,no,0,30,10,10,0,B01J23/887;;B01J23/8871;;B01J23/8872;;B01J23/8873;;B01J23/8874;;B01J23/8875;;B01J23/8876;;B01J23/8877;;B01J23/8878;;C07C5/48;;B01J23/8873;;B01J23/8875;;B01J23/8878;;B01J23/887;;B01J23/8876;;B01J23/8877;;B01J23/8871;;B01J23/8874;;C07C5/48;;B01J23/8872,B01J23/00;;B01J23/88;;C07B61/00;;C07C1/00;;C07C5/48;;C07C11/12;;C07C67/00,,0,0,,,,DISCONTINUED
658,CA,A,CA 991381 A,041-197-945-691-250,1976-06-22,1976,CA 174177 A,1973-06-15,US 26516272 A,1972-06-22,ENVIRONMENTALLY SAFE DISPOSAL OF ORGANIC POLLUTANTS,,STANDARD OIL CO OHIO,CALLAHAN JAMES L;;HARDMAN HARLEY F;;GRASSELLI ROBERT K,,https://lens.org/041-197-945-691-250,Granted Patent,no,0,0,9,9,0,B01D53/72;;B01D53/72,B01D53/86;;B01D53/72;;B01J23/72;;C02F1/72;;F23G7/07,23-341,0,0,,,,EXPIRED
659,CA,A,CA 1238314 A,051-481-739-878-875,1988-06-21,1988,CA 460840 A,1984-08-13,US 53500083 A,1983-09-22,PROCESS FOR PREPARING BASIC HEPTAPEPTIDE VASOPRESSIN ANTAGONISTS,"PROCESS FOR PREPARING BASIC HEPTAPEPTIDE VASOPRESSIN ANTAGONISTS Certain cyclic vasopressin antagonists, which have an .omega.-amino- or guanidinoalkyl substituent attached to the cysteine in the 6-position of a vasopressin-like ring, are prepared by the processes of this invention. A species prepared thusly is ¢1-(.beta.-mercapto-.beta.,.beta.-cyclopentamethylene-propionic acid)-2-(O-ethyl-D-tyrosine)-4-valine-8-(1,5-diaminopentane)-8-desarginine-9-desglycinamide! vasopressin.",SMITH KLINE FRENCH CANADA LTD,CALLAHAN JAMES F;;MOORE MICHAEL L;;YIM NELSON C,,https://lens.org/051-481-739-878-875,Granted Patent,no,0,0,30,31,0,A61K38/00;;C07K7/16;;A61P5/00;;A61P7/10;;C07K7/06,A61K38/00;;A61K38/095;;A61P5/00;;A61P7/10;;C07K1/00;;C07K1/113;;C07K7/16;;C07K7/50;;C07K14/575,260-128.5,0,0,,,,EXPIRED
660,AU,B2,AU 578758 B2,057-648-791-171-252,1988-11-03,1988,AU 1985/049740 A,1985-11-11,US 67228684 A,1984-11-16,SYNTHESIS OF MOLECULAR SIEVING METALLOSILICATES USING SILICA-TRANSITION METAL OXIDE SOLS,,STANDARD OIL CO OHIO,PEPERA MARC ANTHONY;;DESMOND MICHAEL JOSEPH;;CALLAHAN JAMES LOUIS,,https://lens.org/057-648-791-171-252,Granted Patent,no,0,0,10,10,0,B01J29/04;;B01J29/04;;C01B33/2884;;C01B33/2884;;C01B33/2876;;C01B33/2876,C01B33/20;;B01J29/00;;B01J29/04;;C01B39/06;;C07B61/00;;C07C1/20;;C07C5/27;;C07C15/073;;C07C15/08,,0,0,,,,EXPIRED
661,CA,A1,CA 2603163 A1,114-018-761-855-61X,2006-10-05,2006,CA 2603163 A,2006-03-24,US 66515405 P;;US 2006/0010859 W,2005-03-25,"PROCESS FOR PREPARING PYRIDO[2,3-D]PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE DERIVATIVES",,GLAXO GROUP LTD,YAN HONGXING;;WAN ZEHONG;;BOEHM JEFFREY;;CALLAHAN JAMES FRANCIS,,https://lens.org/114-018-761-855-61X,Patent Application,no,0,0,22,22,0,C07D471/04;;C07D487/04;;A61P43/00;;C07D471/04;;C07D487/04;;C07D487/04;;C07D471/04,A61K31/519;;C07D487/02,,0,0,,,,DISCONTINUED
662,EP,A2,EP 1865959 A2,116-788-433-478-345,2007-12-19,2007,EP 06739572 A,2006-03-24,US 2006/0010859 W;;US 66515405 P,2005-03-25,"PROCESS FOR PREPARING PYRIDOÝ2,3-D¨PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDOÝ4,5-D¨PYRIMIDIN-2(1H)-ONE DERIVATIVES",,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;BOEHM JEFFREY;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/116-788-433-478-345,Patent Application,yes,0,0,22,22,0,C07D471/04;;C07D487/04;;A61P43/00;;C07D471/04;;C07D487/04;;C07D487/04;;C07D471/04,C07D413/04;;A61K31/519;;C07D471/04;;C07D487/04,,0,0,,,,DISCONTINUED
663,US,A,US 3431292 A,139-132-316-307-785,1969-03-04,1969,US 3431292D A,1966-12-23,US 60411866 A,1966-12-23,OLEFINIC NITRILES BY AMMOXIDATION OF OLEFINS WITH PROMOTED ANTIMONY OXIDEURANIUM OXIDE CATALYST,,STANDARD OIL CO,CALLAHAN JAMES L;;GRASSELLI ROBERT K;;KNIPPLE WARREN R,,https://lens.org/139-132-316-307-785,Granted Patent,no,2,18,1,1,0,B01J23/16;;B01J23/6445;;B01J23/681;;B01J23/8435;;C07C253/26;;Y02P20/52;;C07C253/26;;B01J23/6445;;B01J23/8435;;B01J23/16;;B01J23/681;;Y02P20/52,B01J23/16;;B01J23/644;;B01J23/68;;B01J23/843,260/465.3,0,0,,,,EXPIRED
664,CS,B2,CS 194814 B2,170-625-391-192-745,1979-12-31,1979,CS 503677 A,1977-07-29,US 71101476 A,1976-08-02,PROCESS FOR PREPARING METHACROLEINE,,STANDARD OIL CO OHIO,HARDMAN HARLEY F;;GRASSELI ROBERT K;;CALLAHAN JAMES L,,https://lens.org/170-625-391-192-745,Granted Patent,no,0,0,26,29,0,B01J23/8876;;B01J2523/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C51/235;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J23/8876;;C07C45/33;;C07C45/34;;C07C51/235;;C07C45/32;;C07C45/37;;C07C51/252;;C07C45/27;;B01J2523/00;;C07C253/24;;Y02P20/52,B01J23/00;;B01J23/88;;C07C57/05;;C07B61/00;;C07C1/00;;C07C5/48;;C07C11/00;;C07C45/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C47/22;;C07C51/00;;C07C51/235;;C07C51/25;;C07C67/00;;C07C253/00;;C07C255/08,,0,0,,,,EXPIRED
665,US,A,US 3409697 A,189-860-553-874-045,1968-11-05,1968,US 59498466 A,1966-11-17,US 59498466 A;;US 50771665 A,1965-11-15,Process for oxidative dehydrogenation of olefins,,STANDARD OIL CO,CALLAHAN JAMES L;;GRASSELLI ROBERT K;;KNIPPLE WARREN R,,https://lens.org/189-860-553-874-045,Granted Patent,no,2,9,1,3,0,B01J23/84;;B01J23/843;;B01J23/8435;;B01J23/8437;;B01J23/888;;B01J23/8892;;C07C5/48;;C07C45/34;;C07C45/35;;C07C253/26;;Y02P20/52;;B01J23/8437;;C07C45/34;;B01J23/888;;C07C5/48;;B01J23/8892;;C07C45/35;;B01J23/843;;B01J23/8435;;B01J23/84;;C07C253/26;;Y02P20/52,B01J23/84;;B01J23/843;;C07C5/48;;C07C45/34;;C07C45/35,260/680,0,0,,,,EXPIRED
666,US,A,US 3326817 A,177-298-453-134-735,1967-06-20,1967,US 39645864 A,1964-08-27,US 39645864 A;;US 18083362 A,1962-03-19,Process and catalyst for the manufacture of unsaturated carboxylic acids,,STANDARD OIL CO,LOUIS CALLAHAN JAMES;;MILBERGER ERNEST C;;UTTER RICHARD E,,https://lens.org/177-298-453-134-735,Granted Patent,no,4,6,2,3,0,B01J27/19;;B01J27/19;;C07C51/252;;C07C51/252,B01J27/19;;C07C51/25,,0,0,,,,EXPIRED
667,US,A,US 4065507 A,013-575-545-781-425,1977-12-27,1977,US 71101476 A,1976-08-02,US 71101476 A,1976-08-02,Preparation of methacrylic derivatives from tertiary butyl-containing compounds,"The present invention relates to a process for the conversion of tertiary-butyl-containing compounds to methacrylic derivatives, and more particularly to a process for the conversion of tertiary-butyl-containing compounds selected from the group consisting of alkyl tertiary-butyl ethers, tertiary-butyl alcohol, isobutylene dimer (2,2,4-trimethylpentene) and isobutylene trimer, to methacrolein, methacrylic acid or methacrylonitrile.",STANDARD OIL CO,HARDMAN HARLEY F;;CALLAHAN JAMES L;;GRASSELLI ROBERT K,,https://lens.org/013-575-545-781-425,Granted Patent,yes,4,28,26,29,0,B01J23/8876;;B01J2523/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C51/235;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J23/8876;;C07C45/33;;C07C45/34;;C07C51/235;;C07C45/32;;C07C45/37;;C07C51/252;;C07C45/27;;B01J2523/00;;C07C253/24;;Y02P20/52,B01J23/00;;C07C57/05;;B01J23/88;;C07B61/00;;C07C1/00;;C07C5/48;;C07C11/00;;C07C45/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C47/22;;C07C51/00;;C07C51/235;;C07C51/25;;C07C67/00;;C07C253/00;;C07C255/08,260604R,0,0,,,,EXPIRED
668,FI,A,FI 833132 A,028-730-373-354-268,1984-03-30,1984,FI 833132 A,1983-09-02,US 42824182 A,1982-09-29,BANOEVERFOERINGSFOERFARANDE,,BELOIT CORP,WICKS LAURIE DAVID;;CRONIN DENNIS CALLAHAN;;CHANCE JAMES LARRY,"BELOIT TECHNOLOGIES, INC. (1998-10-12)",https://lens.org/028-730-373-354-268,Patent Application,no,0,0,23,23,0,D21F2/00;;D21F3/04;;D21F3/045;;D21F3/04;;D21F3/045;;D21F2/00;;D21F3/04,D21F1/00;;B65H20/06;;D21F2/00;;D21F3/02;;D21F3/04,,0,0,,,,EXPIRED
669,US,A,US 4341717 A,023-174-389-805-020,1982-07-27,1982,US 96755778 A,1978-12-08,US 96755778 A;;US 33908273 A,1973-03-08,Reactor for contacting gases and a particulate solid,The present invention is a reactor that consists of a single shell that contains a reaction zone and a regeneration zone. The reaction zone and regeneration zone are arranged in such a manner that (a) a particulate solid may be transferred by flow of gases from the regeneration zone to the reaction zone by a first route and then back to the regeneration zone by a second route; and (b) the gases passing through the regeneration zone are not transferred to the reaction zone and the gases passing through the reaction zone are not transferred to the regeneration zone.,STANDARD OIL CO OHIO,CALLAHAN JAMES L;;HARDMAN HARLEY F;;MILBERGER ERNEST C,,https://lens.org/023-174-389-805-020,Granted Patent,yes,1,24,1,2,0,B01J8/26;;B01J8/386;;C07C45/28;;C07C45/29;;C07C45/35;;C07C253/26;;C07C253/26;;C07C45/28;;B01J8/26;;C07C45/35;;B01J8/386;;C07C45/29,B01J8/26;;B01J8/38;;C07C45/28;;C07C45/29;;C07C45/35,260/465.3,0,0,,,,EXPIRED
670,BR,A2,BR 102017023802 A2,041-467-836-215-500,2018-12-18,2018,BR 102017023802 A,2017-11-06,US 201615383851 A,2016-12-19,sistema para indicar o status do uso de compartimentos de bagagem superiores de aeronaves,"""sistema para indicar o status do uso de compartimentos de bagagem superiores de aeronaves"". a presente invenção refere-se a um sistema e um método para indicar o status de armazenagem de compartimentos de bagagem superiores em uma aeronave. é provida uma câmera que é montada com um campo de visão dirigido a uma porção interna de um grupo de compartimentos de bagagem abertos. a câmera é acoplada de maneira comunicativa a um controlador e fornece seletivamente imagens da porção interna dos compartimentos de bagagem imediatamente antes do momento quando os compartimentos de bagagem são fechados ao controlador. um projetor também é provido para cada grupo de compartimentos de bagagem. o projetor é acoplado de maneira comunicativa ao controlador e montado de maneira tal que uma imagem recebida do controlador é projetada em uma superfície externa dos compartimentos de bagagem fechados. o controlador recebe imagens de cada uma das câmeras e fornece seletivamente tais imagens ao projetor associado com cada câmera de modo que uma exibição do status de armazenagem é projetada em uma superfície externa dos compartimentos de bagagem.",BOEING CO,JAMES P SCHALLA;;KEVIN S CALLAHAN;;YAKENTIM M IBRAHIM,,https://lens.org/041-467-836-215-500,Patent Application,no,0,0,16,16,0,B64D11/00;;B64D11/003;;H04N23/63;;B64D47/08;;B61D37/003;;B64D45/00;;B64D2045/007;;B64D47/08;;B64D11/003;;H04N23/63;;B64D11/00;;B64D47/08;;H04N7/18;;H04N23/60;;H04N23/90;;B64D47/08;;B64D11/003;;H04N7/181;;H04N9/31;;B64D45/00;;B61D37/003;;B64D2045/007;;G06V20/52;;H04N23/63;;H04N23/90,B64D11/00;;B64D45/00;;B64D47/08,,0,0,,,,ACTIVE
671,EP,A1,EP 1349851 A1,047-229-306-477-700,2003-10-08,2003,EP 01995214 A,2001-11-14,US 0143994 W;;US 24919900 P,2000-11-16,COMPOUNDS,,SMITHKLINE BEECHAM CORP,BENDER PAUL E;;BURGESS JOELLE L;;CALLAHAN JAMES F,,https://lens.org/047-229-306-477-700,Patent Application,yes,0,0,6,6,0,A61P1/04;;A61P1/16;;A61P9/04;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/02;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P27/02;;A61P43/00;;C07D401/04;;C07D401/04;;C07D401/14;;C07D401/14;;C07D405/14;;C07D405/14,A61K31/4439;;A61K31/4709;;A61P1/04;;A61P1/16;;A61P9/04;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/02;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P27/02;;A61P43/00;;C07D401/04;;C07D401/14;;C07D405/14,,0,0,,,,DISCONTINUED
672,US,A,US 4152393 A,111-713-392-946-879,1979-05-01,1979,US 75860777 A,1977-01-12,US 33908273 A,1973-03-08,REACTOR FOR CONTACTING GASES AND A PARTICULATE SOLID,A reactor that consists of a single shell that contains a reaction zone and a regeneration zone. The reaction zone and regeneration zone are arranged in such a manner that (a) a particulate solid may be transferred by flow of gases from the regeneration zone to the reaction zone by a first route and then back to the regeneration zone by a second route; and (b) the gases passing through the regeneration zone are not transferred to the reaction zone and the gases passing through the reaction zone are not transferred to the regeneration zone.,STANDARD OIL CO OHIO,CALLAHAN JAMES L;;HARDMAN HARLEY F;;MILBERGER ERNEST C,,https://lens.org/111-713-392-946-879,Granted Patent,yes,4,25,1,2,0,B01J8/386;;C07C45/28;;C07C45/29;;C07C45/35;;C07C253/26;;C07C253/26;;C07C45/35;;C07C45/29;;B01J8/386;;C07C45/28,B01J8/24;;B01J8/38;;C07C45/28;;C07C45/29;;C07C45/35,B1F FCF           CF;;B1F F113          CF;;B1F F215          CF;;B1F F223          CF;;B1F F511          CF;;B1F F612          CF;;B1F F913          CF;;B1F F914          CF,0,0,,,,EXPIRED
673,CA,A,CA 1182803 A,118-921-908-234-882,1985-02-19,1985,CA 388995 A,1981-10-29,US 22185980 A,1980-12-31,MIXED METAL PHOSPHORUS OXIDE CATALYST FOR THE OXIDATIVE DEHYDROGENATION OF CARBOXYLIC ACIDS,"A process is provided for the oxydehydrogenation of saturated carboxylic acids with oxygen in the presence of iron phosphorus oxide catalysts containing promoters selected from the group Ag, Al, B, Be, Cd, Co, Cr, Cu, Ga, Ge, In, Mn, Ni, Te, Th, Ti, Tl, U, V, Zn, Zr, rare earths and mixtures thereof.",STANDARD OIL CO OHIO,PEDERSEN SVEND E;;CALLAHAN JAMES L;;HARDMAN HARLEY F,,https://lens.org/118-921-908-234-882,Granted Patent,no,0,0,9,11,0,B01J27/18;;B01J27/186;;B01J23/89;;B01J23/8933;;B01J27/1853;;C07C51/377;;C07C51/377,C07C57/04;;B01J23/89;;B01J27/00;;B01J27/18;;B01J27/185;;B01J27/186;;C07B61/00;;C07C51/00;;C07C51/377;;C07C67/00;;C07C253/00;;C07C255/23,252-53B,0,0,,,,EXPIRED
674,WO,A2,WO 2008/101164 A2,104-187-207-164-189,2008-08-21,2008,US 2008/0054092 W,2008-02-15,US 90196307 P;;US 2765108 A;;US 2767208 A,2007-02-16,THERMAL SPRAY COATINGS AND APPLICATIONS THEREFOR,"This invention relates to coatings for a metal or non-metal substrate comprising (i) a thermal sprayed bondcoat layer applied to said substrate comprising an alloy of MCrAlM' wherein M is an element selected from nickel, cobalt, iron and mixtures thereof, and M' is an element selected from yttrium, zirconium, hafnium, ytterbium and mixtures thereof, and wherein M comprises from about 35 to about 80 weight percent of said alloy, Cr comprises from about 15 to about 45 weight percent of said alloy, Al comprises from about 5 to about 30 weight percent of said alloy, and M' comprises from about 0.01 to about 1.0 weight percent of said alloy, said alloy thermally sprayed from a powder having a mean particle size of 50 percentile point in distribution of from about 5 microns to about 100 microns, said bondcoat having a surface roughness of at least 200 micro-inches, and said bondcoat having a thermal expansion of about 6.5 millimeters per meter or less between a temperature of from about 25°C to about 525°C, and (ii) a thermal sprayed ceramic layer applied to said bondcoat layer; wherein said coating has a helium leak rate of less than 6 x 10""6 standard cubic centimeters per second. The coatings are useful for extending the service life under severe conditions, such as those associated with metallurgical vessels' lances, nozzles and tuyeres.",PRAXAIR TECHNOLOGY INC;;APTE PRASAD SHRIKRISMNA;;MEAGHER JAMES PATRICK;;CALLAHAN SHAWN W,APTE PRASAD SHRIKRISMNA;;MEAGHER JAMES PATRICK;;CALLAHAN SHAWN W,,https://lens.org/104-187-207-164-189,Patent Application,yes,0,0,9,9,0,C23C4/02;;C23C28/3215;;C23C28/34;;C23C28/341;;C23C28/345;;C23C28/3455;;C23C28/36;;C23C28/321;;C23C4/073;;C22C19/05;;C22C19/058;;Y10T428/256;;Y10T428/24355;;Y10T428/24612;;Y10T428/12618;;Y10T428/12931;;Y10T428/24413;;Y10T428/249969;;Y10T428/256;;Y10T428/24355;;Y10T428/24612;;Y10T428/12618;;Y10T428/12931;;Y10T428/24413;;Y10T428/249969;;C23C4/02;;C23C28/34;;C23C28/3455;;C23C28/341;;C23C28/345;;C23C28/36;;C23C28/3215;;C23C28/321;;C22C19/058;;C22C19/05;;C23C4/073,C23C4/08;;C22C19/00;;C23C28/00,,0,0,,,,PENDING
675,EP,A1,EP 3335991 A1,120-768-437-749-671,2018-06-20,2018,EP 17196258 A,2017-10-12,US 201615383851 A,2016-12-19,SYSTEM FOR DISPLAYING THE STATUS OF USE OF AIRCRAFT OVERHEAD LUGGAGE STORAGE BINS,"A system and method are disclosed for displaying the storage status of overhead luggage storage bins in an aircraft. A camera is provided that is mounted with a field of view directed at an inner portion of a group of open bins. The camera is communicatively coupled to a controller and selectively provides images of the inner portion of the bins immediately prior to when the bins are closed to the controller. A projector is also provided for each group of bins. The projector is communicatively coupled to the controller and is mounted such that an image received from the controller is projected onto an outer surface of the closed bins. The controller receives images from each of the cameras and selectively provides such images to the projector associated with each camera so that a storage status display is projected on an outer surface of the bins.
",BOEING CO,IBRAHIM YAKENTIM M;;CALLAHAN KEVIN S;;SCHALLA JAMES P,,https://lens.org/120-768-437-749-671,Patent Application,yes,5,6,16,16,0,B64D11/00;;B64D11/003;;H04N23/63;;B64D47/08;;B61D37/003;;B64D45/00;;B64D2045/007;;B64D47/08;;B64D11/003;;H04N23/63;;B64D11/00;;B64D47/08;;H04N7/18;;H04N23/60;;H04N23/90;;B64D47/08;;B64D11/003;;H04N7/181;;H04N9/31;;B64D45/00;;B61D37/003;;B64D2045/007;;G06V20/52;;H04N23/63;;H04N23/90,B64D11/00;;B60R5/00;;B60R7/04;;B61D37/00;;B64D45/00;;B64D47/08,,0,0,,,,ACTIVE
676,WO,A2,WO 2002/081728 A2,131-058-182-559-755,2002-10-17,2002,US 0210657 W,2002-04-04,US 28222901 P,2001-04-06,QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES,"This invention relates to novel quinoline inhibitors of hYAK1 and hYAK3 kinases and pharmaceutically acceptable salts, hydrates or solvates thereof, pharmaceutical compositions thereof, and methods of treatment of diseases in which an excessive amount of either such kinase is a factor.",SMITHKLINE BEECHAM CORP;;BRYAN DEBORAH L;;BURGESS JOELLE L;;CALLAHAN JAMES F,BRYAN DEBORAH L;;BURGESS JOELLE L;;CALLAHAN JAMES F,,https://lens.org/131-058-182-559-755,Patent Application,yes,0,0,8,8,0,A61K31/47;;A61K31/47;;A61K31/4709;;A61K31/4709;;A61P7/00;;A61P7/06;;A61P13/12;;A61P15/16;;A61P19/00;;A61P25/28;;A61P31/00;;A61P31/10;;A61P31/12;;A61P31/18;;A61P33/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P39/00;;A61P43/00;;C07D401/12;;C07D401/12;;C07D215/54;;C07D215/54,A61K31/47;;A61K31/4709;;A61K31/5377;;A61P7/00;;A61P7/06;;A61P13/12;;A61P15/16;;A61P19/00;;A61P25/28;;A61P31/00;;A61P31/10;;A61P31/12;;A61P31/18;;A61P33/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P39/00;;A61P43/00;;C07D215/54;;C07D401/12,,0,0,,,,PENDING
677,BR,A2,BR PI0908008 A2,175-635-542-571-090,2015-08-18,2015,BR PI0908008 A,2009-02-05,US 2656308 P;;US 2009/0033128 W,2008-02-06,Farmacóforo dual - pde4-antagonistas muscarínicos,,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/175-635-542-571-090,Patent Application,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/08;;A61P43/00;;C07D471/04;;C07D519/00,A01N43/90;;A01N43/56;;A61K31/519,,0,0,,,,DISCONTINUED
678,UY,A1,UY 31635 A1,156-548-515-361-392,2009-08-31,2009,UY 31635 A,2009-02-04,US 2657208 P,2008-02-06,FARMACÓFOROS DUALES-ANTAGONISTAS MUSCARÍNICOS DE PDE4,"La presente invención se refiere a nuevos compuestos de Fórmula (I), a composiciones farmacéuticas y a su uso en terapia, por ejemplo como inhibidores de fosfodiesterasa tipo IV (PDE4) y como antagonistas de receptores muscarínicos de acetilcolina (m AChRs), en el tratamiento y/o profilaxis de enfermedades respiratorias, incluyendo enfermedades inflamatorias y/o alérgicas tales como enfermedad pulmonar obstructiva crónica (COPD), asma, rinitis (por ejemplo, riniris alérgica), dermatitis atópica o psoriasis.",,LIN GOULIANG;;CALLAHAN JAMES FRANCIS;;YAN HONGXING;;WAN ZEHONG,,https://lens.org/156-548-515-361-392,Patent Application,no,0,0,20,20,0,C07D471/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/00;;A61P37/08;;A61P43/00;;C07D471/04,A61P11/00;;C07D231/00;;C07D471/00;;C07D487/00,,0,0,,,,DISCONTINUED
679,RO,A,RO 68029 A,179-520-781-997-254,1980-10-30,1980,RO 7976674 A,1974-08-14,US 39017573 A,1973-08-20,PROCEDE DE REACTIVATION DES CATALYSURS D'OXYDATION A TENEUR DE MO¿YBDENE EN REACTEURS A LITS FLUIDIFIES,,STANDARD OIL CO OHIO,CALLAHAN JAMES L;;MILLER ARTHUR F;;SHAW WILFRID G,,https://lens.org/179-520-781-997-254,Unknown,no,0,0,23,23,0,B01J8/26;;B01J23/28;;B01J23/86;;B01J23/92;;B01J23/94;;B01J38/16;;C07C253/26;;Y10S585/901;;Y02P20/584;;Y02P20/52;;B01J35/19;;B01J38/16;;B01J8/26;;C07C253/26;;B01J23/94;;B01J23/28;;B01J23/92;;B01J23/86;;Y10S585/901;;Y02P20/584;;Y02P20/52;;B01J35/19,C07C5/48;;B01J8/26;;B01J23/36;;B01J23/86;;B01J23/92;;B01J23/94;;B01J38/00;;C07B31/00;;C07B33/00;;C07B61/00;;C07C1/00;;C07C11/00;;C07C67/00;;C07C253/00;;C07C255/08,,0,0,,,,DISCONTINUED
680,US,A,US 4323520 A,194-539-189-860-818,1982-04-06,1982,US 79487577 A,1977-05-09,US 79487577 A;;US 71101476 A,1976-08-02,Preparation of methacrylic derivatives from tertiary-butyl-containing compounds,"The present invention relates to a process for the conversion of tertiary-butyl-containing compounds to methacrylic derivatives, and more particularly to a process for the conversion of tertiary-butyl-containing compounds selected from the group consisting of alkyl tertiary-butyl ethers, tertiary-butyl alcohol, isobutylene dimer (2,2,4-trimethylpentene) and isobutylene trimer, to methacrolein, methacrylic acid or methacrylonitrile.",STANDARD OIL CO OHIO,HARDMAN HARLEY F;;CALLAHAN JAMES L;;GRASSELLI ROBERT K,,https://lens.org/194-539-189-860-818,Granted Patent,yes,6,7,1,29,0,B01J23/8876;;B01J23/8876;;B01J23/887;;B01J23/887;;B01J2523/00;;B01J2523/00;;C07C45/32;;C07C45/32;;C07C45/34;;C07C45/34;;C07C45/37;;C07C45/37;;C07C51/235;;C07C51/235;;C07C51/252;;C07C51/252;;C07C253/24;;C07C253/24;;Y02P20/52;;Y02P20/52,B01J23/88;;C07C45/32;;C07C45/34;;C07C45/37;;C07C51/235;;C07C51/25,260/465.9,1,0,,,"Derwent Abstract Report of Belgium Patent No. 835,935-44047X/24, 11/27/74.",EXPIRED
681,US,A,US 3338952 A,048-144-122-601-061,1967-08-29,1967,US 50771665 A,1965-11-15,US 50771665 A,1965-11-15,Process for the catalytic ammoxidation of olefins to nitriles,,STANDARD OIL CO,CALLAHAN JAMES L;;GRASSELLI ROBERT K;;KNIPPLE WARREN R,,https://lens.org/048-144-122-601-061,Granted Patent,no,6,57,1,3,0,B01J23/84;;B01J23/84;;B01J23/843;;B01J23/843;;C07C253/26;;C07C253/26;;C07C5/48;;C07C5/48;;C07C45/34;;C07C45/34;;C07C45/35;;C07C45/35;;Y02P20/52;;Y02P20/52,B01J23/84;;B01J23/843;;C07C5/48;;C07C45/34;;C07C45/35,,0,0,,,,EXPIRED
682,DE,A1,DE 2435031 A1,062-335-780-245-483,1975-02-27,1975,DE 2435031 A,1974-07-20,US 39017573 A,1973-08-20,VERFAHREN ZUR OXYDATIVEN UMWANDLUNG VON KOHLENWASSERSTOFFVERBINDUNGEN,,STANDARD OIL CO OHIO,CALLAHAN JAMES LOUIS;;MILLER ARTHUR FRANCIS;;SHAW WILFRID GARSIDE,,https://lens.org/062-335-780-245-483,Patent Application,no,2,4,23,23,0,B01J8/26;;B01J23/28;;B01J23/86;;B01J23/92;;B01J23/94;;B01J38/16;;C07C253/26;;Y10S585/901;;Y02P20/584;;Y02P20/52;;B01J35/19;;B01J38/16;;B01J8/26;;C07C253/26;;B01J23/94;;B01J23/28;;B01J23/92;;B01J23/86;;Y10S585/901;;Y02P20/584;;Y02P20/52;;B01J35/19,C07C5/48;;B01J8/26;;B01J23/36;;B01J23/86;;B01J23/92;;B01J23/94;;B01J38/00;;C07B31/00;;C07B33/00;;C07B61/00;;C07C1/00;;C07C11/00;;C07C67/00;;C07C253/00;;C07C255/08,,0,0,,,,EXPIRED
683,EP,A1,EP 0061830 A1,060-005-159-812-625,1982-10-06,1982,EP 82300739 A,1982-02-15,US 23535381 A,1981-02-17,Preparation of composite oxidation catalyst and use thereof for the production of unsaturated aldehydes and acids from propylene and isobutylene.,A composite oxidation catalyst is prepared by forming and activating a first oxidation catalyst; forming a second oxidation catalyst; contacting the first catalyst with the second catalyst and a substantially non-aqueous organic fluid to form a composite catalyst; and drying the composite catalyst. The second catalyst may be formed in situ on the first. The catalyst has utility in preparing unsaturated aldehydes and acids from propylene and isobutylene in a single reactor.,STANDARD OIL CO OHIO,CALLAHAN JAMES LOUIS;;SHAW WILFRID GARSIDE;;GRASSELLI ROBERT KARL,,https://lens.org/060-005-159-812-625,Patent Application,yes,4,6,4,4,0,B01J37/0203;;B01J37/04;;C07C45/35;;B01J35/19,C07C57/05;;B01J23/84;;B01J27/192;;B01J35/00;;B01J37/02;;B01J37/04;;C07B61/00;;C07C45/00;;C07C45/35;;C07C47/22;;C07C51/00;;C07C51/215;;C07C67/00,,0,0,,,,EXPIRED
684,US,A,US 3390202 A,049-599-375-021-96X,1968-06-25,1968,US 63857767 A,1967-05-15,US 63857767 A;;US 27930863 A;;US 31165763 A,1963-05-09,Promoted catalysts for the oxidation of olefins,,STANDARD OIL CO,CALLAHAN JAMES L;;GRASSELLI ROBERT K;;KNIPPLE WARREN R,,https://lens.org/049-599-375-021-96X,Granted Patent,no,2,2,12,15,0,B01J21/00;;B01J21/00;;B01J23/16;;B01J23/16;;B01J23/18;;B01J23/18;;B01J23/6445;;B01J23/6445;;B01J23/681;;B01J23/681;;B01J23/8435;;B01J23/8435;;B01J27/1815;;B01J27/1815;;B01J37/0009;;B01J37/0009;;C07C5/48;;C07C5/48;;C07C45/35;;C07C45/35;;C07C253/26;;C07C253/26;;Y02P20/52;;Y02P20/52;;Y10S502/503;;Y10S502/503;;Y10S502/504;;Y10S502/504;;Y10S585/906;;Y10S585/906,B01J21/00;;B01J23/16;;B01J23/18;;B01J23/644;;B01J23/68;;B01J23/843;;B01J27/18;;B01J37/00;;C07C5/48;;C07C45/35,260/680,0,0,,,,EXPIRED
685,CA,A,CA 1191828 A,065-939-960-274-894,1985-08-13,1985,CA 401808 A,1982-04-28,US 27145881 A;;US 27148781 A,1981-06-08,METHOD FOR THE PREPARATION OF HIGH ACTIVITY PHOSPHOMOLYBDIC ACID BASED CATALYSTS,"The present invention relates to a method for the preparation of phosphomolybdic acid based catalysts by forming a solution of hydrated phosphomolybdic acid in a substantially anhydrous alkyl alcohol, optionally adding a base to the solution, evaporating the solution to yield a catalyst powder and thereafter drying and calcining the powder to form the active catalyst. A second method for preparation is also provided and includes the steps of forming a solution of hydrated phosphomolybdic acid in a substantially anhydrous alkyl alcohol evaporating the solution to form a concentrate, impregnating a catalyst support material with the concentrate, contacting the impregnated support with ammonia gas in an amount sufficient to form an insoluble precipitate of ammonium alkyl phosphomolybdic acid within the pore structure of said support material and thereafter drying and calcining said impregnated support material so as to form a coated catalyst.",STANDARD OIL CO OHIO,CALLAHAN JAMES L;;SHAW WILFRID G;;MILLER ARTHUR F,,https://lens.org/065-939-960-274-894,Granted Patent,no,0,0,3,7,0,B01J27/188;;B01J27/19;;B01J37/0215;;C07C51/235;;C07C51/252,B01J27/188;;B01J27/19;;B01J37/02;;C07C51/235;;C07C51/25;;C07C57/055,252-52K,0,0,,,,EXPIRED
686,US,A,US 4742035 A,091-867-698-337-927,1988-05-03,1988,US 771687 A,1987-01-28,US 771687 A;;US 22185980 A,1980-12-31,Mixed metal phosphorus oxide catalysts for the oxidative dehydrogenation of carboxylic acids,"A process is provided for the oxydehydrogenation of saturated carboxylic acids with oxygen in the presence of iron phosphorus oxide catalysts containing promoters selected from the group Ag, Al, B, Cd, Co, Cr, Cu, Ga, Ge, In, Mn, Ni, Te, Th, Ti, Tl, U, V, Zn, Zr, rare earths and mixtures thereof.",STANDARD OIL CO OHIO,PEDERSON S ERIK;;CALLAHAN JAMES L;;HARDMAN HARLEY F,,https://lens.org/091-867-698-337-927,Granted Patent,yes,30,1,1,11,0,B01J23/8933;;B01J27/1853;;B01J27/186;;C07C51/377;;B01J27/186;;B01J23/8933;;C07C51/377;;B01J27/1853,B01J23/89;;B01J27/185;;B01J27/186;;C07C51/377,502/210;;502/208;;502/213,3,0,,,"Gabel et al., A Study of Parameters Which Affect Corrosion Between Solid Film Lubricants and Aircraft Alloys , Proc. ISLE ASLE Int. Lubr. Conf., 1975 (Publ. 1976), pp. 804 811 Chem. Abst. 86(12):77307p .;;Rajagopalan et al., Indian Patent No. 145,268, issued 9/16/78 Chem. Abst. 92(6):49421b .;;European Patent Appln. No. 0 000 617 The Standard Oil Company Production of Unsubstituted and Substituted Indene .",EXPIRED
687,EP,A2,EP 1372654 A2,113-603-348-815-359,2004-01-02,2004,EP 02725526 A,2002-04-04,US 0210657 W;;US 28222901 P,2001-04-06,QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES,,SMITHKLINE BEECHAM CORP,BRYAN DEBORAH L;;BURGESS JOELLE L;;CALLAHAN JAMES F,,https://lens.org/113-603-348-815-359,Patent Application,yes,0,0,8,8,0,A61K31/47;;A61K31/47;;A61K31/4709;;A61K31/4709;;A61P7/00;;A61P7/06;;A61P13/12;;A61P15/16;;A61P19/00;;A61P25/28;;A61P31/00;;A61P31/10;;A61P31/12;;A61P31/18;;A61P33/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P39/00;;A61P43/00;;C07D401/12;;C07D401/12;;C07D215/54;;C07D215/54,A61K31/47;;A61K31/4709;;A61K31/5377;;A61P7/00;;A61P7/06;;A61P13/12;;A61P15/16;;A61P19/00;;A61P25/28;;A61P31/00;;A61P31/10;;A61P31/12;;A61P31/18;;A61P33/00;;A61P35/00;;A61P35/02;;A61P37/00;;A61P39/00;;A61P43/00;;C07D215/12;;C07D215/16;;C07D215/18;;C07D215/38;;C07D215/54;;C07D401/12,,0,0,,,,DISCONTINUED
688,WO,A1,WO 2009/100167 A1,141-990-894-360-054,2009-08-13,2009,US 2009/0033129 W,2009-02-05,US 2656808 P,2008-02-06,DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS,"The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.",GLAXO GROUP LTD;;CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/141-990-894-360-054,Patent Application,yes,2,3,21,21,0,C07D471/04;;C07D519/00;;A61P1/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P17/04;;A61P17/06;;A61P27/02;;A61P37/08;;C07D471/04;;C07D519/00,A01N43/42,,1,0,,,See also references of EP 2247184A4,PENDING
689,CA,A,CA 1113498 A,132-754-755-678-686,1981-12-01,1981,CA 282896 A,1977-07-15,US 71101476 A,1976-08-02,PREPARATION OF METHACRYLIC DERIVATIVES FROM TERTIARY BUTYL-CONTAINING COMPOUND,"PREPARATION OF METHACRYLIC DERIVATIVES FROM TERTIARY BUTYL-CONTAINING COMPOUND The present invention relates to a process for the conversion of tertiary-butyl-containing compounds to methacrylic derivatives, and more particularly to a process for the conversion of tertiary-butyl-containing compounds selected from the group consisting of alkyl tertiary-butyl ethers, tertiary-butyl alcohol, isobutylene dimer (2,2,4-trimethylpentene) and isobutylene trimer, to methacrolein, methacrylic acid or methacrylonitrile.",STANDARD OIL CO OHIO,HARDMAN HARLEY F;;GRASSELLI ROBERT K;;CALLAHAN JAMES L,,https://lens.org/132-754-755-678-686,Granted Patent,no,0,0,26,29,0,B01J23/8876;;B01J2523/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C51/235;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J23/8876;;C07C45/33;;C07C45/34;;C07C51/235;;C07C45/32;;C07C45/37;;C07C51/252;;C07C45/27;;B01J2523/00;;C07C253/24;;Y02P20/52,B01J23/00;;C07C57/05;;B01J23/88;;C07B61/00;;C07C1/00;;C07C5/48;;C07C11/00;;C07C45/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C47/22;;C07C51/00;;C07C51/235;;C07C51/25;;C07C67/00;;C07C253/00;;C07C255/08,260-568.6,0,0,,,,EXPIRED
690,US,A,US 4315838 A,167-068-536-988-174,1982-02-16,1982,US 91265178 A,1978-06-05,US 91265178 A,1978-06-05,Catalyst preparation technique,Catalysts with improved catalytic properties are produced by a novel process in which not all of the heat-decomposable salt in the pre-catalyst is driven off during pre-heating and the powdery pre-catalyst obtained by pre-heating is agglomerated by dropping a slurry of the powder onto a particle bed.,STANDARD OIL CO,MILLER ARTHUR F;;CALLAHAN JAMES L;;SHAW WILFRID G,,https://lens.org/167-068-536-988-174,Granted Patent,yes,2,1,1,1,0,B01J27/186;;B01J37/0018;;C07C253/26;;Y02P20/52;;C07C253/26;;B01J27/186;;B01J37/0018;;Y02P20/52,B01J27/18;;B01J27/186;;B01J37/00,252/448,0,0,,,,EXPIRED
691,MA,B1,MA 29391 B1,157-885-812-209-307,2008-04-01,2008,MA 30296 A,2007-10-11,US 66515405 P,2005-03-25,"PROCEDE DE PREPARATION DE DERIVES PYRIDO [2,3-D]PYRIMIDIN-7-ONE et 3,4- DIHYDROPYRIMIDO [4,5-D]PYRIMIDIN-2(1H)-ONE","L'INVENTION CONCERNE UN NOUVEAU PROCÉDÉ DE PRÉPARATION DE PHARMACOPHORES DE PYRIDO[2,3-D]PYRIMIDIN-7-ONE TRISUBSTITUÉ EN 2,4,8, DE FORMULE (II) OU (A) DANS LAQUELLE G1 REPRÉSENTE CH2 OU NH ; G2 REPRÉSENTE CH OU AZOTE, RX REPRÉSENTE CHLORO, BROMO, IODO, OU O-S(O)2CF3; RG REPRÉSENTE UN FRAGMENT ALKYLE C1 10; M VAUT 0 OU UN ENTIER POSSÉDANT LA VALEUR 1 OU 2 ; 2; R3 REPRÉSENTE UN ALKYLE C1-10, CYCLOALKYLE C3-7, CYCLOALKYLE C3-7 ALKYLE C1-10, ARYLE, ARYLALKYLE C1-10, HÉTÉROARYLE, HÉTÉROARYLALKYLE C1-10, UN COMPOSÉ HÉTÉROCYCLIQUE OU HÉTÉROCYCLYLALKYLEC1-10, ET DANS LAQUELLE CHACUN DE CES FRAGMENTS PEUT ÊTRE ÉVENTUELLEMENT SUBSTITUÉ. LEDIT PROCÉDÉ CONSISTE À FAIRE RÉAGIR UN COMPOSÉ DE FORMULE (A) DANS LAQUELLE RY REPRÉSENTE CHLORO, BROMO, IODO, O-S(O)2CF3; ET RG REPRÉSENTE UN ALKYLE C1-10; AVEC UN RÉACTIF FORMANT UNE OLÉFINE DANS UNE BASE APPROPRIÉE POUR DE PRODUIRE UN COMPOSÉ DE FORMULE (II) OU (IIA), DANS LAQUELLE M=0, ET À OXYDER LE SOUFRE SELON LES BESOINS OU LES EXIGENCES.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;BOEHM JEFFREY;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/157-885-812-209-307,Granted Patent,no,0,0,22,22,0,C07D471/04;;C07D487/04;;A61P43/00;;C07D471/04;;C07D487/04;;C07D487/04;;C07D471/04,,,0,0,,,,ACTIVE
692,US,A,US 3546138 A,188-403-765-236-440,1970-12-08,1970,US 3546138D A,1968-06-05,US 73452768 A,1968-06-05,PROMOTED ANTIMONY-IRON OXIDATION CATALYST,,STANDARD OIL CO,CALLAHAN JAMES L;;GRASSELLI ROBERT K;;KNIPPLE WARREN R,,https://lens.org/188-403-765-236-440,Granted Patent,no,7,18,2,2,0,B01J23/84;;B01J23/84;;B01J23/8973;;B01J23/8973;;C07C253/26;;C07C253/26;;C07C45/35;;C07C45/35;;Y02P20/52;;Y02P20/52,B01J23/84;;B01J23/89;;C07C45/35,252/456,0,0,,,,EXPIRED
693,US,A,US 3966639 A,189-260-080-108-981,1976-06-29,1976,US 49042974 A,1974-07-22,US 49042974 A;;US 27138772 A,1972-07-13,Amphora aggregates,"Hard, rounded aggregates are produced by preparing droplets of a slurry consisting of suspending liquid containing distinct particles of a solid and dropping the droplets of the slurry onto a bed of particles under conditions where the suspending liquid of the slurry droplet is removed. This technique is especially desirable for making unique fixed-bed catalysts.",STANDARD OIL CO,CALLAHAN JAMES L;;MILLER ARTHUR F;;SHAW WILFRID G,,https://lens.org/189-260-080-108-981,Granted Patent,yes,9,9,1,15,0,B01J2/02;;B01J37/0072;;B01J2/02;;B01J37/0072,B01J2/02;;B01J37/00,252/439,0,0,,,,EXPIRED
694,AU,A,AU 2002/025730 A,192-221-125-590-73X,2002-05-27,2002,AU 2002/025730 A,2001-11-14,US 24919900 P;;US 0143994 W,2000-11-16,Compounds,,SMITHKLINE BEECHAM CORP,BENDER PAUL E;;BURGESS JOELLE L;;CALLAHAN JAMES F,,https://lens.org/192-221-125-590-73X,Patent Application,no,0,0,6,6,0,A61P1/04;;A61P1/16;;A61P9/04;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/02;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P27/02;;A61P43/00;;C07D401/04;;C07D401/04;;C07D401/14;;C07D401/14;;C07D405/14;;C07D405/14,A61K31/4439;;A61K31/4709;;A61P1/04;;A61P1/16;;A61P9/04;;A61P9/10;;A61P11/00;;A61P13/12;;A61P17/02;;A61P19/02;;A61P19/10;;A61P25/00;;A61P25/28;;A61P27/02;;A61P43/00;;C07D401/04;;C07D401/14;;C07D405/14,,0,0,,,,PENDING
695,DE,A1,DE 2806255 A1,193-427-021-145-017,1978-12-21,1978,DE 2806255 A,1978-02-15,US 80526477 A,1977-06-10,VERFAHREN ZUR HERSTELLUNG VON CARBONSAEUREMETHYLESTERN,,STANDARD OIL CO OHIO,GUTTMANN ANDREW TYTUS;;GRASSELLI ROBERT KARL;;CALLAHAN JAMES LOUIS,,https://lens.org/193-427-021-145-017,Patent Application,no,0,0,16,18,0,C07C1/20;;C07C7/14891;;C07C67/24,C07C67/24;;B01J23/00;;B01J27/00;;C07B61/00;;C07C1/20;;C07C7/148,,0,0,,,,DISCONTINUED
696,EP,B1,EP 0061830 B1,189-752-952-114-993,1984-08-29,1984,EP 82300739 A,1982-02-15,US 23535381 A,1981-02-17,PREPARATION OF COMPOSITE OXIDATION CATALYST AND USE THEREOF FOR THE PRODUCTION OF UNSATURATED ALDEHYDES AND ACIDS FROM PROPYLENE AND ISOBUTYLENE,,THE STANDARD OIL COMPANY,"CALLAHAN, JAMES LOUIS;;SHAW, WILFRID GARSIDE;;GRASSELLI, ROBERT KARL",,https://lens.org/189-752-952-114-993,Granted Patent,yes,0,0,4,4,0,B01J37/0203;;B01J37/04;;C07C45/35;;B01J35/19,C07C57/05;;B01J23/84;;B01J27/192;;B01J35/00;;B01J37/02;;B01J37/04;;C07B61/00;;C07C45/00;;C07C45/35;;C07C47/22;;C07C51/00;;C07C51/215;;C07C67/00,,0,0,,,,EXPIRED
697,MX,A,MX 2010008692 A,026-690-033-917-46X,2010-11-25,2010,MX 2010008692 A,2009-02-05,US 2657208 P;;US 2009/0033130 W,2008-02-06,DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS.,"The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/ and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.",GLAXO GROUP LTD,WAN ZEHONG;;YAN HONGXING;;CALLAHAN JAMES FRANCIS;;LIN GUOLIANG,,https://lens.org/026-690-033-917-46X,Patent Application,no,0,0,20,20,0,C07D471/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/00;;A61P37/08;;A61P43/00;;C07D471/04,A01N43/42,,0,0,,,,PENDING
698,AT,A,AT A555377 A,034-453-819-573-225,1980-01-15,1980,AT 555377 A,1977-07-28,US 71101476 A,1976-08-02,VERFAHREN ZUR HERSTELLUNG VON METHACROLEIN,,STANDARD OIL CO OHIO,HARDMAN HARLEY FOCH;;GRASSELLI ROBERT KARL;;JAMES LOUIS CALLAHAN,,https://lens.org/034-453-819-573-225,Patent Application,no,0,0,26,29,0,B01J23/8876;;B01J2523/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C51/235;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J23/8876;;C07C45/33;;C07C45/34;;C07C51/235;;C07C45/32;;C07C45/37;;C07C51/252;;C07C45/27;;B01J2523/00;;C07C253/24;;Y02P20/52,C07C57/05;;B01J23/00;;B01J23/88;;C07B61/00;;C07C1/00;;C07C5/48;;C07C11/00;;C07C45/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C47/22;;C07C51/00;;C07C51/235;;C07C51/25;;C07C67/00;;C07C253/00;;C07C255/08,"12E1,010",0,0,,,,EXPIRED
699,US,A,US 4622424 A,034-721-697-024-305,1986-11-11,1986,US 77314585 A,1985-09-06,US 77314585 A;;US 95426278 A,1978-10-24,Preparation of acrylic acid and methacrylic acid in a combination fixed-fluid bed reactor,"A process for conducting a combination of fixed and fluid-bed catalytic reactions is achieved by employing fixed-bed catalysts on supports within the fluid bed. The fluid-bed catalysts may move in both directions through the fixed bed, thereby giving advantages of both types of beds in one reactor.",STANDARD OIL CO OHIO,CALLAHAN JAMES L;;MILLER ARTHUR F;;SHAW WILFRID G,,https://lens.org/034-721-697-024-305,Granted Patent,yes,5,4,1,6,0,B01J8/0453;;B01J8/0453;;B01J8/048;;B01J8/048;;B01J8/34;;B01J8/34;;C07C51/252;;C07C51/252,B01J8/04;;B01J8/34;;C07C51/25,562/545;;422/139;;422/141;;549/258;;560/208;;562/546;;562/547;;568/476;;568/479;;568/480,0,0,,,,EXPIRED
700,HU,A2,HU P0300758 A2,054-623-873-288-104,2003-08-28,2003,HU P0300758 A,2001-07-16,US 21984200 P;;US 22063600 P;;US 0122267 W,2000-07-21,CALCILYTIC COMPOUNDS AND THEIR AS CALCIUM RECEPTOR ANTAGONISTS,"A találmány (I) általános képletű vegyületekre - amelynek képletében Ajelentése szén- vagy nitrogénatom, és egy vagy két nitrogénatom van azI. gyűrűben; D jelentése szén- vagy nitrogénatom, és egy vagy kétnitrogénatom van a II. gyűrűben, ami a képletben jelzett 4-es vagy 5-ös helyzetben kapcsolódik az I. gyűrűhöz; X jelentése ciano-,nitrocsoport, klór-, fluor- vagy hidrogénatom; Y jelentése - ha Ajelentése szénatom - klór-, fluor-, bróm-, jód- vagy hidrogénatom; Qjelentése - ha A jelentése szénatom - hidrogénatom, -R1, -SO2R1', -R1C(O)OR1' általános képletű csoport, tetrazolil-, hidroxi-metil-,formilcsoport, -SO2NR1'R1<, -C(O)-NR1'R1< vagy -NR1SO2R1' általánosképletű csoport, ahol R1 jelentése hidrogénatom, 1-4 szénatomosalkilcsoport vagy adott esetben szubsztituált alkilcsoport, R1' és R1<jelentése egymástól függetlenül hidrogénatom, 1-4 szénatomosalkilcsoport vagy adott esetben szubsztituált alkilcsoport, vagy R1'és R2< együtt egy 3-7 tagú, adott esetben szubsztituált heterociklusosgyűrűt képez; és Ar jelentése adott esetben szubsztituált fenil- vagynaftilcsoport, adott esetben szubsztituált heteroaril- vagy kondenzáltheteroaril-csoport, amelyben a heterogyűrű nitrogén-, oxigén- vagykénatomot tartalmazhat és aromás, dihidro- vagy tetrahidro-származéklehet és a vegyületek kalciumreceptor-antagonistákként történőalkalmazására vonatkozik. Ó",SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP K;;CALLAHAN JAMES F;;LAGO AMPARO M,,https://lens.org/054-623-873-288-104,Patent Application,no,0,0,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,A61K31/4418;;C07D213/77;;A61K31/4436;;A61K45/06;;A61K47/10;;A61K47/24;;A61K47/28;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,DISCONTINUED
701,EP,B1,EP 1368318 B1,067-780-611-740-229,2007-12-05,2007,EP 01954696 A,2001-07-16,US 0122267 W;;US 21984200 P;;US 22063600 P,2000-07-21,CALCILYTIC COMPOUNDS,,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP K;;CALLAHAN JAMES F;;LAGO AMPARO M,"ONE FRANKLIN PLAZA, PO BOX 7929, PHLILADELPHIA, PE (2007-12-05);;SMITHKLINE BEECHAM CORP. (2007-12-05);;SMITHKLINE BEECHAM CORPORATION (2008-04-09)",https://lens.org/067-780-611-740-229,Granted Patent,yes,4,0,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,C07D213/77;;A61K31/44;;C07D213/78;;A61K31/4418;;A61K31/4436;;A61K45/06;;A61K47/10;;A61K47/24;;A61K47/28;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,EXPIRED
702,CR,A,CR 11665 A,070-129-098-580-855,2011-01-11,2011,CR 11665 A,2010-09-01,US 2656308 P,2008-02-06,FARMACOFOROS DUALES-ANTAGONISTAS MUSCARINICOS DE PDE4,"La presente invención se refiere a nuevos compuestos de la fórmula (I) y a sus sales farmacéuticamente aceptables, a composiciones farmacéuticas y a su uso como cromóforos duales que tienen actividad inhibitoria contra receptores de PDE4 y receptores muscarínicos de acetilcolina (maChRs), siendo así de utilidad para tratar enfermedades respiratorias.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/070-129-098-580-855,Patent Application,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/08;;A61P43/00;;C07D471/04;;C07D519/00,A01N43/90;;A01N43/56;;A61K31/519,,0,0,,,,DISCONTINUED
703,WO,A3,WO 2008/101164 A3,087-991-627-317-615,2010-02-25,2010,US 2008/0054092 W,2008-02-15,US 90196307 P;;US 2765108 A;;US 2767208 A,2007-02-16,THERMAL SPRAY COATINGS AND APPLICATIONS THEREFOR,"This invention relates to coatings for a metal or non-metal substrate comprising (i) a thermal sprayed bondcoat layer applied to said substrate comprising an alloy of MCrAlM' wherein M is an element selected from nickel, cobalt, iron and mixtures thereof, and M' is an element selected from yttrium, zirconium, hafnium, ytterbium and mixtures thereof, and wherein M comprises from about 35 to about 80 weight percent of said alloy, Cr comprises from about 15 to about 45 weight percent of said alloy, Al comprises from about 5 to about 30 weight percent of said alloy, and M' comprises from about 0.01 to about 1.0 weight percent of said alloy, said alloy thermally sprayed from a powder having a mean particle size of 50 percentile point in distribution of from about 5 microns to about 100 microns, said bondcoat having a surface roughness of at least 200 micro-inches, and said bondcoat having a thermal expansion of about 6.5 millimeters per meter or less between a temperature of from about 25°C to about 525°C, and (ii) a thermal sprayed ceramic layer applied to said bondcoat layer; wherein said coating has a helium leak rate of less than 6 x 10'6 standard cubic centimeters per second. The coatings are useful for extending the service life under severe conditions, such as those associated with metallurgical vessels' lances, nozzles and tuyeres.",PRAXAIR TECHNOLOGY INC;;APTE PRASAD SHRIKRISMNA;;MEAGHER JAMES PATRICK;;CALLAHAN SHAWN W,APTE PRASAD SHRIKRISMNA;;MEAGHER JAMES PATRICK;;CALLAHAN SHAWN W,,https://lens.org/087-991-627-317-615,Search Report,yes,4,0,9,9,0,C23C4/02;;C23C28/3215;;C23C28/34;;C23C28/341;;C23C28/345;;C23C28/3455;;C23C28/36;;C23C28/321;;C23C4/073;;C22C19/05;;C22C19/058;;Y10T428/256;;Y10T428/24355;;Y10T428/24612;;Y10T428/12618;;Y10T428/12931;;Y10T428/24413;;Y10T428/249969;;Y10T428/256;;Y10T428/24355;;Y10T428/24612;;Y10T428/12618;;Y10T428/12931;;Y10T428/24413;;Y10T428/249969;;C23C4/02;;C23C28/34;;C23C28/3455;;C23C28/341;;C23C28/345;;C23C28/36;;C23C28/3215;;C23C28/321;;C22C19/058;;C22C19/05;;C23C4/073,C23C4/08;;C22C19/00;;C23C28/00,,0,0,,,,PENDING
704,US,E,US RE030569 E,097-758-773-364-673,1981-04-07,1981,US 74502776 A,1976-11-26,US 74502776 A;;US 27138772 A,1972-07-13,Process for preparing aggregates,"Hard, rounded aggregates are produced by preparing droplets of a slurry consisting of suspending liquid containing distinct particles of a solid and dropping the droplets of the slurry onto a bed of particles under conditions where the suspending liquid of the slurry droplet is removed. This technique is especially desirable for making unique fixed-bed catalysts.",,Callahan; James L.;;Miller; Arthur F.;;Shaw; Wilfrid G.,,https://lens.org/097-758-773-364-673,Amended Patent,yes,13,2,1,15,0,B01J37/0072;;B01J37/0072;;B01J2/02;;B01J2/02;;B01J2/04;;B01J2/04,B01J2/02;;B01J2/04;;B01J37/00,264 13;;252448;;252456;;252458;;252459;;427215,0,0,,,,DISCONTINUED
705,IN,B,IN 159744 B,111-486-727-277-420,1987-06-06,1987,IN 1069CA1983 A,1983-09-02,US 42824182 A,1982-09-29,IMPROVEMENT IN PAPER MAKING MACHINE AND PARTICULARLY TO METHOD AND MECHANISM FOR POSITIVE WEB PRESS SECTION OF THE MACHINE,,BELOIT CORP,WICKS LAURIE DAVID;;CRONIN DENNIS CALLAHAN;;CHANCE JAMES LARRY,,https://lens.org/111-486-727-277-420,Granted Patent,no,0,0,23,23,0,D21F2/00;;D21F3/04;;D21F3/045;;D21F3/04;;D21F3/045;;D21F2/00;;D21F3/04,D21F1/00;;B65H20/06;;D21F2/00;;D21F3/02;;D21F3/04,,0,0,,,,EXPIRED
706,KR,A,KR 20080002865 A,112-667-773-200-589,2008-01-04,2008,KR 20077024430 A,2007-10-24,US 66515405 P,2005-03-25,"PROCESS FOR PREPARING PYRIDO[2,3-D]PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE DERIVATIVES","The present invention is directed to a novel method of preparing of 2, 4,8-trisubstituted pyrido[2,3-d]pyrimidin-7-one pharmacophores of Formula (II) or (Ha) wherein GHs CH2 Or NH: G2 is CH or nitrogen; Rx is chloro, bromo, iodo, or O-S(O)2CF3; Rg is a C1 10 alkyl; m is 0, or an integer having a value of 1, or 2; R3 is a C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-10 alkyl, aryl, arylC1-10 alkyl, heteroaryl, heteroarylC1-10 alkyl, heterocyclic or a heterocyclylC1-10 alkyl moiety, and wherein each of these moieties may be optionally substituted. which comprises reacting a compound of the formula: wherein Ry is chloro, bromo, iodo, O-S(O)2CF3; and Rg is a C1-10 alkyl; with a olefin forming reagent in a suitable base to yield a compound of Formula (II), or (Ha) wherein m=0 and oxidizing the sulphur as necessary or desired.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;BOEHM JEFFREY;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/112-667-773-200-589,Patent Application,no,0,0,22,22,0,C07D471/04;;C07D487/04;;A61P43/00;;C07D471/04;;C07D487/04;;C07D487/04;;C07D471/04,C07D487/04;;C07D471/04,,0,0,,,,DISCONTINUED
707,US,A,US 3445521 A,104-223-550-347-703,1969-05-20,1969,US 3445521D A,1966-11-17,US 59498566 A,1966-11-17,PROMOTED ANTIMONY-IRON OXIDATION CATALYST,,STANDARD OIL CO,CALLAHAN JAMES L;;GRASSELLI ROBERT K;;KNIPPLE WARREN R,,https://lens.org/104-223-550-347-703,Granted Patent,no,2,28,1,1,0,B01J23/84;;B01J23/8973;;C07C5/48;;C07C45/35;;C07C253/26;;Y02P20/52;;C07C253/26;;B01J23/8973;;C07C45/35;;C07C5/48;;B01J23/84;;Y02P20/52,B01J23/84;;B01J23/89;;C07C5/48;;C07C45/35,260/604,0,0,,,,EXPIRED
708,US,A,US 3290658 A,135-735-054-212-467,1966-12-06,1966,US 32963963 A,1963-12-11,US 32963963 A,1963-12-11,Electronic computer with interrupt facility,,RCA CORP,CALLAHAN JAMES F;;SMITH RICHARD D;;YEN RICHARD H,,https://lens.org/135-735-054-212-467,Granted Patent,no,4,20,4,5,0,G06F9/4812;;G06F9/4812,G06F9/48,,0,0,,,,EXPIRED
709,TW,A,TW 200724142 A,157-881-647-172-732,2007-07-01,2007,TW 95109982 A,2006-03-23,US 66534705 P,2005-03-25,Novel compounds,"Novel substituted 1,5,7-trisubstituted-3,4-dihydro-pyrimido [4,5-d]pyrimidin-2-(1H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;WAN ZE-HONG;;YAN HONG-XING,,https://lens.org/157-881-647-172-732,Patent of Addition,no,0,0,33,33,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P33/06;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D487/04;;C07D487/04,A61K31/519;;C07D487/02,,0,0,,,,PENDING
710,US,A,US 4528398 A,153-963-107-433-448,1985-07-09,1985,US 44270282 A,1982-11-18,US 44270282 A;;US 27145881 A,1981-06-08,Method for the preparation of unsaturated carboxylic acid with high activity phosphomolybdic acid based catalysts,"The present invention relates to a method for the preparation of phosphomolybdic acid based catalysts utilized in the oxidation of aldehydes to unsaturated carboxylic acids by forming a solution of hydrated phosphomolybdic acid in a substantially anhydrous alkanol, adding a base to the solution, evaporating the solution to yield a catalyst powder and thereafter drying and calcining the powder to form the active catalyst. A second method for preparation is also provided and includes the steps of forming a solution of hydrated phosphomolybdic acid in a substantially anhydrous alkanol, evaporating the solution to form a concentrate, impregnating a catalyst support material with the concentrate, contacting the impregnated support with ammonia gas in an amount sufficient to form an insoluble precipitate of ammonium alkyl phosphomolybdic acid within the pore structure of said support material and thereafter drying and calcining said impregnated support material so as to form a coated catalyst.",STANDARD OIL CO OHIO,CALLAHAN JAMES L;;SHAW WILFRID G;;MILLER ARTHUR F,,https://lens.org/153-963-107-433-448,Granted Patent,yes,3,9,1,7,0,B01J27/188;;B01J37/0215;;C07C51/235;;C07C51/252;;C07C51/235;;C07C51/252;;B01J27/188;;B01J37/0215,B01J27/188;;B01J37/02;;C07C51/235;;C07C51/25;;C07C57/055,562/534;;260/405.5;;260/413;;502/162;;502/164;;502/167;;502/200;;502/209;;502/211;;502/212;;562/532;;562/535;;568/479,0,0,,,,EXPIRED
711,CL,A1,CL 2009000250 A1,178-749-483-396-871,2009-09-11,2009,CL 2009000250 A,2009-02-04,US 2656308 P,2008-02-06,"Compuestos derivados de pirazolo[3,4-b]piridina carboxamida; composicion farmaceutica que los comprende; y su uso en el tratamiento del asma, epoc y rinitis.","Compuestos derivados de pirazolo [3,4b] piridin-carboxamida; composición farmacéutica; y su uso en el tratamiento del asma, enfermedad pulmonar obstructiva crónica, rinitis.",GLAXO GROUP LTD,WAN ZEHONG;;YAN HONGXING;;CALLAHAN JAMES FRANCIS;;LIN GOULIANG,,https://lens.org/178-749-483-396-871,Patent Application,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/08;;A61P43/00;;C07D471/04;;C07D519/00,A61K31/4152;;A61K31/416;;A61K31/4439;;A61K31/4745;;A61P11/00;;A61P11/02;;A61P11/06;;C07D213/00;;C07D231/00;;C07D403/02;;C07D405/02;;C07D471/02,,0,0,,,,PENDING
712,EP,A1,EP 2249646 A1,176-668-645-641-263,2010-11-17,2010,EP 09707940 A,2009-02-05,US 2009/0033132 W;;US 2657408 P,2008-02-06,DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS,,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LI TINDY;;WAN ZEHONG;;YAN HONGXING,GLAXO GROUP LIMITED (2013-05-01),https://lens.org/176-668-645-641-263,Patent Application,yes,0,0,3,3,0,A61P11/08;;A61P37/06;;C07D471/04,C07D471/04;;A01N43/42;;A61K31/437;;A61P11/08;;A61P37/06,,0,0,,,,DISCONTINUED
713,EP,A4,EP 2259681 A4,173-979-772-464-342,2012-04-04,2012,EP 09708282 A,2009-02-05,US 2009/0033128 W;;US 2656308 P,2008-02-06,DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS,,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,GLAXO GROUP LIMITED (2013-05-01),https://lens.org/173-979-772-464-342,Search Report,no,2,0,21,21,0,C07D471/04;;C07D519/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/08;;A61P43/00;;C07D471/04;;C07D519/00,A01N43/90;;A01N43/56;;A61K31/519,,1,0,,,See also references of WO 2009100166A1,DISCONTINUED
714,PE,A1,PE 20091553 A1,174-918-431-039-409,2009-10-30,2009,PE 2009000166 A,2009-02-04,US 2657208 P,2008-02-06,FARMACOFOROS DUALES - ANTAGONISTAS MUSCARINICOS DE PDE4,"SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE X1 ES O, N(R4a); R4a Y R5a SON CADA UNO H, ALQUILO C1-C2; Z ES C(O), CONH, COO, ENTRE OTROS; Z1 ES CO, HNCO, OCO, ENTRE OTROS; v ES 1-5; n ES 1-3; n3 ES 1-4; Y4 ES H, HALOGENO, ALQUILO C1-C4, ALCOXI C1-C4, ENTRE OTROS; R1 ES ALQUILO C1-C3, CH2-FLUOROALQUILO C1-C2, -CH2CH2OH; R2 ES H, ALQUILO C1-C4, CICLOPROPILO, CICLOBUTILO, ENTRE OTROS; R3 ES CICLOALQUILO C4-C7 OPCIONALEMNTE SUSTITUIDO, CICLOALQUENILO C5-C7 MONO-SATURADO, HETEROCICLICO SUSTITUIDO O NO, ENTRE OTROS; Ar1 Y Ar2 SON CADA UNO FENILO SUSTITUIDO O NO, HETEROARILO MONOCICLICO SUSTITUIDO O NO, ENTRE OTROS; R4 Y R5 SON CADA UNO H, ALQUILO C1-C4, CICLOALQUILO C3-C7HETEROCICLILO, ENTRE OTROS; R6 ES ANILLO C5-C7 MIEMBROS SUSTITUIDO O NO QUE CONTIENE 1-2 NITROGENOS O ANILLO BICICLICO CORRESPONDIENTE QUE CONTIENE 1-2 NITROGENOS, ENTRE OTROS; X ES CH2, O-XH2, SO-CH2, ENTRE OTROS. UN COMPUESTO PREFERIDO ES N-{[1,6-DIETIL-4-(TETRAHIDRO-2H-PIRAN-4-ILAMINO)-1H-PIRAZOLO[3,4-b]PIRIDIN-5-IL]METIL}-N'-{[6-FLUORO-3'-(4-MORFOLINILMETIL)-3-BIFENILIL]METIL}-1,3-BENCENODICARBOXAMIDA. DICHOS COMPUESTOS SON INHIBIDORES DE FOSFODIESTERASA TIPO IV UTILES EN EL TRATAMIENTO DE ENFERMEDADES RESPIRATORIAS, INFLAMATORIAS Y/O ALERGICAS",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/174-918-431-039-409,Patent Application,no,0,0,20,20,0,C07D471/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/00;;A61P37/08;;A61P43/00;;C07D471/04,A01N43/34;;A01N43/42,,0,0,,,,DISCONTINUED
715,AU,A1,AU 2009/212409 A1,162-970-809-845-510,2009-08-13,2009,AU 2009/212409 A,2009-02-05,US 2656808 P;;US 2009/0033129 W,2008-02-06,Dual Pharmacophores- PDE4-muscarinic antagonistics,,GLAXO GROUP LTD,WAN ZEHONG;;YAN HONGXING;;CALLAHAN JAMES FRANCIS;;LIN GUOLIANG,,https://lens.org/162-970-809-845-510,Patent Application,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P1/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P17/04;;A61P17/06;;A61P27/02;;A61P37/08;;C07D471/04;;C07D519/00,A01N43/42,,0,0,,,,DISCONTINUED
716,US,B2,US 10936879 B2,046-468-599-672-746,2021-03-02,2021,US 201615383851 A,2016-12-19,US 201615383851 A,2016-12-19,System for displaying the status of use of aircraft overhead luggage storage bins,A system and method are disclosed for displaying the storage status of overhead luggage storage bins in an aircraft. A camera is provided that is mounted with a field of view directed at an inner portion of a group of open bins. The camera is communicatively coupled to a controller and selectively provides images of the inner portion of the bins immediately prior to when the bins are closed to the controller. A projector is also provided for each group of bins. The projector is communicatively coupled to the controller and is mounted such that an image received from the controller is projected onto an outer surface of the closed bins. The controller receives images from each of the cameras and selectively provides such images to the projector associated with each camera so that a storage status display is projected on an outer surface of the bins.,BOEING CO,IBRAHIM YAKENTIM M;;CALLAHAN KEVIN S;;SCHALLA JAMES P,THE BOEING COMPANY (2016-12-15),https://lens.org/046-468-599-672-746,Granted Patent,yes,35,3,16,16,0,B64D11/00;;B64D11/003;;H04N23/63;;B64D47/08;;B61D37/003;;B64D45/00;;B64D2045/007;;B64D47/08;;B64D11/003;;H04N23/63;;B64D11/00;;B64D47/08;;H04N7/18;;H04N23/60;;H04N23/90;;B64D47/08;;B64D11/003;;H04N7/181;;H04N9/31;;B64D45/00;;B61D37/003;;B64D2045/007;;G06V20/52;;H04N23/63;;H04N23/90,G06K9/00;;B61D37/00;;B64D11/00;;B64D45/00;;B64D47/08;;H04N5/232;;H04N5/247;;H04N7/18;;H04N9/31,,3,0,,,"European Extended Search Report for EP 17196258.2-1754, dated Nov. 22, 2017.;;European Extended Search Report for EP 3244618A1, dated Sep. 18, 2017, 7 pgs.;;Office Action dated Nov. 3, 2020 issued in corresponding Canadian Application No. 2,982,184, pp. 1-4.",ACTIVE
717,EP,A1,EP 2259681 A1,047-454-723-266-796,2010-12-15,2010,EP 09708282 A,2009-02-05,US 2009/0033128 W;;US 2656308 P,2008-02-06,DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS,,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,GLAXO GROUP LIMITED (2013-05-01),https://lens.org/047-454-723-266-796,Patent Application,yes,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/08;;A61P43/00;;C07D471/04;;C07D519/00,A01N43/90;;A01N43/56;;A61K31/519,,0,0,,,,DISCONTINUED
718,US,A,US 4277290 A,061-672-950-789-784,1981-07-07,1981,US 11518380 A,1980-01-25,US 11518380 A,1980-01-25,Low temperature washing and chemical sanitizing of foodware,"Soiled foodware is cleaned in a batch-type machine in which the foodware is subjected to a washing cycle and a chemical sanitizing rinsing cycle. A controlled flow of fresh preheated rinse water is supplied to an accumulation tank during the wash cycle while a drying agent is optionally added to the water in the tank. Thereafter, the rinse cycle is initiated by pumping the accumulated fresh water into a rinse line at a predetermined pressure to provide uniform flow in the rinse line. A liquid chemical sanitizing agent is then introduced directly into the uniform flow of water in the rinse line. This sequence of operations provides a desired uniform water pressure, independent of water supply pressure, for effective rinsing action and accurate metering of sanitizing agent into the uniform flow of water in the rinse line. Direct introduction of sanitizing agent into the rinse line minimizes contact time between the sanitizing agent and the fresh rinse water, which may contain a drying agent relatively incompatible with the sanitizing agent. Controlled flow of preheated rinse water into the accumulation tank during substantially the entire wash cycle minimizes the energy requirements of the system by reducing the heat losses in the machine.",AMERICAN STERILIZER CO,ANDREWS JAMES P;;CALLAHAN ARTHUR C;;GENDY MOHEB M,AUTOMATED WASHING SYSTEMS INC (1982-12-27),https://lens.org/061-672-950-789-784,Granted Patent,yes,8,49,2,2,0,A47L15/0002;;A47L15/0028;;A47L15/0036;;A47L15/0055;;A47L15/0078;;A47L15/4236;;A47L15/4287;;A47L2401/09;;A47L2501/01;;A47L2601/16;;A47L15/0002;;A47L15/4236;;A47L15/4287;;A47L2501/01;;A47L15/0078;;A47L2401/09;;A47L15/0055;;A47L15/0028;;A47L15/0036;;A47L2601/16,A47L15/00;;A47L15/42;;A47L15/44,134/10,1,0,,,"Tech Data Catalog No. 16682, ""FW-60-SR and SRC Champion Chemical Washer"", Apr. 1979.",EXPIRED
719,US,B2,US 8084449 B2,084-650-493-099-012,2011-12-27,2011,US 36593009 A,2009-02-05,US 36593009 A;;US 2656308 P,2008-02-06,Dual pharmacophores—PDE4-muscarinic antagonistics,"The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.",CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING;;GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,GLAXO GROUP LIMITED (2009-03-12),https://lens.org/084-650-493-099-012,Granted Patent,yes,60,2,21,21,0,C07D471/04;;C07D519/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/08;;A61P43/00;;C07D471/04;;C07D519/00,A61K31/496;;A61K31/437;;A61K31/551;;C07D487/04,514/218;;514/253.04;;514/303;;540/575;;544/362;;546/119,22,21,013-305-499-855-39X;;085-539-684-450-953;;057-386-729-999-377;;160-648-363-217-721;;042-639-754-892-131;;043-607-002-676-313;;018-053-786-180-165;;076-570-583-816-169;;033-924-461-315-45X;;037-623-086-376-926;;033-654-076-845-238;;044-015-154-458-347;;079-742-950-125-229;;106-308-211-550-278;;167-283-521-131-663;;039-034-918-191-754;;144-276-616-179-010;;048-179-313-509-030;;022-114-988-092-666;;001-547-902-527-406;;051-293-667-054-800,10.1016/j.bmcl.2009.04.121;;19447034;;19399831;;10.1002/med.20158;;22111532;;10.1586/ecp.09.48;;10.1164/ajrccm.158.supplement_2.13tac120;;10.1016/s0024-3205(98)00587-6;;10069509;;10.1164/ajrccm.163.5.2101039;;11316667;;10.1016/j.pharmthera.2007.05.007;;17597218;;10.1016/j.ddmec.2006.02.008;;10.1002/jhet.5570090212;;6121711;;10.1016/0014-2999(82)90034-6;;10.1021/jm00132a011;;2573731;;10.1002/ardp.19743070304;;4849253;;10.1016/j.bmc.2004.05.032;;15246087;;10.1248/cpb.52.1098;;15340197;;10.1002/(sici)1098-2299(199709)42:1<41::aid-ddr4>3.0.co;2-r;;10.1016/s0960-894x(01)00483-8;;11549462;;12383013;;10.1021/jm0209580;;15481980;;10.1021/jm0401006;;16439121;;10.1016/j.bmcl.2006.01.006;;10.1016/j.bmcl.2007.03.047;;17398090;;10.1016/j.bmcl.2003.10.025;;14684291,"Naganuma et al. Bioorganic & Medicinal Chemistry Letters, vol. 19, pp. 3174-3176 (2009).;;Peretto et al. Medicinal Research Reviews, vol. 29, pp. 867-902 (2009) (Abstract).;;Laine Expert Review of Clinical Pharmacology,vol. 3, pp. 43-53 (2010) (Abstract).;;Fryer and Jacoby, ""Muscarinic Receptors and Control of Airway Smooth Muscle"" Am J. Respir Crit Care Med; 1998; vol. 158 (5); pp. S154-S160).;;Fryer, et al. ""Effects of inflammatory cells on neuronal M2 muscarinic receptor function in the lung"" Life Sciences;1999; vol. 64(6-7); pp. 449-455 (Abstract provided) .;;Pauwels, et al., ""Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease"" Am J. Respir Crit Care Med; 2001; vol. 163; pp. 1256-1276 .;;Gwilt, et al., ""The non-neuronal cholinergic system in the airways: An unappreciated regulatory role in pulmonary inflammation?"" Pharmacology & Therapeutics; 2007; pp. 208-222.;;Kummer and Lips, ""Non-neuronal acetylcholine release and its contribution to COPD pathology"" Drug Discovery Today: Disease Mechanisms; 2006; vol. 3; pp. 47-52.;;Hohn, et al., ""1H-Pyrazolo[3,4-b] pyridines"" Journal of Heterocyclic Chemistry; 1972; vol. 9(2); pp. 235-253.;;Patel and Malick, ""Pharmacological Properties of Tracazolate: A New Non-Benzodiazepine Anxiolytic Agent"" European Journal of Pharmacology; 1982; vol. 78; pp. 323-333.;;Bare, et al., ""Synthesis and Structure-Activity Relationships of a Series of Anxioselective Pyrazolopyridine Ester and Amide Anxiolytic Agents"" J. Med. Chem; 1989; vol. 32; pp. 2561-2573.;;Denzel, ""Neue Synthese 1-unsubstituierter 1H-Pyrazolo [3,4-b] pyridin-5-carbon-saureeser"" Archiv der Pharmazie; 1974; vol. 307(3); pp. 177-186.;;Ochiai, et al., ""New orally active PDE4 inhibitors with therapeutic potential"" Bioorganic & Medicinal Chemistry; 2004; vol. 12; pp. 4089-4100.;;Ochiai, et al., ""Discovery of New Orally Active Phosphodiesterase (PDE4) Inhibitors"" Chem. Pharm. Bull.; 2004; vol. 52(9); pp. 1098-1104.;;Shi, et al., ""Pyrazolopyridines: Effect of Structural Alterations on Activity at Adenosine- and GABAa-Receptors"" Drug Development Research; 1997; vol. 42; pp. 41-56.;;Schenone, et al., ""Synthesis and Biological Data of 4-Amino-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-b] pyridine-5-carboxylic Acid Ethyl Esters, a New Series of Al-Adenosine Receptor (A1AR) Ligands"" Bioorganic & Medicinal Chemistry Letters; 2001; vol. 11; pp. 2529-2531.;;Bondavalli, et al., ""Synthesis, Molecular Modeling Studies, and Pharmacological Activity of Selective A1 Receptor Antagonists"" 2002; vol. 45; pp. 4875-4887.;;De Mello, et al., ""Antileishmanial Pyrazolopyridine Derivatives: Synthesis and Structure-Activity Relationship Analysis"" J. Med. Chem; 2004; vol. 47; pp. 5427-5432.;;Provins, et al., ""First dual M3 antagonists-PDE4 inhibitors: Synthesis and SAR of 4,6-diaminopyrimidine derivatives"" Bioorganic & Medicinal Chemistry Letters; 2006; vol. 16; pp. 1834-1839.;;Provins, et al., ""Dual M3 antagonists-PDE4 inhibitors. Part 2: Synthesis and SAR of 3-substituted azetidinyl derivatives"" Bioorganic & Medicinal Chemistry Letters; 2007; vol. 17; pp. 3077-3080.;;Ochiai, et al., ""New orally active PDE4 inhibitors with therapeutic potential"" Bioorganic & Medicinal Chemistry Letters; 2004; vol. 14; pp. 29-32.;;Daly J. W. et al.; 1-methy1-4-substituted-1H-pyrazolo [3, 4-b] pyridine-5-carboxylic acid derivatives: effect of structural alterations on activity at A1 and A2 adenosine receptors; Medicinal Chemistry Research; 1994; 4(5); pp. 293-306; Birkhaeuser; Boston US.",INACTIVE
720,US,A1,US 2008/0199722 A1,073-085-807-278-825,2008-08-21,2008,US 2765108 A,2008-02-07,US 2765108 A;;US 90196307 P,2007-02-16,THERMAL SPRAY COATINGS AND APPLICATIONS THEREFOR,"This invention relates to coatings for a metal or non-metal substrate comprising (i) a thermal sprayed bondcoat layer applied to said substrate comprising an alloy of MCrAlM′ wherein M is an element selected from nickel, cobalt, iron and mixtures thereof, and M′ is an element selected from yttrium, zirconium, hafnium, ytterbium and mixtures thereof, and wherein M comprises from about 35 to about 80 weight percent of said alloy, Cr comprises from about 15 to about 45 weight percent of said alloy, Al comprises from about 5 to about 30 weight percent of said alloy, and M′ comprises from about 0.01 to about 1.0 weight percent of said alloy, said alloy thermally sprayed from a powder having a mean particle size of 50 percentile point in distribution of from about 5 microns to about 100 microns, said bondcoat having a surface roughness of at least 200 micro-inches, and said bondcoat having a thermal expansion of about 6.5 millimeters per meter or less between a temperature of from about 25° C. to about 525° C., and (ii) a thermal sprayed ceramic layer applied to said bondcoat layer; wherein said coating has a helium leak rate of less than 6×10 −6 standard cubic centimeters per second. The coatings are useful for extending the service life under severe conditions, such as those associated with metallurgical vessels' lances, nozzles and tuyeres.",APTE PRASAD SHRIKRISHNA;;MEAGHER JAMES PATRICK;;CALLAHAN SHAWN W,APTE PRASAD SHRIKRISHNA;;MEAGHER JAMES PATRICK;;CALLAHAN SHAWN W,PRAXAIR S. T. TECHNOLOGY INC (2008-02-14),https://lens.org/073-085-807-278-825,Patent Application,yes,14,13,9,9,0,C23C4/02;;C23C28/3215;;C23C28/34;;C23C28/341;;C23C28/345;;C23C28/3455;;C23C28/36;;C23C28/321;;C23C4/073;;C22C19/05;;C22C19/058;;Y10T428/256;;Y10T428/24355;;Y10T428/24612;;Y10T428/12618;;Y10T428/12931;;Y10T428/24413;;Y10T428/249969;;Y10T428/256;;Y10T428/24355;;Y10T428/24612;;Y10T428/12618;;Y10T428/12931;;Y10T428/24413;;Y10T428/249969;;C23C4/02;;C23C28/34;;C23C28/3455;;C23C28/341;;C23C28/345;;C23C28/36;;C23C28/3215;;C23C28/321;;C22C19/058;;C22C19/05;;C23C4/073,C23C28/00;;B32B15/04,428/633;;427/453;;427/451;;428/148;;428/312.6,0,0,,,,ACTIVE
721,KR,A,KR 20100120296 A,072-537-618-110-837,2010-11-15,2010,KR 20107019715 A,2009-02-05,US 2657208 P,2008-02-06,DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS,,GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUOLIANG;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/072-537-618-110-837,Patent Application,no,0,0,20,20,0,C07D471/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/00;;A61P37/08;;A61P43/00;;C07D471/04,C07D471/04;;A61K31/437;;A61P11/06;;C07D413/14,,0,0,,,,DISCONTINUED
722,NO,L,NO 20030303 L,094-481-493-189-446,2003-03-20,2003,NO 20030303 A,2003-01-20,US 21984200 P;;US 22063600 P;;US 0122267 W,2000-07-21,Kalsilytiske forbindelser,,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP KUMAR;;CALLAHAN JAMES F;;LAGO AMPARO M,,https://lens.org/094-481-493-189-446,Abstract,no,0,0,26,26,0,A61K45/06;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07D213/30,A61K31/4418;;C07D213/77;;A61K31/4436;;A61K45/06;;A61K47/10;;A61K47/24;;A61K47/28;;A61K47/42;;A61K47/46;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D213/65;;C07D213/80;;C07D213/84;;C07D409/12,,0,0,,,,EXPIRED
723,MX,A,MX 159134 A,095-974-749-230-740,1989-04-21,1989,MX 19890583 A,1983-09-29,US 42824182 A,1982-09-29,MEJORAS EN METODO Y APARATO PARA LA TRANSFERENCIA DIRECTA DE LA BOBINA EN UNA SECCION DE PRENSA DE UNA MAQUINA DE FABRICACION DE PAPEL,,BELOIT CORP,WICES LAURIE DAVID;;CRONIN DENNIS CALLAHAN;;CHANGE JAMES LARRY,,https://lens.org/095-974-749-230-740,Granted Patent,no,0,0,23,23,0,D21F2/00;;D21F3/04;;D21F3/045;;D21F3/04;;D21F3/045;;D21F2/00;;D21F3/04,D21F1/00;;D21F2/00;;D21F3/02;;B65H20/06;;D21F3/04,,0,0,,,,EXPIRED
724,AU,A1,AU 2009/212410 A1,120-034-789-216-307,2009-08-13,2009,AU 2009/212410 A,2009-02-05,US 2657208 P;;US 2009/0033130 W,2008-02-06,Dual pharmacophores - PDE4-muscarinic antagonistics,,GLAXO GROUP LTD,YAN HONGXING;;LIN GUOLIANG;;WAN ZEHONG;;CALLAHAN JAMES FRANCIS,,https://lens.org/120-034-789-216-307,Patent Application,no,0,0,20,20,0,C07D471/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/00;;A61P37/08;;A61P43/00;;C07D471/04,A01N43/42,,0,0,,,,DISCONTINUED
725,DE,D1,DE 3260617 D1,134-976-052-662-086,1984-10-04,1984,DE 3260617 T,1982-02-15,US 23535381 A,1981-02-17,PREPARATION OF COMPOSITE OXIDATION CATALYST AND USE THEREOF FOR THE PRODUCTION OF UNSATURATED ALDEHYDES AND ACIDS FROM PROPYLENE AND ISOBUTYLENE,,STANDARD OIL CO OHIO,CALLAHAN JAMES LOUIS;;SHAW WILFRID GARSIDE;;GRASSELLI ROBERT KARL,,https://lens.org/134-976-052-662-086,Granted Patent,no,0,0,4,4,0,B01J37/0203;;B01J37/04;;C07C45/35;;B01J35/19,C07C57/05;;B01J23/84;;B01J27/192;;B01J35/00;;B01J37/02;;B01J37/04;;C07B61/00;;C07C45/00;;C07C45/35;;C07C47/22;;C07C51/00;;C07C51/215;;C07C67/00,,0,0,,,,EXPIRED
726,US,A,US 4412547 A,136-950-063-966-269,1983-11-01,1983,US 25858881 A,1981-04-29,US 25858881 A,1981-04-29,Neurological monitoring device,"A brain wave monitoring device for monitoring brain wave activity measures the frequency and amplitude of brain wave signals from the left and right hemispheres of the brain. The brain wave signals are filtered and applied to an amplitude detecting device, and a frequency-to-voltage converter which employs a zero-crossing technique such that signal frequencies are detected independent of signal magnitude. The amplitude and frequency information is displayed on separate power and frequency displays on the front panel of the brain wave monitoring device. Each of the power and frequency displays employ a pair of linear LED arrays such that a ""bar graph"" of the amplitude and frequency of the brain waves is produced. Additionally, signals indicative of the power of the brain waves on the left and right hemispheres are selectively applied to a voltage controlled oscillator having an earphone output, such that the operator may listen for differences in amplitude between left and right hemisphere brain waves.",NEUROLOGICS INC,CALLAHAN ALFRED S;;RHODES JAMES S;;JOHNSON TIMOTHY L,NEUROLOGICS INC. A CORP. OF DE (1981-04-27);;DURDEN ENTERPRISES LIMITED INC (1987-02-18),https://lens.org/136-950-063-966-269,Granted Patent,yes,22,21,1,1,0,G01R23/16;;A61B5/316;;A61B5/369;;G01R23/16;;A61B5/316;;A61B5/369,A61B5/04;;A61B5/0476;;G01R23/16,128/731,0,0,,,,EXPIRED
727,AU,A,AU 1985/049740 A,161-456-025-168-189,1986-05-22,1986,AU 1985/049740 A,1985-11-11,US 67228684 A,1984-11-16,SYNTHESIS OF MOLECULAR SIEVING METALLOSILICATES USING SILICA-TRANSITION METAL OXIDE SOLS,,STANDARD OIL CO OHIO,PEPERA MARC ANTHONY;;DESMOND MICHAEL JOSEPH;;CALLAHAN JAMES LOUIS,,https://lens.org/161-456-025-168-189,Patent Application,no,0,1,10,10,0,B01J29/04;;B01J29/04;;C01B33/2884;;C01B33/2884;;C01B33/2876;;C01B33/2876,C01B33/20;;B01J29/00;;B01J29/04;;C01B39/06;;C07B61/00;;C07C1/20;;C07C5/27;;C07C15/073;;C07C15/08,,0,0,,,,EXPIRED
728,FR,A1,FR 2360545 A1,172-309-438-814-408,1978-03-03,1978,FR 7723447 A,1977-07-29,US 71101476 A,1976-08-02,PREPARATION DE DERIVES METHACRYLIQUES A PARTIR DE COMPOSES CONTENANT UN GROUPE BUTYLE TERTIAIRE,"<P>Procédé de préparation de dérivés méthacryliques. </P><P>Ce procédé consiste à soumettre à une oxydation ou ammoxydation un composé comportant un groupement butyle tertiaire, par passage du mélange réactionnel sur un catalyseur ayant pour formule :</P>",STANDARD OIL CO,HARDMAN HARLEY FOCH;;CALLAHAN JAMES LOUIS;;GRASSELLI ROBERT KARL,,https://lens.org/172-309-438-814-408,Patent Application,no,5,0,26,29,0,B01J23/8876;;B01J2523/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C51/235;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J23/8876;;C07C45/33;;C07C45/34;;C07C51/235;;C07C45/32;;C07C45/37;;C07C51/252;;C07C45/27;;B01J2523/00;;C07C253/24;;Y02P20/52,B01J23/00;;B01J23/88;;C07C57/05;;C07B61/00;;C07C1/00;;C07C5/48;;C07C11/00;;C07C45/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C47/22;;C07C51/00;;C07C51/235;;C07C51/25;;C07C67/00;;C07C253/00;;C07C255/08,,1,0,,,CA1977,DISCONTINUED
729,CH,A5,CH 635056 A5,189-850-040-016-142,1983-03-15,1983,CH 942877 A,1977-07-29,US 71101476 A,1976-08-02,VERFAHREN ZUR HERSTELLUNG VON METHACROLEIN UND METHACRYLSAEURE.,,STANDARD OIL CO,HARDMAN HARLEY FOCH;;GRASSELLI ROBERT KARL;;CALLAHAN JAMES LOUIS,,https://lens.org/189-850-040-016-142,Granted Patent,no,0,0,26,29,0,B01J23/8876;;B01J2523/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C51/235;;C07C51/252;;C07C253/24;;Y02P20/52;;B01J23/8876;;C07C45/33;;C07C45/34;;C07C51/235;;C07C45/32;;C07C45/37;;C07C51/252;;C07C45/27;;B01J2523/00;;C07C253/24;;Y02P20/52,B01J23/00;;B01J23/88;;C07C57/05;;C07B61/00;;C07C1/00;;C07C5/48;;C07C11/00;;C07C45/00;;C07C45/27;;C07C45/32;;C07C45/33;;C07C45/34;;C07C45/37;;C07C47/22;;C07C51/00;;C07C51/235;;C07C51/25;;C07C67/00;;C07C253/00;;C07C255/08,,0,0,,,,EXPIRED
730,US,A,US 4624943 A,199-043-246-985-16X,1986-11-25,1986,US 71373285 A,1985-03-20,US 71373285 A,1985-03-20,Aromatic basic-tailed vasopressin antagonists,"Certain new vasopressin-like peptides which have structures characterized by having a bisaminoalkylbenzene present in the vasopressin tail at the 7- or 8-position retain vasopressin antagonist activity. A species of the invention is [1-.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid)-2-(O-ethyl)-D-tyrosine-4-valine-8-1',4'-bis(aminomethyl)benzene-9-de sglycinamide]-vasopressin.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES F;;MOORE MICHAEL L;;YIM NELSON C,SMITHKLINE BECKMAN CORPORATION (1985-03-13),https://lens.org/199-043-246-985-16X,Granted Patent,yes,3,1,14,14,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P13/02;;A61P15/00;;A61P7/10;;A61P9/12;;C07K7/16;;A61K38/00;;Y10S930/15,A61K38/00;;A61K38/04;;C07K1/113;;A61K38/095;;A61P7/10;;A61P9/12;;A61P13/02;;A61P15/00;;C07K7/06;;C07K7/16,514/11;;514/807;;530/315,1,1,027-224-402-419-545,10.1038/308652a0;;6709073,"M. Manning et al., Nature, 308 652 (1984).",EXPIRED
731,WO,A2,WO 2004/092780 A2,103-300-880-422-518,2004-10-28,2004,US 2004/0011019 W,2004-04-09,US 46199403 P,2003-04-11,INTRAOCULAR LENS STORAGE AND INSERTION DEVICE AND METHOD OF USE THEREOF,"The present invention is a device (10) for rolling, storing and inserting into an eye an extremely thin intraocular lens (IOL) (12). The device (10) performs as a roller and injector. Also disclosed herein are methods of using the lens rolling device. The chamber for rolling the intraocular lens includes curved walls, a hollow chamber, and a funnel for receiving a plunger, and a port for extruding a rolled lens. The IOL is effectively rolled by engaging the two parts of the rolling device. After rolling, the lens (12) is ejected from the device through a cannula and into an eye.",THINOPTX INC;;CALLAHAN WAYNE B;;CALLAHAN JEFFERY S;;SIMMS JAMES J;;DEMENTIEV DIMITRII D M D;;WRIGHT WILLIAM BERNARD,CALLAHAN WAYNE B;;CALLAHAN JEFFERY S;;SIMMS JAMES J;;DEMENTIEV DIMITRII D M D;;WRIGHT WILLIAM BERNARD,,https://lens.org/103-300-880-422-518,Patent Application,yes,0,9,3,3,0,A61F2/1678;;A61F2/167;;A61F2/1691,A61F2/16;;A61F9/013;;G02B/,,0,0,,,,PENDING
732,WO,A3,WO 2004/092780 A3,199-800-984-096-212,2006-06-29,2006,US 2004/0011019 W,2004-04-09,US 46199403 P,2003-04-11,INTRAOCULAR LENS STORAGE AND INSERTION DEVICE AND METHOD OF USE THEREOF,"The present invention is a device (10) for rolling, storing and inserting into an eye an extremely thin intraocular lens (IOL) (12). The device (10) performs as a roller and injector. Also disclosed herein are methods of using the lens rolling device. The chamber for rolling the intraocular lens includes curved walls, a hollow chamber, and a funnel for receiving a plunger, and a port for extruding a rolled lens. The IOL is effectively rolled by engaging the two parts of the rolling device. After rolling, the lens (12) is ejected from the device through a cannula and into an eye.",THINOPTX INC;;CALLAHAN WAYNE B;;CALLAHAN JEFFERY S;;SIMMS JAMES J;;DEMENTIEV DIMITRII D M D;;WRIGHT WILLIAM BERNARD,CALLAHAN WAYNE B;;CALLAHAN JEFFERY S;;SIMMS JAMES J;;DEMENTIEV DIMITRII D M D;;WRIGHT WILLIAM BERNARD,,https://lens.org/199-800-984-096-212,Search Report,yes,2,0,3,3,0,A61F2/1678;;A61F2/167;;A61F2/1691,A61F9/013;;A61F2/16;;G02B/,,0,0,,,,PENDING
733,US,A1,US 2013/0302707 A1,012-424-901-561-679,2013-11-14,2013,US 201313938826 A,2013-07-10,US 201313938826 A;;US 53325809 A,2009-07-31,ELECTROCHEMICAL CELL,"An electrochemical cell having two or more diffusion bonded layers, which demonstrates a high degree of ruggedness, reliability, efficiency and attitude insensitiveness, is provided. The novel cell structure simplifies construction and operation of these cells. Also provided is a method for passive water removal from these cells. The inventive cell, as well as stacks made using these cells, is suitable for use in applications such as commercial space power systems, long endurance aircraft, undersea power systems, remote backup power systems, and regenerative fuel cells.",INFINITY FUEL CELL AND HYDROGEN INC,CALLAHAN CHRISTOPHER;;MCELROY JAMES F;;MEYER ALFRED;;SMITH WILLIAM F,INFINITY FUEL CELL AND HYDROGEN INC (2009-11-28),https://lens.org/012-424-901-561-679,Patent Application,yes,1,1,8,8,0,H01M8/0245;;H01M8/04164;;H01M8/04171;;Y02E60/50;;H01M8/04164;;H01M8/04171;;H01M8/0245;;H01M8/04291,H01M8/04;;C25B9/23,429/414;;429/535,0,0,,,,ACTIVE
734,US,A1,US 2008/0051416 A1,018-317-258-374-229,2008-02-28,2008,US 57674805 A,2005-10-05,US 57674805 A;;US 61606504 P;;US 71972905 P;;US 2005/0035743 W,2004-10-05,Novel Compounds,"The present invention is directed to novel compounds of formula (I): or pharmaceutically acceptable derivatives thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.",SMITHKLINE BEECHAM CORP,BOEHM JEFFREY C;;CALLAHAN JAMES F;;WAN ZEHONG;;YAN HONGXING,SMITHKLINE BEECHAM CORPORATION (2005-09-28),https://lens.org/018-317-258-374-229,Patent Application,yes,99,8,1,9,0,C07C233/65;;C07C233/66;;C07C233/69;;C07C233/78;;C07C255/24;;C07C275/42;;C07C311/37;;C07D207/14;;C07D211/58;;C07D213/75;;C07D231/40;;C07D233/61;;C07D277/46;;C07D285/08;;C07D295/13;;C07D417/12;;C07C2601/02;;C07C2601/08;;C07C2601/14;;A61P43/00;;C07C311/37;;C07D213/75;;C07D211/58;;C07C233/65;;C07D207/14;;C07D295/13;;C07C233/69;;C07D417/12;;C07D233/61;;C07D285/08;;C07D231/40;;C07C233/66;;C07D277/46;;C07C275/42;;C07C233/78;;C07C255/24;;C07C2601/02;;C07C2601/14;;C07C2601/08,A61K31/164;;A61K31/495;;A61K31/195;;A61K31/215;;A61K31/40;;A61K31/4164;;A61K31/426;;A61K31/44;;A61K31/445;;A61P43/00;;C07C229/00;;C07C233/00;;C07C311/01;;C07D207/00;;C07D213/02;;C07D221/00;;C07D233/54;;C07D277/02;;C07D295/00,514/254.02;;514/252.12;;514/255.01;;514/326;;514/327;;514/352;;514/371;;514/399;;514/428;;514/535;;514/563;;514/603;;514/616;;544/369;;544/383;;544/400;;546/208;;546/221;;546/309;;548/195;;548/338.1;;548/567;;560/19;;562/433;;564/153;;564/157;;564/86,0,0,,,,DISCONTINUED
735,DK,D0,DK 125186 D0,036-594-918-400-129,1986-03-18,1986,DK 125186 A,1986-03-18,US 71373285 A,1985-03-20,AROMATISKE VASOPRESSINANTAGONISTER MED BASISK HALE,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;YIM NELSON CHI-FAI,,https://lens.org/036-594-918-400-129,Patent Application,no,0,0,14,14,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P13/02;;A61P15/00;;A61P7/10;;A61P9/12;;C07K7/16;;A61K38/00;;Y10S930/15,C07K1/113;;A61K38/00;;A61K38/04;;A61K38/095;;A61P7/10;;A61P9/12;;A61P13/02;;A61P15/00;;C07K7/06;;C07K7/16,,0,0,,,,DISCONTINUED
736,DE,D1,DE 3470544 D1,074-478-029-389-265,1988-05-26,1988,DE 3470544 T,1984-08-23,US 53500083 A,1983-09-22,BASIC HEXA- AND HEPTA-PEPTIDE VASOPRESSIN ANTAGONISTS,"Compounds of the formula (I) <CHEM> in which: A is -NR-(CH2)n,-NH2 or -NR-(CH2)n-NH-@@NR2; Z is Phe, Phe(4 min -Alk) or Tyr(Alk); X is D-Phe, D-Phe(4 min Alk), D-Val, D-Nva, D-Leu, D-Ile, D-Pba, D-Nle, D-Cha, D-Abu, D-Met, D-Chg, D-Tyr, L-Tyr, D-Tyr(Alk) or L-Tyr(Alk); P is D-Pro, L-Pro, DELTA <3>-Pro, L-Ala, L-N-MeAla, L-Gly, L-Sar or a single bond; Y is Val, Ile, Abu, Ala, Chg, Gln, Lys, Cha, Nle, Phe, Leu or Gly; R is, in each case, hydrogen or C1-5-alkyl; n is an integer from 2-8; m is an integer from 0-2; and Alk is C1-4-alkyl; and pharmaceutically acceptable acid addition salts thereof are vasopressin antagonists. Their preparation and pharmaceutical use are described.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;CHI-FAI YIM NELSON,,https://lens.org/074-478-029-389-265,Granted Patent,no,0,0,30,31,0,A61K38/00;;C07K7/16;;A61P5/00;;A61P7/10;;C07K7/06,A61K38/00;;A61K38/095;;A61P5/00;;A61P7/10;;C07K1/00;;C07K1/113;;C07K7/16;;C07K7/50;;C07K14/575,,0,0,,,,EXPIRED
737,EP,A3,EP 0231077 A3,092-589-917-411-322,1989-06-07,1989,EP 87300312 A,1987-01-15,US 81933686 A,1986-01-16,POLYPEPTIDE COMPOUNDS,"New compounds which have potent V 2 -vasopressin antagonistic activity are prepared by a 1,6-cyclization using peptide bond formation. The structures of the compounds are characterized by a Pas 1,6  or Tas 1,6  cyclized unit.",SMITHKLINE BECKMAN CORPORATION,"CALLAHAN, JAMES FRANCIS;;HUFFMANNN, WILLIAM FRANCIS;;YIM, NELSON CHI-FAI",,https://lens.org/092-589-917-411-322,Search Report,yes,2,0,20,24,0,A61K38/00;;A61P7/10;;A61P9/12;;C07K7/16;;C07K7/16;;F28D15/02,C07K14/575;;A61K38/00;;A61K38/095;;A61P7/10;;A61P9/12;;C07C67/00;;C07C227/00;;C07C227/24;;C07C229/28;;C07C239/00;;C07C253/00;;C07C255/31;;C07C269/00;;C07K1/113;;C07K7/06;;C07K7/16,,1,1,047-367-924-087-860,10.1021/ja00765a056;;5032960,"JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 17th May 1972, pages 3590-3600; SATOE HASE et al.: ""1,6-Aminosuberic acid analogs of Cysine- and arginine-vasopressin and -vasotocin. Synthesis and biological properties""",DISCONTINUED
738,ZW,A1,ZW 387 A1,094-484-362-713-512,1987-05-13,1987,ZW 387 A,1987-01-16,US 81933686 A,1986-01-16,"1,6-DICARBA-POLYPEPTIDE COMPOUNDS",,SMITHKLINE BECKMAN CORP,JAMES FRANCIS CALLAHAN;;WILLIAM FRANCIS HUFFMAN;;NELSON CHI-FAI YIM,,https://lens.org/094-484-362-713-512,Granted Patent,no,0,0,20,24,0,A61K38/00;;A61P7/10;;A61P9/12;;C07K7/16;;C07K7/16;;F28D15/02,C07K14/575;;A61K38/00;;A61K38/095;;A61P7/10;;A61P9/12;;C07C67/00;;C07C227/00;;C07C227/24;;C07C229/28;;C07C239/00;;C07C253/00;;C07C255/31;;C07C269/00;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,EXPIRED
739,DK,A,DK 20687 A,110-189-978-430-891,1987-07-17,1987,DK 20687 A,1987-01-15,US 81933686 A,1986-01-16,POLYPEPTIDFORBINDELSER OG FREMGANGSMAADE TIL FREMSTILLING DERAF,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS;;YIM NELSON CHI-FAI,,https://lens.org/110-189-978-430-891,Patent Application,no,0,0,20,24,0,A61K38/00;;A61P7/10;;A61P9/12;;C07K7/16;;C07K7/16;;F28D15/02,C07K14/575;;A61K38/00;;A61K38/095;;A61P7/10;;A61P9/12;;C07C67/00;;C07C227/00;;C07C227/24;;C07C229/28;;C07C239/00;;C07C253/00;;C07C255/31;;C07C269/00;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,DISCONTINUED
740,FR,A1,FR 2790748 A1,073-534-151-598-201,2000-09-15,2000,FR 0002913 A,2000-03-07,US 26425899 A,1999-03-08,PROCEDE ET APPAREIL DE DETECTION DE FEUILLES SUPERPOSEES DANS UN CHEMIN DE TRANSPORT,"<P>On détecte la présence de feuilles superposées dans un chemin de transport de papier (22, 24) en employant ces feuilles comme un filtre acoustique à interférences. Un faisceau d'énergie ultrasonore à fréquence appropriée, émis par un transducteur émetteur (12) dans une orientation inclinée par rapport au chemin de transport, subira une atténuation très supérieure à celle calculée sur la base de l'atténuation d'une seule feuille, du fait de la combinaison destructive de fronts d'onde réfléchis par les surfaces en regard des feuilles superposées.Application à la lecture automatique de documents.</P>",SCAN OPTICS INC,BRAZEAL JR EARL H;;CALLAHAN JAMES D;;SOUSSOUNIS JAMES M;;STONE DAVID H,,https://lens.org/073-534-151-598-201,Patent Application,no,0,1,3,3,0,B65H7/125;;B65H2553/30;;G01N2291/0237;;B65H7/125;;G01N2291/0237;;B65H2553/30,B65H7/12,,0,0,,,,DISCONTINUED
741,AU,B2,AU 595506 B2,059-612-262-030-612,1990-04-05,1990,AU 1986/054706 A,1986-03-13,US 71373285 A,1985-03-20,AROMATIC BASIC-TAILED VASOPRESSIN ANTAGONISTS,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;YIM NELSON CHI-FAI,,https://lens.org/059-612-262-030-612,Granted Patent,no,3,0,14,14,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P13/02;;A61P15/00;;A61P7/10;;A61P9/12;;C07K7/16;;A61K38/00;;Y10S930/15,C07K1/113;;A61K38/00;;A61K38/04;;A61K38/095;;A61P7/10;;A61P9/12;;A61P13/02;;A61P15/00;;C07K7/06;;C07K7/16,,0,0,,,,EXPIRED
742,CA,A1,CA 3135380 A1,075-704-321-951-613,2020-10-08,2020,CA 3135380 A,2020-04-01,US 201962828169 P;;US 2020/0026235 W,2019-04-02,METHODS INVOLVING CEMENTS THAT EMPLOY CARBON DIOXIDE AS A REACTANT,"A method of cementing an annular space between a pipe string and a well bore, the method comprising the steps of (a) providing a cement composition including a calcium-deficient calcium silicate; (b) mixing the cement composition with water to form a cement slurry; (c) mixing the cement slurry composition with carbon dioxide form a foamed cement; and (d) placing the foamed cement in the annular space between the pipe string and the wellbore.",OXY LOW CARBON VENTURES LLC,COWAN KENNETH M;;ZELLER III;;CALLAHAN III;;WILLIS JAMES S,,https://lens.org/075-704-321-951-613,Patent Application,no,0,0,4,4,0,C09K8/473;;C04B38/103;;Y02P40/18;;C04B28/188;;C04B38/103;;C04B40/0231;;C04B2111/00706;;C09K8/46;;E21B33/14,C04B38/10;;C09K8/473,,0,0,,,,PENDING
743,CA,A,CA 781066 A,099-867-701-066-840,1968-03-19,1968,CA 781066D A,,CA 781066T A,,ELECTRONIC COMPUTER WITH INTERRUPT FACILITY,,RCA CORP,CALLAHAN JAMES F;;SMITH RICHARD D;;YEN RICHARD HSIN-YUNG,,https://lens.org/099-867-701-066-840,Granted Patent,no,0,0,1,1,0,,,,0,0,,,,EXPIRED
744,US,A1,US 2008/0096905 A1,166-251-555-884-273,2008-04-24,2008,US 90883906 A,2006-03-24,US 90883906 A;;US 66515405 P;;US 2006/0010859 W,2005-03-25,"Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives","The present invention is directed to a novel method of preparing of 2,4,8-trisubstituted pyrido[2,3-d]pyrimidin-7-one pharmacophores of Formula (II) wherein G1 is CH 2 or NH: G2 is CH or nitrogen;Rx is chloro, bromo, iodo, or O—S(O) 2 CF 3 ;R g is a C 1-10 alkyl; m is 0, or an integer having a value of 1, or 2;R 3 is a C 1-10 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl C 1-10 alkyl, aryl, arylC 1-10 alkyl, heteroaryl, heteroarylC 1-10 alkyl, heterocyclic or a heterocyclylC 1-10 alkyl moiety, and wherein each of these moieties may be optionally substituted. which comprises reacting a compound of the formula: whereinRy is chloro, bromo, iodo, O—S(O) 2 CF 3 ; andRg is a C 1-10 alkyl; with a olefin forming reagent in a suitable base to yield a compound of Formula (II), wherein m=0 and oxidizing the sulphur as necessary or desired.",GLAXO GROUP LTD,CALLAHAN JAMES F;;BOEHM JEFFREY C;;WAN ZEHONG;;YAN HOHGXING,GLAXO GROUP LIMITED (2006-04-13),https://lens.org/166-251-555-884-273,Patent Application,yes,50,7,22,22,0,C07D471/04;;C07D487/04;;A61P43/00;;C07D471/04;;C07D487/04;;C07D487/04;;C07D471/04,A61K31/519;;C07D487/02,514/264.1;;544/279,0,0,,,,DISCONTINUED
745,DK,D0,DK 20687 D0,037-811-555-742-297,1987-01-15,1987,DK 20687 A,1987-01-15,US 81933686 A,1986-01-16,POLYPEPTIDFORBINDELSER OG FREMGANGSMAADE TIL FREMSTILLING DERAF,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS;;YIM NELSON CHI-FAI,,https://lens.org/037-811-555-742-297,Patent Application,no,0,0,20,24,0,A61K38/00;;A61P7/10;;A61P9/12;;C07K7/16;;C07K7/16;;F28D15/02,C07K14/575;;A61K38/00;;A61K38/095;;A61P7/10;;A61P9/12;;C07C67/00;;C07C227/00;;C07C227/24;;C07C229/28;;C07C239/00;;C07C253/00;;C07C255/31;;C07C269/00;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,DISCONTINUED
746,WO,A1,WO 2011/014658 A1,115-997-105-831-52X,2011-02-03,2011,US 2010/0043715 W,2010-07-29,US 53325809 A,2009-07-31,AN IMPROVED ELECTROCHEMICAL CELL,"An electrochemical cell having two or more diffusion bonded layers, which demonstrates a high degree of ruggedness, reliability, efficiency and attitude insensitiveness, is provided. The novel cell structure simplifies construction and operation of these cells. Also provided is a method for passive water removal from these cells. The inventive cell, as well as stacks made using these cells, is suitable for use in applications such as commercial space power systems, long endurance aircraft, undersea power systems, remote backup power systems, and regenerative fuel cells.",INFINITY FUEL CELL AND HYDROGEN INC;;CALLAHAN CHRISTOPHER;;MCELROY JAMES F;;MEYER ALFRED;;SMITH WILLIAM F,CALLAHAN CHRISTOPHER;;MCELROY JAMES F;;MEYER ALFRED;;SMITH WILLIAM F,,https://lens.org/115-997-105-831-52X,Patent Application,no,9,0,8,8,0,H01M8/0245;;H01M8/04164;;H01M8/04171;;Y02E60/50;;H01M8/04164;;H01M8/04171;;H01M8/0245;;H01M8/04291,H01M8/04;;C25B9/23;;H01M8/02,,0,0,,,,PENDING
747,WO,A2,WO 2006/110173 A2,110-605-040-551-422,2006-10-19,2006,US 2005/0035743 W,2005-10-05,US 61606504 P;;US 71972905 P,2004-10-05,NOVEL COMPOUNDS,"The present invention is directed to novel compounds of formula (I): or pharmaceutically acceptable derivatives thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.",SMITHKLINE BEECHAM CORP;;BOEHM JEFFREY C;;CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,BOEHM JEFFREY C;;CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/110-605-040-551-422,Patent Application,yes,0,12,8,9,0,A61P1/00;;A61P1/04;;A61P1/18;;A61P3/10;;A61P7/04;;A61P9/00;;A61P9/10;;A61P9/12;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P37/06;;A61P43/00;;C07C233/65;;C07C233/63;;C07C233/69;;C07C233/78;;C07C275/42;;C07C2601/02;;C07D211/58;;C07D213/75;;C07D277/46,A61K31/165,,1,0,,,See references of EP 1805132A4,PENDING
748,ES,T3,ES 2552390 T3,102-858-977-029-25X,2015-11-27,2015,ES 10745044 T,2010-07-29,US 53325809 A;;US 2010/0043715 W,2009-07-31,Una celda electroquímica mejorada,"Una celda (24) electroquímica, que comprende un ensamblaje (34, 44) de electrodo de membrana, que tiene un lado ánodo y un lado del cátodo, y un ensamblaje (42) de placa bipolar unido por difusión, comprendiendo el ensamblaje de placa bipolar: - un campo (28, 50) de flujo de agua; - una pantalla de oxígeno/ensamblaje (10, 46) de marco que tiene una malla de la pantalla que incluye una pluralidad de aberturas que forman los espacios (16) de flujo de fluido; y - una placa (30, 48) hidrófila porosa que comprende una membrana porosa metálica sinterizada para la separación de agua/gas, la placa (30, 48) hidrófilo porosa está situado entre y unida por difusión para el campo (28, 50) de flujo de agua y la pantalla de oxígeno/ensamblaje (10, 46) de marco, y la pantalla de oxígeno/ensamblaje (10, 46) de marco se encuentran en el lado del cátodo del ensamblaje (34, 44) de electrodo de membrana.",INFINITY FUEL CELL AND HYDROGEN INC,CALLAHAN CHRISTOPHER;;MCELROY JAMES F;;MEYER ALFRED;;SMITH WILLIAM F,,https://lens.org/102-858-977-029-25X,Granted Patent,no,0,0,8,8,0,H01M8/0245;;H01M8/04164;;H01M8/04171;;Y02E60/50;;H01M8/04164;;H01M8/04171;;H01M8/0245;;H01M8/04291,H01M8/04;;C25B9/23;;H01M8/02,,0,0,,,,ACTIVE
749,AU,A,AU 1984/033037 A,110-345-945-857-081,1985-03-28,1985,AU 1984/033037 A,1984-09-14,US 53500083 A,1983-09-22,VASOPRESSIN ANTAGONISTS,"Compounds of the formula (I) <CHEM> in which: A is -NR-(CH2)n,-NH2 or -NR-(CH2)n-NH-@@NR2; Z is Phe, Phe(4 min -Alk) or Tyr(Alk); X is D-Phe, D-Phe(4 min Alk), D-Val, D-Nva, D-Leu, D-Ile, D-Pba, D-Nle, D-Cha, D-Abu, D-Met, D-Chg, D-Tyr, L-Tyr, D-Tyr(Alk) or L-Tyr(Alk); P is D-Pro, L-Pro, DELTA <3>-Pro, L-Ala, L-N-MeAla, L-Gly, L-Sar or a single bond; Y is Val, Ile, Abu, Ala, Chg, Gln, Lys, Cha, Nle, Phe, Leu or Gly; R is, in each case, hydrogen or C1-5-alkyl; n is an integer from 2-8; m is an integer from 0-2; and Alk is C1-4-alkyl; and pharmaceutically acceptable acid addition salts thereof are vasopressin antagonists. Their preparation and pharmaceutical use are described.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;YIM NELSON CHI-FAI,,https://lens.org/110-345-945-857-081,Patent Application,no,0,2,30,31,0,A61K38/00;;C07K7/16;;A61P5/00;;A61P7/10;;C07K7/06,A61K38/00;;A61K38/095;;A61P5/00;;A61P7/10;;C07K1/00;;C07K1/113;;C07K7/16;;C07K7/50;;C07K14/575,,0,0,,,,EXPIRED
750,WO,A1,WO 2020/206011 A1,144-984-718-062-777,2020-10-08,2020,US 2020/0026235 W,2020-04-01,US 201962828169 P,2019-04-02,METHODS INVOLVING CEMENTS THAT EMPLOY CARBON DIOXIDE AS A REACTANT,"A method of cementing an annular space between a pipe string and a well bore, the method comprising the steps of (a) providing a cement composition including a calcium-deficient calcium silicate; (b) mixing the cement composition with water to form a cement slurry; (c) mixing the cement slurry composition with carbon dioxide form a foamed cement; and (d) placing the foamed cement in the annular space between the pipe string and the wellbore.",OXY LOW CARBON VENTURES LLC,COWAN KENNETH M;;ZELLER III;;CALLAHAN III;;WILLIS JAMES S,,https://lens.org/144-984-718-062-777,Patent Application,yes,26,6,4,4,0,C09K8/473;;C04B38/103;;Y02P40/18;;C04B28/188;;C04B38/103;;C04B40/0231;;C04B2111/00706;;C09K8/46;;E21B33/14,C04B38/10;;C09K8/473,,0,0,,,,PENDING
751,DK,A,DK 408284 A,171-525-896-207-63X,1985-03-23,1985,DK 408284 A,1984-08-27,US 53500083 A,1983-09-22,BASISKE HEPTAPEPTIDER DER ER VASOPRESSINANTAGONISTER,"Compounds of the formula (I) <CHEM> in which: A is -NR-(CH2)n,-NH2 or -NR-(CH2)n-NH-@@NR2; Z is Phe, Phe(4 min -Alk) or Tyr(Alk); X is D-Phe, D-Phe(4 min Alk), D-Val, D-Nva, D-Leu, D-Ile, D-Pba, D-Nle, D-Cha, D-Abu, D-Met, D-Chg, D-Tyr, L-Tyr, D-Tyr(Alk) or L-Tyr(Alk); P is D-Pro, L-Pro, DELTA <3>-Pro, L-Ala, L-N-MeAla, L-Gly, L-Sar or a single bond; Y is Val, Ile, Abu, Ala, Chg, Gln, Lys, Cha, Nle, Phe, Leu or Gly; R is, in each case, hydrogen or C1-5-alkyl; n is an integer from 2-8; m is an integer from 0-2; and Alk is C1-4-alkyl; and pharmaceutically acceptable acid addition salts thereof are vasopressin antagonists. Their preparation and pharmaceutical use are described.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;YIM NELSON CHI-FAI,,https://lens.org/171-525-896-207-63X,Patent Application,no,0,0,30,31,0,A61K38/00;;C07K7/16;;A61P5/00;;A61P7/10;;C07K7/06,A61K38/00;;A61K38/095;;A61P5/00;;A61P7/10;;C07K1/00;;C07K1/113;;C07K7/16;;C07K7/50;;C07K14/575,,0,0,,,,DISCONTINUED
752,US,B2,US 8715871 B2,023-819-329-112-420,2014-05-06,2014,US 201313938826 A,2013-07-10,US 201313938826 A;;US 53325809 A,2009-07-31,Electrochemical cell,"An electrochemical cell having two or more diffusion bonded layers, which demonstrates a high degree of ruggedness, reliability, efficiency and attitude insensitiveness, is provided. The novel cell structure simplifies construction and operation of these cells. Also provided is a method for passive water removal from these cells. The inventive cell, as well as stacks made using these cells, is suitable for use in applications such as commercial space power systems, long endurance aircraft, undersea power systems, remote backup power systems, and regenerative fuel cells.",INFINITY FUEL CELL AND HYDROGEN INC,CALLAHAN CHRISTOPHER;;MCELROY JAMES F;;MEYER ALFRED;;SMITH WILLIAM F,INFINITY FUEL CELL AND HYDROGEN INC (2009-11-28),https://lens.org/023-819-329-112-420,Granted Patent,yes,17,0,8,8,0,H01M8/0245;;H01M8/04164;;H01M8/04171;;Y02E60/50;;H01M8/04164;;H01M8/04171;;H01M8/0245;;H01M8/04291,C25B9/23;;H01M8/04,429/414;;429/450;;429/457;;429/533;;429/535,0,0,,,,ACTIVE
753,AU,A,AU 1987/067624 A,026-507-386-530-967,1987-07-23,1987,AU 1987/067624 A,1987-01-16,US 81933686 A,1986-01-16,DICARBA-VASOPRESSINS,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS;;YIM NELSON CHI-FAI,,https://lens.org/026-507-386-530-967,Patent Application,no,0,0,20,24,0,A61K38/00;;A61P7/10;;A61P9/12;;C07K7/16;;C07K7/16;;F28D15/02,C07K14/575;;A61K38/00;;A61K38/095;;A61P7/10;;A61P9/12;;C07C67/00;;C07C227/00;;C07C227/24;;C07C229/28;;C07C239/00;;C07C253/00;;C07C255/31;;C07C269/00;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,DISCONTINUED
754,US,A1,US 2011/0024295 A1,011-532-377-554-297,2011-02-03,2011,US 53325809 A,2009-07-31,US 53325809 A,2009-07-31,ELECTROCHEMICAL CELL,"An electrochemical cell having two or more diffusion bonded layers, which demonstrates a high degree of ruggedness, reliability, efficiency and attitude insensitiveness, is provided. The novel cell structure simplifies construction and operation of these cells. Also provided is a method for passive water removal from these cells. The inventive cell, as well as stacks made using these cells, is suitable for use in applications such as commercial space power systems, long endurance aircraft, undersea power systems, remote backup power systems, and regenerative fuel cells.",CALLAHAN CHRISTOPHER;;MCELROY JAMES F;;MEYER ALFRED;;SMITH WILLIAM F,CALLAHAN CHRISTOPHER;;MCELROY JAMES F;;MEYER ALFRED;;SMITH WILLIAM F,INFINITY FUEL CELL AND HYDROGEN INC (2010-01-14),https://lens.org/011-532-377-554-297,Patent Application,yes,15,9,8,8,0,H01M8/0245;;H01M8/04164;;H01M8/04171;;Y02E60/50;;H01M8/04164;;H01M8/04171;;H01M8/0245;;H01M8/04291,C25B9/23;;B01D61/56;;C25C7/04;;H01M8/04,204/538;;204/252;;204/253;;429/413;;429/463,0,0,,,,ACTIVE
755,US,B2,US 8506787 B2,037-148-212-572-806,2013-08-13,2013,US 53325809 A,2009-07-31,US 53325809 A,2009-07-31,Electrochemical cell,"An electrochemical cell having two or more diffusion bonded layers, which demonstrates a high degree of ruggedness, reliability, efficiency and attitude insensitiveness, is provided. The novel cell structure simplifies construction and operation of these cells. Also provided is a method for passive water removal from these cells. The inventive cell, as well as stacks made using these cells, is suitable for use in applications such as commercial space power systems, long endurance aircraft, undersea power systems, remote backup power systems, and regenerative fuel cells.",CALLAHAN CHRISTOPHER;;MCELROY JAMES F;;MEYER ALFRED;;SMITH WILLIAM F;;INFINITY FUEL CELL AND HYDROGEN INC,CALLAHAN CHRISTOPHER;;MCELROY JAMES F;;MEYER ALFRED;;SMITH WILLIAM F,INFINITY FUEL CELL AND HYDROGEN INC (2010-01-14),https://lens.org/037-148-212-572-806,Granted Patent,yes,18,1,8,8,0,H01M8/0245;;H01M8/04164;;H01M8/04171;;Y02E60/50;;H01M8/04164;;H01M8/04171;;H01M8/0245;;H01M8/04291,C25B9/23;;H01M8/10,205/252;;204/255;;204/256;;204/257;;204/258;;429/414;;429/457;;429/490;;429/505,0,0,,,,ACTIVE
756,FI,L,FI 843723 L,043-543-572-031-170,1985-03-23,1985,FI 843723 A,1984-09-21,US 53500083 A,1983-09-22,FOERFARANDE FOER FRAMSTAELLNING AV BASISKA HEPTAPEPTID-VASOPRESSIN-ANTAGONISTER.,"Compounds of the formula (I) <CHEM> in which: A is -NR-(CH2)n,-NH2 or -NR-(CH2)n-NH-@@NR2; Z is Phe, Phe(4 min -Alk) or Tyr(Alk); X is D-Phe, D-Phe(4 min Alk), D-Val, D-Nva, D-Leu, D-Ile, D-Pba, D-Nle, D-Cha, D-Abu, D-Met, D-Chg, D-Tyr, L-Tyr, D-Tyr(Alk) or L-Tyr(Alk); P is D-Pro, L-Pro, DELTA <3>-Pro, L-Ala, L-N-MeAla, L-Gly, L-Sar or a single bond; Y is Val, Ile, Abu, Ala, Chg, Gln, Lys, Cha, Nle, Phe, Leu or Gly; R is, in each case, hydrogen or C1-5-alkyl; n is an integer from 2-8; m is an integer from 0-2; and Alk is C1-4-alkyl; and pharmaceutically acceptable acid addition salts thereof are vasopressin antagonists. Their preparation and pharmaceutical use are described.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;YIM NELSON CHI-FAI,,https://lens.org/043-543-572-031-170,Abstract,no,0,0,30,31,0,A61K38/00;;C07K7/16;;A61P5/00;;A61P7/10;;C07K7/06,A61K38/00;;A61K38/095;;A61P5/00;;A61P7/10;;C07K1/00;;C07K1/113;;C07K7/16;;C07K7/50;;C07K14/575,,0,0,,,,DISCONTINUED
757,WO,A3,WO 2006/110173 A3,025-297-525-489-599,2006-11-23,2006,US 2005/0035743 W,2005-10-05,US 61606504 P;;US 71972905 P,2004-10-05,NOVEL COMPOUNDS,"The present invention is directed to novel compounds of formula (I): or pharmaceutically acceptable derivatives thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.",SMITHKLINE BEECHAM CORP;;BOEHM JEFFREY C;;CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,BOEHM JEFFREY C;;CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/025-297-525-489-599,Search Report,yes,2,0,8,9,0,A61P1/00;;A61P1/04;;A61P1/18;;A61P3/10;;A61P7/04;;A61P9/00;;A61P9/10;;A61P9/12;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P37/06;;A61P43/00;;C07C233/65;;C07C233/63;;C07C233/69;;C07C233/78;;C07C275/42;;C07C2601/02;;C07D211/58;;C07D213/75;;C07D277/46,C07C233/05;;A61K31/165;;A61K31/195;;A61K31/425;;A61K31/445;;A61K31/495;;C07C229/00;;C07D211/22;;C07D241/04;;C07D277/04,,1,0,,,See also references of EP 1805132A4,PENDING
758,AT,T1,AT E33659 T1,044-486-279-182-04X,1988-05-15,1988,AT 84305764 T,1984-08-23,EP 84305764 A;;US 53500083 A,1983-09-22,BASISCHE HEXA- UND HEPTAPEPTIDE ALS VASOPRESSIN- ANTAGONISTEN.,"Compounds of the formula (I) <CHEM> in which: A is -NR-(CH2)n,-NH2 or -NR-(CH2)n-NH-@@NR2; Z is Phe, Phe(4 min -Alk) or Tyr(Alk); X is D-Phe, D-Phe(4 min Alk), D-Val, D-Nva, D-Leu, D-Ile, D-Pba, D-Nle, D-Cha, D-Abu, D-Met, D-Chg, D-Tyr, L-Tyr, D-Tyr(Alk) or L-Tyr(Alk); P is D-Pro, L-Pro, DELTA <3>-Pro, L-Ala, L-N-MeAla, L-Gly, L-Sar or a single bond; Y is Val, Ile, Abu, Ala, Chg, Gln, Lys, Cha, Nle, Phe, Leu or Gly; R is, in each case, hydrogen or C1-5-alkyl; n is an integer from 2-8; m is an integer from 0-2; and Alk is C1-4-alkyl; and pharmaceutically acceptable acid addition salts thereof are vasopressin antagonists. Their preparation and pharmaceutical use are described.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;CHI-FAI YIM NELSON,,https://lens.org/044-486-279-182-04X,Granted Patent,no,0,0,30,31,0,A61K38/00;;C07K7/16;;A61P5/00;;A61P7/10;;C07K7/06,A61K38/00;;A61K38/095;;A61P5/00;;A61P7/10;;C07K1/00;;C07K1/113;;C07K7/16;;C07K7/50;;C07K14/575,,0,0,,,,DISCONTINUED
759,ZW,A1,ZW 13284 A1,077-921-976-919-554,1984-11-07,1984,ZW 13284 A,1984-08-15,US 53500083 A,1983-09-22,BASIC HEPTAPEPTIDE VASOPRESSIN ANTAGONISTS,"Compounds of the formula (I) <CHEM> in which: A is -NR-(CH2)n,-NH2 or -NR-(CH2)n-NH-@@NR2; Z is Phe, Phe(4 min -Alk) or Tyr(Alk); X is D-Phe, D-Phe(4 min Alk), D-Val, D-Nva, D-Leu, D-Ile, D-Pba, D-Nle, D-Cha, D-Abu, D-Met, D-Chg, D-Tyr, L-Tyr, D-Tyr(Alk) or L-Tyr(Alk); P is D-Pro, L-Pro, DELTA <3>-Pro, L-Ala, L-N-MeAla, L-Gly, L-Sar or a single bond; Y is Val, Ile, Abu, Ala, Chg, Gln, Lys, Cha, Nle, Phe, Leu or Gly; R is, in each case, hydrogen or C1-5-alkyl; n is an integer from 2-8; m is an integer from 0-2; and Alk is C1-4-alkyl; and pharmaceutically acceptable acid addition salts thereof are vasopressin antagonists. Their preparation and pharmaceutical use are described.",SMITHKLINE BECKMAN CORP,JAMES FRANCIS CALLAHAN;;NELSON CHI-FAI YIM;;MICHAEL LEE MOORE,,https://lens.org/077-921-976-919-554,Granted Patent,no,0,0,30,31,0,A61K38/00;;C07K7/16;;A61P5/00;;A61P7/10;;C07K7/06,A61K38/00;;A61K38/095;;A61P5/00;;A61P7/10;;C07K1/00;;C07K1/113;;C07K7/16;;C07K7/50;;C07K14/575,,0,0,,,,EXPIRED
760,EP,A3,EP 0135379 A3,176-683-571-356-333,1986-03-12,1986,EP 84305764 A,1984-08-23,US 53500083 A,1983-09-22,BASIC HEXA- AND HEPTA-PEPTIDE VASOPRESSIN ANTAGONISTS,"Compounds of the formula (I)
  in which: A is -NR-(CH 2 ) n -NR 2  or
  Z is Phe, Phe(4' -Alk) or Tyr(Alk); X is D-Phe, D-Phe(4' Alk), D-Val, D-Nva, D-Leu, D-IIe, D-Pba, D-Nle, D-Cha, D-Abu, D-Met, D-Chg, D-Tyr, L-Tyr, D-Tyr(Alk) or L-Tyr(Alk); P is D-Pro, L-Pro, Δ 3 -Pro, L-Ala, L-N-MeAla, L-Gly, L-Sar or a single bond; Y is Val, Ile, Abu, Ala, Chg, Gln, Lys, Cha, Nle, Phe, Leu or Glv; R is, in each case, hydrogen or C 1-5 -alkyl; n is an integer from 2-8; m is an integer from 0-2; and Alk is C 1-4 -alkyl; and pharmaceutically acceptable acid addition salts thereof are vasopressin antagonists. Their preparation and pharmaceutical use are described.",SMITHKLINE BECKMAN CORPORATION,"CALLAHAN, JAMES FRANCIS;;MOORE, MICHAEL LEE;;CHI-FAI YIM, NELSON",,https://lens.org/176-683-571-356-333,Search Report,yes,2,0,30,31,0,A61K38/00;;C07K7/16;;A61P5/00;;A61P7/10;;C07K7/06,A61K38/00;;A61K38/095;;A61P5/00;;A61P7/10;;C07K1/00;;C07K1/113;;C07K7/16;;C07K7/50;;C07K14/575,,2,0,,,"CHEMICAL ABSTRACTS, vol. 100, no. 15, 9th April 1984, page 643, column 2, abstract no. 121603r, Columbus, Ohio, US; M. MANNING et al. ""Potent and selective antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta, beta-pentamethylenepropionic acid), -2-D-isoleucine, 4-valine]arginine-vasopressin at position 4""; & J. MED.CHEM. 1984, 27(4), 423-429; (Cat. A,P,D);;CHEMICAL ABSTRACTS, vol. 101, no. 1, page 926, clumns 1,2, abstract no. 930g, Columbus, Ohio, US; M. MANNING ""Carboxy terminus of vasopressin required for activity but not binding""; & NATURE (London), 1984, 308 (5960), 652-653",EXPIRED
761,ZA,B,ZA 87275 B,014-266-005-494-502,1988-08-31,1988,ZA 87275 A,1987-01-15,US 81933686 A,1986-01-16,POLYPEPTIDE COMPOUNDS,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS;;YIM NELSON CHI-FAI,,https://lens.org/014-266-005-494-502,Granted Patent,no,0,0,20,24,0,A61K38/00;;A61P7/10;;A61P9/12;;C07K7/16;;C07K7/16;;F28D15/02,C07K14/575;;A61K38/00;;A61K38/095;;A61P7/10;;A61P9/12;;C07C67/00;;C07C227/00;;C07C227/24;;C07C229/28;;C07C239/00;;C07C253/00;;C07C255/31;;C07C269/00;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,EXPIRED
762,EP,A4,EP 1805132 A4,073-190-991-219-183,2010-01-20,2010,EP 05857821 A,2005-10-05,US 2005/0035743 W;;US 61606504 P;;US 71972905 P,2004-10-05,NOVEL COMPOUNDS,,SMITHKLINE BEECHAM CORP,BOEHM JEFFREY C;;CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,GLAXOSMITHKLINE LLC (2010-03-31),https://lens.org/073-190-991-219-183,Search Report,no,6,0,8,9,0,C07C233/63;;C07C233/65;;C07C233/69;;C07C233/78;;C07C275/42;;C07D211/58;;C07D213/75;;C07D277/46;;C07C2601/02;;A61P1/00;;A61P1/04;;A61P1/18;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P37/06;;A61P43/00;;A61P7/04;;A61P9/00;;A61P9/10;;A61P9/12;;A61P3/10,C07C233/05;;A61K31/165;;A61K31/195;;A61K31/425;;A61K31/445;;A61K31/495;;C07C229/00;;C07D211/22;;C07D241/04;;C07D277/04,,0,0,,,,DISCONTINUED
763,NO,D0,NO 870175 D0,141-026-549-888-552,1987-01-15,1987,NO 870175 A,1987-01-15,US 81933686 A,1986-01-16,VASOPRESSINFORBINDELSER.,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS;;YIM NELSON CHI-FAI,,https://lens.org/141-026-549-888-552,Patent Application,no,0,0,20,24,0,A61K38/00;;A61P7/10;;A61P9/12;;C07K7/16;;C07K7/16;;F28D15/02,C07K14/575;;A61K38/00;;A61K38/095;;A61P7/10;;A61P9/12;;C07C67/00;;C07C227/00;;C07C227/24;;C07C229/28;;C07C239/00;;C07C253/00;;C07C255/31;;C07C269/00;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,DISCONTINUED
764,NO,L,NO 870175 L,152-379-055-350-827,1987-07-17,1987,NO 870175 A,1987-01-15,US 81933686 A,1986-01-16,POLYPEPTIDFORBINDELSER,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS;;YIM NELSON CHI-FAI,,https://lens.org/152-379-055-350-827,Abstract,no,0,0,20,24,0,A61K38/00;;A61P7/10;;A61P9/12;;C07K7/16;;C07K7/16;;F28D15/02,C07K14/575;;A61K38/00;;A61K38/095;;A61P7/10;;A61P9/12;;C07C67/00;;C07C227/00;;C07C227/24;;C07C229/28;;C07C239/00;;C07C253/00;;C07C255/31;;C07C269/00;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,DISCONTINUED
765,NO,L,NO 20075232 L,162-565-370-808-967,2007-11-28,2007,NO 20075232 A,2007-10-12,US 66515405 P;;US 2006/0010859 W,2005-03-25,"Fremgangsmate for fremstilling av pyrido[2,3-d]pyrimidin-7-on og 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1 H)-on derivater","Foreliggende oppfinnelse angår en ny fremgangsmåte for fremstilling av 2,4,8-trisubstituerte pyrido[2,3-d]pyrimdin-7-on farmakoforer med formel (II) eller (IIa) hvor de variable substituentene er som definert i beskrivelsen.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;BOEHM JEFFREY C;;WAN ZEHONG;;YAN HONGXING,,https://lens.org/162-565-370-808-967,Abstract,no,0,0,22,22,0,C07D471/04;;C07D487/04;;A61P43/00;;C07D471/04;;C07D487/04;;C07D487/04;;C07D471/04,C07D471/04;;A61K31/519;;C07D487/04,,0,0,,,,DISCONTINUED
766,EP,B1,EP 2460217 B1,004-117-684-859-590,2015-09-09,2015,EP 10745044 A,2010-07-29,US 53325809 A;;US 2010/0043715 W,2009-07-31,AN IMPROVED ELECTROCHEMICAL CELL,,INFINITY FUEL CELL AND HYDROGEN INC,CALLAHAN CHRISTOPHER;;MCELROY JAMES F;;MEYER ALFRED;;SMITH WILLIAM F,,https://lens.org/004-117-684-859-590,Granted Patent,yes,7,0,8,8,0,H01M8/0245;;H01M8/04164;;H01M8/04171;;Y02E60/50;;H01M8/04164;;H01M8/04171;;H01M8/0245;;H01M8/04291,H01M8/04;;C25B9/23;;H01M8/02,,0,0,,,,ACTIVE
767,PE,A1,PE 20060493 A1,009-464-017-439-486,2006-09-03,2006,PE 2005001166 A,2005-10-03,US 61606504 P;;US 71972905 P,2004-10-05,COMPUESTOS DERIVADOS DE BIFENIL (DI O TRI) CARBOXAMIDAS COMO INHIBIDORES DE SERINA/TREONINA QUINASA P38,"SE REFIERE A UN COMPUESTO DE FORMULA (I) EN DONDE R1 ES H, ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON HALOGENO, CICLOALQUILO(C3-C7), ALCOXI(C1-C6), ENTRE OTROS; R2 ES H, ALQUILO(C1-C6) O -(CH2)P-CICLOALQUILO(C3-C7) OPCIONALMENTE SUSTITUIDO CON UNO O MAS GRUPOS ALQUILO(C1-C6) EN DONDE P ES 0 A 2; R3 ES HALOGENO O METILO; R4 ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C7), ENTRE OTROS; R8 ES H, ALQUILO(C1-C6), CICLOALQUILO(C3-C7), OPCIONALMENTE SUSTITUIDO; Y E X SE SELECCIONA INDEPENDIENTEMENTE ENTRE H, METILO Y HALOGENO; Z ES -(CH2)SCOOR16 O -(CH2)SCONR16R17, DONDE S ES 0 A 4, R16 Y R17 JUNTO CON NITROGENO FORMAN UN ANILLO DE 5 A 6 MIEMBROS OPCIONALMENTE SUSTITUIDO. SON COMPUESTOS PREFERIDOS: ACIDO 5'-[(CICLOPROPILAMINO)CARBONIL]-4-{[(2,2-DIMETILPROPIL)AMINO]-CARBONIL}-3'-FLUORO-2'-METIL-2-BIFENILCARBOXILICO, N2-[(1S)-1-CICLOHEXILETIL]-N3'-CICLOPROPIL-N4-(2,2-DIMETILPROPIL)-5'-FLUORO-6'-METIL-2,3',4-BIFENILTRICARBOXAMIDA, N3-CICLOPROPIL-N4'-(2,2-DIMETILPROPIL)-5-FLUORO-2'-[(4-HIDROXI-1-PIPERIDINIL)CARBONIL]-6-METIL-3,4'-BIFENILDICARBOXAMIDA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DE LA SERINA/TREONINA QUINASA P38 SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES COMO ARTRITIS REUMATOIDE, ATEROSCLEROSIS",SMITHKLINE BEECHAM CORP,BOEHM JEFFREY CHARLES;;CALLAHAN JAMES FRANCIS;;YANG HONGXING;;WANG ZEHONG,,https://lens.org/009-464-017-439-486,Patent Application,no,0,0,8,9,0,A61P1/00;;A61P1/04;;A61P1/18;;A61P3/10;;A61P7/04;;A61P9/00;;A61P9/10;;A61P9/12;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P37/06;;A61P43/00;;C07C233/65;;C07C233/63;;C07C233/69;;C07C233/78;;C07C275/42;;C07C2601/02;;C07D211/58;;C07D213/75;;C07D277/46,A61K31/519;;C07D487/04,,0,0,,,,DISCONTINUED
768,EP,A1,EP 2460217 A1,019-376-746-610-274,2012-06-06,2012,EP 10745044 A,2010-07-29,US 53325809 A;;US 2010/0043715 W,2009-07-31,AN IMPROVED ELECTROCHEMICAL CELL,,INFINITY FUEL CELL AND HYDROGEN INC,CALLAHAN CHRISTOPHER;;MCELROY JAMES F;;MEYER ALFRED;;SMITH WILLIAM F,,https://lens.org/019-376-746-610-274,Patent Application,yes,0,0,8,8,0,H01M8/0245;;H01M8/04164;;H01M8/04171;;Y02E60/50;;H01M8/04164;;H01M8/04171;;H01M8/0245;;H01M8/04291,H01M8/04;;C25B9/23;;H01M8/02,,0,0,,,,ACTIVE
769,US,A1,US 2006/0258687 A1,033-924-079-660-615,2006-11-16,2006,US 38837506 A,2006-03-24,US 38837506 A;;US 66515405 P,2005-03-25,"Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives","The present invention is directed to a novel method of preparing of 2,4,8-trisubstituted pyrido[2,3-d]pyrimidin-7-one pharmacophores of Formula (II) or (IIa) wherein G1 is CH 2 or NH: G2 is CH or nitrogen;Rx is chloro, bromo, iodo, or O—S(O) 2 CF 3 ;R g is a C 1-10 alkyl; m is 0, or an integer having a value of 1, or 2;R 3 is a C 1-10 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl C 1-10 alkyl, aryl, arylC 1-10 alkyl, heteroaryl, heteroarylC 1-10 alkyl, heterocyclic or a heterocyclylC 1-10 alkyl moiety, and wherein each of these moieties may be optionally substituted. which comprises reacting a compound of the formula: whereinRy is chloro, bromo, iodo, O—S(O) 2 CF 3 ; andRg is a C 1-10 alkyl; with a olefin forming reagent in a suitable base to yield a compound of Formula (II), or (IIa) wherein m=0 and oxidizing the sulphur as necessary or desired.",BOEHM JEFFREY C;;CALLAHAN JAMES F;;WAN ZEHONG;;YAN HONGXING,BOEHM JEFFREY C;;CALLAHAN JAMES F;;WAN ZEHONG;;YAN HONGXING,GLAXO GROUP LIMITED (2006-05-25),https://lens.org/033-924-079-660-615,Patent Application,yes,49,28,22,22,0,C07D471/04;;C07D487/04;;A61P43/00;;C07D471/04;;C07D487/04;;C07D487/04;;C07D471/04,A61K31/519;;C07D487/02,514/262.1;;544/255;;544/279;;514/264.1,0,0,,,,INACTIVE
770,ZA,B,ZA 200303082 B,067-348-012-881-609,2004-04-28,2004,ZA 200303082 A,2003-04-22,US 24300600 P,2000-10-25,Calcilytic compounds.,,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP BURGESS JOELL;;CALLAHAN JAMES F;;LAGO MARIA A,,https://lens.org/067-348-012-881-609,Granted Patent,no,0,0,20,20,0,A61K31/565;;A61K31/59;;A61K31/66;;A61K38/23;;A61K45/06;;C07D213/84;;A61P1/02;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P35/04;;A61P43/00;;A61P5/18;;A61P5/22;;C07D213/63;;C07D213/84;;A61K31/59;;A61K31/565;;A61K31/66;;A61K45/06;;A61K38/23,A61K31/137;;A61K31/44;;A61K31/565;;A61K31/59;;A61K31/593;;A61K31/66;;A61K38/00;;A61K38/23;;A61K45/00;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P5/22;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P35/04;;A61P43/00;;C07D213/84,,0,0,,,,EXPIRED
771,US,A1,US 2003/0143326 A1,153-612-541-157-568,2003-07-31,2003,US 5997802 A,2002-01-29,US 5997802 A,2002-01-29,Deposition of thin films using an infrared laser,"
   This invention pertains to transfer of a solid target material onto a substrate by vaporizing the material by irradiating it with intense light of a resonant vibrational mode of the material and depositing the vaporized material on a substrate in a solid form. 
",BUBB DANIEL;;HORWITZ JAMES;;CALLAHAN JOHN;;HAGLUND RICHARD;;PAPANTONAKIS MICHAEL,BUBB DANIEL;;HORWITZ JAMES;;CALLAHAN JOHN;;HAGLUND RICHARD;;PAPANTONAKIS MICHAEL,THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (2002-06-13),https://lens.org/153-612-541-157-568,Patent Application,yes,6,14,2,3,0,C23C14/12;;C23C14/28;;C23C14/12;;C23C14/28,C23C14/12;;C23C14/28,427/248.1;;427/596,0,0,,,,EXPIRED
772,NZ,A,NZ 218954 A,169-562-028-151-622,1990-03-27,1990,NZ 21895487 A,1987-01-15,US 81933686 A,1986-01-16,VASOPRESSIN ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS;;YIM NELSON CHI-FAI,,https://lens.org/169-562-028-151-622,Patent Application,no,0,0,20,24,0,A61K38/00;;A61P7/10;;A61P9/12;;C07K7/16;;C07K7/16;;F28D15/02,C07K14/575;;A61K38/00;;A61K38/095;;A61P7/10;;A61P9/12;;C07C67/00;;C07C227/00;;C07C227/24;;C07C229/28;;C07C239/00;;C07C253/00;;C07C255/31;;C07C269/00;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,DISCONTINUED
773,PE,A1,PE 20071167 A1,034-627-095-190-698,2008-01-31,2008,PE 2006000381 A,2006-04-10,PE 2006000381 A,2006-04-10,"PROCESO PARA PREPARAR PIRIDO[2,3-d]PIRIMIDIN-7-ONA Y DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA","SE REFIERE A UN PROCESO ALTERNATIVO QUE COMPRENDE HACER REACCIONAR UN UN COMPUESTO DE FORMULA Va DONDE RY ES Cl, Br, I, -O-S(O)2CF3; RG ES ALQUILO C1-C10 CON UN REACTIVO FORMADOR DE OLEOFINA TAL COMO BIS(2,2,2-TRIFLUOROETIL)(METOXICARBONILMETIL)FOSFONATOESTER ETILICO DEL ACIDO (DIISOPROPOXI-FOSFORIL)-ACETICO, ENTRE OTROS EN UNA BASE ADECUADA SELECCIONADA DE TRIETILAMINA, PIRIDINA, PIRROLIDINA. SE OBTIENE COMPUESTO DE FORMULA II O IIa, DONDE G1 ES CH2, NH; G2 ES CH, N; RX ES Cl, Br, I; O-S(O)2CF3; RG ES ALQUILO C1-C10; m ES 0-2; R3 ES ALQUILO C1-C10, CICLOALQUILO C3-C7, ARILO, HETEROARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 4-CLORO-8-(4-TRIFLUOROMETIL-FENIL)-2-METILSULFANIL-8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA; 4-CLORO-8-(2,4-DIFLUORO-FENIL)-2-METILSULFINIL-8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA.",GLAXO GROUP LTD,BOEHM JEFFREY C;;CALLAHAN JAMES FRANCIS;;YAN HONGXING;;WAN ZEHONG,,https://lens.org/034-627-095-190-698,Patent Application,no,0,0,1,1,0,,A61K31/519;;C07D487/02,,0,0,,,,DISCONTINUED
774,EP,B1,EP 0135379 B1,059-471-481-402-918,1988-04-20,1988,EP 84305764 A,1984-08-23,US 53500083 A,1983-09-22,BASIC HEXA- AND HEPTA-PEPTIDE VASOPRESSIN ANTAGONISTS,"Compounds of the formula (I) <CHEM> in which: A is -NR-(CH2)n,-NH2 or -NR-(CH2)n-NH-@@NR2; Z is Phe, Phe(4 min -Alk) or Tyr(Alk); X is D-Phe, D-Phe(4 min Alk), D-Val, D-Nva, D-Leu, D-Ile, D-Pba, D-Nle, D-Cha, D-Abu, D-Met, D-Chg, D-Tyr, L-Tyr, D-Tyr(Alk) or L-Tyr(Alk); P is D-Pro, L-Pro, DELTA <3>-Pro, L-Ala, L-N-MeAla, L-Gly, L-Sar or a single bond; Y is Val, Ile, Abu, Ala, Chg, Gln, Lys, Cha, Nle, Phe, Leu or Gly; R is, in each case, hydrogen or C1-5-alkyl; n is an integer from 2-8; m is an integer from 0-2; and Alk is C1-4-alkyl; and pharmaceutically acceptable acid addition salts thereof are vasopressin antagonists. Their preparation and pharmaceutical use are described.",SMITHKLINE BECKMAN CORPORATION,"CALLAHAN, JAMES FRANCIS;;MOORE, MICHAEL LEE;;CHI-FAI YIM, NELSON",,https://lens.org/059-471-481-402-918,Granted Patent,yes,2,0,30,31,0,A61K38/00;;C07K7/16;;A61P5/00;;A61P7/10;;C07K7/06,A61K38/00;;A61K38/095;;A61P5/00;;A61P7/10;;C07K1/00;;C07K1/113;;C07K7/16;;C07K7/50;;C07K14/575,,2,0,,,"CHEMICAL ABSTRACTS, vol. 100, no. 15, 9th April 1984, page 643, column 2, abstract no. 121603r, Columbus, Ohio, US; M. MANNING et al. ""Potent and selective antagonists of the antidiuretic responses to arginine-vasopressin based on modifications of [1-(beta-mercapto-beta, beta-pentamethylenepropionic acid), -2-D-isoleucine, 4-valine]arginine-vasopressin at position 4"";;CHEMICAL ABSTRACTS, vol. 101, no. 1, page 926, clumns 1,2, abstract no. 930g, Columbus, Ohio, US; M. MANNING ""Carboxy terminus of vasopressin required for activity but not binding""",EXPIRED
775,FI,A,FI 870156 A,138-052-813-525-98X,1987-07-17,1987,FI 870156 A,1987-01-15,US 81933686 A,1986-01-16,FOERFARANDE FOER FRAMSTAELLNING AV VASOPRESSINFOERENINGAR.,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS;;YIM NELSON CHI-FAI,,https://lens.org/138-052-813-525-98X,Patent Application,no,0,0,20,24,0,A61K38/00;;A61P7/10;;A61P9/12;;C07K7/16;;C07K7/16;;F28D15/02,C07K14/575;;A61K38/00;;A61K38/095;;A61P7/10;;A61P9/12;;C07C67/00;;C07C227/00;;C07C227/24;;C07C229/28;;C07C239/00;;C07C253/00;;C07C255/31;;C07C269/00;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,DISCONTINUED
776,FI,A0,FI 843723 A0,166-916-767-442-980,1984-09-21,1984,FI 843723 A,1984-09-21,US 53500083 A,1983-09-22,FOERFARANDE FOER FRAMSTAELLNING AV BASISKA HEPTAPEPTID-VASOPRESSIN-ANTAGONISTER.,"Compounds of the formula (I) <CHEM> in which: A is -NR-(CH2)n,-NH2 or -NR-(CH2)n-NH-@@NR2; Z is Phe, Phe(4 min -Alk) or Tyr(Alk); X is D-Phe, D-Phe(4 min Alk), D-Val, D-Nva, D-Leu, D-Ile, D-Pba, D-Nle, D-Cha, D-Abu, D-Met, D-Chg, D-Tyr, L-Tyr, D-Tyr(Alk) or L-Tyr(Alk); P is D-Pro, L-Pro, DELTA <3>-Pro, L-Ala, L-N-MeAla, L-Gly, L-Sar or a single bond; Y is Val, Ile, Abu, Ala, Chg, Gln, Lys, Cha, Nle, Phe, Leu or Gly; R is, in each case, hydrogen or C1-5-alkyl; n is an integer from 2-8; m is an integer from 0-2; and Alk is C1-4-alkyl; and pharmaceutically acceptable acid addition salts thereof are vasopressin antagonists. Their preparation and pharmaceutical use are described.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;YIM NELSON CHI-FAI,,https://lens.org/166-916-767-442-980,Patent Application,no,0,0,30,31,0,A61K38/00;;C07K7/16;;A61P5/00;;A61P7/10;;C07K7/06,A61K38/00;;A61K38/095;;A61P5/00;;A61P7/10;;C07K1/00;;C07K1/113;;C07K7/16;;C07K7/50;;C07K14/575,,0,0,,,,DISCONTINUED
777,ZA,B,ZA 846450 B,170-330-109-002-867,1985-05-29,1985,ZA 846450 A,1984-08-20,US 53500083 A,1983-09-22,BASIC HEPTAPEPTIDE VASOPRESSIN ANTAGONISTS,"Compounds of the formula (I) <CHEM> in which: A is -NR-(CH2)n,-NH2 or -NR-(CH2)n-NH-@@NR2; Z is Phe, Phe(4 min -Alk) or Tyr(Alk); X is D-Phe, D-Phe(4 min Alk), D-Val, D-Nva, D-Leu, D-Ile, D-Pba, D-Nle, D-Cha, D-Abu, D-Met, D-Chg, D-Tyr, L-Tyr, D-Tyr(Alk) or L-Tyr(Alk); P is D-Pro, L-Pro, DELTA <3>-Pro, L-Ala, L-N-MeAla, L-Gly, L-Sar or a single bond; Y is Val, Ile, Abu, Ala, Chg, Gln, Lys, Cha, Nle, Phe, Leu or Gly; R is, in each case, hydrogen or C1-5-alkyl; n is an integer from 2-8; m is an integer from 0-2; and Alk is C1-4-alkyl; and pharmaceutically acceptable acid addition salts thereof are vasopressin antagonists. Their preparation and pharmaceutical use are described.",SMITHKLINE BECKMAN CORP,MOORE MICHAEL LEE;;YIM NELSON CHI-FAI;;CALLAHAN JAMES FRANCIS,,https://lens.org/170-330-109-002-867,Granted Patent,no,0,0,30,31,0,A61K38/00;;C07K7/16;;A61P5/00;;A61P7/10;;C07K7/06,A61K38/00;;A61K38/095;;A61P5/00;;A61P7/10;;C07K1/00;;C07K1/113;;C07K7/16;;C07K7/50;;C07K14/575,,0,0,,,,EXPIRED
778,CN,A,CN 87100308 A,199-963-890-356-374,1987-09-16,1987,CN 87100308 A,1987-01-16,US 81933686 A,1986-01-16,POLYPETIDE COMPOUNDS,,SMITHKLINE BECKMAN CORP.,JAMES FRANCIS CALLAHAN;;WILLIAM FRANCIS HUFFMAN;;NELSON CHI-FAI YIM,,https://lens.org/199-963-890-356-374,Patent Application,no,0,0,20,24,0,A61K38/00;;A61P7/10;;A61P9/12;;C07K7/16;;C07K7/16;;F28D15/02,C07K14/575;;A61K38/00;;A61K38/095;;A61P7/10;;A61P9/12;;C07C67/00;;C07C227/00;;C07C227/24;;C07C229/28;;C07C239/00;;C07C253/00;;C07C255/31;;C07C269/00;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,DISCONTINUED
779,ZA,B,ZA 861956 B,125-742-932-133-360,1986-12-30,1986,ZA 861956 A,1986-03-17,US 71373285 A,1985-03-20,AROMATIC BASIC-TAILED VASOPRESSIN ANTAGONISTS,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;YIM NELSON CHI-FAI,,https://lens.org/125-742-932-133-360,Granted Patent,no,0,0,14,14,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P13/02;;A61P15/00;;A61P7/10;;A61P9/12;;C07K7/16;;A61K38/00;;Y10S930/15,A61K38/00;;C07K1/113;;A61K38/04;;A61K38/095;;A61P7/10;;A61P9/12;;A61P13/02;;A61P15/00;;C07K7/06;;C07K7/16,,0,0,,,,EXPIRED
780,FI,A0,FI 870156 A0,189-189-481-902-458,1987-01-15,1987,FI 870156 A,1987-01-15,US 81933686 A,1986-01-16,FOERFARANDE FOER FRAMSTAELLNING AV VASOPRESSINFOERENINGAR.,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS;;YIM NELSON CHI-FAI,,https://lens.org/189-189-481-902-458,Patent Application,no,0,0,20,24,0,A61K38/00;;A61P7/10;;A61P9/12;;C07K7/16;;C07K7/16;;F28D15/02,C07K14/575;;A61K38/00;;A61K38/095;;A61P7/10;;A61P9/12;;C07C67/00;;C07C227/00;;C07C227/24;;C07C229/28;;C07C239/00;;C07C253/00;;C07C255/31;;C07C269/00;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,DISCONTINUED
781,US,B1,US 6212130 B1,184-252-138-210-523,2001-04-03,2001,US 26425899 A,1999-03-08,US 26425899 A,1999-03-08,Method and apparatus for plural document detection,"The presence of overlapped sheets on a paper transport is detected by employing such sheets as an acoustic interference filter. A beam of ultrasonic energy of appropriate frequency, angularly oriented to the planar transport path, will be attenuated to a much greater extent than the attenuation calculated based on the attenuation of a single sheet, as a result of destructive combining of wavefronts reflected from the facing surfaces of the overlapped sheets.",SCAN OPTICS INC,BRAZEAL JR EARL H;;CALLAHAN JAMES D;;SOUSSOUNIS JAMES M;;STONE DAVID H,PATRIARCH PARTNERS AGENCY SERVICES LLC (2004-03-30);;SCAN-OPTICS LLC (2005-08-05);;SCAN-OPTICS INC (1999-02-23),https://lens.org/184-252-138-210-523,Granted Patent,yes,6,58,3,3,0,B65H7/125;;B65H2553/30;;G01N2291/0237;;B65H7/125;;G01N2291/0237;;B65H2553/30,B65H7/12,367/93;;271/258.01;;340/674,0,0,,,,EXPIRED
782,NO,L,NO 843816 L,008-027-315-447-298,1985-03-25,1985,NO 843816 A,1984-09-21,US 53500083 A,1983-09-22,FREMGANGSMAATE VED FREMSTILLING AV BASISKE HEPTAPEPTID-VASOPRESSINANTAGONISTER,"Compounds of the formula (I) <CHEM> in which: A is -NR-(CH2)n,-NH2 or -NR-(CH2)n-NH-@@NR2; Z is Phe, Phe(4 min -Alk) or Tyr(Alk); X is D-Phe, D-Phe(4 min Alk), D-Val, D-Nva, D-Leu, D-Ile, D-Pba, D-Nle, D-Cha, D-Abu, D-Met, D-Chg, D-Tyr, L-Tyr, D-Tyr(Alk) or L-Tyr(Alk); P is D-Pro, L-Pro, DELTA <3>-Pro, L-Ala, L-N-MeAla, L-Gly, L-Sar or a single bond; Y is Val, Ile, Abu, Ala, Chg, Gln, Lys, Cha, Nle, Phe, Leu or Gly; R is, in each case, hydrogen or C1-5-alkyl; n is an integer from 2-8; m is an integer from 0-2; and Alk is C1-4-alkyl; and pharmaceutically acceptable acid addition salts thereof are vasopressin antagonists. Their preparation and pharmaceutical use are described.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;YIM NELSON CHI-FAI,,https://lens.org/008-027-315-447-298,Abstract,no,0,0,30,31,0,A61K38/00;;C07K7/16;;A61P5/00;;A61P7/10;;C07K7/06,A61K38/00;;A61K38/095;;A61P5/00;;A61P7/10;;C07K1/00;;C07K1/113;;C07K7/16;;C07K7/50;;C07K14/575,,0,0,,,,DISCONTINUED
783,US,A1,US 2011/0005860 A1,093-248-913-504-530,2011-01-13,2011,US 50152909 A,2009-07-13,US 50152909 A,2009-07-13,EXHAUST COMPONENT WITH REDUCED PACK,A vehicle exhaust component provides comparable fully packed noise reduction capability without requiring a fully packed configuration. A pack is mounted within an internal cavity defined by an exhaust component body. A plurality of pack positions are defined within the internal cavity and at least one pack is positioned at a desired pack position to provide a desired noise reduction.,ABRAM KWIN;;WILLATS ROBIN;;ARBUCKLE IVAN;;CALLAHAN JOSEPH;;EGAN JAMES,ABRAM KWIN;;WILLATS ROBIN;;ARBUCKLE IVAN;;CALLAHAN JOSEPH;;EGAN JAMES,EMCON TECHNOLOGIES LLC (2009-06-17),https://lens.org/093-248-913-504-530,Patent Application,yes,34,1,1,1,0,F01N1/04;;F01N1/04;;F01N1/003;;F01N1/003;;F01N1/006;;F01N1/006;;F01N1/082;;F01N1/082;;F01N2310/02;;F01N2310/02;;F01N2450/06;;F01N2450/06;;F01N2490/18;;F01N2490/18;;Y10T29/49398;;Y10T29/49398,F01N1/10;;B23P17/00;;F01N1/08,181/252;;181/264;;29/890.08,0,0,,,,DISCONTINUED
784,AU,B2,AU 576519 B2,172-229-623-589-29X,1988-09-01,1988,AU 1984/033037 A,1984-09-14,US 53500083 A,1983-09-22,VASOPRESSIN ANTAGONISTS,"Compounds of the formula (I) <CHEM> in which: A is -NR-(CH2)n,-NH2 or -NR-(CH2)n-NH-@@NR2; Z is Phe, Phe(4 min -Alk) or Tyr(Alk); X is D-Phe, D-Phe(4 min Alk), D-Val, D-Nva, D-Leu, D-Ile, D-Pba, D-Nle, D-Cha, D-Abu, D-Met, D-Chg, D-Tyr, L-Tyr, D-Tyr(Alk) or L-Tyr(Alk); P is D-Pro, L-Pro, DELTA <3>-Pro, L-Ala, L-N-MeAla, L-Gly, L-Sar or a single bond; Y is Val, Ile, Abu, Ala, Chg, Gln, Lys, Cha, Nle, Phe, Leu or Gly; R is, in each case, hydrogen or C1-5-alkyl; n is an integer from 2-8; m is an integer from 0-2; and Alk is C1-4-alkyl; and pharmaceutically acceptable acid addition salts thereof are vasopressin antagonists. Their preparation and pharmaceutical use are described.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;YIM NELSON CHI-FAI,,https://lens.org/172-229-623-589-29X,Granted Patent,no,3,1,30,31,0,A61K38/00;;C07K7/16;;A61P5/00;;A61P7/10;;C07K7/06,A61K38/00;;A61K38/095;;A61P5/00;;A61P7/10;;C07K1/00;;C07K1/113;;C07K7/16;;C07K7/50;;C07K14/575,,0,0,,,,EXPIRED
785,GR,B,GR 860698 B,188-560-891-524-506,1986-07-11,1986,GR 860100698 A,1986-03-14,US 71373285 A,1985-03-20,PROCESS FOR PREPARING AROMATIC BASIC-TAILED VASOPRESSIN ANTAGONISTS,,SMITHKLINE BECKMAN CORP,JAMES CALLAHAN FRANCIS;;MICHAEL MOORE LEE;;NELSON YIM CHI-FAI,,https://lens.org/188-560-891-524-506,Granted Patent,no,0,0,14,14,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P13/02;;A61P15/00;;A61P7/10;;A61P9/12;;C07K7/16;;A61K38/00;;Y10S930/15,C07K1/113;;A61K38/00;;A61K38/04;;A61K38/095;;A61P7/10;;A61P9/12;;A61P13/02;;A61P15/00;;C07K7/06;;C07K7/16,,0,0,,,,EXPIRED
786,CN,A,CN 113811518 A,020-114-174-326-870,2021-12-17,2021,CN 202080027440 A,2020-04-01,US 201962828169 P;;US 2020/0026235 W,2019-04-02,METHODS INVOLVING CEMENTS THAT EMPLOY CARBON DIOXIDE AS A REACTANT,"A method of cementing an annular space between a pipe string and a well bore, the method comprising the steps of (a) providing a cement composition including a calcium-deficient calcium silicate; (b) mixing the cement composition with water to form a cement slurry; (c) mixing the cement slurry composition with carbon dioxide form a foamed cement; and (d) placing the foamed cement in the annular space between the pipe string and the wellbore.",OXY LOW CARBON VENTURES LLC,COWAN KENNETH M;;ZELLER III;;CALLAHAN III;;WILLIS JAMES S,,https://lens.org/020-114-174-326-870,Patent Application,no,9,1,4,4,0,C09K8/473;;C04B38/103;;Y02P40/18;;C04B28/188;;C04B38/103;;C04B40/0231;;C04B2111/00706;;C09K8/46;;E21B33/14,C04B38/10;;C09K8/473,,0,0,,,,PENDING
787,US,S,US D0370456 S,026-951-119-415-930,1996-06-04,1996,US 3732195 F,1995-04-04,US 3732195 F,1995-04-04,"Large, single deck, high wing airplane",,BOEING CO,BUCHSEL CHRISTIAN K C;;CALLAHAN JAMES D;;CLINTON DAVID C,BOEING COMPANY THE (1995-03-30),https://lens.org/026-951-119-415-930,Design Right,yes,4,11,1,1,0,,,D12/340,0,0,,,,EXPIRED
788,EP,A2,EP 1805132 A2,078-516-725-880-883,2007-07-11,2007,EP 05857821 A,2005-10-05,US 2005/0035743 W;;US 61606504 P;;US 71972905 P,2004-10-05,NOVEL COMPOUNDS,,SMITHKLINE BEECHAM CORP,BOEHM JEFFREY C;;CALLAHAN JAMES FRANCIS;;WAN ZEHONG;;YAN HONGXING,GLAXOSMITHKLINE LLC (2010-03-31),https://lens.org/078-516-725-880-883,Patent Application,yes,0,0,8,9,0,A61P1/00;;A61P1/04;;A61P1/18;;A61P3/10;;A61P7/04;;A61P9/00;;A61P9/10;;A61P9/12;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P37/06;;A61P43/00;;C07C233/65;;C07C233/63;;C07C233/69;;C07C233/78;;C07C275/42;;C07C2601/02;;C07D211/58;;C07D213/75;;C07D277/46,C07C233/05;;A61K31/165;;A61K31/195;;A61K31/425;;A61K31/445;;A61K31/495;;C07C229/00;;C07D211/22;;C07D241/04;;C07D277/04,,0,0,,,,DISCONTINUED
789,EP,A3,EP 0195673 A3,067-483-260-559-610,1989-05-31,1989,EP 86302047 A,1986-03-19,US 71373285 A,1985-03-20,AROMATIC BASIC-TAILED VASOPRESSIN ANTAGONISTS,"Certain new vasopressin-like peptides which have structures characterized by having a bisaminoalkylbenzene present in the vasopressin tail at the 7- or 8-position retain vasopressin antagonist activity. A species of the invention is [1-β-mercapto-β,β-cyclopentamethylenepropionic acid)-2-(O-ethyl)-D-tyrosine-4-valine-8-1',4'-bis(aminomethyl)-benzene-9-desglycinamide]vasopressin.",SMITHKLINE BECKMAN CORPORATION,"CALLAHAN, JAMES FRANCIS;;MOORE, MICHAEL LEE;;YIM, NELSON CHI-FAI",,https://lens.org/067-483-260-559-610,Search Report,yes,3,0,14,14,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P13/02;;A61P15/00;;A61P7/10;;A61P9/12;;C07K7/16;;A61K38/00;;Y10S930/15,C07K1/113;;A61K38/00;;A61K38/04;;A61K38/095;;A61P7/10;;A61P9/12;;A61P13/02;;A61P15/00;;C07K7/06;;C07K7/16,,0,0,,,,DISCONTINUED
790,ZA,B,ZA 200708524 B,058-010-445-946-311,2009-08-26,2009,ZA 200708524 A,2007-10-05,US 66515405 P,2005-03-25,"Process for preparing pyrido[2,3-D]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-D]pyrimidin-2(1H)-one derivatives",,GLAXO GROUP LTD,FRANCIS CALLAHAN JAMES;;BOEHM JEFFREY C;;ZEHONG WAN;;HONGXING YAN,,https://lens.org/058-010-445-946-311,Granted Patent,no,0,0,22,22,0,C07D471/04;;C07D487/04;;A61P43/00;;C07D471/04;;C07D487/04;;C07D487/04;;C07D471/04,A61K/;;C07D/,,0,0,,,,ACTIVE
791,DK,D0,DK 408284 D0,183-898-526-305-440,1984-08-27,1984,DK 408284 A,1984-08-27,US 53500083 A,1983-09-22,BASISKE HEPTAPEPTIDER DER ER VASOPRESSINANTAGONISTER,"Compounds of the formula (I) <CHEM> in which: A is -NR-(CH2)n,-NH2 or -NR-(CH2)n-NH-@@NR2; Z is Phe, Phe(4 min -Alk) or Tyr(Alk); X is D-Phe, D-Phe(4 min Alk), D-Val, D-Nva, D-Leu, D-Ile, D-Pba, D-Nle, D-Cha, D-Abu, D-Met, D-Chg, D-Tyr, L-Tyr, D-Tyr(Alk) or L-Tyr(Alk); P is D-Pro, L-Pro, DELTA <3>-Pro, L-Ala, L-N-MeAla, L-Gly, L-Sar or a single bond; Y is Val, Ile, Abu, Ala, Chg, Gln, Lys, Cha, Nle, Phe, Leu or Gly; R is, in each case, hydrogen or C1-5-alkyl; n is an integer from 2-8; m is an integer from 0-2; and Alk is C1-4-alkyl; and pharmaceutically acceptable acid addition salts thereof are vasopressin antagonists. Their preparation and pharmaceutical use are described.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;YIM NELSON CHI-FAI,,https://lens.org/183-898-526-305-440,Patent Application,no,0,0,30,31,0,A61K38/00;;C07K7/16;;A61P5/00;;A61P7/10;;C07K7/06,A61K38/00;;A61K38/095;;A61P5/00;;A61P7/10;;C07K1/00;;C07K1/113;;C07K7/16;;C07K7/50;;C07K14/575,,0,0,,,,DISCONTINUED
792,MY,A,MY 142645 A,174-306-787-349-62X,2010-12-15,2010,MY PI20061611 A,2006-04-07,MY PI20061611 A,2006-04-07,"PROCESS FOR PREPARING PYRIDO[2,3-D]PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE DERIVATIVES","THE PRESENT INVENTION IS DIRECTED TO A NOVEL METHOD OF PREPARING OF 2,4.8- TRISUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONE PHARMACOPHORES OF FORMULA (11) OR (IIA) RX @C G1 4,,N G 2 5 N II II 15_ C7, D @, @',T'2 , _51_ C7, C2 0 N8 N S(O)RNRG 0 N 8 N _S(O)MRG II R3 R 3 LA) WHEREIN GI IS CH2 OR NH: G2 IS CH OR NITROGEN; RX IS CHLORO, BROMO. IODO, OR O-S(0)2CF3; RG IS A CI - I 0 ALKYL M IS 0. OR AN INTEGER HAVING A VALUE OF 1, OR 2; R3 IS A C1 -10 ATKYL. C3-7 CYCLOALKYL, C3-7 CYCLOALKYL C1 -10 ALKYL, ARYL , ARYLC ALKYL, HETEROARYL, HETEROARYLC 1-10 ALKYL, HETEROCYCLIC OR A HETEROCYCLY]C1 - 10 ALKYL MOIETY, AND WHEREIN EACH OF THESE MOIETIES MAY BE OPTIONALLY SUBSTITUTED. WHICH COMPRISES REACTING A COMPOUND OF THE FORMULA: 0 RY H C1 @N_' S RG (VA)WHEREIN RY IS CHLORO, BROMO. IODO, O-S (0)2CF3-; AND RG IS A C1- 10 ALKYL WITH A OLEFIN FORMING REAGENT IN A SUITABLE BASE TO YIELD A COMPOUND OF FOI MULA (II). OR (IIA) WHEREIN M=0 AND OXIDIZING THE SULPHUR AS NECESSARY OR DESIRED.",GLAXO GROUP LTD,BOEHM JEFFREY C;;CALLAHAN JAMES FRANCIS;;ZEHONG WAN;;HONGXING YAN,,https://lens.org/174-306-787-349-62X,Granted Patent,no,0,0,1,1,0,,C07D487/04,,0,0,,,,ACTIVE
793,DE,A1,DE 2402934 A1,053-620-028-631-227,1974-08-01,1974,DE 2402934 A,1974-01-22,US 32570873 A,1973-01-22,DIFFERENZVERSTAERKER,,TEXAS INSTRUMENTS INC,CALLAHAN JUN MICHAEL JAMES;;TALLEY JAMES REGGIE;;EVERETT CHAUNCEY LOVELL;;PUMPHREY EDWARD GARY,,https://lens.org/053-620-028-631-227,Patent Application,no,0,0,5,5,0,H03F3/45076,H03F3/34;;H03F3/45,,0,0,,,,DISCONTINUED
794,EP,A2,EP 0135379 A2,021-013-162-830-061,1985-03-27,1985,EP 84305764 A,1984-08-23,US 53500083 A,1983-09-22,Basic hexa- and hepta-peptide vasopressin antagonists.,"Compounds of the formula (I)
  in which: A is -NR-(CH 2 ) n -NR 2  or
  
 Z is Phe, Phe(4' -Alk) or Tyr(Alk); X is D-Phe, D-Phe(4' Alk), D-Val, D-Nva, D-Leu, D-IIe, D-Pba, D-Nle, D-Cha, D-Abu, D-Met, D-Chg, D-Tyr, L-Tyr, D-Tyr(Alk) or L-Tyr(Alk); P is D-Pro, L-Pro, Δ 3 -Pro, L-Ala, L-N-MeAla, L-Gly, L-Sar or a single bond; Y is Val, Ile, Abu, Ala, Chg, Gln, Lys, Cha, Nle, Phe, Leu or Glv; R is, in each case, hydrogen or C 1-5 -alkyl; n is an integer from 2-8; m is an integer from 0-2; and Alk is C 1-4 -alkyl; and pharmaceutically acceptable acid addition salts thereof are vasopressin antagonists. Their preparation and pharmaceutical use are described.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;CHI-FAI YIM NELSON,,https://lens.org/021-013-162-830-061,Patent Application,yes,0,4,30,31,0,A61K38/00;;C07K7/16;;A61P5/00;;A61P7/10;;C07K7/06,A61K38/00;;A61K38/095;;A61P5/00;;A61P7/10;;C07K1/00;;C07K1/113;;C07K7/16;;C07K7/50;;C07K14/575,,0,0,,,,EXPIRED
795,GR,B,GR 80427 B,049-738-862-949-48X,1985-01-18,1985,GR 840180427 A,1984-09-20,US 53500083 A,1983-09-22,PROCESS FOR PREPARING BASIC HEPTAPEPTIDE VASOPRESS IN ANTGONISTS,"Compounds of the formula (I) <CHEM> in which: A is -NR-(CH2)n,-NH2 or -NR-(CH2)n-NH-@@NR2; Z is Phe, Phe(4 min -Alk) or Tyr(Alk); X is D-Phe, D-Phe(4 min Alk), D-Val, D-Nva, D-Leu, D-Ile, D-Pba, D-Nle, D-Cha, D-Abu, D-Met, D-Chg, D-Tyr, L-Tyr, D-Tyr(Alk) or L-Tyr(Alk); P is D-Pro, L-Pro, DELTA <3>-Pro, L-Ala, L-N-MeAla, L-Gly, L-Sar or a single bond; Y is Val, Ile, Abu, Ala, Chg, Gln, Lys, Cha, Nle, Phe, Leu or Gly; R is, in each case, hydrogen or C1-5-alkyl; n is an integer from 2-8; m is an integer from 0-2; and Alk is C1-4-alkyl; and pharmaceutically acceptable acid addition salts thereof are vasopressin antagonists. Their preparation and pharmaceutical use are described.",SMITHKLINE BECKMAN CORP,JAMES CALLAHAN FRANCIS;;MICHAEL MOORE LEE;;NELSON YIM CHI-FAI,,https://lens.org/049-738-862-949-48X,Granted Patent,no,0,0,30,31,0,A61K38/00;;C07K7/16;;A61P5/00;;A61P7/10;;C07K7/06,A61K38/00;;A61K38/095;;A61P5/00;;A61P7/10;;C07K1/00;;C07K1/113;;C07K7/16;;C07K7/50;;C07K14/575,,0,0,,,,EXPIRED
796,AU,A,AU 1986/054706 A,066-383-870-226-667,1986-09-25,1986,AU 1986/054706 A,1986-03-13,US 71373285 A,1985-03-20,AROMATIC BASIC-TAILED VASOPRESSIN ANTAGONISTS,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;YIM NELSON CHI-FAI,,https://lens.org/066-383-870-226-667,Patent Application,no,0,1,14,14,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P13/02;;A61P15/00;;A61P7/10;;A61P9/12;;C07K7/16;;A61K38/00;;Y10S930/15,C07K1/113;;A61K38/00;;A61K38/04;;A61K38/095;;A61P7/10;;A61P9/12;;A61P13/02;;A61P15/00;;C07K7/06;;C07K7/16,,0,0,,,,EXPIRED
797,EP,A2,EP 0195673 A2,084-589-891-575-037,1986-09-24,1986,EP 86302047 A,1986-03-19,US 71373285 A,1985-03-20,Aromatic basic-tailed vasopressin antagonists.,"Certain new vasopressin-like peptides which have structures characterized by having a bisaminoalkylbenzene present in the vasopressin tail at the 7- or 8-position retain vasopressin antagonist activity. A species of the invention is [1-β-mercapto-β,β-cyclopentamethylenepropionic acid)-2-(O-ethyl)-D-tyrosine-4-valine-8-1',4'-bis(aminomethyl)-benzene-9-desglycinamide]vasopressin.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;YIM NELSON CHI-FAI,,https://lens.org/084-589-891-575-037,Patent Application,yes,0,2,14,14,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P13/02;;A61P15/00;;A61P7/10;;A61P9/12;;C07K7/16;;A61K38/00;;Y10S930/15,C07K1/113;;A61K38/00;;A61K38/04;;A61K38/095;;A61P7/10;;A61P9/12;;A61P13/02;;A61P15/00;;C07K7/06;;C07K7/16,,0,0,,,,DISCONTINUED
798,DE,C2,DE 2643359 C2,139-982-351-811-742,1985-08-22,1985,DE 2643359 A,1976-09-25,US 61795575 A,1975-09-29,DE 2643359 C2,,"MOSTEK CORP. (N.D.GES.D.STAATES DELAWARE), CARROLLTON, TEX., US","HOFFMANN, GORDON BATES;;CALLAHAN JUN., MICHAEL JAMES, DALLAS, TEX., US","SGS-THOMSON MICROELECTRONICS, INC. (N.D.GES.DES ST (1994-07-28)",https://lens.org/139-982-351-811-742,Granted Patent,no,0,0,23,24,0,H04M1/505;;H04M1/505,H03B11/00;;H03B28/00;;H03L7/18;;H04L27/26;;H04M1/50,,0,0,,,,EXPIRED
799,DE,A1,DE 1474063 A1,000-388-230-139-74X,1970-05-14,1970,DE 1474063 A,1964-12-07,US 32963963 A,1963-12-11,Datenverarbeitungsanlage,,RCA CORP,FRANCIS CALLAHAN JAMES;;DEMING SMITH RICHARD;;YEN RICHARD HSIN-YUNG,,https://lens.org/000-388-230-139-74X,Patent Application,no,0,0,4,5,0,G06F9/4812;;G06F9/4812,G06F9/48,,0,0,,,,DISCONTINUED
800,DK,A,DK 125186 A,058-641-734-319-470,1986-09-21,1986,DK 125186 A,1986-03-18,US 71373285 A,1985-03-20,AROMATISKE VASOPRESSINANTAGONISTER MED BASISK HALE,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;YIM NELSON CHI-FAI,,https://lens.org/058-641-734-319-470,Patent Application,no,0,0,14,14,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P13/02;;A61P15/00;;A61P7/10;;A61P9/12;;C07K7/16;;A61K38/00;;Y10S930/15,C07K1/113;;A61K38/00;;A61K38/04;;A61K38/095;;A61P7/10;;A61P9/12;;A61P13/02;;A61P15/00;;C07K7/06;;C07K7/16,,0,0,,,,DISCONTINUED
801,JO,B1,JO 1335 B1,133-580-707-260-225,1986-11-30,1986,JO P19841335 A,1984-09-29,US 53500083 A,1983-09-22,Basic heptapeptid vasopressin antagonists,"Certain cyclic vasopressin-like peptides, which have an omega -amino- or guanidinoalkyl substituent attached to the cysteine in the 6-position of the ring, have vasopressin antagonist activity. A species of this series of new compounds is [1-( beta -mercapto- beta , beta -cyclopentamethylenepropionic acid)-2-(O-ethyl-D-tyrosine)-4-valine-8-(1,5-diaminopentane)-8-desargi nine-9-desglycinamide]-vasopressin.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCE;;MOORE MICHAEL LEE;;YIM NELSON CHI-FAI,,https://lens.org/133-580-707-260-225,Granted Patent,no,0,0,30,31,0,A61K38/00;;C07K7/16;;A61P5/00;;A61P7/10;;C07K7/06,A61K38/00;;A61K38/095;;A61P5/00;;A61P7/10;;C07K1/00;;C07K1/113;;C07K7/16;;C07K7/50;;C07K14/575,,0,0,,,,EXPIRED
802,EP,A2,EP 0231077 A2,176-165-296-860-753,1987-08-05,1987,EP 87300312 A,1987-01-15,US 81933686 A,1986-01-16,Polypeptide compounds.,"New compounds which have potent V 2 -vasopressin antagonistic activity are prepared by a 1,6-cyclization using peptide bond formation. The structures of the compounds are characterized by a Pas 1,6  or Tas 1,6  cyclized unit.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;HUFFMANNN WILLIAM FRANCIS;;YIM NELSON CHI-FAI,,https://lens.org/176-165-296-860-753,Patent Application,yes,0,1,20,24,0,A61K38/00;;A61P7/10;;A61P9/12;;C07K7/16;;C07K7/16;;F28D15/02,C07K14/575;;A61K38/00;;A61K38/095;;A61P7/10;;A61P9/12;;C07C67/00;;C07C227/00;;C07C227/24;;C07C229/28;;C07C239/00;;C07C253/00;;C07C255/31;;C07C269/00;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,DISCONTINUED
803,DE,D1,DE 60315826 D1,039-126-834-207-307,2007-10-04,2007,DE 60315826 T,2003-04-18,US 37421902 P;;US 38855702 P;;US 0312127 W,2002-04-19,NEUE VERBINDUNGEN,,SMITHKLINE BEECHAM CORP,BOEHM JEFFREY C;;WIDDOWSON KATHERINE L;;CALLAHAN JAMES F;;WAN ZEHONG,,https://lens.org/039-126-834-207-307,Granted Patent,no,0,0,23,24,0,C07D471/04;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P9/02;;A61P9/10;;A61P3/10;;C07D471/04;;A61K31/519;;C07D487/00;;C07D471/04,A61K31/519;;C07D239/42;;A01N43/90;;A61P1/04;;A61P3/10;;A61P9/02;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;C07D471/04;;C07D487/00,,0,0,,,,EXPIRED
804,CA,A1,CA 2426730 A1,093-278-048-865-389,2002-05-16,2002,CA 2426730 A,2001-10-25,US 24300600 P;;US 0146184 W,2000-10-25,CALCILYTIC COMPOUNDS,Novel phosphate esters compounds and methods of using them as calcilytic compounds are provided.,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES F;;LAGO MARIA A;;BHATNAGAR PRADIP;;BURGESS JOELLE L,,https://lens.org/093-278-048-865-389,Patent Application,no,0,1,20,20,0,A61K31/565;;A61K31/59;;A61K31/66;;A61K38/23;;A61K45/06;;C07D213/84;;A61P1/02;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P35/04;;A61P43/00;;A61P5/18;;A61P5/22;;C07D213/63;;C07D213/84;;A61K31/59;;A61K31/565;;A61K31/66;;A61K45/06;;A61K38/23,A61K31/137;;A61K31/44;;A61K31/565;;A61K31/59;;A61K31/593;;A61K31/66;;A61K38/00;;A61K38/23;;A61K45/00;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P5/22;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P35/04;;A61P43/00;;C07D213/84,,0,0,,,,DISCONTINUED
805,IS,A,IS 7507 A,090-458-120-977-369,2004-10-15,2004,IS 7507 A,2004-10-15,US 0312127 W;;US 37421902 P;;US 38855702 P,2002-04-19,Ný efnasambönd,,SMITHKLINE BEECHAM CORP,BOEHM JEFFREY C;;WIDDOWSON KATHERINE L;;CALLAHAN JAMES F;;WAN ZEHONG,,https://lens.org/090-458-120-977-369,Patent Application,no,0,0,23,24,0,C07D471/04;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P9/02;;A61P9/10;;A61P3/10;;C07D471/04;;A61K31/519;;C07D487/00;;C07D471/04,C07D239/42;;A01N43/90;;A61K31/519;;A61P1/04;;A61P3/10;;A61P9/02;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;C07D471/04;;C07D487/00,,0,0,,,,PENDING
806,WO,A1,WO 2002/024428 A1,167-878-476-019-287,2002-03-28,2002,US 0123760 W,2001-07-30,US 66872800 A,2000-09-22,COLD ISOPRESSING METHOD AND MOLD,"A cold isopressing method and mold for compacting a granular ceramic material (28) in which the granular ceramic material (28) is introduced into a cylindrical pressure bearing element (10) of an isopressing mold (1). The cylindrical pressure bearing element (10) is sufficiently rigid so as to maintain its shape during the introducing of the granular ceramic material (28). Such element (10) is also sufficiently resilient in a radial direction thereof to deform and bear against the granular ceramic material (28) upon the application of the hydrostatic pressure and to substantially return to its original shape upon the relaxation of the hydrostatic pressure, thereby to allow retraction of the cylindrical pressure bearing element (10) from the granular ceramic material (28) after compaction. In a further aspect, an isopressing method and mold is provided in which the cylindrical pressure bearing element (10) is provided with an enlarged end bore (20) to form an enlarged end section (40) in the finished ceramic tube (36) for sealing purposes.",PRAXAIR TECHNOLOGY INC,APTE PRASAD;;CALLAHAN SHAWN W;;SCHNEIDER JAMES S;;CHEN JACK C,,https://lens.org/167-878-476-019-287,Patent Application,yes,3,3,9,9,0,B01D67/0041;;B01D71/024;;B28B3/003;;B29C33/405;;B29C43/003;;B29C43/006;;B29C43/10;;B29C43/146;;B29C2043/3238;;B29C2043/3628;;B29C2043/3652;;B29L2023/00;;B30B11/001;;B30B15/302;;B01D69/04;;B01D2323/10;;B01D2323/24;;B29C43/003;;B29C33/405;;B29C2043/3238;;B29C2043/3652;;B30B11/001;;B29C43/10;;B28B3/003;;B29L2023/00;;B30B15/302;;B29C2043/3628;;B29C43/146;;B29C43/006;;B01D69/04;;B01D2323/10;;B01D2323/24;;B01D67/00411,B01D67/00;;B01D71/02;;B28B3/00;;B29C33/40;;B29C43/00;;B29C43/10;;B29C43/14;;B30B11/00;;B30B15/30,,1,0,,,See also references of EP 1377423A4,PENDING
807,EP,B1,EP 1383511 B1,198-754-087-684-654,2006-10-25,2006,EP 01988571 A,2001-10-25,US 0146233 W;;US 24300700 P,2000-10-25,CALCILYTIC COMPOUNDS,Novel calcilytic compounds and methods of using them are provided.,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP;;BRYAN WILLIAM M;;CALLAHAN JAMES F;;HUFFMAN WILLIAM F,SMITHKLINE BEECHAM CORPORATION (2006-10-18),https://lens.org/198-754-087-684-654,Granted Patent,yes,8,0,13,13,0,A61K45/06;;C07C255/54;;C07F9/091;;C07F9/655345;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07F9/655345;;C07F9/091;;C07C255/54;;A61K45/06,A61K31/675;;A61K45/00;;A61K31/661;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07C255/54;;C07F9/09;;C07F9/6553,,0,0,,,,EXPIRED
808,AU,A1,AU 2018/262902 A1,021-155-339-847-074,2019-11-07,2019,AU 2018/262902 A,2018-05-02,AU 2017/901600 A;;IB 2018053018 W,2017-05-02,System and method for assessing tax governance and managing tax risk,"A computer-implemented method comprising: receiving, at a server, survey results relating to tax governance and tax risk management from one or more participants; computing, via a processor, scores for each of a plurality of tax governance assessment categories based on weighted values assigned to one or more survey questions; computing, via the processor, scores representative of gaps between assessed tax governance controls and benchmark controls, based on weighted values assigned to one or more survey questions; generating, via the processor, an action item if a score is below a threshold; displaying, on a user device, a graphical representation of the scores computed for each assessment category; displaying, on user device, a graphical representation of the computed gaps relative to each benchmark control.",KPMG AUSTRALIA IP HOLDINGS PTY LTD,CALLAHAN STEPHEN;;GORDON JAMES;;BERKMAN STACEY;;GREEN TROY;;DOS SANTOS ALLINE,,https://lens.org/021-155-339-847-074,Patent Application,no,0,0,2,2,0,G06Q40/10,G06Q40/00;;G06Q10/06;;G06Q10/10,,0,0,,,,PENDING
809,EP,A2,EP 1404654 A2,021-727-000-079-118,2004-04-07,2004,EP 01987253 A,2001-10-25,US 0146184 W;;US 24300600 P,2000-10-25,CALCILYTIC COMPOUNDS,,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP;;BURGESS JOELLE L;;CALLAHAN JAMES F;;LAGO MARIA A,GLAXOSMITHKLINE LLC (2010-03-03),https://lens.org/021-727-000-079-118,Patent Application,yes,0,0,20,20,0,A61K31/565;;A61K31/59;;A61K31/66;;A61K38/23;;A61K45/06;;C07D213/84;;A61P1/02;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P35/04;;A61P43/00;;A61P5/18;;A61P5/22;;C07D213/63;;C07D213/84;;A61K31/59;;A61K31/565;;A61K31/66;;A61K45/06;;A61K38/23,A61K31/137;;A61K31/44;;A61K31/565;;A61K31/59;;A61K31/593;;A61K31/66;;A61K38/00;;A61K38/23;;A61K45/00;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P5/22;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P35/04;;A61P43/00;;C07D213/84,,0,0,,,,DISCONTINUED
810,EP,A4,EP 1377423 A4,077-452-746-940-930,2004-03-31,2004,EP 01957309 A,2001-07-30,US 0123760 W;;US 66872800 A,2000-09-22,COLD ISOPRESSING METHOD AND MOLD,,PRAXAIR TECHNOLOGY INC,APTE PRASAD;;CALLAHAN SHAWN W;;SCHNEIDER JAMES S;;CHEN JACK C,,https://lens.org/077-452-746-940-930,Search Report,no,2,0,9,9,0,B01D67/0041;;B01D71/024;;B28B3/003;;B29C33/405;;B29C43/003;;B29C43/006;;B29C43/10;;B29C43/146;;B29C2043/3238;;B29C2043/3628;;B29C2043/3652;;B29L2023/00;;B30B11/001;;B30B15/302;;B01D69/04;;B01D2323/10;;B01D2323/24;;B29C43/003;;B29C33/405;;B29C2043/3238;;B29C2043/3652;;B30B11/001;;B29C43/10;;B28B3/003;;B29L2023/00;;B30B15/302;;B29C2043/3628;;B29C43/146;;B29C43/006;;B01D69/04;;B01D2323/10;;B01D2323/24;;B01D67/00411,B01D67/00;;B01D71/02;;B28B3/00;;B29C33/40;;B29C43/00;;B29C43/10;;B29C43/14;;B30B11/00;;B30B15/30,,2,0,,,"PATENT ABSTRACTS OF JAPAN vol. 0152, no. 35 (M - 1125) 17 June 1991 (1991-06-17);;See also references of WO 0224428A1",DISCONTINUED
811,DE,T2,DE 60315826 T2,167-862-306-587-971,2008-05-21,2008,DE 60315826 T,2003-04-18,US 37421902 P;;US 38855702 P;;US 0312127 W,2002-04-19,NEUE VERBINDUNGEN,,SMITHKLINE BEECHAM CORP,BOEHM JEFFREY C;;WIDDOWSON KATHERINE L;;CALLAHAN JAMES F;;WAN ZEHONG,,https://lens.org/167-862-306-587-971,Granted Patent,no,0,0,23,24,0,C07D471/04;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P9/02;;A61P9/10;;A61P3/10;;C07D471/04;;A61K31/519;;C07D487/00;;C07D471/04,A61K31/519;;C07D239/42;;A01N43/90;;A61P1/04;;A61P3/10;;A61P9/02;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;C07D471/04;;C07D487/00,,0,0,,,,EXPIRED
812,WO,A3,WO 2002/034204 A3,194-411-900-175-693,2003-11-06,2003,US 0146233 W,2001-10-25,US 24300700 P,2000-10-25,CALCILYTIC COMPOUNDS,Novel calcilytic compounds and methods of using them are provided.,SMITHKLINE BEECHAM CORP;;BHATNAGAR PRADIP;;BRYAN WILLIAM M;;CALLAHAN JAMES F;;HUFFMAN WILLIAM F,BHATNAGAR PRADIP;;BRYAN WILLIAM M;;CALLAHAN JAMES F;;HUFFMAN WILLIAM F,,https://lens.org/194-411-900-175-693,Search Report,yes,2,0,13,13,0,A61K45/06;;C07C255/54;;C07F9/091;;C07F9/655345;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07F9/655345;;C07F9/091;;C07C255/54;;A61K45/06,A61K31/661;;A61K45/00;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07C255/54;;C07F9/09;;C07F9/6553,,0,0,,,,PATENTED
813,US,A,US 3088969 A,021-307-514-725-315,1963-05-07,1963,US 10453361 A,1961-04-21,US 10453361 A,1961-04-21,Manufacture of t-butyl esters of unsaturated acids,,STANDARD OIL CO,CALLAHAN JAMES L;;MILLER ARTHUR F;;STAMM JOHN A;;FRANKLIN VEATCH,,https://lens.org/021-307-514-725-315,Granted Patent,no,2,15,1,1,0,C07C67/04;;C07C67/04,C07C69/54,,0,0,,,,EXPIRED
814,WO,A1,WO 2003/088972 A1,156-529-747-717-999,2003-10-30,2003,US 0312127 W,2003-04-18,US 37421902 P;;US 38855702 P,2002-04-19,NOVEL COMPOUNDS,"Novel substituted 2, 4, 8-trisubstituted-8H-pyrido⏧2,3-d&rsqb;pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.",SMITHKLINE BEECHAM CORP;;BOEHM JEFFREY C;;WIDDOWSON KATHERINE L;;CALLAHAN JAMES F;;WAN ZEHONG,BOEHM JEFFREY C;;WIDDOWSON KATHERINE L;;CALLAHAN JAMES F;;WAN ZEHONG,,https://lens.org/156-529-747-717-999,Patent Application,yes,3,0,23,24,0,C07D471/04;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P9/02;;A61P9/10;;A61P3/10;;C07D471/04;;A61K31/519;;C07D487/00;;C07D471/04,C07D239/42;;A01N43/90;;A61K31/519;;A61P1/04;;A61P3/10;;A61P9/02;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;C07D471/04;;C07D487/00,,0,0,,,,PATENTED
815,WO,A2,WO 2002/034204 A2,037-120-356-559-737,2002-05-02,2002,US 0146233 W,2001-10-25,US 24300700 P,2000-10-25,CALCILYTIC COMPOUNDS,Novel calcilytic compounds and methods of using them are provided.,SMITHKLINE BEECHAM CORP;;BHATNAGAR PRADIP;;BRYAN WILLIAM M;;CALLAHAN JAMES F;;HUFFMAN WILLIAM F,BHATNAGAR PRADIP;;BRYAN WILLIAM M;;CALLAHAN JAMES F;;HUFFMAN WILLIAM F,,https://lens.org/037-120-356-559-737,Patent Application,yes,0,11,13,13,0,A61K45/06;;C07C255/54;;C07F9/091;;C07F9/655345;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07F9/655345;;C07F9/091;;C07C255/54;;A61K45/06,A61K31/661;;A61K45/00;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07C255/54;;C07F9/09;;C07F9/6553,,0,0,,,,PATENTED
816,US,A1,US 2004/0009980 A1,059-813-042-760-534,2004-01-15,2004,US 41512003 A,2003-04-24,US 41512003 A;;US 0146184 W;;US 24300600 P,2000-10-25,Calcilytic compounds,"
   Novel phosphate esters compounds and methods of using them as calcilytic compounds are provided. 
",BHATNAGAR PRADIP;;BURGESS JOELLE L.;;CALLAHAN JAMES F.;;LAGO MARIA A.,BHATNAGAR PRADIP;;BURGESS JOELLE L;;CALLAHAN JAMES F;;LAGO MARIA A,SMITHKLINE BEECHAM CORPORATION (2002-11-17),https://lens.org/059-813-042-760-534,Patent Application,yes,0,8,20,20,0,A61K31/565;;A61K31/59;;A61K31/66;;A61K38/23;;A61K45/06;;C07D213/84;;A61P1/02;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P35/04;;A61P43/00;;A61P5/18;;A61P5/22;;C07D213/63;;C07D213/84;;A61K31/59;;A61K31/565;;A61K31/66;;A61K45/06;;A61K38/23,A61K31/137;;A61K31/44;;A61K31/565;;A61K31/59;;A61K31/593;;A61K31/66;;A61K38/00;;A61K38/23;;A61K45/00;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P5/22;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P35/04;;A61P43/00;;C07D213/84,514/241;;514/247;;514/252.01;;514/252.1;;514/269;;514/345;;X54629;;544/182;;544/239;;544/316,0,0,,,,DISCONTINUED
817,NO,L,NO 20045025 L,125-229-294-116-074,2004-11-18,2004,NO 20045025 A,2004-11-18,US 37421902 P;;US 38855702 P;;US 0312127 W,2002-04-19,Nye forbindelser,"Nye substituerte 2,4,8-trisubstituerte-8H-pyrido[2,3-d]pyrimidin-7-on forbindelser og sammensetninger for anvendelse ved behandling som CSBP/p38 kinase inhibitorer.",SMITHKLINE BEECHAM CORP,BOEHM JEFFREY C;;WIDDOWSON KATHERINE L;;CALLAHAN JAMES E;;WAN ZEHONG,,https://lens.org/125-229-294-116-074,Abstract,no,0,0,23,24,0,C07D471/04;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P9/02;;A61P9/10;;A61P3/10;;C07D471/04;;A61K31/519;;C07D487/00;;C07D471/04,C07D239/42;;A01N43/90;;A61K31/519;;A61P1/04;;A61P3/10;;A61P9/02;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;C07D471/04;;C07D487/00,,0,0,,,,DISCONTINUED
818,US,A1,US 2006/0293348 A1,121-207-148-476-968,2006-12-28,2006,US 51177003 A,2003-04-18,US 51177003 A;;US 37421902 P;;US 38855702 P;;US 0312127 W,2002-04-19,Novel compounds,"Novel substituted 2, 4, 8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.",SMITHKLINE BEECHAM CORP,BOEHM JEFFREY C;;WIDDOWSON KATHERINE L;;CALLAHAN JAMES F;;WAN ZEHONG,GLAXOSMITHKLINE LLC (2003-04-17),https://lens.org/121-207-148-476-968,Patent Application,yes,47,2,23,24,0,C07D471/04;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P9/02;;A61P9/10;;A61P3/10;;C07D471/04;;A61K31/519;;C07D487/00;;C07D471/04,A61K31/519;;C07D239/42;;A01N43/90;;A61P1/04;;A61P3/10;;A61P9/02;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;C07D471/04;;C07D487/00;;C07D487/02,514/264.1;;544/279,0,0,,,,EXPIRED
819,WO,A2,WO 2002/038106 A2,069-026-130-401-398,2002-05-16,2002,US 0146184 W,2001-10-25,US 24300600 P,2000-10-25,CALCILYTIC COMPOUNDS,Novel phosphate esters compounds and methods of using them as calcilytic compounds are provided.,SMITHKLINE BEECHAM CORP;;BHATNAGAR PRADIP;;BURGESS JOELLE L;;CALLAHAN JAMES F;;LAGO MARIA A,BHATNAGAR PRADIP;;BURGESS JOELLE L;;CALLAHAN JAMES F;;LAGO MARIA A,,https://lens.org/069-026-130-401-398,Patent Application,yes,0,12,20,20,0,A61K31/565;;A61K31/59;;A61K31/66;;A61K38/23;;A61K45/06;;C07D213/84;;A61P1/02;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P35/04;;A61P43/00;;A61P5/18;;A61P5/22;;C07D213/63;;C07D213/84;;A61K31/59;;A61K31/565;;A61K31/66;;A61K45/06;;A61K38/23,A61K31/137;;A61K31/44;;A61K31/565;;A61K31/59;;A61K31/593;;A61K31/66;;A61K38/00;;A61K38/23;;A61K45/00;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P5/22;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P35/04;;A61P43/00;;C07D213/84,,0,0,,,,PENDING
820,BR,A,BR 0309053 A,066-099-109-538-515,2005-02-22,2005,BR 0309053 A,2003-04-18,US 37421902 P;;US 38855702 P;;US 0312127 W,2002-04-19,Compostos,"""COMPOSTOS"". Novos compostos e composições 8H-pirido [2,3-d]pirimidin-7-ona 2,4,8-trissubstituídos, para uso na terapia como inibidores de CSBP/p38 quinase.",SMITHKLINE BEECHAM CORP,BOEHM JEFFREY C;;WIDDOWSON KATHERINE L;;CALLAHAN JAMES F;;WAN ZEHONG,,https://lens.org/066-099-109-538-515,Patent Application,no,0,0,23,24,0,C07D471/04;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P9/02;;A61P9/10;;A61P3/10;;C07D471/04;;A61K31/519;;C07D487/00;;C07D471/04,C07D239/42;;A01N43/90;;A61K31/519;;A61P1/04;;A61P3/10;;A61P9/02;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;C07D471/04;;C07D487/00,,0,0,,,,DISCONTINUED
821,US,B2,US 8365522 B2,113-835-845-969-677,2013-02-05,2013,US 54199209 A,2009-08-17,US 54199209 A;;US 9067608 P,2008-08-21,Dual exhaust system with independent valve control,A dual exhaust system includes a first exhaust component defining a first exhaust path and a second exhaust component defining a second exhaust path that is different from the first exhaust path. A first valve is associated with the first exhaust path and a second valve is associated with the second exhaust path. The first valve and second valve operate independently of each other to vary exhaust flow and provide sufficient noise control for varying applications.,EMCON TECHNOLOGIES LLC;;ABRAM KWIN;;ARBUCKLE IVAN;;CALLAHAN JOSEPH E;;EGAN JAMES;;WILLATS ROBIN,ABRAM KWIN;;ARBUCKLE IVAN;;CALLAHAN JOSEPH E;;EGAN JAMES;;WILLATS ROBIN,EMCON TECHNOLOGIES LLC (2009-08-14),https://lens.org/113-835-845-969-677,Granted Patent,yes,8,6,2,2,0,F01N13/04;;F01N13/04;;F01N1/16;;F01N1/16;;F01N1/168;;F01N1/168;;F01N2240/36;;F01N2240/36,F01N1/00,60/324;;60/274;;181/253;;181/254,0,0,,,,INACTIVE
822,HU,A2,HU P0301582 A2,128-131-676-400-808,2003-10-28,2003,HU P0301582 A,2001-10-25,US 24300600 P;;US 0146184 W,2000-10-25,CALCILYTIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM,"A találmány (I) általános képletű vegyületekre - amelyek képletében Ajelentése adott esetben a következők közül kiválasztott bármelyatommal és/vagy csoporttal szubsztituált aril- vagy kondenzált aril-,kondenzált dihidro- vagy tetrahidroaril-, heteroaril-, kondenzáltheteroaril-, kondenzált dihidro- vagy tetrahidroarilcsoport:hidroxicsoport, halogénatom, 1-4 szénatomos alkilcsoport, 1-4szénatomos alkoxicsoport, 3-6 szénatomos cikloalkilcsoport, trifluor-metil-, trifluor-metoxi-, ciano- és nitrocsoport; D jelentése szén-vagy nitrogénatom, ahol a gyűrű egy vagy két nitrogénatomot tartalmaz,azzal a megkötéssel, hogy ha D jelentése nitrogénatom, akkor X1-X5nincs jelen; X1 és X5 jelentése egymástól függetlenül hidrogén-,halogénatom, ciano- vagy nitrocsoport, azzal a megkötéssel, hogy X1 ésX5 egyikének a jelentése hidrogénatom, továbbá azzal a megkötéssel,hogy ha D jelentése nitrogénatom, akkor X1 és X5 nincs jelen; X2, X3és X4 jelentése hidrogén-, halogénatom, 1-4 szénatomos alkoxicsoportvagy -J-K általános képletű csoport; amelyben J jelentése kovalenskötés, alkilén-, -O-alkilén vagy alkeniléncsoport; és K jelentése -CO2R5, -CONR4R'4 általános képletű csoport, hidroxicsoport, -NR4R'4általános képletű csoport és cianocsoport, azzal a megkötéssel, hogyha D jelentése nitrogénatom, akkor X2, X3 és X4 nincs jelen; R4 és R'4jelentése egymástól függetlenül hidrogénatom, alkil-, aril- vagyheteroarilcsoport; R5 jelentése hidrogénatom, alkilcsoport, -alkil-(O-alkil)m-O-alkil általános képletű csoport, aril- vagyheteroarilcsoport; n értéke 0, 1, 2, 3 vagy 4; és m értéke 1, 2 vagy 3- és a vegyületek kalciumreceptor-antagonistákként történőalkalmazására vonatkozik. Ó",SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP;;BURGESS JOELLE L;;CALLAHAN JAMES F;;LAGO MARIA A,,https://lens.org/128-131-676-400-808,Patent Application,no,0,0,20,20,0,A61K31/565;;A61K31/59;;A61K31/66;;A61K38/23;;A61K45/06;;C07D213/84;;A61P1/02;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P35/04;;A61P43/00;;A61P5/18;;A61P5/22;;C07D213/63;;C07D213/84;;A61K31/59;;A61K31/565;;A61K31/66;;A61K45/06;;A61K38/23,A61K31/137;;A61K31/44;;A61K31/565;;A61K31/59;;A61K31/593;;A61K31/66;;A61K38/00;;A61K38/23;;A61K45/00;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P5/22;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P35/04;;A61P43/00;;C07D213/84,,0,0,,,,DISCONTINUED
823,AU,A,AU 2002/039489 A,127-491-771-750-964,2002-05-21,2002,AU 2002/039489 A,2001-10-25,US 24300600 P;;US 0146184 W,2000-10-25,Calcilytic compounds,,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP;;BURGESS JOELLE L;;CALLAHAN JAMES F;;LAGO MARIA A,,https://lens.org/127-491-771-750-964,Patent Application,no,0,0,20,20,0,A61K31/565;;A61K31/59;;A61K31/66;;A61K38/23;;A61K45/06;;C07D213/84;;A61P1/02;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P35/04;;A61P43/00;;A61P5/18;;A61P5/22;;C07D213/63;;C07D213/84;;A61K31/59;;A61K31/565;;A61K31/66;;A61K45/06;;A61K38/23,A61K31/137;;A61K31/44;;A61K31/565;;A61K31/59;;A61K31/593;;A61K31/66;;A61K38/00;;A61K38/23;;A61K45/00;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P5/22;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P35/04;;A61P43/00;;C07D213/84,,0,0,,,,PENDING
824,EP,A1,EP 1377423 A1,176-196-408-363-906,2004-01-07,2004,EP 01957309 A,2001-07-30,US 0123760 W;;US 66872800 A,2000-09-22,COLD ISOPRESSING METHOD AND MOLD,,PRAXAIR TECHNOLOGY INC,APTE PRASAD;;CALLAHAN SHAWN W;;SCHNEIDER JAMES S;;CHEN JACK C,,https://lens.org/176-196-408-363-906,Patent Application,yes,0,0,9,9,0,B01D67/0041;;B01D71/024;;B28B3/003;;B29C33/405;;B29C43/003;;B29C43/006;;B29C43/10;;B29C43/146;;B29C2043/3238;;B29C2043/3628;;B29C2043/3652;;B29L2023/00;;B30B11/001;;B30B15/302;;B01D69/04;;B01D2323/10;;B01D2323/24;;B29C43/003;;B29C33/405;;B29C2043/3238;;B29C2043/3652;;B30B11/001;;B29C43/10;;B28B3/003;;B29L2023/00;;B30B15/302;;B29C2043/3628;;B29C43/146;;B29C43/006;;B01D69/04;;B01D2323/10;;B01D2323/24;;B01D67/00411,B01D67/00;;B01D71/02;;B28B3/00;;B29C33/40;;B29C43/00;;B29C43/10;;B29C43/14;;B30B11/00;;B30B15/30,,0,0,,,,DISCONTINUED
825,EP,A4,EP 1499320 A4,008-757-045-909-775,2006-05-17,2006,EP 03721779 A,2003-04-18,US 0312127 W;;US 37421902 P;;US 38855702 P,2002-04-19,NOVEL COMPOUNDS,,SMITHKLINE BEECHAM CORP,BOEHM JEFFREY C;;WIDDOWSON KATHERINE L;;CALLAHAN JAMES F;;WAN ZEHONG,SMITHKLINE BEECHAM CORPORATION (2007-08-08),https://lens.org/008-757-045-909-775,Search Report,no,0,0,23,24,0,C07D471/04;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P9/02;;A61P9/10;;A61P3/10;;C07D471/04;;A61K31/519;;C07D487/00;;C07D471/04,C07D239/42;;C07D487/00;;A01N43/90;;A61K31/519;;A61P1/04;;A61P3/10;;A61P9/02;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;C07D471/04,,1,0,,,No further relevant documents disclosed,EXPIRED
826,PL,A1,PL 365643 A1,056-828-682-836-034,2005-01-10,2005,PL 36564301 A,2001-10-25,US 0146184 W;;US 24300600 P,2000-10-25,CALCILYTIC COMPOUNDS,,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP;;BURGESS JOELLE L;;CALLAHAN JAMES F;;LAGO MARIA A,,https://lens.org/056-828-682-836-034,Patent Application,no,0,0,20,20,0,A61K31/565;;A61K31/59;;A61K31/66;;A61K38/23;;A61K45/06;;C07D213/84;;A61P1/02;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P35/04;;A61P43/00;;A61P5/18;;A61P5/22;;C07D213/63;;C07D213/84;;A61K31/59;;A61K31/565;;A61K31/66;;A61K45/06;;A61K38/23,A61K31/137;;A61K31/44;;A61K31/565;;A61K31/59;;A61K31/593;;A61K31/66;;A61K38/00;;A61K38/23;;A61K45/00;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P5/22;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P35/04;;A61P43/00;;C07D213/84,,0,0,,,,DISCONTINUED
827,US,B2,US 7629350 B2,070-136-298-373-127,2009-12-08,2009,US 51177003 A,2003-04-18,US 51177003 A;;US 37421902 P;;US 38855702 P;;US 0312127 W,2002-04-19,Compounds,"Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.",SMITHKLINE BEECHAM CORP,BOEHM JEFFREY C;;WIDDOWSON KATHERINE L;;CALLAHAN JAMES F;;WAN ZEHONG,GLAXOSMITHKLINE LLC (2003-04-17),https://lens.org/070-136-298-373-127,Granted Patent,yes,78,0,23,24,0,C07D471/04;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P9/02;;A61P9/10;;A61P3/10;;C07D471/04;;A61K31/519;;C07D487/00;;C07D471/04,A61K31/517;;C07D239/42;;A01N43/90;;A61K31/519;;A61P1/04;;A61P3/10;;A61P9/02;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;C07D239/02;;C07D471/04;;C07D487/00,514/264.1;;544/279;;544/330,66,37,070-362-282-817-737;;012-960-512-921-932;;010-281-016-005-743;;050-202-509-159-647;;027-044-424-195-732;;009-270-336-024-717;;132-837-931-216-979;;008-272-662-905-432;;133-314-409-345-472;;032-681-612-390-618;;182-920-176-787-532;;052-009-228-330-151;;116-338-838-439-338;;018-278-523-061-292;;086-270-071-053-469;;131-233-054-471-359;;044-639-268-079-201;;021-487-746-185-54X;;062-434-801-823-152;;149-456-985-467-499;;088-330-706-671-194;;115-003-256-166-770;;056-064-561-723-239;;031-226-339-998-209;;019-815-058-706-805;;076-427-946-117-710;;019-006-450-328-079;;122-627-349-497-578;;096-687-947-774-372;;070-362-282-817-737;;009-889-849-410-719;;174-103-218-570-797;;051-392-666-499-166;;014-078-643-675-713;;024-792-986-385-671;;124-684-411-903-025;;056-095-325-335-121,7997261;;10.1038/372739a0;;10.1021/jo00426a013;;839323;;10.1016/8756-3282(94)90277-1;;7980964;;10.1135/cccc19811167;;7914033;;10.1126/science.7914033;;9308510;;10.1001/archinte.1997.00440380091009;;10.1001/archinte.157.17.1981;;10.1248/cpb.37.2214;;10.1074/jbc.272.30.18518;;9228012;;10.1517/13543776.10.1.25;;10.1002/jhet.5570210229;;10.1002/jhet.5570340520;;10.1016/s0040-4039(00)86691-5;;10.1021/jo01047a024;;10.1021/jo00200a045;;10.1016/s0040-4039(01)92491-8;;2101013;;15341488;;10.1021/jm0499054;;12565952;;10.1016/s0960-894x(02)00990-3;;10.1248/cpb.24.2057;;991360;;12937622;;10.1517/13543776.7.7.729;;10.1016/s0960-894x(98)00589-7;;9873730;;10.1016/s1357-4310(99)01544-0;;10498912;;5671228;;10.1021/jm00310a015;;10.1089/jir.2005.25.1;;15684617;;10878289;;10.1016/s0162-3109(00)00206-x;;11468165;;10.1182/blood.v98.3.667;;10.1016/0092-8674(95)90401-8;;7834738;;7601337;;10.1096/fasebj.9.9.7601337;;7997261;;10.1038/372739a0;;10.1016/0092-8674(95)90402-6;;7834739;;17708980;;10.1016/s0962-8924(97)01105-7;;8627606;;10.1021/jm9508651;;10.1021/jo00815a045;;10734180;;10525088;;7690817,"Lee J.C. et. al., ""A protein kinase involved in the regulation of inflammatory cytokine biosynthesis"", Nature, Dec. 1994, vol. 372, pp. 739-746.;;Adams et al., Progress in Medicinal Chemistry, vol. 38, pp. 2-61 (2001).;;Armarego, W., Chem. Soc., Quinazolines, Part IV (JCSOA9) p. 561 (1962).;;Anderson et al., J. Org. Chem., 1977, vol. 42, p. 993.;;Baker et al., J. Heterocyclic Chem., 1964, vol. 1, pp. 263-270.;;Votta et al., Bone, vol. 15 (5) pp. 533-538 (1994).;;Bradlerova et al., Chem. Zvesti, vol. 29 (6), pp. 795-802 (1975).;;de Silva et al., J. Chem. Soc., vol. 4, pp. 685-690 (1995).;;Engel & Steglich, Liebigs Ann. Chem., p. 1916 (1978).;;Ferles et al., Collect. Czech. Chem. Commun., vol. 5 (46), pp. 1167-1172 (1981).;;Fischer et al., Rec. Trav. Chim. Pays. Bas., vol. 84, p. 439 (1965).;;Fulmer et al., J. Heterocycl. Chem., vol. 17 (4), pp. 799-800 (1980).;;Gilbert, E., Synthesis, pp. 30-32 (1972).;;Han et al., Science, vol. 265, pp. 808-811 (1994).;;Hunter et al., Academic Press, San Diego, vol. 200, p. 3 (1991).;;Irwin et al., Archives of Internal Medicine, vol. 157 (17), pp. 1981-1987 (1997).;;Ishibashi et al., Chem. Pharm. Bull., vol. 37(8), pp. 2214-2216 (1989).;;Johnson et al., PG.A., J.Chem.Soc., Perkin Trans., vol. 1, pp. 895-905 (1996) .;;Jurkowska-Kowalczyk, R., Chem., vol. 51 (6), pp. 1191-1199 (1977).;;Katritzky et al., Synthesis, pp. 45-47 (Jan. 1993).;;Kawasaki et al., J. Bio. Chem., vol. 272(30), pp. 18518-18521 (1997) .;;Boehm, et al., Expert Opinion on Therapeutic Patents, vol. 10(1), pp. 25-37 (2000) .;;Carboni et al., Gazzetta Chimica Italiana, vol. 97(8) pp. 1262-1273 (1967).;;Carboni et al., Gazzetta Chimica Italiana, vol. 98(10) pp. 1174-1188 (1968) .;;Ferrarini et al., Journal of Heterocyclic Chemistry, vol. 21(2) pp. 417-419 (1984) .;;Ferrarini et al., Journal of Heterocyclic Chemistry, vol. 34(5) pp. 1501-1510 (1997) .;;Mikailu et al., Zh. Obshch. Khim., vol. 56 (7), pp. 1513-1517 (1986).;;Morton et al., Tetrahedron Letters, p. 4123 (1982).;;Protecting Groups in Organic Synthesis, 2nd Edition, Greene TW and Wuts PSM, Wiley-Interscience, New York, pp. 10-174 (Hydroxyl and Phenolic) and pp. 309-403 (NH protection) (1991).;;Santilli et al., J. Heterocycl Chem., vol. 8, pp. 445-453 (1971).;;Snieckus, V., Tetrahedron Letters, vol. 29, p. 2135 (1988).;;Stille et al., J. Amer. Chem. Soc., vol. 109, p. 5478 (1978).;;Strzybny et al., J. Org. Chem., vol. 28, p. 3381 (1963).;;M., Chem. Pharm. Bull., vol. 11, p. 4755 (1985), (Ishikura et. al.).;;Thompson et al., J. Org. Chem., vol. 49, p. 5237 (1984).;;Uno et al., Bull. Chem. Soc. Japan., vol. 69, pp. 1763-1767 (1996).;;Victory et al., Heterocycles, 1985, 23(5), pp. 1135-1141.;;Garigipati, R., Tetrahedron Letters, vol. 31, p. 190 (1989).;;Kumada et al., Tetrahedron Letters, vol. 22, p. 5319 (1981).;;Lamartina et al., Boll. Chim. Farm., vol. 129 (12), pp. 314-316 (1990).;;Victory et al., Heterocycles, 1985, 23(8), pp. 1947-1950.;;Victory et al., Afinidad, Mar. 1989, vol. 46, pp. 107-113 (Spanish).;;Klotzer et al., Monatsh Chem., 1965, vol. 96, p. 1567.;;Zavyalov, et al., Khim Farm Zh, vol. 26(3), p. 88 (1992) (With Translation).;;Hare, et al., J. Med Chem., vol. 47 pp. 4731-4740 (2004).;;Hunt, et al., Bioorganic & Medicinal Chemistry Letters, vol. 13 pp. 467-470 (2003).;;Nishikawa et al., Chemical Pharm. Bull., 1976, vol. 24(9), pp. 2057-2077.;;Foster, et al., Drug News Perspect., vol. 13(8) pp. 488-497 (2000).;;Hanson, G., Expert Opinion on Therapeutic Patents, vol. 7(7) pp. 729-733 (1997).;;Henry, et al., Bioorganic & Medicinal Chemistry Letters, vol. 8 pp. 3335-3340 (1998).;;Herlaar, et al., Molecular Medicine Today, vol. 5 pp. 439-447 (1999).;;Hurlbert, et al., J. Med. Chem., 1968, vol. 11, pp. 703-707.;;Khabar, Khalid, Journal of Interferon & Cytokine Research, vol. 25 pp. 1-10 (2005).;;Lee, et al., Immunopharmacology, vol. 47(2-3) pp. 185-201 (2000).;;Marin, et al., Blood, vol. 98(3) pp. 667-673 (2001).;;Marshall, Cell, vol. 80(2) pp. 179-186 (1995).;;Seger, et al., FASEB, vol. 9(9) pp. 726-735 (1995).;;Lee, et al., Nature, vol. 372(6508) pp. 739-747 (1994).;;Herskowitz, Cell, vol. 80(2) pp. 187-197 (1995).;;Cohen, Trends in Cell Biology, vol. 7(9) pp. 353-361 (1997).;;Rewcastle, et al.,. Med Chem, vol. 39 pp. 1823-1835 (1996).;;Schoffstall, J Org Chem, vol. 36(16) pp. 2385-2387 (1971).;;Underwood, et al., Journal of Pharmacology and Experimental Therapeutics, vol. 293 (1) pp. 281-288 (2000).;;Victory, et al., J Heterocyclic Chem, vol.v 25 pp. 245-247 (1988).;;Wadsworth, et al., Journal of Pharma and Exp Therapeutics, vol. 291(2) pp. 680-687 (1999).;;Weinstein, et al., J. Immunol., vol. 151(7) pp. 3829-3838 (1993).",INACTIVE
828,US,B2,US 6998156 B2,129-996-267-427-427,2006-02-14,2006,US 5997802 A,2002-01-29,US 5997802 A,2002-01-29,Deposition of thin films using an infrared laser,This invention pertains to transfer of a solid target material onto a substrate by vaporizing the material by irradiating it with intense light of a resonant vibrational mode of the material and depositing the vaporized material on a substrate in a solid form.,US NAVY,BUBB DANIEL;;HORWITZ JAMES;;CALLAHAN JOHN;;HAGLUND JR RICHARD;;PAPANTONAKIS MICHAEL,THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (2002-06-13),https://lens.org/129-996-267-427-427,Granted Patent,yes,16,12,2,3,0,C23C14/12;;C23C14/28;;C23C14/12;;C23C14/28,C23C14/28;;B23K26/40;;C23C14/12;;C23C14/32,427/596;;427/561;;219/121.85,0,0,,,,EXPIRED
829,EP,A4,EP 1404654 A4,180-171-959-890-650,2008-12-03,2008,EP 01987253 A,2001-10-25,US 0146184 W;;US 24300600 P,2000-10-25,CALCILYTIC COMPOUNDS,,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP;;BURGESS JOELLE L;;CALLAHAN JAMES F;;LAGO MARIA A,GLAXOSMITHKLINE LLC (2010-03-03),https://lens.org/180-171-959-890-650,Search Report,no,0,0,20,20,0,A61K31/565;;A61K31/59;;A61K31/66;;A61K38/23;;A61K45/06;;C07D213/84;;A61P1/02;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P35/04;;A61P43/00;;A61P5/18;;A61P5/22;;C07D213/63;;C07D213/84;;A61K31/59;;A61K31/565;;A61K31/66;;A61K45/06;;A61K38/23,A61K31/137;;A61K31/44;;A61K31/565;;A61K31/59;;A61K31/593;;A61K31/66;;A61K38/00;;A61K38/23;;A61K45/00;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P5/22;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P35/04;;A61P43/00;;C07D213/84,,1,0,,,No further relevant documents disclosed,DISCONTINUED
830,AT,T1,AT E343390 T1,030-654-210-616-761,2006-11-15,2006,AT 01988571 T,2001-10-25,US 24300700 P,2000-10-25,KALZILYTISCHE VERBINDUNGEN,Novel calcilytic compounds and methods of using them are provided.,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP;;BRYAN WILLIAM M;;CALLAHAN JAMES F;;HUFFMAN WILLIAM F,,https://lens.org/030-654-210-616-761,Granted Patent,no,0,0,13,13,0,A61K45/06;;C07C255/54;;C07F9/091;;C07F9/655345;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07F9/655345;;C07F9/091;;C07C255/54;;A61K45/06,A61K45/00;;A61K31/661;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07C255/54;;C07F9/09;;C07F9/6553,,0,0,,,,EXPIRED
831,CZ,A3,CZ 20031144 A3,041-693-783-184-581,2004-08-18,2004,CZ 20031144 A,2001-10-25,US 24300600 P,2000-10-25,Calcilytic compounds,,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP;;BURGESS JOELLE L;;CALLAHAN JAMES F;;LAGO MARIA A,,https://lens.org/041-693-783-184-581,Patent Application,no,0,0,20,20,0,A61K31/565;;A61K31/59;;A61K31/66;;A61K38/23;;A61K45/06;;C07D213/84;;A61P1/02;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P35/04;;A61P43/00;;A61P5/18;;A61P5/22;;C07D213/63;;C07D213/84;;A61K31/59;;A61K31/565;;A61K31/66;;A61K45/06;;A61K38/23,A61K31/137;;A61K31/44;;A61K31/565;;A61K31/59;;A61K31/593;;A61K31/66;;A61K38/00;;A61K38/23;;A61K45/00;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P5/22;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P35/04;;A61P43/00;;C07D213/84,,0,0,,,,PENDING
832,ES,T3,ES 2273909 T3,073-242-599-977-862,2007-05-16,2007,ES 01988571 T,2001-10-25,US 24300700 P,2000-10-25,COMPUESTOS CALCILITICOS.,Novel calcilytic compounds and methods of using them are provided.,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP;;BRYAN WILLIAM M;;CALLAHAN JAMES F;;HUFFMAN WILLIAM F,,https://lens.org/073-242-599-977-862,Granted Patent,no,0,0,13,13,0,A61K45/06;;C07C255/54;;C07F9/091;;C07F9/655345;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07F9/655345;;C07F9/091;;C07C255/54;;A61K45/06,A61K31/675;;A61K45/00;;A61K31/661;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07C255/54;;C07F9/09;;C07F9/6553,,0,0,,,,EXPIRED
833,EP,A2,EP 1383511 A2,129-805-704-563-757,2004-01-28,2004,EP 01988571 A,2001-10-25,US 0146233 W;;US 24300700 P,2000-10-25,CALCILYTIC COMPOUNDS,Novel calcilytic compounds and methods of using them are provided.,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP;;BRYAN WILLIAM M;;CALLAHAN JAMES F;;HUFFMAN WILLIAM F,SMITHKLINE BEECHAM CORPORATION (2006-10-18),https://lens.org/129-805-704-563-757,Patent Application,yes,0,0,13,13,0,A61K45/06;;C07C255/54;;C07F9/091;;C07F9/655345;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07F9/655345;;C07F9/091;;C07C255/54;;A61K45/06,A61K45/00;;A61K31/661;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07C255/54;;C07F9/09;;C07F9/6553,,0,0,,,,EXPIRED
834,AU,A,AU 2001/079067 A,024-798-580-177-52X,2002-04-02,2002,AU 2001/079067 A,2001-07-30,US 66872800 A;;US 0123760 W,2000-09-22,Cold isopressing method and mold,,PRAXAIR TECHNOLOGY INC,APTE PRASAD;;CALLAHAN SHAWN W;;SCHNEIDER JAMES S;;CHEN JACK C,,https://lens.org/024-798-580-177-52X,Patent Application,no,0,0,9,9,0,B01D67/0041;;B01D71/024;;B28B3/003;;B29C33/405;;B29C43/003;;B29C43/006;;B29C43/10;;B29C43/146;;B29C2043/3238;;B29C2043/3628;;B29C2043/3652;;B29L2023/00;;B30B11/001;;B30B15/302;;B01D69/04;;B01D2323/10;;B01D2323/24;;B29C43/003;;B29C33/405;;B29C2043/3238;;B29C2043/3652;;B30B11/001;;B29C43/10;;B28B3/003;;B29L2023/00;;B30B15/302;;B29C2043/3628;;B29C43/146;;B29C43/006;;B01D69/04;;B01D2323/10;;B01D2323/24;;B01D67/00411,B01D67/00;;B01D71/02;;B28B3/00;;B29C33/40;;B29C43/00;;B29C43/10;;B29C43/14;;B30B11/00;;B30B15/30,,0,0,,,,PENDING
835,WO,A3,WO 2002/038106 A3,082-517-539-961-953,2004-01-29,2004,US 0146184 W,2001-10-25,US 24300600 P,2000-10-25,CALCILYTIC COMPOUNDS,Novel phosphate esters compounds and methods of using them as calcilytic compounds are provided.,SMITHKLINE BEECHAM CORP;;BHATNAGAR PRADIP;;BURGESS JOELLE L;;CALLAHAN JAMES F;;LAGO MARIA A,BHATNAGAR PRADIP;;BURGESS JOELLE L;;CALLAHAN JAMES F;;LAGO MARIA A,,https://lens.org/082-517-539-961-953,Search Report,yes,4,0,20,20,0,A61K31/565;;A61K31/59;;A61K31/66;;A61K38/23;;A61K45/06;;C07D213/84;;A61P1/02;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P35/04;;A61P43/00;;A61P5/18;;A61P5/22;;C07D213/63;;C07D213/84;;A61K31/59;;A61K31/565;;A61K31/66;;A61K45/06;;A61K38/23,A61K31/137;;A61K31/44;;A61K31/565;;A61K31/59;;A61K31/593;;A61K31/66;;A61K38/00;;A61K38/23;;A61K45/00;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P5/22;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P35/04;;A61P43/00;;C07D213/84,,3,0,,,"DATABASE CAPLUS [online] CHEM. ABSTR. (COLUMBUS, OH, USA); HANCOCK ET AL.: ""Preparation of aryloxypropanolamines for treatment of wastinig syndromes"", XP002909787, accession no. ACS Database accession no. 1985:113523;;DATABASE CAPLUS [online] CHEM. ABSTR. (COLUMBUS, OH, USA); KNOLLE ET AL.: ""3-((arylalkyl)amino)propoxypyridine derivatives, pharmaceutical preparations containing them and their use"", XP002909786, accession no. ACS Database accession no. 1985:45782;;DATABASE CAPLUS [online] CHEM. ABSTR. (COLUMBUS, OH, USA); MCCLURE ET AL.: ""Antihypertensive .beta.adrenergic blocking agents: N-aralkyl analogs of 2-(3-(tert-butylamino)-2-hydroxy)-3-cyanopyridine"", XP002909785, accession no. ACS Database accession no. 1983:432759",PENDING
836,US,A1,US 2004/0014723 A1,121-424-205-210-324,2004-01-22,2004,US 41511803 A,2003-04-24,US 41511803 A;;US 0146233 W;;US 24300700 P,2000-10-25,Calcilytic compounds,"
   Novel calcilytic compounds and methods of using them are provided. 
",BHATNAGAR PRADIP;;BRYAN WILLIAM M;;CALLAHAN JAMES F;;HUFFMAN WILLIAM F,BHATNAGAR PRADIP;;BRYAN WILLIAM M;;CALLAHAN JAMES F;;HUFFMAN WILLIAM F,SMITHKLINE BEECHAM CORPORATION (2002-01-11),https://lens.org/121-424-205-210-324,Patent Application,yes,0,6,13,13,0,A61K45/06;;C07C255/54;;C07F9/091;;C07F9/655345;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07F9/655345;;C07F9/091;;C07C255/54;;A61K45/06,A61K31/661;;A61K45/06;;A61P1/02;;A61P3/14;;A61K45/00;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07C255/54;;C07F9/09;;C07F9/6553,514/86;;514/89;;544/232;;544/243;;544/337;;546/22,0,0,,,,DISCONTINUED
837,US,A1,US 2009/0319160 A1,176-344-592-726-683,2009-12-24,2009,US 19575908 A,2008-08-21,US 19575908 A;;US 7504408 P,2008-06-24,ACTIVE EXHAUST VALVE CONTROL STRATEGY FOR IMPROVED FUEL CONSUMPTION,"A control system for an exhaust valve and a method of actively controlling an exhaust valve includes monitoring at least a first engine characteristic, a second engine characteristic, and at least one additional noise determining characteristic. An exhaust valve position is then adjusted based on the first engine characteristic, the second engine characteristic, and the at least one additional noise determining characteristic to improve fuel economy without adversely affecting noise levels.",CALLAHAN JOSEPH E;;ABRAM KWIN;;WILLATS ROBIN;;ARBUCKLE IVAN;;EGAN JAMES,CALLAHAN JOSEPH E;;ABRAM KWIN;;WILLATS ROBIN;;ARBUCKLE IVAN;;EGAN JAMES,EMCON TECHNOLOGIES LLC (2008-08-21),https://lens.org/176-344-592-726-683,Patent Application,yes,31,27,1,1,0,F02D9/04;;F02D41/0225;;F02D41/1497;;F02D2041/001;;F02D2200/025;;F02D2200/502;;F02D2200/701;;F02D41/1497;;F02D41/0225;;F02D2041/001;;F02D2200/701;;F02D2200/502;;F02D2200/025;;F02D9/04,F01N7/00;;F02D45/00,701/111;;60/324,0,0,,,,DISCONTINUED
838,CN,A,CN 1646131 A,193-079-468-182-14X,2005-07-27,2005,CN 03808793 A,2003-04-18,US 37421902 P;;US 38855702 P,2002-04-19,Novel compounds,,SMITHKLINE BEECHAM CORP,BOEHM JEFFREY C;;WIDDOWSON KATHERINE L;;CALLAHAN JAMES F;;ZEHONG WAN,,https://lens.org/193-079-468-182-14X,Patent Application,no,0,0,23,24,0,C07D471/04;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P9/02;;A61P9/10;;A61P3/10;;C07D471/04;;A61K31/519;;C07D487/00;;C07D471/04,C07D239/42;;A01N43/90;;A61K31/519;;A61P1/04;;A61P3/10;;A61P9/02;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;C07D471/04;;C07D487/00,,0,0,,,,DISCONTINUED
839,EP,A4,EP 1383511 A4,017-105-968-201-348,2005-05-18,2005,EP 01988571 A,2001-10-25,US 0146233 W;;US 24300700 P,2000-10-25,CALCILYTIC COMPOUNDS,Novel calcilytic compounds and methods of using them are provided.,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP;;BRYAN WILLIAM M;;CALLAHAN JAMES F;;HUFFMAN WILLIAM F,SMITHKLINE BEECHAM CORPORATION (2006-10-18),https://lens.org/017-105-968-201-348,Search Report,no,6,0,13,13,0,A61K45/06;;C07C255/54;;C07F9/091;;C07F9/655345;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07F9/655345;;C07F9/091;;C07C255/54;;A61K45/06,A61K45/00;;A61K31/661;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07C255/54;;C07F9/09;;C07F9/6553,,0,0,,,,EXPIRED
840,WO,A8,WO 2002/034204 A8,050-114-319-775-983,2003-12-24,2003,US 0146233 W,2001-10-25,US 24300700 P,2000-10-25,CALCILYTIC COMPOUNDS,Novel calcilytic compounds and methods of using them are provided.,SMITHKLINE BEECHAM CORP;;BHATNAGAR PRADIP;;BRYAN WILLIAM M;;CALLAHAN JAMES F;;HUFFMAN WILLIAM F,BHATNAGAR PRADIP;;BRYAN WILLIAM M;;CALLAHAN JAMES F;;HUFFMAN WILLIAM F,,https://lens.org/050-114-319-775-983,Patent Application,no,0,0,13,13,0,A61K45/06;;C07C255/54;;C07F9/091;;C07F9/655345;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07F9/655345;;C07F9/091;;C07C255/54;;A61K45/06,A61K31/661;;A61K45/00;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07C255/54;;C07F9/09;;C07F9/6553,,0,0,,,,PATENTED
841,PL,A1,PL 373339 A1,144-204-892-828-483,2005-08-22,2005,PL 37333903 A,2003-04-18,US 37421902 P;;US 38855702 P,2002-04-19,NOVEL COMPOUNDS,,SMITHKLINE BEECHAM CORP,BOEHM JEFFREY C;;WIDDOWSON KATHERINE L;;CALLAHAN JAMES F;;WAN ZEHONG,,https://lens.org/144-204-892-828-483,Patent Application,no,0,0,23,24,0,C07D471/04;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P9/02;;A61P9/10;;A61P3/10;;C07D471/04;;A61K31/519;;C07D487/00;;C07D471/04,C07D239/42;;A01N43/90;;A61K31/519;;A61P1/04;;A61P3/10;;A61P9/02;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;C07D471/04;;C07D487/00,,0,0,,,,PENDING
842,ZA,B,ZA 919439 B,134-607-152-997-250,1992-12-30,1992,ZA 919439 A,1991-11-29,US 62097890 A,1990-11-30,HTV PROTEASE INHIBITORS,,SMITHKLINE BEECHAM CORP,HUFFMAN WILLIAM FRANCIS;;WILLIAM FRANCIS HUFFMAN;;CALLAHAN JAMES FRANCIS;;JAMES FRANCIS CALLAHAN;;MOORE MICHAEL LEE;;MICHAEL LEE MOORE;;NEWLANDER KENNETH ALLEN;;KENNETH ALLEN NEWLANDER,,https://lens.org/134-607-152-997-250,Granted Patent,no,0,0,10,10,0,A61K38/00;;C07C69/757;;C07D223/04;;C07D223/06;;C07D233/64;;C07D243/08;;C07K5/06052;;C07K5/06139;;C07K5/0821;;C07K7/02;;A61P31/12;;A61P43/00;;A61P9/12;;C07D233/64;;C07C69/757;;C07K5/0821;;C07K5/06139;;C07D223/06;;C07D243/08;;A61K38/00;;C07K5/06052;;C07D223/04;;C07K7/02,A61K38/00;;A61K31/55;;A61K38/55;;A61P9/12;;A61P31/12;;A61P43/00;;C07C69/757;;C07D223/04;;C07D223/06;;C07D223/08;;C07D223/10;;C07D233/54;;C07D243/06;;C07D243/08;;C07K1/113;;C07K5/06;;C07K5/078;;C07K5/08;;C07K5/097;;C07K7/02;;C07K14/81;;C12N9/99,,0,0,,,,EXPIRED
843,CA,A1,CA 2482022 A1,002-956-171-591-204,2003-10-30,2003,CA 2482022 A,2003-04-18,US 37421902 P;;US 38855702 P;;US 0312127 W,2002-04-19,NOVEL COMPOUNDS,"Novel substituted 2, 4, 8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.",SMITHKLINE BEECHAM CORP,BOEHM JEFFREY C;;WAN ZEHONG;;CALLAHAN JAMES F;;WIDDOWSON KATHERINE L,,https://lens.org/002-956-171-591-204,Patent Application,no,0,0,23,24,0,C07D471/04;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P9/02;;A61P9/10;;A61P3/10;;C07D471/04;;A61K31/519;;C07D487/00;;C07D471/04,C07D239/42;;A01N43/90;;A61K31/519;;A61P1/04;;A61P3/10;;A61P9/02;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;C07D471/04;;C07D487/00,,0,0,,,,DISCONTINUED
844,WO,A1,WO 1999/065299 A1,047-755-847-346-447,1999-12-23,1999,US 9914065 W,1999-06-18,US 9001998 P,1998-06-19,COMPOSITIONS AND METHODS FOR EXPANSION OF HEMATOPOIETIC CELLS,"The present invention relates to the field of hematopoiesis in mammals, and more particularly to the use of certain novel compounds and known compounds for the in vitro, ex vivo, or in vivo expansion of hematopoietic cells.",SMITHKLINE BEECHAM CORP;;BHATNAGAR PRADIP KUMAR;;CALLAHAN JAMES F;;HOROWITZ DANIEL;;KING ANDREW G,BHATNAGAR PRADIP KUMAR;;CALLAHAN JAMES F;;HOROWITZ DANIEL;;KING ANDREW G,,https://lens.org/047-755-847-346-447,Patent Application,yes,1,5,1,1,0,A61K38/00;;C07K5/06043;;C07K5/0812;;C07K5/1016;;C12N5/0647;;C12N2500/32;;C12N2501/125;;C12N2501/22;;C12N2501/23;;C12N2501/998,A61K38/00;;C07K5/06;;C07K5/087;;C07K5/107;;C12N5/0789,,4,2,133-853-829-691-438;;054-718-393-772-863,10.1021/jm960099d;;8809169;;10.1038/336688a0;;3143917,"HOROWITZ et al., ""Ex Vivo Expansion of Hematopoietic Cells with Glycinamide"", BLOOD, 15 November 1998, Vol. 92, No. 10, Suppl. 1, Part 1-2, page 311B. XP002930008.;;CALLAHAN et al., ""Identification of Glycinamide as the Active Principal Responsible for the Effects of Tyr-MIF on Hematopoietic Progenitor Cells"", BLOOD, 15 November 1998, Vol. 92, No. 10, Suppl. 1, Part 1-2, page 581A, XP002930009.;;BHATNAGAR P. K., ET AL.: ""STRUCTURE-ACTIVITY RELATIONSHIPS OF NOVEL HEMATOREGULATORY PEPTIDES."", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 39., no. 19., 13 September 1996 (1996-09-13), US, pages 3814 - 3819., XP000611484, ISSN: 0022-2623, DOI: 10.1021/jm960099d;;SMITH A. G., ET AL.: ""INHIBITION OF PLURIPOTENTIAL EMBRYONIC STEM CELL DIFFERENTIATION BYPURIFIED POLYPEPTIDES."", NATURE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 336., no. 6200., 1 December 1988 (1988-12-01), United Kingdom, pages 688 - 690., XP000955109, ISSN: 0028-0836, DOI: 10.1038/336688a0",PENDING
845,AU,A1,AU 2003/225072 A1,083-602-904-593-777,2003-11-03,2003,AU 2003/225072 A,2003-04-18,US 37421902 P;;US 38855702 P;;US 0312127 W,2002-04-19,NOVEL COMPOUNDS,,SMITHKLINE BEECHAM CORP,WAN ZEHONG;;BOEHM JEFFREY C;;WIDDOWSON KATHERINE L;;CALLAHAN JAMES F,,https://lens.org/083-602-904-593-777,Patent Application,no,0,0,23,24,0,C07D471/04;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P9/02;;A61P9/10;;A61P3/10;;C07D471/04;;A61K31/519;;C07D487/00;;C07D471/04,C07D239/42;;A01N43/90;;A61K31/519;;A61P1/04;;A61P3/10;;A61P9/02;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;C07D471/04;;C07D487/00,,0,0,,,,DISCONTINUED
846,BR,A,BR 0114884 A,129-473-715-852-230,2004-07-06,2004,BR 0114884 A,2001-10-25,US 24300600 P;;US 0146184 W,2000-10-25,Compostos calcilìticos,"""COMPOSTOS CALCILìTICOS"". Novos compostos fosfato ésteres e processo de uso dos mesmos como compostos calcilíticos são providos.",SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP;;BURGESS JOELLE L;;CALLAHAN JAMES F;;LAGO MARIA A,,https://lens.org/129-473-715-852-230,Patent Application,no,0,0,20,20,0,A61K31/565;;A61K31/59;;A61K31/66;;A61K38/23;;A61K45/06;;C07D213/84;;A61P1/02;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P35/04;;A61P43/00;;A61P5/18;;A61P5/22;;C07D213/63;;C07D213/84;;A61K31/59;;A61K31/565;;A61K31/66;;A61K45/06;;A61K38/23,A61K31/137;;A61K31/44;;A61K31/565;;A61K31/59;;A61K31/593;;A61K31/66;;A61K38/00;;A61K38/23;;A61K45/00;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P5/22;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P35/04;;A61P43/00;;C07D213/84,,0,0,,,,DISCONTINUED
847,WO,A1,WO 2018/203238 A1,000-408-017-590-860,2018-11-08,2018,IB 2018053018 W,2018-05-02,AU 2017/901600 A,2017-05-02,SYSTEM AND METHOD FOR ASSESSING TAX GOVERNANCE AND MANAGING TAX RISK,"A computer-implemented method comprising: receiving, at a server, survey results relating to tax governance and tax risk management from one or more participants; computing, via a processor, scores for each of a plurality of tax governance assessment categories based on weighted values assigned to one or more survey questions; computing, via the processor, scores representative of gaps between assessed tax governance controls and benchmark controls, based on weighted values assigned to one or more survey questions; generating, via the processor, an action item if a score is below a threshold; displaying, on a user device, a graphical representation of the scores computed for each assessment category; displaying, on user device, a graphical representation of the computed gaps relative to each benchmark control.",KPMG AUSTRALIA IP HOLDINGS PTY LTD,CALLAHAN STEPHEN;;GORDON JAMES;;BERKMAN STACEY;;GREEN TROY;;DOS SANTOS ALLINE,,https://lens.org/000-408-017-590-860,Patent Application,yes,5,1,2,2,0,G06Q40/10,G06Q40/00;;G06Q10/06;;G06Q10/10,,0,0,,,,PENDING
848,EP,B1,EP 1499320 B1,024-018-630-037-34X,2007-08-22,2007,EP 03721779 A,2003-04-18,US 0312127 W;;US 37421902 P;;US 38855702 P,2002-04-19,NOVEL COMPOUNDS,,SMITHKLINE BEECHAM CORP,BOEHM JEFFREY C;;WIDDOWSON KATHERINE L;;CALLAHAN JAMES F;;WAN ZEHONG,SMITHKLINE BEECHAM CORPORATION (2007-08-08),https://lens.org/024-018-630-037-34X,Granted Patent,yes,3,0,23,24,0,C07D471/04;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P9/02;;A61P9/10;;A61P3/10;;C07D471/04;;A61K31/519;;C07D487/00;;C07D471/04,C07D239/42;;C07D487/00;;A01N43/90;;A61K31/519;;A61P1/04;;A61P3/10;;A61P9/02;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;C07D471/04,,0,0,,,,EXPIRED
849,ES,T3,ES 2291630 T3,022-523-857-023-289,2008-03-01,2008,ES 03721779 T,2003-04-18,US 37421902 P;;US 38855702 P,2002-04-19,NUEVOS COMPUESTOS.,"El compuesto que es: 8-(2, 4, 6-trifluorofenil)-4-(2, 4-difluorofenil)-2-(2-hidroxi-1-hidroximetiletilamino)-8H-pirido[2, 3-d]pirimidin-7-ona; 4, 8-Bis-(2, 4-difluoro-fenil)-2-(2-hidroxi-1-hidroximetil-etilamino)-8H-pirido-[2, 3-d]-pirimidin-7-ona; 8-(2, 4, 6-trifluorofenil)-4-(2-fluorofenil)-2-(2-hidroxi-1-hidroximetiletilamino)-8H-pirido[2, 3-d]pirimidin-7-ona; 8-(2, 4, 6-trifluorofenil)-4-(4-fluorofenil)-2-(2-hidroxi-1-hidroximetiletilamino)-8H-pirido[2, 3-d]pirimidin-7-ona; 4-(2-fluoro-fenil)-8-(2, 4-difluoro-fenil)-2-((S)-2-hidroxi-1-metiletilamino)-8H-pirido-[2, 3-d]-pirimidin-7-ona; 4-(2, 4-Difluoro-fenil)-8-(4-fluoro-fenil)-2-((S)-2-hidroxi-I-metiletilamino)-8H-pirido-[2, 3-d]-pirimidin-7-ona; 4, 8-Bis-(2, 4-difluoro-fenil)-2-(2-hidroxi-1-metil-etilamino)-8H-pirido-[2, 3-d]-pirimidin-7-ona; 8-(2, 4-Difluorofenil)-4-(2-cloro-4-fluorofenil)-2-(2-hidroxi-1-hidroximetiletilamino)-8H-pirido[2, 3-d]pirimidin-7-ona; o 8-(2, 3-difluorofenil)-4-(2, 4-difluorofenil)-2-(2-hidroxi-1-hidroximetiletilamino)-8H-pirido[2, 3-d]pirimidin-7-ona; o una sal farmacéuticamente aceptable de los mismos.",SMITHKLINE BEECHAM CORP,BOEHM JEFFREY C;;WIDDOWSON KATHERINE L;;CALLAHAN JAMES F;;WAN ZEHONG,,https://lens.org/022-523-857-023-289,Granted Patent,no,0,0,23,24,0,C07D471/04;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P9/02;;A61P9/10;;A61P3/10;;C07D471/04;;A61K31/519;;C07D487/00;;C07D471/04,C07D239/42;;C07D487/00;;A01N43/90;;A61K31/519;;A61P1/04;;A61P3/10;;A61P9/02;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;C07D471/04,,0,0,,,,EXPIRED
850,ZA,B,ZA 200301316 B,065-558-550-718-238,2004-02-03,2004,ZA 200301316 A,2003-02-18,US 66872800 A,2000-09-22,Cold isopressing method and mold.,,PRAXAIR TECHNOLOGY INC,APTE PRASAD;;CALLAHAN SHAWN W;;SCHNEIDER JAMES S;;CHEN JACK C,,https://lens.org/065-558-550-718-238,Granted Patent,no,0,0,9,9,0,B01D67/0041;;B01D71/024;;B28B3/003;;B29C33/405;;B29C43/003;;B29C43/006;;B29C43/10;;B29C43/146;;B29C2043/3238;;B29C2043/3628;;B29C2043/3652;;B29L2023/00;;B30B11/001;;B30B15/302;;B01D69/04;;B01D2323/10;;B01D2323/24;;B29C43/003;;B29C33/405;;B29C2043/3238;;B29C2043/3652;;B30B11/001;;B29C43/10;;B28B3/003;;B29L2023/00;;B30B15/302;;B29C2043/3628;;B29C43/146;;B29C43/006;;B01D69/04;;B01D2323/10;;B01D2323/24;;B01D67/00411,B01D67/00;;B01D71/02;;B28B3/00;;B29C33/40;;B29C43/00;;B29C43/10;;B29C43/14;;B30B11/00;;B30B15/30,,0,0,,,,EXPIRED
851,EP,A1,EP 1499320 A1,148-540-856-749-815,2005-01-26,2005,EP 03721779 A,2003-04-18,US 0312127 W;;US 37421902 P;;US 38855702 P,2002-04-19,NOVEL COMPOUNDS,,SMITHKLINE BEECHAM CORP,BOEHM JEFFREY C;;WIDDOWSON KATHERINE L;;CALLAHAN JAMES F;;WAN ZEHONG,SMITHKLINE BEECHAM CORPORATION (2007-08-08),https://lens.org/148-540-856-749-815,Patent Application,yes,0,0,23,24,0,C07D471/04;;A61P1/04;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;A61P9/02;;A61P9/10;;A61P3/10;;C07D471/04;;A61K31/519;;C07D487/00;;C07D471/04,C07D239/42;;C07D487/00;;A01N43/90;;A61K31/519;;A61P1/04;;A61P3/10;;A61P9/02;;A61P9/10;;A61P11/00;;A61P11/06;;A61P13/02;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/14;;A61P31/16;;A61P31/20;;A61P33/06;;A61P35/00;;A61P35/02;;A61P35/04;;A61P37/06;;A61P43/00;;C07D471/04,,0,0,,,,EXPIRED
852,US,A1,US 2010/0043398 A1,154-078-585-129-269,2010-02-25,2010,US 54199209 A,2009-08-17,US 54199209 A;;US 9067608 P,2008-08-21,DUAL EXHAUST SYSTEM WITH INDEPENDENT VALVE CONTROL,A dual exhaust system includes a first exhaust component defining a first exhaust path and a second exhaust component defining a second exhaust path that is different from the first exhaust path. A first valve is associated with the first exhaust path and a second valve is associated with the second exhaust path. The first valve and second valve operate independently of each other to vary exhaust flow and provide sufficient noise control for varying applications.,ABRAM KWIN;;ARBUCKLE IVAN;;CALLAHAN JOSEPH E;;EGAN JAMES;;WILLATS ROBIN,ABRAM KWIN;;ARBUCKLE IVAN;;CALLAHAN JOSEPH E;;EGAN JAMES;;WILLATS ROBIN,EMCON TECHNOLOGIES LLC (2009-08-14),https://lens.org/154-078-585-129-269,Patent Application,yes,8,10,2,2,0,F01N13/04;;F01N13/04;;F01N1/16;;F01N1/16;;F01N1/168;;F01N1/168;;F01N2240/36;;F01N2240/36,F01N7/08,60/273;;60/324,0,0,,,,INACTIVE
853,US,B2,US 7479558 B2,020-325-635-249-67X,2009-01-20,2009,US 38837506 A,2006-03-24,US 38837506 A;;US 66515405 P,2005-03-25,"Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives","The present invention is directed to a novel method of preparing of 2,4,8-trisubstituted pyrido[2,3-d]pyrimidin-7-one pharmacophores of Formula (II) or (IIa) wherein G1 is CH 2 or NH:G2 is CH or nitrogen;Rx is chloro, bromo, iodo, or O—S(O) 2 CF 3 ;R g is a C 1-10 alkyl;m is 0, or an integer having a value of 1, or 2;R 3 is a C 1-10 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl C 1-10 alkyl, aryl, arylC 1-10 alkyl, heteroaryl, heteroarylC 1-10 alkyl, heterocyclic or a heterocyclylC 1-10 alkyl moiety, and wherein each of these moieties may be optionally substituted. which comprises reacting a compound of the formula: wherein Ry is chloro, bromo, iodo, O—S(O) 2 CF 3 ; andRg is a C 1-10 alkyl; with a olefin forming reagent in a suitable base to yield a compound of Formula (II), or (IIa) wherein m=0 and oxidizing the sulphur as necessary or desired.",GLAXO GROUP LTD,CALLAHAN JAMES F;;BOEHM JEFFREY C;;WAN ZEHONG;;YAN HONGXING;;LIN XICHEN,GLAXO GROUP LIMITED (2006-05-25),https://lens.org/020-325-635-249-67X,Granted Patent,yes,81,5,22,22,0,C07D471/04;;C07D487/04;;A61P43/00;;C07D471/04;;C07D487/04;;C07D487/04;;C07D471/04,C07D487/04;;C07D239/30;;C07D413/04;;C07D471/04,544/118;;544/256;;544/117;;544/279;;544/318,64,23,017-276-191-390-210;;075-868-082-984-637;;010-281-016-005-743;;050-202-509-159-647;;027-044-424-195-732;;009-270-336-024-717;;132-837-931-216-979;;008-272-662-905-432;;052-009-228-330-151;;021-487-746-185-54X;;044-639-268-079-201;;116-338-838-439-338;;018-278-523-061-292;;031-226-339-998-209;;012-960-512-921-932;;014-078-643-675-713;;070-293-335-615-447;;086-270-071-053-469;;131-233-054-471-359;;051-392-666-499-166;;062-434-801-823-152;;032-681-612-390-618;;182-920-176-787-532,15877472;;10.1021/cc049828y;;8831759;;10.1021/jm960415o;;10.1016/8756-3282(94)90277-1;;7980964;;10.1135/cccc19811167;;7914033;;10.1126/science.7914033;;9308510;;10.1001/archinte.1997.00440380091009;;10.1001/archinte.157.17.1981;;10.1248/cpb.37.2214;;10.1074/jbc.272.30.18518;;9228012;;10.1016/s0040-4039(00)86691-5;;12565952;;10.1016/s0960-894x(02)00990-3;;15341488;;10.1021/jm0499054;;10.1021/jo01047a024;;10.1021/jo00200a045;;5671228;;10.1021/jm00310a015;;10.1021/jo00426a013;;839323;;10.1021/jo00815a045;;10.1016/s0968-0896(96)00212-x;;9043657;;10.1016/s0040-4039(01)92491-8;;2101013;;8627606;;10.1021/jm9508651;;10.1248/cpb.24.2057;;991360;;10.1002/jhet.5570210229;;10.1002/jhet.5570340520,"Martinez-Teipel, et al., J. Combinatorial Chem., 2005, 7(3), 436-448.;;U.S. Appl. No. 11/613,517, filed Dec. 20, 2006, Adams et al.;;U.S. Appl. No. 11/613,598, filed Dec. 20, 2006, Adams et al.;;U.S. Appl. No. 11/839,830, filed Aug. 16, 2007, Adams et al.;;U.S. Appl. No. 11/839,833, filed Aug. 16, 2007, Adams et al.;;U.S. Appl. No. 11/839,834, filed Aug. 16, 2007, Adams et al.;;U.S. Appl. No. 11/908,340, filed Sep. 11, 2007, Boehm et al.;;U.S. Appl. No. 11/908,435, filed Sep. 12, 2007, Callahan et al.;;U.S. Appl. No. 11/908,440, filed Sep. 12, 2007, Callahan et al.;;U.S. Appl. No. 11/908,839, filed Sep. 17, 2007, Callahan et al.;;U.S. Appl. No. 11/871,039, filed Oct. 11, 2007, Adams et al.;;Adams et al., Progress in Medicinal Chemistry, vol. 38, pp. 2-61 (2001).;;Armarego, W., Chem. Soc., Quinazolines, Part IV. (JCS OA9) p. 561 (1962).;;Boehm et al., J. Med. Chem. vol. 39, pp. 3929-3937 (1996).;;Votta et al., Bone, vol. 15, No. 5, pp. 533-538 (1994).;;Bradlerova et al., Chem. Zvesti, vol. 29 (6), pp. 795-802 (1975).;;de Silva et al., J. Chem. Soc., vol. 4, pp. 685-690 (1995).;;Engel & Steglich, Liebigs Ann. Chem., p. 1916 (1978).;;Ferles et al., Collect. Czech. Chem. Commun., 5 (46), pp. 1167-1172 (1981).;;Fischer et al., Rec. Trav. Chim. Pays. Bas., vol. 84, p. 439 (1965).;;Fulmer et al., J. Heterocycl. Chem., vol. 17 (4), pp. 799-800 (1980).;;Gilbert, E., Synthesis, pp. 30-32 (1972).;;Han et al., Science, vol. 265, pp. 808-811 (1994).;;Hunter et al., Academic Press, San Diego, vol. 200, p. 3 (1991).;;Irwin et al., Archives of Internal Medicine, vol. 157 (17), pp. 1981-1987 (1997).;;Ishibashi et al., Chem. Pharm. Bull., vol. 37 (8), pp. 2214-2216 (1989).;;Johnson et al., PG.A., J.Chem.Soc., Perkin Trans., vol. 1, pp. 895-905 (1996).;;Jurkowska-Kowalczyk, R., Chem., vol. 51 (6), pp. 1191-1199 (1977).;;Katritzky et al., Synthesis, pp. 45-47 (Jan. 1993).;;Kawasaki et al., J. Bio. Chem., vol. 272 (30), pp. 18518-18521 (1997).;;Mikailu et al., Zh. Obshch. Khim., vol. 56 (7), pp. 1513-1517 (1986).;;Morton et al., Tetrahedron Letters, p. 4123 (1982).;;Protecting Groups in Organic Synthesis, 2nd Edition, Greene TW and Wuts PSM, Wiley-Interscience, New York, pp. 10-174 (Hydroxyl and Phenolic) and pp. 309-403 (NH protection) (1991).;;Santilli et al., J. Heterocycl Chem., vol. 8, pp. 445-453 (1971).;;Snieckus, V., Tetrahedron Letters, vol. 29, p. 2135 (1988).;;Hunt, et al., Bioorganic & Medicinal Chemistry Letters, vol. 13, pp. 467-470 (2003).;;Hare, et al., J. Med Chem., vol. 47 pp. 4731-4740 (2004).;;Stille et al., J. Amer. Chem. Soc., vol. 109, p. 5478 (1978).;;Strzybny et al., J. Org. Chem., vol. 28, p. 3381 (1963).;;Terashimia et al., M., Chem. Pharm. Bull., vol. 11, p. 4755 (1985).;;Thompson et al., J. Org. Chem., vol. 49, p. 5237 (1984).;;Uno et al., Bull. Chem. Soc. Japan., vol. 69, pp. 1763-1767 (1996).;;Vartanyan et al., vol. 40, (9), pp. 552-560 (1987).;;Borrel, et al., Coll. Czech. Chem. Commun., 1996, 61(6) pp. 901-909.;;Hurlbert, et al., J. Med Chem., 1968, vol. 11, pp. 703-707.;;Baker et al., J. Heterocyclic Chem., 1964, vol. 1, pp. 263-270.;;Anderson et al., J. Org. Chem., 1977, vol. 42, p. 993.;;Schoffstall et al., J. Org. Chem., 1971, 36(16), pp. 2385-2387.;;Victory et al., Heterocycles, 1985, 23(5), pp. 1135-1141.;;Gallagher et al., Bioorganic and Med Chem, vol. 5(1), pp. 49-64 (1997).;;Garigipati, R., Tetrahedron Letters, vol. 31,p. 190 (1989).;;Kumada et al., Tetrahedron Letters, vol. 22, p. 5319 (1981).;;Lamartina et al., Boll. Chim. Farm. vol. 129 (12), pp. 314-316 (1990).;;Victory et al., Heterocycles, 1985, 23(8), pp. 1947-1950.;;Victory et al., Afinidad, Mar. 1989, vol. 46, pp. 107-113 (Spanish).;;Klotzer et al., Monatsh Chem., 1965, vol. 96, p. 1567.;;Rewcastle et al., Journal of Medicinal Chemistry, 1996 39(6), pp. 1823-1835.;;Victory et al., J. Heterocycl. Chem, 1988, vol. 25, pp. 245-247.;;Nishikawa et al., Chemical Pharm. Bull., 1976, vol. 24(9), pp. 2057-2077.;;Carboni et al., Gazzetta Chimica Italiana, vol. 97(8) pp. 1262-1273 (1967).;;Carboni et al., Gazzetta Chimica Italiana, vol. 98(10) pp. 1174-1188 (1968).;;Ferrarini et al., Journal of Heterocyclic Chemistry, vol. 21(2) pp. 417-419 (1984).;;Ferrarini et al., Journal of Heterocyclic Chemistry, vol. 34(5) pp. 1501-1510 (1997).;;Zavyalov, et al., Khim Farm Zh, vol. 26(3), p. 88 (1992) (With Translation).",INACTIVE
854,CH,A,CH 466314 A,056-194-854-388-046,1968-12-15,1968,CH 1402466 A,1966-09-27,US 49229365 A,1965-10-01,Procédé de préparation de dérivés halogénés et hydroxylés du diphénylméthane,,ARMOUR & CO,HARLAN E TIEFENTHAL;;ERIC JUNGERMANN;;EUGENE JAMES JR MILLER;;JOHN JOSEPH CALLAHAN,,https://lens.org/056-194-854-388-046,Granted Patent,no,0,0,3,4,0,C07C37/20;;C07C37/115,C07C37/11;;C07C37/20,"12Q,15/01",0,0,,,,EXPIRED
855,US,B2,US 11117905 B2,106-566-144-560-549,2021-09-14,2021,US 201716467193 A,2017-12-11,US 201716467193 A;;US 201662434013 P;;IB 2017057801 W,2016-12-14,Bisaryl heterocycles as NRF2 activators,"The present invention relates to bisaryl heterocycle compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to bisaryl heterocycles of Formula (I),",GLAXOSMITHKLINE IP DEV LTD,CALLAHAN JAMES FRANCIS;;DAVIS RODERICK S;;GOODWIN NICOLE CATHLEEN;;KERNS JEFFREY K,GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (2018-02-01),https://lens.org/106-566-144-560-549,Granted Patent,yes,4,0,5,5,0,A61K9/0019;;A61K9/0053;;A61K9/0073;;A61P11/00;;A61P37/00;;C07D515/04;;C07D515/04;;C07D243/08;;C07D285/36;;C07D291/08;;C07D409/14;;C07D409/14;;C07D417/14;;C07D498/04;;C07D513/04,A61K8/00;;A61K9/00;;C07D243/08;;C07D281/02;;C07D285/36;;C07D291/08;;C07D409/14;;C07D513/04;;C07D515/04,,5,5,091-571-642-061-252;;067-540-319-320-152;;040-431-064-551-991;;033-610-045-781-687;;033-582-039-536-612,pmc4785809;;26419687;;10.1016/j.jnutbio.2015.08.001;;10.1021/jm9508853;;8667363;;10.1016/j.molmed.2011.02.006;;21459041;;10.1021/acs.jmedchem.6b00228;;10.3410/f.726256171.793523282;;10.1021/acs.jmedchem.6b00228.s001;;27031670;;10.1021/acs.jmedchem.9b00279.s001;;10.1021/acs.jmedchem.9b00279;;10.1021/acs.jmedchem.9b00279.s002;;30973731,"Huang et al. Journal of Nutritional Biochemistry 26 (2015) 1401-1413.;;Carmen Almansa, et al. “Diphenylpropionic Acids as New AT 1 Selective Angiotensin II Antagonists”. J. Med. Chem., 39(11): 2197-2206 (Jan. 1, 1996).;;Boutten, A., et al. “NRF2 Targeting: A Promising Therapeutic Strategy in Chronic Obstructive Pulmonary Disease”. Trends in Molec. Med., 17(7): 363-371 (Jul. 1, 2011).;;Davies, et al. “Mono-acidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-related Factor 2 (KEAP1 :NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-based Discovery”. J. Med. Chern., 59: 3991-4006 (2016).;;Heightman, et al. “Structure-Activity and Structure-Conformation Relationships of Aryl Propionic Acid Inhibitors of the Kelch-like ECH-associated protein 1: Nuclear factor erythroid 2-related factor 2 (KEAP1:NRF2) protein-protein interaction”. J. Med. Chern., 62: 4683-4702 (2019).",ACTIVE
856,IS,B,IS 2897 B,138-836-939-563-725,2014-09-15,2014,IS 7880 A,2005-06-02,US 0337461 W;;US 42910502 P,2002-11-26,Efnasambönd sem hamla gegn virkni kalkviðtaka,,SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/138-836-939-563-725,Granted Patent,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C229/00;;A61K31/185;;A61K31/21;;A61P19/00;;A61P19/08;;C07C217/32;;C07C217/34;;C07C217/36,,0,0,,,,EXPIRED
857,US,A1,US 2003/0006537 A1,135-261-856-958-090,2003-01-09,2003,US 16263202 A,2002-06-06,US 16263202 A;;US 66872800 A,2000-09-22,Cold isopressing method and mold,"
   A cold isopressing method and mold for compacting a granular ceramic material in which the granular ceramic material is introduced into a cylindrical pressure bearing element of an isopressing mold. The cylindrical pressure bearing element is sufficiently rigid so as to maintain its shape during the introducing of the granular ceramic material. Such element is also sufficiently resilient in a radial direction thereof to deform and bear against the granular ceramic material upon the application of the hydrostatic pressure and to substantially return to its original shape upon the relaxation of the hydrostatic pressure, thereby to allow retraction of the cylindrical pressure bearing element from the granular ceramic material after compaction. In a further aspect, an isopressing method and mold is provided in which the cylindrical pressure bearing element thereof is provided with an enlarged end bore to form an enlarged end section in the finished ceramic tube for sealing purposes. 
",APTE PRASAD S.;;CALLAHAN SHAWN W.;;SCHNEIDER JAMES S.;;CHEN JACK C.,APTE PRASAD S;;CALLAHAN SHAWN W;;SCHNEIDER JAMES S;;CHEN JACK C,PRAXAIR TECHNOLOGY INC (2002-07-08),https://lens.org/135-261-856-958-090,Patent Application,yes,19,3,9,9,0,B01D67/0041;;B01D71/024;;B28B3/003;;B29C33/405;;B29C43/003;;B29C43/006;;B29C43/10;;B29C43/146;;B29C2043/3238;;B29C2043/3628;;B29C2043/3652;;B29L2023/00;;B30B11/001;;B30B15/302;;B01D69/04;;B01D2323/10;;B01D2323/24;;B29C43/003;;B29C33/405;;B29C2043/3238;;B29C2043/3652;;B30B11/001;;B29C43/10;;B28B3/003;;B29L2023/00;;B30B15/302;;B29C2043/3628;;B29C43/146;;B29C43/006;;B01D69/04;;B01D2323/10;;B01D2323/24;;B01D67/00411,B01D67/00;;B01D71/02;;B28B3/00;;B29C33/40;;B29C43/00;;B29C43/10;;B29C43/14;;B30B11/00;;B30B15/30,26457;;264/313;;X26432;;425/405.2;;X425DIG044,0,0,,,,EXPIRED
858,GB,B,GB 2418077 B,171-784-495-841-820,2007-04-11,2007,GB 0518357 A,2005-09-08,US 93600404 A,2004-09-08,Seat power bus with discrete connection ports,,BOEING CO,CALLAHAN KEVIN S;;LAIB TREVOR M;;MITCHELL BRADLEY J;;HENLEY JAMES T,,https://lens.org/171-784-495-841-820,Granted Patent,no,5,0,5,5,0,B60R16/0207;;B64D11/06;;H01R25/16;;B64D11/0624;;B60R16/0215;;H01R25/16;;H02G3/04;;H02G3/385;;B60R16/0207;;H01R25/16;;B64D11/0624;;B64D11/06,H01R25/16;;B60R16/02;;H02G3/04;;H02G3/38,H2C CCL           CCL;;H2C CCM           CCM;;H2C CEG           CEG;;H2E ECJE          ECJE;;H2E EDBB          EDBB;;H2E EDCG          EDCG;;U1S S1839;;U1S S1857,0,0,,,,ACTIVE
859,WO,A2,WO 2004/047751 A2,090-933-334-087-900,2004-06-10,2004,US 0337461 W,2003-11-25,US 42910502 P,2002-11-26,CALCILYTIC COMPOUNDS,Novel calcilytic compounds and methods of using them are provided.,SMITHKLINE BEECHAM CORP;;MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/090-933-334-087-900,Patent Application,yes,2,8,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/34;;C07C217/36;;C07C229/00,,5,3,012-350-880-278-92X;;050-666-092-844-379;;018-257-117-484-529,10.1016/0143-4160(90)90032-p;;2194657;;10.1016/0143-4160(90)90033-q;;2194658;;1964812;;10.1007/bf01116610,"BROWN ET AL., NATURE, vol. 366, 1993, pages 574;;NEMETH ET AL., CELL CALCIUM, vol. 11, 1990, pages 319;;NEMETH, CELL CALCIUM, vol. 11, 1990, pages 323;;ZAIDI, BIOSCIENCE REPORTS, vol. 10, 1990, pages 493;;See also references of EP 1569892A4",PENDING
860,CY,T1,CY 1113083 T1,154-761-373-669-059,2016-04-13,2016,CY 121100784 T,2012-09-03,EP 03783752 A;;US 42910502 P,2002-11-26,ΑΣΒΕΣΤΙΟΛΥΤΙΚΕΣ ΕΝΩΣΕΙΣ,Παρέχονται καινοφανείς ασβεστιολυτικές ενώσεις και μέθοδοι χρήσης αυτών.,GLAXOSMITHKLINE LLC,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/154-761-373-669-059,Granted Patent,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C229/00;;A61K31/185;;A61K31/21;;A61P19/00;;A61P19/08;;C07C217/32;;C07C217/34;;C07C217/36,,0,0,,,,ACTIVE
861,NO,B1,NO 332304 B1,154-371-075-690-163,2012-08-20,2012,NO 20053071 A,2005-06-22,US 42910502 P;;US 0337461 W,2002-11-26,Kalsilytiske forbindelser.,Nye kalsilytiske forbindelser og fremgangsmåter for anvendelse av dem er tilveiebrakt.,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M,,https://lens.org/154-371-075-690-163,Granted Patent,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/36;;A61K31/195;;A61P19/00;;C07C217/34;;C07C229/00,,0,0,,,,EXPIRED
862,DE,C3,DE 1950501 C3,173-428-266-173-859,1974-01-17,1974,DE 1950501 A,1969-10-07,US 76720468 A,1968-10-14,DE 1950501 C3,,"THE AIR PREHEATER CO. INC., WINDSOR, CONN. (V.ST.A.)","BAKKER, LUBERTUS;;KRUMM, EUGENE DONALD;;WELLSVILLE, N.Y.;;CONDE, JAMES CALLAHAN, PITTSBURGH, PA.",,https://lens.org/173-428-266-173-859,Granted Patent,no,0,0,14,14,0,F23G5/444;;F23G5/444,F23G5/44,,0,0,,,,EXPIRED
863,US,B2,US 8033501 B2,018-906-744-492-04X,2011-10-11,2011,US 15057805 A,2005-06-10,US 15057805 A,2005-06-10,Method and apparatus for attaching electrically powered seat track cover to through hole seat track design,"A system for communicating electrical signals between two spaced apart seat assemblies on a mobile platform, for example an aircraft. The seat assemblies are secured to seat tracks mounted on a floor of the aircraft cabin. The seat tracks have a plurality of spaced apart holes that enable seat assembly mounting. A seat track cover is snap-fit onto one or more seat track mount devices. Each of the seat track mount devices includes one or more cleats or knobs that can be snap fit into the openings in the seat track to quickly and easily secure the seat track cover to the seat track. The seat track cover and mount devices enable a simple, planar seat track having spaced apart holes to be employed, rather than a C-shaped seat mounting track.",BOEING CO,CALLAHAN KEVIN S;;MITCHELL BRADLEY J;;LAIB TREVOR M;;EBNER JAMES E,BOEING COMPANY THE (2005-08-24),https://lens.org/018-906-744-492-04X,Granted Patent,yes,14,15,5,5,0,B64C1/20;;B64C1/20;;H02G3/00;;H02G3/00;;H01R13/62933;;H01R13/62933;;H02G11/00;;H02G11/00,B64D11/06,244/118.6;;X244122 R;;439/110;;X174 74 R,1,0,,,"Extended-European Search Report for corresponding European Application 06252904.5-2207 / 1732188 dated Feb. 4, 2011.",ACTIVE
864,NO,L,NO 20031837 L,047-457-621-789-047,2003-06-20,2003,NO 20031837 A,2003-04-24,US 24300600 P;;US 0146184 W,2000-10-25,Kalsilytiske forbindelser,,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP KUMAR;;BURGESS JOELLE L;;CALLAHAN JAMES F;;LAGO MARIA A,,https://lens.org/047-457-621-789-047,Abstract,no,0,0,20,20,0,A61K31/565;;A61K31/59;;A61K31/66;;A61K38/23;;A61K45/06;;C07D213/84;;A61P1/02;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P35/04;;A61P43/00;;A61P5/18;;A61P5/22;;C07D213/63;;C07D213/84;;A61K31/59;;A61K31/565;;A61K31/66;;A61K45/06;;A61K38/23,A61K31/137;;A61K31/44;;A61K31/565;;A61K31/59;;A61K31/593;;A61K31/66;;A61K38/00;;A61K38/23;;A61K45/00;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P5/22;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P35/04;;A61P43/00;;C07D213/84,,0,0,,,,DISCONTINUED
865,EP,A3,EP 0214738 A3,051-650-886-876-487,1987-06-03,1987,EP 86305748 A,1986-07-25,US 76992585 A,1985-08-26,POLYOXOMETALATE-MODIFIED CARBON ELECTRODES AND USES THEREFOR,"Improved activated carbon electrodes are disclosed, which electrodes have increased charge storage capacity. Such improved electrodes are incorporated into energy storage devices such as electrical double layer capacitors. The improved charge storage capacity is due to the adsorption of polyoxometalate compounds into the activated carbon, which compounds are capable of reversible redox reactions and so provide a secondary charge storage mechanism without decreasing the charge storage ability of the activated carbon.",THE STANDARD OIL COMPANY,"CALLAHAN, JAMES L.;;DESMOND, MICHAEL J.;;CUELLAR, EDWARD A.;;CURRIE, JOHN C.",,https://lens.org/051-650-886-876-487,Search Report,yes,1,0,7,7,0,H01M4/5825;;H01M4/583;;H01M10/05;;Y02E60/10;;H01G11/32;;H01G11/34;;H01G4/002;;H01M4/5825;;Y02E60/13;;H01M4/583;;H01M10/05;;H01G11/54;;H01G11/52;;H01G11/32;;H01G11/34,H01G9/00;;H01G11/22;;H01G11/24;;H01G11/26;;H01G11/30;;H01G11/42;;H01G11/46;;H01G11/86;;H01M4/133;;H01M4/58;;H01M4/583;;H01M10/05;;H01M10/0566;;H01M10/36,,2,0,,,"CHEMICAL ABSTRACTS, vol. 101, no. 16, 15th October 1984, page 738, abstract no. 142440w, Columbus, Ohio, US; & JP-A-59 60 818 (TEIJIN LTD) 06-04-1984;;CHEMICAL ABSTRACTS, vol. 99, no. 8, 22nd August 1983, page 441, abstract no. 60780h, Columbus, Ohio, US; S. MEGURO et al.: ""Modified electrodes with ion associate complexes of heteropoly acids"", & DENKI KAGAKU OYOBI KOGYO BUTSURI KAGAKU 1983, 51(1), 87-8",DISCONTINUED
866,US,A,US 4684621 A,053-357-186-301-762,1987-08-04,1987,US 85287086 A,1986-04-16,US 85287086 A;;US 67382984 A,1984-11-21,Methods of producing vasodilation or antioxytocic activity,"Certain vasopressin-like peptides, which have an acyclic unit at position 1 and which have an .omega.-amino- or guanidinoalkyl substituent attached to the cysteine in the 6-position of the ring, have V.sub.1 -vasopressin and oxytocin antagonist activity. A species of this series of new compounds is [1-desaminopenicillamine-2-(O-ethyl-D-tyrosine)-8-(1,4-diaminobutane)-9-de sglycinamide]-vasopressin.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES F;;HUFFMAN WILLIAM F;;MOORE MICHAEL L;;YIM NELSON C,,https://lens.org/053-357-186-301-762,Granted Patent,yes,3,5,1,20,3,A61K38/00;;C07K7/16;;Y10S930/15;;C07K7/16;;A61K38/00;;Y10S930/15,A61K38/00;;C07K7/16,514/11,8,3,082-931-819-394-264;;066-417-528-968-713;;014-946-675-773-50X,10.1021/jm00191a019;;458806;;926126;;10.1021/jm00219a026;;10.1021/jm00323a001;;5969030,"Rudinger, Peptide Hormones, Parson (ed), U. Park Press, Baltimore, 1976 pp. 1 7.;;J. Lowbridge et al., J. Med. Chem. 22 565 (1979).;;M. Manning et al., J. Med. Chem. 20 1228 (1977).;;J. Bankowski et al., J. Med. Chem. 21 350 (1978).;;H. Schulz et al., J. Med. Chem. 9 647 (1966).;;Derwent Abstract of European Patent No. 112,809 A.;;M. Manning et al., J. Med. Chem. 25 (1982).;;Peptides: Chemistry, Structure and Biology (Ann Arbor Sciences) 737 (1975).",EXPIRED
867,CA,A,CA 1268033 A,132-949-776-805-517,1990-04-24,1990,CA 514106 A,1986-07-18,US 76992585 A,1985-08-26,POLYOXOMETALATE MODIFIED CARBON ELECTRODES AND USES THEREFOR,"POLYOXOMETALATE-MODIFIED CARBON ELECTRODES AND USES THEREFOR Improved activated carbon electrodes are disclosed, which electrodes have increased charge storage capacity. Such improved electrodes are incorporated into energy storage devices such as electrical double layer capacitors. The improved charge storage capacity is due to the adsorption of polyoxometalate compounds into the activated carbon, which compounds are capable of reversible redox reactions and so provide a secondary charge storage mechanism without decreasing the charge storage ability of the activated carbon.",STANDARD OIL CO OHIO,CALLAHAN JAMES L;;CUELLAR EDWARD A;;DESMOND MICHAEL J;;CURRIE JOHN C,,https://lens.org/132-949-776-805-517,Granted Patent,no,0,0,7,7,0,H01M4/5825;;H01M4/583;;H01M10/05;;Y02E60/10;;H01G11/32;;H01G11/34;;H01G4/002;;H01M4/5825;;Y02E60/13;;H01M4/583;;H01M10/05;;H01G11/54;;H01G11/52;;H01G11/32;;H01G11/34,H01G9/00;;H01G11/22;;H01G11/24;;H01G11/26;;H01G11/30;;H01G11/42;;H01G11/46;;H01G11/86;;H01M4/133;;H01M4/58;;H01M4/583;;H01M10/05;;H01M10/0566;;H01M10/36,31-106,0,0,,,,EXPIRED
868,US,A1,US 2006/0058391 A1,157-126-321-659-12X,2006-03-16,2006,US 53641605 A,2005-05-25,US 53641605 A;;US 42910502 P;;US 0337461 W,2002-11-26,Calcilytic compounds,Novel Calcilytic compounds and methods of using them are provided.,SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES F,GLAXOSMITHKLINE LLC (2003-11-19),https://lens.org/157-126-321-659-12X,Patent Application,yes,26,3,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,A61K31/195;;C07C217/34;;C07C217/36;;C07C229/00;;C07C229/64,514/567;;562/445;;560/60,0,0,,,,EXPIRED
869,WO,A3,WO 2004/047751 A3,005-461-832-112-739,2004-08-19,2004,US 0337461 W,2003-11-25,US 42910502 P,2002-11-26,CALCILYTIC COMPOUNDS,Novel calcilytic compounds and methods of using them are provided.,SMITHKLINE BEECHAM CORP;;MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/005-461-832-112-739,Search Report,yes,1,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/34;;C07C217/36;;C07C229/00,,0,0,,,,PENDING
870,BG,B1,BG 64581 B1,019-680-389-369-713,2005-08-31,2005,BG 10329999 A,1999-03-31,US 9718001 W;;US 2732096 P;;US 4377697 P,1996-10-02,VITRONECTINE RECEPTOR ANTAGONISTS,"The compounds are useful for the treatment of osteoporosis, angiogenesis, tumour growth, metastasis, atherosclerosis, restenosis and inflammations. They have a structure with benzodiazepinyl nucleus and are antagonists of vitronectine receptor.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES;;COUSINS RUSSELL;;KEENAN RICHARD;;KWON CHET;;MILLER WILLIAM;;UZINKAS IRENE,,https://lens.org/019-680-389-369-713,Granted Patent,no,0,0,59,64,0,A61K31/55;;A61K45/06;;C07D223/16;;C07D401/12;;C07D403/12;;C07D417/12;;Y02P20/582;;Y02P20/55;;A61P19/10;;A61P29/00;;A61P35/00;;A61P35/04;;A61P43/00;;A61P9/00;;A61P9/10;;A61K33/243;;C07D223/00;;A61K33/243,C07D223/00;;A61K31/415;;A61K31/44;;A61K31/445;;A61K31/47;;A61K31/4704;;A61K31/495;;A61K31/52;;A61K31/55;;A61K31/551;;A61K33/243;;A61K45/06;;A61P9/00;;A61P9/10;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D223/16;;C07D233/56;;C07D233/64;;C07D235/18;;C07D235/22;;C07D243/14;;C07D401/00;;C07D401/12;;C07D401/14;;C07D403/12;;C07D413/12;;C07D417/12;;C07D487/00,,0,0,,,,EXPIRED
871,US,B2,US 7514473 B2,070-648-323-387-31X,2009-04-07,2009,US 53641605 A,2005-05-25,US 53641605 A;;US 42910502 P;;US 0337461 W,2002-11-26,Calcilytic compounds,Novel Calcilytic compounds and methods of using them are provided.,SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,GLAXOSMITHKLINE LLC (2003-11-19),https://lens.org/070-648-323-387-31X,Granted Patent,yes,48,10,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C229/00;;A61K31/195;;C07C217/34;;C07C217/36,514/567;;562/442,14,4,036-156-900-072-948;;052-282-079-353-17X;;047-288-123-595-421;;052-282-079-353-17X,6102605;;10.1021/jm00177a015;;8257738;;10.1016/0731-7085(93)80182-z;;10.1016/s0040-4039(97)01421-4;;8257738;;10.1016/0731-7085(93)80182-z,"U.S. Appl. No. 10/587,771, filed Jan. 2005, Marquis et al.;;U.S. Appl. No. 10/587,771, Marquis et al., Calcilytic Compounds, filed Feb. 4, 2005, published Aug. 25, 2005 (see WO 05/077892 A1).;;CA Abstract DN 88:22352 Dr. Andreu. 1-Aryloxy-2-hydroxy-3-alkylaminopropanes. Spanish Application 442062. Apr. 1, 1977.;;CA Abstract DN 85:142815 Dr. Andreu. 1-Aryloxy-3-(aralkylamino)-2-propanols. Spanish Application 421076. Apr. 1, 1986.;;CA Abstract DN 117:7640 Bercher, H. and Grisk, S. (to Ernst-Moritz-Arndt Univ.) Process for the preparation of 1-(dihalophenoxy)-3-[(1,1-dimethyl-2-phenylethyl)amino]-2-propanols and their use as beta-adrenergic agaonists or antagonists. German (DDR) Patent 298506. Feb. 27, 1992.;;Castedo et al., ""Bloqueantes beta-Adrenergicos: Sintesis Del (R)-1-[(1,1-Dimetil-2-Feniletil)Amino]-3-(3,4-Dichlorofenox])-2-Propanol"", Anales De Quimica, vol. 80, No. 3, pp. 281-294 (1984) (Spanish).;;F. Espinosa and A. Paniello, Anales De Quimica, vol. 77, No. 1, pp. 22-27 (1981) (Spanish).;;Abstract 91-194494/27 (Derwent Information Ltd.) Geisen et al. Use of 3-amino-propan-1,2-di:ol derivatives as racemate, Enantiomeric mixture of pure enantiomer in treatment of diabetes melliltus. German Patent DE 40 40 186 A1. Jun. 27, 1991.;;Kreighbaum et al., ""Antihypertensive Indole Derivatives of Phenoxypropanolamines with beta-Adrenergic Receptor Antagonist and Vasodilating Activity"", J. Med. Chem, vol. 23, No. 3, pp. 285-289 (1980).;;B. Law and L. Stafford, Journal of Pharmaceutical & Biomedical Analysis, vol. II, No. 8, pp. 729-736 (1993).;;CA Abstract DN 93:167911 Montoro, F. et al. [to Especialidades Latinas Medicamentos Universales) 1-(-4-Chloro-alpha,alpha-dibenzomethylbenzenoethanamino)-2-hydroxy-3-(aryloxy)propanes. Spanish Application 480066. Apr. 1, 1980.;;Shuker et al., ""The Application of High-Throughput Synthesis and Purification to the Preparation of Ethanolamines"", Tetrahedron Letters, vol. 38, No. 35, pp. 6149-6152 (1997).;;CA Abstract Geisen et al. Use of 3-amino-propan-1,2-di:ol derivatives as racemate, Enantiomeric mixture of pure enantiomer in treatment of diabetes mellitus. German Patent DE 40 40 186 A1.;;B. Law and L. Stafford, Journal of Pharmaceutical & Biomedical Analysis, vol. II, No. 8, pp. 729-736 (1993).",INACTIVE
872,PL,A1,PL 376965 A1,136-155-195-481-113,2006-01-09,2006,PL 37696503 A,2003-11-25,US 42910502 P,2002-11-26,CALCILYTIC COMPOUNDS,,SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/136-155-195-481-113,Patent Application,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/54;;A61K31/21;;A61P19/10;;C07C217/34;;C07C217/36;;C07C229/00,,0,0,,,,EXPIRED
873,PE,A1,PE 20040845 A1,150-524-340-629-259,2004-11-28,2004,PE 2003001196 A,2003-11-25,US 42910502 P,2002-11-26,COMPUESTOS CALCILITICOS,"SE REFIERE A COMPUESTOS DE FORMULA I DONDE R1 Y R5 SON H, HALO; R2, R3 Y R4 SON H, HALO Y J-K; DONDE J ES UN ENLACE COVALENTE, ALQUILENO O ALQUENILO Y K ES CO2R8; R8 ES H O ALQUILO; R6 ES H, ALQUILO; R7 ES ARILO, ARILO CONDENSADO, DIHIDRO, TETRAHIDRO ARILO CONDENSADO, HETEROARILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS CLORHIDRATO DE (E)-3-{3,4-DIFLUOR-5-[(R)-2-HIDROXI-3-(2-INDAN-2-IL-1,1-DIMETILETILAMINO)-PROPOXI]-FENIL}-ACRILICO, CLORHIDRATO DE ACIDO 3-{3,4-DIFLUOR-5-[(R)-2-HIDROXI-3-(2-INDAN-2-IL-1,1-DIMETILETILAMINO)-PROPOXI]-FENIL}-ACRILICO, CLORHIDRATO DE ESTER ETILICO DEL ACIDO 3-{3,4-DIFLUOR-5-[(R)-2-HIDROXI-3-(2-INDAN-2-IL-1,1-DIMETIL-ETIL-AMINO)-PROPOXI]-FENIL}-PENTANOICO, ENTRE OTROS. SE REFIERE TAMBIEN A COMPOSICIONES FARMACEUTICAS. LOS COMPUESTOS MENCIONADOS INHIBEN LA ACTIVIDAD DEL RECEPTOR DE CALCIO Y SON UTILES PARA EL TRATAMIENTO DE TRASTORNO OSEO COMO FRACTURAS, OSTEOARTRITIS, ARTRITIS REUMATOIDEA",SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/150-524-340-629-259,Patent Application,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C57/30;;C07C62/04;;C07C217/34;;C07C217/36;;C07C229/00,,0,0,,,,EXPIRED
874,NZ,A,NZ 540275 A,174-943-963-610-877,2007-11-30,2007,NZ 54027503 A,2003-11-25,US 42910502 P;;US 0337461 W,2002-11-26,Calcilytic compounds and their use as calcium receptor antagonists,"Calcilytic compounds of formula (I), pharmaceutically acceptable salts and complexes thereof are disclosed, wherein: R1 and R5 are independently selected from the group consisting of H and halogen; R2 and R3 are independently selected from the group consisting of H, halogen and J-K wherein: J is a covalent bond, alkylene or alkenyl: and K is selected from the group of CO2R8, such that R8 is H or alkyl; R4 is J1-K1 wherein: J1 represents C2-C4 alkylene or C2-C4 alkenyl, and K1 represents CO2H, CO2Me or CO2Et; R6 is selected from the group consisting of H or alkyl; R7 is indanyl, unsubstituted or substituted with any substituent selected from the group consisting of OH, halogen, C1-4 alkyl, C1-4 alkoxy, C3-6 cycloalkyl CF3, OCF3, CN and NO2. These calcilytic compounds are suitable for increasing serum parathyroid hormone levels in mammals; and for treating disease or disorder characterized by abnormal bone or mineral homeostasis, wherein the bone or mineral disorder is selected from the group consisting of osteosarcoma, periodontal disease, fracture healing, osteoathritis, rheumatoid arthritis, Paget's decease, humoral hypercalcemia malignancy, and osteoporosis.",SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/174-943-963-610-877,Patent Application,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/34;;C07C217/36;;C07C229/00,,0,0,,,,DISCONTINUED
875,DE,A1,DE 1543316 A1,193-004-152-512-986,1969-12-11,1969,DE 1543316 A,1966-09-09,US 49229365 A,1965-10-01,Verfahren zur Herstellung von substituierten Diphenylmethanen,,ARMOUR & CO,E TIEFENTHAL HARLAN;;JUNGERMANN ERIC;;JAMES MILLER JUN EUGENE;;JOSEPH CALLAHAN JOHN,,https://lens.org/193-004-152-512-986,Patent Application,no,0,0,3,4,0,C07C37/20;;C07C37/115,C07C37/11;;C07C37/20,,0,0,,,,DISCONTINUED
876,US,A1,US 2011/0054021 A1,071-446-959-635-412,2011-03-03,2011,US 89464410 A,2010-09-30,US 89464410 A;;US 39328409 A;;US 53641605 A;;US 0337461 W;;US 42910502 P,2002-11-26,Calcilytic Compounds,Novel calcilytic compounds and methods of using them are provided.,GLAXOSMITHKLINE LLC,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/071-446-959-635-412,Patent Application,yes,30,1,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,A61K31/216;;A61K31/195;;A61P5/18;;C07C217/34;;C07C217/36;;C07C229/00,514/510;;514/567,0,0,,,,EXPIRED
877,NO,D0,NO 20031837 D0,090-756-693-096-070,2003-04-24,2003,NO 20031837 A,2003-04-24,US 24300600 P;;US 0146184 W,2000-10-25,Kalsilytiske forbindelser,,SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP KUMAR;;BURGESS JOELLE L;;CALLAHAN JAMES F;;LAGO MARIA A,,https://lens.org/090-756-693-096-070,Patent Application,no,0,0,20,20,0,A61K31/565;;A61K31/59;;A61K31/66;;A61K38/23;;A61K45/06;;C07D213/84;;A61P1/02;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/14;;A61P35/00;;A61P35/04;;A61P43/00;;A61P5/18;;A61P5/22;;C07D213/63;;C07D213/84;;A61K31/59;;A61K31/565;;A61K31/66;;A61K45/06;;A61K38/23,A61K31/137;;A61K31/44;;A61K31/565;;A61K31/59;;A61K31/593;;A61K31/66;;A61K38/00;;A61K38/23;;A61K45/00;;A61K45/06;;A61P1/02;;A61P3/14;;A61P5/18;;A61P5/22;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;A61P35/04;;A61P43/00;;C07D213/84,,0,0,,,,DISCONTINUED
878,AU,B2,AU 2003/291157 B2,132-513-992-407-858,2011-01-20,2011,AU 2003/291157 A,2003-11-25,US 42910502 P;;US 0337461 W,2002-11-26,Calcilytic compounds,,SMITHKLINE BEECHAM CORP,CASILLAS LINDA N;;CALLAHAN JAMES FRANCIS;;RAMANJULU JOSHI M;;MARQUIS ROBERT W,,https://lens.org/132-513-992-407-858,Granted Patent,no,1,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/36;;C07C217/34;;C07C229/00,,0,0,,,,EXPIRED
879,FR,B1,FR 2561311 B1,165-299-240-960-581,1990-07-20,1990,FR 8503735 A,1985-03-14,US 59066184 A,1984-03-19,SYSTEME EN VUE D'EMPECHER LES A-COUPS D'UN MOTEUR,,UNITED TECHNOLOGIES CORP,CALLAHAN DAVID JOHN;;MAZZAWY ROBERT SALEM;;STRYKER HOWARD YOUNG;;KELLY JAMES BAILEY,,https://lens.org/165-299-240-960-581,Granted Patent,no,0,0,8,8,0,F04D27/001;;F04D27/023;;F04D27/001;;F04D27/023,F02C9/18;;F02C9/28;;F02C9/52;;F04D27/02,,0,0,,,,EXPIRED
880,TW,A,TW 200946525 A,198-396-818-472-843,2009-11-16,2009,TW 98103479 A,2009-02-04,US 2656808 P,2008-02-06,Dual pharmacophores-PDE4-muscarinic antagonistics,"The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUO-LIANG;;WAN ZE-HONG;;YAN HONG-XING,,https://lens.org/198-396-818-472-843,Patent of Addition,no,0,0,21,21,0,C07D471/04;;C07D519/00;;A61P1/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P11/08;;A61P17/04;;A61P17/06;;A61P27/02;;A61P37/08;;C07D471/04;;C07D519/00,C07D471/04;;A61K31/437;;A61P11/00,,0,0,,,,PENDING
881,MX,A,MX 9102311 A,015-150-715-236-489,1993-01-29,1993,MX 9102311 A,1991-11-29,US 62097890 A,1990-11-30,INHIBIDORES DE PROTEASA DE VIH.,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS;;MOORE MICHAEL LEE;;NEWLANDER KENNETH ALLEN,,https://lens.org/015-150-715-236-489,Patent Application,no,0,0,10,10,0,A61K38/00;;C07C69/757;;C07D223/04;;C07D223/06;;C07D233/64;;C07D243/08;;C07K5/06052;;C07K5/06139;;C07K5/0821;;C07K7/02;;A61P31/12;;A61P43/00;;A61P9/12;;C07D233/64;;C07C69/757;;C07K5/0821;;C07K5/06139;;C07D223/06;;C07D243/08;;A61K38/00;;C07K5/06052;;C07D223/04;;C07K7/02,A61K31/55;;A61K38/00;;A61K38/55;;A61P9/12;;A61P31/12;;A61P43/00;;C07C69/757;;C07D223/04;;C07D223/06;;C07D223/08;;C07D223/10;;C07D233/54;;C07D243/06;;C07D243/08;;C07K1/113;;C07K5/06;;C07K5/078;;C07K5/08;;C07K5/097;;C07K7/02;;C07K14/81;;C12N9/99,,0,0,,,,PENDING
882,US,B2,US 9227914 B2,036-912-560-816-322,2016-01-05,2016,US 201514640711 A,2015-03-06,US 201514640711 A;;US 201314069447 A;;US 201313764126 A;;US 89464410 A;;US 39328409 A;;US 53641605 A;;US 0337461 W;;US 42910502 P,2002-11-26,Calcilytic compounds,Novel calcilytic compounds and methods of using them are provided.,GLAXOSMITHKLINE LLC,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,GLAXOSMITHKLINE LLC (2003-11-19),https://lens.org/036-912-560-816-322,Granted Patent,yes,53,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,A61K31/195;;C07C217/30;;C07C217/32;;C07C217/34;;C07C217/36;;C07C217/54;;C07C229/00;;C07C229/34,,10,3,052-282-079-353-17X;;036-156-900-072-948;;047-288-123-595-421,8257738;;10.1016/0731-7085(93)80182-z;;6102605;;10.1021/jm00177a015;;10.1016/s0040-4039(97)01421-4,"Abstract 91-194494/27 (Derwent information Ltd.) Geisen et al. Use of 3-amino-propan-1,2-diol derivatives as racemate, Enantiomeric mixture of pure enantiomer in treatment of diabetes melliltus. German Patent DE 40 40 186 A1. Jun. 27, 1991.;;B. Law and L. Stafford, Journal of Pharmaceutical & Biomedical Analysis, vol. II, No. 8, pp. 729-736 (1993).;;CA Abstract DN 117:7640 Bercher, H. and Grisk, S. (to Ernst-Moritz-Arndt Univ.) Process for the preparation of 1-(dihalophenoxy)-3-[(1-1-dimethyl-2-phenylethyl(amino]-2-propanols and their use as beta-adrenergic agaonists or antagonists. German (DDR) Patent 298506. Feb. 27, 1992.;;CA Abstract DM 85:142815 Dr. Andreau. 1-Aryloxy-2-(aralkylamino)-2-propanols. Spanish Application 421076, Apr. 1, 1986.;;CA Abstract DN 88:22352 Dr. Andreu. 1-Aryloxy-2-hydroxy-3-alkylaminopropanes. Spanish Application 442062. Apr. 1, 1977.;;CA Abstract DN 93:167911 Montoro, F. et al. [to Especialidades Latinas Medicamentos Universales) 1-(4-Chloro-alpha,alpha-dibenzomethylbenzenoethanamino)-2-hydroxy-3-(aryloxy)propanes. Spanish Application 480066, Apr. 1, 1980.;;Castedo et al., ""Bloqueantes beta-Andrenergicos: Sintesis Del (R)-1-[(1,1-Dimetil-2-Feniletil)Amino]-3-(3,4-Dichlorofenox])-2-Propanol"", Anales De Quimica, vol. 80, No. 3, pp. 291-294 (1984) (Spanish).;;F. Espinosa and A. Paniello, Anales De Quimica, vol. 77, No. 1, pp. 22-27 (1981) (Spanish).;;Kreighbaum et al., ""Antihypertensive Indole Derivatives of Phenoxypropanolamines with beta-Adrenergic Receptor Antagonist and Vasodilating Activity"", J. Med. Chem, vol. 23, No. 3, pp. 285-289 (1980).;;Shuker et al., ""The Application of High-Throughput Synthesis and Purification to the Preparation of Ethanolamines"", Tetrahedron Letters, vol. 38, No. 35, pp. 6149-6152 (1997).",EXPIRED
883,MA,A1,MA 27528 A1,044-592-438-541-871,2005-09-01,2005,MA 28294 A,2005-05-23,US 42910502 P,2002-11-26,COMPOSES CALCILYTIQUES,L'invention concerne des nouveaux composés calcilytiques ainsi que des procédés permettant de les utiliser.,SMITHKLINE BEECHAM CORP,ROBERT W MARQUIS;;LINDA N CASILLAS;;JOSHI M RAMANJULU;;JAMES FRANCIS CALLAHAN,,https://lens.org/044-592-438-541-871,Granted Patent,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/34;;C07C217/36;;C07C229/00,,0,0,,,,ACTIVE
884,US,B1,US 10845239 B1,049-989-923-085-109,2020-11-24,2020,US 201916561704 A,2019-09-05,US 201916561704 A,2019-09-05,Laser-induced spectroscopy system and process,"Specialized linkage assemblies for Laser-Induced Breakdown Spectroscopy (“LIBS”) systems are provided. The linkage assemblies may facilitate the attachment of the laser housing of the LIBS system onto an existing sample supply chamber, such as a volumetric or gravimetric feeder. Generally, the linkage assemblies may comprise a specialized purge head and inert gas assembly that facilitate the attachment of the laser housing and may enhance the functionality of the LIBS system.",SCHENCK PROCESS LLC,MONAHAN RANDY JAMES;;NOWAKOWSKI JOHN JOSEPH;;CALLAHAN LAUREN ELIZABETH;;URBANEK GEOFFREY K,SCHENCK PROCESS LLC (2020-02-12),https://lens.org/049-989-923-085-109,Granted Patent,yes,16,0,1,7,0,G01J3/0202;;G01J3/0291;;G01J3/0208;;G01J3/0208;;G01J3/0243;;G01J3/443;;G01N21/01;;G01N21/718;;G01N21/718;;G01N21/85;;G01N2021/151,G01J3/30;;G01J3/02;;G01J3/443;;G01N21/71,,0,0,,,,ACTIVE
885,WO,A1,WO 1992/009297 A1,072-040-578-316-641,1992-06-11,1992,US 9108850 W,1991-11-25,US 62097890 A,1990-11-30,HIV PROTEASE INHIBITORS,"Peptide mimics, having a constrained peptide backbone conformation, are HIV protease inhibitors. A compound of this invention is, for example, 3-Benzyl-5(alaninyl-1-aminoethyl)-2,3,6,7-tetrahydro-N-azepinyl-2-propionyl-valinyl-valinyl methyl ester.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS;;MOORE MICHAEL LEE;;NEWLANDER KENNETH ALLEN,,https://lens.org/072-040-578-316-641,Patent Application,yes,1,28,10,10,0,A61K38/00;;C07C69/757;;C07D223/04;;C07D223/06;;C07D233/64;;C07D243/08;;C07K5/06052;;C07K5/06139;;C07K5/0821;;C07K7/02;;A61P31/12;;A61P43/00;;A61P9/12;;C07D233/64;;C07C69/757;;C07K5/0821;;C07K5/06139;;C07D223/06;;C07D243/08;;A61K38/00;;C07K5/06052;;C07D223/04;;C07K7/02,A61K38/00;;A61K38/55;;A61K31/55;;A61P9/12;;A61P31/12;;A61P43/00;;C07C69/757;;C07D223/04;;C07D223/06;;C07D223/08;;C07D223/10;;C07D233/54;;C07D243/06;;C07D243/08;;C07K1/113;;C07K5/06;;C07K5/078;;C07K5/08;;C07K5/097;;C07K7/02;;C07K14/81;;C12N9/99,,2,0,,,"Proceeding Of the Tenth American Peptide Symposium, issued 23-28 May 1987, HUFFMAN et al., ""Reverse Turn Mimics"", pages 105-108, see entire article.;;See also references of EP 0559793A4",PENDING
886,US,A,US 4550564 A,167-334-939-527-021,1985-11-05,1985,US 59066184 A,1984-03-19,US 59066184 A,1984-03-19,Engine surge prevention system,A surge prevention system for a fan jet engine of an aircraft serves to manifest a signal whenever pressure distortions at the engine's inlet is calculated by judiciously located total pressure probes mounted downstream of the fan on the fan struts in the fan discharge duct. The engine's bleed valve is automatically opened to prevent surge and the fuel control's speed sensor is automatically reset to compensate for any loss of thrust. Safety switches are included to render the system inoperative whenever the aircraft is in the margin of stall and the reset feature is rendered inoperative for normal bleed open operating conditions.,UNITED TECHNOLOGIES CORP,CALLAHAN DAVID J;;MAZZAWY ROBERT S;;STRYKER HOWARD Y;;KELLY JAMES B,UNITED TECHNOLOGIESE CORPORATION A DE CORP (1984-03-13),https://lens.org/167-334-939-527-021,Granted Patent,yes,6,31,8,8,0,F04D27/001;;F04D27/023;;F04D27/001;;F04D27/023,F02C9/18;;F02C9/28;;F02C9/52;;F04D27/02,60/39.093;;60/39.27;;60/39.29;;60/226.1,0,0,,,,EXPIRED
887,US,A1,US 2014/0057980 A1,037-554-124-304-75X,2014-02-27,2014,US 201314069447 A,2013-11-01,US 201314069447 A;;US 201313764126 A;;US 89464410 A;;US 39328409 A;;US 53641605 A;;US 0337461 W;;US 42910502 P,2002-11-26,CALCILYTIC COMPOUNDS,Novel calcilytic compounds and methods of using them are provided.,GLAXOSMITHKLINE LLC,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,GLAXOSMITHKLINE LLC (2003-11-19),https://lens.org/037-554-124-304-75X,Patent Application,yes,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C229/34;;C07C217/34;;C07C217/36;;C07C229/00,514/530;;514/567,0,0,,,,EXPIRED
888,PT,E,PT 1569892 E,076-667-773-754-609,2012-09-06,2012,PT 03783752 T,2003-11-25,US 42910502 P,2002-11-26,CALCILYTIC COMPOUNDS,,GLAXOSMITHKLINE LLC,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/076-667-773-754-609,Granted Patent,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C229/00;;A61K31/185;;A61K31/21;;A61P19/00;;A61P19/08;;C07C217/32;;C07C217/34;;C07C217/36,,0,0,,,,EXPIRED
889,US,B2,US 8399517 B2,083-439-694-367-212,2013-03-19,2013,US 89464410 A,2010-09-30,US 89464410 A;;US 39328409 A;;US 53641605 A;;US 0337461 W;;US 42910502 P,2002-11-26,Calcilytic compounds,Novel calcilytic compounds and methods of using them are provided.,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS;;GLAXOSMITHKLINE LLC,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/083-439-694-367-212,Granted Patent,yes,52,2,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,A61K31/195;;C07C217/34;;C07C217/36;;C07C229/00,514/567;;562/442,10,3,052-282-079-353-17X;;036-156-900-072-948;;047-288-123-595-421,8257738;;10.1016/0731-7085(93)80182-z;;6102605;;10.1021/jm00177a015;;10.1016/s0040-4039(97)01421-4,"Abstract 91-194494/27 (Derwent Information Ltd.) Geisen et al. Use of 3-amino-propan-1,2-di:ol derivatives as racemate, Enantiomeric mixture of pure enantiomer in treatment of diabetes mellitus. German Patent DE 40 40 186 A1. Jun. 27, 1991.;;B. Law and L. Stafford. Journal of Pharmaceutical & Biomedical Analysis. vol. II, No. 8, pp. 729-736 (1993).;;CA Abstract DN 117:7640 Bercher, H. and Grisk, S. (to Ernst-Moritz-Arndt Univ.) Process for the preparation of 1-(dihalophenoxy)-3-[(1,1-dimethyl-2-phenylethyl)amino]-2-propanols and their use as beta-adrenergic agaonists or antagonists. German (DDR) Patent 298506. Feb. 27, 1992.;;CA Abstract DN 85:142815 Dr. Andreu. 1-Aryloxy-3-(aralkylamino)-2-propanols. Spanish Application 421076. Apr. 1, 1986.;;CA Abstract DN 88:22352 Dr. Andreu. 1-Aryloxy-2-hydroxy-3-alkylaminopropanes. Spanish Application 442062. Apr. 1, 1977.;;CA Abstract DN 93:167911 Montoro, F. et al. [to Especialidades Latinas Medicamentos Universales) 1-(4-Chloro-alpha,alpha-dibenzomethylbenzenoethanamino)-2-hydroxy-3-(aryloxy)propanes. Spanish Application 480066. Apr. 1, 1980.;;Castedo et al., ""Bloqueantes beta-Andrenergicos: Sintesis Del (R)-1-[(1,1-Dimetil-2-Feniletil)Amino]-3-(3,4-Dichlorofenox])-2-Propanol"", Anales De Quimica, vol. 80, No. 3, pp. 291-294 (1984) (Spanish).;;F. Espinosa and A. Paniello, Anales De Quimica, vol. 77, No. 1, pp. 22-27 (1981) (Spanish).;;Kreighbaum et al., ""Antihypertensive Indole Derivatives of Phenoxypropanolamines with beta-Andrenergic Receptor Antagonist and Vasodilating Activity"", J. Med. Chem, vol. 23, No. 3, pp. 285-289 (1980).;;Shuker et al., ""The Application of High-Throughput Synthesis and Purification to the Preparation of Ethanolamines"", Tetrahedron Letters, vol. 38, No. 35, pp. 6149-6152 (1997).",EXPIRED
890,EP,A2,EP 1732188 A2,149-651-354-503-098,2006-12-13,2006,EP 06252904 A,2006-06-05,US 15057805 A,2005-06-10,Method and apparatus for attaching electrically powered seat track cover to through hole seat track,"A system for communicating electrical signals between two spaced apart seat assemblies on a mobile platform, for example an aircraft. The seat assemblies are secured to seat tracks mounted on a floor of the aircraft cabin. The seat tracks have a plurality of spaced apart holes that enable seat assembly mounting. A seat track cover is snap-fit onto one or more seat track mount devices. Each of the seat track mount devices includes one or more cleats or knobs that can be snap fit into the openings in the seat track to quickly and easily secure the seat track cover to the seat track. The seat track cover and mount devices enable a simple, planar seat track having spaced apart holes to be employed, rather than a C-shaped seat mounting track.
",BOEING CO,CALLAHAN KEVIN S;;MITCHELL BRADLEY J;;LAIB TREVOR M;;EBNER JAMES E,,https://lens.org/149-651-354-503-098,Patent Application,yes,1,1,5,5,0,B64C1/20;;B64C1/20;;H02G3/00;;H02G3/00;;H01R13/62933;;H01R13/62933;;H02G11/00;;H02G11/00,H02G3/00,,0,0,,,,ACTIVE
891,US,A1,US 2009/0048444 A1,164-507-788-690-756,2009-02-19,2009,US 25332708 A,2008-10-17,US 25332708 A;;US 38837506 A;;US 66515405 P,2005-03-25,"Process for Preparing Pyrido[2,3-d]pyrimidin-7-one and 3,4-Dihydropyrimido[4,5-d]pyrimidin-2(1H)-one Derivatives","The present invention is directed to a novel method of preparing of 2,4,8-trisubstituted pyrido[2,3-d]pyrimidin-7-one pharmacophores of Formula (II) or (IIa) wherein G1 is CH 2 ;G2 is CH;Rx is chloro, bromo, iodo, or O—S(O) 2 CF 3 ;R g is a C 1-10 alkyl;m is 0, or an integer having a value of 1, or 2;R 3 is a C 1-10 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl C 1-10 alkyl, aryl, arylC 1-10 alkyl, heteroaryl, heteroarylC 1-10 alkyl, heterocyclic or a heterocyclylC 1-10 alkyl moiety, and wherein each of these moieties may be optionally substituted. which comprises reacting a compound of the formula: wherein Ry is chloro, bromo, iodo, O—S(O) 2 CF 3 ; andRg is a C 1-10 alkyl; with a olefin forming reagent in a suitable base to yield a compound of Formula (II), or (IIa) wherein m=0 and oxidizing the sulphur as necessary or desired.",GLAXO GROUP LTD,CALLAHAN JAMES F;;BOEHM JEFFREY C;;WAN ZEHONG;;YAN HONGXING;;LIN XICHEN,,https://lens.org/164-507-788-690-756,Patent Application,yes,98,3,22,22,0,C07D471/04;;C07D487/04;;A61P43/00;;C07D471/04;;C07D487/04;;C07D487/04;;C07D471/04,C07D487/04;;C07D471/04,544/256;;544/279,0,0,,,,DISCONTINUED
892,GB,A,GB 2418077 A,161-318-910-584-040,2006-03-15,2006,GB 0518357 A,2005-09-08,US 93600404 A,2004-09-08,Seat power or data bus,"A power or data bus 32 is mounted in a seat track, for example of an aircraft. Connectors 60 are provided so that a seat connector 66 may provide power or data to the seat. The connectors may be recessed (see Fig 4) or may pivot between a recessed position and an extended position (See Figs 5A, 5B). A protective cover (221, Fig 5B) may protect the connector in its recessed position. The arrangement need not be used on a seat bus but to provide power or data to a variety of individual locations.",BOEING CO,CALLAHAN KEVIN S;;LAIB TREVOR M;;MITCHELL BRADLEY J;;HENLEY JAMES T,,https://lens.org/161-318-910-584-040,Patent Application,no,1,3,5,5,0,B60R16/0207;;B64D11/06;;H01R25/16;;B64D11/0624;;B60R16/0215;;H01R25/16;;H02G3/04;;H02G3/385;;B60R16/0207;;H01R25/16;;B64D11/0624;;B64D11/06,H01R25/16;;B60R16/02;;H02G3/04;;H02G3/38,H2C CCL           CCL;;H2C CCM           CCM;;H2C CEG           CEG;;H2E ECJE          ECJE;;H2E EDBB          EDBB;;H2E EDCG          EDCG;;U1S S1839;;U1S S1857,0,0,,,,ACTIVE
893,US,A,US 4604378 A,020-032-633-924-96X,1986-08-05,1986,US 67382984 A,1984-11-21,US 67382984 A,1984-11-21,Basic V1-vasopressin antagonists,"Certain vasopressin-like peptides, which have an acyclic unit at position 1 and which have an .omega.-amino- or guanidinoalkyl substituent attached to the cysteine in the 6-position of the ring, have V.sub.1 -vasopressin and oxytocin antagonist activity. A species of this series of new compounds is [1-desaminopenicillamine-2-(O-ethyl-D-tyrosine)-8-(1,4-diaminobutane)-9-de sglycinamide]-vasopressin.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES F;;HUFFMAN WILLIAM F;;MOORE MICHAEL L;;YIM NELSON C,SMITHKLINE BECKMAN CORPORATION (1984-11-19),https://lens.org/020-032-633-924-96X,Granted Patent,yes,2,18,18,20,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P5/00;;A61P9/08;;C07K7/16;;A61K38/00;;Y10S930/15,A61K38/00;;A61K38/095;;C07K14/575;;A61P5/00;;A61P9/08;;C07K1/113;;C07K7/06;;C07K7/16,514/11;;X2601125 R;;530/315,7,4,082-931-819-394-264;;066-417-528-968-713;;014-946-675-773-50X;;031-606-129-981-518,10.1021/jm00191a019;;458806;;926126;;10.1021/jm00219a026;;10.1021/jm00323a001;;5969030;;10.1021/jm00346a015;;7069719,"J. Lowbridge et al., J. Med. Chem., 22, 565 (1979).;;M. Manning et al., J. Med. Chem., 20, 1228 (1977).;;K. Bankowski et al., J. Med. Chem., 21, 350 (1978).;;H. Schulz et al., J. Med. Chem., 9, 647 (1966).;;Derwent Abstract of European Patent No. 112,809 A.;;M. Manning et al., J. Med. Chem., 25, 408 414 (1982).;;Peptides: Chemistry, Structure and Biology (Ann Arbor Sciences) 737 (1975).",EXPIRED
894,EP,A4,EP 1569892 A4,094-907-716-542-717,2010-09-15,2010,EP 03783752 A,2003-11-25,US 0337461 W;;US 42910502 P,2002-11-26,CALCILYTIC COMPOUNDS,,GLAXOSMITHKLINE LLC,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,GLAXOSMITHKLINE LLC (2010-03-03),https://lens.org/094-907-716-542-717,Search Report,no,6,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C229/00;;A61K31/185;;A61K31/21;;A61P19/00;;A61P19/08;;C07C217/32;;C07C217/34;;C07C217/36,,1,0,,,See also references of WO 2004047751A2,EXPIRED
895,US,A,US 5438118 A,109-890-437-912-038,1995-08-01,1995,US 6613693 A,1993-07-26,US 6613693 A;;US 62097890 A;;US 9108850 W,1990-11-30,HIV protease inhibitors,"Peptide mimics, having a constrained peptide backbone conformation, are HIV protease inhibitors. A compound of this invention is, for example, 3-Benzyl-5(alaninyl-1-aminoethyl)-2,3,6,7-tetrahydro-N-azepinyl-2-propiony l-valinyl-valinyl methyl ester.",SMITHKLINE BEECHMAN CORP,CALLAHAN JAMES F;;HUFFMAN WILLIAM F;;MOORE MICHAEL L;;NEWLANDER KENNETH A,SMITHKLINE BEECHAM CORP (1993-06-01);;GLAXOSMITHKLINE LLC (2009-10-27),https://lens.org/109-890-437-912-038,Granted Patent,yes,1,11,10,10,0,A61K38/00;;C07C69/757;;C07D223/04;;C07D223/06;;C07D233/64;;C07D243/08;;C07K5/06052;;C07K5/06139;;C07K5/0821;;C07K7/02;;A61P31/12;;A61P43/00;;A61P9/12;;C07D233/64;;C07C69/757;;C07K5/0821;;C07K5/06139;;C07D223/06;;C07D243/08;;A61K38/00;;C07K5/06052;;C07D223/04;;C07K7/02,A61K31/55;;A61K38/00;;A61K38/55;;A61P9/12;;A61P31/12;;A61P43/00;;C07C69/757;;C07D223/04;;C07D223/06;;C07D223/08;;C07D223/10;;C07D233/54;;C07D243/06;;C07D243/08;;C07K1/113;;C07K5/06;;C07K5/078;;C07K5/08;;C07K5/097;;C07K7/02;;C07K14/81;;C12N9/99,530/330;;530/331;;540/492;;540/526;;540/531,5,2,031-939-516-689-715;;055-017-891-566-848,10.1128/microbe.7.368.1;;2675834;;10.1016/0006-291x(89)92318-8,"Huffman et al. Proc. of the 10th American Peptide Symposium, issued 5/87 pp. 105 108.;;ASM News 7/90, vol. 56 p. 368.;;Blumenstein et al. Biochem Biophys. Res. Comm. vol. 163 p. 980 (1989).;;Bolis et al. J. Med Chem. vol. 30 p. 1730 (1987).;;Burger, Med. Chem. (1960) p. 565.",EXPIRED
896,US,B2,US 7207523 B2,114-493-388-577-465,2007-04-24,2007,US 93600404 A,2004-09-08,US 93600404 A,2004-09-08,Seat power bus with discrete connection ports,"A power/data bus for conducting at least one of data and power signals to a variety of different locations on a mobile platform. The bus has a plurality of discrete connection ports, and at least one conductive cable. The power/data bus extends across an area where access to at least one of data and electricity is desired. The discrete connection ports are spaced apart at different locations along the power/data bus. The conductive cable extends through the power/data bus and is connected to at least one of the discrete connection ports. The conductive cable conducts at least one of power and data signals between the discrete connection ports and a data/power source. At least one of the connection ports are operable to cooperate with a connector of an external device to supply at least one of power and data signals to the external device. The power/data bus, when used in an aircraft passenger cabin, eliminates the need to extend individual data and/or power cables to or between each passenger seat group.",BOEING CO,CALLAHAN KEVIN S;;LAIB TREVOR M;;MITCHELL BRADLEY J;;HENLEY JAMES T,BOEING COMPANY THE (2004-09-02),https://lens.org/114-493-388-577-465,Granted Patent,yes,18,47,5,5,0,B60R16/0207;;B64D11/06;;H01R25/16;;B64D11/0624;;B60R16/0215;;H01R25/16;;H02G3/04;;H02G3/385;;B60R16/0207;;H01R25/16;;B64D11/0624;;B64D11/06,B64D11/06;;B60R16/02;;H01R25/16,244/118.6;;439/210;;174/10,0,0,,,,ACTIVE
897,SI,T1,SI 1569892 T1,132-887-444-950-08X,2012-09-28,2012,SI 200332179 T,2003-11-25,US 42910502 P;;US 0337461 W;;EP 03783752 A,2002-11-26,CALCILYTIC COMPOUNDS,,GLAXOSMITHKLINE LLC,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/132-887-444-950-08X,Granted Patent,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C229/00;;A61K31/00;;A61P19/00;;C07C217/00;;C07C217/34;;C07C217/36;;C07C229/00,,0,0,,,,EXPIRED
898,TW,A,TW 200510276 A,158-493-272-182-142,2005-03-16,2005,TW 92132853 A,2003-11-24,US 42910502 P,2002-11-26,Calcilytic compounds,Novel calcilytic compounds and methods of using them are provided.,SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/158-493-272-182-142,Patent of Addition,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/48;;A61P19/00;;C07C217/34;;C07C217/36;;C07C229/00,,0,0,,,,EXPIRED
899,AU,A1,AU 2003/291157 A1,158-118-287-502-730,2004-06-18,2004,AU 2003/291157 A,2003-11-25,US 42910502 P;;US 0337461 W,2002-11-26,CALCILYTIC COMPOUNDS,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M,,https://lens.org/158-118-287-502-730,Patent Application,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/34;;C07C217/36;;C07C229/00,,0,0,,,,EXPIRED
900,EP,A4,EP 4025900 A4,108-636-720-977-961,2023-12-27,2023,EP 20861366 A,2020-08-21,US 201916561638 A;;US 201916561704 A;;US 2020/0047309 W,2019-09-05,LASER-INDUCED SPECTROSCOPY SYSTEM AND PROCESS,,SCHENCK PROCESS LLC,MONAHAN RANDY JAMES;;NOWAKOWSKI JOHN JOSEPH;;CALLAHAN LAUREN ELIZABETH;;URBANEK GEOFFREY K,,https://lens.org/108-636-720-977-961,Search Report,no,5,0,5,7,0,G01N21/718;;G01N21/01;;G01N33/222;;G01N21/718;;G01N2021/151;;G01J3/443;;G01J3/0291;;G01J3/0202;;G01J3/0208;;G01N21/85;;G01J3/0202;;G01J3/0208;;G01J3/0291;;G01J3/443;;G01N21/718;;G01N2021/151,G01N21/71;;G01J3/02;;G01J3/30;;G01J3/443;;G01N21/15;;G01N21/85,,1,0,,,See also references of WO 2021045911A1,PENDING
901,IS,A,IS 7880 A,110-721-521-610-399,2005-06-02,2005,IS 7880 A,2005-06-02,US 0337461 W;;US 42910502 P,2002-11-26,Efnasambönd sem hamla gegn virkni kalkviðtaka,,SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/110-721-521-610-399,Patent Application,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/34;;C07C217/36;;C07C229/00,,0,0,,,,EXPIRED
902,OA,A,OA 12962 A,114-288-786-822-611,2006-10-13,2006,OA 1200500152 A,2003-11-25,US 42910502 P,2002-11-26,Calcilytic compounds.,,SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;RAMANJULU JOSHI M;;CASILLAS LINDA N;;CALLAHAN JAMES FRANCIS,,https://lens.org/114-288-786-822-611,Granted Patent,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/34;;C07C217/36;;C07C229/00;;C07C229/00,,0,0,,,,EXPIRED
903,EP,A1,EP 3555078 A1,118-929-139-924-016,2019-10-23,2019,EP 17818302 A,2017-12-11,US 201662434013 P;;IB 2017057801 W,2016-12-14,BISARYL HETEROCYCLES AS NRF2 ACTI,,GLAXOSMITHKLINE IP DEV LTD,CALLAHAN JAMES FRANCIS;;DAVIS RODERICK S;;GOODWIN NICOLE CATHLEEN;;KERNS JEFFREY K,,https://lens.org/118-929-139-924-016,Patent Application,yes,0,0,5,5,0,C07D409/14;;C07D417/14;;C07D498/04;;C07D515/04;;A61P11/00;;A61P37/00;;A61K9/0019;;A61K9/0053;;A61K9/0073;;C07D243/08;;C07D285/36;;C07D291/08;;C07D409/14;;C07D513/04;;C07D515/04,C07D409/14;;A61K31/553;;A61K31/554;;A61P11/00;;A61P37/00;;C07D417/14;;C07D498/04;;C07D515/04,,0,0,,,,ACTIVE
904,NO,D0,NO 20031272 D0,141-114-623-991-68X,2003-03-19,2003,NO 20031272 A,2003-03-19,US 66872800 A;;US 0123760 W,2000-09-22,Fremgangsmåte og form for kald isopressing,,PRAXAIR TECHNOLOGY INC,APTE PRASAD S;;CALLAHAN SHAWN W;;SCHNEIDER JAMES S;;CHEN JACK C,,https://lens.org/141-114-623-991-68X,Patent Application,no,0,0,9,9,0,B01D67/0041;;B01D71/024;;B28B3/003;;B29C33/405;;B29C43/003;;B29C43/006;;B29C43/10;;B29C43/146;;B29C2043/3238;;B29C2043/3628;;B29C2043/3652;;B29L2023/00;;B30B11/001;;B30B15/302;;B01D69/04;;B01D2323/10;;B01D2323/24;;B29C43/003;;B29C33/405;;B29C2043/3238;;B29C2043/3652;;B30B11/001;;B29C43/10;;B28B3/003;;B29L2023/00;;B30B15/302;;B29C2043/3628;;B29C43/146;;B29C43/006;;B01D69/04;;B01D2323/10;;B01D2323/24;;B01D67/00411,B01D67/00;;B01D71/02;;B28B3/00;;B29C33/40;;B29C43/00;;B29C43/10;;B29C43/14;;B30B11/00;;B30B15/30,,0,0,,,,DISCONTINUED
905,EP,B1,EP 1569892 B1,174-613-181-652-608,2012-06-13,2012,EP 03783752 A,2003-11-25,US 0337461 W;;US 42910502 P,2002-11-26,CALCILYTIC COMPOUNDS,,GLAXOSMITHKLINE LLC,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,GLAXOSMITHKLINE LLC (2010-03-03),https://lens.org/174-613-181-652-608,Granted Patent,yes,7,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C229/00;;A61K31/185;;A61K31/21;;A61P19/00;;A61P19/08;;C07C217/32;;C07C217/34;;C07C217/36,,0,0,,,,EXPIRED
906,KR,A,KR 20220053654 A,195-349-877-904-81X,2022-04-29,2022,KR 20227010574 A,2020-08-21,US 201916561638 A;;US 201916561704 A;;US 2020/0047309 W,2019-09-05,레이저 유도 분광 시스템 및 방법,"레이저 유도 파괴 분광(""LIBS"") 시스템을 위한 특수 연결 조립체가 제공된다. 연결 조립체는 LIBS 시스템의 레이저 하우징을 부피 측정 또는 중량 측정 공급기와 같은 기존 샘플 공급 챔버에 쉽게 부착할 수 있다. 일반적으로, 연결 조립체는 레이저 하우징의 부착을 용이하게 하고 LIBS 시스템의 기능을 향상시킬 수 있는 특수 퍼지 헤드 및 불활성 가스 조립체를 포함할 수 있다.",SCHENCK PROCESS LLC,MONAHAN RANDY JAMES;;NOWAKOWSKI JOHN JOSEPH;;CALLAHAN LAUREN ELIZABETH;;URBANEK GEOFFREY K,,https://lens.org/195-349-877-904-81X,Patent Application,no,0,0,5,7,0,G01N21/718;;G01N21/01;;G01N33/222;;G01N21/718;;G01N2021/151;;G01J3/443;;G01J3/0291;;G01J3/0202;;G01J3/0208;;G01N21/85;;G01J3/0202;;G01J3/0208;;G01J3/0291;;G01J3/443;;G01N21/718;;G01N2021/151,G01J3/02;;G01J3/443;;G01N21/15;;G01N21/71,,0,0,,,,PENDING
907,KR,A,KR 20050086786 A,115-901-957-209-686,2005-08-30,2005,KR 20057009379 A,2005-05-25,US 42910502 P,2002-11-26,CALCILYTIC COMPOUNDS,Novel calcilytic compounds and methods of using them are provided.,SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/115-901-957-209-686,Patent Application,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/34;;C07C217/36;;C07C229/00,,0,0,,,,DISCONTINUED
908,EP,B1,EP 1732188 B1,129-021-354-723-355,2012-05-30,2012,EP 06252904 A,2006-06-05,US 15057805 A,2005-06-10,Method and apparatus for attaching electrically powered seat track cover to through hole seat track,,BOEING CO,CALLAHAN KEVIN S;;MITCHELL BRADLEY J;;LAIB TREVOR M;;EBNER JAMES E,,https://lens.org/129-021-354-723-355,Granted Patent,yes,1,0,5,5,0,B64C1/20;;B64C1/20;;H02G3/00;;H02G3/00;;H01R13/62933;;H01R13/62933;;H02G11/00;;H02G11/00,H02G3/00,,0,0,,,,ACTIVE
909,TW,B,TW I316511 B,135-481-683-115-478,2009-11-01,2009,TW 92132853 A,2003-11-24,US 42910502 P,2002-11-26,Calcilytic compounds,,SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/135-481-683-115-478,Granted Patent,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/34;;C07C217/36;;C07C229/00,,0,0,,,,EXPIRED
910,EP,A3,EP 1732188 A3,159-956-802-511-930,2011-03-09,2011,EP 06252904 A,2006-06-05,US 15057805 A,2005-06-10,Method and apparatus for attaching electrically powered seat track cover to through hole seat track design,"A system for communicating electrical signals between two spaced apart seat assemblies on a mobile platform, for example an aircraft. The seat assemblies are secured to seat tracks mounted on a floor of the aircraft cabin. The seat tracks have a plurality of spaced apart holes that enable seat assembly mounting. A seat track cover is snap-fit onto one or more seat track mount devices. Each of the seat track mount devices includes one or more cleats or knobs that can be snap fit into the openings in the seat track to quickly and easily secure the seat track cover to the seat track. The seat track cover and mount devices enable a simple, planar seat track having spaced apart holes to be employed, rather than a C-shaped seat mounting track.
",BOEING CO,CALLAHAN KEVIN S;;MITCHELL BRADLEY J;;LAIB TREVOR M;;EBNER JAMES E,,https://lens.org/159-956-802-511-930,Search Report,yes,1,0,5,5,0,B64C1/20;;B64C1/20;;H02G3/00;;H02G3/00;;H01R13/62933;;H01R13/62933;;H02G11/00;;H02G11/00,H02G3/00,,0,0,,,,ACTIVE
911,FR,A1,FR 2561311 A1,145-742-828-050-296,1985-09-20,1985,FR 8503735 A,1985-03-14,US 59066184 A,1984-03-19,SYSTEME EN VUE D'EMPECHER LES A-COUPS D'UN MOTEUR,"<P>L'INVENTION CONCERNE UN SYSTEME EN VUE D'EMPECHER LES A-COUPS D'UN MOTEUR.</P><P>CE SYSTEME ENGENDRE UN SIGNAL CHAQUE FOIS QUE DES DISTORSIONS DE PRESSION SONT DETECTEES A L'ENTREE DU MOTEUR PAR DES SONDES DE PRESSION TOTALE 20, 22, 24 JUDICIEUSEMENT LOCALISEES ET MONTEES EN AVAL DU VENTILATEUR DANS LE CONDUIT DE DECHARGE 12 DE CE DERNIER. LE CLAPET DE PURGE 44 DU MOTEUR EST AUTOMATIQUEMENT OUVERT POUR PREVENIR UN A-COUP, TANDIS QUE LE CAPTEUR DE VITESSE DE LA COMMANDE DE CARBURANT EST AUTOMATIQUEMENT REMIS A ZERO AFIN DE COMPENSER TOUTE PERTE DE POUSSEE.</P><P>L'INVENTION EST UTILISEE DANS LES MOTEURS A REACTION A DOUBLE FLUX POUR AVIONS EN VUE DE PREVENIR LES A-COUPS DANS LE FONCTIONNEMENT DU MOTEUR, TOUT EN COMPENSANT UNE PERTE DE POUSSEE EVENTUELLE.</P>",UNITED TECHNOLOGIES CORP,CALLAHAN DAVID JOHN;;MAZZAWY ROBERT SALEM;;STRYKER HOWARD YOUNG;;KELLY JAMES BAILEY,,https://lens.org/145-742-828-050-296,Patent Application,no,4,0,8,8,0,F04D27/001;;F04D27/023;;F04D27/001;;F04D27/023,F02C9/18;;F02C9/28;;F02C9/52;;F04D27/02,,0,0,,,,EXPIRED
912,AU,A,AU 1991/091223 A,168-606-123-076-718,1992-06-25,1992,AU 1991/091223 A,1991-11-25,US 62097890 A,1990-11-30,HIV PROTEASE INHIBITORS,,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS;;MOORE MICHAEL LEE;;NEWLANDER KENNETH ALLEN,,https://lens.org/168-606-123-076-718,Patent Application,no,0,6,10,10,0,A61K38/00;;C07C69/757;;C07D223/04;;C07D223/06;;C07D233/64;;C07D243/08;;C07K5/06052;;C07K5/06139;;C07K5/0821;;C07K7/02;;A61P31/12;;A61P43/00;;A61P9/12;;C07D233/64;;C07C69/757;;C07K5/0821;;C07K5/06139;;C07D223/06;;C07D243/08;;A61K38/00;;C07K5/06052;;C07D223/04;;C07K7/02,A61K31/55;;A61K38/00;;A61K38/55;;A61P9/12;;A61P31/12;;A61P43/00;;C07C69/757;;C07D223/04;;C07D223/06;;C07D223/08;;C07D223/10;;C07D233/54;;C07D243/06;;C07D243/08;;C07K1/113;;C07K5/06;;C07K5/078;;C07K5/08;;C07K5/097;;C07K7/02;;C07K14/81;;C12N9/99,,0,0,,,,PENDING
913,US,A1,US 2007/0018045 A1,183-108-113-453-358,2007-01-25,2007,US 15057805 A,2005-06-10,US 15057805 A,2005-06-10,Method of attaching electrically powered seat track cover to through hole seat track design,"A system for communicating electrical signals between two spaced apart seat assemblies on a mobile platform, for example an aircraft. The seat assemblies are secured to seat tracks mounted on a floor of the aircraft cabin. The seat tracks have a plurality of spaced apart holes that enable seat assembly mounting. A seat track cover is snap-fit onto one or more seat track mount devices. Each of the seat track mount devices includes one or more cleats or knobs that can be snap fit into the openings in the seat track to quickly and easily secure the seat track cover to the seat track. The seat track cover and mount devices enable a simple, planar seat track having spaced apart holes to be employed, rather than a C-shaped seat mounting track.",CALLAHAN KEVIN S;;MITCHELL BRADLEY J;;LAIB TREVOR M;;EBNER JAMES E,CALLAHAN KEVIN S;;MITCHELL BRADLEY J;;LAIB TREVOR M;;EBNER JAMES E,BOEING COMPANY THE (2005-08-24),https://lens.org/183-108-113-453-358,Patent Application,yes,99,16,5,5,0,B64C1/20;;B64C1/20;;H02G3/00;;H02G3/00;;H01R13/62933;;H01R13/62933;;H02G11/00;;H02G11/00,B64D11/06;;B64D25/00,244/118.6;;X24412200R,0,0,,,,ACTIVE
914,WO,A1,WO 2018/109643 A1,001-107-856-054-804,2018-06-21,2018,IB 2017057801 W,2017-12-11,US 201662434013 P,2016-12-14,BISARYL HETEROCYCLES AS NRF2 ACTI,"The present invention relates to bisaryl heterocycle compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to bisaryl heterocycles of Formula (I),",GLAXOSMITHKLINE IP DEV LTD,CALLAHAN JAMES FRANCIS;;DAVIS RODERICK S;;GOODWIN NICOLE CATHLEEN;;KERNS JEFFREY K,,https://lens.org/001-107-856-054-804,Patent Application,yes,28,9,5,5,0,C07D409/14;;C07D417/14;;C07D498/04;;C07D515/04;;A61P11/00;;A61P37/00;;A61K9/0019;;A61K9/0053;;A61K9/0073;;C07D243/08;;C07D285/36;;C07D291/08;;C07D409/14;;C07D513/04;;C07D515/04,C07D409/14;;A61K31/553;;A61K31/554;;A61P11/00;;A61P37/00;;C07D417/14;;C07D498/04;;C07D515/04,,42,26,067-540-319-320-152;;040-431-064-551-991;;040-431-064-551-991;;117-104-050-445-630;;036-696-966-106-757;;016-771-480-659-409;;056-302-568-463-40X;;036-491-941-724-533;;072-094-641-876-486;;035-681-747-570-877;;053-501-734-015-681;;025-344-212-761-140;;042-104-997-417-393;;044-688-797-366-91X;;030-272-147-467-375;;066-776-867-026-346;;087-472-043-506-186;;036-986-906-651-142;;128-583-555-247-584;;044-972-986-941-619;;018-275-584-239-994;;126-545-810-473-379;;022-171-015-959-156;;013-165-909-408-989;;099-893-220-873-704;;007-364-858-655-289,10.1021/jm9508853;;8667363;;10.1016/j.molmed.2011.02.006;;21459041;;10.1016/j.molmed.2011.02.006;;21459041;;10.1007/s00204-015-1557-y;;pmc6779142;;26194645;;19646463;;10.1016/j.taap.2009.07.024;;10.1126/scitranslmed.3002042;;pmc4927975;;21490276;;10.1371/journal.pone.0098671;;24910991;;pmc4049587;;pmc2563038;;10.1371/journal.pone.0003367;;18846238;;pmc2957774;;10.1124/jpet.110.170084;;20605904;;1942091;;10.1016/0022-2828(91)90133-7;;11110775;;10.1161/01.res.87.12.1172;;10.1371/journal.pone.0044899;;pmc3444497;;23028668;;pmc4418517;;24747945;;10.1016/j.yjmcc.2014.04.006;;19608979;;pmc2735849;;10.1161/circresaha.109.199919;;10.1016/j.yjmcc.2010.05.011;;20685357;;10.1523/jneurosci.4014-05.2005;;16267240;;pmc6725780;;19158945;;10.1371/journal.pone.0004253;;pmc2617762;;pmc3580177;;10.1158/1940-6207.capr-08-0028;;19138955;;21457933;;pmc3081196;;10.1016/j.ajpath.2011.01.036;;10.1167/iovs.12-10119;;pmc3428112;;22836768;;19914374;;10.1016/j.freeradbiomed.2009.11.007;;pmc2867209;;20478997;;10.1101/gad.568810;;24463449;;pmc3904618;;10.1172/jci70812;;24954650;;10.1016/j.aanat.2014.04.002;;23722164;;10.1016/j.freeradbiomed.2013.05.024;;pmc4130652;;10.1002/jps.2600660104;;833720,"CARMEN ALMANSA ET AL: ""Diphenylpropionic Acids as New AT 1 Selective Angiotensin II Antagonists"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 11, 1 January 1996 (1996-01-01), pages 2197 - 2206, XP055047700, ISSN: 0022-2623, DOI: 10.1021/jm9508853;;BOUTTEN A ET AL: ""NRF2 targeting: a promising therapeutic strategy in chronic obstructive pulmonary disease"", TRENDS IN MOLECULAR MEDICINE, vol. 17, no. 7, 1 July 2011 (2011-07-01), pages 363 - 371, XP028238947, ISSN: 1471-4914, [retrieved on 20110305], DOI: 10.1016/J.MOLMED.2011.02.006;;YAMADA, K. ET AL., BMC PULMONARY MEDICINE, vol. 16, 2016, pages 27;;BOUTTEN, A. ET AL., TRENDS MOL. MED., vol. 17, 2011, pages 363 - 371;;CHO, H.Y.; KLEEBERGER, S.R., ARCH TOXICOL., vol. 89, 2015, pages 1931 - 1957;;ZHAO, H. ET AL., AM J PHYSIOL LUNG CLEE MOL PHYSIOL, vol. 312, 18 November 2016 (2016-11-18), pages L155 - L162;;CHO, H.Y.; KLEEBERGER, S.R., TOXICOL. APPL. PHARMACOL., vol. 244, 2010, pages 43 - 56;;HARVEY, C. ET AL., SCI. TRANSL. MED., vol. 3, 2011, pages 78ra32;;NOAH, T.L. ET AL., PLOS ONE, vol. 9, no. 6, 2014, pages e98671;;CF, CHEN, J. ET AL., PLOS ONE., vol. 3, no. 10, 2008, pages e3367;;ALEKSUNES, L.M. ET AL., J. PHARMACOL. EXP. THER., vol. 335, 2010, pages 2 - 12;;SHELTON, L.M. ET AL., KIDNEY INTERNATIONAL., 19 June 2013 (2013-06-19);;CIRC, vol. 76, no. 2, 1987, pages 458 - 468;;J OF MOL & CELL CARDIO, vol. 23, no. 8, 1991, pages 899 - 918;;CIRC RES, vol. 87, no. 12, 2000, pages 1172 - 1179;;ARTERIOSCLER THROMB VASE BIOL, vol. 29, no. 11, 2009, pages 1843 - 5 1850;;PLOS ONE, vol. 7, no. 9, 2012, pages e44899;;ARTERIOSCLER THROMB VASE BIOL, vol. 29, no. 11, 2009;;J OF MOL & CELL CARDIO, vol. 72, 2014, pages 305 - 315;;PLOS ONE, vol. 7, no. 9, 2012, pages 1843 - 1850;;CIRC RES, vol. 105, no. 4, 2009, pages 365 - 374;;J OF MOL & CELL CARDIO, vol. 49, no. 4, 2010, pages 576 - 586;;OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, vol. 2013, 2013, pages 10;;BRAIN RES., vol. 1446, 12 January 2012 (2012-01-12), pages 109 - 18;;SHIH, A.Y., J. NEUROSCI., vol. 25, 2005, pages 10321 - 10335;;PAUPE V. ET AL., PLOS ONE, vol. 4, no. 1, 2009, pages e4253;;KHOR, T.O. ET AL., CANCER PREV. RES. (PHILA, vol. 1, 2008, pages 187 - 191;;SCHIMEL ET AL., AM. J. PATHOL., vol. 178, 2011, pages 2032 - 2043;;BITAR, M.S. ET AL., INVEST OPHTHALMOL. VIS. SCI., vol. 53, no. 9, 24 August 2012 (2012-08-24), pages 5806 - 5813;;CHOWDHRY S. ET AL., FREE RAD. BIOL. & MED., vol. 48, 2010, pages 357 - 371;;SHIMOZONO R. ET AL., MOLECULAR PHARMACOLOGY, vol. 84, 2012, pages 62 - 70;;OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, vol. 2013, 2013, pages 9;;DIPALI P.K. ET AL., INDIAN J CLIN BIOCHEM., vol. 25, no. 4, October 2010 (2010-10-01), pages 388 - 392;;SCHAFER, M. ET AL., GENES & DEVL., vol. 24, 2010, pages 1045 - 1058;;KIM, J.H. ET AL., J. CLIN. INVEST., vol. 124, no. 2, 3 February 2014 (2014-02-03), pages 730 - 41;;ANNALS OF ANATOMY - ANATOMISCHER ANZEIQER, vol. 196, no. 5, September 2014 (2014-09-01), pages 268 - 277;;LISK C. ET AL., FREE RADIC BIOL MED., vol. 63, October 2013 (2013-10-01), pages 264 - 273;;BERGE, J., PHARM. SCI., vol. 66, 1977, pages 1 - 19;;""Handbook of Pharmaceutical Salts; Properties, Selection and Use"", 2011, WILEY- VCH/VHCA;;""Remington's Pharmaceutical Sciences"", MACK PUBLISHING COMPANY;;""The Handbook of Pharmaceutical Additives"", GOWER PUBLISHING LIMITED;;""The Handbook of Pharmaceutical Excipients"", AMERICAN PHARMACEUTICAL ASSOCIATION AND THE PHARMACEUTICAL PRESS",PENDING
915,EP,A1,EP 0559793 A1,014-587-588-937-973,1993-09-15,1993,EP 92901654 A,1991-11-25,US 62097890 A,1990-11-30,HIV PROTEASE INHIBITORS.,"Des imitateurs de peptides possédant une conformation de squelette de peptide contrainte sont des inhibiteurs de la protéase du VIH. Un composé selon cette invention, est, par exemple, l'ester méthylique de 3-benzyl-5(alaninyl-1-aminoéthyl)-2,3,6,7-tétrahydro-N-azépinyl-2-proprionyl-valinyl-valinyle.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS;;MOORE MICHAEL LEE;;NEWLANDER KENNETH ALLEN,,https://lens.org/014-587-588-937-973,Patent Application,yes,0,0,10,10,0,A61K38/00;;C07C69/757;;C07D223/04;;C07D223/06;;C07D233/64;;C07D243/08;;C07K5/06052;;C07K5/06139;;C07K5/0821;;C07K7/02;;A61P31/12;;A61P43/00;;A61P9/12;;C07D233/64;;C07C69/757;;C07K5/0821;;C07K5/06139;;C07D223/06;;C07D243/08;;A61K38/00;;C07K5/06052;;C07D223/04;;C07K7/02,A61K31/55;;A61K38/00;;A61K38/55;;A61P9/12;;A61P31/12;;A61P43/00;;C07C69/757;;C07D223/04;;C07D223/06;;C07D223/08;;C07D223/10;;C07D233/54;;C07D243/06;;C07D243/08;;C07K1/113;;C07K5/06;;C07K5/078;;C07K5/08;;C07K5/097;;C07K7/02;;C07K14/81;;C12N9/99,,0,0,,,,DISCONTINUED
916,KR,A,KR 20110124806 A,027-117-989-581-045,2011-11-17,2011,KR 20117025893 A,2003-11-25,US 0337461 W;;US 42910502 P,2002-11-26,CALCILYTIC COMPOUNDS,,GLAXOSMITHKLINE LLC,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/027-117-989-581-045,Patent Application,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C229/34;;A61K31/195;;A61P19/08;;A61P35/00;;C07C217/34;;C07C217/36;;C07C229/00,,0,0,,,,EXPIRED
917,EP,A2,EP 0214738 A2,069-693-792-190-920,1987-03-18,1987,EP 86305748 A,1986-07-25,US 76992585 A,1985-08-26,Polyoxometalate-modified carbon electrodes and uses therefor.,"Improved activated carbon electrodes are disclosed, which electrodes have increased charge storage capacity. Such improved electrodes are incorporated into energy storage devices such as electrical double layer capacitors. The improved charge storage capacity is due to the adsorption of polyoxometalate compounds into the activated carbon, which compounds are capable of reversible redox reactions and so provide a secondary charge storage mechanism without decreasing the charge storage ability of the activated carbon.",STANDARD OIL CO OHIO,CALLAHAN JAMES L;;DESMOND MICHAEL J;;CUELLAR EDWARD A;;CURRIE JOHN C,,https://lens.org/069-693-792-190-920,Patent Application,yes,0,4,7,7,0,H01M4/5825;;H01M4/583;;H01M10/05;;Y02E60/10;;H01G11/32;;H01G11/34;;H01G4/002;;H01M4/5825;;Y02E60/13;;H01M4/583;;H01M10/05;;H01G11/54;;H01G11/52;;H01G11/32;;H01G11/34,H01G9/00;;H01G11/22;;H01G11/24;;H01G11/26;;H01G11/30;;H01G11/42;;H01G11/46;;H01G11/86;;H01M4/133;;H01M4/58;;H01M4/583;;H01M10/05;;H01M10/0566;;H01M10/36,,0,0,,,,DISCONTINUED
918,US,A,US 4638056 A,067-386-480-774-342,1987-01-20,1987,US 52885783 A,1983-09-02,US 52885783 A;;US 51634183 A,1983-07-22,Opthalmic wafer,"Damage to endothelial and epithelial cells subject to trauma can be substantially reduced by using a wafer of a viscoelastic material. This method is particularly useful when applied prior to ophthalic surgery, particularly intraocular lens implantation surgery. Lens implantation is facilitated by the compression of lens haptics by this delivery system.",CILCO INC,CALLAHAN WAYNE B;;KOCH HAROLD O;;PALIN PHILIP R;;COOK JAMES R,NESTLE S.A (1990-10-02);;CILCO INC (1983-10-27),https://lens.org/067-386-480-774-342,Granted Patent,yes,3,18,1,1,0,A61F2/1662;;A61L27/20;;A61L27/26;;A61L2430/16;;A61L27/14;;A61L27/20;;A61F2/1662;;A61L2430/16;;A61L27/26,A61F2/16;;A61L27/20;;A61L27/26,A5R RAE           RAE,3,0,,,"Healon (Sodium Hyaluronate) Product Monograph, (Pharmacia Laboratories).;;Chondron Product Monograph (Kaken Pharmaceutial Co., Ltd.).;;Drugs in Japan, Ethical Drug Edition, p. 216, (Japan Pharmaceutical Information Center 1975) (with English Translation).",EXPIRED
919,US,A1,US 2013/0158114 A1,117-158-820-395-988,2013-06-20,2013,US 201313764126 A,2013-02-11,US 201313764126 A;;US 89464410 A;;US 39328409 A;;US 53641605 A;;US 0337461 W;;US 42910502 P,2002-11-26,Calcilytic Compounds,Novel calcilytic compounds and methods of using them are provided.,GLAXOSMITHKLINE LLC;;GLAXOSMITHKLINE LLC,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,GLAXOSMITHKLINE LLC (2003-11-19),https://lens.org/117-158-820-395-988,Patent Application,yes,0,1,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/54;;C07C217/34;;C07C217/36;;C07C229/00,514/530;;560/42,0,0,,,,EXPIRED
920,CA,A1,CA 2507226 A1,137-960-947-894-841,2004-06-10,2004,CA 2507226 A,2003-11-25,US 42910502 P;;US 0337461 W,2002-11-26,CALCILYTIC COMPOUNDS,Novel calcilytic compounds and methods of using them are provided.,SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;CALLAHAN JAMES FRANCIS;;CASILLAS LINDA N;;RAMANJULU JOSHI M,,https://lens.org/137-960-947-894-841,Patent Application,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/34;;C07C217/36;;C07C229/00,,0,0,,,,EXPIRED
921,US,A1,US 2015/0183723 A1,149-317-622-555-545,2015-07-02,2015,US 201514640711 A,2015-03-06,US 201514640711 A;;US 201314069447 A;;US 201313764126 A;;US 89464410 A;;US 39328409 A;;US 53641605 A;;US 0337461 W;;US 42910502 P,2002-11-26,Calcilytic Compounds,Novel calcilytic compounds and methods of using them are provided.,GLAXOSMITHKLINE LLC,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,GLAXOSMITHKLINE LLC (2003-11-19),https://lens.org/149-317-622-555-545,Patent Application,yes,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/34;;C07C217/54;;C07C217/36;;C07C229/00,,0,0,,,,EXPIRED
922,US,A1,US 2006/0049311 A1,172-841-402-163-472,2006-03-09,2006,US 93600404 A,2004-09-08,US 93600404 A,2004-09-08,Seat power bus with discrete connection ports,"A power/data bus for conducting at least one of data and power signals to a variety of different locations on a mobile platform. The bus has a plurality of discrete connection ports, and at least one conductive cable. The power/data bus extends across an area where access to at least one of data and electricity is desired. The discrete connection ports are spaced apart at different locations along the power/data bus. The conductive cable extends through the power/data bus and is connected to at least one of the discrete connection ports. The conductive cable conducts at least one of power and data signals between the discrete connection ports and a data/power source. At least one of the connection ports are operable to cooperate with a connector of an external device to supply at least one of power and data signals to the external device. The power/data bus, when used in an aircraft passenger cabin, eliminates the need to extend individual data and/or power cables to or between each passenger seat group.",CALLAHAN KEVIN S;;LAIB TREVOR M;;MITCHELL BRADLEY J;;HENLEY JAMES T,CALLAHAN KEVIN S;;LAIB TREVOR M;;MITCHELL BRADLEY J;;HENLEY JAMES T,BOEING COMPANY THE (2004-09-02),https://lens.org/172-841-402-163-472,Patent Application,yes,18,20,5,5,0,B60R16/0207;;B64D11/06;;H01R25/16;;B64D11/0624;;B60R16/0215;;H01R25/16;;H02G3/04;;H02G3/385;;B60R16/0207;;H01R25/16;;B64D11/0624;;B64D11/06,B64D11/06;;B60R16/02;;H01R25/16,244/118.6,0,0,,,,ACTIVE
923,TW,A,TW 200735876 A,031-542-407-504-595,2007-10-01,2007,TW 95111084 A,2006-03-30,US 66515405 P,2005-03-25,"Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives","The present invention is directed to a novel method of preparing of 2,4,8-trisubstituted pyrido[2,3-d]pyrimidin -7-one pharmacophores of Formula (II) or (IIa), wherein G1 is CH2 or NH ; G2 is CH or nitrogen; Rx is chloro, bromo, iodo, or O-S(O)2-CF3; Rg is a C1-10 alkyl; m is 0, or an integer having a value of 1, or 2; R3 is a C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-10 alkyl, aryl, arylC1-10 alkyl, heteroaryl, heteroarylC1-10 alkyl, heretocyclic or hetercyclylC1-10 alkyl moiety, and wherein each of these moieties may be optionally substituted. which comprises reacting a compound of the formula: wherein Ry is chloro, bromo, iodo, O-S(O)2-CF3; and Rg is a C1-10 alkyl; With a olefin forming reagent in a suitable base to yield a compound of Formula(II), or (IIa) wherein m=0 and oxidizing the sulphur as necessary or desired.",GLAXO GROUP LTD,BOEHM JEFFREY C;;CALLAHAN JAMES FRANCIS;;WAN ZE-HONG;;YAN HONG-XING,,https://lens.org/031-542-407-504-595,Patent of Addition,no,0,0,22,22,0,C07D471/04;;C07D487/04;;A61P43/00;;C07D471/04;;C07D487/04;;C07D487/04;;C07D471/04,A61K31/519;;C07D487/02,,0,0,,,,PENDING
924,GB,B,GB 2155999 B,035-939-309-971-318,1987-07-15,1987,GB 8505820 A,1985-03-06,US 59066184 A,1984-03-19,JET ENGINE SURGE PREVENTION SYSTEM,,UNITED TECHNOLOGIES CORP,CALLAHAN DAVID JOHN;;MAZZAWY ROBERT SALEM;;STRYKER HOWARD YOUNG;;KELLY JAMES BAILEY,,https://lens.org/035-939-309-971-318,Granted Patent,no,0,0,8,8,0,F04D27/001;;F04D27/023;;F04D27/001;;F04D27/023,F02C9/18;;F02C9/28;;F02C9/52;;F04D27/02,F1C103;;F1C501;;F1C513;;F1C519;;F1C602;;F1CD;;F1G10E1B1B;;F1G10E1B3;;F1G10E2X;;U1S1987;;U1SF1C;;U1SF1G,0,0,,,,EXPIRED
925,PL,B1,PL 211571 B1,094-295-611-112-978,2012-05-31,2012,PL 37696503 A,2003-11-25,US 42910502 P,2002-11-26,CALCILYTIC COMPOUNDS,,SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/094-295-611-112-978,Granted Patent,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/54;;A61K31/21;;A61P19/10;;C07C217/34;;C07C217/36;;C07C229/00,,0,0,,,,EXPIRED
926,US,B2,US 7829594 B2,102-607-416-589-47X,2010-11-09,2010,US 39328409 A,2009-02-26,US 39328409 A;;US 53641605 A;;US 0337461 W;;US 42910502 P,2002-11-26,Calcilytic compounds,Novel calcilytic compounds and methods of using them are provided.,GLAXOSMITHKLINE LLC,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,GLAXOSMITHKLINE LLC (2009-10-27),https://lens.org/102-607-416-589-47X,Granted Patent,yes,48,6,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,A61K31/195;;C07C217/34;;C07C217/36;;C07C229/00,514/567;;562/442,12,3,036-156-900-072-948;;052-282-079-353-17X;;047-288-123-595-421,6102605;;10.1021/jm00177a015;;8257738;;10.1016/0731-7085(93)80182-z;;10.1016/s0040-4039(97)01421-4,"CA Abstract DN 88:22352 Dr. Andreu. 1-Aryloxy-2-hydroxy-3-alkylaminopropanes. Spanish Application 442062. Apr. 1, 1977.;;CA Abstract DN 85:142815 Dr. Andreu. 1-Aryloxy-3-(aralkylamino)-2-propanols. Spanish Application 421076. Apr. 1, 1986.;;CA Abstract DN 117:7640 Bercher, H. and Grisk, S. (to Ernst-Moritz-Arndt Univ.) Process for the preparation of 1-(dihalophenoxy)-3-[(1,1-dimethyl-2-phenylethyl)amino]-2- propanols and their use as beta-adrenergic agaonists or antagonists. German (DDR) Patent 298506. Feb. 27, 1992.;;Castedo et al., ""Bloqueantes beta-Adrenergicos: Sintesis Del (R)-1-[(1,1-Dimetil-2-Feniletil)Amino]-3-(3,4-Dichlorofenox])-2-Propanol"", Anales De Quimica, vol. 80, No. 3, pp. 291-294 (1984) (Spanish).;;F. Espinosa and A. Paniello, Anales De Quimica, vol. 77, No. 1, pp. 22-27 (1981) (Spanish).;;Abstract 91-194494/27 (Derwent Information Ltd.) Geisen et al. Use of 3-amino-propan-1,2-di:ol derivatives as racemate, Enantiomeric mixture of pure enantiomer in treatment of diabetes melliltus. German Patent DE 40 40 186 A1. Jun. 27, 1991.;;Kreighbaum et al., ""Antihypertensive Indole Derivatives of Phenoxypropanolamines with beta-Adrenergic Receptor Antagonist and Vasodilating Activity"", J. Med. Chem, vol. 23, No. 3, pp. 285-289 (1980).;;B. Law and L. Stafford, Journal of Pharmaceutical & Biomedical Analysis, vol. II, No. 8, pp. 729-736 (1993).;;CA Abstract DN 93:167911 Montoro, F. et al. [to Especialidades Latinas Medicamentos Universales) 1-(4-Chloro-alpha,alpha-dibenzomethylbenzenoethanamino)-2-hydroxy-3-(aryloxy)propanes. Spanish Application 480066. Apr. 1, 1980.;;Shuker et al., ""The Application of High-Throughput Synthesis and Purification to the Preparation of Ethanolamines"", Tetrahedron Letters, vol. 38, No. 35, pp. 6149-6152 (1997).;;CA Abstract DN 93:167911 Montoro, F. et al. [to Especialidades Latinas Medicamentos Universales) 1-(4-Chloro-alpha,alpha-dibenzomethylbenzenoethanamino)-2-hydroxy-3-(aryloxy)propanes. Spanish Application 480066. Apr. 1, 1980.;;U.S. Appl. No. 10/587,771, Marquis et al., Calcilytic Compounds, filed Feb. 4, 2005, published Aug. 25, 2005 (see WO 2005/077892 A1).",EXPIRED
927,HK,A1,HK 1082914 A1,116-458-048-170-617,2006-06-23,2006,HK 06102773 A,2006-03-02,US 0337461 W;;US 42910502 P,2002-11-26,CALCILYTIC COMPOUNDS,,GLAXOSMITHKLINE LLC,MARQUIS ROBERT W;;RAMANJULU JOSHI M;;CASILLAS LINDA N;;CALLAHAN JAMES FRANCIS,,https://lens.org/116-458-048-170-617,Patent Application,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,A61K/;;A61P/;;C07C/;;C07C217/34;;C07C217/36;;C07C229/00,,0,0,,,,DISCONTINUED
928,US,A1,US 2009/0163589 A1,134-340-044-004-047,2009-06-25,2009,US 39328409 A,2009-02-26,US 39328409 A;;US 53641605 A;;US 0337461 W;;US 42910502 P,2002-11-26,Calcilytic Compounds,Novel calcilytic compounds and methods of using them are provided.,SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,GLAXOSMITHKLINE LLC (2009-10-27),https://lens.org/134-340-044-004-047,Patent Application,yes,25,5,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,A61K31/216;;A61K31/195;;C07C217/34;;C07C217/36;;C07C229/00,514/539;;514/567,0,0,,,,EXPIRED
929,TW,A,TW 200946526 A,015-948-596-352-948,2009-11-16,2009,TW 98103480 A,2009-02-04,US 2657208 P,2008-02-06,Dual pharmacophores-PDE4-muscarinic antagonistics,"The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUO-LIANG;;WAN ZE-HONG;;YAN HONG-XING,,https://lens.org/015-948-596-352-948,Patent of Addition,no,0,0,20,20,0,C07D471/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/00;;A61P37/08;;A61P43/00;;C07D471/04,C07D471/04;;A61K31/437,,0,0,,,,PENDING
930,DK,T3,DK 1569892 T3,029-426-591-995-32X,2012-08-27,2012,DK 03783752 T,2003-11-25,US 42910502 P;;US 0337461 W,2002-11-26,Kalcilytiske forbindelser,,GLAXOSMITHKLINE LLC,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/029-426-591-995-32X,Granted Patent,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C229/00;;A61K31/185;;A61K31/21;;A61P19/00;;A61P19/08;;C07C217/32;;C07C217/34;;C07C217/36,,0,0,,,,EXPIRED
931,MY,A,MY 143244 A,024-069-915-729-788,2011-04-15,2011,MY PI20034511 A,2003-11-24,US 42910502 P,2002-11-26,CALCILYTIC COMPOUNDS,NOVEL CALCILYTIC COMPOUNDS AND METHODS OF USING THEM ARE PROVIDED,SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/024-069-915-729-788,Granted Patent,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C229/00;;C07C217/34;;C07C217/36,,0,0,,,,EXPIRED
932,US,B2,US 6776941 B2,066-269-339-789-132,2004-08-17,2004,US 16263202 A,2002-06-06,US 16263202 A;;US 66872800 A,2000-09-22,Cold isopressing method and mold,"
    A cold isopressing method and mold for compacting a granular ceramic material in which the granular ceramic material is introduced into a cylindrical pressure bearing element of an isopressing mold. The cylindrical pressure bearing element is sufficiently rigid so as to maintain its shape during the introducing of the granular ceramic material. Such element is also sufficiently resilient in a radial direction thereof to deform and bear against the granular ceramic material upon the application of the hydrostatic pressure and to substantially return to its original shape upon the relaxation of the hydrostatic pressure, thereby to allow retraction of the cylindrical pressure bearing element from the granular ceramic material after compaction. In a further aspect, an isopressing method and mold is provided in which the cylindrical pressure bearing element thereof is provided with an enlarged end bore to form an enlarged end section in the finished ceramic tube for sealing purposes. 
",PRAXAIR TECHNOLOGY INC,APTE PRASAD S;;CALLAHAN SHAWN W;;SCHNEIDER JAMES S;;CHEN JACK C,PRAXAIR TECHNOLOGY INC (2002-07-08),https://lens.org/066-269-339-789-132,Granted Patent,yes,19,8,9,9,0,B01D67/0041;;B01D71/024;;B28B3/003;;B29C33/405;;B29C43/003;;B29C43/006;;B29C43/10;;B29C43/146;;B29C2043/3238;;B29C2043/3628;;B29C2043/3652;;B29L2023/00;;B30B11/001;;B30B15/302;;B01D69/04;;B01D2323/10;;B01D2323/24;;B29C43/003;;B29C33/405;;B29C2043/3238;;B29C2043/3652;;B30B11/001;;B29C43/10;;B28B3/003;;B29L2023/00;;B30B15/302;;B29C2043/3628;;B29C43/146;;B29C43/006;;B01D69/04;;B01D2323/10;;B01D2323/24;;B01D67/00411,B01D67/00;;B01D71/02;;B28B3/00;;B29C33/40;;B29C43/00;;B29C43/10;;B29C43/14;;B30B11/00;;B30B15/30,264/71;;264/544;;264/570;;264/109;;425/405.2,0,0,,,,EXPIRED
933,TW,A,TW 200628153 A,065-209-761-001-864,2006-08-16,2006,TW 94134430 A,2005-10-03,US 61606504 P;;US 71972905 P,2004-10-05,Novel compounds,"The present invention is directed to novel compounds of formula (I): or pharmaceutically acceptable derivatives thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.",SMITHKLINE BEECHAM CORP,BOEHM JEFFREY CHARLES;;CALLAHAN JAMES FRANCIS;;WAN ZE-HONG;;YAN HONG-XING,,https://lens.org/065-209-761-001-864,Patent of Addition,no,0,0,8,9,0,A61P1/00;;A61P1/04;;A61P1/18;;A61P3/10;;A61P7/04;;A61P9/00;;A61P9/10;;A61P9/12;;A61P11/06;;A61P11/08;;A61P13/12;;A61P17/00;;A61P17/02;;A61P19/02;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/06;;A61P25/14;;A61P25/16;;A61P25/28;;A61P27/02;;A61P29/00;;A61P31/04;;A61P31/12;;A61P31/16;;A61P31/18;;A61P33/06;;A61P35/00;;A61P37/06;;A61P43/00;;C07C233/65;;C07C233/63;;C07C233/69;;C07C233/78;;C07C275/42;;C07C2601/02;;C07D211/58;;C07D213/75;;C07D277/46,,,0,0,,,,PENDING
934,EP,A4,EP 0559793 A4,075-045-628-666-490,1994-04-27,1994,EP 92901654 A,1991-11-25,US 62097890 A,1990-11-30,EP 0559793 A4,,SMITHKLINE BEECHAM CORPORATION,"CALLAHAN, JAMES, FRANCIS;;HUFFMAN, WILLIAM, FRANCIS;;MOORE, MICHAEL, LEE;;NEWLANDER, KENNETH, ALLEN",,https://lens.org/075-045-628-666-490,Search Report,no,0,0,10,10,0,A61K38/00;;C07C69/757;;C07D223/04;;C07D223/06;;C07D233/64;;C07D243/08;;C07K5/06052;;C07K5/06139;;C07K5/0821;;C07K7/02;;A61P31/12;;A61P43/00;;A61P9/12;;C07D233/64;;C07C69/757;;C07K5/0821;;C07K5/06139;;C07D223/06;;C07D243/08;;A61K38/00;;C07K5/06052;;C07D223/04;;C07K7/02,A61K31/55;;A61K38/00;;A61K38/55;;A61P9/12;;A61P31/12;;A61P43/00;;C07C69/757;;C07D223/04;;C07D223/06;;C07D223/08;;C07D223/10;;C07D233/54;;C07D243/06;;C07D243/08;;C07K1/113;;C07K5/06;;C07K5/078;;C07K5/08;;C07K5/097;;C07K7/02;;C07K14/81;;C12N9/99,,1,1,097-406-017-636-611,10.1073/pnas.86.24.9752;;pmc298579;;2690072,"G.B.DREYER ET AL: ""Inhibition of HIV 1 protease in vitro;rational design of substrate analogue inhibitors"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 86, December 1989 (1989-12-01), WASHINGTON US, pages 9752 - 9756",DISCONTINUED
935,CA,A,CA 1249398 A,080-476-033-684-580,1989-01-24,1989,CA 495291 A,1985-11-14,US 67382984 A,1984-11-21,PROCESS FOR PREPARING BASIC V1-VASOPRESSIN ANTAGONISTS,"PROCESS FOR PREPARING BASIC V1-VASOPRESSIN ANTAGONISTS Certain vasopressin-like peptides, which have an acyclic unit at position 1 and which have an .omega.-amino- or guanidinoalkyl substituent attached to the cysteine in the 6-position of the ring, have V1-vasopressin and oxytocin antagonist activity. The process of this invention prepares such compounds. A species prepared using this process is ¢1-desaminopenicillamine-2-(0-ethyl-D-tyrosine)-8-(1,4-diaminobutane)-9-desglycinamide!-vasopressin.",SMITH KLINE FRENCH CANADA LTD,CALLAHAN JAMES F;;HUFFMAN WILLIAM F;;MOORE MICHAEL L;;YIM NELSON C,,https://lens.org/080-476-033-684-580,Granted Patent,no,0,0,18,20,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P5/00;;A61P9/08;;C07K7/16;;A61K38/00;;Y10S930/15,A61K38/00;;A61K38/095;;C07K14/575;;A61P5/00;;A61P9/08;;C07K1/113;;C07K7/06;;C07K7/16,530-7.16,0,0,,,,EXPIRED
936,NO,L,NO 20053071 L,143-828-334-782-504,2005-06-22,2005,NO 20053071 A,2005-06-22,US 42910502 P;;US 0337461 W,2002-11-26,Kalsilytiske forbindelser.,Nye kalsilytiske forbindelser og fremgangsmåter for anvendelse av dem er tilveiebrakt.,SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M,,https://lens.org/143-828-334-782-504,Abstract,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/34;;C07C217/36;;C07C229/00,,0,0,,,,EXPIRED
937,EP,A2,EP 1569892 A2,145-326-613-483-585,2005-09-07,2005,EP 03783752 A,2003-11-25,US 0337461 W;;US 42910502 P,2002-11-26,CALCILYTIC COMPOUNDS,,SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,GLAXOSMITHKLINE LLC (2010-03-03),https://lens.org/145-326-613-483-585,Patent Application,yes,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C229/00;;A61K31/185;;A61K31/21;;A61P19/00;;A61P19/08;;C07C217/32;;C07C217/34;;C07C217/36,,0,0,,,,EXPIRED
938,US,B2,US 8980950 B2,004-289-732-098-521,2015-03-17,2015,US 201314069447 A,2013-11-01,US 201314069447 A;;US 201313764126 A;;US 89464410 A;;US 39328409 A;;US 53641605 A;;US 0337461 W;;US 42910502 P,2002-11-26,Calcilytic compounds,Novel calcilytic compounds and methods of using them are provided.,GLAXOSMITHKLINE LLC,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,GLAXOSMITHKLINE LLC (2003-11-19),https://lens.org/004-289-732-098-521,Granted Patent,yes,52,1,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,A61K31/195;;C07C217/30;;C07C217/32;;C07C217/34;;C07C217/36;;C07C217/54;;C07C229/00;;C07C229/34,514/567;;562/442;;562/445,18,6,052-282-079-353-17X;;036-156-900-072-948;;047-288-123-595-421;;020-040-426-369-369;;086-987-406-282-115;;057-761-352-971-017,8257738;;10.1016/0731-7085(93)80182-z;;6102605;;10.1021/jm00177a015;;10.1016/s0040-4039(97)01421-4;;21742071;;10.1016/j.bone.2011.06.017;;10.1002/jbmr.554;;22052452;;21593114;;10.1210/jc.2010-2855,"Abstract 91-194494/27 (Derwent information Ltd.) Geisen et al. Use of 3-amino-propan-1,2-di:ol derivatives as racemate, Enantiomeric mixture of pure enantiomer in treatment of diabetes mellitus. German Patent DE 40 40 186 A1. Jun. 27, 1991.;;B. Law and L. Stafford, Journal of Pharmaceutical & Biomedical Analysis, vol. II, No. 8, pp. 729-736 (1993).;;CA Abstract DN 117:7640 Bercher, H. and Grisk, S. (to Ernst-Moritz-Arndt Univ.) Process for the preparation of 1-(dihalophenoxy)-3-[(1,1-dimethyl-2-phenylethyl)amino]-2-propanols and their use as beta-adrenergic agaonists or antagonists. German (DDR) Patent 298506. Feb. 27, 1992.;;CA Abstract DN 85:142815 Dr. Andreu. 1-Aryloxy-3-(araikylamino)-2-propanols. Spanish Application 421076. Apr. 1, 1986.;;CA Abstract DN 88:22352 Dr. Andreu. 1-Aryloxy-2-hydroxy-3-alkylaminopropanes. Spanish Application 442062. Apr. 1, 1977.;;CA Abstract DN 93:167911 Montoro, F. et al. [to Especialidades Latinas Medicamentos Universales) 1-(4-Chloro-alpha,alpha-dibenzomethylbenzenoethanamino)-2-hydroxy-3-(aryloxy)propanes. Spanish Application 480066. Apr. 1, 1980.;;Castedo et al., ""Bloqueantes beta-Adrenergicos: Sintesis Del (R)-1-[(1,1-Dimetil-2-Feniletil)Amino]-3-(3,4-Dichlorofenox])-2-Propanol"", Anales De Quimica, vol. 80, No. 3, pp. 291-292 (1984) (Spanish).;;F. Espinosa and A. Paniello, Anales De Quimica, vol. 77, No. 1, pp. 22-27 (1981) (Spanish).;;Kreighbaum et al., ""Antihypertensive Indole Derivatives of Phenoxypropanolamines with beta-Adrenergic Receptor Antagonist and Vasodilating Activity"", J. Med. Chem. vol. 23, No. 3, pp. 285-289 (1980).;;Shuker et al., ""The Application of High-Throughput Synthesis and Purification to the Preparation of Ethanolamines"", Tetrahedron Letters, vol. 38, No. 35, pp. 6149-6152 (1997).;;Study CR9108914 ""A Proof-of-Concept Study of SB-751689 in Men and Post-menopausal Women With a Fractured Distal Radius""-Result Summary. GSK Clinical Study Register http://www.gsk-clinicalstudyregister.com/study/CR9108914#rs (1st received Mar. 4, 2010; last updated Mar. 21, 2013).;;Study CR9108963 ""Study CR9108963: A 12-month randomized, double-blind, parallel-group, placebo and active-controlled dose-range finding study of the efficacy and safety of SB-751689 in post-menopausal women with osteoporosis""-Result Summary. GSK Clinical Study Register http://www.gsk-clinicalstudyregister.com/study/CR9108963#rs (1st received Mar. 4, 2010; last updated Feb. 21, 2013).;;Study CR9112792 ""Study CR9112792, a study to assess bone mineral density changes in post-menopausal osteoporotic women following discontinuation of ronacaleret or placebo treatment in study CR9108963""-Result Summary. GSK Clinical Study Register http://www.gsk-clinicalstudyregister.com/study/112792#rs (1st received/last updated Mar. 4, 2010).;;L. Fitzpatrick et al., ""Ronacaleret, a Calcium-Sensing Receptor Antagonist, has No Significant Effect on Radial Fracture Healing Time: Results of a Randomized, Double-blinded, Placebo-Controlled Phase II Clinical Trial"", Bone 2011;49(4):845-52.;;Fitzpatrick LA, et al., ""Ronacalaret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women"", J Bone Miner Res. Feb. 2012;27(2):255-62 doi: 10.1002/jbmr.554.;;Fitzpatrick LA, et al., ""The effects of ronacaleret, a calcium-sensing receptor antagonist on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density"", J Clin Endocrinol Metab. Aug. 2011;96(8):2441-9 doi: 10.1210/jc.2010-2855. Epub May 18, 2011.;;A Phase II Study Evaluating SB-751689 in Post-Menopausal Women With Osteoporosis. ClinicalTrials.gov, Identifier: NCT00471237. http://clinicaltrials.gov/ct2/show/NCT00471237?term=ronacaleret&rank=5 (1st received May 7, 2007; last updated Mar. 27, 2014).;;CR9112792, a Follow-up of Study CR9108963, ClinicalTrials.gov, Identifier: NCT00891553. http://clinicaltrials.gov/ct2/show/NCT00891553?term=ronacaleret&rank=4 (1st received Apr. 23, 2009, last updated Feb. 21, 2013).",EXPIRED
939,NO,L,NO 20031272 L,017-725-296-757-809,2003-05-19,2003,NO 20031272 A,2003-03-19,US 66872800 A;;US 0123760 W,2000-09-22,Fremgangsmåte og form for kald isopressing,,PRAXAIR TECHNOLOGY INC,APTE PRASAD S;;CALLAHAN SHAWN W;;SCHNEIDER JAMES S;;CHEN JACK C,,https://lens.org/017-725-296-757-809,Abstract,no,0,0,9,9,0,B01D67/0041;;B01D71/024;;B28B3/003;;B29C33/405;;B29C43/003;;B29C43/006;;B29C43/10;;B29C43/146;;B29C2043/3238;;B29C2043/3628;;B29C2043/3652;;B29L2023/00;;B30B11/001;;B30B15/302;;B01D69/04;;B01D2323/10;;B01D2323/24;;B29C43/003;;B29C33/405;;B29C2043/3238;;B29C2043/3652;;B30B11/001;;B29C43/10;;B28B3/003;;B29L2023/00;;B30B15/302;;B29C2043/3628;;B29C43/146;;B29C43/006;;B01D69/04;;B01D2323/10;;B01D2323/24;;B01D67/00411,B01D67/00;;B01D71/02;;B28B3/00;;B29C33/40;;B29C43/00;;B29C43/10;;B29C43/14;;B30B11/00;;B30B15/30,,0,0,,,,DISCONTINUED
940,US,A,US 4658015 A,048-561-102-787-417,1987-04-14,1987,US 85286986 A,1986-04-16,US 85286986 A;;US 67382984 A,1984-11-21,Polypeptide intermediates,"Certain vasopressin-like peptides, which have an acyclic unit at position 1 and which have an .omega.-amino- or guanidinoalkyl substituent attached to the cysteine in the 6-position of the ring, have V.sub.1 -vasopressin and oxytocin antagonist activity. A species of this series of new compounds is [1-desaminopenicillamine-2-(O-ethyl-D-tyrosine)-8-(1,4-diaminobutane)-9-de sglycinamide]-vasopressin.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES F;;HUFFMAN WILLIAM F;;MOORE MICHAEL L;;YIM NELSON C,,https://lens.org/048-561-102-787-417,Granted Patent,yes,1,1,1,20,2,A61K38/00;;C07K7/16;;Y10S930/15;;C07K7/16;;A61K38/00;;Y10S930/15,A61K38/00;;C07K7/16,530/329;;530/315;;514/807,20,8,018-377-786-134-442;;162-369-890-067-391;;037-352-404-303-297;;074-445-265-388-335;;006-451-650-264-851;;082-931-819-394-264;;066-417-528-968-713;;014-946-675-773-50X,5061145;;10.1021/ja00758a043;;10.1135/cccc19780511;;291004;;10.1073/pnas.76.7.3309;;pmc383814;;10.1016/0006-291x(72)90474-3;;4344685;;10.1021/ja00770a052;;5040852;;10.1021/jm00191a019;;458806;;926126;;10.1021/jm00219a026;;10.1021/jm00323a001;;5969030,"Journal of the American Chem. Soc. 94, (1972) 982 4.;;Chem. Abstr. vol. 84, (1976) 122328.;;Collect. Czechoslov. Chem. Commun., vol. 43, (1978) 511 522.;;Chem. Abstr., vol. 81, (1974) 114962.;;Chem. Abstr., vol. 84, (1976) 31421.;;Chem. Abstr., vol. 93, (1980) 215771.;;Proc. Natl. Acad. Sci. 76, pp. 3309 3313 (1979).;;Biochem. and Biophys. Res. Commun. 49, (1972) 748 51.;;Chem. Abstr., vol. 78, (1973) 72580.;;Chem. Abstr., vol. 76, (1972) 55474.;;Chem. Abstr., vol. 80, (1974) 108863.;;Chem. Abstr., vol. 82, (1975) 26429.;;Journal of the American Chem. Soc. 94, (1972) 5478 80.;;J. Lowbridge et al., J. Med. Chem. 22 565 (1979).;;M. Manning et al., J. Med. Chem. 20 1228 (1977).;;J. Bankowski et al., J. Med. Chem. 21 350 (1978).;;H. Schulz et al., J. Med. Chem. 9 647 (1966).;;Derwent Abstract of European Patent No. 112,809-A.;;M. Manning et al., J. Med. Chem. 25 (1982).;;Peptides: Chemistry, Structure and Biology (Ann Arbor Sciences) 737 (1975).",EXPIRED
941,TW,A,TW 201000476 A,053-187-607-618-276,2010-01-01,2010,TW 98103478 A,2009-02-04,US 2656308 P,2008-02-06,Dual pharmacophores-PDE4-muscarinic antagonistics,"The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.",GLAXO GROUP LTD,CALLAHAN JAMES FRANCIS;;LIN GUO-LIANG;;WAN ZE-HONG;;YAN HONG-XING,,https://lens.org/053-187-607-618-276,Patent of Addition,no,0,1,21,21,0,C07D471/04;;C07D519/00;;A61P11/00;;A61P11/02;;A61P11/06;;A61P17/00;;A61P17/06;;A61P37/08;;A61P43/00;;C07D471/04;;C07D519/00,C07D471/04;;A61K31/519;;A61P11/00;;A61P11/06,,0,0,,,,PENDING
942,BR,A,BR 0316544 A,061-127-437-121-704,2005-10-04,2005,BR 0316544 A,2003-11-25,US 42910502 P;;US 0337461 W,2002-11-26,Compostos calcilìticos,"""COMPOSTOS CALCILìTICOS"". São proporcionados novos compostos calcilíticos e métodos de uso destes.",SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,GLAXOSMITHKLINE LLC (US) (2011-10-18),https://lens.org/061-127-437-121-704,Patent Application,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/34;;C07C217/36;;C07C229/00,,0,0,,,,PENDING
943,US,A1,US 2020/0062781 A1,074-873-005-454-763,2020-02-27,2020,US 201716467193 A,2017-12-11,US 201716467193 A;;US 201662434013 P;;IB 2017057801 W,2016-12-14,BISARYL HETEROCYCLES AS NRF2 ACTIVATORS,"The present invention relates to bisaryl heterocycle compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to bisaryl heterocycles of Formula (I),",GLAXOSMITHKLINE IP DEV LTD,CALLAHAN JAMES FRANCIS;;DAVIS RODERICK S;;GOODWIN NICOLE CATHLEEN;;KERNS JEFFREY K,GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (2018-02-01),https://lens.org/074-873-005-454-763,Patent Application,yes,0,2,5,5,0,A61K9/0019;;A61K9/0053;;A61K9/0073;;A61P11/00;;A61P37/00;;C07D515/04;;C07D515/04;;C07D243/08;;C07D285/36;;C07D291/08;;C07D409/14;;C07D409/14;;C07D417/14;;C07D498/04;;C07D513/04,C07D515/04;;A61K9/00;;C07D243/08;;C07D285/36;;C07D291/08;;C07D409/14;;C07D513/04,,0,0,,,,ACTIVE
944,US,B1,US 10761029 B1,109-784-007-538-315,2020-09-01,2020,US 201916561638 A,2019-09-05,US 201916561638 A,2019-09-05,Laser-induced spectroscopy system and process,"Specialized linkage assemblies for Laser-Induced Breakdown Spectroscopy (“LIBS”) systems are provided. The linkage assemblies may facilitate the attachment of the laser housing of the LIBS system onto an existing sample supply chamber, such as a volumetric or gravimetric feeder. Generally, the linkage assemblies may comprise a specialized purge head and inert gas assembly that facilitate the attachment of the laser housing and may enhance the functionality of the LIBS system.",SCHENCK PROCESS LLC,MONAHAN RANDY JAMES;;NOWAKOWSKI JOHN JOSEPH;;CALLAHAN LAUREN ELIZABETH;;URBANEK GEOFFREY K,SCHENCK PROCESS LLC (2019-09-26),https://lens.org/109-784-007-538-315,Granted Patent,yes,5,0,1,7,0,G01N21/01;;G01N21/718;;G01N33/222;;G01N21/718;;G01N33/222;;G01N21/01,G01J3/30;;G01N21/01;;G01N21/71;;G01N33/22,,0,0,,,,ACTIVE
945,WO,A1,WO 2021/045911 A1,125-112-709-257-313,2021-03-11,2021,US 2020/0047309 W,2020-08-21,US 201916561638 A;;US 201916561704 A,2019-09-05,LASER-INDUCED SPECTROSCOPY SYSTEM AND PROCESS,"Specialized linkage assemblies for Laser-Induced Breakdown Spectroscopy (""LIBS"") systems are provided. The linkage assemblies may facilitate the attachment of the laser housing of the LIBS system onto an existing sample supply chamber, such as a volumetric or gravimetric feeder. Generally, the linkage assemblies may comprise a specialized purge head and inert gas assembly that facilitate the attachment of the laser housing and may enhance the functionality of the LIBS system.",SCHENCK PROCESS LLC,MONAHAN RANDY JAMES;;NOWAKOWSKI JOHN JOSEPH;;CALLAHAN LAUREN ELIZABETH;;URBANEK GEOFFREY K,,https://lens.org/125-112-709-257-313,Patent Application,yes,5,2,5,7,0,G01N21/718;;G01N21/01;;G01N33/222;;G01N21/718;;G01N2021/151;;G01J3/443;;G01J3/0291;;G01J3/0202;;G01J3/0208;;G01N21/85;;G01J3/0202;;G01J3/0208;;G01J3/0291;;G01J3/443;;G01N21/718;;G01N2021/151,G01N21/71;;G01J3/30;;G01N21/15,,1,0,,,See also references of EP 4025900A4,PENDING
946,GB,A,GB 2155999 A,139-000-890-197-539,1985-10-02,1985,GB 8505820 A,1985-03-06,US 59066184 A,1984-03-19,JET ENGINE SURGE PREVENTION SYSTEM,,UNITED TECHNOLOGIES CORP,CALLAHAN DAVID JOHN;;MAZZAWY ROBERT SALEM;;STRYKER HOWARD YOUNG;;KELLY JAMES BAILEY,,https://lens.org/139-000-890-197-539,Patent Application,no,0,3,8,8,0,F04D27/001;;F04D27/023;;F04D27/001;;F04D27/023,F02C9/18;;F02C9/28;;F02C9/52;;F04D27/02,F1C CD            CD;;F1C C103          CD;;F1C C501          CD;;F1C C513          CD;;F1C C519          CD;;F1C C602          CD;;F1G G10E1B1B      G10E2X;;F1G G10E1B3       G10E2X;;F1G G10E2X        G10E2X;;U1S S1987,0,0,,,,EXPIRED
947,AU,C1,AU 2003/291157 C1,189-293-770-942-86X,2011-05-12,2011,AU 2003/291157 A,2003-11-25,US 42910502 P;;US 0337461 W,2002-11-26,Calcilytic compounds,,SMITHKLINE BEECHAM CORP,CASILLAS LINDA N;;CALLAHAN JAMES FRANCIS;;RAMANJULU JOSHI M;;MARQUIS ROBERT W,,https://lens.org/189-293-770-942-86X,Amended Patent,no,1,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/36;;C07C217/34;;C07C229/00,,0,0,,,,EXPIRED
948,CA,C,CA 1268033 C,054-232-958-532-294,1990-04-24,1990,CA 514106 A,1986-07-18,US 76992585 A,1985-08-26,POLYOXOMETALATE MODIFIED CARBON ELECTRODES AND USES THEREFOR,"ABSTRACT POLYOXOMETALATE-MODIFIED CARBON ELECTRODES AND USES THEREFOR Improved activated carbon electrodes are disclosed, which electrodes have increased charge storage capacity. Such improved electrodes are incorporated into energy storage devices such as electrical double layer capacitors. The improved charge storage capacity is due to the adsorption of polyoxometalate compounds into the activated carbon, which compounds are capable of reversible redox reactions and so provide a secondary charge storage mechanism without decreasing the charge storage ability of the activated carbon.",,CALLAHAN JAMES L;;CUELLAR EDWARD A;;DESMOND MICHAEL J;;CURRIE JOHN C,,https://lens.org/054-232-958-532-294,Unknown,no,0,0,7,7,0,H01M4/5825;;H01M4/583;;H01M10/05;;Y02E60/10;;H01G11/32;;H01G11/34;;H01G4/002;;H01M4/5825;;Y02E60/13;;H01M4/583;;H01M10/05;;H01G11/54;;H01G11/52;;H01G11/32;;H01G11/34,H01M4/02;;H01G9/00;;H01G9/04;;H01G11/22;;H01G11/24;;H01G11/26;;H01G11/30;;H01G11/42;;H01G11/46;;H01G11/86;;H01M4/133;;H01M4/58;;H01M4/583;;H01M10/05;;H01M10/0566;;H01M10/36,31/106;;X334/5,0,0,,,,EXPIRED
949,CA,C,CA 2507226 C,098-325-116-023-943,2011-11-15,2011,CA 2507226 A,2003-11-25,US 42910502 P;;US 0337461 W,2002-11-26,PHENYL ETHERS AS CALCILYTIC COMPOUNDS,"The present invention features calcilytic compounds having the following chemical formula: (see above formula) Calcilytic compounds refer to compounds able to inhibit calcium receptor activity which mean that the compound cause a decrease in one or more calcium receptor activities evoked by extracellular Ca 2+. Also described are the use of calcilytic compounds to inhibit calcium receptor activity and/or achieve a beneficial effect in a patient, and techniques which can be used to obtain additional calcilytic compounds.",SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/098-325-116-023-943,Granted Patent,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C229/00;;C07C217/34;;C07C217/36,,0,0,,,,EXPIRED
950,PT,A,PT 99653 A,132-895-931-533-726,1992-10-30,1992,PT 9965391 A,1991-11-29,US 62097890 A,1990-11-30,"PROCESSO DE PREPARACAO DE INIBIDORES DE PROTEASE DE HIV POR EXEMPLO O ESTER METILICO DE 3-BENZIL-5-(ALANIL-1-AMINOETIL)-2,3,6,7-TETRA-HIDRO-N-AZEPINIL-2-PROPINIL-VALINILVALINA E DE COMPOSICOES FARMACEUTICAS",,SMITHKLINE BEECHAM CORP,HUFFMAN WILLIAM FRANCIS;;MOORE MICHAEL LEE;;CALLAHAN JAMES FRANCIS;;NEWLANDER KENNETH ALLEN,,https://lens.org/132-895-931-533-726,Patent Application,no,0,0,10,10,0,A61K38/00;;C07C69/757;;C07D223/04;;C07D223/06;;C07D233/64;;C07D243/08;;C07K5/06052;;C07K5/06139;;C07K5/0821;;C07K7/02;;A61P31/12;;A61P43/00;;A61P9/12;;C07D233/64;;C07C69/757;;C07K5/0821;;C07K5/06139;;C07D223/06;;C07D243/08;;A61K38/00;;C07K5/06052;;C07D223/04;;C07K7/02,A61K31/55;;A61K38/00;;A61K38/55;;A61P9/12;;A61P31/12;;A61P43/00;;C07C69/757;;C07D223/04;;C07D223/06;;C07D223/08;;C07D223/10;;C07D233/54;;C07D243/06;;C07D243/08;;C07K1/113;;C07K5/06;;C07K5/078;;C07K5/08;;C07K5/097;;C07K7/02;;C07K14/81;;C12N9/99,,0,0,,,,DISCONTINUED
951,UY,A1,UY 28089 A1,129-018-541-623-504,2004-06-30,2004,UY 28089 A,2003-11-24,US 42910502 P,2002-11-26,COMPUESTOS CALCILITICOS,Se proporcionan compuestos calcilíticos novedosos y métodos para usar los mismos,SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJUILU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/129-018-541-623-504,Patent Application,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/34;;C07C217/36;;C07C229/00,,0,0,,,,PENDING
952,US,A,US 4424816 A,008-485-390-792-663,1984-01-10,1984,US 25858781 A,1981-04-29,US 25858781 A,1981-04-29,Neurological monitoring device test circuitry,"Circuitry for use with a brain wave monitoring device is provided for selectively monitoring the impedance of the current paths in the patient's scalp concurrently with brain wave monitoring, and circuitry for self-testing the system for proper functioning.",NEUROLOGICS INC,CALLAHAN ALFRED S;;RHODES JAMES S;;JOHNSON TIMOTHY L;;DURDEN JOHN G,NEUROLOGICS INC. A CORP. OF DE (1981-04-29);;DURDEN ENTERPRISES LIMITED INC (1987-02-18),https://lens.org/008-485-390-792-663,Granted Patent,yes,22,23,1,1,0,A61B5/276;;A61B5/369;;A61B5/369;;A61B5/276,A61B5/276,128/731,0,0,,,,EXPIRED
953,UA,C2,UA 81642 C2,043-796-289-512-548,2008-01-25,2008,UA 2005005005 A,2003-11-25,US 42910502 P;;US 0337461 W,2002-11-26,"CALCILYTIC COMPOUND, METHOD FO TREATMENT AND METHOD FOR INCREASE OF A PARATHYROID HORMONE LEVEL","Compounds of formula (I), pharmaceutically acceptable salts and complexes thereof are disclosed, wherein: Rand Rare independently selected from the group consisting of H and halogen; Rand Rare independently selected from the group consisting of H, halogen and J-K wherein: J is a covalent bond, alkylene or alkenyl: and K is selected from the group of COR, such that Ris H or alkyl; Ris J-Kwherein: Jrepresents C-Calkylene or C-Calkenyl, and Krepresents COH, COMe or COEt; Ris selected from the group consisting of H or alkyl; Ris indanyl, unsubstituted or substituted with any substituent selected from the group consisting of OH, halogen, C-alkyl, C-alkoxy, C-cycloalkyl CF, OCF, CN and NO. These calcilytic compounds are suitable for increasing serum parathyroid hormone levels in mammals.",SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,,https://lens.org/043-796-289-512-548,Limited Patent,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C217/34;;C07C217/00;;C07C217/36;;C07C229/00;;C07C229/00,,0,0,,,,EXPIRED
954,EA,B1,EA 009603 B1,129-847-624-537-415,2008-02-28,2008,EA 200500878 A,2003-11-25,US 42910502 P;;US 0337461 W,2002-11-26,CALCILYTIC COMPOUNDS,"Novel calcilytic compounds and methods of using them are provided and methods for use thereof. In particular, the invention relates to a compound having a formula.and pharmaceutically acceptable salts thereof and a pharmaceutical composition based thereon. There also proposed a method for treating a disease or a disorder characterized by abnormal bone or mineral homeostasis and a method for increasing the level of parathyroid hormone in mammals which comprises the administration to a subject in need of treatment thereof an effective amount of a compound according to the invention.",SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANSIS,,https://lens.org/129-847-624-537-415,Granted Patent,no,4,1,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,C07C229/00;;C07C217/34;;C07C217/36,,0,0,,,,EXPIRED
955,US,B2,US 8586631 B2,130-753-895-329-659,2013-11-19,2013,US 201313764126 A,2013-02-11,US 201313764126 A;;US 89464410 A;;US 39328409 A;;US 53641605 A;;US 0337461 W;;US 42910502 P,2002-11-26,Calcilytic compounds,Novel calcilytic compounds and methods of using them are provided.,GLAXOSMITHKLINE LLC,MARQUIS ROBERT W;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES FRANCIS,GLAXOSMITHKLINE LLC (2003-11-19),https://lens.org/130-753-895-329-659,Granted Patent,yes,51,1,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,A61K31/24;;C07C217/34;;C07C217/36;;C07C229/00,514/538;;560/42,10,3,052-282-079-353-17X;;036-156-900-072-948;;047-288-123-595-421,8257738;;10.1016/0731-7085(93)80182-z;;6102605;;10.1021/jm00177a015;;10.1016/s0040-4039(97)01421-4,"Abstract 91-194494/27 (Derwent Information Ltd.) Geisen et al. Use of 3-amino-propan-1,2-diol derivatives as racemate, Enantiomeric mixture of pure enantiomer in treatment of diabetes mellitus. German Patent DE 40 40 186 A1. Jun. 27, 1991.;;B. Law and L. Stafford. Journal of Pharmaceutical & Biomedical Analysis. vol. II, No. 8, pp. 729-736 (1993).;;CA Abstract DN 117:7640 Bercher, H. and Grisk, S. (to Ernst-Moritz-Amdt Unvi.) Process for the preparation of 1-dihalophenoxy)-3-[(1, 1-dimethyl-2-phenylethyl)amino]-2-propanols and their use as beta-adrenergic agaonists or antagonists. German (DDR) Patent 298506. Feb. 27, 1992.;;CA Abstract DN 85:142815 Dr. Andreu. 1-Aryloxy-3-(aralkylamino)-2-propanols. Spanish Application 421076. Apr. 1, 1986.;;CA Abstract DN 88:22352 Dr. Andreu. 1-Aryloxy-2-hydroxy-3-alkylaminopropanes. Spanish Application 442062. Apr. 1, 1977.;;CA Abstract DN 93:167911 Montoro, F. et al. [to Especialidades Latinas Medicamentos Universales) 1-(4-Chloro-alpha,alpha-dibenzomethylbenzenoethanamino)-2-hydroxy-3-(aryloxy)propanes. Spanish Application 480066. Apr. 1, 1980.;;Castedo et al., ""Bloqueantes beta-Adrenergicos: Sintesis Del (R)-1-[1,1-Dimetil-2-Feniletil)Amino]-3-(3,4-Dichlorofenox])-2-Propanol"", Anales De Quimica, vol. 80, No. 3, pp. 291-294 (1984) (Spanish).;;F. Espinosa and A. Paniello, Anales De Quimica, vol. 77, No. 1, pp. 22-27 (1981) (Spanish).;;Kreighbaum et al., ""Antihypertensive Indole Derivatives of Phenoxypropanolamines with beta-Adrenergic Receptor Antagonist and Vasodilating Activity"", J. Med. Chem, vol. 23, No. 3, pp. 285-289 (1980).;;Shuker et al., ""The Application of High-Throughput Synthesis and Purification to the Preparation of Ethanolamines"", Tetrahedron Letters, vol. 38, No. 35, pp. 6149-6152 (1997).",EXPIRED
956,EP,A1,EP 4025900 A1,186-720-172-316-580,2022-07-13,2022,EP 20861366 A,2020-08-21,US 201916561638 A;;US 201916561704 A;;US 2020/0047309 W,2019-09-05,LASER-INDUCED SPECTROSCOPY SYSTEM AND PROCESS,,SCHENCK PROCESS LLC,MONAHAN RANDY JAMES;;NOWAKOWSKI JOHN JOSEPH;;CALLAHAN LAUREN ELIZABETH;;URBANEK GEOFFREY K,,https://lens.org/186-720-172-316-580,Patent Application,yes,0,0,5,7,0,G01N21/718;;G01N21/01;;G01N33/222;;G01N21/718;;G01N2021/151;;G01J3/443;;G01J3/0291;;G01J3/0202;;G01J3/0208;;G01N21/85;;G01J3/0202;;G01J3/0208;;G01J3/0291;;G01J3/443;;G01N21/718;;G01N2021/151,G01N21/71;;G01J3/30;;G01N21/15,,0,0,,,,PENDING
957,GR,B,GR 852779 B,067-048-216-098-443,1986-03-14,1986,GR 850102779 A,1985-11-18,US 67382984 A,1984-11-21,GR 852779 B,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;HUFFMAN WILLIAM FRANCIS;;YIM NELSON CHI-FAI,,https://lens.org/067-048-216-098-443,Granted Patent,no,0,0,18,20,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P5/00;;A61P9/08;;C07K7/16;;A61K38/00;;Y10S930/15,C07K14/575;;A61K38/00;;A61K38/095;;A61P5/00;;A61P9/08;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,EXPIRED
958,FI,A0,FI 854580 A0,083-943-775-834-380,1985-11-20,1985,FI 854580 A,1985-11-20,US 67382984 A,1984-11-21,FOERFARANDE FOER FRAMSTAELLNING AV BASISKA V1-VASOPRESSINANTAGONISTER.,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS;;MOORE MICHAEL LEE;;YIM NELSON CHI-FAI,,https://lens.org/083-943-775-834-380,Patent Application,no,0,0,18,20,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P5/00;;A61P9/08;;C07K7/16;;A61K38/00;;Y10S930/15,A61K38/00;;C07K14/575;;A61K38/095;;A61P5/00;;A61P9/08;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,DISCONTINUED
959,WO,A3,WO 2011/120003 A3,187-367-032-674-185,2012-01-19,2012,US 2011/0030072 W,2011-03-25,US 73215310 A,2010-03-25,SYSTEM AND METHOD FOR ENHANCING AND AUTHENTICATING AN INSURANCE ELIGIBILITY TRANSACTION,"The disclosure presents a system, method, and computer readable medium for execution on a computer processor, for authenticating and enhancing an insurance eligibility transaction, such as a 270/271 healthcare system transaction. In a particular embodiment, an insurance eligibility transaction request, such as a 270 transaction, is received/intercepted by the system prior to being received by the payor and data from one or more sources, such as a credit bureau database containing credit file data, is used to enhance, verify and correct the accuracy of data fields particular to the insurance eligibility transaction. The payor's database(s) can also be enhanced accordingly. The system also has capability to, among other things, identify fraud-related issues, charity qualification, and patient payment estimation as part of the transaction.",TRANS UNION LLC;;BAZZANI ROD;;BOHNSACK JAMES;;CALLAHAN MARTIN;;SILVA-CRAIG MILTON;;BABCOCK KATHY;;SNITMAN MICHAEL,BAZZANI ROD;;BOHNSACK JAMES;;CALLAHAN MARTIN;;SILVA-CRAIG MILTON;;BABCOCK KATHY;;SNITMAN MICHAEL,,https://lens.org/187-367-032-674-185,Search Report,yes,4,0,5,5,0,G06Q40/08;;G06Q40/00;;G06Q40/08;;G06Q40/00,G06Q40/08,,0,0,,,,PENDING
960,US,A1,US 2011/0238451 A1,066-900-102-837-070,2011-09-29,2011,US 73215310 A,2010-03-25,US 73215310 A,2010-03-25,SYSTEM AND METHOD FOR ENHANCING AND AUTHENTICATING AN INSURANCE ELGIBILITY TRANSACTION,"The disclosure presents a system, method, and computer readable medium for execution on a computer processor, for authenticating and enhancing an insurance eligibility transaction, such as a 270/271 healthcare system transaction. In a particular embodiment, an insurance eligibility transaction request, such as a 270 transaction, is received/intercepted by the system prior to being received by the payor and data from one or more sources, such as a credit bureau database containing credit file data, is used to enhance, verify and correct the accuracy of data fields particular to the insurance eligibility transaction. The payor's database(s) can also be enhanced accordingly. The system also has capability to, among other things, identify fraud-related issues, charity qualification, and patient payment estimation as part of the transaction.",TRANSUNION LLC,BAZZANI ROD;;BOHNSACK JAMES;;CALLAHAN MARTIN;;SILVA-CRAIG MILTON;;BABCOCK KATHY;;SNITMAN MICHAEL,TRANS UNION LLC (2010-07-15);;TRANSUNION HEALTHCARE INC (2021-12-06),https://lens.org/066-900-102-837-070,Patent Application,yes,31,25,5,5,0,G06Q40/08;;G06Q40/00;;G06Q40/08;;G06Q40/00,G06Q40/08,705/4,0,0,,,,ACTIVE
961,ZA,B,ZA 200504104 B,126-897-698-986-359,2006-03-29,2006,ZA 200504104 A,2006-02-07,US 42910502 P,2002-11-26,Calcilytic compounds,,SMITHKLINE BEECHAM CORP,MARQUIS ROBERT W JR;;CASILLAS LINDA N;;RAMANJULU JOSHI M;;CALLAHAN JAMES F,,https://lens.org/126-897-698-986-359,Granted Patent,no,0,0,60,60,0,C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;A61P1/02;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P3/02;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;C07C229/00;;C07C217/34;;C07C217/30;;C07C217/32;;C07C217/34;;C07C2602/08;;C07C217/54;;C07C229/34,A61K/;;C07C217/34;;C07C217/36;;C07C229/00,,0,0,,,,ACTIVE
962,FI,A,FI 854580 A,125-918-716-406-359,1986-05-22,1986,FI 854580 A,1985-11-20,US 67382984 A,1984-11-21,FOERFARANDE FOER FRAMSTAELLNING AV BASISKA V1-VASOPRESSINANTAGONISTER.,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS;;MOORE MICHAEL LEE;;YIM NELSON CHI-FAI,,https://lens.org/125-918-716-406-359,Patent Application,no,0,0,18,20,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P5/00;;A61P9/08;;C07K7/16;;A61K38/00;;Y10S930/15,A61K38/00;;C07K14/575;;A61K38/095;;A61P5/00;;A61P9/08;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,DISCONTINUED
963,US,A1,US 2014/0324485 A1,186-124-870-504-828,2014-10-30,2014,US 201414329519 A,2014-07-11,US 201414329519 A;;US 73215310 A,2010-03-25,SYSTEM AND METHOD FOR ENHANCING AND AUTHENTICATING AN INSURANCE ELIGIBILITY TRANSACTION,"The disclosure presents a system, method, and computer readable medium for execution on a computer processor, for authenticating and enhancing an insurance eligibility transaction, such as a 270/271 healthcare system transaction. In a particular embodiment, an insurance eligibility transaction request, such as a 270 transaction, is received/intercepted by the system prior to being received by the payor and data from one or more sources, such as a credit bureau database containing credit file data, is used to enhance, verify and correct the accuracy of data fields particular to the insurance eligibility transaction. The payor's database(s) can also be enhanced accordingly. The system also has capability to, among other things, identify fraud-related issues, charity qualification, and patient payment estimation as part of the transaction.",TRANS UNION LLC,BAZZANI ROD;;BOHNSACK JAMES;;CALLAHAN MARTIN;;SILVA-CRAIG MILTON;;BABCOCK KATHY;;SNITMAN MICHAEL,,https://lens.org/186-124-870-504-828,Patent Application,yes,2,0,5,5,0,G06Q40/08;;G06Q40/00;;G06Q40/08;;G06Q40/00,G06Q40/08,705/4,0,0,,,,DISCONTINUED
964,CO,A1,CO 5021223 A1,023-449-828-895-399,2001-03-27,2001,CO 99020600 A,1999-04-08,US 8108798 P,1998-04-08,COMPUESTOS CALCILITICOS CALCILITICOS,"Un compuesto según la fórmula (I) que figura a continuación:en la que: Y1 es un enlace covalente, alquileno o alquenileno de hasta 4 átomos de carbono, sin sustituir o sustituido con alquilo de C1-4 u O; Y2 es metileno, sin sustituir o sustituido con alquilo o haloalquilo de C1-4 ; Y3 es un enlace covalente u O, S, N-RIV o alquileno de C1-4 -O, alquileno de C1-4 -S, o alquileno de C1-4 -N-RIV ; RIV se selecciona entre el grupo que consta de H, alquilo de C1-4 , o cicloalquilo de C3-6 ; R3 y R4 son, independientemente, metilo o etilo, o, juntos, forman ciclopropilo; R5 es heteroarilo o heteroarilo fusionado; en el que el anillo heterocíclico contiene N, O o S, y es aromático, dihidro o tetrahidro, sin sustituir o sustituido con cualesquiera sustituyentes seleccionados entre el grupo que consta de OH, OCH3 , CH(CH3 )2 , halógeno, alquilo de C1-4 , alcoxi de C1-4 , cicloalquilo de C3-6 , OSO2 RIV , CN, NO2 , OCF3 , CF3 , CH2 CF3 , (CH2 )n CO2 H, (CH2 )n CO2 RIV , y O-(CH2 )n CO2 RIV ; n es un número entero de 0 a 3; G es un enlace covalente, CHR6 o C-R6 , en cuyas fórmulas R6 es H, OH u O (formando una cetona); R7 es H, OH, u O-alquilo de C1-4 ; - 2 -R8 es H o alquilo de C1-4 ; o R7 y R8 juntos forman una cetona; A y B se seleccionan independientemente entre el grupo que consta de un enlace, CH2 , NH, O, S y C=O, con tal que o bien A o B se seleccione entre CH2 y NH; o A y B juntos forman un enlace; o el resto A-B está representado por CH=CH o CºC; X se selecciona entre las subfórmulas (Ia) a (Ie) que se indican a continuación; en las que: W se selecciona entre el grupo que consta de R1 , SO2 R1 , C(O)R1 , SO2 NR1 R1 ´, C(O)NR1 R1 ´, C(O)OR1 , y SO3 R1 ´, en cuyas fórmulas R1 y R1 ´ se seleccionan independientemente entre el grupo que consta de hidrógeno, alquilo de C1-4 , cicloalquilo de C3-6 , alquenilo de C2-5 , alquinilo de C2-5 , heterocicloalquilo, arilo y aril-alquilo de C1-4 ; o R1 y R1 ´ juntos forman un anillo heterocíclico de 3 a 7 miembros opcionalmente sustituido; en el que cualesquiera sustituyentes se seleccionan entre el grupo que consta de CN, arilo, CO2 R, CO2 NHR, OH, OR, NH2 , halo, CF3 , OCF3 y NO2 ; en cuyas fórmulas R representa alquilo de C1-4 o cicloalquilo de C3-6 ; X1 se selecciona entre el grupo que consta de CN, NO2 , Cl, F, Br, I, H, R´, OR´. CF3 , OCF3 y OSO2 R´, en cuyas fórmulas R´ representa alquilo de C1-4 o cicloalquilo de C3-6 ; X2 , X3 y X4 se seleccionan, independientemente, entre el grupo que consta de CN, NO2 , Cl, F, Br, I, H, R"", OR"", CF3 , OCF3 y OSO2 R"", con tal que o bien X1 o X3 sea H, en cuyas fórmulas R"" es alquilo o haloalquilo de C1-4 ; o X1 y X2 juntos forman un anillo arílico o heteroarílico, sustituido o sin sustituir, en el que el heteroátomo se selecciona entre N, S y O; y cualesquiera sustituyentes se seleccionan entre el grupo que consta de halo, alquilo de C1-4 , OCF3 , CF3 , OMe, CN, OSO2 R ´ y NO2 ; o X3 y X4 , independientemente, representan C(O)R1 ; y R2 se selecciona entre el grupo que consta de hidrógeno, alquilo de C1-4 , cicloalquilo de C3-6 , alquenilo de C2-5 , alquinilo de C2-5 , heterocicloalquilAND#8209;arilo y arilAND#8209;alquilo de C1-4 ; X1 "" se selecciona entre el grupo que consta de CN, NO2 , Cl, F, Br, I, H, R, OR, CF3 , OCF3 y OSO2 R, en cuyas fórmulas R representa alquilo de C1-4 o cicloalquilo de C3-6 ; X2 "", X3 "" y X4 "" se seleccionan, independientemente, entre el grupo que consta de CN, NO2 , Cl, F, Br, I, H, R´, OR´. CF3 , OCF3 y OSO2 R´. con tal que o bien X""1 o X""3 sea H, en cuyas fórmulas R´ es alquilo o haloalquilo de C1-4 ; o X1 "" y X2 "" juntos forman un anillo arílico o heteroarílico, sustituido o sin sustituir, en el que el heteroátomo se selecciona entre N, S y O, y cualesquiera sustituyentes se seleccionan entre el grupo que consta de halo, alquilo de C1-4 , OCF3 , CF3 , OMe, CN, OSO2 AND#8209;alquilo de C1-4 , OSO2 AND#8209;cicloalquilo de C3-6 y NO2 ; o X3 "" y X4 "", independientemente, representan C(O)R1 ; y R1 "" y R2 "" se seleccionan, independientemente, entre el grupo que consta de hidrógeno, alquilo de C1-4 , cicloalquilo de C3-6 , alquenilo de C2-5 , alquinilo de C2-5 , heterocicloalquilo y arilo; o R1 "" y R2 "" juntos forman un anillo heterocíclico de 3 a 7 miembros opcionalmente sustituido; en el que cualesquiera sustituyentes se seleccionan entre el grupo que consta de CN, arilo, CO2 R"", CO2 NHR"", OH, OR"", NH2 , halo, CF3 , OCF3 y NO2 ; en cuyas fórmulas R"" representa alquilo de C1-4 o cicloalquilo de C3-6 ; X1 ""´ se selecciona entre el grupo que consta de CN, NO2 , Cl, F, Br, I, H, R, OR, CF3 , OCF3 y OSO2 R, en cuyas fórmulas R representa alquilo de C1-4 o cicloalquilo de C3-6 ; X2 ""´, X3 ""´ y X4 ""´ se seleccionan, independientemente, entre el grupo que consta de CN, NO2 , Cl, F, Br, I, H, R´, OR´. CF3 , OCF3 y OSO2 R´. con tal que o bien X""´1 o X""´3 sea H, en cuyas fórmulas R´ es alquilo o haloalquilo de C1-4 ; o X1 ""´ y X2 ""´ juntos forman un anillo arílico o heteroarílico, sustituido o sin sustituir, en el que el heteroátomo se selecciona entre N. S y O y los sustituyentes se seleccionan entre el grupo que consta de halo, alquilo de C1-4 , OCF3 , CF3 , OMe, CN, OSO2 AND#8209;alquilo de C1-4 , OSO2 AND#8209;cicloalquilo de C3AND#8209;6 y NO2 ; o X3 ""´ y X4 ""´ representan, independientemente, C(O)R1 ; R1 ""´ y R2 ""´ se seleccionan, independientemente, entre el grupo que consta de hidrógeno, alquilo de C1-4 , cicloalquilo de C3-6 , alquenilo de C2-5 , alquinilo de C2-5 , heterocicloalquilo y arilo; o R1 ""´ y R2 ""´ juntos forman un anillo heterocíclico de 3 a 7 miembros, opcionalmente sustituido, en el que los sustituyentes se seleccionan entre el grupo que consta de CN, arilo, CO2 R"", CO2 NHR"", OH, OR"", NH2 , halo, CF3 , OCF3 y NO2 , en cuyas fórmulas R"" representa alquilo de C1-4 o cicloalquilo de C3-6 ; D se selecciona entre el grupo que consta de H, CN, NO2 , Cl, F, Br, I, R, OR, SR, CF3 , OCF3 y OSO2 R, en cuyas fórmulas R representa alquilo de C1-4 , cicloalquilo de C3-6 o arilo o heteroarilo de C1-10 , en el que el heteroátomo se selecciona entre N, S y O y los sustituyentes se seleccionan entre el grupo que consta de halo, alquilo de C1-4 , OCF3 , CF3 , OMe, CN, O SO2 AND#8209;alquilo de C1-4 , OSO2 AND#8209;cicloalquilo de C3-6 y NO2 ; n es el número entero 1 ó 2; cada E es independientemente C o N, con tal que no más de dos restos E sean N; con tal que, además, cuando n es 2. cada E es C; a y b son opcionalmente enlaces presentes; R1 IV se selecciona entre el grupo que consta de (CH2 )n CO2 R´, (CH2 )n CO2 H, (CH2 )n CONR´2 , (CH2 )n CH2 OR´, OR´. SR´. CN, NO2 , Cl, F, Br, I, H, CF3 , OCF3 , OSO2 R´, R´ y H, en cuyas fórmulas R´ representa alquilo de C1-4 o cicloalquilo de C3-6 ; o R1 IV es O, formando una cetona tal que YR1 IV representa AND#8209;C=O; R21 IV se selecciona entre el grupo que consta de hidrógeno, CN, NO2 , Cl, F, Br, I, H, R"" OR"", CF3 , OCF3 y OSO2 R"", en cuyas fórmulas R"" representa alquilo de C1-4 o cicloalquilo de C3-6 .Y se selecciona entre el grupo que consta de C, CH, O, N y S, con tal que cuando Y es S, R1 IV es O o no está presente; con tal que, además, cuando Y es O, R1 IV no está presente; X´ se selecciona entre el grupo que consta de CH2 , NH, O y S. R9 se selecciona entre el grupo que consta de OAND#8209;alquilo, OAND#8209;CH2 AND#8209;arilo y OAND#8209;arilo; X1 """" se selecciona entre el grupo que consta de CN, NO2 , Cl, F, Br, I, H, R, OR, CF3 , OCF3 y OSO2 R, en cuyas fórmulas R representa alquilo de C1-4 o cicloalquilo de C3-6 ; X2 """", X3 """" y X4 """" se seleccionan, independientemente, entre el grupo que consta de CN, NO2 , Cl, F, Br, I, H, R´, OR´, CF3 , OCF3 y OSO2 R´, con tal que o bien X""""1 o X""""3 sea H, en cuyas fórmulas R´ es alquilo o haloalquilo de C1-4 ; o X1 """" y X2 """" juntos forman un anillo arílico o heteroarílico, sustituido o sin sustituir, en el que el heteroátomo se selecciona entre N, S y O y los sustituyentes se seleccionan entre el grupo que consta de halo, alquilo de C1-4 , OCF3 , CF3 , OMe, CN, OSO2 AND#8209;alquilo de C1-4 , OSO2 AND#8209;cicloalquilo de C3-6 y NO2 ; o X2 """" y X4 """", independientemente, representan C(O)R1 ; y sus sales y complejos farmacéuticamente aceptables.",SMITHKLINE BEECHAM CORP;;NPS PHARMA INC,PRADIP KUMAR BHATNAGAR;;LAGO MARIA AMPARO;;CALLAHAN JAMES FRANCIS;;DEL MAR ERIC G,,https://lens.org/023-449-828-895-399,Patent Application,no,0,0,8,9,0,A61P1/02;;A61P3/12;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;C07D307/79;;C07C255/54;;C07D213/38;;C07D215/12;;C07D217/14,A61K31/13;;A61K31/18;;A61K31/235;;A61K31/275;;A61K31/343;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/5377;;A61P1/02;;A61P3/12;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;C07C255/54;;C07D213/38;;C07D215/12;;C07D217/14;;C07D307/79,,0,0,,,,PENDING
965,AU,B2,AU 579205 B2,101-723-170-659-424,1988-11-17,1988,AU 1985/049901 A,1985-11-14,US 67382984 A,1984-11-21,BASIC V1- VASOPRESSIN ANTAGONISTS,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;HUFFMAN WILLIAM FRANCIS;;YIM NELSON CHI-FAI,,https://lens.org/101-723-170-659-424,Granted Patent,no,0,0,18,20,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P5/00;;A61P9/08;;C07K7/16;;A61K38/00;;Y10S930/15,C07K14/575;;A61K38/00;;A61K38/095;;A61P5/00;;A61P9/08;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,EXPIRED
966,EP,A2,EP 0182627 A2,015-679-897-598-914,1986-05-28,1986,EP 85308326 A,1985-11-15,US 67382984 A,1984-11-21,Basic V1-vasopressin antagonists.,"Compounds of Formula:
  in which:
 A is -NR-(CH 2 ) n -NR 2  or
  I P is Phe, Ile, Phe(4'-Alk), Tyr or Tyr(Alk); X is a D or L isomer of Val, Nva, Leu, Ile, Pba, Phe, Phe(4'-Alk), Trp, Nle, Cha, Abu, Met, Chg, Tyr or Tyr(Alk); Y is Val, lie, Abu, Ala, Chg, Gln, Lys, Cha, Thr, Nle, Phe, Leu or Gly; Z is Gly, Sar, a single bond or a D or L isomer of Pro, Δ3-Pro, Ala or N-Me-Ala; R 1  is, each, hydrogen or methyl; n is an integer from 2-8; and R is, each, hydrogen or methyl; or a pharmaceutically acceptable salt thereof. The compounds are V,-vasopressin antagonists and are useful in the treatment of hypertension and cardiac ischaemic diseases.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;HUFFMAN WILLIAM FRANCIS;;YIM NELSON CHI-FAI,,https://lens.org/015-679-897-598-914,Patent Application,yes,0,2,18,20,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P5/00;;A61P9/08;;C07K7/16;;A61K38/00;;Y10S930/15,A61K38/00;;A61K38/095;;A61P5/00;;C07K14/575;;A61P9/08;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,DISCONTINUED
967,US,A,US 3631486 A,094-919-832-731-492,1971-12-28,1971,US 3631486D A,1969-06-24,US 83599569 A,1969-06-24,PROCESSING METHOD AND COMMUTATION SYSTEM FOR PULSE DOPPLER RADAR,,WESTINGHOUSE ELECTRIC CORP,ANDERS ROLAND A;;CALLAHAN DAVID E;;MYERS F STEWART JR;;SABOE JAMES M,,https://lens.org/094-919-832-731-492,Granted Patent,no,1,9,1,1,0,G01S13/585;;G01S13/585,G01S13/58,343/8,0,0,,,,EXPIRED
968,WO,A2,WO 2011/120003 A2,124-620-886-217-093,2011-09-29,2011,US 2011/0030072 W,2011-03-25,US 73215310 A,2010-03-25,SYSTEM AND METHOD FOR ENHANCING AND AUTHENTICATING AN INSURANCE ELIGIBILITY TRANSACTION,"The disclosure presents a system, method, and computer readable medium for execution on a computer processor, for authenticating and enhancing an insurance eligibility transaction, such as a 270/271 healthcare system transaction. In a particular embodiment, an insurance eligibility transaction request, such as a 270 transaction, is received/intercepted by the system prior to being received by the payor and data from one or more sources, such as a credit bureau database containing credit file data, is used to enhance, verify and correct the accuracy of data fields particular to the insurance eligibility transaction. The payor's database(s) can also be enhanced accordingly. The system also has capability to, among other things, identify fraud-related issues, charity qualification, and patient payment estimation as part of the transaction.",TRANS UNION LLC;;BAZZANI ROD;;BOHNSACK JAMES;;CALLAHAN MARTIN;;SILVA-CRAIG MILTON;;BABCOCK KATHY;;SNITMAN MICHAEL,BAZZANI ROD;;BOHNSACK JAMES;;CALLAHAN MARTIN;;SILVA-CRAIG MILTON;;BABCOCK KATHY;;SNITMAN MICHAEL,,https://lens.org/124-620-886-217-093,Patent Application,yes,0,1,5,5,0,G06Q40/08;;G06Q40/00;;G06Q40/08;;G06Q40/00,G06Q40/08,,0,0,,,,PENDING
969,AU,A,AU 1999/035513 A,091-837-663-729-376,1999-10-25,1999,AU 1999/035513 A,1999-04-08,US 8108798 P;;US 9907760 W,1998-04-08,Calcilytic compounds and method of use,,NPS PHARMA INC;;SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP KUMAR;;CALLAHAN JAMES FRANCIS;;MAR ERIC G DEL;;LAGO MARIA AMPARO,,https://lens.org/091-837-663-729-376,Patent Application,no,0,0,8,9,0,A61P1/02;;A61P3/12;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;C07D307/79;;C07C255/54;;C07D213/38;;C07D215/12;;C07D217/14,A61K31/18;;A61K31/235;;A61K31/275;;A61K31/343;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/5377;;A61P1/02;;A61P3/12;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;C07C255/54;;C07D213/38;;C07D215/12;;C07D217/14;;C07D307/79,,0,0,,,,DISCONTINUED
970,EP,A4,EP 1069901 A4,135-150-451-884-829,2001-06-13,2001,EP 99917374 A,1999-04-08,US 9907760 W;;US 8108798 P,1998-04-08,CALCILYTIC COMPOUNDS AND METHOD OF USE,,SMITHKLINE BEECHAM CORP;;NPS PHARMA INC,BHATNAGAR PRADIP KUMAR;;CALLAHAN JAMES FRANCIS;;DEL MAR ERIC G;;LAGO MARIA AMPARO,,https://lens.org/135-150-451-884-829,Search Report,no,0,0,8,9,0,A61P1/02;;A61P3/12;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;C07D307/79;;C07C255/54;;C07D213/38;;C07D215/12;;C07D217/14,A61K31/18;;A61K31/235;;A61K31/275;;A61K31/343;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/5377;;A61P1/02;;A61P3/12;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;C07C255/54;;C07D213/38;;C07D215/12;;C07D217/14;;C07D307/79,,2,0,,,No further relevant documents disclosed;;See also references of WO 9951241A1,DISCONTINUED
971,ZA,B,ZA 858892 B,171-107-695-791-612,1986-10-29,1986,ZA 858892 A,1985-11-20,US 67382984 A,1984-11-21,BASIC V1-VASOPRESSIN ANTAGONISTS,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;HUFFMAN WILLIAM FRANCIS;;YIM NELSON CHI-FAI,,https://lens.org/171-107-695-791-612,Granted Patent,no,0,0,18,20,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P5/00;;A61P9/08;;C07K7/16;;A61K38/00;;Y10S930/15,A61K38/00;;C07K14/575;;A61K38/095;;A61P5/00;;A61P9/08;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,EXPIRED
972,WO,A1,WO 1999/051241 A1,003-383-479-309-827,1999-10-14,1999,US 9907760 W,1999-04-08,US 8108798 P,1998-04-08,CALCILYTIC COMPOUNDS AND METHOD OF USE,Calcilytic compounds and compositions and their use in treating abnormal bone or mineral homeostasis.,SMITHKLINE BEECHAM CORP;;NPS PHARMA INC;;BHATNAGAR PRADIP KUMAR;;CALLAHAN JAMES FRANCIS;;DEL MAR ERIC G;;LAGO MARIA AMPARO,BHATNAGAR PRADIP KUMAR;;CALLAHAN JAMES FRANCIS;;DEL MAR ERIC G;;LAGO MARIA AMPARO,,https://lens.org/003-383-479-309-827,Patent Application,yes,1,37,8,9,0,A61P1/02;;A61P3/12;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;C07D307/79;;C07C255/54;;C07D213/38;;C07D215/12;;C07D217/14,A61K31/18;;A61K31/235;;A61K31/275;;A61K31/343;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/5377;;A61P1/02;;A61P3/12;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;C07C255/54;;C07D213/38;;C07D215/12;;C07D217/14;;C07D307/79,,2,0,,,"Chemical Abstracts Service (C A S); 1 January 1998 (1998-01-01), BARMORE R M, ET AL: ""PREPARATION OF ARYLALKYLAMINE AS CALCILYTIC COMPOUNDS"", XP002945355, Database accession no. 129-302376P;;See also references of EP 1069901A4",PENDING
973,DK,D0,DK 538985 D0,127-699-017-586-413,1985-11-21,1985,DK 538985 A,1985-11-21,US 67382984 A,1984-11-21,BASISKE V1-VASOPRESSIN-ANTAGONISTER,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;HUFFMAN WILLIAM FRANCIS;;YIM NELSON CHI-FAI,,https://lens.org/127-699-017-586-413,Patent Application,no,0,0,18,20,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P5/00;;A61P9/08;;C07K7/16;;A61K38/00;;Y10S930/15,A61K38/00;;C07K14/575;;A61K38/095;;A61P5/00;;A61P9/08;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,DISCONTINUED
974,US,A1,US 2002/0052509 A1,113-285-968-659-499,2002-05-02,2002,US 549001 A,2001-12-04,US 549001 A;;US 64779400 A;;US 8108798 P,1998-04-08,Calcilytic compounds and method of use,"
   Calcilytic compounds and compositions and their use in treating abnormal bone or mineral homeostasis. 
",SMITHKLINE BEECHAM CORP,BHATNAGAR PRADIP KUMAR;;CALLAHAN JAMES FRANCIS;;DEL MAR ERIC G;;LAGO MARIA AMPARO,,https://lens.org/113-285-968-659-499,Patent Application,yes,0,6,1,9,0,C07C255/54;;C07D213/38;;C07D215/12;;C07D217/14;;C07D307/79;;C07D307/79;;C07D217/14;;C07D215/12;;C07D213/38;;C07C255/54,C07C255/54;;C07D213/38;;C07D215/12;;C07D217/14;;C07D307/79,546/329;;546/229;;548/566;;549/74;;549/492,0,0,,,,DISCONTINUED
975,EP,A1,EP 1069901 A1,167-995-277-635-493,2001-01-24,2001,EP 99917374 A,1999-04-08,US 9907760 W;;US 8108798 P,1998-04-08,CALCILYTIC COMPOUNDS AND METHOD OF USE,,SMITHKLINE BEECHAM CORP;;NPS PHARMA INC,BHATNAGAR PRADIP KUMAR;;CALLAHAN JAMES FRANCIS;;DEL MAR ERIC G;;LAGO MARIA AMPARO,,https://lens.org/167-995-277-635-493,Patent Application,yes,0,2,8,9,0,A61P1/02;;A61P3/12;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;C07D307/79;;C07C255/54;;C07D213/38;;C07D215/12;;C07D217/14,A61K31/18;;A61K31/235;;A61K31/275;;A61K31/343;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/5377;;A61P1/02;;A61P3/12;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;C07C255/54;;C07D213/38;;C07D215/12;;C07D217/14;;C07D307/79,,0,0,,,,DISCONTINUED
976,AU,A,AU 1985/049901 A,137-833-123-369-575,1986-05-29,1986,AU 1985/049901 A,1985-11-14,US 67382984 A,1984-11-21,BASIC V1- VASOPRESSIN ANTAGONISTS,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;HUFFMAN WILLIAM FRANCIS;;YIM NELSON CHI-FAI,,https://lens.org/137-833-123-369-575,Patent Application,no,0,0,18,20,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P5/00;;A61P9/08;;C07K7/16;;A61K38/00;;Y10S930/15,C07K14/575;;A61K38/00;;A61K38/095;;A61P5/00;;A61P9/08;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,EXPIRED
977,DK,A,DK 538985 A,085-643-450-716-579,1986-05-22,1986,DK 538985 A,1985-11-21,US 67382984 A,1984-11-21,BASISKE V1-VASOPRESSIN-ANTAGONISTER,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;MOORE MICHAEL LEE;;HUFFMAN WILLIAM FRANCIS;;YIM NELSON CHI-FAI,,https://lens.org/085-643-450-716-579,Patent Application,no,0,0,18,20,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P5/00;;A61P9/08;;C07K7/16;;A61K38/00;;Y10S930/15,A61K38/00;;C07K14/575;;A61K38/095;;A61P5/00;;A61P9/08;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,DISCONTINUED
978,NO,L,NO 854645 L,015-904-841-043-061,1986-05-22,1986,NO 854645 A,1985-11-20,US 67382984 A,1984-11-21,FREMGANGSMAATE FOR FREMSTILLING AV BASISKE CYKLISKE PEPTIDER.,,SMITHKLINE BECKMAN CORP,CALLAHAN JAMES FRANCIS;;HUFFMAN WILLIAM FRANCIS;;MOORE MICHAEL LEE;;YIM NELSON CHI-FAI,,https://lens.org/015-904-841-043-061,Abstract,no,0,0,18,20,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P5/00;;A61P9/08;;C07K7/16;;A61K38/00;;Y10S930/15,A61K38/00;;C07K14/575;;A61K38/095;;A61P5/00;;A61P9/08;;C07K1/113;;C07K7/06;;C07K7/16,,0,0,,,,DISCONTINUED
979,US,A,US 4760052 A,055-943-494-607-389,1988-07-26,1988,US 4365887 A,1987-04-28,US 4365887 A;;US 81933686 A,1986-01-16,"1,6-dicarba-vasopressin compounds","New compounds which have potent V.sub.2 -vasopressin antagonistic activity are prepared by a 1,6-cyclization using peptide bond formation. The structures of the compounds are characterized by a Pas.sup.1,6 or Tas.sup.1,6 cyclized unit. Also a chiral synthesis of the optically pure Pas intermediates is described.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES F;;HUFFMAN WILLIAM F;;NEWLANDER KENNETH A;;YIM NELSON C F,SMITHKLINE BECKMAN CORPORATION ONE FRANKLIN PLAZA A CORP. OF PA (1987-05-21),https://lens.org/055-943-494-607-389,Granted Patent,yes,8,8,1,24,0,A61K38/00;;C07C403/02;;C07K7/16;;Y10S930/15;;C07C2601/14;;C07C403/02;;C07K7/16;;A61K38/00;;Y10S930/15;;C07C2601/14,A61K38/00;;C07K7/16,514/11;;514/807;;530/315,6,4,033-397-815-760-883;;138-521-888-181-885;;060-751-920-827-603;;013-751-719-419-734,6317675;;10.1016/s0021-9258(17)43742-2;;10.1016/0006-291x(84)91187-2;;6089787;;6263733;;10.1016/0303-7207(81)90086-1;;10.1021/jo01303a028,"S. Hase et al., Journal of American Chemical Society, pp. 3591 3600, 5/17/1972.;;Fahrenholz et al., Journal of Biological Chemistry, pp. 14861 14867, 12/25/1983.;;Fahrenholz et al., Biochemical and Biophysical Research Communications, vol. 122, No. 3, pp. 974 982, Aug. 16, 1984.;;Jost et al., Collection Czechoslov. Chem. Commun. Institute of Organic Chemistry and Biochemistry, Czechoslovak Academy of Sciences, Prague 6, Jun. 5, 1970.;;Sawyer et al., Molecular and Cellular Endocrinology, pp. 117 134, 1981.;;Nutt et al., J. Org. Chem., pp. 3078 3080, 1980.",EXPIRED
980,US,A,US 4908475 A,092-367-343-515-929,1990-03-13,1990,US 19273688 A,1988-05-09,US 19273688 A;;US 81933686 A,1986-01-16,"Intermediates for preparing 1,6-dicarba-vasopressin compounds","New compounds which have potent V.sub.2 -vasopressin antagonistic activity are prepared by a 1,6-cyclization using peptide bond formation. The structures of the compounds are characterized by a Pas.sup.1,6 or Tas.sup.1,6 cyclized unit. Also a chiral synthesis of the optically pure Pas intermediates is described.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES F;;HUFFMAN WILLIAM F;;NEWLANDER KENNETH A;;YIM NELSON C F,,https://lens.org/092-367-343-515-929,Granted Patent,yes,0,6,1,24,0,A61K38/00;;A61K38/00;;C07K7/16;;C07K7/16,A61K38/00;;C07K7/16,560/115;;560/12;;560/17;;560/121;;560/125;;562/430;;562/431;;562/503;;562/507,0,0,,,,EXPIRED
981,EP,A3,EP 0182627 A3,150-945-563-216-852,1988-10-05,1988,EP 85308326 A,1985-11-15,US 67382984 A,1984-11-21,BASIC V1-VASOPRESSIN ANTAGONISTS,"Compounds of Formula:
  in which:
 A is -NR-(CH 2 ) n -NR 2  or
  I P is Phe, Ile, Phe(4'-Alk), Tyr or Tyr(Alk); X is a D or L isomer of Val, Nva, Leu, Ile, Pba, Phe, Phe(4'-Alk), Trp, Nle, Cha, Abu, Met, Chg, Tyr or Tyr(Alk); Y is Val, lie, Abu, Ala, Chg, Gln, Lys, Cha, Thr, Nle, Phe, Leu or Gly; Z is Gly, Sar, a single bond or a D or L isomer of Pro, Δ3-Pro, Ala or N-Me-Ala; R 1  is, each, hydrogen or methyl; n is an integer from 2-8; and R is, each, hydrogen or methyl; or a pharmaceutically acceptable salt thereof. The compounds are V,-vasopressin antagonists and are useful in the treatment of hypertension and cardiac ischaemic diseases.",SMITHKLINE BECKMAN CORPORATION,"CALLAHAN, JAMES FRANCIS;;MOORE, MICHAEL LEE;;HUFFMAN, WILLIAM FRANCIS;;YIM, NELSON CHI-FAI",,https://lens.org/150-945-563-216-852,Search Report,yes,1,0,18,20,0,A61K38/00;;C07K7/16;;Y10S930/15;;A61P5/00;;A61P9/08;;C07K7/16;;A61K38/00;;Y10S930/15,A61K38/00;;A61K38/095;;C07K14/575;;A61P5/00;;A61P9/08;;C07K1/113;;C07K7/06;;C07K7/16,,3,2,114-135-622-371-458;;019-359-311-496-287,10.1135/cccc19793128;;10.1021/jm00150a003;;2933517,"CHEMICAL ABSTRACTS, Band 92, Nr. 21, Mai 1980, Seite 701, Zusammenfassung Nr. 181626b, Columbus, Ohio, US; M. ZAORAL et al.: ""Vasopressin anaolgs modified in position 3. Influence of changes of configuration"", & COLLECT. CZECH. CHEM. COMMUN. 1979, 44(10), 3128-32;;CHEMICAL ABSTRACTS, Band 92, Nr. 3, Januar 1980, Seite 714, Zusammenfassung Nr. 22796r, Columbus, Ohio, US; V. KRCHNAK et al.: ""Amino acids and peptides. CLIV. [1-beta mercaptopropionic acid. 8-alpha,beta-diaminopropionic acid]vasopressin and [1-beta-mercaptopropionic acid, 8-D-alpah,beta-diaminopropionic acid]vasopressin. Two lysine-vasopressin analogs with considerable antidiuretic effect"", & COLLECT. CZECH. CHEM. COMMUN. 1979, 44(7), 2161-4;;JOURNAL OF MEDICAL CHEMISTRY, Band 28, Nr. 12, 1985, Seiten 1759-1760, American Chemical Society; J.R. HUFF et al.: ""Novel vasopressin analogues that help define a minimum effective antagonist pharmacophore""",DISCONTINUED
982,CA,A1,CA 2327188 A1,065-946-291-719-627,1999-10-14,1999,CA 2327188 A,1999-04-08,US 8108798 P;;US 9907760 W,1998-04-08,CALCILYTIC COMPOUNDS AND METHOD OF USE,Calcilytic compounds and compositions and their use in treating abnormal bone or mineral homeostasis.,SMITHKLINE BEECHAM CORP;;NPS PHARMA INC,LAGO MARIA AMPARO;;BHATNAGAR PRADIP KUMAR;;CALLAHAN JAMES FRANCIS;;DEL MAR ERIC G,,https://lens.org/065-946-291-719-627,Patent Application,no,0,0,8,9,0,A61P1/02;;A61P3/12;;A61P19/00;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;C07D307/79;;C07C255/54;;C07D213/38;;C07D215/12;;C07D217/14,A61K31/18;;A61K31/235;;A61K31/275;;A61K31/343;;A61K31/4402;;A61K31/4406;;A61K31/47;;A61K31/472;;A61K31/5377;;A61P1/02;;A61P3/12;;A61P19/02;;A61P19/08;;A61P19/10;;A61P29/00;;A61P35/00;;C07C255/54;;C07D213/38;;C07D215/12;;C07D217/14;;C07D307/79,,0,0,,,,DISCONTINUED
983,US,B2,US 8781850 B2,098-710-951-451-723,2014-07-15,2014,US 73215310 A,2010-03-25,US 73215310 A,2010-03-25,System and method for enhancing and authenticating an insurance eligibility transaction,"The disclosure presents a system, method, and computer readable medium for execution on a computer processor, for authenticating and enhancing an insurance eligibility transaction, such as a 270/271 healthcare system transaction. In a particular embodiment, an insurance eligibility transaction request, such as a 270 transaction, is received/intercepted by the system prior to being received by the payor and data from one or more sources, such as a credit bureau database containing credit file data, is used to enhance, verify and correct the accuracy of data fields particular to the insurance eligibility transaction. The payor's database(s) can also be enhanced accordingly. The system also has capability to, among other things, identify fraud-related issues, charity qualification, and patient payment estimation as part of the transaction.",BAZZANI ROD;;BOHNSACK JAMES;;CALLAHAN MARTIN;;SILVA-CRAIG MILTON;;BABCOCK KATHY;;SNITMAN MICHAEL;;TRANS UNION LLC,BAZZANI ROD;;BOHNSACK JAMES;;CALLAHAN MARTIN;;SILVA-CRAIG MILTON;;BABCOCK KATHY;;SNITMAN MICHAEL,TRANS UNION LLC (2010-07-15);;TRANSUNION HEALTHCARE INC (2021-12-06),https://lens.org/098-710-951-451-723,Granted Patent,yes,34,12,5,5,0,G06Q40/08;;G06Q40/00;;G06Q40/08;;G06Q40/00,G06Q40/08;;G06Q50/22,705/2;;705/3;;705/4,1,0,,,"International Search Report and Written Opinion for International Patent Application No. PCT/US2011/030072 dated Nov. 28, 2011.",ACTIVE
984,US,A,US 4810778 A,194-928-101-501-095,1989-03-07,1989,US 19167388 A,1988-05-09,US 19167388 A;;US 81933686 A,1986-01-16,"Intermediates for preparing 1,6-dicarba-vasopressin compounds","New compounds which have potent V.sub.2 -vasopressin antagonistic activity are prepared by a 1,6-cyclization using peptide bond formation. The structures of the compounds are characterized by the Pas.sup.1,6 or Tas.sup.1,6 cyclized unit. Also a chiral synthesis of the optically pure Pas intermediates is described.",SMITHKLINE BECKMAN CORP,CALLAHAN JAMES F;;HUFFMAN WILLIAM F;;NEWLANDER KENNETH A;;YIM NELSON C F,,https://lens.org/194-928-101-501-095,Granted Patent,yes,1,2,1,24,0,A61K38/00;;C07K7/16;;Y10S930/15;;C07K7/16;;A61K38/00;;Y10S930/15,A61K38/00;;C07K7/16,530/328;;530/332,0,0,,,,EXPIRED
985,EP,A4,EP 1556379 A4,164-090-375-154-698,2007-06-13,2007,EP 03776396 A,2003-10-15,US 0332625 W;;US 41891502 P,2002-10-16,CHEMICAL COMPOUNDS,,SMITHKLINE BEECHAM CORP,BURGESS JOELLE L;;CALLAHAN JAMES F;;HAMAJIMA TOSHIHIRO;;IDA SATORU;;TANG JUN;;MORI ICHIRO,,https://lens.org/164-090-375-154-698,Search Report,no,3,0,9,9,0,C07D215/54;;C07D401/12;;C07D405/12;;A61P13/12;;A61P15/00;;A61P25/28;;A61P35/00;;A61P37/02;;A61P43/00;;A61P7/00;;A61P7/06;;C07D401/12;;C07D215/54;;C07D405/12,A61K/;;A61K31/47;;C07D215/54;;C07D401/12;;C07D405/12;;C07D453/02,,7,2,131-676-777-114-614;;023-184-478-457-792,10.1021/jm00177a010;;6767846;;10.1002/1521-4184(200212)335:9<403::aid-ardp403>3.0.co;2-9;;12447913,"DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; OUYANG, JIE ET AL: ""Synthesis of 7,8-methylenedioxy-4-oxo-3,4-dihydropyrimido[4,5- b]quinoline derivatives"", XP002430811, retrieved from STN Database accession no. 1995:436368;;DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CHEN, WEI ET AL: ""Syntheses of 3,4-dihydro-4-oxopyrimido[4,5-b]quinolines"", XP002430812, retrieved from STN Database accession no. 1991:42719;;ALTHUIS, T. H. ET AL: ""Structure-activity relationships in a series of novel 3,4-dihydro-4-oxopyrimido[4,5-b]quinoline-2-carboxylic acid antiallergy agents"", JOURNAL OF MEDICINAL CHEMISTRY , 23(3), 262-9 CODEN: JMCMAR; ISSN: 0022-2623, 1980, XP002430804;;DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SOMASEKHARA, I. S. ET AL: ""Synthesis of fused heterocyclics"", XP002430813, retrieved from STN Database accession no. 1956:16402;;DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GANAPATHI, K.: ""Chemotherapy of bacterial infections. II. Synthesis of some sulfanilamide derivatives and the relation of chemical constitution to chemotherapeutic action"", XP002430814, retrieved from STN Database accession no. 1940:41115;;DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TROGER, J. ET AL: ""Quinoline syntheses carried out with 6-amino-3-methoxybenzaldehyde and a condensation product resulting from this aldehyde"", XP002430815, retrieved from STN Database accession no. 1928:621;;EL-SAYED, OLA A. ET AL: ""Synthesis of some novel quinoline-3-carboxylic acids and pyrimidoquinoline derivatives as potential antimicrobial agents"", ARCHIV DER PHARMAZIE (WEINHEIM, GERMANY) , 335(9), 403-410 CODEN: ARPMAS; ISSN: 0365-6233, 2002, XP002430805",DISCONTINUED
986,AT,T1,AT E423762 T1,192-635-840-724-610,2009-03-15,2009,AT 01910349 T,2001-01-24,US 17768300 P,2000-01-24,CALCILYTISCHE VERBINDUNGEN,,SMITHKLINE BEECHAM CORP;;NPS PHARMA INC,LAGO AMPARO M;;CALLAHAN JAMES;;BHATNAGAR PRADIP;;DEL MAR ERIC;;BRYAN WILLIAM;;BURGESS JOELLE,,https://lens.org/192-635-840-724-610,Granted Patent,no,0,0,37,37,0,C07C69/616;;C07C69/738;;C07C211/30;;C07C233/05;;C07C251/48;;C07C255/57;;C07C255/58;;C07D303/22;;C07C2602/08;;C07C2602/10;;A61P1/02;;A61P19/02;;A61P19/08;;A61P19/10;;A61P3/14;;A61P35/00;;A61P43/00;;A61P5/18;;A61P5/22;;C07C255/50,A61K45/00;;A61K31/192;;A61K31/216;;A61K31/275;;A61K31/565;;A61K31/593;;A61K31/663;;A61K38/22;;A61P1/02;;A61P3/14;;A61P5/18;;A61P19/02;;A61P19/08;;A61P19/10;;A61P35/00;;A61P43/00;;C07C69/616;;C07C69/738;;C07C211/30;;C07C233/05;;C07C251/48;;C07C255/57;;C07C255/58;;C07D303/22,,0,0,,,,EXPIRED
987,WO,A3,WO 2004/073628 A3,079-666-565-388-16X,2005-05-12,2005,US 2004/0004406 W,2004-02-13,US 44741003 P;;US 53809504 P,2003-02-14,NOVEL COMPOUNDS,"Novel substituted 1,5,7-trisubstituted-1,8-napthyridin-2(1H)-one compounds; 1,5,7 trisubstituted-1,6-napthyridine-2-(1H)-one compounds and 1,5,7-trisubstituted quinoline-2(1H)-one compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy.",SMITHKLINE BEECHAM CORP;;BOEHM JEFFREY CHARLES;;CALLAHAN JAMES FRANCIS;;HALL RALPH F;;LIN XICHEN;;WIDDOWSON KATHERINE LOUISE,BOEHM JEFFREY CHARLES;;CALLAHAN JAMES FRANCIS;;HALL RALPH F;;LIN XICHEN;;WIDDOWSON KATHERINE LOUISE,,https://lens.org/079-666-565-388-16X,Search Report,yes,2,0,12,13,0,C07D215/227;;C07D215/38;;C07D471/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P33/06;;A61P35/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/04;;A61P9/10;;C07D215/227;;C07D215/38;;C07D471/04,A61K/;;A61K31/00;;A61K31/4375;;A61P29/00;;A61P31/12;;C07D215/22;;C07D215/227;;C07D215/38;;C07D471/04,,4,0,,,"DATABASE CAPLUS [online] FERRARINI ET AL.: ""Unusual nitration of substituted 7-amino-1,8-naphthyridine in the synthesis of compounds with antiplatelet activity"", XP002984278, accession no. STN Database accession no. 1997:751963;;DATABASE CAPLUS [online] FERRARINI ET AL.: ""Synthesis of bis(2-chloroethyl)amino-1,8-napthyridines for evaluation as anticancer agents"", XP002984279, accession no. STN Database accession no. 1984:530612;;DATABASE CAPLUS [online] CARBONI ET AL.: ""Tetrazolo derivatives of 1,8-naphthyridines. IV"", XP002984280, accession no. STN Database accession no. 1969:68265;;DATABASE CAPLUS [online] CARBONI ET AL.: ""Anthyridines. II"", XP002984281, accession no. STN Database accession no. 1968:95722",PENDING
988,GB,A,GB 2487823 A,103-899-931-251-549,2012-08-08,2012,GB 201200740 A,2012-01-17,US 201113021238 A,2011-02-04,Oil management system for a compressor,"An oil management system for a swash plate compressor comprises a first fluid flow path to permit a flow of the working fluid from the crank chamber 18 to the suction chamber 20, via a passage 54, 55 through the drive shaft 48. Working fluid and oil enters a passage 56 formed in the rotor, but oil is expelled due to centrifugal force so that only the working fluid (refrigerant) is passed to the suction chamber 20. A second fluid flow path 80 allows flow of a mixture of the working fluid and a lubricating fluid from the crank chamber 18 to the suction chamber 20, and the second fluid flow path 80 is selectively opened and closed by the outer surface 72 of an annular sleeve 58. In this way, the passage 80 may be closed for some positions of the swash plate, and opened in other positions (figure 2)",VISTEON GLOBAL TECH INC,GANSTER PETE EDWARD;;BHATIA KANWAL;;THEODORE MICHAEL GREGORY;;CALLAHAN RODNEY JAMES;;KELM BRIAN ROBERT,,https://lens.org/103-899-931-251-549,Patent Application,no,3,0,9,9,0,F04B27/109;;F04B27/1036;;F04B27/1036;;F04B27/1045;;F04B27/1045;;F04B27/109;;F04B27/109;;F04B27/18;;F04B39/02;;F04B39/02,F04B27/10,,0,0,,,,ACTIVE
989,WO,A2,WO 2004/073628 A2,177-941-537-156-763,2004-09-02,2004,US 2004/0004406 W,2004-02-13,US 44741003 P;;US 53809504 P,2003-02-14,NOVEL COMPOUNDS,"Novel substituted 1,5,7-trisubstituted-1,8-napthyridin-2(1H)-one compounds; 1,5,7 trisubstituted-1,6-napthyridine-2-(1H)-one compounds and 1,5,7-trisubstituted quinoline-2(1H)-one compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy.",SMITHKLINE BEECHAM CORP;;BOEHM JEFFREY CHARLES;;CALLAHAN JAMES FRANCIS;;HALL RALPH F;;LIN XICHEN;;WIDDOWSON KATHERINE LOUISE,BOEHM JEFFREY CHARLES;;CALLAHAN JAMES FRANCIS;;HALL RALPH F;;LIN XICHEN;;WIDDOWSON KATHERINE LOUISE,,https://lens.org/177-941-537-156-763,Patent Application,yes,0,21,12,13,0,C07D215/227;;C07D215/38;;C07D471/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P33/06;;A61P35/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/04;;A61P9/10;;C07D215/227;;C07D215/38;;C07D471/04,A61K/;;A61K31/00;;A61K31/4375;;A61P29/00;;A61P31/12;;C07D215/22;;C07D215/227;;C07D215/38;;C07D471/04,,0,0,,,,PENDING
990,US,A1,US 2006/0106058 A1,030-945-354-068-629,2006-05-18,2006,US 53098605 A,2005-04-12,US 53098605 A;;US 41891502 P;;US 0332625 W,2002-10-16,Chemical compounds,"3-carboxy quinoline derivatives, which are useful as YAK3 inhibitors are described herein. The described invention also includes methods of making such 3-carboxy quinoline derivatives as well as methods of using the same in the treatment of diseases mediated by inappropriate YAK3 activity.",BURGESS JOELLE L;;CALLAHAN JAMES F;;HAMAJIMA TOSHIHIRO;;IDA SATORU;;MORI ICHIRO;;TANG JUN,BURGESS JOELLE L;;CALLAHAN JAMES F;;HAMAJIMA TOSHIHIRO;;IDA SATORU;;MORI ICHIRO;;TANG JUN,,https://lens.org/030-945-354-068-629,Patent Application,yes,3,7,9,9,0,C07D215/54;;C07D401/12;;C07D405/12;;A61P13/12;;A61P15/00;;A61P25/28;;A61P35/00;;A61P37/02;;A61P43/00;;A61P7/00;;A61P7/06;;C07D401/12;;C07D215/54;;C07D405/12,A61K31/4709;;A61K/;;A61K31/47;;C07D215/38;;C07D215/54;;C07D401/12;;C07D403/02;;C07D405/02;;C07D405/12;;C07D453/02,514/311;;514/314;;546/169,0,0,,,,EXPIRED
991,TW,B,TW 487702 B,080-149-746-594-800,2002-05-21,2002,TW 86114545 A,1998-02-10,US 2732096 P;;US 4377697 P,1996-10-02,Vitronectin receptor antagonists,"Compounds of the formula (I) are disclosed which are vitronectin receptor antagonists and are useful in the treatment of osteoporosis: wherein: R1 is R7, or A-C0-4alkyl, A-C2-4alkenyl, A-C2-4alkynyl, A-C3-4oxoalkenyl, A-C3-4oxoalkynyl, A-C1-4aminoalkyl, A-C3-4aminoalkenyl, A-C3-4aminoalkynyl, optionally substituted by any accessible combination of one or more of R10 or R7; A is H, C3-6cycloalkyl, Het or Ar; R7 is -COR8, -COCR'2R9, -C(S)R8, -S(O)mOR', -S(O)mNR'R"""", -PO(OR'), -PO(OR')2, -B(OR')2, -NO2, or tetrazolyl; each R8 independently is -OR', -NR'R"""", -NR'SO2R', -NR'OR', or -OCR'2CO(O)R'; R9 is -OR', -CN, -S(O)rR', -S(O)mNR'2, -C(O)R', C(O)NR'2, or -CO2R'; R10 is H, halo, -OR11, -CN, -NR'R11, -NO2, -CF3, CF3S(O)r, -CO2R', -CONR'2, A-C0-6alkyl-, A-C1-6oxoalkyl-, A-C2-6alkenyl-, A-C2-6alkynyl-, A-C0-6alkyloxy-, A-C0-6alkylamino- or A-C0-6alkyl-S(O)r-; R11 is R', -C(O)R', -C(O)NR'2, -C(O)OR', -S(O)mR', or -S(O)mNR'2; R2 is formula, W is -(CHRg)a-U-(CHRg)b-; U is absent or CO, CRg2, C(=CRg2), S(O)k, O, NRg, CRgORg, CRg(ORk)CRg2, CRg2CRg(ORk), C(O)CRg2, CRg2C(O), CON Ri N Ri CO OC(O), C(O)O, C(S)O, OC(S), C(S)NRg, NRgC(S), S(O)2NRg, NRgS(O)2 N=N, NRgNRg, NRgCRg2, NRgCRg2, CRg2O, OCRg2, C≡C or CRg=CRg; G is NRe, S or O; Rg is H, C1-6alkyl, Het-C0-6alkyl, C3-7cycloalkyl-C0-6alkyl, or Ar-C0-6alkyl; Rk is Rg, -C(O)Rg, or -C(O)ORf; Ri is H, C1-6alkyl, Het-C0-6alkyl, C3-7cycloalkyl-C0-6alkyl, Ar-C0-6alkyl, or C1-6alkyl substituted by one to three groups chosen from halogen, CN, NRg2, ORg, SRg, CO2Rg, and CON(Rg)2; Rf is H, C1-6alkyl or Ar-C1-6alkyl; Re is H, C1-6alkyl, Ar-C1-6alkyl, Het-C1-6alkyl, C3-7cycloalkyl-C1-6alkyl, or (CH2)kCO2Rg; Rb and Rc are independently selected from H, C1-6alkyl, Ar-C0-6alkyl, Het-C0-6alkyl, or C3-6cycloalkyl-C0-6alkyl, halogen, CF3, ORf, S(O)kRf, CORf, NO2, N(Rf)2, CO(NRf)2, CH2N(Rf)2, or Rb and Rc are joined together to form a five or six membered aromatic or non-aromatic carbocyclic or heterocyclic ring, optionally substituted by up to three substituents chosen from halogen, CF3, C1-4alkyl, ORf, S(O)kRf, CORf, CO2Rf, OH, NO2, N(Rf)2, CO(NRf)2, and CH2N(Rf)2; or methylenedioxy; Q1, Q2, Q3 and Q4 are independently N or C-Ry, provided that no more than one of Q1, Q2, Q3 and Q4 is N; R' is H, C1-6alkyl, Ar-C0-6alkyl or C3-6cycloalkyl-C0-6alkyl; R"""" is R', -C(O)R' or -C(O)OR'; R""""' is H, C1-6alkyl, Ar-C0-6alkyl, Het-C0-6atkyl, or C3-6cycloalkyl-C0-6alkyl, halogen, CF3, ORf, S(O)kRf, CORf, NO2, N(Rf)2, CO(NRf)2, CH2N(Rf)2; Ry is H, halo, -ORg, -SRg, -CN, -NRgRk, -NO2, -CF3, CF3S(O)r-, -CO2Rg, -CORg or -CONRg2, or C1-6alkyl optionally substituted by halo, -ORg, -SRg, -CN, -NRgR"""", -NO2, -CF3, R'S(O)r-, -CO2Rg, -CORg or -CONRg2; a is 0, 1 or 2; b is 0, 1 or 2; k is 0, 1 or 2; m is 1 or 2; r is 0, 1 or 2; s is 0, 1 or 2; u is 0 or 1; and v is 0 or 1; or a pharmaceutically acceptable salt thereof.",SMITHKLINE BEECHAM CORP,CALLAHAN JAMES FRANCIS;;COUSINS RUSSELL DONOVAN;;KEENAN RICHARD MCCULLOCK;;KWON CHET;;MILLER WILLIAM HENRY,,https://lens.org/080-149-746-594-800,Granted Patent,no,0,0,59,64,0,A61K31/55;;A61K45/06;;C07D223/16;;C07D401/12;;C07D403/12;;C07D417/12;;Y02P20/582;;Y02P20/55;;A61P19/10;;A61P29/00;;A61P35/00;;A61P35/04;;A61P43/00;;A61P9/00;;A61P9/10;;A61K33/243;;C07D223/00;;A61K33/243,A61K31/415;;A61K31/44;;C07D223/00;;A61K31/445;;A61K31/47;;A61K31/4704;;A61K31/495;;A61K31/52;;A61K31/55;;A61K31/551;;A61K33/243;;A61K45/06;;A61P9/00;;A61P9/10;;A61P19/10;;A61P29/00;;A61P35/00;;A61P43/00;;C07D223/16;;C07D233/56;;C07D233/64;;C07D235/18;;C07D235/22;;C07D243/14;;C07D401/00;;C07D401/12;;C07D401/14;;C07D403/12;;C07D413/12;;C07D417/12;;C07D487/00,,0,0,,,,EXPIRED
992,DE,C3,DE 1493224 C3,159-331-003-630-415,1973-10-11,1973,DE 1493224 A,1965-10-30,US 40872364 A,1964-11-04,DE 1493224 C3,,"THE STANDARD OIL CO., CLEVELAND OHIO (V.ST.A.)","CALLAHAN, JAMES LOUIS, BEDORD HEIGHTS;;MILBERGER, ERNEST CARL, MAPLE HEIGHTS;;GRASSELLI, ROBERT KARL, CLEVELAND",,https://lens.org/159-331-003-630-415,Granted Patent,no,0,0,15,16,0,B01J8/26;;B01J8/26;;B01J21/08;;B01J21/08;;B01J23/12;;B01J23/12;;B01J23/18;;B01J23/18;;C07C45/34;;C07C45/34;;C07C45/35;;C07C45/35;;C07C253/26;;C07C253/26;;Y02P20/52;;Y02P20/52,C07C47/22;;B01J8/26;;B01J21/08;;B01J23/00;;B01J23/12;;B01J23/18;;B01J35/00;;C07B61/00;;C07C45/00;;C07C45/34;;C07C45/35;;C07C67/00;;C07C253/00;;C07C255/08,,0,0,,,,EXPIRED
993,US,B2,US 7476802 B2,084-933-429-718-595,2009-01-13,2009,US 8523205 A,2005-03-22,US 8523205 A;;US 55491504 P,2004-03-22,Programmable automation controller assembly,"A programmable logic controller or programmable automation controller assembly that can be used in harsh environments. A plurality of user-configurable housings are used to accommodate a customer's desired functionality design. A two-board design is featured to enable electronics in the controller assembly. The two-board design includes an active board that houses a majority of electrical components in the controller assembly, and a wiring hub that is used for wiring terminations. A mechanism is provided for a field-removable labeling system that withstands harsh environmental conditions.",FAIRMONT AUTOMATION INC,CANE GARY R;;CALLAHAN BRIAN M;;IOCCA JAMES R;;DIBONA STEVE D;;LEBAUDY ANDRES,FAIRMONT AUTOMATION INC (2005-06-08),https://lens.org/084-933-429-718-595,Granted Patent,yes,10,8,2,2,0,H05K7/1465;;H05K7/1465;;H05K5/061;;H05K5/061;;H05K7/1474;;H05K7/1474;;H05K7/1478;;H05K7/1478,H01J5/00;;H03K19/177;;H05K5/06;;H05K7/14,174/50;;174/59;;174/60;;174/61;;361/737,0,0,,,,ACTIVE
994,US,A1,US 2009/0239897 A1,149-116-630-187-446,2009-09-24,2009,US 46640109 A,2009-05-15,US 46640109 A;;US 54556505 A;;US 2004/0004406 W;;US 44741003 P;;US 53809504 P,2003-02-14,NOVEL COMPOUNDS,"Novel substituted 1,5,7-trisubstituted-1,8-napthyridin-2(1H)-one compounds; 1,5,7 trisubstituted-1,6-napthyridine-2-(1H)-one compounds and 1,5,7-trisubstituted quinoline-2(1H)-one compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy.",SMITHKLINE BEECHAM CORP,BOEHM JEFFREY CHARLES;;CALLAHAN JAMES FRANCIS;;HALL RALPH F;;LIN XICHEN;;WIDDOWSON KATHERINE LOUISE,,https://lens.org/149-116-630-187-446,Patent Application,yes,18,4,12,13,1,C07D215/227;;C07D215/38;;C07D471/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P33/06;;A61P35/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/04;;A61P9/10;;C07D215/227;;C07D215/38;;C07D471/04,A61K31/4375;;A61K/;;A61K31/00;;A61P29/00;;A61P31/00;;A61P31/12;;C07D215/22;;C07D215/227;;C07D215/38;;C07D471/04,514/300;;546/122,0,0,,,,DISCONTINUED
995,ES,T3,ES 2398246 T3,087-195-271-798-966,2013-03-14,2013,ES 06748672 T,2006-03-24,US 66531505 P;;US 2006/0010855 W,2005-03-25,"8-FENIL-7,8-DIHIDROPIRIDO(2,3-D) PIRIMIDIN-7-ONAS","Un compuesto que es 3-{8-(2,6-difluorofenil)-2-[(1H-imidazol-2-ilmetil)amino]-7-oxo-7,8-dihidropirido[2,3-d]pirimidin-4-il}-4-metil-N-1,3-tiazol-2-ilbenzamida**Fórmula** o una sal del mismo farmacéuticamente aceptable.",GLAXO GROUP LTD,CALLAHAN JAMES;;BOEHM JEFFREY;;COOPER ANTHONY;;LIVIA STEFANO;;NEVINS NEYSA;;WAN ZEHONG;;NORTON BETH,,https://lens.org/087-195-271-798-966,Granted Patent,no,0,0,50,50,0,C07D487/04;;A61P1/00;;A61P1/04;;A61P11/00;;A61P11/02;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/06;;A61P17/16;;A61P19/00;;A61P19/02;;A61P19/06;;A61P19/08;;A61P19/10;;A61P21/00;;A61P25/00;;A61P25/28;;A61P27/00;;A61P27/02;;A61P27/16;;A61P29/00;;A61P3/00;;A61P31/00;;A61P31/04;;A61P35/00;;A61P35/04;;A61P37/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/00;;A61P9/04;;A61P9/10;;A61P3/10;;C07D471/04;;A61K31/519;;C07D487/04,C07D487/04;;A61K31/519;;A61P19/00;;A61P19/02;;A61P29/00,,0,0,,,,ACTIVE
996,EP,A2,EP 1596860 A2,122-076-053-628-761,2005-11-23,2005,EP 04711237 A,2004-02-13,US 2004/0004406 W;;US 44741003 P;;US 53809504 P,2003-02-14,NOVEL COMPOUNDS,,SMITHKLINE BEECHAM CORP,BOEHM JEFFREY CHARLES;;CALLAHAN JAMES FRANCIS;;HALL RALPH F;;LIN XICHEN;;WIDDOWSON KATHERINE LOUISE,GLAXOSMITHKLINE LLC (2010-03-03),https://lens.org/122-076-053-628-761,Patent Application,yes,0,0,12,13,0,C07D215/227;;C07D215/38;;C07D471/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P33/06;;A61P35/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/04;;A61P9/10;;C07D215/227;;C07D215/38;;C07D471/04,C07D215/38;;A61K/;;A61K31/00;;A61K31/4375;;A61P29/00;;A61P31/12;;C07D215/22;;C07D215/227;;C07D471/04,,0,0,,,,DISCONTINUED
997,CA,A1,CA 2515939 A1,114-937-812-078-548,2004-09-02,2004,CA 2515939 A,2004-02-13,US 44741003 P;;US 53809504 P;;US 2004/0004406 W,2003-02-14,NOVEL COMPOUNDS,,SMITHKLINE BEECHAM CORP,LIN XICHEN;;CALLAHAN JAMES FRANCIS;;BOEHM JEFFREY CHARLES;;HALL RALPH F;;WIDDOWSON KATHERINE LOUISE,,https://lens.org/114-937-812-078-548,Patent Application,no,0,0,12,13,0,C07D215/227;;C07D215/38;;C07D471/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P33/06;;A61P35/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/04;;A61P9/10;;C07D215/227;;C07D215/38;;C07D471/04,A61K/;;A61K31/00;;A61K31/4375;;A61P29/00;;A61P31/12;;C07D215/22;;C07D215/227;;C07D215/38;;C07D471/04,,0,0,,,,DISCONTINUED
998,US,A1,US 2022/0186103 A1,171-403-726-416-505,2022-06-16,2022,US 202017600833 A,2020-04-01,US 202017600833 A;;US 201962828169 P;;US 2020/0026235 W,2019-04-02,METHODS INVOLVING CEMENTS THAT EMPLOY CARBON DIOXIDE AS A REACTANT,"A method of cementing an annular space between a pipe string and a well bore, the method comprising the steps of (a) providing a cement composition including a calcium-deficient calcium silicate; (b) mixing the cement composition with water to form a cement slurry; (c) mixing the cement slurry composition with carbon dioxide form a foamed cement; and (d) placing the foamed cement in the annular space between the pipe string and the wellbore.",OXY LOW CARBON VENTURES LLC,COWAN KENNETH M;;ZELLER III ROBERT L;;CALLAHAN III ELIAS R;;WILLIS JAMES S,OXY LOW CARBON VENTURES LLC (2021-09-23),https://lens.org/171-403-726-416-505,Patent Application,yes,4,0,4,4,0,C09K8/473;;C04B38/103;;Y02P40/18;;C04B28/188;;C04B38/103;;C04B40/0231;;C04B2111/00706;;C09K8/46;;E21B33/14,C09K8/46;;C04B28/18;;C04B38/10;;C04B40/02;;E21B33/14,,0,0,,,,PENDING
999,WO,A1,WO 2003/029241 A1,095-921-901-035-685,2003-04-10,2003,US 0231752 W,2002-10-04,US 32697701 P,2001-10-04,CHK1 KINASE INHIBITORS,Novel compounds useful in the inhibition of damage response kinases are provided.,SMITHKLINE BEECHAM CORP;;PARRISH CYNTHIA A;;CALLAHAN JAMES F;;LI YUE;;STAVENGER ROBERT A;;HOLT DENNIS A,PARRISH CYNTHIA A;;CALLAHAN JAMES F;;LI YUE;;STAVENGER ROBERT A;;HOLT DENNIS A,,https://lens.org/095-921-901-035-685,Patent Application,yes,3,0,1,1,0,A61K31/381;;C07D409/04;;C07D333/36;;C07D333/38,A61K31/381;;C07D333/36;;C07D333/38;;C07D409/04,,0,0,,,,PENDING
1000,EP,A4,EP 1596860 A4,176-605-030-636-582,2009-05-27,2009,EP 04711237 A,2004-02-13,US 2004/0004406 W;;US 44741003 P;;US 53809504 P,2003-02-14,NOVEL COMPOUNDS,,SMITHKLINE BEECHAM CORP,BOEHM JEFFREY CHARLES;;CALLAHAN JAMES FRANCIS;;HALL RALPH F;;LIN XICHEN;;WIDDOWSON KATHERINE LOUISE,GLAXOSMITHKLINE LLC (2010-03-03),https://lens.org/176-605-030-636-582,Search Report,no,1,0,12,13,0,C07D215/227;;C07D215/38;;C07D471/04;;A61P1/00;;A61P11/00;;A61P11/06;;A61P13/12;;A61P17/00;;A61P17/04;;A61P17/06;;A61P19/02;;A61P19/06;;A61P19/10;;A61P25/00;;A61P29/00;;A61P31/00;;A61P31/12;;A61P33/06;;A61P35/00;;A61P37/06;;A61P43/00;;A61P7/02;;A61P9/04;;A61P9/10;;C07D215/227;;C07D215/38;;C07D471/04,A61K/;;A61K31/00;;A61K31/4375;;A61P29/00;;A61P31/12;;C07D215/22;;C07D215/227;;C07D215/38;;C07D471/04,,6,5,020-233-743-094-46X;;003-548-441-074-869;;082-145-284-112-751;;179-061-969-331-366;;023-786-359-952-713,10.1021/jm00104a012;;1336055;;2553036;;10230055;;10.1016/s0014-827x(98)00094-9;;12049520;;10.1021/ol025950z;;10.1124/dmd.31.2.215;;12527703,"SINGH B ET AL: ""NOVEL CAMP PDE III INHIBITORS: 1,6-NAPHTYRIDIN-2(1H)-ONES"", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON., US, vol. 35, no. 26, 1 January 1992 (1992-01-01), pages 4858 - 4865, XP001007030, ISSN: 0022-2623;;P. FERRARINI: ""study of inhibition of platelet aggregation of 1,8-naphtyridine derivatives."", FARMACO., vol. 44, no. 6, 1989, SOCIETA CHIMICA ITALIANA, PAVIA., pages 579 - 584, XP008105245;;P. FERRARINI ET AL.: ""synthesis and evaluation of antimycobacterial activity of 4-phenyl- 1,8-naphtyridine derivatives."", FARMACO., vol. 53, no. 12, 1998, SOCIETA CHIMICA ITALIANA, PAVIA., pages 741 - 746, XP002523614;;C. SAVARIN ET AL.: ""an expedient synthesis of highly functionalized naphthyridones and quinolines"", ORGANIC LETTERS, vol. 4, no. 12, 2002, washington, pages 2071 - 2074, XP002523615;;WENJI YIN ET AL.: ""a novel p-450-catalysed transformation of the 2,2,6,6-tetramethylpiperidine moiety to a 2,2-dimethyl pyrrolidine in human liver microsomes."", DRUG METABOLISM AND DISPOSITION, vol. 31, no. 2, 2003, usa, pages 215 - 223, XP002523616;;C. BELLED ET AL.: ""fototransposicion de fries de esteres fenolicos de los acidos antranilico y n-acetylantranilico."", ANALES DE QUIMICA, vol. 86, no. 4, 1990, es, pages 431 - 435, XP002523617",DISCONTINUED
